<SEC-DOCUMENT>0000950170-25-061850.txt : 20250501
<SEC-HEADER>0000950170-25-061850.hdr.sgml : 20250501
<ACCEPTANCE-DATETIME>20250501161517
ACCESSION NUMBER:		0000950170-25-061850
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		59
CONFORMED PERIOD OF REPORT:	20250331
FILED AS OF DATE:		20250501
DATE AS OF CHANGE:		20250501

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ascendis Pharma A/S
		CENTRAL INDEX KEY:			0001612042
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			G7
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36815
		FILM NUMBER:		25903295

	BUSINESS ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
		BUSINESS PHONE:		45 70 22 22 44

	MAIL ADDRESS:	
		STREET 1:		TUBORG BOULEVARD 12
		CITY:			HELLERUP
		STATE:			G7
		ZIP:			DK-2900
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>asnd-20250331.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-01T14:03:37.8833+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:srt="http://fasb.org/srt/2024" xmlns:asnd="http://ascendispharma.com/20250331" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>6-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="padding:8px;margin:auto!important;z-index:0;position:relative;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_f2cf25c4-038c-4484-b84c-37f91bd227bb" name="dei:EntityCentralIndexKey" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073">0001612042</ix:nonNumeric><ix:nonNumeric id="F_c0654d5c-1874-4d66-b463-3092a66edcbd" name="dei:DocumentPeriodEndDate" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" format="ixt:date-monthname-day-year-en">Mar 31, 2025</ix:nonNumeric><ix:nonNumeric id="F_72311a40-51cd-40a6-bc29-cfa61cfce1cf" name="dei:AmendmentFlag" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073">false</ix:nonNumeric><ix:nonNumeric id="F_37a85b0b-0f71-44f0-985d-5ff41358175d" name="dei:CurrentFiscalYearEndDate" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073">--12-31</ix:nonNumeric><ix:nonNumeric id="F_c451b9bd-d4fc-4fbd-bc67-4f897c1d8a45" name="dei:DocumentFiscalPeriodFocus" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073">Q1</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="asnd-20250331.xsd"/></ix:references><ix:resources><xbrli:context id="C_819dfe51-28d5-4314-9ec5-4ee09ed7b84b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8277197c-cb86-45e7-aa61-4d5b1f0fbafb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_83ada807-1cec-4221-a92a-f07c205009a0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_84ecf827-5c4e-400c-9fed-cfb85e09d515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_866661ff-8c14-41eb-b4d7-4a85755a6b03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8782f887-b4d8-4794-87db-2dcfd88fdd71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8dd8b82a-4cc6-45e8-bd7c-3ba7efecfb55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e42c784-999f-4c5e-ad5c-d7c4484f02e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_909af02d-d3e3-49eb-8ac9-f629568438a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_90ec9194-a47f-4c6f-ba12-88ada7bf522a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9110cafd-2d7b-4304-9249-9a5b3d9c4dfe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_935a7fad-4793-4877-9ec1-f6ddf2e4a58c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95321c00-437c-4833-bb27-d621eaa3e8b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_975c08fa-b467-40ed-8b0f-240242f397d5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98da32b7-acae-4c20-a13b-26ca6c11a9ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_990b5b82-ee02-43ea-90c9-a7eeb3873527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:VisenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99940134-84fa-4775-8956-5bbfab5ab4d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99b14b08-2c6d-4423-a4ca-73022572e1c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9c274d2a-5811-4366-95fa-54518a9e968b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9cac6737-58ef-4123-8b45-22b55e55c632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9f6f334e-9595-42e6-a9bd-d1e679cfd8ad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a4ee514e-86ba-4531-8150-a8cfaa788eb8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a633f67b-4c57-46fb-bcde-1a16d86b23b4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7a008d3-7a3d-4804-83b9-58bcf05b742c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a904418f-a475-4203-9ad0-fc0801b5f9a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9ccce3c-1020-4eff-921e-177f04314020"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac6e452f-b851-4366-98b0-9dbd4cb50f3e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_af8ce046-66d9-47ba-a2db-115fd2735a92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b125fc88-e513-4da8-966f-995e9855cd6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b829287e-56df-49a2-b424-3fed6680c9cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bf7f8faa-849d-4587-84f1-bdcde1f91d6f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c21b8c71-d449-4b9c-a8e1-039a12e96fc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c4e71d44-6541-42a1-b85a-412e5d5807d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c79f5454-5ba5-4cc3-9ef2-650e50056d2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cbd88d82-c8c4-4bcf-bb15-ad99f773c0e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce5fb7a1-960a-40b8-96ca-a59d1361c834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cfea5658-1faf-4539-ad78-6f615eb69073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d09921c8-e6c9-41c6-87a5-4292b2ecb35e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-12</xbrli:startDate><xbrli:endDate>2025-02-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0d9b779-1a60-4cc4-a381-04a9bc619b06"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d182cba3-f8ff-423d-8e1e-a44b81fe3740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d39182d1-57bd-4617-8a6a-98d8b663a8a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationsAndLicenseAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d394cb1a-3b0a-4dbc-a6eb-8741f78af1f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d6ec2449-d89f-452d-9858-a0c38174ef96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d979433b-7c92-4bed-ad15-dbb8a17d94f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9cca70d-ddde-47cd-a1a3-3f846e0b2ad1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_da6b292e-7c16-4b6b-be4d-1a791f59c406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc16f5c8-e5a3-4b82-8f15-702a29cdd088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">asnd:ForeignCurrencyConversionOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e21b606d-3548-4aad-9554-94ae80a18cab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e430f24c-0233-4114-a208-350b297af714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e98d5d36-1e29-442d-a2a2-e8e647fa92b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ebf7f8d8-9a88-4b74-9ba0-b9f6929c0ab5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed9a4cd9-a9ca-454a-9615-64678e2fdefe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee51bcae-74d0-4e67-89b0-e987214d4543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ef94f77b-e835-49b6-9fa5-da367d813217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:VisenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1cc25de-2681-466f-9005-4cacf85b0437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f3608329-0a27-421b-9eed-d655fd107402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f365e58b-1e31-4938-9a9f-6ae4a53dfc7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f73819d7-55e0-42b4-8ce8-858bcc257ffe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f8d4e6cd-e972-4517-950c-c2e4ca607adc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_faaf4bfc-6ed7-4797-9957-11c2e997c3a3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_facec156-4e04-482e-8239-ca86a66ecd9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff030c5c-71d1-4446-bcd4-d002a0413fae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff410c6d-6879-4a59-a3ae-5c1857693086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0180a343-84b5-4550-8e9e-0e9d94787b6a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_043c9c52-1128-4558-9421-751a6d2b10ae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04aedc44-3b7e-46d5-ade6-eeb4fd969b26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_06503dc6-abee-4161-b4cf-ae017326cf5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_080c73e3-b2aa-450a-ba77-af1301298b4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_084e81ae-053b-4124-8ea0-cf00fb92aefd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_08de1782-376b-48ac-8b33-acaf2bd1c052"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0ce1e53d-f85e-4cd5-8a39-323d29baed2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0ed1d82f-1028-46f4-b7d1-1a4f01140861"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0f12ae56-033f-4e22-8363-af8518013748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1226e5c0-e438-4068-ae93-f55dd69d5fc6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_13256690-d69b-40e3-a745-f42b7767f286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1376235c-5b88-401d-85b1-b3795ce9a8cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17a14604-dfe5-4082-bab4-5778ed12841c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c3c7589-8585-40b4-8f1e-8ae31626083c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1c8e5090-f187-4c40-bee7-aaf30930188c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1d3ec492-aaf3-4c50-8780-bc2563b2b216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_226651eb-e9b1-44d1-82dd-4b5f380929d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_27448f17-97d9-4695-8836-7cbae988447b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_290aeeba-a386-42b8-856c-a68d382312e1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2a483356-316b-4a65-8bf7-a9551532b29b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c892acc-02da-4c15-9353-950413a810ff"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e1b63bd-d863-46b8-8fa6-18b4bf555975"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_351470c2-85b2-48d4-96cb-01998edc0281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36356f4b-0e07-4b7c-876a-5c08a3b2de70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyEightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36943fab-c0c6-4437-adcd-1f9a290d164c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b05cb12-2e51-444c-a128-f7f8902c20db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c3f2d33-74af-4a32-80dc-2766d5dbca67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3cb7ddc6-ca0e-4f90-83dc-2681c7bb17c0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3d08e8ed-f880-4006-95c6-262b0ebc3c04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41423738-faf9-4d2a-bcc1-37650e709689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_41b6f38d-a596-4e87-b38c-e28360d02d02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_434feb09-9876-4024-9170-6094ccac6b87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a04a12f-c2bb-4f60-9173-69088979902b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a87b703-b453-4069-82f0-40f1f09886fb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e24ca41-f7d8-4b85-bcc0-e6602bf707f4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f687d92-bd5b-418e-bafe-85fdef35c02e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ffe96aa-eccd-4c58-806f-aeb003cfacb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_53d7776f-82d5-4f1e-a852-ddb489a39552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5b83b77f-547e-42d3-9a2c-5c6ae9438f49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5eb53229-0864-44c9-9f9d-2c5f527f1088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62ad3de7-4eca-483d-b815-5062d2cbf5a5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_650908d3-c211-42ad-819c-acf17f2e9e86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-09-03</xbrli:startDate><xbrli:endDate>2024-09-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_65c9897b-d13e-4f01-a77c-114baa4945b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_685d7bbe-e597-4efe-81c5-62074784e614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:VisenPharmaceuticalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-21</xbrli:startDate><xbrli:endDate>2025-03-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d2a3784-98f4-4b88-81d4-8cfaf226f5fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6df1c7ad-9308-4d74-81ba-3a4e8314fa4f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6f20e6a7-a161-4a7a-8def-bd1f1b851f84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76d949ec-eebb-4b57-b947-ed0df0081070"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76e6e803-d4db-4b29-9ab8-219028b47903"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_76ef0cc1-54a9-485d-af12-f694616423d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_79d64e56-848d-43de-a89c-390b0257c619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c0a269e-a617-410a-a9a6-957f53860b47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7dc36b02-c138-4fcc-b62f-16eb456e91be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7ebbd176-7e24-4431-8904-088669448bc7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001612042</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_DkkPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:DKK</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_UnitedStatesOfAmericaDollarsShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_Multiple"><xbrli:measure>asnd:Multiple</xbrli:measure></xbrli:unit><xbrli:unit id="U_Days"><xbrli:measure>asnd:Days</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>asnd:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_XBB"><xbrli:measure>iso4217:XBB</xbrli:measure></xbrli:unit><xbrli:unit id="U_EurPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_HkPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:HKD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_5dd3c7e2-62e7-4202-87b6-5365ff6957b5" fromRefs="F_9e4d657f-478f-4433-bce1-27fd0273275a F_54a2db4f-0a64-42f5-8719-d72d0fff50fc"/></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57b57f06-d777-425f-ae5b-2898aed08b29" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">REPORT OF FOREIGN PRIVATE ISSUER</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PURSUANT TO SECTION 13a-16 OR 15d-16</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the month of May, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e140cf13-9958-4211-b2d4-6d4cf1289dc5" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="dei:DocumentFiscalYearFocus"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2025</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Commission File Number: 001-36815</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a08824b7-7c36-4fdc-82ae-9c002e657968" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Exact Name of Registrant as Specified in Its Charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Tuborg Boulevard 12</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">DK-2900 Hellerup</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Denmark</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Address of principal executive offices)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="margin-left:40%;padding-bottom:1pt;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;border-bottom:1pt solid;margin-right:40%;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Form 20-F  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9746;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">                Form 40-F  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;font-kerning:none;min-width:fit-content;">&#9744;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:2.25pt double;padding-top:1pt;font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INCORPORATION BY REFERENCE</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This report on Form 6-K shall be deemed to be incorporated by reference into the registration statements on Form S-8 (Registration Numbers 333-228576, 333-203040, 333-210810, 333-211512, 333-213412, 333-214843, 333-216883, 333-254101, 333-261550, 333-270088, 333-277519, 333-281916, and 333-285322) and Form F-3 (Registration Numbers 333-209336 and 333-282196) of Ascendis Pharma A/S (the &#8220;Company&#8221;) (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="border-top:0.75pt solid #000000;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Information Contained in this Report on Form 6-K</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This report contains the Company&#8217;s Unaudited Condensed Consolidated Interim Financial Statements as of and for the period ended March 31, 2025, including Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations for the period presented therein.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SIGNATURES</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:1.333%;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:50.347%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:3.061%;box-sizing:content-box;"/>
     <td style="width:45.571%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="2" style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S</span></p></td>
    </tr>
    <tr style="height:12.25pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Date: May 1, 2025</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">By:</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">/s/ Michael Wolff Jensen</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Michael Wolff Jensen</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Executive Vice President, Chief Legal Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="toc"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TABLE OF CONTENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:99.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:2.525%;box-sizing:content-box;"/>
     <td style="width:92.465%;box-sizing:content-box;"/>
     <td style="width:5.01%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#condensed_consolidate_nterim_financia"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unaudited Condensed Consolidated Interim Financial Statements &#8211; March 31, 2025</span><span style="color:#0000ff;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.</span></p></td>
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#managements_discussion"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
     <td style="padding-top:0in;padding-left:0.1in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASCENDIS PHARMA A/S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="condensed_consolidate_nterim_financia"><span id="index"></span><span id="tx355617_1"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:98.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:91.837%;box-sizing:content-box;"/>
     <td style="width:8.163%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Page</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unaudited_cond_consol_interim__of_profit"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unaudited Condensed Consolidated Interim Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) for the Three Months Ended March 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-2</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#un_cond_co_int_st_of_financial_position"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unaudited Condensed Consolidated Interim Statements of Financial Position as of March 31, 2025 and December 31, 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-3</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#una_cons_inter_state_of_chan_in_equity"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unaudited Condensed Consolidated Interim Statements of Changes in Equity as of March 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-4</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#unaudited_co_consolid_interim_cash_flow"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Unaudited Condensed Consolidated Interim Cash Flow Statements for the Three Months Ended March 31, 2025 and 2024</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-5</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0in;text-indent:12pt;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="text-indent:-2.277%;padding-left:2.227%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="#notes"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Notes to the Unaudited Condensed Consolidated Interim Financial Statements</span></a></p></td>
     <td style="padding-top:0in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;F-6</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="unaudited_cond_consol_interim__of_profit"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited Conden</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">sed Consolidated Interim Statements of Profit or (Loss)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">and Other Comprehensive Income or (Loss) for the Three Months Ended March 31, 2025 and 2024</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:61.505%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:6.723%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.665000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.665000000000001%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Notes</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Consolidated Statement of Profit or (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75db0625-7d60-47ca-9e63-264474ed104a" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,954</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_13b2878f-a76c-469f-b095-b15abf951f03" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,894</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cost of sales</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_00757fb4-ccec-419e-b455-25adf7f0d093" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,517</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_329dbb35-d8ef-41ae-b64f-898aabb884ca" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:CostOfSales" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,569</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a80f5787-f38b-4a60-909f-39497046abc8" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">83,437</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2346e90a-a178-4628-812e-a591762c8d75" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:GrossProfit" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,325</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ba1e2d8-869a-43e9-9d80-095a609684e9" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">86,603</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbeedbe4-a48d-487b-977c-4666ed8d8e75" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ResearchAndDevelopmentExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">70,687</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64d986a5-e866-488a-bd4b-5bf43fc610dc" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">101,046</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_470323ca-42a2-4d42-b527-5fbf7462b9d3" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:SellingGeneralAndAdministrativeExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,783</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating profit/(loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dbead0cd-f66a-4a39-bef3-0dc2f494205f" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">104,212</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_77da58b6-846e-453e-911b-00ccef1d574f" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProfitLossFromOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49,145</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share of profit/(loss) of associates</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46eba6bc-5c2b-4eb7-ad5a-504689ab3a9a" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,579</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ad48c08-aaad-4c12-a947-12d827a28d0d" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,796</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a10ab0a1-1e4e-48c5-996f-2a19e00be422" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f0568b1-19a2-470d-ac44-cb881dedcc11" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,575</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef055c3a-c308-463c-8682-55f2c9ec577f" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,786</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0fa5691-78ef-41d7-8fb6-65bfdb2ea481" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Profit/(loss) before tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fde4415e-236f-48d0-b3d8-947b595f0789" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">93,565</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f59f63e9-0d4a-4b19-8b62-ffa15c51322b" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProfitLossBeforeTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">128,527</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes (expenses)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5bacf309-c117-495e-93b4-6a07f6e7116a" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,061</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b8277e3-70fb-44e9-a4b9-973e97d9f662" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3bf475a7-5aec-44f5-ba4f-85751d04026b" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a3c29925-0784-440f-973f-3d686ad9657d" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attributable to owners of the Company</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f241af0d-99ce-4e25-b503-63fd9ed5f8f9" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42c06cb1-87db-4e59-898e-e90fc2f1a49a" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProfitLossAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Basic and diluted earnings/(loss) per share</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_010e2736-aa71-406a-8cc7-fb86585be8b9" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_7f58efb0-1dae-42d4-80e5-c88a60655465" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">1.58</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">&#8364;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87653904-2912-4b4a-ad3c-c81105e00a1f" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:BasicEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal"><ix:nonFraction id="F_0bbbb128-c349-435c-81b2-8f39f047af5f" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:DilutedEarningsLossPerShare" unitRef="U_EurPerShare" scale="0" decimals="2" sign="-" format="ixt:num-dot-decimal">2.30</ix:nonFraction></ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Number of shares used for calculation (basic and diluted) </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9e4d657f-478f-4433-bce1-27fd0273275a" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">60,018,550</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54a2db4f-0a64-42f5-8719-d72d0fff50fc" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:WeightedAverageShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">56,883,257</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Consolidated Statement of Comprehensive Income or (Loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be73e098-e453-4629-90aa-48a4f3349b23" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7fa36d63-3c00-4050-8acc-365dc5de2372" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-style:italic;font-kerning:none;min-width:fit-content;">Items that may be reclassified subsequently to profit or (loss):</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exchange differences on translating foreign operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f3b9d9b-bd3e-44d3-bac6-d1bebe3940b9" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d64351c3-2098-42cc-b0f4-39f137a8c833" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss) for the period, net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5a7de9d-bcf9-4be7-a8b9-bd52c8df48f4" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9001a691-c0dc-4c09-b1ee-f241a3a77ef3" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income/(loss) for the period, net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_79f888bd-dd25-4a14-86d4-2045a8d5d69f" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,701</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cfc78e8-4e7d-4601-b0c3-d891572f8b63" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,972</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Attributable to owners of the Company</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_037f0420-4498-4ecd-a7e5-913e4068a641" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,701</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6522d9b1-7660-4b76-b4b8-37efe57f8a01" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,972</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="transform:scale(0.67);color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8pt;font-family:Times New Roman;transform-origin:top left;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><ix:footnote id="FNT_5dd3c7e2-62e7-4202-87b6-5365ff6957b5" xml:lang="en-US"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ca4defbf-7d8e-42c3-ac39-3803aa7e3128" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,017,157</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ce0a0aa-a0c0-4512-a064-0b0293180562" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">6,031,498</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aa94a497-32c1-498c-9312-edf9a920a758" contextRef="C_9c274d2a-5811-4366-95fa-54518a9e968b" name="asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">575,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible senior notes which can potentially be converted into </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cabc28a0-d2a6-4fc1-b4ec-66eef6b60ad2" contextRef="C_1c8e5090-f187-4c40-bee7-aaf30930188c" name="asnd:NumberOfWarrantsOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">3,456,785</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented.</span></ix:footnote><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="tx355617_4"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited Condensed Consol</span><span id="un_cond_co_int_st_of_financial_position"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">idated Interim Statements of Financial Position as of March 31, 2025 and December 31, 2024</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:61.48%;box-sizing:content-box;"/>
     <td style="width:1.48%;box-sizing:content-box;"/>
     <td style="width:6.72%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:12.14%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Notes</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Intangible assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6b7dceeb-2795-4594-ac46-2f88a5033d7e" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,909</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_939eaeaa-6f21-4e06-b125-a4f7418bcf51" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:IntangibleAssetsAndGoodwill" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,028</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Property, plant and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_757cac15-5ace-496d-b723-62e36f8d0c18" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,447</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1226b186-3517-4217-8a3f-7430379b82fb" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:PropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,714</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investments in associates</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9bd575f-d9c4-4828-ab45-c1c3a3cd9972" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:InvestmentsInAssociates" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,938</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_114675d2-77d7-49d5-a82f-a8137c556dd2" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:InvestmentsInAssociates" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,575</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_61bb4aee-1225-4469-8da4-d71027a9acb2" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:OtherNoncurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,657</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_73b9b40d-7f69-44a0-90dc-1f9c10d4a0f9" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:OtherNoncurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,317</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9124cea-5b21-4040-b982-05646f6e125f" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:NoncurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">139,951</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1ee9ba1-bc0b-4678-bf85-b83218aa94a6" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:NoncurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">118,634</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_29da52a2-88da-4b7d-a4fd-ab6c0c2d5d9f" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:Inventories" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">293,071</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dc3aec69-9f5d-44e5-99ce-b8acb0ea7238" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:Inventories" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">295,609</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b16d402-51ac-4294-a130-a34d9c1d1397" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentTradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,685</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bfea62af-a3f4-4f86-a92e-040a99c8e409" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentTradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,280</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax receivables</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_71cb1531-7a5b-413b-b0ff-8cf7cb6ee773" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentTaxAssetsCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,614</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84029437-ef61-45ef-8ab9-f21d284825ec" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentTaxAssetsCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,775</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2d4e5785-42fb-4561-8786-b84c25bb4ef5" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:OtherCurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,522</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fa99376a-4002-408f-998b-bf2c9eeeebff" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:OtherCurrentReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">9,385</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_80920282-aca6-4876-bc9b-bb2d4f18bb8e" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentPrepayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,672</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5533b535-f6da-4749-8e85-b1b12d41775c" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentPrepayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,269</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc30886e-96dd-448f-8884-a88961610f27" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,923</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_78eba5d8-980d-4125-a6f0-8038ddcebc9e" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,543</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e9ae4e68-bb9e-4ccb-a960-2a3ba781680c" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">921,487</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8acfffca-141c-4375-bd47-136c081ca9cf" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,060,861</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total assets</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0261099a-0d73-4bb4-b90b-4c566cd80524" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:Assets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,061,438</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8d50a3b-1aee-4128-b7b0-e83adff5db13" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:Assets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,179,495</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity and liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share capital</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">8</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_47551b81-81f7-4ca3-8664-b5324fa285a6" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:IssuedCapital" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,187</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd45d026-03ed-40a1-8e53-f5f7d2713abf" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:IssuedCapital" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,149</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Distributable equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_63756cdb-d80e-46ce-8d0b-625f49fa5435" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:DistributableEquity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">197,994</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1781e5e-d827-471b-83c3-1ee4617483b0" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="asnd:DistributableEquity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">113,855</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total equity</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f9dc2101-db1c-4a60-bb50-a626dc070448" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">189,807</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c999d42-4e61-4b01-a786-a18aa247e2f0" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105,706</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54ea4066-e937-4c60-bafb-28d62e845061" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:LongtermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">357,312</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3f99752d-b49b-4c45-9182-7c7a3f309664" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:LongtermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">365,080</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9a8dc1d-f84a-4115-9203-31e5cda6e791" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:NoncurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">692</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5158ed34-8415-4211-a2c3-81f1b78fa727" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:NoncurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,000</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Deferred tax liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a838692f-94b0-4d64-9034-344721ec9d35" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:DeferredTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,733</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0a46c21e-47a8-48ce-88a0-8f84fd75c75c" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:DeferredTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,258</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f878320d-7916-4476-8680-ed0bcd657d3b" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:NoncurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">365,737</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e5b01b31-e4b5-4aab-abcc-b7c6489a30f1" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:NoncurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">377,338</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible notes, matures in April 2028</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7080ecaf-bfc1-465c-8c0f-82799d1b59e8" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:ShorttermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">449,562</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec6c8c7c-15a5-4e3f-b779-7b56af22bb3e" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:ShorttermBorrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,207</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0779233d-a24b-456f-b815-f18d2353bc75" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,581</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1201a739-e52a-48d8-ad6f-705dfe555097" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentDerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fdd3ebb6-3f9c-44b0-a4d1-df7087f8897b" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:ConvertibleNotesCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">624,143</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4934b513-87bd-45c0-b7a3-38afe53750be" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="asnd:ConvertibleNotesCurrent" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">608,877</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-style:italic;font-kerning:none;min-width:fit-content;">Other current liabilities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2dcad403-a876-4a62-b817-7095b7bbe6de" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:ShortTermBorrowingOther" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">40,398</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03079570-0d24-4c8b-b6c4-78a0540bdc75" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="asnd:ShortTermBorrowingOther" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">33,329</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a95111a1-a025-4e81-a09a-fdfd9617d6fc" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,190</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c22a0164-0755-4863-8c2a-be533f4bb661" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">936</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1cf85990-c4e1-48e7-a7f1-99a90868d248" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,370</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ddbbd8fc-3631-4fd3-a6ec-63ed035a898b" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,394</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">10</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0da8e3fd-bdab-429e-b2ca-fd527185f160" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:OtherCurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">38,062</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a597b8d9-d692-4d75-806a-735ada7325de" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:OtherCurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">67,956</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income tax payables</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_436b4487-b105-4425-8344-0975eb3cf6a3" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,573</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_02aa0275-a410-42e2-84bd-30a22958ab34" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentTaxLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,222</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provisions</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e56774fb-a74a-47ff-aa45-cac0d42c9b09" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,772</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbc42b50-66f6-4da9-a250-a51e10e54e3a" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">99,149</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b881e958-e8cf-4fe8-ae70-263e93196401" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:OtherCurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">261,365</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08fa6aa8-bd86-4c9b-8252-8ebee5987701" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:OtherCurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">298,986</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05642524-f1e0-428b-86d4-9f5cc9173366" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">885,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_775f8892-781e-4e7c-b104-0a16f1512816" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">907,863</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ad08ebed-f4d7-4ecb-8e08-95bab613b7aa" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:Liabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,251,245</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb3e32f2-ad26-4193-bd3e-2a98011c6687" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:Liabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,285,201</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total equity and liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:middle;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_088a18d9-ac12-4291-87ad-b33b03d041b1" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:EquityAndLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,061,438</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_921b3e54-0974-4f61-9de5-64a50b1a01ec" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:EquityAndLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,179,495</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="tx355617_5"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited </span><span id="una_cons_inter_state_of_chan_in_equity"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Condensed Consolidated Interim Statements of Changes in Equity as of March 31, 2025 and 2024</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39.808%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Distributable Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share<br/>Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share<br/>Premium</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury<br/>Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Foreign<br/>Currency<br/>Translation<br/>Reserve</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity as of January 1, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d3db7f86-8d28-460a-9440-4ab47e7050dd" contextRef="C_a904418f-a475-4203-9ad0-fc0801b5f9a8" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,149</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4b4bf6d0-806e-4c00-b27b-c1e329efe5ca" contextRef="C_d0d9b779-1a60-4cc4-a381-04a9bc619b06" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,444,175</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97c8b315-09cf-4455-9c74-059630286fe1" contextRef="C_7c0a269e-a617-410a-a9a6-957f53860b47" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26e54fa2-ae81-4130-8741-36f13ca54f93" contextRef="C_226651eb-e9b1-44d1-82dd-4b5f380929d8" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,783</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1691dc2c-d3cd-4e1c-9b6e-dc3008647c92" contextRef="C_8e42c784-999f-4c5e-ad5c-d7c4484f02e6" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,559,700</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_371462b7-1097-4a3d-9970-25c113da8ce2" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">105,706</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_250a7375-e2dc-42d9-b86c-bc7fa3e9a803" contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_23953e66-2211-4130-99d2-0cd65b0429f9" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss), net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55b9f4d4-eba0-4e72-8395-9ca2f066155d" contextRef="C_53d7776f-82d5-4f1e-a852-ddb489a39552" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf327139-9977-447d-ad58-25cf5a0fd271" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income/(loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5c9d277-663e-47cc-b1a4-bd870744a0a3" contextRef="C_53d7776f-82d5-4f1e-a852-ddb489a39552" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">75</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ead8e43-0ee8-47ad-b74c-d5798315c387" contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87437602-7f31-4a48-9e26-0d73c9cd223e" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,701</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transactions with Owners</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment (Note 7)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2615997d-9e43-41b3-b1bc-98d90a6b8de6" contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,558</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cbcc3102-56aa-4d98-8946-8a497d70d32b" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,558</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of treasury shares (Note 9)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b795aff1-373f-4ed1-a045-228fa4cbb647" contextRef="C_d6ec2449-d89f-452d-9858-a0c38174ef96" name="ifrs-full:PurchaseOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ec6e113f-636b-4211-be9e-b67b1eee769a" contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281" name="ifrs-full:PurchaseOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,380</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7f0cf22e-d97e-4298-bd9c-1e30f8e2fc9d" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:PurchaseOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,396</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transfer under stock incentive programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e956ae6-ca0c-402d-968e-565720a7eef9" contextRef="C_d6ec2449-d89f-452d-9858-a0c38174ef96" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08d4ba98-06b1-43c6-a6b6-418f0794e2f5" contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net settlement under stock incentive programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e67a78b7-e9b0-4cd2-a640-c8ab721671a8" contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281" name="asnd:NetSettlementUnderStockIncentivePrograms" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,396</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b55fd53b-fc08-4745-8456-45a249ba4317" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:NetSettlementUnderStockIncentivePrograms" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,396</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital increase (Note 8)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2a28a812-9ff1-4c79-8597-dd930c0d0956" contextRef="C_ff410c6d-6879-4a59-a3ae-5c1857693086" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">38</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e6437c33-a44e-4923-80e7-c25fb69c7db8" contextRef="C_65c9897b-d13e-4f01-a77c-114baa4945b3" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,796</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b317c03-67c1-42fa-8cb6-314a59e6123e" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,834</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity as of March 31, 2025</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0905e98d-fa33-48ad-96fd-7d0397bea481" contextRef="C_a4ee514e-86ba-4531-8150-a8cfaa788eb8" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">8,187</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a985ab4-87a0-4e8d-bb09-ec765f2a7a9b" contextRef="C_76d949ec-eebb-4b57-b947-ed0df0081070" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,457,971</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5317c889-c295-487b-9505-ed756c81be38" contextRef="C_cbd88d82-c8c4-4bcf-bb15-ad99f773c0e4" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2550266-a050-4c1e-99ef-c357edc2a5ca" contextRef="C_f8d4e6cd-e972-4517-950c-c2e4ca607adc" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,708</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34f86f73-3b96-4705-bc5c-1afa3b6c4849" contextRef="C_83ada807-1cec-4221-a92a-f07c205009a0" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,657,593</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7e2d8af0-eb7d-4f43-9f77-1f69b9814a30" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">189,807</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:39.808%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:6.941%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:7.481%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Distributable Equity</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share<br/>Capital</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Share<br/>Premium</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury<br/>Shares</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Foreign<br/>Currency<br/>Translation<br/>Reserve</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Accumulated<br/>Deficit</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="22" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity as of January 1, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ef7b1dda-1421-40d1-b2b9-f84616de9280" contextRef="C_c4e71d44-6541-42a1-b85a-412e5d5807d3" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,749</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3646271b-26cc-4c86-91fa-c621a5b492d5" contextRef="C_1376235c-5b88-401d-85b1-b3795ce9a8cc" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,123,074</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_83822012-a219-48be-b114-e14bd1aa70c6" contextRef="C_4e24ca41-f7d8-4b85-bcc0-e6602bf707f4" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">146</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cb5ebdca-7f79-4ce7-a629-8de6294bd1c8" contextRef="C_866661ff-8c14-41eb-b4d7-4a85755a6b03" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">721</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b0ebea4a-f61f-4763-bdf6-67e9f5258cb2" contextRef="C_c21b8c71-d449-4b9c-a8e1-039a12e96fc6" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,277,095</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a42e8cc0-ba6b-483a-a96f-fa0d984c2a6d" contextRef="C_17a14604-dfe5-4082-bab4-5778ed12841c" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">145,697</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da758bc8-d9a0-45a3-96d0-480d2bded778" contextRef="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b77db574-38a8-4dfa-bef4-a93bda9d4845" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other comprehensive income/(loss), net of tax</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0606d50d-f5a4-4065-89a3-7d0cd2753757" contextRef="C_6d2a3784-98f4-4b88-81d4-8cfaf226f5fc" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7aae737c-5875-4de5-976b-6a1e442c3778" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total comprehensive income/(loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d532bad1-2a86-4bd0-8e0d-cd6f247699d2" contextRef="C_6d2a3784-98f4-4b88-81d4-8cfaf226f5fc" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">63</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3082c5f6-efbb-4be9-a292-d109a05a99da" contextRef="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b6219bf-1032-4593-b7e8-58cdbd2b23d9" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ComprehensiveIncome" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">130,972</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Transactions with Owners</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment (Note 7)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9db77b79-0fc0-4ff6-b9e1-0e7a0b542b6d" contextRef="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,281</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e3e49c1a-d08c-4a7d-a9ed-afbf112b3159" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,281</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transfer under stock incentive programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7032d2a9-d820-4441-be02-7e077376b235" contextRef="C_a9ccce3c-1020-4eff-921e-177f04314020" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ee34a1c9-97dd-4bad-bb73-ca051d06b72b" contextRef="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c" name="ifrs-full:SaleOrIssueOfTreasuryShares" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">28</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Capital increase</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c24cabdb-3e34-421c-a60b-f01692346ebe" contextRef="C_98da32b7-acae-4c20-a13b-26ca6c11a9ae" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">69</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a459a0d-680e-44f6-996f-f263d5cc9d14" contextRef="C_4f687d92-bd5b-418e-bafe-85fdef35c02e" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,140</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_660f40bf-6814-4a9c-a356-83fe06cc90c0" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,209</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Equity as of March 31, 2024</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ad6c852-45f1-4ef0-b8ed-0c3a9af2d6eb" contextRef="C_41423738-faf9-4d2a-bcc1-37650e709689" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,818</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_75a21b35-7ad1-43d2-a295-596936c82097" contextRef="C_8dd8b82a-4cc6-45e8-bd7c-3ba7efecfb55" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,144,214</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_08e212cc-f7d9-4477-bddc-e5d15bc961a5" contextRef="C_95321c00-437c-4833-bb27-d621eaa3e8b8" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_55960f7c-5d32-4520-928c-f820af24e848" contextRef="C_62ad3de7-4eca-483d-b815-5062d2cbf5a5" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">784</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85329f3c-92a9-4833-9436-466d609da408" contextRef="C_9f6f334e-9595-42e6-a9bd-d1e679cfd8ad" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">2,390,877</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-kerning:none;min-width:fit-content;">(</span><span style="font-size:9pt;color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e2206e9-67b4-4893-90c6-0c16d6cfd4b6" contextRef="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4" name="ifrs-full:Equity" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">238,179</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;" id="tx355617_6"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unaudited Condensed </span><span id="unaudited_co_consolid_interim_cash_flow"></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Consolidated Interim Cash Flow Statements for the Three Months Ended March 31, 2025 and 2024</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:66.967%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.357%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1.16%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:13.357%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53765ade-166e-400c-8a74-275c299c7d6c" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">94,626</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_307dba81-ac9f-4d25-a288-ab210220d68a" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProfitLoss" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">131,035</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reversal of finance income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2cc0650-87f3-4d22-839a-6ccd7e41ef4b" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">28,854</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_34054e9b-82da-42a5-8ea2-614325791208" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:FinanceIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,575</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reversal of finance expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ae8420b7-6db8-4747-be2b-46b4e81449f1" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,786</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1a848538-4f5d-494e-92dd-f090165087df" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:FinanceCosts" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">77,161</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reversal of (gain)/loss on disposal of property, plant and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7c631ea-3e2c-4e2e-bde3-9b6c48c6e243" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_114b354b-59f1-48b4-aaad-ec4cc7a980d6" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">91</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Reversal of income taxes</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_97f33022-75f2-484f-aa12-905c9cc46ea8" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,061</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_41f6ea0b-9924-4642-b82b-35c30611ade9" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:IncomeTaxExpenseContinuingOperations" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Adjustments for non-cash items:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-cash consideration relating to revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fae34957-34a9-405c-8b87-233f79d115da" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:AdjustmentsForNonCashConsiderationRegardingRevenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,402</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31cad99d-0faa-440c-a112-38c016f57331" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="asnd:AdjustmentsForNonCashConsiderationRegardingRevenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,770</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share of (profit)/loss of associates</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b2eeae59-53e9-427a-9587-532e9d6257e8" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">26,579</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f2d157f2-971f-4ff3-87fd-5893c458b0ae" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,796</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Share-based payment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_de8a394d-d7ae-48a9-bb1d-946715dccf8e" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">25,558</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6d36d971-f717-4cb6-a2c0-ac9b5f5ea8db" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForSharebasedPayments" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,281</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c83f99b7-30f7-479e-ae6a-a922a03579b5" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForDepreciationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,426</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_44486be0-9b01-4683-8bee-dd2f3ef4cec0" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForDepreciationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,359</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment of property, plant and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2c3b8f3-6c84-4ffc-822d-e0fe43628ba9" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,508</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9fb4dd5d-ccdf-43da-812d-36d7b4ff6068" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f04b6a8b-b2e4-4e88-98a9-546fca4fc6ef" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForAmortisationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">119</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_af351725-3250-4f0e-9c39-5b9498ef00b2" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForAmortisationExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">118</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Changes in working capital:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Inventories</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ede7b8fe-0fa9-4b2b-8076-1caf6323813a" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,538</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c900aa32-f9b7-4567-8f46-33d0dfbf520c" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">23,750</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Receivables</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_076e5154-0239-4171-bd7a-50c62f7c2949" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">98,032</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_638a433e-be8a-48dd-ad1b-0faf0e08d885" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">11,286</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Prepayments</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0cc67f51-d5d5-4788-95c3-7933e5fa5390" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">5,521</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b9edacc-a146-44aa-a539-0fef8a0721f0" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">3,904</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Contract liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_372981b2-9b9d-424c-a1d2-ab9f58c032c5" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">4,054</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5b056389-f721-4a1c-affa-bc08647e3f90" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">950</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_89dcffc1-8a83-454b-a714-8dcb1974ef33" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">40,767</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b72c249b-3861-425f-b52b-7e83ba73e8c1" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">19,025</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Provisions</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d05c361a-2b6a-4de3-81f9-f9b040e7fa43" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:AdjustmentsForProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">260</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6ceacd0f-8f5e-4885-92c8-bf70505a3290" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:AdjustmentsForProvisions" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,076</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows generated from/(used in) operations</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ff4ec38e-72cd-4b5e-a85c-317039030df0" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:CashFlowsFromUsedInOperations" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">17,515</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9350fb55-04b4-4799-a872-3d3aa711c4a3" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:CashFlowsFromUsedInOperations" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">104,087</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income received</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4ea1124-395d-485f-b6a0-7ff4ec45cbb5" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,208</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_959e86c0-6afb-4760-915c-dbb6554b83be" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,588</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance expenses paid</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5054e018-e6e3-4e1f-b539-2dceb292fb69" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">954</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84e4f7be-b75c-46ed-a57a-50a211f73e9f" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">877</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Income taxes received/(paid)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_faee241f-e336-4d76-8a77-a1a5f5a61428" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">52</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d769db85-e133-49b1-aa9f-7b6cb0bbc260" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">206</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b1ec8993-35a3-4616-9d44-f412fb9e6be0" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">14,313</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8296eae3-3921-4c6b-acf5-ebc3d7600102" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">101,582</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of intangible assets and property, plant and equipment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_481b0b49-0f1c-4c62-874b-1d04d12a753f" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">703</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_465d0eb7-c531-4acd-885b-67770266c15c" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">199</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settlement of marketable securities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_91b2e269-ab2e-460d-bc1f-a76d6a37d83a" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18fa620b-9260-4d91-b668-8cff558ada8b" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,354</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df935dbf-8d23-4159-a58d-b1715d4a4094" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">703</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_381226d6-2378-4fb4-abe8-aefbfe973dad" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">7,155</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Repayment of borrowings</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3467c572-7470-4dda-bf77-f197c6d0d3ef" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,066</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffbe77b3-2146-4a28-b50c-275fb52b3ebe" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,786</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Proceeds from exercise of warrants</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cf5415a4-06cf-4cad-a2b5-10d6c13524c3" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">13,834</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7677515-2b66-45e1-aaf2-34c20284984c" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:ProceedsFromExerciseOfWarrants" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,209</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquisition of treasury shares, net of transaction costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0491fa69-4b94-4335-860e-79b939bd927d" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:PaymentsToAcquireOrRedeemEntitysShares" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">17,396</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Payment of withholding taxes under stock incentive programs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a7712fe-afe6-4f0d-aacb-cf98980913a7" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">11,396</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_356e046b-8455-4161-a038-069d6d9245c3" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">18,024</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c041424-9f31-495c-85c7-1484f2ca4500" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">18,423</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Increase/(decrease) in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7357538-65b6-45b4-b90c-b3dda4973ad9" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">33,040</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_881b0baa-d6e9-455a-93dc-69cb58f7647f" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">76,004</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at January 1</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a0ac9270-b735-46b3-b121-88792d2ac9f9" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,543</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_113b6618-6985-4dfd-b75b-037d86537909" contextRef="C_17a14604-dfe5-4082-bab4-5778ed12841c" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">392,164</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Effect of exchange rate changes on balances held in foreign currencies</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cc6bfe71-8e2e-4533-a70c-12d0891b355f" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">8,580</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_43824fec-bcd0-4fab-9731-148b63caa01e" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,079</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at March 31</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da9e20dc-920f-41f9-a794-45bf9da48607" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,923</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3b9f6b6b-6dcb-43f2-90a9-f8caf4781514" contextRef="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,239</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents include:</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Bank deposits</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a9c36755-4a29-4201-b4df-9012b4f9c2e9" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:BalancesWithBanks" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,923</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_685c830e-5837-416b-95ae-22072a979463" contextRef="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4" name="ifrs-full:BalancesWithBanks" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,239</ix:nonFraction></span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash and cash equivalents at March 31</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a41fdf8-eca1-4c8d-a905-a3e918e21647" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,923</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_88045699-9041-40cd-8c40-cc675eef0110" contextRef="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">320,239</ix:nonFraction></span></p></td>
     <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Notes to the Unaudited Condensed Consolidated Interim Financial Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b4a6956c-1b89-465f-b490-91eca49c4776" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;" id="notes"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">te 1&#8212;General Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S, together with its subsidiaries, is a global biopharmaceutical company focused on applying its innovative TransCon technology platform to make a meaningful difference for patients. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Ascendis Pharma A/S and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The address of the Company&#8217;s registered office is Tuborg Boulevard 12, DK-2900, Hellerup, Denmark. The Company&#8217;s registration number in Denmark is 29918791.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#8220;ADSs&#8221;), representing the Company&#8217;s ordinary shares, under the symbol &#8220;ASND&#8221; in the United States on the Nasdaq Global Select Market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved these unaudited condensed consolidated interim financial statements on May 1, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_6042c995-1c53-433b-a94a-35a465af8226" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" escape="true" continuedAt="F_6042c995-1c53-433b-a94a-35a465af8226_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2&#8212;Summary of Material Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_756faa6e-da4e-47fa-9121-ffde483d87b7" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements for the year ended December 31, 2024 and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#8220;IASB&#8221;) and as adopted by the European Union (the &#8220;EU&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_e4153f92-69f1-48fa-b0b6-2b2fa51a7947" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations" escape="true" continuedAt="F_e4153f92-69f1-48fa-b0b6-2b2fa51a7947_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New and Amended IFRS Accounting Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, the IASB amended IAS 21, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to help entities determine whether a currency is exchangeable into another currency and which spot exchange rate to use when it is not. These new requirements apply for annual reporting periods beginning on or after January 1, 2025. The Company does not expect these amendments to have a material impact on its operations or financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New IFRS Accounting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discontinued operations.</span></div></div></ix:nonNumeric></div></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_6042c995-1c53-433b-a94a-35a465af8226_1"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_e4153f92-69f1-48fa-b0b6-2b2fa51a7947_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unaudited condensed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:continuation></div></ix:continuation></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e6d7c98d-fd47-4637-a63c-2fd057423da0" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3&#8212;Significant Accounting Judgements and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the application of the Company&#8217;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unaudited condensed consolidated interim financial statements do not include all disclosures for significant accounting judgements, estimates and assumptions, that are required in the annual consolidated financial statements, and therefore should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#8217;s ongoing revisions of critical accounting estimates and underlying assumptions have not revealed any material impact in any of the periods presented in the unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the application of significant accounting judgements or estimation uncertainties regarding accounting estimates compared to December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_6586aab1-d732-4ced-ad59-04c0df71db4b" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:SignificantEventsInTheReportingPeriodTextBlock" escape="true" continuedAt="F_6586aab1-d732-4ced-ad59-04c0df71db4b_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 4&#8212;Significant Events in the Reporting Period</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals Initial Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 20, 2025, VISEN Pharmaceuticals (&#8220;VISEN&#8221;) announced the pricing of its initial public offering (&#8220;IPO&#8221;) on the Hong Kong Stock Exchange. The IPO closed on March 21, 2025, and VISEN&#8217;s shares began trading under the stock code 2561.HK.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s investment in VISEN is accounted for using the equity method in the consolidated financial statements as the Company has determined that it has significant influence over the investment. Following the IPO, the Company owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a92a0131-d30f-4f94-96d9-4ab3ffa14b37" contextRef="C_685d7bbe-e597-4efe-81c5-62074784e614" name="ifrs-full:ProportionOfOwnershipInterestInAssociate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">39.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in VISEN. As a result, a non-cash gain of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b31dfd38-913c-44ab-888a-936f59c85de4" contextRef="C_685d7bbe-e597-4efe-81c5-62074784e614" name="asnd:NonCashGainRecognizedOnOwnershipInterestInAssociate" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">33.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized in the consolidated statement of profit or loss as part of share of profit/(loss) of associates. The IPO did not change the accounting treatment of VISEN. As of March 31, 2025, VISEN&#8217;s share price was HK$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5ce0f466-d439-43f4-aa6e-cbce7c34cf13" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:SharePriceOfEntity" unitRef="U_HkPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">53.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, reflecting a total market value of the Company&#8217;s equity position of approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eee8b18c-fb86-4f8a-92dc-c25bab3608c8" contextRef="C_990b5b82-ee02-43ea-90c9-a7eeb3873527" name="ifrs-full:Equity" unitRef="U_EUR" scale="6" decimals="-6" format="ixt:num-dot-decimal">260</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the carrying amount of VISEN using the equity method was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_697e5323-f443-4dfe-8b87-ed417ce7c5e3" contextRef="C_990b5b82-ee02-43ea-90c9-a7eeb3873527" name="ifrs-full:InvestmentAccountedForUsingEquityMethod" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">28.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The management and existing shareholders of VISEN, including Ascendis Pharma, have entered into customary lock-up agreements restricting the sale of VISEN shares for six months following the IPO; </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad7a215e-fd83-4b79-a692-a32ba8d41011" contextRef="C_ef94f77b-e835-49b6-9fa5-da367d813217" name="asnd:SharesAgreementDescription"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additionally, certain significant shareholders of VISEN, including the Company, are subject to an additional lock-up obligation during the period commencing on the date that is six months after the IPO and ending on the date that is 12 months after the IPO during which such shareholders may not sell shares of VISEN to an extent that would cause such shareholder to cease being a controlling shareholder of VISEN pursuant to applicable listing rules.</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Repurchase Program</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 12, 2025, the Company announced that the Board has authorized the Company to repurchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_05f1b3c8-4dec-4345-85a8-bd690c40c142" contextRef="C_d09921c8-e6c9-41c6-87a5-4292b2ecb35e" name="asnd:PaymentForRepurchaseOfShares" unitRef="U_EUR" scale="6" decimals="-4" format="ixt:num-dot-decimal">18.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s ADSs, each of which represents one ordinary share of Ascendis Pharma A/S (the &#8220;Share Repurchase Program&#8221;). On March 4, 2025, the Share Repurchase Program was fully executed in compliance with Rules 10b-18 and 10b5-1 of the Securities Exchange Act of 1934, as amended.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company was authorized to repurchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_648bef5d-818c-4760-8028-e109124055bb" contextRef="C_2e1b63bd-d863-46b8-8fa6-18b4bf555975" name="asnd:SharesAuthorizedToRepurchase" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">1,726,015</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company's ADSs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holding of treasury shares is disclosed in Note 9, &#8220;Treasury Shares.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment on Property, Plant and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> includes an impairment charge of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_92828342-a026-4a20-859b-5e7f08dd404b" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">7.5</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, related to change in activities at one of our sites in the U.S. and is included as part of research and development expenses, and selling general and administrative expenses.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6586aab1-d732-4ced-ad59-04c0df71db4b_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the unaudited condensed consolidated interim statements of financial position presented a negative balance of equity of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d9e1a13b-9584-4e4d-91f7-b74b44a743d3" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:Equity" unitRef="U_EUR" scale="6" decimals="-5" sign="-" format="ixt:num-dot-decimal">189.8</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company, holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on its current operating plan, the Company believes that the existing capital resources as of March 31, 2025, will be sufficient to meet projected cash requirements for at least twelve months from the date of this report. However, the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s operating plan may change as a result of many factors that are currently unknown, and the Company may need to seek additional funds sooner than planned. Further details regarding borrowings including maturity analysis are provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_31d86558-77a6-4be7-a7c2-5fd995553c34" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfRevenueExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 5&#8212;Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9423c522-76af-4479-b2d3-be62831a76f8" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" escape="true" continuedAt="F_9423c522-76af-4479-b2d3-be62831a76f8_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss with the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df03be5f-61e6-4231-a5c4-a0bb23dc3bf5" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8291bd2e-06b3-4902-b276-b214457599d1" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,499</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rendering of services and clinical supply</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b9aba91d-b641-48c7-8b36-938f156c8f31" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:RevenueFromRenderingOfServicesAndClinicalSupply" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,524</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c92dc3cd-a29f-4e9a-b7ee-cfbe7b63fe50" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="asnd:RevenueFromRenderingOfServicesAndClinicalSupply" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,625</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e90120d2-5516-41fa-b4bb-e224547ef208" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,402</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4862a4f7-4bb7-4910-a692-702a10978c9f" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:LicenceFeeIncome" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">24,770</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64102551-5fa4-4dfd-b062-4e654dc9e321" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,954</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10c7658e-3d33-4608-b6d1-de9bd6892b52" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,894</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified per geographical area</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cce6caaa-dd7a-4e9d-a0aa-edd0e8823674" contextRef="C_99940134-84fa-4775-8956-5bbfab5ab4d4" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">21,328</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_350103fd-5724-4859-8c7a-e0f32aa99dba" contextRef="C_e98d5d36-1e29-442d-a2a2-e8e647fa92b3" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,567</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_53b521f1-f0bc-4a40-b891-701e079c8990" contextRef="C_76e6e803-d4db-4b29-9ab8-219028b47903" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">73,686</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bb2b500b-4124-4326-84d8-f117c7cbac57" contextRef="C_d394cb1a-3b0a-4dbc-a6eb-8741f78af1f4" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">92,681</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rest of world</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_006564ed-48ad-4c02-a7ac-edf823904223" contextRef="C_9cac6737-58ef-4123-8b45-22b55e55c632" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">5,940</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_19d125a2-7c64-4726-925d-d1558c888b11" contextRef="C_043c9c52-1128-4558-9421-751a6d2b10ae" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,646</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_512b3bc3-ee95-4f99-9dd4-382f16d1b77a" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">100,954</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ada2b7ef-ba1b-4f74-a63f-f6a61b72c439" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:Revenue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">95,894</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="font-size:9pt;font-family:Times New Roman;"><ix:continuation id="F_9423c522-76af-4479-b2d3-be62831a76f8_1"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025, Denmark, the country of domicile, contributed with &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6a3dcf1b-da28-46a8-a515-0ff70d878fdc" contextRef="C_da6b292e-7c16-4b6b-be4d-1a791f59c406" name="ifrs-full:Revenue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">2.4</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue. For the three months ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5e2da064-d99f-4dee-8908-3715075cdc97" contextRef="C_4a87b703-b453-4069-82f0-40f1f09886fb" name="ifrs-full:Revenue" unitRef="U_EUR" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue was attributable to Denmark.</span></ix:continuation></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Commercial Products</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_309a20fa-0dec-4ac2-adf4-435d7c0325db" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:DisclosureOfRevenueToCommercialProductsExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sale of commercial products were as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue from commercial products</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SKYTROFA&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_df33290c-3945-4ea4-be15-0cbdb7fff40c" contextRef="C_6f20e6a7-a161-4a7a-8def-bd1f1b851f84" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">51,340</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_54b23a34-22c7-4490-b322-e7ea2003b839" contextRef="C_8782f887-b4d8-4794-87db-2dcfd88fdd71" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">65,005</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">YORVIPATH&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d56a1195-7c3e-45f9-b29d-6ad76f899895" contextRef="C_ce5fb7a1-960a-40b8-96ca-a59d1361c834" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">44,688</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cab843f3-68c7-4113-a571-fb4731bc2a6d" contextRef="C_c79f5454-5ba5-4cc3-9ef2-650e50056d2e" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,494</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue from commercial products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4516e69b-173d-46cd-9d36-04ae0111752e" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,028</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fcb5aa6a-76db-402d-9d60-091c666a7b1c" contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20" name="ifrs-full:RevenueFromSaleOfGoods" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,499</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the Company has established an integrated organization to commercialize the Company&#8217;s approved Endocrinology Rare Disease products, SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In Europe, the Company is expanding its presence by building integrated organizations in select countries (&#8220;Europe Direct&#8221;), where the Company has launched SKYTROFA and YORVIPATH. Beyond the U.S. and Europe Direct, SKYTROFA and YORVIPATH may also be sold through exclusive distribution agreements with geographic market leaders (&#8220;International Markets&#8221;) and under certain strategic collaboration agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YORVIPATH and SKYTROFA is approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and authorized by the European Commission (&#8220;EC&#8221;) and other regulatory agencies. The Company began selling YORVIPATH in Europe in the first quarter of 2024 and in the U.S. in December 2024. The Company began selling SKYTROFA in the U.S. in the fourth quarter of 2021 and in Europe in the third quarter of 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other revenue is attributable to collaborations and license agreements, and relates to Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;), Eyconis, Inc. (&#8220;Eyconis&#8221;), Teijin Limited (&#8220;Teijin&#8221;) and VISEN. Under the collaborations and license agreements, the Company provides various research and development services and clinical supply. Costs associated with these activities are presented as cost of sales in the unaudited condensed consolidated statement of profit or loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_730fd49a-dece-476f-92ad-efa8d0359d6e" contextRef="C_d39182d1-57bd-4617-8a6a-98d8b663a8a6" name="ifrs-full:RevenueFromContractsWithCustomers" unitRef="U_EUR" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue from royalties or milestones has been recognized under the collaborations and license agreements.</span></p></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bcc74714-b748-4d15-84fe-69fc371dee23" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 6&#8212;Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bebca6b8-0bac-4e9c-bbf6-446beaf1861b" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:NumberOfReportableOperatingSegments" unitRef="U_Segment" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 5 &#8220;Revenue.&#8221; Revenue is specified on geographical areas according to the location of the customer.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_9036335c-5df1-4579-8dcb-83a6c6fdd535" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" escape="true" continuedAt="F_9036335c-5df1-4579-8dcb-83a6c6fdd535_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 7&#8212;Share-based Payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a Restricted Stock Unit (&#8220;RSU&#8221;) program adopted in December 2021, and a Performance Stock Unit (&#8220;PSU&#8221;) program adopted in February 2023, which are all classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based Compensation Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation costs are determined using the grant date fair value and are recognized over the vesting period as research and development expenses, selling, general and administrative expenses, or cost of sales. For the three months ended March 31, 2025 and 2024, share-based compensation costs recognized in the unaudited condensed consolidated interim statement of profit or loss were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_3457be94-807a-44ad-ae21-1eac8a8178e1" contextRef="C_ed9a4cd9-a9ca-454a-9615-64678e2fdefe" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">25.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_2f4b9fc3-544a-40cb-bed9-ec3d5a63e3a4" contextRef="C_5b83b77f-547e-42d3-9a2c-5c6ae9438f49" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">17.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are granted by the Board to members of senior management, other employees and members of the Board (the &#8220;RSU-holders&#8221;), as stipulated in the program. In addition, RSUs may be granted to select consultants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One RSU represents a right for the RSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting, if the vesting conditions are met. RSUs granted vest over three years with 1/3 of the RSUs vesting on each anniversary date from the date of grant, and require RSU-holders to be employed, appointed as member of the Board, or retained as a consultant (the &#8220;service conditions&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs are granted by the Board to certain members of senior management (the &#8220;PSU-holders&#8221;), as stipulated in the program. In addition, PSUs may be granted to other employees, select consultants and members of the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_30f79539-83a3-4d4b-a28b-8eb309721bd8" contextRef="C_7dc36b02-c138-4fcc-b62f-16eb456e91be" name="ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1acd3baf-0a91-435f-9143-032c7d4b3377" contextRef="C_909af02d-d3e3-49eb-8ac9-f629568438a7" name="asnd:PercentageOfVestingRightsForShareBasedPaymentArrangement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:num-dot-decimal">100</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, nor will it result in additional grants. </span></ix:nonNumeric></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU and PSU Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ef17e5e0-41e5-4266-b392-69f91a752f64" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number of outstanding RSUs and PSUs:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.423%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.164%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.164%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.244%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5eca3eb-d370-4b6e-be77-8e2614e032b1" contextRef="C_084e81ae-053b-4124-8ea0-cf00fb92aefd" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">993,807</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a49653eb-c072-4754-8891-78bf7d6751f3" contextRef="C_06503dc6-abee-4161-b4cf-ae017326cf5f" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">156,667</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e8a81a8c-c8bb-448b-851e-1770f7dc6e7d" contextRef="C_f1cc25de-2681-466f-9005-4cacf85b0437" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,150,474</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ce1a870-c7e7-40bf-be76-00061ed8d00a" contextRef="C_79d64e56-848d-43de-a89c-390b0257c619" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">634,589</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_52393215-83ed-45aa-af4c-07212acd71e4" contextRef="C_975c08fa-b467-40ed-8b0f-240242f397d5" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">73,583</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5dc97203-13b1-4f78-a135-1a6ef3393f81" contextRef="C_84ecf827-5c4e-400c-9fed-cfb85e09d515" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">708,172</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settled during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b179bd8b-f46c-440a-a51b-4d16f3db535f" contextRef="C_79d64e56-848d-43de-a89c-390b0257c619" name="asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">60,056</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3136ce89-6bb1-44d6-9daf-01e7592481b9" contextRef="C_975c08fa-b467-40ed-8b0f-240242f397d5" name="asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">15,716</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eaf9212d-03a7-49c9-8b3d-f9a39123eb49" contextRef="C_84ecf827-5c4e-400c-9fed-cfb85e09d515" name="asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">75,772</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d60cca9-fdf0-4f0e-9567-6c807a01851f" contextRef="C_79d64e56-848d-43de-a89c-390b0257c619" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" sign="-" format="ixt:num-dot-decimal">321,392</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_eb9d92f6-fbe5-4fc4-9a71-baa70f8527cc" contextRef="C_975c08fa-b467-40ed-8b0f-240242f397d5" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" sign="-" format="ixt:num-dot-decimal">46,588</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b53532de-ca9a-4c1d-8748-5198696a70b7" contextRef="C_84ecf827-5c4e-400c-9fed-cfb85e09d515" name="asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" unitRef="U_pure" decimals="0" sign="-" format="ixt:num-dot-decimal">367,980</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a465a7c-f773-4e0a-8756-6fb132e166fa" contextRef="C_79d64e56-848d-43de-a89c-390b0257c619" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">25,760</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_74416a83-694e-475a-a366-fe6d7afe9a4d" contextRef="C_975c08fa-b467-40ed-8b0f-240242f397d5" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">2,688</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b3298939-fa8f-41b8-b288-e39e01541f90" contextRef="C_84ecf827-5c4e-400c-9fed-cfb85e09d515" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">28,448</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ae0d903-4966-47ef-8fb2-30500a092444" contextRef="C_9110cafd-2d7b-4304-9249-9a5b3d9c4dfe" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,221,188</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_896b7bff-1dfd-4c99-a65b-44eaf72c93c5" contextRef="C_3cb7ddc6-ca0e-4f90-83dc-2681c7bb17c0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">165,258</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d65535fe-c44a-495b-8573-74df70bec615" contextRef="C_76ef0cc1-54a9-485d-af12-f694616423d3" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,386,446</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by vesting year</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c5f63ec3-49f6-4954-abf6-da5e1d1072d8" contextRef="C_290aeeba-a386-42b8-856c-a68d382312e1" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">583,076</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e10193d0-521a-4c2a-ac66-2aaa388182d7" contextRef="C_a633f67b-4c57-46fb-bcde-1a16d86b23b4" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">86,659</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c05b1662-9218-4796-8fcc-ef0877c8c919" contextRef="C_04aedc44-3b7e-46d5-ade6-eeb4fd969b26" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">669,735</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e74f2ec6-3fc5-455d-9424-cb5cbd8b61fc" contextRef="C_d182cba3-f8ff-423d-8e1e-a44b81fe3740" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">427,429</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a5ebb3e-a331-48b3-9d12-de8ca7beef12" contextRef="C_ee51bcae-74d0-4e67-89b0-e987214d4543" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">54,066</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7ba6ccc-09b1-4720-93b6-4b48dc131084" contextRef="C_ebf7f8d8-9a88-4b74-9ba0-b9f6929c0ab5" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">481,495</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7bc8d2c4-8442-4d8f-9255-d8aaa5fe7134" contextRef="C_2c892acc-02da-4c15-9353-950413a810ff" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">210,683</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d6090db6-21b6-43ce-b21b-037e5574c8cf" contextRef="C_434feb09-9876-4024-9170-6094ccac6b87" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">24,533</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1a9a6fc-cde5-47fa-bb51-9524812860d4" contextRef="C_36356f4b-0e07-4b7c-876a-5c08a3b2de70" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">235,216</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d2bba917-0810-45ab-bf01-0c414b490996" contextRef="C_9110cafd-2d7b-4304-9249-9a5b3d9c4dfe" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,221,188</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_972c8484-3697-46f1-b2df-7f848602b83e" contextRef="C_3cb7ddc6-ca0e-4f90-83dc-2681c7bb17c0" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">165,258</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c59728f-9923-4d56-9dd7-06bcbae7d4d1" contextRef="C_76ef0cc1-54a9-485d-af12-f694616423d3" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="0" format="ixt:num-dot-decimal">1,386,446</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants. Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6afe45ec-20fa-4af6-a87c-34bf8ad73378" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:ParValuePerShare" unitRef="U_DkkPerShare" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The exercise price is fixed at the fair market value of the Company&#8217;s ordinary shares at the time of grant as determined by the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_9036335c-5df1-4579-8dcb-83a6c6fdd535_1"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c78fd1d8-61d1-47bb-ba13-1951b6563709" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number and weighted average exercise prices of, and movements in warrants:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3803b3b4-4506-449e-9eed-a272dae5046f" contextRef="C_4ffe96aa-eccd-4c58-806f-aeb003cfacb4" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">6,204,122</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_cd26bd6a-ac61-4f29-8db3-30f70234baa6" contextRef="C_4ffe96aa-eccd-4c58-806f-aeb003cfacb4" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">93.25</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_457262cf-b84b-4b40-af3d-e91ca56be86c" contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">148,663</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2205e64d-9c27-4f9e-9087-d2d01f2849a1" contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">126.98</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4da12f65-ff98-408f-b89b-e39c4ed097db" contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc" name="ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">281,078</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3c452e75-eba4-4b26-ad17-3006e8f0aec7" contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">46.66</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38f03d8f-fac4-46ef-9553-fab918c8d12c" contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">54,550</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8529f30d-e9fa-4b37-852e-e505df9dda71" contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">95.24</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_03019cb8-1201-40b2-8065-d23b598be3fb" contextRef="C_13256690-d69b-40e3-a745-f42b7767f286" name="ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">6,017,157</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1ca80e77-7a33-44b0-9926-f38d3456961f" contextRef="C_13256690-d69b-40e3-a745-f42b7767f286" name="ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">96.26</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e4c38388-75f7-47b2-a57d-2699d999ba4f" contextRef="C_13256690-d69b-40e3-a745-f42b7767f286" name="asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_pure" decimals="INF" format="ixt:num-dot-decimal">5,057,771</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_407bac10-7321-4263-80bc-27ace6cd06be" contextRef="C_13256690-d69b-40e3-a745-f42b7767f286" name="asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">92.31</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise prices of outstanding warrants under the Company&#8217;s warrant programs range from &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_63dac866-a17e-48f8-95b0-cdef58bf90c2" contextRef="C_d979433b-7c92-4bed-ad15-dbb8a17d94f5" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">11.98</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_26b2594f-e870-404e-ae43-1f8b1460e40c" contextRef="C_935a7fad-4793-4877-9ec1-f6ddf2e4a58c" name="ifrs-full:ExercisePriceOfOutstandingShareOptions2019" unitRef="U_EurPerShare" scale="0" decimals="2" format="ixt:num-dot-decimal">145.50</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">depending on the grant dates.</span></p></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81ee1130-2f1e-4f3f-8cc8-d8a1f400b814" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8&#8212;Share Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The share capital of Ascendis Pharma A/S consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c98362e-e349-4872-8761-28c64df4ba71" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:NumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">60,970,565</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> fully paid shares at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_479112f7-7425-4766-80b4-121666cadc25" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:ParValuePerShare" unitRef="U_DkkPerShare" decimals="0" format="ixt:num-dot-decimal">1</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all in the same share class, and which includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c14eb925-35f0-4a82-8ad8-fe8240889c0a" contextRef="C_4a04a12f-c2bb-4f60-9173-69088979902b" name="ifrs-full:NumberOfSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">597,055</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares represented by ADSs held by Ascendis Pharma A/S. For the three months ended March 31, 2025, the share capital was increased with </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"><ix:nonFraction id="F_f6edb24c-a60a-401e-b5f4-5971f19fe4c7" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued" unitRef="U_shares" decimals="INF" format="ixt:num-dot-decimal">281,078</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> number of shares.</span></p></ix:nonNumeric></div><div><ix:nonNumeric id="F_9c835721-5658-4e9a-9b91-843d53230ad7" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:DisclosureOfInformationAboutTreasurySharesExplanatory" escape="true"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9&#8212;Treasury Shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f0c7503a-9634-4395-aa25-f2ea12d1f850" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfTreasurySharesExplanatory" escape="true" continuedAt="F_f0c7503a-9634-4395-aa25-f2ea12d1f850_1"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in the holding of treasury shares was as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.423%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.164%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.164%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:11.245%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>values</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc5004e9-3c8c-4b7f-84d7-b75ed9c9e325" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="asnd:TreasurySharesOfNominalValue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">113</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aff91079-71bd-450b-a06e-56e5da1a2e6b" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="asnd:NumberOfTreasurySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">845,887</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d5a28fe3-921c-4d12-b78a-2482eac39cbc" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.4</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired from third parties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d1b4c352-f5b5-41b5-b5c3-c1ef6ddeb907" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:TreasurySharesAcquiredFromThirdParties" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">16</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fc356da8-7762-4f21-b92a-4a505a87fcaf" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">119,148</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e1443069-a8ff-486f-b659-c5eb52c08cac" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:TreasurySharesHoldingInPercentageAcquiredFromThirdParties" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_66b1ca9b-c4e6-4b1c-b903-f45f1bace38b" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" unitRef="U_EUR" scale="3" decimals="-3" sign="-" format="ixt:num-dot-decimal">49</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5f4e3ae4-bdf2-4dc9-88b3-b439bbe611b6" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" unitRef="U_shares" decimals="0" sign="-" format="ixt:num-dot-decimal">367,980</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f07d747-4754-41bc-822b-17dc992d0410" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" unitRef="U_pure" scale="-2" decimals="2" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e60536d-21ed-4a67-b9d6-28c04d2c8fa7" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:TreasurySharesOfNominalValue" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">80</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_aebaa212-b5db-464a-9316-09320c8efd3a" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:NumberOfTreasurySharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:num-dot-decimal">597,055</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f7fef095-2adb-44e1-bbde-763b049db16b" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:num-dot-decimal">1.0</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></ix:nonNumeric></div></ix:nonNumeric></div><div><ix:continuation id="F_f0c7503a-9634-4395-aa25-f2ea12d1f850_1"></ix:continuation></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:nonNumeric id="F_6e82cb6c-9160-4331-9959-971e7522eaac" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" escape="true" continuedAt="F_6e82cb6c-9160-4331-9959-971e7522eaac_1"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10&#8212;Financial Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_cd3e28f8-7723-4378-b7bb-66a5e2468f1e" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial assets and liabilities comprise the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets by category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8397acdd-7623-4ea2-93cf-c8ed3d9a9428" contextRef="C_facec156-4e04-482e-8239-ca86a66ecd9e" name="ifrs-full:TradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">66,685</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8a37754d-2ea9-47eb-a898-66d4af69bdcc" contextRef="C_0180a343-84b5-4550-8e9e-0e9d94787b6a" name="ifrs-full:TradeReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">166,280</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables (excluding indirect tax receivables)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bdde90ba-57b1-405f-bf6d-59c5b5375fd0" contextRef="C_facec156-4e04-482e-8239-ca86a66ecd9e" name="ifrs-full:OtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">4,501</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6132d99f-622c-4b82-9906-0161b3a6e7af" contextRef="C_0180a343-84b5-4550-8e9e-0e9d94787b6a" name="ifrs-full:OtherReceivables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,964</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57fe67ae-82bd-4bdf-ae41-90a4115ed842" contextRef="C_facec156-4e04-482e-8239-ca86a66ecd9e" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">517,923</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8be38b6b-64ec-479b-870e-21e1078f45f3" contextRef="C_0180a343-84b5-4550-8e9e-0e9d94787b6a" name="ifrs-full:CashAndCashEquivalents" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">559,543</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3e9fe951-d476-4522-901e-a162bdc80f8b" contextRef="C_facec156-4e04-482e-8239-ca86a66ecd9e" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">589,109</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_35c27f60-a9df-4bfe-94a0-a7280de8f59f" contextRef="C_0180a343-84b5-4550-8e9e-0e9d94787b6a" name="ifrs-full:FinancialAssetsAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">729,787</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7b576df2-15ac-494a-ab92-32c8947042fc" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">589,109</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84c29880-c30b-46cb-8ad7-943f657c0685" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">729,787</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f056295-9f59-4f4f-bf9b-efd8ec086149" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:NoncurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,657</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0c088d14-dd56-4904-b32c-79508db42793" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:NoncurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">2,317</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_508b217f-8bdf-420d-b3de-1b6b6a026e61" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">586,452</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1c240fac-4cdb-4192-9a88-34e30d00bb03" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentFinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">727,470</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_deab0556-bb08-4058-8a29-79ec0b746bfb" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">589,109</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_d34ede4f-0369-4f4f-be2d-f357ec160a62" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:FinancialAssets" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">729,787</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities by category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9dadf656-1020-4039-a18d-40e6268ca053" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">449,562</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fb1938fc-74d3-45c9-86ce-b00eceb30146" contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f" name="asnd:ConvertibleSeniorNotes" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,207</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10f7c8fc-72ce-4bd7-93dc-d8be2c4e3ee5" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">303,347</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3a52b06-0a17-48d7-b150-a8ace2a57e07" contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,379</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c7abeb24-09fa-4bd7-bc21-cb124cbb5f88" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,363</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_655a4e00-e144-41be-b3a5-d7a75fb70557" contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">93,030</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dd9d2feb-a1a8-4501-85ee-246eadeb72ed" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">84,370</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2063a04b-8cad-4dbb-8be0-482f34aeca9a" contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f" name="ifrs-full:TradeAndOtherPayablesToTradeSuppliers" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">96,394</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities (excluding indirect tax, and employee related payables)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_67410072-42eb-4c24-84f2-fca79c29af6f" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="ifrs-full:OtherFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">3,870</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_46c3bddf-3f89-4b0b-b9c9-0245a94d198d" contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f" name="ifrs-full:OtherFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">311</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_65f8affb-ba2e-47ca-b2ea-152e4419d744" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">935,512</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_489a21ad-9a46-4b75-a8c5-bcffbe4a2bd9" contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">953,321</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0ee96722-3ee1-461d-a04f-67c3ff6c907a" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,581</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_fbe9e628-3538-4bc1-9bae-c9cd227495b4" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c40471c9-20c5-4ac5-bf18-a651a3523353" contextRef="C_8277197c-cb86-45e7-aa61-4d5b1f0fbafb" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,581</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_738b81d6-094f-409c-b1b5-155c4a865619" contextRef="C_b829287e-56df-49a2-b424-3fed6680c9cc" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ce07d45a-44a2-4a42-b2d0-38b547bc27e0" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,110,093</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_85b02a2b-622a-4266-8d9c-faddcda0e51e" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103,991</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3d2f9d78-7722-4691-95b4-980eb4221484" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:NoncurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">357,312</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_673d19ec-4a0b-4c84-9177-706eb728612f" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:NoncurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">365,080</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c1dc12ab-0ac6-4b91-86cd-53af6c246385" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:CurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">752,781</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b464075e-e857-43dd-a03a-75eb0fedc770" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:CurrentFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">738,911</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f35de755-ecf1-40c6-b309-7ce52964f91b" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,110,093</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8ae80e7c-c827-411a-9ef8-bfc13badc431" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,103,991</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, the Company issued an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_278bcc7f-b567-4e50-9656-ca7a09853c27" contextRef="C_f73819d7-55e0-42b4-8ce8-858bcc257ffe" name="ifrs-full:NotionalAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">575.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of fixed rate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8278bf84-7446-4f65-8556-ade5e7aaa171" contextRef="C_1d3ec492-aaf3-4c50-8780-bc2563b2b216" name="ifrs-full:BorrowingsInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% convertible notes. The net proceeds from the offering of the convertible notes were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f79f9c75-c653-4c2e-a970-5b41f89754c6" contextRef="C_08de1782-376b-48ac-8b33-acaf2bd1c052" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">557.9</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e7802c11-6d0d-4c3c-9574-804c9fe334aa" contextRef="C_08de1782-376b-48ac-8b33-acaf2bd1c052" name="ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">503.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting the initial purchasers&#8217; discounts and commissions and offering expenses. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bb9a1cfb-d468-44cf-900a-2341abbf0a01" contextRef="C_08de1782-376b-48ac-8b33-acaf2bd1c052" name="ifrs-full:BorrowingsMaturity"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2028</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes accrue interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_435e74b2-6c3a-4e1c-9577-d8a2792a585c" contextRef="C_1226e5c0-e438-4068-ae93-f55dd69d5fc6" name="ifrs-full:BorrowingsInterestRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">2.25</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#8217;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_87d32fbd-c74d-4d17-9bd0-6ccd6faecc43" contextRef="C_6df1c7ad-9308-4d74-81ba-3a4e8314fa4f" name="asnd:ConversionRatePerNote" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="4" format="ixt:num-dot-decimal">6.0118</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ADSs per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_81243061-325f-490a-9415-1ed519871b2a" contextRef="C_819dfe51-28d5-4314-9ec5-4ee09ed7b84b" name="ifrs-full:NotionalAmount" unitRef="U_USD" decimals="0" format="ixt:num-dot-decimal">1,000</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> principal amount of convertible notes, which represents an initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64a82063-f43f-4001-96b7-334a546bbe15" contextRef="C_bf7f8faa-849d-4587-84f1-bdcde1f91d6f" name="asnd:ConversionPricePerShare" unitRef="U_UnitedStatesOfAmericaDollarsShare" scale="0" decimals="2" format="ixt:num-dot-decimal">166.34</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#8217;s option at any time, and from time to time, on or after </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_045148c3-63d0-46a7-bd33-493faae562f5" contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b" name="asnd:BorrowingsRedemptionPeriod"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 7, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23f0a94b-948d-488f-9b0a-b9d99f2608ef" contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b" name="asnd:BorrowingsConditionForRedemption"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">but only if the last reported sale price per ADS exceeds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8fdc7a97-5ed6-4f95-b8d4-a86f7e46aee4" contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b" name="asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">130</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the conversion price on (i) each of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_bbaf6fb8-b78f-4f67-b1f5-9c6afb9b60df" contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b" name="asnd:BorrowingsThresholdTradingDaysForRedemption" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">20</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trading days, whether or not consecutive, during the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a7ba30d9-4fa6-4f3d-a1a3-6e263238bb90" contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b" name="asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption" unitRef="U_Days" decimals="0" format="ixt:num-dot-decimal">30</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</span></ix:nonNumeric></span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div><ix:continuation id="F_6e82cb6c-9160-4331-9959-971e7522eaac_1" continuedAt="F_6e82cb6c-9160-4331-9959-971e7522eaac_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into capped synthetic royalty funding agreements with Royalty Pharma (the &#8220;Purchaser&#8221;), which is presented as part of borrowings, and represents the Company&#8217;s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">YORVIPATH Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dca93ad5-bdac-4f72-928e-b2cd693a812d" contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8" name="asnd:FundingReceivedInExchangeOfRoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Yorvipath Agreement&#8221;) with the Purchaser. The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64e731c3-1d06-4033-97a4-c6820428fa3d" contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">148.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a82b0719-e82a-4819-8e54-3a11bf6fd3e1" contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">134.2</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Royalty Pharma Yorvipath Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_84361bda-2fd1-44e2-a95d-27b00ae888e3" contextRef="C_e21b606d-3548-4aad-9554-94ae80a18cab" name="asnd:FundingReceivedInExchange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Yorvipath Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_26199328-1862-41de-a2df-252cec2c2bad" contextRef="C_e21b606d-3548-4aad-9554-94ae80a18cab" name="asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net revenue from sales of YORVIPATH in the U.S. (the &#8220;Yorvipath Revenue Payments&#8221;). The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_ffaa9146-e14b-461f-923d-a80aee64fcea" contextRef="C_650908d3-c211-42ad-819c-acf17f2e9e86" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="1" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_b07ec019-7240-47ae-a920-d9cc92dfb10c" contextRef="C_27448f17-97d9-4695-8836-7cbae988447b" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times if the Purchaser receives Yorvipath Revenue Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_35cfc049-06ae-4162-aca9-b3030af0d102" contextRef="C_e21b606d-3548-4aad-9554-94ae80a18cab" name="asnd:RoyaltyPaymentEndingPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2029</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Yorvipath Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2b34099d-17f3-4cbd-9c37-f8720df8fde6" contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="1" format="ixt:num-dot-decimal">2.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to September 30, 2028, and the Company has paid the Purchaser, Yorvipath Revenue Payments equal to the Yorvipath Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a082efb6-cb43-4ca7-b78f-953d58272682" contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SKYTROFA Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_14a27633-56e5-411e-803a-cd2b77ca655b" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:FundingReceivedInExchangeOfRoyaltyPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Skytrofa Agreement&#8221;) with the Purchaser. The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_38857d0e-a79b-4c6f-93b5-586b1cc903ce" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">146.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_828b5753-0153-4c26-ab1c-6561ebac7dd6" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">136.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Royalty Pharma Skytrofa Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7ac467e3-7f86-4312-a076-ce4ae1132f3a" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:FundingReceivedInExchange" unitRef="U_USD" scale="6" decimals="-5" format="ixt:num-dot-decimal">150.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Skytrofa Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1fb15e28-6c5c-499a-86e2-5b463a855246" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" unitRef="U_pure" scale="-2" decimals="4" format="ixt:num-dot-decimal">9.15</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05a7e72e-1eff-495e-b35a-948d338cc2c6" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:RoyaltyPaymentBeginningPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Skytrofa Revenue Payments&#8221;). The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c31b8262-e18f-4cf0-9e9b-7bfcd589a5be" contextRef="C_36943fab-c0c6-4437-adcd-1f9a290d164c" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="3" format="ixt:num-dot-decimal">1.925</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_68f1546e-f998-4492-88ac-8f40cb901680" contextRef="C_080c73e3-b2aa-450a-ba77-af1301298b4f" name="asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" unitRef="U_Multiple" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times if the Purchaser receives Skytrofa Revenue Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_49833bd5-113f-45a0-a65a-a24791202beb" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:RoyaltyPaymentEndingPeriod" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2031</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Skytrofa Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9ab6c38a-2191-4a7a-ac84-76f78541c6cc" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="3" format="ixt:num-dot-decimal">1.925</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser, Skytrofa Revenue Payments equal to the Skytrofa Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8b0d6ad3-fabe-4a67-85ad-1aa659c44a20" contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a" name="asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" unitRef="U_XBB" scale="0" decimals="2" format="ixt:num-dot-decimal">1.65</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value cannot be measured based on quoted prices in active markets or other observable inputs, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#8217;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#8217;s share price (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9d334c57-7057-42ff-83c2-a2a973161c18" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:SharePriceAppliedForValuation" unitRef="U_EurPerShare" decimals="INF" format="ixt:num-dot-decimal">49.7</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_9745f22e-fa5b-4b9a-81a1-23344d8e69ab" contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54" name="asnd:SharePriceAppliedForValuation" unitRef="U_EurPerShare" decimals="INF" format="ixt:num-dot-decimal">49.6</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2025 and December 31, 2024, respectively).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional description of fair values, refer to the following section &#8220;Fair Value Measurement.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sensitivity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_06d19c16-6e4c-428f-96ce-df272ea5f1ef" contextRef="C_99b14b08-2c6d-4423-a4ca-73022572e1c7" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_884597a5-7946-4808-8e89-7fe4f683d33e" contextRef="C_dc16f5c8-e5a3-4b82-8f15-702a29cdd088" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">15.0</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abc426bc-de35-457e-84c7-062f224a8731" contextRef="C_99b14b08-2c6d-4423-a4ca-73022572e1c7" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% relative decrease in volatility indicates the opposite impact.</span></p></ix:continuation></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;">&#160;</p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div style="font-size:10pt;font-family:Times New Roman;"><ix:continuation id="F_6e82cb6c-9160-4331-9959-971e7522eaac_2"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, on March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1b57ae6a-62e9-4aab-ab34-046cca841848" contextRef="C_0ce1e53d-f85e-4cd5-8a39-323d29baed2c" name="ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% increase in the share price, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2ae7c441-680f-4fb1-b7db-648bca9c6d39" contextRef="C_3d08e8ed-f880-4006-95c6-262b0ebc3c04" name="asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" unitRef="U_EUR" scale="6" decimals="-5" format="ixt:num-dot-decimal">35.3</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_107c51f8-8154-414b-913c-22e2c37d736f" contextRef="C_0ce1e53d-f85e-4cd5-8a39-323d29baed2c" name="ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" unitRef="U_pure" scale="-2" decimals="2" format="ixt:num-dot-decimal">10</ix:nonFraction></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% decrease in the share price indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value of lease liabilities are not disclosed. Fair value compared to carrying amount of convertible notes, royalty funding liabilities and derivative liabilities, and their level in the fair value hierarchy is summarized in the following table, where:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are unobservable inputs for the asset or liability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bcacf43-1a5c-43fb-8717-42af7f8b2415" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" escape="true">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value level</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(1-3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_a327dfb5-4194-4911-b0d8-7d231f5717f8" contextRef="C_0ed1d82f-1028-46f4-b7d1-1a4f01140861" name="ifrs-full:NotesAndDebenturesIssued" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">449,562</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_57d4a3e6-19e9-4773-a132-28545245e5cf" contextRef="C_3b05cb12-2e51-444c-a128-f7f8902c20db" name="ifrs-full:NotesAndDebenturesIssued" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">433,666</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7443f6fb-66f1-4832-8252-4c320b5b656f" contextRef="C_ff030c5c-71d1-4446-bcd4-d002a0413fae" name="ifrs-full:NotesAndDebenturesIssued" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">458,207</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_28034750-794a-4559-9f5d-339ee9a1c3a7" contextRef="C_1c3c7589-8585-40b4-8f1e-8ae31626083c" name="ifrs-full:NotesAndDebenturesIssued" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">438,288</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_31166c82-f9e6-4591-9b28-f65757b8b55c" contextRef="C_0ed1d82f-1028-46f4-b7d1-1a4f01140861" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">303,347</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7a29f3d5-ddd1-4af3-a219-4d945da4c2d9" contextRef="C_3b05cb12-2e51-444c-a128-f7f8902c20db" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">308,018</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_8f296cc5-2c43-4332-b0fa-ff6de42e52e9" contextRef="C_ff030c5c-71d1-4446-bcd4-d002a0413fae" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,379</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_375e8fd4-eab6-45ce-9387-c50d9c6ffd51" contextRef="C_1c3c7589-8585-40b4-8f1e-8ae31626083c" name="asnd:RoyaltyFundingLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">305,673</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_504e3d70-7fd3-4a2f-96a5-6c400220cdb7" contextRef="C_41b6f38d-a596-4e87-b38c-e28360d02d02" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">752,909</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_64848f32-307b-4f88-a651-8f55bc76296a" contextRef="C_f365e58b-1e31-4938-9a9f-6ae4a53dfc7b" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">741,684</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60caf843-173f-4b66-93fe-aef016bd20a1" contextRef="C_0f12ae56-033f-4e22-8363-af8518013748" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">763,586</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_60759da4-869e-42ac-a877-1550c831ebe9" contextRef="C_d9cca70d-ddde-47cd-a1a3-3f846e0b2ad1" name="ifrs-full:FinancialLiabilitiesAtAmortisedCost" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">743,961</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_656ca7bf-4766-411d-9714-8d18c804d83a" contextRef="C_0ed1d82f-1028-46f4-b7d1-1a4f01140861" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,581</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f294cc78-7a1c-4859-9773-dba9aa5cc8fa" contextRef="C_3b05cb12-2e51-444c-a128-f7f8902c20db" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,581</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33ed9378-7462-46d7-9260-85fd05d9778a" contextRef="C_ff030c5c-71d1-4446-bcd4-d002a0413fae" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_21edf338-261e-419f-87b9-4359f93146a7" contextRef="C_1c3c7589-8585-40b4-8f1e-8ae31626083c" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_524c4142-9430-40f8-8670-9321be641fc8" contextRef="C_41b6f38d-a596-4e87-b38c-e28360d02d02" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,581</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_7c75bf25-c39c-45fe-9787-919ea1a64959" contextRef="C_f365e58b-1e31-4938-9a9f-6ae4a53dfc7b" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,581</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_20319a7b-4763-4489-940b-d704d14fd43e" contextRef="C_0f12ae56-033f-4e22-8363-af8518013748" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_1f7489e0-d85a-4f80-91e0-05db46984240" contextRef="C_d9cca70d-ddde-47cd-a1a3-3f846e0b2ad1" name="ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2457973-6a0a-402b-8b41-4c9212bb3d0d" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1.16%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:13.357%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_da29635f-1d03-46c3-b256-63276260b273" contextRef="C_faaf4bfc-6ed7-4797-9957-11c2e997c3a3" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">150,670</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c3b6daab-854c-474c-aa41-06d05dde42f7" contextRef="C_ac6e452f-b851-4366-98b0-9dbd4cb50f3e" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">143,296</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement recognized in finance (income) or expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_33d5623d-224f-40f1-ad89-b86a90d966c9" contextRef="C_a7a008d3-7a3d-4804-83b9-58bcf05b742c" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">23,911</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_42f255f6-c9b2-4e9d-971c-4bb45eb0a7f3" contextRef="C_e430f24c-0233-4114-a208-350b297af714" name="asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">53,995</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4294561e-e3d5-4d50-8e05-1061fbfaa501" contextRef="C_3c3f2d33-74af-4a32-80dc-2766d5dbca67" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">174,581</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_111430f3-ef55-4155-b731-a9a8f14a47fb" contextRef="C_90ec9194-a47f-4c6f-ba12-88ada7bf522a" name="ifrs-full:DerivativeFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">197,291</ix:nonFraction></span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></ix:nonNumeric></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Maturity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d8225212-2468-40d0-a156-27b9c894807e" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock" escape="true"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.04%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
         <td style="width:8.42%;box-sizing:content-box;"/>
         <td style="width:1%;box-sizing:content-box;"/>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&lt; 1 year</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1-5 years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&gt;5 years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_4f7ff782-ff0f-475f-8095-b8a147b782ab" contextRef="C_5eb53229-0864-44c9-9f9d-2c5f527f1088" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">39,585</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_abb6b823-0ab2-43e2-a031-ba65b5b5cda5" contextRef="C_af8ce046-66d9-47ba-a2db-115fd2735a92" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">991,636</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_0bfaeb4f-f7b8-4a42-b014-b55f540eb2c2" contextRef="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_10542aa7-99d3-45b8-9fae-f3247c694926" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,031,221</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_f0be01d7-dbd5-482f-aa86-70daf96b4049" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="ifrs-full:Borrowings" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">752,909</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c46c2666-9d2d-4e54-9e80-422f8010a927" contextRef="C_5eb53229-0864-44c9-9f9d-2c5f527f1088" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">15,129</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_142e481b-85c0-44d9-86ad-f28a93b64bca" contextRef="C_af8ce046-66d9-47ba-a2db-115fd2735a92" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">57,607</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_18d035ea-305b-4796-81de-f8f44935f39d" contextRef="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,250</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_e2e9fe2c-22da-4e50-9d52-8009e26daefe" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">107,986</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_6cb45085-beaf-4ae0-a017-a65800372e8e" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="ifrs-full:LeaseLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">94,363</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_27cf3dab-fde9-4523-93ef-04433381cfe4" contextRef="C_5eb53229-0864-44c9-9f9d-2c5f527f1088" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,240</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be9d4166-8ecc-42be-a992-97d196c0a570" contextRef="C_af8ce046-66d9-47ba-a2db-115fd2735a92" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_c233b869-7874-462e-ac22-923969e223a8" contextRef="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:fixed-zero">&#8212;</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_17c1c307-2e54-442b-93e8-fef9b167750e" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,240</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_dedbf337-a822-434c-ad82-f82ee787c26e" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="ifrs-full:TradeAndOtherPayables" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">88,240</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_3da6c1fc-70ac-450b-b58c-5839e3bb4981" contextRef="C_5eb53229-0864-44c9-9f9d-2c5f527f1088" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">142,954</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_842500e2-2f31-44c4-95dc-64feeac47053" contextRef="C_af8ce046-66d9-47ba-a2db-115fd2735a92" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,049,243</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_5cc2760a-9b2e-4291-b2d1-0ebafe0f007a" contextRef="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">35,250</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_be418eaa-d1c9-45db-bf0a-2af4129d83fc" contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7" name="asnd:ContractualUndiscountedCashflowOfFinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">1,227,447</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><ix:nonFraction id="F_2bdf08e2-6968-4106-a0e6-ffa13ae8e118" contextRef="C_f3608329-0a27-421b-9eed-d655fd107402" name="ifrs-full:FinancialLiabilities" unitRef="U_EUR" scale="3" decimals="-3" format="ixt:num-dot-decimal">935,512</ix:nonFraction></span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Borrowings (excluding lease liabilities)&#8221; comprise convertible notes and royalty funding liabilities. Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.</span></p></ix:nonNumeric></div></ix:continuation></div><div style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a24ae31b-ac47-4dd9-8d7f-0fea10d40267" contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" escape="true"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 11&#8212;Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No events have occurred after the balance sheet date that would influence the evaluation of these unaudited condensed consolidated interim financial statements.</span></p></ix:nonNumeric></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">F-</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ASCENDIS PHARMA A/S</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="managements_discussion"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">MANAGEMENT&#8217;S DISCUS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SION AND ANALYSIS OF FINANCIAL CONDITION AND</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RESULTS OF OPERATIONS</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated interim financial statements, including the notes thereto, included with this report and the section contained in our Annual Report on Form 20-F for the year ended December 31, 2024 &#8211; &#8220;Item 5. Operating and Financial Review and Prospects.&#8221; The following discussion is based on our financial information prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. IFRS as issued by the International Accounting Standards Board, and as adopted by the European Union, might differ in material respects from generally accepted accounting principles in other jurisdictions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Special Note Regarding Forward-Looking Statements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This report contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;goal,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; and other similar expressions that are predictions or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing or likelihood of regulatory filings and approvals for our products and product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the commercial availability of our approved products;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the commercialization of our products and product candidates, if approved for commercial use; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our commercialization, marketing and manufacturing capabilities of our products and product candidates and associated devices; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope, timing, progress, results and costs of developing our product candidates or any other future product candidates, and conducting preclinical studies and clinical trials; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our pursuit of oncology as an independent therapeutic area of focus and our development of product candidates related to oncology; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Eyconis&#8217; ability to develop, manufacture, and commercialize TransCon ophthalmology assets globally;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding the potential market opportunities and patient populations for our products and product candidates, if approved for commercial use; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our existing collaborations and license agreements and our ability to enter into new collaborations and license agreements;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential benefits of using our products and product candidates in combination with each other and other therapies; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations with regard to the ability to develop additional product candidates using our TransCon technologies and submit Investigational New Drug Applications (&#8220;INDs&#8221;) or similar for such product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to benefit from established data of clinically validated parent drugs or pathways to which we apply our TransCon technologies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations with regard to our current and future collaboration partners to pursue the development of our product candidates and submit INDs or similar for such product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our development plans with respect to our products and product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our pursuit of additional indications for TransCon hGH; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the implementation of our business model and strategic plans for our business, our products and product candidates and technologies, including global commercialization strategies; </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">1</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the scope of protection we are able to establish and maintain for intellectual property rights covering our products and product candidates; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations regarding our ability to apply our technology platform and algorithm for product innovation to develop highly differentiated product candidates to address unmet medical needs;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to apply our TransCon technology platform to build a leading, fully integrated, global biopharmaceutical company;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our use of our TransCon technologies to create new and potentially best-in-class therapies;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our goals for Vision 2030; </span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:1pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">estimates of our expenses, future revenue, capital requirements, needs for additional financing and ability to obtain additional capital; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our financial performance; </span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to attract and hire qualified personnel;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">developments and projections relating to our market conditions, competitors and industry;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our expectations with respect to ongoing and potential litigation;</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the impact of international economic, political, legal, compliance, social and business factors, including inflation, tariffs, geopolitical conflicts and energy shortages; and</span></div></div><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the effects on our business of pandemics and the ongoing conflicts in the region surrounding Ukraine and Russia and the conflict between Israel and Hamas.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">These forward-looking statements are based on senior management&#8217;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this report may turn out to be inaccurate. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the section in our Annual Report on Form 20-F for the year ended December 31, 2024 &#8212; &#8220;Item 3.D. Risk Factors.&#8221; You are urged to consider these factors carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this report. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. Given these risks and uncertainties, you are cautioned not to rely on such forward-looking statements as predictions of future events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additionally, certain information included herein or elsewhere (such as our website) is informed by various stakeholder expectations or third-party frameworks, and therefore should not necessarily be interpreted as rising to the level of materiality as defined under U.S. federal securities laws and regulations, even if we use the language &#8220;material&#8221; or &#8220;materiality.&#8221; Particularly in the ESG context, materiality is subject to varying definitions that are often different (and more expansive) than the concept for U.S. federal securities laws purposes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">You should read this report and the documents that we reference in this report and have filed as exhibits to this report completely and with the understanding that our actual future results may be materially different from what we expect. You should also review the factors and risks we describe in the reports we will file or submit from time to time with the Securities and Exchange Commission after the date of this report. We qualify all of our forward-looking statements by these cautionary statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Overview</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we develop TransCon based therapies that demonstrate best-in-class potential to address unmet medical needs. Our portfolio of approved Endocrinology Rare Disease products and product candidates addresses hypoparathyroidism as well as growth hormone deficiency and achondroplasia. To create additional value, we have established partnerships to develop and bring to market TransCon-based products in large therapeutic areas including Metabolic, Cardiovascular and Ophthalmology.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our Vision</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As announced in January 2024, Vision 2030 is our vision to achieve blockbuster status for multiple products and expand our engine for future innovation. This includes:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Be the Leading Endocrinology Rare Disease Company</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Achieve blockbuster status (&gt;$1B) for each of TransCon PTH, TransCon hGH, and TransCon CNP through worldwide commercialization</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Be the leader in growth disorders and hypoparathyroidism, pursuing clinical conditions, innovative life cycle management, and complementary patient offerings</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Expand pipeline with Endocrinology Rare Disease blockbuster product opportunities</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Create Value in Additional Therapeutic Areas through Innovative Business Models</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Obtain accelerated approval in oncology with registrational trials ongoing</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pursue TransCon product opportunities in &gt;$5B indications</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Maximize value creation of these product opportunities through collaboration with therapeutic area market leaders</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Differentiate with Ascendis Fundamentals</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outperform industry drug development benchmarks with Ascendis&#8217; product innovation algorithm</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Remain independent as a profitable biopharma through lean and flexible ways of working</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Let our values Patients, Science, Passion drive our decisions to success</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our products and product candidates combine our TransCon technologies with clinically validated parent drugs or pathways, with the goal of optimizing safety, efficacy, tolerability, and convenience.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We apply these technologies using our algorithm with the goal of creating product candidates with the potential to be best-in-class. Using this approach, we plan to expand our pipeline with Endocrinology Rare Disease product opportunities in large addressable markets. In addition, our vision is to pursue TransCon product opportunities in &gt;$5B indications in other therapeutic areas and maximize value creation of these product opportunities through collaboration with therapeutic area market leaders. We believe our approach to product innovation may reduce the risks associated with traditional drug development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">   </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Algorithm for Product Innovation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img149481191_0.jpg" alt="img149481191_0.jpg" style="width:720px;height:173px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">When we apply our TransCon technologies to clinically validated parent drugs or pathways, we may benefit from established clinical safety and efficacy data, which we believe increases the probability of success compared to traditional drug development. As illustrated above, our algorithm for product innovation focuses on identifying indications that have an unmet medical need, have a clinically validated parent drug or pathway, are suitable to our TransCon technologies, have potential for creating a clearly differentiated product, have a potential established development pathway, and have the potential to address a large market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Program Summaries</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We currently have two marketed products and a diversified portfolio of four product candidates in clinical development in the areas of Endocrinology Rare Disease and Oncology, and we are working to apply our TransCon technology platform in additional therapeutic areas such as the glucagon-like peptide 1 (&#8220;GLP-1&#8221;) class, where we believe we have designed a potentially best-in-class, once-monthly program.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">3</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SKYTROFA&#174; (lonapegsomatropin-tcgd) is our first marketed product. It was developed as TransCon hGH and it was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone, also known as growth hormone deficiency (&#8220;GHD&#8221;). SKYTROFA has been commercially available for prescription in the United States since October 2021. In addition, the European Commission (&#8220;EC&#8221;) has authorized SKYTROFA (lonapegsomatropin) in the European Union (&#8220;EU&#8221;) for the treatment of children and adolescents (3 &#8211; 18 years) with growth failure due to GHD. In the EU, SKYTROFA has been commercially available for prescription in Germany since September 2023. SKYTROFA has also been authorized by other regulatory authorities globally.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YORVIPATH&#174; (palopegteriparatide) is our second marketed product. It was developed as TransCon PTH and is approved by the FDA, and authorized by the EC and other regulatory agencies for the treatment of adults with hypoparathyroidism. In the EU, YORVIPATH has been commercially available for prescription in Germany and Austria since January 2024 and is also available in other EU countries through named patient programs. In the United States, YORVIPATH has been commercially available for prescription since December 2024. Through March 31, 2025, more than 1,750 new prescriptions have been written by over 1,000 unique prescribing healthcare providers in the U.S.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Endocrinology Rare Disease Pipeline </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8211; Two product candidates in our Endocrinology Rare Disease portfolio are currently in development spanning multiple indications and geographies. These product candidates are TransCon hGH (lonapegsomatropin) for adult GHD and children with Turner syndrome and TransCon CNP (navepegritide) for infants, children, and adolescents with achondroplasia. We are also investigating TransCon CNP in combination with TransCon hGH in children with achondroplasia. In addition, we plan to investigate TransCon hGH in other established daily growth hormone indications. Through our strategic collaboration, Teijin Limited (&#8220;Teijin&#8221;) is developing and, if approved, plans to commercialize TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. In addition, through our strategic collaboration, VISEN Pharmaceuticals (&#8220;VISEN&#8221;) is developing and, if approved, plans to commercialize TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare diseases in the People&#8217;s Republic of China, Hong Kong, Macau, and Taiwan (&#8220;Greater China&#8221;).  </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Oncology Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; In Oncology, we are leveraging our TransCon technologies with the goal of enhancing the anti-tumor effects of clinically-validated parent drugs and pathways and to provide sustained modulation of tumor microenvironments and activate cytotoxic immune cells. We initiated clinical development of two programs: TransCon TLR7/8 Agonist, an investigational, long-acting prodrug of resiquimod, a small molecule agonist of Toll-like receptors (&#8220;TLR&#8221;) 7 and 8, for intratumoral delivery, and TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(onvapegleukin alfa) for systemic delivery, which is designed for prolonged exposure to an IL-2 variant that selectively activates IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> with minimal binding to IL-2R&#945;. During the fourth quarter of 2024, we closed enrollment in our BelieveIT-201 clinical trial and to dose expansion cohorts involving TransCon TLR7/8 Agonist in the transcendIT-101 and IL-Believe trials to prioritize our efforts on TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Product Candidates Pipeline</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other than the rights we have granted to Eyconis Inc. (&#8220;Eyconis&#8221;), Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;), Teijin, and VISEN as noted in this report, we hold worldwide rights to our TransCon technologies and, other than our royalty financing arrangements with Royalty Pharma as noted in this report, we owe no third-party royalty or milestone payment obligations with respect to our TransCon technologies, TransCon hGH, TransCon PTH or any of our other product candidates. The following chart lists our current clinical trial activities.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">4</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img149481191_1.jpg" alt="img149481191_1.jpg" style="width:703px;height:313px;"/></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ApproaCH Trial (NCT05598320). NDA submitted to U.S. FDA. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">2.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">AttaCH Trial (NCT05929807). Includes patients from ACcomplisH and ApproaCH </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">3.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">sBLA submitted to U.S. FDA, PDUFA goal date July 27</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">th</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2025.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">4.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New InsiGHTS Trial (NCT05690386).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">5.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">reACHin Trial (NCT06079398).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">6.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">teACH Trial (NCT06732895).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">7.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">COACH Trial (NCT06433557). </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">8.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals&#8217; Phase 3 trial. </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">9.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Japanese riGHt Trial.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">10.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PaTHway China (NCT05387070).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">11.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">PaTHway Japan.</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">12.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ACcomplisH China (NCT05246033).</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">13.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IL-Believe Trial (NCT05081609).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain an intellectual property portfolio comprising over 425 issued patents and over 525 patent applications as of December 31, 2024, which includes patents and patent applications applicable to our products and product candidates with claims directed to composition of matter, process, formulation and/or methods-of-use for our products and product candidates, including a product-specific device and core TransCon technologies. While our TransCon prodrugs may incorporate already approved parent drugs, TransCon hGH, TransCon PTH, and each of our other product candidates are new molecular entities and therefore eligible to be granted new intellectual property rights, including new composition of matter patents.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Global Commercialization Strategy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are establishing a global presence to commercialize TransCon products and product candidates, where approved, to address patients&#8217; unmet medical needs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">5</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., we have established an integrated organization to commercialize our approved Endocrinology Rare Disease products, SKYTROFA and YORVIPATH. Our U.S. organization includes various departments, including sales, market access, patient support, and medical affairs teams. The sales team engages with HCPs and present products, usage and safety guidelines in accordance with the label. Our market access team engages with health authorities, insurance companies, and payers to support patients in need of our products gain access to them. Our patient support team facilitates reimbursement support, out of pocket assistance, provides educational resources and product training. Our medical affairs team provides scientific exchange to the physician and medical community. We have also established a network of specialty pharmacies to support product distribution.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In Europe, we are expanding our presence by building integrated organizations in select countries, which we call (&#8220;Europe Direct&#8221;), beginning with Germany, where we have launched our Endocrinology Rare Disease products, SKYTROFA and YORVIPATH. We are establishing commercial infrastructure in other Europe Direct country clusters, including DACH (Germany, Austria, Switzerland), France &amp; BeNeLux (Belgium, the Netherlands, and Luxembourg), Iberia (Portugal and Spain), Italy, Nordics (Denmark, Norway, Sweden, Iceland, Finland), and the United Kingdom &amp; Ireland.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Beyond the U.S. and Europe Direct, we are expanding global reach for our Endocrinology Rare Disease programs through exclusive distribution agreements with geographic market leaders, which we call (&#8220;International Markets&#8221;). As of March 31, 2025, we have agreements covering over 75 countries.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Finally, we are making our products commercially available in select markets under exclusive license agreements with partners with local development and commercialization expertise and infrastructure which we call strategic collaborations. In Greater China, VISEN has exclusive license rights to develop and commercialize TransCon hGH, TransCon PTH, and TransCon CNP. In Japan, Teijin has exclusive license rights to develop and commercialize TransCon hGH, TransCon PTH, and TransCon CNP.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On April 2, 2025, an </span><span><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">executive order</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> was issued in the United States implementing &#8220;Reciprocal Tariffs,&#8221; on most U.S. trading partners, and on April 9, 2025, implementation of most of the Reciprocal Tariffs was paused for 90 days. Some goods will not initially be subject to the Reciprocal Tariffs, including pharmaceuticals. While there can be no assurance that pharmaceuticals will remain free from Reciprocal Tariffs or other trade barriers in the future, we currently believe the impact of the Reciprocal Tariffs on our operations will be immaterial. We continue to monitor and assess the possible impacts of existing and potential tariffs on our operations.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Technologies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon technologies are designed to combine the benefits of conventional prodrug and sustained release technologies to solve the fundamental limitations seen in other approaches to extending duration of a drug&#8217;s action in the body, with the goal of developing highly differentiated product candidates based on efficacy, safety, tolerability, and convenience. In addition to retaining the original mode of action of the parent drug and potentially supporting dosing frequency from daily up to six months or more, we believe that predictable release over time can improve treatment safety and efficacy, increase the likelihood of clinical development success, and provide intellectual property benefits.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon molecules can have up to three components: a parent drug, an inert carrier that protects it, and a linker that temporarily binds the two. When bound, the carrier inactivates and shields the parent drug from clearance. When injected into the body, physiologic pH and temperature conditions initiate the release of the active, unmodified parent drug in a predictable release manner.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Depending upon the type of TransCon carrier we employ, we can design our TransCon prodrugs for sustained localized or systemic delivery.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">6</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img149481191_2.jpg" alt="img149481191_2.jpg" style="width:719px;height:269px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Technology Components</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Carriers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon technologies incorporate three carrier platforms that can be used to provide sustained localized or systemic drug exposure. These biocompatible carrier platforms include our TransCon systemic carriers and TransCon localized carriers (self-eliminating hydrogels). Our carriers inactivate and protect the drug through a shielding effect, which may prevent rapid excretion and degradation of the parent drug and enable benefits that include improved injection site tolerability, reduced systemic adverse effects, and low immunogenicity.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Systemic</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Our TransCon systemic carriers are used to provide systemic drug exposure and are based on soluble compounds such as methoxypolyethylene glycol (&#8220;mPEG&#8221;) or other natural or synthetic polymers, as well as our albumin avidity approach, where 2 or more albumin binding moieties are incorporated into the drug molecule to facilitate sustained exposure. Prodrugs created using our systemic carriers are readily absorbed into the bloodstream after administration, thus minimizing exposure of the subcutaneous tissue to active drug, which we believe may improve injection site tolerability. TransCon hGH, TransCon PTH, and TransCon CNP utilize mPEG as a carrier molecule. mPEG is widely used to improve the pharmacokinetic or pharmacodynamic properties of marketed therapeutics. Below is an illustration of our systemic carrier:</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">7</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img149481191_3.jpg" alt="img149481191_3.jpg" style="width:464px;height:152px;"/></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Localized</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> &#8211; Our TransCon localized carriers include TransCon hydrogels based on PEG, hyaluronic acid, or other biopolymers. TransCon hydrogel is designed to self-eliminate to soluble, biocompatible molecules after the drug payload has been released. When applied for localized delivery, the TransCon hydrogel enables the release of a parent drug at high local concentrations within the target area while minimizing systemic exposure. We believe this may widen the therapeutic window for parent drugs that suffer from significant systemic side effects and toxicities, facilitating the development of highly efficacious product candidates with improved safety and tolerability profiles. Below is an illustration of our hydrogel carrier:</span></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img149481191_4.jpg" alt="img149481191_4.jpg" style="width:448px;height:163px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Linkers</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our reversible TransCon linkers are designed to enable the transient conjugation of a broad range of therapeutics, including proteins, peptides, and small molecules, to our TransCon carriers. We have a large library of TransCon linkers that may be applicable to various types of parent drugs, and that can be tailored to potentially achieve half-life extension enabling daily, weekly, monthly, and half-yearly dosing and to customize the potential pharmacokinetic profile for each individual product candidate with the goal of optimizing the potential therapeutic effect. TransCon linkers are self-cleaving through a process called intra-molecular assisted cleavage, which causes the linker to release the unmodified parent drug. We can tailor the release properties of the linker to a given therapeutic indication and parent drug by modifying the linker structures. We believe the self-cleaving process of our linker avoids many of the shortcomings of conventional prodrug technologies, which often depend on metabolic processes, such as enzymatic degradation, to convert the prodrug into the active drug. The rate of metabolic conversion of prodrugs in these types of processes may differ between patients, and even within different tissues in the same patient. As a result, conventional prodrugs do not always offer predictable release of the parent drug. Our TransCon linkers are designed to predictably release an unmodified active parent drug at predetermined rates governed by physiological pH and temperature conditions, which are tightly regulated in the body. Consequently, we believe we can design our prodrugs to release the unmodified parent drug at predictable rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Parent Drugs</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon technologies are applicable across a broad range of therapeutic classes and are currently used to create long-acting product candidates with best-in-class potential based on proteins, peptides, and small molecules. By primarily focusing on biological targets that have been clinically validated, we can leverage available knowledge regarding a target&#8217;s activity. Based on this selective approach, we know what drug levels must be maintained in the body for optimal efficacy and safety, and we can design the release half-life and dosing frequency of our TransCon prodrugs to maintain these levels to achieve the desired pharmacological effect. We move a product candidate into development after it demonstrates the desired profile in non-clinical models. Furthermore, based on the established translational relationships between preclinical animal models and clinical efficacy, we believe experimental results generated in animal models are highly predictive of clinical results and reduce the development risk for our TransCon prodrugs. This strategy is designed to reduce risk and increase productivity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">8</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">This approach has enabled us to develop two approved products and generate a pipeline of product candidates designed to address significant unmet medical needs and to become potential sources of significant revenue for our company. Because our TransCon technologies leverage clinically validated parent drugs or pathways, we believe we may benefit from a higher development and regulatory success rate compared to development of drug compounds without established biology.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Products and Product Candidates - Endocrinology Rare Diseases</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Growth Hormone (hGH)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity for Recombinant Human Growth Hormone</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Growth hormone deficiency is a serious orphan disease that affects both children and adults. Children with GHD are characterized by short stature, metabolic and cardiovascular abnormalities, cognitive deficiencies, and poor quality of life. GHD in adults is associated with increased adiposity, or fat mass, as well as psychiatric-cognitive, cardiovascular, muscular, metabolic and skeletal abnormalities. In childhood and adolescence, growth hormone plays an essential role in normal longitudinal growth, muscle and bone strength, and distribution of body fat. In adults, growth hormone contributes to body composition, cardiovascular function, and bone health. The current standard of care for GHD has been daily subcutaneous injections of somatropin, a recombinant human growth hormone (&#8220;hGH&#8221;). These daily hGH therapies have been shown to be safe and well-tolerated.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In both therapy-compliant children and adults with GHD, daily subcutaneous injections of hGH have resulted in improved body composition parameters, bone density, cardiovascular outcomes, and quality of life. Growth hormone-deficient children who are fully adherent to their daily hGH treatment regimen may achieve a height in adulthood that is comparable to that of their family members and national norms.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite the demonstrated benefits of daily hGH therapy, many GHD patients are not adequately treated, and adherence continues to be a challenge, as reported in a 2021 paper published by Kaplowitz et al. (Kaplowitz P, Manjelievskaia J, Lopez-Gonzalez L, et al. Economic burden of GHD in a U.S. pediatric population. </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">J Manag Care Spec Pharm.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> 2021; 27(8):1118-1128). The observational retrospective cohort analysis utilized administrative claims data from two databases on over 20,000 pediatric patients diagnosed with GHD. Approximately 68% of commercial patients and approximately 63% of Medicaid patients received daily growth hormone treatment, whereas approximately 32% of commercial patients and approximately 37% of Medicaid patients were untreated. In addition, mean adherence as measured by proportions of days covered, which is defined as the number of days covered by any daily growth hormone prescription during the follow-up period, was approximately 60% in the commercial cohort and approximately 50% in the Medicaid cohort. Only 32% of commercial and 18% of Medicaid patients reported adherence rates greater than 80%.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For adult patients with GHD, underdiagnosis and undertreatment are also a concern. Untreated adult GHD (&#8220;AGHD&#8221;) patients can experience reduced quality of life and increased risk of morbidity and mortality. A retrospective cohort study presented at ENDO 2023 analyzed an electronic health records database and selected adult patients with suspected AGHD. Of the 51,588 patients with suspected AGHD, fewer than 4% were treated with growth hormone.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the introduction of hGH in 1981, a number of the world&#8217;s largest pharmaceutical companies have developed and marketed daily-administered hGH products. All currently marketed daily hGH products in the United States &#8211; Norditropin</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (Novo Nordisk A/S), Humatrope</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Eli Lilly and Company), Genotropin</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Pfizer Inc.), Zomacton</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Ferring Pharmaceuticals, Inc.) and Omnitrope</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(Sandoz GmbH) &#8211; contain unmodified somatropin and are administered by subcutaneous injections. The global market for daily hGH products is largely composed of products from Novo Nordisk, Pfizer, Eli Lilly, Sandoz, and Merck KGaA, which together account for most of the global market share. However, according to the FDA drug shortage website, Humatrope has been discontinued due to a business decision which might impact the hGH global market share in the future.</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:'Segoe UI',sans-serif;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary indications for hGH in children are GHD, idiopathic short stature, chronic kidney disease, Prader-Willi syndrome, small for gestational age, and Turner syndrome. In adults, primary indications for hGH include GHD and AIDS-induced weight loss. We estimate pediatric indications comprise up to 90% of the total hGH market, of which approximately half is for pediatric GHD.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Since the 1990s, the pharmaceutical industry has employed various approaches to develop long-acting growth hormone products to reduce the burden of daily injections on patients and increase patient compliance with the dosing regimen. These approaches generally fall into two categories: unmodified somatropin and permanent modification of growth hormone:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unmodified somatropin</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Two long-acting growth hormone products using encapsulation technologies previously received regulatory approval in the U.S. and Europe, but were subsequently discontinued due to commercial challenges. These include Nutropin Depot</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, formerly marketed by Genentech, and Somatropin Biopartners, developed by LG Life Sciences and Biopartners GmbH. Nutropin Depot was approved by the FDA in 1999 and later withdrawn; Somatropin Biopartners (LB03002) was authorized by the EC in 2013, and later withdrawn. We believe that the lack of market acceptance was a result of the various safety and tolerability issues that tend to arise with encapsulation technologies.</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">9</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Permanent modification of growth hormone</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">: Modification technologies prolong activity in the body by creating analogs of growth hormone through permanent modification of the growth hormone molecule. This modification may alter the molecular size and interaction with the growth hormone receptor and/or change the natural association affinity to endogenous proteins, as well as the distribution in the body. These changes may alter and reduce the efficacy of these drugs compared to unmodified daily somatropin and may also negatively impact the drug&#8217;s safety. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novo Nordisk received regulatory approval in various countries and regions including the U.S., Japan, and EU for once-weekly somapacitan (SOGROYA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) in adult and pediatric patients with GHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Pfizer (in collaboration with OPKO Health Inc.) received regulatory approval of once-weekly somatrogon (NGENLA&#153;) in various countries and regions including the U.S., Japan, and EU for pediatric GHD.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">A permanently PEGylated long-acting growth hormone developed by GeneScience Pharmaceuticals Co., Ltd. (Jintrolong</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) is available in China for pediatric GHD, Turner syndrome and idiopathic short stature and the Somatropin Biopartners product (LB03002) is available in Korea. Other experimental growth hormone therapies based on permanent modification are in different stages of clinical development by various companies, including Genexine Inc., I-MAB, Amoytop, UnionGene, Anhui Anke Biotechnology, Alteogen, JCR Pharmaceuticals Co., Ltd., Kexing Biopharm, Qianhon Biopharma (Zonhon) and Evive Biotech (Yifan).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: TransCon hGH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH is a prodrug composed of somatropin that is transiently bound to a carrier by a proprietary linker. TransCon hGH is administered once weekly and is designed to maintain the same mode of action as daily therapies by providing sustained release of active, unmodified somatropin, the same recombinant growth hormone molecule used in the daily hGH therapies that have historically been the standard of care.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Growth Hormone (hGH) for Pediatric GHD</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH, marketed under the brand name SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(lonapegsomatropin-tcgd), received regulatory approval in the U.S. for the treatment of pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone, also known as GHD. SKYTROFA has been commercially available for prescription in the United States since October 2021. In the EU, Norway, Iceland, Liechtenstein, and Great Britain (covering England, Wales, Scotland), we received marketing authorization for TransCon hGH &#8211; known by its brand name SKYTROFA (lonapegsomatropin) &#8211; as a once-weekly subcutaneous injection for the treatment of children and adolescents aged 3 to 18 years with growth failure due to insufficient secretion of endogenous growth hormone. SKYTROFA has been commercially available for prescription in Germany since September 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced top-line results from the completed enliGHten Trial, an open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with GHD. The enliGHten Trial enrolled 298 participants (mean age 10.3 years) from the Phase 3 heiGHt Trial of treatment-na&#239;ve pediatric GHD patients and the Phase 3 fliGHt Trial of pediatric GHD patients switching from daily somatropin treatment. Patients in these trials received a total of up to 6 years of treatment with TransCon hGH. At the time of the enliGHten Trial closure, 81 participants were designated as treatment completers, based on their physician&#8217;s determination that treatment for pediatric GHD was no longer required. Of these treatment completers, 59% met or exceeded their average parental height standard deviation score (&#8220;SDS&#8221;), with mean TransCon hGH treatment duration of 3.2 years.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Trial of TransCon hGH in Japanese Pediatric GHD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the Phase 3 riGHt Trial, we are evaluating TransCon hGH (N=15) compared to somatropin (N=16) as a treatment in Japanese children with GHD. The trial achieved its primary objective with Week 52 top-line results consistent with our pivotal heiGHt Trial and VISEN&#8217;s Phase 3 trial. In the riGHt Trial, TransCon hGH was generally well tolerated with a safety profile that was similar to that of somatropin&#8217;s. Trial subjects continue in the extension period.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Proprietary Auto-Injector</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SKYTROFA includes the SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Auto-Injector and cartridges. The auto-injector provides for room temperature storage, includes an empty-all design, and is expected to last for at least four years. The device enables a single, low-volume injection of less than 0.6 mL for the majority of patients with a thin, 31-gauge needle that is only 4 millimeters in length, which is comparable to needles used to administer daily hGH. We are also working on strategies that will enable the auto-injector to integrate with the digital healthcare system, including Bluetooth connectivity features to allow for easy tracking of dosing adherence over time.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">10</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img149481191_5.jpg" alt="img149481191_5.jpg" style="width:205px;height:345px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Figure: Our state-of-the-art auto-injector is designed to improve treatment compliance.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon Growth Hormone (hGH) for Other Indications</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development in Adult GHD</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced the submission of a supplemental Biologics License Application (&#8220;sBLA&#8221;) to the FDA for TransCon hGH to expand its currently approved label to include eligible adults for the treatment of GHD. The submission was based on results from foresiGHt, a Phase 3 randomized, parallel-arm, placebo-controlled (double-blind), and active-controlled (open-label) trial that compared the efficacy and safety of weekly TransCon hGH with weekly placebo and daily hGH in adults with GHD. In December 2024, we announced the FDA accepted the sBLA for review and set a Prescription Drug User Fee Act (&#8220;PDUFA&#8221;) goal date of July 27, 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, we announced positive top-line results from foresiGHt. The trial aims to evaluate the metabolic benefits of TransCon hGH in adults, with the primary objective to evaluate change in trunk fat percentage.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The foresiGHt Trial evaluated 259 adults with GHD aged 23 to 80 years old, randomized 1:1:1, titrated to receive a target fixed dose of TransCon hGH, placebo, or daily hGH based on age and oral estrogen intake, with approximately equivalent hGH mg/week for TransCon hGH and daily hGH.</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH demonstrated superiority on its primary efficacy endpoint at Week 38:</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in trunk percent fat as measured by dual x-ray absorptiometry (TransCon hGH -1.67% vs. placebo +0.37%, LS mean difference = -2.04%, p &lt; 0.0001)</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH demonstrated superiority on its key secondary efficacy endpoints at Week 38:</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in total body lean mass (TransCon hGH +1.60 kg vs placebo -0.10 kg, LS mean difference = 1.70 kg, p &lt; 0.0001)</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in trunk fat mass (TransCon hGH -0.48 kg vs placebo +0.22 kg, LS mean difference = -0.70 kg, p = 0.0053)</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Exploratory post-hoc analysis at Week 38 demonstrated comparable treatment effect of TransCon hGH and daily hGH on target tissues. For patients with average insulin-like Growth Factor 1 (&#8220;IGF-1&#8221;) SDS levels &#8804; 1.75 at Week 38:</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in trunk percent fat (TransCon hGH -2.42% vs. daily hGH -2.59%)</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in total body lean mass (TransCon hGH +1.70 kg vs daily hGH +1.37 kg)</span></div></div><div class="item-list-element-wrapper" style="margin-left:9.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.989278055754109%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Change from baseline in trunk fat mass (TransCon hGH -0.90 kg vs daily hGH -0.94 kg)</span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">11</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon hGH was generally safe and well tolerated, with no discontinuations related to study drug and with comparable safety and tolerability to daily hGH.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development in Turner Syndrome</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, we announced positive top-line results from the Phase 2 New InsiGHTS Trial. New InsiGHTS randomized and dosed 49 children with Turner syndrome aged 1 to 10 years old into one of four treatment groups 1:1:1:1 &#8211; one of three starting doses of TransCon hGH (0.24, 0.30, or 0.36 mg/kg/week) or an active comparator of daily somatropin with a starting dose of 0.35 mg/kg/week. Doses were individualized based on IGF-1. On the primary endpoint of annualized height velocity (&#8220;AHV&#8221;) and secondary endpoint of change from baseline in height SDS, children treated with TransCon hGH demonstrated improved growth similar to daily somatropin at Week 26, independent of starting dose. As of March 31, 2025, 45 out of the 49 children are ongoing in the trial. TransCon hGH was generally safe and well tolerated, and with comparable safety and tolerability to daily somatropin, with four discontinuations from the trial for reasons unrelated to safety or efficacy of the study drug.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Development Plans</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the third quarter of 2025, we plan to submit an Investigational New Drug (&#8220;IND&#8221;) application or similar for a basket trial evaluating other indications (planned for small for gestational age without catch-up growth; idiopathic short stature; SHOX deficiency (including Turner syndrome)). In addition, we are investigating potential combinations of TransCon hGH and TransCon CNP. For more information see the section entitled &#8220;TransCon CNP + TransCon hGH Combination Therapy.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Hypoparathyroidism</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hypoparathyroidism is a rare endocrine disease caused by insufficient levels of parathyroid hormone (&#8220;PTH&#8221;). As reported in a 2016 paper, most patients with hypoparathyroidism (70-80% of cases) develop the disease following damage to or accidental removal of the parathyroid glands during thyroid surgery. Other etiologies include autoimmune disorders, genetic disorders such as autosomal dominant hypocalcemia type 1, and idiopathic causes. Conventional therapy with oral calcium and active vitamin D (also called calcitriol) does not effectively address the short-term symptoms, long-term complications, or quality-of-life impacts of hypoparathyroidism.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Individuals with hypoparathyroidism may experience a range of severe and potentially life-threatening short-term and long-term complications. Short-term symptoms of hypoparathyroidism include weakness; severe muscle cramps (tetany); abnormal sensations such as tingling, burning, and numbness (paresthesia); memory loss; impaired judgment; and headache. A survey published in 2014 of 374 individuals with hypoparathyroidism showed that 72% experienced more than ten symptoms in the preceding twelve months, with symptoms experienced for a mean of 13 &#177; 9 hours a day. Prolonged use of conventional therapy may increase the risk of major complications, such as calcium deposits in the brain, blood vessels, eyes, and soft tissues. According to a systematic review by Gosmanova et al. published in 2021, chronic hypoparathyroidism treated with conventional therapy is associated with higher rates of renal complications compared to the general population, including nephrolithiasis (up to 36%), nephrocalcinosis (up to 38%), and chronic kidney disease (up to 41%). Studies have found that the burden of hypoparathyroidism negatively impacts health-related quality of life (&#8220;QoL&#8221;), physical functioning, and psychological well-being. Compared with an age-matched general population sample, individuals with hypoparathyroidism have reported markedly lower health-related QoL, irrespective of serum calcium level, as measured by the physical (P&lt;0.001) and mental (P&lt;0.001) component scores of the 36-Item Short Form Health Survey (SF-36) as well as the EuroQol-5 Dimensions Visual Analogue Scale. As reported in a 2021 paper, in interviews conducted on 42 individuals with hypoparathyroidism, 98% reported reduced functioning and well-being, including anxiety (81%), feeling sad or depressed (62%), and feeling irritable or short-tempered (43%) despite management with conventional therapy.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Hypoparathyroidism also imposes a substantial burden on the healthcare system despite the use of conventional therapy. For example, individuals with hypoparathyroidism may require hospitalizations or emergency department visits due to acute severe hypocalcemia (calcium crashes) and those with post-surgical hypoparathyroidism have an increased risk of hospitalization due to infection than age- and sex-matched controls from the general population. Individuals with hypoparathyroidism also have an increased risk of hospitalization due to renal complications, such as chronic kidney disease and renal failure, compared to age- and sex-matched controls. A retrospective review published in 2019 of clinical burden and healthcare resource utilization showed that 90.7% of individuals had &#8805;1 hypoparathyroidism-related healthcare utilization event during a 12-month period, including 87.8% with &#8805;1 outpatient visit, 41% with &#8805;1 emergency department visit, and 19.5% with &#8805;1 hospitalization. The management of hypoparathyroidism is also associated with substantial economic burdens and consequences of hypoparathyroidism may negatively impact employment status and work productivity.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">12</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 2022 Guidelines from the Second International Workshop addressing the prevention, diagnosis, and management of hypoparathyroidism was published in September 2022 in the Journal of Bone and Mineral Research and authored by leading clinicians from North America, Europe, and Asia. The authors suggest consideration of PTH replacement therapy in patients whose hypoparathyroidism is inadequately controlled with conventional therapy. Inadequate control is considered to be any one of the following: symptomatic hypocalcemia, hyperphosphatemia, renal insufficiency, hypercalciuria, or poor quality of life. In addition, the guideline indicates that individuals with poor compliance, malabsorption, or intolerant of large doses of calcium and active vitamin D may also benefit from PTH replacement therapy. Based on this current guideline, we believe PTH replacement therapy could be applicable to most patients with hypoparathyroidism.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2015, Takeda&#8217;s NATPARA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(parathyroid hormone) was approved in the U.S. for once-daily subcutaneous injection as an adjunct to vitamin D and calcium in patients with hypoparathyroidism. NATPARA was voluntarily recalled in September 2019 in the U.S. and is now only available to a limited number of patients through a Special Use Program offered by its manufacturer, Takeda. In October 2022, Takeda announced that it would discontinue manufacturing NATPARA/NATPAR globally by the end of 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are also aware of several academic groups and companies working on making longer-acting agonists of the PTH receptor. In addition, other companies and groups are developing therapies for hypoparathyroidism at the clinical stage, including Calcilytix (a BridgeBio company), Entera Bio, Extend Biosciences, AstraZeneca, MBX Biosciences, and Septerna.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Forteo&#174; (teriparatide, PTH [1-34]), approved since 2002 for the treatment of osteoporosis, has sometimes been used for treatment of hypoparathyroidism using multiple daily injections, despite not being approved for this indication. Clinical research conducted by the U.S. National Institutes of Health in subjects receiving continuous exposure to PTH (1-34), administered by an infusion pump demonstrated simultaneous normalization of serum calcium and urinary calcium, as well as normalization of bone turnover.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We estimate hypoparathyroidism affects over 250,000 patients in the U.S. and Europe. In the U.S., we estimate hypoparathyroidism affects approximately 70,000 to 90,000 patients, including 4,000 to 5,000 patients who we estimate have previously been treated with PTH therapy. In Germany, we estimate hypoparathyroidism affects approximately 70,000 patients. Outside of Germany, we estimate hypoparathyroidism affects over 100,000 patients in the rest of Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: TransCon PTH</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon PTH (palopegteriparatide) is a prodrug of PTH (1-34) that is administered once-daily to achieve and maintain a steady concentration of PTH in the bloodstream within the physiological range. TransCon PTH is designed to provide PTH in the physiological range for 24 hours per day, thereby more fully addressing aspects of the disease, including maintaining normal serum calcium and phosphate levels and normalizing urinary calcium.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon PTH for the Treatment of Hypoparathyroidism</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, the FDA approved YORVIPATH (palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults.</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the FDA granted Orphan Drug exclusivity to YORVIPATH, providing seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in adults. YORVIPATH has been commercially available for prescription since late December 2024 in the United States</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, TransCon PTH received regulatory approval in the EU and European Economic Area and is marketed as YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(palopegteriparatide), a parathyroid hormone replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In addition, YORVIPATH was granted Orphan status in the EU in November 2023 and in Great Britain in April 2024 and provides ten years of market exclusivity. In January 2024, we announced commercial availability of YORVIPATH in Germany and Austria, and we began shipping to customers in February 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, TransCon PTH received regulatory approval in Great Britain as a PTH replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism. In addition, in April 2024, we announced that the United Kingdom&#8217;s Medicines &amp; Healthcare products Regulatory Agency granted YORVIPATH Orphan Drug status.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2022, the FDA allowed us to initiate a U.S. expanded access program (&#8220;EAP&#8221;) for TransCon PTH for eligible adult patients with hypoparathyroidism with prior PTH treatment experience. The EAP closed to new patients on November 29, 2024, in preparation for the U.S. commercial availability of YORVIPATH. Beginning in December 2024, we started enrolling EAP patients into the Ascendis Signature Access Program Ascendis&#8217; patient support program. Patients enrolled in the EAP are now working with their healthcare providers HCPs to transition to the commercially available YORVIPATH.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In July 2021, the Ministry of Health, Labour and Welfare in Japan granted Orphan Drug Designation (&#8220;ODD&#8221;) to TransCon PTH for the treatment of hypoparathyroidism.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">13</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2020, we were granted Orphan Designation (&#8220;OD&#8221;) by the European Commission (&#8220;EC&#8221;) for TransCon PTH for the treatment of hypoparathyroidism.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development of TransCon PTH for Treatment of Hypoparathyroidism in Adults</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon PTH is being evaluated for the treatment of hypoparathyroidism in adults in the Phase 3 PaTHway Trial, Phase 3 PaTHway Japan Trial, and the Phase 2 PaTH Forward Trial. Last patient, last visit (&#8220;LPLV&#8221;) in the Phase 3 PaTHway Trial occurred in January 2024. LPLV in the Phase 2 PaTH Forward Trial is expected in March of 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced results from the ongoing Phase 2 PaTH Forward Trial of adults with hypoparathyroidism showing that long-term treatment with TransCon PTH (palopegteriparatide; marketed as YORVIPATH) through Week 162 drove bone remodeling into the normal range. Deficiency of PTH is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population. In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency. The PaTH Forward Trial recently completed with 56 patients out of 59 patients originally enrolled completing the five year trial. Three patients withdrew from the trial for reasons unrelated to safety or efficacy of the study drug.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2024, we announced two-year (Week 104) results from a post-hoc analysis of the Phase 3 PaTHway Trial demonstrating sustained improvements (nominal p-value &lt;0.05) in renal function in adults with chronic hypoparathyroidism treated with TransCon PTH. The post-hoc analysis examined the impact of treatment with TransCon PTH on renal function using estimated glomerular filtration rate (&#8220;eGFR&#8221;) through Week 104 (n=76) of PaTHway, a Phase 3, double-blind, placebo-controlled trial of 82 dosed adults with chronic hypoparathyroidism randomized 3:1 (TransCon PTH: placebo; both arms initially co-administered with conventional therapy of active vitamin D and calcium), with a 26-week blinded period followed by an ongoing 156-week open-label extension period. Across both treatment arms, TransCon PTH treatment resulted in a mean eGFR increase of 8.9 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(p&lt;0.0001) from baseline at Week 52, sustained at Week 104 with a mean change from baseline of 9.0 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (p&lt;0.0001). Treatment was generally well-tolerated, with no new safety signals.</span></p>
   <table style="border-spacing:0;table-layout:auto;width:85.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:16.88%;box-sizing:content-box;"/>
     <td style="width:19.28%;box-sizing:content-box;"/>
     <td style="width:7.2%;box-sizing:content-box;"/>
     <td style="width:14.48%;box-sizing:content-box;"/>
     <td style="width:6%;box-sizing:content-box;"/>
     <td style="width:14.48%;box-sizing:content-box;"/>
     <td style="width:7.2%;box-sizing:content-box;"/>
     <td style="width:14.48%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:18.15pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="8" style="border-top:0.5pt solid #000000;padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">eGFR* Change from Baseline by Study Arm</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #eeece1;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #eeece1;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Baseline</span></p></td>
     <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
     <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
     <td colspan="2" style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
    </tr>
    <tr style="height:9pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Study Arm</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">eGFR</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"><br/></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(mL/min/1.73m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>N</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mean</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(p value)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>N</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mean<br/>(p value)</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"><br/>N</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Mean<br/>(p value)</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td rowspan="3" style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon PTH / TransCon PTH</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eGFR &lt; 60<br/><br/></span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+11.4<br/>(p=0.0002)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+11.5<br/>(p=0.0003)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+13.4<br/>(p&lt;0.0001)</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eGFR &#8805; 60</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">41</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+6.3<br/>(p=0.0002)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+8.6<br/>(p&lt;0.0001)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">40</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+6.9<br/>(p&lt;0.0001)</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+7.9</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p&lt;0.0001)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">59</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+9.3<br/>(p&lt;0.0001)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">58</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+8.9<br/>(p&lt;0.0001)</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td rowspan="3" style="padding-top:0.01in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Placebo<br/>(first 26 weeks) / TransCon PTH**</span></p></td>
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eGFR &lt; 60</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+0.1<br/>(p=0.9877)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+11.7<br/>(p=0.0018)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+15.6<br/>(p=0.0067)</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">eGFR &#8805; 60</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-2.4<br/>(p=0.3280)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+6.5<br/>(p=0.0199)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">14</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+7.6<br/>(p=0.0121)</span></p></td>
    </tr>
    <tr style="height:9pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">All</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">-1.9</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p=0.3468)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">19</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+7.6</span></p><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(p=0.0014)</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:top;padding-bottom:0.01in;border-bottom:0.5pt solid #000000;padding-right:0.02in;text-align:left;"><p style="font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">+9.4<br/>(p=0.0006)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">*eGFR (an assessment of kidney filtering capacity) was calculated by the trial&#8217;s central lab using the Modification of Diet in Renal Disease Study Group (MDRD) equation (Levey, Ann Intern Med 2006). An eGFR level &lt;60 mL/min/1.73m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">is considered the threshold for impaired kidney function.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">**Patients in the placebo arm switched to TransCon PTH following the Week 26 visit.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon PTH treatment was associated with clinically meaningful increases (&#8805; 5 mL/min/1.73 m</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">) in eGFR within 26 weeks that were sustained through Week 104 of PaTHway:</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">14</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;">
   <table style="border-spacing:0;table-layout:auto;width:86.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:20.16%;box-sizing:content-box;"/>
     <td style="width:11.56%;box-sizing:content-box;"/>
     <td style="width:11.56%;box-sizing:content-box;"/>
     <td style="width:11.3%;box-sizing:content-box;"/>
     <td style="width:12.76%;box-sizing:content-box;"/>
     <td style="width:15.78%;box-sizing:content-box;"/>
     <td style="width:16.88%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:22.2pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="7" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:middle;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Proportion of Participants (%) with &#8805; 5 and &#8805; 10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#160;Increases in eGFR <br/>from Baseline through Week 104*</span></p></td>
    </tr>
    <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
     <td rowspan="4" style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">eGFR Change from Baseline</span></p></td>
     <td colspan="6" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">All Participants</span></p></td>
    </tr>
    <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TransCon PTH / TransCon PTH<br/>(n=61)</span></p></td>
     <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo (first 26 weeks) / TransCon PTH** <br/>(n=21)</span></p></td>
    </tr>
    <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
    </tr>
    <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Switch to PTH</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Switch to PTH</span></p></td>
    </tr>
    <tr style="height:8.4pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;5 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">64%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">61%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">52%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">62%</span></p></td>
    </tr>
    <tr style="height:10.2pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">38%</span></p></td>
    </tr>
    <tr style="height:11.1pt;word-break:break-word;white-space:pre-wrap;">
     <td colspan="7" style="padding-top:0.02in;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;padding-right:0.03in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:17.25pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;">
     <td rowspan="4" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">eGFR Change from Baseline</span></p></td>
     <td colspan="6" style="border-top:0.5pt solid #000000;padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Participants with Baseline eGFR &lt; 60 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-weight:bold;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span></p></td>
    </tr>
    <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">TransCon PTH / TransCon PTH<br/>&#160;(n=19)</span></p></td>
     <td colspan="3" style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo (first 26 weeks) / TransCon PTH** <br/>(n=4)</span></p></td>
    </tr>
    <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 26</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 52</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Week 104</span></p></td>
    </tr>
    <tr style="height:15pt;background-color:#f2f2f2;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">PTH</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Placebo</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Switch to PTH</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Switch to PTH</span></p></td>
    </tr>
    <tr style="height:9.3pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;5 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">68%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">74%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100%</span></p></td>
    </tr>
    <tr style="height:9.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;border-left:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&#8805;</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;10 mL/min/1.73 m</span><span style="color:#000000;top:-4.221pt;white-space:pre-wrap;font-size:6.03pt;position:relative;font-kerning:none;min-width:fit-content;">2</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">47%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">42%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">0%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75%</span></p></td>
     <td style="padding-top:0.02in;border-right:0.5pt solid #000000;padding-left:0.08in;vertical-align:bottom;padding-bottom:0.02in;border-bottom:0.5pt solid #000000;padding-right:0.03in;text-align:left;"><p style="font-size:9pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75%</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">*Percentages were calculated based on all participants. Patients who did not have an eGFR assessment at the visit were still included in the denominator.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">**Patients in the placebo arm switched to TransCon PTH following the Week 26 visit.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The PaTHway Trial recently completed with 73 of 82 patients originally enrolled and dosed completing the 3.5 year trial. Nine patients withdrew from the trial for reasons unrelated to safety or efficacy of the study drug.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On January 8, 2023, we announced top-line data from PaTHway Japan, a single-arm Phase 3 trial to evaluate the safety, tolerability, and efficacy of TransCon PTH in adults with hypoparathyroidism. The study achieved its primary objective, with top-line results consistent with our trials in North America and the EU. Twelve out of thirteen patients met the primary multi-component endpoint, which was defined as serum calcium levels in the normal range (8.3&#8211;10.6 mg/dL) and independence from conventional therapy (no active vitamin D and &#8804;600 mg/day of calcium). In this trial, TransCon PTH was generally well-tolerated, with no discontinuations related to study drug. As of March 31, 2025, 12 patients continue in the ongoing 3-year extension portion of the PaTHway Japan Trial.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, we announced that top-line data from the randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway Trial of TransCon PTH in adults with hypoparathyroidism demonstrated statistically significant higher proportion of participants treated with TransCon PTH achieved the primary multi-component endpoint compared to placebo. The primary endpoint, defined as serum calcium levels in the normal range (8.3&#8211;10.6 mg/dL) and independence from conventional therapy (no active vitamin D and &#8804;600 mg/day of calcium) with no increase in prescribed study drug within the 4 weeks prior to the Week 26 visit, was achieved by 78.7% of TransCon PTH-treated patients (48 of 61), compared to 4.8% for patients (1 of 21) in control group (p-value &lt;0.0001). In addition, all key pre-specified secondary endpoints were met with statistical significance. TransCon PTH was generally well tolerated, with no discontinuations related to study drug. Three patients discontinued during the treatment period, two from the placebo arm and one from the TransCon PTH arm. TransCon PTH-treated patients showed a mean decrease in 24-hour urine calcium excretion into the normal range.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">15</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon CNP</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Overview of Achondroplasia</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Achondroplasia is a rare genetic condition arising from a systemic fibroblast growth factor 3 (&#8220;FGFR3&#8221;) variant, which causes serious muscular, neurological, and cardiorespiratory complications in addition to the well-characterized skeletal dysplasia that leads to disproportionate short stature. Achondroplasia is associated with a well-delineated range of clinical complications and manifestations, occurring in about one in 10,000 to 30,000 newborns or approximately 250,000 worldwide. Achondroplasia results in severe skeletal complications and comorbidities including spinal stenosis due to premature fusion of the foramen magnum, sleep apnea, chronic ear infections, and muscular complications. Patients often face multiple surgeries to alleviate its many complications. There is significant unmet need for treatments that ameliorate complications and improve quality of life in achondroplasia.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Achondroplasia is primarily caused by gain-of-function variants of the FGFR3 gene resulting in constitutive activation of FGFR3 that leads to an imbalance in the effects of the FGFR3 and C-type natriuretic peptide (&#8220;CNP&#8221;) signaling pathways. In achondroplasia, FGFR3 is constitutively activated, suppressing the proliferation and differentiation of chondrocytes resulting in improper cartilage to bone conversion in the growth plate, and dysfunction in the skeletal muscle. Preclinical and clinical data show that the CNP pathway helps to counteract the constitutively activated FGFR3 downstream.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2021, BioMarin Pharmaceutical Inc.&#8217;s daily VOXZOGO</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174; </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(vosoritide) was approved by the FDA to increase linear growth in pediatric patients with achondroplasia with open epiphyses. Additionally, BioMarin is developing a long-acting CNP to build on VOXZOGO. Other companies that are developing therapies for achondroplasia include QED Therapeutics (a BridgeBio company), Ribomic, Tyra Biosciences, GeneScience, ProLynx, Peptron and Abbisko Cayman.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are subject to certain litigation with BioMarin Pharmaceutical, Inc. (&#8220;BioMarin&#8221;), including a case filed by BioMarin before the Unified Patent Court in Munich and a complaint filed by BioMarin with the International Trade Commission in the U.S. In response we have initiated legal action before the Danish Maritime and Commercial High Court as well as the District Court in the Northern District of California. Litigation in Europe relates to alleged infringement of EP3175863 and in the U.S. to alleged infringement of U.S. Reissue Patent No. 48,267. In both European and U.S. cases we take the view that we do not infringe the patents in question and that they are in any event invalid. In parallel, opposition proceedings against EP3175863 are ongoing before the European Patent Office with an appeal hearing set for October 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Changing the Treatment Paradigm of Achondroplasia</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Clinical manifestations of achondroplasia are associated with significant, potentially life-threatening complications and reduced quality of life. While achondroplasia has historically been considered a growth disorder, secondary manifestations beyond linear growth, including reduced muscle strength and stamina, suggest that achondroplasia is also a muscle disorder.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">16</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img149481191_6.jpg" alt="img149481191_6.jpg" style="width:624px;height:221px;"/></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">ACH-AE: Increased incidence of Achondroplasia-related Adverse Events.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">HRQoL: Reduced Health-Related Quality of Life; Height; Reduced height. Muscle Strength/Stamina; Reduced muscular functionality, including reduced strength and stamina.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: TransCon CNP</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon CNP (navepegritide) is an investigational prodrug of CNP administered once weekly and designed to provide sustained release of active CNP supporting continuous exposure for the treatment of achondroplasia. TransCon CNP is designed to provide effective shielding of CNP from neutral endopeptidase degradation in subcutaneous tissue and the blood compartment, minimize binding of CNP to the NPR-C receptor to decrease clearance, reduce binding of CNP to the NPR-B receptor in the cardiovascular system to avoid hypotension, and release unmodified CNP, which is small enough in size to allow effective penetration into growth plates. Shorter-acting CNP and CNP analogs in development have resulted in high maximum serum concentration (&#8220;C</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">max</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8221;) levels that may cause adverse hypotensive events. We believe the therapeutically sustained release of TransCon CNP offers advantages that may mitigate this issue, leading to continuous CNP exposure with a lower C</span><span style="color:#000000;white-space:pre-wrap;vertical-align:sub;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">max </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">to correlate with better therapeutic outcomes.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In February 2019, we were granted ODD by the FDA for TransCon CNP for the treatment of achondroplasia. In July 2020, we received OD from the EC for TransCon CNP for the treatment of achondroplasia.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Clinical Development of TransCon CNP for Achondroplasia</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our ongoing pivotal ApproaCH Trial, our long-term extension trial AttaCH, and COACH, are evaluating the safety and efficacy of TransCon CNP in children with achondroplasia. The reACHin Trial is evaluating the safety, tolerability, and efficacy of TransCon CNP in infants with achondroplasia (aged 0 to &lt; 2 years at the time of randomization). The teACH Trial is evaluating the safety, tolerability, and efficacy of TransCon CNP in adolescents with achondroplasia (aged 12 to 18).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2025, we announced data demonstrating improvements in leg bowing, a common complication in achondroplasia, observed with TransCon CNP compared to worsening observed with placebo in the pivotal ApproaCH Trial.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img149481191_7.jpg" alt="img149481191_7.jpg" style="width:720px;height:244px;"/></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">17</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced top-line data from ApproaCH, a pivotal, multicenter, randomized, double-blind, placebo-controlled trial of once-weekly TransCon CNP versus placebo in 84 children (aged 2 to 11 years) with achondroplasia. Participants were randomized 2:1 to receive TransCon CNP 100 &#181;g/kg/week or placebo for 52 weeks in the double-blind period, after which all participants could choose to receive TransCon CNP at the 100 &#181;g/kg/week dose in an ongoing open-label extension. In the trial, children treated with once-weekly TransCon CNP demonstrated annualized growth velocity (&#8220;AGV&#8221;) superior to those treated with placebo. TransCon CNP also demonstrated statistically significant improvements in other growth parameters, including height Z-score and change from baseline AGV.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Highlights of the ApproaCH Trial Top-line Data</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Primary Endpoint</span></p><div class="item-list-element-wrapper" style="margin-left:5.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5356267702001714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the primary endpoint of AGV at Week 52, children treated with TransCon CNP (n=57) demonstrated an LS mean AGV of 5.89 cm/year compared to 4.41 cm/year in the placebo arm (n=27), an LS mean difference of 1.49 cm/year (p&lt;0.0001).</span></div></div><div class="item-list-element-wrapper" style="margin-left:5.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5356267702001714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Sub-group analyses:</span></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Children aged 2 to &lt;5 years treated with TransCon CNP (n=21) demonstrated an LS mean AGV at Week 52 of 6.07 cm/year compared to 5.06 cm/year in the placebo arm (n=10), an LS mean difference of 1.02 cm/year (p=0.0084).</span></div></div><div class="item-list-element-wrapper" style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.7033333333333336%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">o</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Children aged 5-11 years treated with TransCon CNP (n=36) demonstrated an LS mean AGV at Week 52 of 5.79 cm/year compared to 4.02 cm/year in the placebo arm (n=17), an LS mean difference of 1.78 cm/year (p&lt;0.0001).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">AGV Change from Baseline</span></p><div class="item-list-element-wrapper" style="margin-left:5.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5356267702001714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Children aged 2 to &lt;5 years, treated with TransCon CNP (n=19) demonstrated a change from baseline AGV at Week 52 of 1.57 cm/year compared to 0.43 cm/year in the placebo arm (n=10), an LS mean difference of 1.15 cm/year (p=0.0047).</span></div></div><div class="item-list-element-wrapper" style="margin-left:5.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5356267702001714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Children aged 5-11 years, treated with TransCon CNP (n=35) demonstrated a change from baseline AGV at Week 52 of 2.29 cm/year compared to 0.52 cm/year in the placebo arm (n=17), an LS mean difference of 1.78 cm/year (p&lt;0.0001).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Secondary Endpoints</span></p><div class="item-list-element-wrapper" style="margin-left:5.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5356267702001714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the secondary endpoint of change in ACH Height Z-score, children treated with TransCon CNP (n=57) demonstrated an LS mean change from baseline ACH Height Z-score of 0.30 compared to 0.01 in the placebo arm (n=27), an LS mean difference of 0.28 (p&lt;0.0001).</span></div></div><div class="item-list-element-wrapper" style="margin-left:5.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5356267702001714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the secondary endpoint of change in CDC Height Z-score, children treated with TransCon CNP (n=55) demonstrated an LS mean change from baseline CDC Height Z-score of 0.15 compared to -0.15 in the placebo arm (n=27), an LS mean difference of 0.30 (p=0.0003).</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Safety Results Summary</span></p><div class="item-list-element-wrapper" style="margin-left:5.731%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5356267702001714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon CNP was generally well-tolerated and demonstrated safety profile was similar to that observed in the placebo arm, with generally mild treatment emergent adverse events (&#8220;TEAEs&#8221;), no evidence of hypotensive effect, and a low frequency of injection site reactions (0.41 events per patient year), all mild.</span></div></div><div class="item-list-element-wrapper" style="margin-left:5.731%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:3.5356267702001714%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No adverse events (&#8220;AEs&#8221;) led to discontinuation of TransCon CNP or withdrawal from the trial and no serious adverse events (&#8220;SAEs&#8221;) were assessed as related to TransCon CNP.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We submitted a New Drug Application (&#8220;NDA&#8221;) for the treatment of children with achondroplasia on March 31, 2025. We plan to submit a Marketing Authorisation Application (&#8220;MAA&#8221;) for the treatment of children with achondroplasia to the European Medicines Agency (&#8220;EMA&#8221;) during the third quarter of 2025.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2023, we announced new analyses demonstrating benefits beyond linear growth from the blinded and ongoing OLE periods of ACcomplisH, a Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial of TransCon CNP in children aged 2 to 10 years with achondroplasia. In the trial, all 57 patients have now completed one year of treatment with TransCon CNP at 100 &#181;g/kg/week, the dose agreed with regulatory agencies for the active arm in our pivotal ApproaCH Trial.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We analyzed available data for patients who only received TransCon CNP at the 100 &#181;g/kg/week dose in either the blinded or OLE period and were treated for one year (n=19), compared to those administered placebo for one year (n=15). Results showed that these TransCon CNP-treated patients (data available for 9-16 patients) showed improvements (nominal p-value &lt;0.05) in health-related QoL and disease impacts compared to those receiving placebo (data available for 5-13 patients).</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">18</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Assessments were performed with the SF-10 (a 10-item non-disease specific survey of a child&#8217;s functional health and well-being that has been validated to assess children aged 5 years and older) and the Achondroplasia Child Experience Measure (&#8220;ACEM&#8221;) a condition-specific clinical outcome measure that assesses the impact of achondroplasia on a child&#8217;s health-related quality of life, with statistically significant improved outcome in TransCon CNP-treatment versus placebo for:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">SF-10 Physical Summary (p=0.002, aged 5 years and older)</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACEM Daily Living Function (p=0.047)</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:6pt;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">ACEM Emotional Well-being (p=0.045)</span></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img149481191_8.jpg" alt="img149481191_8.jpg" style="width:624px;height:264px;"/></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The 46 children switching from placebo or a lower dose of TransCon CNP to the 100 &#181;g/kg/week dose in the OLE demonstrated improved growth after one year of treatment, similar to the growth benefits seen in the 11 children treated with 100 &#181;g/kg/week in the one-year randomized, double-blind period of ACcomplisH.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">During the third quarter of 2023, we filed an IND amendment with the FDA to initiate reACHin, a Phase 2, multicenter, double-blind, randomized, placebo-controlled trial, designed to evaluate the safety, tolerability, and efficacy of 100 &#956;g/kg of TransCon CNP once-weekly for 52 weeks in infants with achondroplasia, aged 0 to &lt; 2 years at the time of randomization.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, we announced top-line results from ACcomplisH, a Phase 2 randomized, double-blind, placebo-controlled, dose-escalation trial evaluating the safety and efficacy of once-weekly TransCon CNP compared to placebo in children with achondroplasia aged 2 to 10 years old.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACcomplisH Trial evaluated 57 children with achondroplasia aged 2 to 10 years old, randomized in a 3:1 ratio to receive either sequential ascending doses of once-weekly TransCon CNP (6 &#181;g/kg/week, 20 &#181;g/kg/week, 50 &#181;g/kg/week, 100 &#181;g/kg/week) or placebo for 52 weeks. The trial met its primary objectives, demonstrating that TransCon CNP at 100 &#181;g/kg/week (n=11) was superior to placebo (n=15) on the primary efficacy endpoint of AGV at 52 weeks (p=0.0218).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The ACcomplisH Trial completed in October 2024, with 55 of the original 57 children transitioning into AttaCH (n=53) a multicenter, long-term, open-label extension trial to continue treatment with TransCon CNP 100 &#181;g/kg/week, and into COACH (n=2), a TransCon CNP/TransCon hGH combination trial. For more information, see section entitled, TransCon CNP + TransCon hGH Combination Therapy. As of March 31, 2025, 45 patients continue in AttaCH, and 7 patients continue in COACH.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In 2019, we initiated the ACHieve Study, a five-year, multi-center natural history study designed to gain insight into the experiences of pediatric patients with achondroplasia. ACHieve was designed to evaluate growth velocity, body proportionality, and comorbidities over time in children with achondroplasia up to eight years old. No study medication was administered in the ACHieve Study. The study ended in the first quarter of 2024. We plan to make the results available in 2025.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">19</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon CNP + TransCon hGH Combination Therapy</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">While the CNP pathway may restore normal growth and skeletal muscle function, we believe delayed initiation of therapy could lead to a permanent height deficit. Clinical use of daily growth hormone injection has consistently demonstrated growth improvements in children with achondroplasia, including catch up growth; however, without reports of benefits beyond linear growth. We believe the combination of TransCon CNP and TransCon hGH, taken together once per week, by combining two independent mechanisms of action, may improve outcomes compared to monotherapy.</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">COACH, a Phase 2 open-label single-arm trial, is evaluating TransCon CNP and TransCon hGH in children with achondroplasia (age 2 to 11 years). The primary objective is to evaluate the treatment effect on linear growth and safety. Secondary objectives are to evaluate treatment effect on quality of life, radiological endpoints, physical functioning, and body composition. The trial enrolled 21 patients (treatment na&#239;ve, n=12; prior treatment with TransCon CNP (100 &#181;g/kg/week) for at least 1 year, n=9).</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Topline Week 26 results from our Phase 2 COACH Trial in children with achondroplasia are expected in the second quarter of 2025.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon Product Candidates&#8212;Oncology</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity in Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cancer continues to be one of the leading causes of mortality. Improved understanding of the cellular and molecular mechanisms involved in anti-tumor immune responses has fueled the rapid growth of immuno-oncology therapeutics. Immune checkpoint inhibitors, such as anti-PD-(L)1 and anti-CTLA-4 antibodies, have provided new therapeutic options for patients.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Despite recent advances, a high need for new treatment options remains for patients who do not respond to, or who respond inadequately to, current therapies. In addition to insufficient efficacy, many current treatments are limited by toxicities that result in dose reductions, treatment discontinuations, or long-term health risks to patients.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe that one approach to potentially improve efficacy while limiting adverse events is to create long-acting product candidates using our sustained systemic release TransCon technology, allowing for more consistent circulating drug levels and potentially avoiding high peak concentrations that are often associated with toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently developing TransCon technology in oncology for a variety of solid tumors, with encouraging early data in platinum resistant ovarian cancer and melanoma. Aside from Proleukin being the only approved IL-2, TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may face competition from other IL-2 type drug candidates in development, including those being developed by Mural, Anaveon, Medicenna, Roche, Werewolf, Innovent, Synthekine, Dragonfly, and Aulos. In addition, TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may face competition from drug candidates in development for platinum resistant ovarian cancer, including Merck, Corcept, Genelux, Daiichi Sankyo and Genmab. In melanoma, TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">may face competition from drug candidates in development including from Replimune, Mural, Philogen, Immatics, Immunocore, and Regeneron.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Our Solution: TransCon Technologies for Oncology</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe prolonging the therapeutic activity and targeting the drug activity to the relevant cell types and tissues have the potential to improve treatment outcomes. We believe TransCon is well-suited to improve cancer treatments given the large number of validated targets with known limitations. By applying our unique algorithm for product innovation to clinically validated targets and pathways, we believe TransCon has the potential to improve outcomes currently limited by suboptimal efficacy and systemic toxicity.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We believe TransCon technologies may have the potential to increase the efficacy of small molecules, peptides and proteins without increasing toxicity, which could offer the potential to treat more patients with new combination and multi-agent regimens that would not otherwise be feasible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are currently investigating one clinical-stage product candidate designed to activate the patient&#8217;s own immune system to eradicate malignant cells. We believe our approach, if successfully developed, has the potential to improve the efficacy of systemically administered, clinically validated therapies while limiting adverse effects.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our TransCon product candidate currently being investigated in solid tumors is designed to provide sustained systemic administration, which we believe could provide potent and durable anti-tumor efficacy. Our early clinical and nonclinical studies have shown sustained activation of cytotoxic immune cells that resulted in robust anti-tumor responses by TransCon product candidates using infrequent administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">20</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-style:italic;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:'Symbol',serif;font-style:italic;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">  for Sustained Systemic Release</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">(onvapegleukin alfa) is an investigational long-acting prodrug designed to improve cancer immunotherapy through sustained release of an IL-2 variant that selectively activates IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, with minimal binding to IL-2R&#945;. The IL-Believe Trial, a Phase 1/2 clinical trial to evaluate the safety and efficacy of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> in locally advanced or metastatic solid tumors, alone or in combination with pembrolizumab or other anti-cancer therapies, has completed dose escalation and is enrolling patients in multiple indication-specific dose expansion cohorts, including platinum-resistant ovarian cancer (&#8220;PROC&#8221;), cervical cancer, melanoma, and HER2+ breast cancer.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we announced initial data showing signs of clinical activity in heavily pre-treated patients with PROC treated (cohort 3) with TransCon IL-2 &#946;/&#947; in combination with chemotherapy in the ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 &#946;/&#947;. As of a cutoff date of July 29, 2024, of the 18 patients (median age 64 years) included in the initial assessment, 14 were efficacy evaluable patients who had one or more post-baseline tumor assessment(s), plus an additional four who discontinued treatment before the first post-baseline tumor assessment due to disease progression or death.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of the data cutoff, clinical responses were observed in 29% (4/14) of the efficacy evaluable patients (two confirmed and two unconfirmed partial responses in patients who had received three to seven prior lines of treatment &#8211; including patients whose disease had previously progressed on mirvetuximab soravtansine-gynx), suggesting the potential for clinical activity in heavily pre-treated patients. The data suggest that TransCon IL-2 &#946;/&#947; was generally well-tolerated: the most common TEAEs related to combination therapy with TransCon IL-2 &#946;/&#947; plus chemotherapy were fatigue, thrombocytopenia, neutropenia, and anemia. Most TransCon IL-2 &#946;/&#947;-related TEAEs were grade 1 or 2.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In June 2024, we reported updated results from our ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g.</span><span style="color:#58595b;white-space:pre-wrap;font-size:10pt;font-family:Arial;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Data included the first presentation of Phase 2 dose expansion Cohort 4 (TransCon IL-2 &#946;&#8260;&#947; in combination with TransCon TLR7/8 Agonist) in post anti-PD-1 melanoma and new analyses of patients from dose escalation cohorts with prior disease progression on checkpoint inhibitors, along with biomarker studies correlating cytotoxic immune cell expansion and observed clinical benefit. As of the April 16, 2024 data cutoff, confirmed clinical partial responses were observed in 40% (two out of five) of efficacy-evaluable patients from Cohort 4, suggesting potential synergy of our two novel immunotherapy candidates in patients who did not derive sufficient benefit from checkpoint inhibitors. Of efficacy-evaluable patients with prior disease progression on checkpoint inhibitors to date (from Phase 1 dose escalation cohorts) in the IL-Believe Trial, confirmed clinical responses (per RECIST v1.1) were observed in 45% (five out of eleven) administered TransCon IL-2 &#946;/&#947; doses &#8805;80 &#956;g/kg every 3 weeks, suggesting clinical benefit in treatment-resistant settings (monotherapy (n=4): 1 confirmed partial response (&#8220;PR&#8221;) in colorectal cancer; combination with pembrolizumab (n=2): 1 confirmed complete response and 1 confirmed PR in small-cell lung cancer; combination with TransCon TLR7/8 Agonist (n=5): 2 confirmed PRs in melanoma). In this trial, TransCon IL-2 &#946;&#8260;&#947; alone or in combination with pembrolizumab or TransCon TLR7/8 Agonist was generally well tolerated with no new safety signals.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In October 2023, we announced updated data from the ongoing Phase 1 dose escalation cohort from IL-Believe Trial. Forty-six patients were enrolled into dose escalation cohorts: 25 to monotherapy and 21 to combination therapy. As of the August 15, 2023, data cutoff, anti-tumor clinical responses were observed with TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">monotherapy (colorectal cancer with PR) or in combination with pembrolizumab (small cell lung cancer, one with confirmed PR and one ongoing with unconfirmed complete response) in heavily pre-treated patients who previously progressed on checkpoint inhibitors. TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> every three weeks was generally well-tolerated, with no meaningful effect on Tregs and eosinophils.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we announced completion of Phase 1 dose escalation in combination with pembrolizumab of the IL-Believe Trial with a total of 21 patients enrolled and RP2D determined at 120 &#181;g/kg IV every three weeks. Twenty-one patients were enrolled.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In May 2023, we announced completion of the Phase 1 monotherapy dose escalation of the IL-Believe Trial with RP2D determined at 120 &#181;g/kg IV every three weeks with 25 heavily pre-treated patients enrolled and a median of four prior lines of systemic therapies.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Strategic Collaborations and Investments</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We also engage in strategic collaborations to further leverage our TransCon technologies in certain geographies and therapeutic areas with market-leading biopharmaceutical companies. These collaborations aim to make promising treatment options available to more patients and to further monetize both our TransCon technologies and our internal product candidates, particularly into therapeutic areas where we believe a partner may have more expertise, capability, and capital. In addition, we may choose to pursue a collaboration to develop and market our internal, wholly owned product candidates in geographic markets outside our core focus areas of the United States and Europe.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">21</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Novo Nordisk A/S</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2024, we entered into a research and development collaboration and license agreement with Novo Nordisk pursuant to which we granted Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products (including Semaglutide) in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The agreement includes provisions requiring at least one TransCon Semaglutide product and at least one other TransCon technology-based product to be identified, developed and commercialized in metabolic diseases to maintain certain exclusivities in the field, with additional provisions for cardiovascular diseases. Under the terms of the agreement, Novo Nordisk also receives exclusive rights to expand any resulting metabolic disease products into other therapeutic areas. The lead program in the collaboration is a once-monthly TransCon Semaglutide product candidate that will initially target obesity and type 2 diabetes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, we have the potential to receive total payments of up to $285 million in upfront, development and regulatory milestone payments for the lead program. In addition, we have the potential to receive sales-based milestone payments and tiered royalties on global net sales. The $285 million includes an upfront fee of $100 million for the exclusive license that was paid to us in January 2025. For each additional metabolic or cardiovascular disease product candidate, we will be eligible to receive payments of up to $77.5 million in development and regulatory milestone payments. In addition, we have the potential to receive sales-based milestone payments and tiered royalties on global net sales. Novo Nordisk agreed to pay royalties for each potential licensed product developed under the agreement that are an escalating tiered, mid-single digit percentage of the annual net sales of such licensed product and are subject to reduction due to patent valid claim expiration, biosimilar product market share, payment made under certain licenses for third party intellectual property and Inflation Reduction Act price negotiations.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the agreement, we have agreed to conduct certain pre-agreed early research and development of TransCon product candidates under the collaboration and we are eligible to receive cost reimbursement from Novo Nordisk for its performance of such research and development activities under the agreement with respect to such TransCon product candidates. Novo Nordisk is responsible for any other non-clinical and clinical development, regulatory, commercial manufacturing, and commercialization of such TransCon product candidates, and all costs associated with such activities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Subject to the terms of the agreement, we granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. Additionally, we granted Novo Nordisk an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use its proprietary TransCon technology platform to develop, manufacture and commercialize GLP-1 receptor products using the TransCon technology for all indications, except for (i) certain pre-agreed rare endocrine indications, (ii) all indications in respect of the eye and adnexa and (iii) all indications in respect of oncology.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Until expiry of the last royalty term and for one-year thereafter, we are not permitted to research, develop, manufacture, commercialize, or otherwise exploit outside of the collaboration, any GLP-1 receptor product or any other licensed products that have been subject to the collaboration. We are also not permitted to undertake any research, development, manufacture, commercialization, or other exploitation of products outside of the collaboration in the metabolic field until expiry of the last royalty term of any licensed products that have been subject to the collaboration in metabolic diseases.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Unless earlier terminated, the agreement has a royalty term that continues, on a per licensed product and per country basis, until the later of (i) the expiration of the last valid patent claim for any of our patents, joint improvement patents, licensed product patents as well as any improvements made by Novo Nordisk covering the licensed product&#8217;s dosage regimen or target product profile, or (ii) 11 years after the first commercial sale of such licensed product in such country.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Novo Nordisk has the right to terminate the agreement without cause in its entirety or on a per licensed product basis. We have the right to terminate the agreement in its entirety in case Novo Nordisk brings patent challenges with respect to our patents. The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of the agreement due to Novo Nordisk&#8217;s default, some or all of the licenses granted by us to Novo Nordisk to develop, manufacture and commercialize any of the licensed products will automatically terminate.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Upon termination of the agreement due to certain defaults by us, Novo Nordisk may choose to either (i) have the license granted by us to Novo Nordisk to develop, manufacture and commercialize licensed products terminate in its entirety or on a product-by-product basis; or (ii) continue with respect to the affected licensed product at a reduced payment rate.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">22</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Teijin Limited</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, we announced that we entered into an exclusive license agreement with Teijin for the further development and commercialization of TransCon hGH, TransCon PTH, and TransCon CNP for endocrinology rare disease in Japan. Under the terms of the agreement with Teijin, we received an upfront payment of $70 million, with additional development and regulatory milestones of up to $175 million, transfer pricing and commercial milestones. In addition, we are eligible to receive royalties on net sales in Japan, of up to a mid-20&#8217;s percentage, varying by product.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In December 2024, Teijin announced the submission of an application for manufacturing and marketing approval of palopegteriparatide for the treatment of hypoparathyroidism in Japan.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2018, we announced the formation of VISEN, a company established to develop and commercialize our endocrinology rare disease therapies in Greater China. In connection with the formation of VISEN, we granted VISEN exclusive rights to develop and commercialize certain product candidates based on our proprietary TransCon technologies, including TransCon hGH, TransCon PTH, and TransCon CNP, in Greater China for use in all human indications, subject to certain exceptions. As consideration for the rights granted to VISEN, we received 50.0% ownership in the outstanding shares of VISEN and concurrently with the rights we granted to VISEN, entities affiliated with Vivo Capital and Sofinnova Ventures purchased shares in VISEN for an aggregate purchase price of $40 million in cash. In January 2021, we invested additional $12.5 million in VISEN as part of VISEN&#8217;s $150 million Series B financing.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 20, 2025, VISEN announced the pricing of its initial public offering (&#8220;IPO&#8221;) on the Hong Kong Stock Exchange. The shares offered in the IPO were priced at HKD 68.80 per share and expected to result in gross proceeds of HKD 783,288,000 (approximately USD 100 million) plus a potential greenshoe of up to HKD 117,489,760 (approximately USD 15 million). This amount was calculated before deducting underwriting discounts, commissions, and other offering expenses. The IPO closed on March 21, 2025, and VISEN&#8217;s shares began trading under the stock code 2561.HK. Ascendis Pharma holds 41,136,364 shares in VISEN. Following the IPO, the Company owned 39.2% in VISEN. The management and existing shareholders of VISEN, including Ascendis Pharma, have entered into customary lock-up agreements restricting the sale of VISEN shares for six months following the IPO; additionally, certain significant shareholders of VISEN, including Ascendis Pharma, are subject to an additional lock-up obligation during the period commencing on the date that is six months after the IPO and ending on the date that is 12 months after the IPO during which such shareholders may not sell shares of VISEN to an extent that would cause such shareholder to cease being a controlling shareholder of the VISEN pursuant to applicable listing rules. As of March 31, 2025, VISEN&#8217;s share price was HK$53.15, reflecting a total market value of our equity position of approximately &#8364;260 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2024, VISEN announced top-line data from the 26-week randomized, double-blind, placebo-controlled portion of the Phase 3 PaTHway China Trial of Palopegteriparatide (TransCon PTH) in adults with chronic hypoparathyroidism. VISEN reported a statistically significant higher proportion of patients treated with palopegteriparatide achieved the primary multi-component endpoint compared to placebo. The primary multi-component endpoint was achieved by 77.6% of palopegteriparatide-treated patients (45 of 58), compared to 0.0% of patients (0 of 22) in the placebo group (p-value &lt;0.0001). Results were consistent with those announced by us for its palopegteriparatide Phase 3 trial.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2024, VISEN announced that the BLA for lonapegsomatropin (TransCon hGH) was accepted by the China National Medical Products Administration.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2023, VISEN announced top-line results from the Phase 2 ACcomplisH China Trial in children with achondroplasia aged 2 to 10 years. VISEN reported that patients dosed with TransCon CNP at the 100 &#956;g CNP/kg/week showed significantly higher AGV than placebo at Week 52.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In November 2022, VISEN announced data from its pivotal Phase 3 study of TransCon hGH in children with GHD in China. VISEN reported that patients dosed with TransCon hGH demonstrated an AHV of 10.66 cm/year compared to 9.75 cm/year for the daily hGH at 52 weeks (treatment difference at 0.91 cm/year with a 95 percent confidence interval: 0.37 &#8211; 1.45 cm/year, p=0.0010), reaching its primary objective, demonstrating that TransCon hGH is non-inferior to the daily hGH.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">23</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Market Opportunity in China</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">China is the second largest pharmaceutical market in the world after the United States and represents one of the fastest growing pharmaceutical markets worldwide. In recent years, the Chinese government has initiated a number of regulatory reforms that are expected to accelerate drug development, as well as drive growth and demand for new therapeutics in China. In addition to joining an international organization that standardizes regulations for clinical development, the National Medical Products Administration has introduced initiatives such as fast track review for drugs for unmet medical needs and adopted new rules that streamline the drug approval process in China for global companies.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The purpose of our investment in VISEN is to support our strategy to extend our endocrinology rare disease portfolio globally and establish a presence in China in partnership with collaborators who have significant experience and knowledge of the biopharmaceutical opportunity in China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Rights Agreements</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under three exclusive license agreements, each effective November 7, 2018, and as amended January 4, 2021, between the Company and VISEN (collectively, the &#8220;Rights Agreements&#8221;), VISEN must use diligent efforts to develop and commercialize licensed products in Greater China. Additionally, we and VISEN will conduct certain research and development activities allocated to the respective party under a research and technical development plan, and VISEN will reimburse us for costs of conducting such activities, including costs of our personnel committed to performing such activities in Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We entered into a clinical supply agreement with VISEN in 2018 to provide product supply for use in conducting clinical trials in Greater China. Additionally, during 2023, we entered into a commercial supply agreement governing commercial supply of licensed product (TransCon hGH) to VISEN on the terms and conditions set forth in the Rights Agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the Rights Agreements, we agreed not to research, develop, or commercialize competing products in Greater China, and VISEN agreed not to grant certain rights under its interest in any inventions or intellectual property arising out of the activities conducted under the Rights Agreements to third-parties, in each case, under the terms and conditions specified in the Rights Agreements. We will have the right to exploit inventions and intellectual property arising out of the activities conducted under the Rights Agreements outside of Greater China. Additionally, we granted VISEN a right of first negotiation to develop and commercialize certain of our endocrinology products in Greater China.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Rights Agreements continue in effect for as long as a valid claim of a licensed patent exists in Greater China. VISEN may terminate a Rights Agreement for convenience, for uncured material breach by us of a Rights Agreement and for our bankruptcy or insolvency-related events. We may terminate a Rights Agreement for certain specified material breaches thereof by VISEN, in the event VISEN undergoes a change of control in favor of a competitor, if VISEN challenges the validity of any of the licensed patents and for VISEN&#8217;s bankruptcy or insolvency-related events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Eyconis, Inc</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In January 2024, we announced the formation and launch with Frazier Life Sciences of Eyconis, a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with a $150 million commitment from an investor syndicate that included Frazier, RA Capital Management, venBio, and HealthQuest Capital.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, we are eligible to receive development, regulatory, and sales milestone payments, plus single digit royalties on global net sales of commercialized products, if any. As of December 31, 2024, our ownership in Eyconis was 41.6%.</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">24</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Results of Operations</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financial Highlights (unaudited)</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.423%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.244%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100,954</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95,894</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,060</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Gross profit</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">83,437</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,325</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,888</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating expenses </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">187,649</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">137,470</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,179</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating profit/(loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(104,212</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(49,145</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(55,067</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Net profit/(loss) for the period</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(94,626</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(131,035</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">36,409</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash flows from/(used in) operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,313</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(101,582</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,269</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><div class="item-list-element-wrapper" style="display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.537%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating expenses comprise research and development expenses and selling, general and administrative expenses.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating loss for the three months ended March 31, 2025, represented an increase of &#8364;55.1 million, compared to the same period last year primarily attributable to higher operating expenses. Revenue for the three months ended March 31, 2025 primarily benefited from the launch of YORVIPATH in the U.S., partly offset by primarily lower license revenue.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We had a net loss of &#8364;94.6 million for the three months ended March 31, 2025, compared to a net loss of &#8364;131.0 million for the same period last year. This development was also attributable to a decline in net financial expenses of &#8364;57.7 million, compared to the same period last year. In addition, net loss was positively impacted by share of profit/(loss) of associates, which includes a non-cash gain of &#8364;33.6 million related to the Initial Public Offering of VISEN in March 2025. Refer to Note 4, &#8220;Significant Events in the Reporting Period&#8221; for further information.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Total equity presented a negative balance of &#8364;189.8 million as of March 31, 2025, compared to a negative balance of &#8364;105.7 million as of December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Further details about our results of operations and cash flows are described in the following sections.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Comparison of the Three Months Ended March 31, 2025 and 2024 (unaudited)</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies our revenue for the three months ended March 31, 2025 and 2024:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.423%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.244%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial products</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,028</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,499</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">29,529</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rendering of services and clinical supply</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,524</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,625</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,101</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,402</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,770</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23,368</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;">
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,954</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">95,894</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#ffffff;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,060</span></p></td>
     <td style="background-color:#cff0fc;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue for the three months ended March 31, 2025 were &#8364;101.0 million, representing an increase of &#8364;5.1 million compared to the same period last year. Revenue from sale of commercial products were as follows:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.423%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.244%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue from commercial products</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SKYTROFA&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,340</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,005</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,665</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">YORVIPATH&#174;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,688</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,494</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">43,194</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue from commercial products</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">96,028</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">66,499</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">29,529</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">25</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sale of commercial products represented an increase of &#8364;29.5 million, primarily due to the launch of YORVIPATH in the U.S. Revenue from sales of SKYTROFA was lower, primarily due to higher sales deductions, partly offset by continued demand growth and sale of commercial products under one of our collaboration agreements. Revenue for the three months ended March 31, 2024 benefited from lower than realized sales deductions of approximately &#8364;20 million related to sales of SKYTROFA in the U.S., and which was recognized as a negative adjustment to prior periods estimates and assumptions for sales deductions later in 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from licenses for the three months ended March 31, 2025 was lower due to non-cash license revenue related to our exclusive license agreement with Eyconis in January 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cost of Sales</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cost of sales for the three months ended March 31, 2025 was &#8364;17.5 million, representing an increase of &#8364;9.9 million compared to the same period last year. This increase was primarily attributable to higher volume of commercial sales, including costs attributable to our collaboration agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Research and Development Expenses</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies external project costs on the development pipeline and other research and development (&#8220;R&amp;D&#8221;) expenses.</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.423%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.244%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">External project costs</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon hGH</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,625</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">11,816</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(4,191</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon PTH</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,323</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6,319</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">12,642</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon CNP</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,071</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,744</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(5,673</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon IL-2 &#223;/&#947;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10,047</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,964</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,083</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">TransCon TLR7/8 Agonist</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,705</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,910</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(1,205</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other project costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,082</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,224</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(142</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total external project costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">36,853</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">32,339</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">4,514</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Other research and development expenses</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">37,945</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,266</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,679</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,595</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,843</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">752</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,156</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,239</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(83</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,054</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,054</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total other research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">49,750</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">38,348</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">11,402</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total research and development expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">86,603</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">70,687</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">15,916</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">R&amp;D expenses for the three months ended March 31, 2025 were &#8364;86.6 million, representing an increase of &#8364;15.9 million compared to the same period last year. This increase was primarily due to:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The three months ended March 31, 2024 benefited from reversal (income) of prior period write-downs related to pre-launch inventories for TransCon PTH of &#8364;10.6 million due to the launch of YORVIPATH in the EU in the first quarter of 2024, partly offset by overall maturity of our endocrinology rare disease pipeline;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Increased clinical trial expenses on TransCon IL-2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">b</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">/</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Symbol',serif;font-kerning:none;min-width:fit-content;">g</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> programs, partly offset by lower expenses on TransCon TLR7/8 Agonist, due to cessation of program activities in 2025;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Higher employee costs to support future growth; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Impairment charge on property, plant and equipment due to change in activities at one of our sites in the U.S. </span></div></div></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">26</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Selling, General and Administrative Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies selling, general and administrative expenses:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.423%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.244%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Selling, general, and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Employee costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">50,320</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,543</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16,777</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other costs</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">45,328</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">31,795</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">13,533</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Depreciation</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,944</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,445</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">499</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Impairment</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,454</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,454</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total selling, general, and administrative expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">101,046</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">66,783</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">34,263</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Selling, general, and administrative (&#8220;SG&amp;A&#8221;) expenses for the three months ended March 31, 2025 were &#8364;101.0 million, representing an increase of &#8364;34.3 million compared to the same period last year. This increase was primarily due to the impact from commercial expansion including global launch activities for YORVIPATH. Impairment charge relates to property, plant and equipment due to change in activities at one of our sites in the U.S.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Finance Income and Finance Expenses</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the result of finance income and expenses, further disaggregated into cash and non-cash items:</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.423%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.244%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td colspan="11" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net finance income/(expenses)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,854</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,575</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,279</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance expenses</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(44,786</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(77,161</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">32,375</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total net finance income/(expenses)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(15,932</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(73,586</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">57,654</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified in cash and non-cash items</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Cash items</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance income received</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,208</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,588</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">620</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Finance expenses paid</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(954</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(877</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(77</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;text-decoration:underline solid;font-kerning:none;min-width:fit-content;">Non-cash items</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement gain/(loss) of financial liabilities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(23,911</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(53,995</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30,084</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Currency gain/(loss)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,646</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(8,620</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33,266</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Amortization charges, accruals, and other items</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(19,921</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(13,682</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(6,239</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total net finance income/(expenses)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(15,932</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(73,586</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">57,654</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in non-cash items was primarily due to lower remeasurement loss of financial liabilities, and net currency gains, primarily driven by conversion of U.S. dollar denominated monetary positions into Euro, primarily cash and cash equivalents, convertible notes and royalty funding liabilities. The increase in amortization charges, accruals, and other items primarily relates to amortization charges on our royalty funding agreement related to YORVIPATH, which we entered into in September 2024. Refer to &#8220;Liquidity and Capital Resources&#8221; for further information about our royalty funding agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">27</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Liquidity and Capital Resources</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our liquidity and capital resources comprise cash and cash equivalents, which as of March 31, 2025, amounted to &#8364;517.9 million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our expenditures primarily relate to R&amp;D and SG&amp;A activities to support our business, including our continued development of product and product candidates within our Endocrinology Rare Disease and Oncology portfolios, the commercialization of SKYTROFA and YORVIPATH, and expenses made in anticipation of potential future product launches. We manage our liquidity risk by maintaining adequate cash reserves and banking facilities. We monitor the risk of a shortage of funds through a liquidity planning tool to ensure sufficient funds are available to settle liabilities as they become due.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">  </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the unaudited condensed consolidated interim statements of financial position presented a negative balance of equity of &#8364;189.8 million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company, holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on our current operating plan, we believe that our existing capital resources as of March 31, 2025 will be sufficient to meet our projected cash requirements for at least twelve months from the date of this report. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Historically, we have funded our operations primarily through the issuance of preference shares, ordinary shares (including public offerings and exercise of warrants), convertible debt securities, payments to us made under collaboration agreements, and our royalty funding agreements. Including our initial public offering, since February 2015, we have completed public offerings of American Depositary Shares (&#8220;ADSs&#8221;), most recently in September 2024, with total net proceeds of $2,580.2 million (or &#8364;2.259.0 million at the time of the offerings).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have entered into capped synthetic royalty funding agreements with Royalty Pharma (the &#8220;Purchaser&#8221;), which are presented as part of borrowings, and represents the Company&#8217;s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, we entered into a $150.0 million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Yorvipath Agreement&#8221;) with the Purchaser. Under the terms of the Royalty Pharma Yorvipath Agreement, we received an upfront payment of $150.0 million (the &#8220;Yorvipath Purchase Price&#8221;) in exchange for a 3% royalty on net revenue from sales of YORVIPATH in the U.S. (the &#8220;Yorvipath Revenue Payments&#8221;). The net proceeds were $148.2 million (&#8364;134.2 million) after deducting offering expenses. The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of 2.0 times, or 1.65 times if the Purchaser receives Yorvipath Revenue Payments in that amount by December 31, 2029. The Royalty Pharma Yorvipath Agreement includes a buy-out option under various terms and conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, we entered into a $150.0 million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Skytrofa Agreement&#8221;) with the Purchaser. Under the terms of the Royalty Pharma Skytrofa Agreement, we received an upfront payment of $150.0 million (the &#8220;Skytrofa Purchase Price&#8221;) in exchange for a 9.15% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on January 1, 2025 (the &#8220;Skytrofa Revenue Payments&#8221;). The net proceeds were $146.3 million (&#8364;136.3 million) after deducting offering expenses. The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of 1.925 times, or 1.65 times if the Purchaser receives Skytrofa Revenue Payments in that amount by December 31, 2031. The Royalty Pharma Skytrofa Agreement includes a buy-out option under various terms and conditions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, we issued an aggregate principal amount of $575.0 million of fixed rate 2.25% convertible notes. The net proceeds from the offering of the convertible notes were $557.9 million (&#8364;503.3 million), after deducting the initial purchasers&#8217; discounts and commissions, and transaction costs. The coupon interest is payable semi-annually. Unless earlier converted or redeemed, the convertible notes will mature on April 1, 2028. Refer to Note 10, &#8220;Financial Assets and Liabilities&#8221; for further information about our convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional description of our cash requirements, public offerings, expense structure and commitments, refer to &#8220;Item 5B. Liquidity and Capital Resources,&#8221; set forth in our Annual Report on Form 20-F filed with the Securities and Exchange Commission on February 12, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">28</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we are able to generate product revenue from sales of our products;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the manufacturing, selling and marketing costs associated with our products and product candidates, if approved, including the cost and timing of building our sales and marketing capabilities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the timing, receipt, and amount of sales of, or royalties on, approved products and any future products; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the sales price and the availability of adequate third-party coverage and reimbursement for our products and product candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs related to manufacturing of our products and product candidates, including the timing of when we incur such costs and the potential impact of any tariffs or trade restrictions;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to establish and maintain strategic partnerships, licensing or other arrangements and the financial terms of such agreements; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our ability to collect payments which are due to us from customers and collaboration partners (if any), which in turn is impacted by the financial standing of any such customers and collaboration partners; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the progress, timing, scope, results and costs of our preclinical studies and clinical trials and manufacturing activities for our products and product candidates, including the ability to enroll patients in a timely manner for clinical trials; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time and cost necessary to obtain regulatory approvals for our products and product candidates and the costs of post-marketing studies that could be required by regulatory authorities; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the cash requirements of any future acquisitions or discovery of products or product candidates; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the number and scope of preclinical and discovery programs that we decide to pursue or initiate; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the potential acquisition and in-licensing of other technologies, products or assets; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the time and cost necessary to respond to technological and market developments, including further development of our TransCon platform; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the achievement of development, regulatory and commercial milestones resulting in the payment to us from collaboration partners of contractual milestone payments and the timing of receipt of such payments, if any; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">our progress in the successful commercialization and co-promotion of our products and product candidates, if approved, and our efforts to develop and commercialize our other existing product candidates;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the market opportunities and patient populations for our products and product candidates, if approved,  and our ability to obtain market acceptance of our products and product candidates, if approved; </span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the costs of filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights, including litigation costs and the outcome of such litigation, including costs of defending any claims of infringement brought by others in connection with the development, manufacture or commercialization of our product candidates; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">the extent to which we purchase ADSs prior to granting rights or awards for such shares under our equity incentive plans. </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Additional funds may not be available if we need them or on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, scale back or cease our research and development and commercialization activities.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">29</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes our cash flows for the three months ended March 31, 2025 and 2024:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:57.423%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.164%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:11.244%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Change</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Cash flows from/(used in)</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Operating activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(14,313</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(101,582</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">87,269</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Investing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(703</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7,155</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(7,858</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Financing activities</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(18,024</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18,423</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(36,447</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Net increase/(decrease) in cash and cash equivalents</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(33,040</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(76,004</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">)</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">42,964</span></p></td>
     <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows from/(used in) Operating Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows used in operating activities for the three months ended March 31, 2025, were &#8364;14.3 million, representing a decrease of &#8364;87.3 million compared to the same period last year. This improvement was primarily related to working capital balances with &#8364;102.3 million, primarily due to settlement of the upfront payment from our exclusive license agreement with Novo Nordisk of $100 million plus indirect taxes, partly offset by increased operating expenditures.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows from/(used in) Investing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows used in investing activities for the three months ended March 31, 2025, were &#8364;0.7 million, representing an increase of &#8364;7.9 million compared to the same period last year. This increase was primarily attributable to &#8364;7.3 million settlements of marketable securities in 2024.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Cash Flows from/(used in) Financing Activities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Cash flows used in financing activities for the three months ended March 31, 2025 were &#8364;18.0 million, representing an increase of &#8364;36.4 million compared to the same period last year. This increase was primarily attributable to acquisition of treasury shares of &#8364;17.4 million, payment of withholding taxes under stock incentive programs of &#8364;11.4 million, and lower proceeds from exercise of warrants of &#8364;7.4 million compared to the same period last year.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Off-Balance Sheet Arrangements</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have not entered into any off-balance sheet arrangements or any holdings in variable interest entities.</span></p><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Qualitative Disclosures about Market Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Our activities expose us to financial risks of changes in foreign currency exchange rates, inflation rates and interest rates. We do not enter into derivative financial instruments to manage our exposure to such risks. Further, we are exposed to credit risk, equity risk and liquidity risk. For a description of our exposure to liquidity risks, including risks associated with the royalty funding liabilities and processes for managing these risks, please refer to &#8220;Liquidity and Capital Resources,&#8221; set forth above, and maturity analysis for non-derivative financial liabilities provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Foreign Currency Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the U.S. Dollar. While we generate revenue in Euro, a significant portion of our revenue is denominated in U.S. Dollars. Similarly, a significant portion of our operating expenses are denominated in U.S. Dollars. In addition, our outstanding convertible notes and royalty funding liabilities are denominated in U.S. Dollars. We seek to minimize our exchange rate risk by maintaining cash positions in the currencies in which we expect to incur the majority of our future expenses and we make payments from those positions.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Interest Rate Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Outstanding convertible notes comprise a 2.25% coupon fixed rate structure. In addition, the interest rate on lease liabilities is fixed at the lease commencement date. Future indebtedness, including those related to lease arrangements, if any, may be subject to higher interest rates. In addition, future interest income from interest-bearing bank deposits may fall short of expectations due to changes in interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative liabilities are measured at fair value through profit or loss. Accordingly, since the fair value is exposed from the development in interest rates, the profit or loss is exposed to volatility from such development.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">30</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
  <div style="padding-top:0.5in;z-index:2;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#160;</span></p></div>
  <div class="main-content-container" style="z-index:5;position:relative;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Inflation Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Inflation affects us as our vendors may pass on any increased costs to us and accordingly increase our R&amp;D expenses, SG&amp;A expenses and cost of manufacturing. We do not believe that inflation had a material impact on our results of operation for the three months ended March 31, 2025.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">    </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Credit Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We have adopted an investment policy with the primary purpose of preserving capital, fulfilling our liquidity needs and diversifying the risks associated with cash, cash equivalents and marketable securities. Our investment policy establishes minimum ratings for institutions with which we hold cash, cash equivalents and marketable securities, as well as rating and concentration limits for marketable securities held. All material counterparties are considered creditworthy. While the concentration of credit risk may be significant, the credit risk for each individual counterpart is considered to be low. Our exposure to credit risk primarily relates to cash and cash equivalents. The credit risk on our bank deposits is limited because the counterparties holding significant deposits are banks with high credit-ratings (minimum A3/A-) assigned by international credit-rating agencies.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We maintain the majority of our cash and cash equivalents in accounts with major financial institutions, and our deposits at these institutions exceed insured limits. Market conditions can impact the viability of these institutions. In the event of failure of any of the financial institutions where we maintain our cash and cash equivalents, there can be no assurance that we would be able to access uninsured funds in a timely manner or at all. Any inability to access or delay in accessing these funds could adversely affect our business and financial position. The banks are reviewed on a regular basis and deposits may be transferred during the year to mitigate credit risk.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In order to mitigate the concentration of credit risks on bank deposits and to preserve capital, a portion of the bank deposits may be placed into marketable securities. Our investment policy, approved by the Board, only allows investment in marketable securities having investment grade credit-ratings, assigned by international credit-rating agencies. As of March 31, 2025, we do not hold marketable securities.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On each reporting date, we consider the risk of expected credit loss on bank deposits and marketable securities, if any, including the hypothetical impact arising from the probability of default, which is considered in conjunction with the expected loss caused by default by banks or securities with similar credit-ratings and attributes. In line with previous periods, this assessment did not reveal a material impairment loss, and accordingly no provision for expected credit loss has been recognized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Risk</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">We are exposed from the development in our share price, when remeasuring derivative liabilities at fair value.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes and are measured at fair value through profit or loss. Fair value cannot be measured based on quoted prices in active markets or other observable inputs, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model, where the pricing is exposed from changes in our share price. Sensitivity analysis over derivative liabilities is disclosed in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div>
  <div style="z-index:2;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">31</span></p></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img149481191_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_0.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $$!#@# 2(  A$! Q$!_\0
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M^5:-M\>;=B1=Z-Y&.ZS[\].@P3^OZ5WT^.^&:ED\=.DWLJN$Q4?O:I2BOO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%86K>*/#.@HTNN>(M"T:-2
M0TFJZM8:>@(Z@M=W$(!]LYKS+4OVD/V?='F,&J?&[X4Z?,O)BN_'OAB%Q]5?
M4P:Z*6$Q5?6CAL167>E1J5/_ $B+./$9CE^$TQ6.P>&?;$8FC1WV_B3CN>U4
M5X'!^U3^S/<L%M_C]\'IF+! L?Q$\*LQ9N%7 U3.3V%=]H7Q5^&/B<[?#GQ$
M\$:ZV<;-)\4Z)?OGK@);7TCG\%JZF QU%<U7!8NE%;NIAZT%]\H)&='-\JQ,
ME##YGE^(F]%&CC<-5DWV4:=63?W'?44R.6*9!)#)'*AZ/&ZNA^C*2#U'0T^N
M0]#?8**** "BBB@ HHHH **** (Y?]4_^Z:*)?\ 5/\ [IHH ^</C7_R%M,_
MZ]&_]#->)5[;\:_^0MIG_7HW_H9KQ*OY[XN_Y*+-/^PB/_J/0/"Q7\6O_C7Y
M1(&ZGZG^=1OT'U_H:D;J?J?YU&_0?7^AKYLQ?P?*/Z$5(W0_0_RI:1NA^A_E
M6,_B?R_)&1!1114FD?@E\_R05"_WC^'\A4U0O]X_A_(5$MX>OZHA;2]/U0VB
MBBLA%>HGZCZ?U-2U$_4?3^IK-_#/_$_S0#****REL_1_D!'#_K8O^NB?^A"K
MFJ?\?]Q_O#_T$53A_P!;%_UT3_T(5<U3_C_N/]X?^@BG+^#4_P"OU+_TW5'T
M?JORD9]5ZL57KDEO#U_5"(7^\?P_D*;3G^\?P_D*;6<MWZO\R9_"_E^:"H7^
M\?P_D*FJ%_O'\/Y"I>WSC^:,X_:_PO\ 0;2-T/T/\J6D;H?H?Y5E/XG\OR1)
M!37^Z?P_F*=37^Z?P_F*DN.T_3]&0TC=#]#_ "I:1NA^A_E7.004445,_A?R
M_- :>H_ZC2?^O1O_ $*L5NI^I_G6UJ/^HTG_ *]&_P#0JQ6ZGZG^=/$_QY?X
M*'_J/2![O_MW_P!(B1N 5.0.W;W%1@D< D?0D?R(J5_NG\/YBH:XZF_R_5@1
MN.A))(.06)8C@_WB:F2]O8QB.[N(@.@CE9,<8XVD']:B?H/K_0U%6=EV7W(#
M4MM;U>S;?;:C>1-G.1<SGGUYDQFMI/'WC.-E:/Q)JL>P !8KID0@?WEPV3[]
MATKD:*U6*Q5!)T<5B:+35G1Q%:DUITY)QMLMA.4HIN,I1?DVNJ[/R/2K7XS?
M$2S $.O3L1T:9O./7/(90.PR>YSD5NV?[0GQ'M>9]1AO,9.'MHEXY.#C&>N!
M].1G%>(4C=#]#_*O1I\2\18=VH9]G%-*UDLQQ;2T72562Z=C55JRVK55JG_$
MGT]7Y'TA;_M/^-(V02V&E2QJN&WQ/O9O7<C* /;!KHX?VK+V&/-SX=AN91CY
M(97A0^OS-N(]CCKQR>*^1::_W3^'\Q7H4?$'C2@VH<0XV2BKI5HX:O>UM_;4
M)MWZZ_H.&.Q:O^_D[)O6TOONG_7R/MFQ_:NTN4+]N\-7%J<?-Y=V)1^'[D?7
M!-=%;?M1>!97"36.KPG^)Q%$T8YXY:1"?7I7Y_45ZE'Q9XVI-<V/PF(2Z5\O
MPVNV[HQHO[K&BS3%K[4)>L%Y=K?TS]*8/VA/AK)'YDVJS6HR!B6W+-D] %B9
MR3T[8YZUTME\7OA[J$(N+?Q%;>27\O?+'/$ ^,E29(UP0 <_IFORPP/0?E6F
M[-_8(^9A_P 3-^C,/X?0&O6PGC3Q1[ZKX/)ZZA2G._L,52DW'ELKQQ;BNM_=
M]$NFL<VQ.K<*+M&_PR5W=+?G\^Q^JUO\0/!-TP2#Q1HKN?X/MT*N.V"KLI'/
M%;D&N:-=#=;ZKITP]8[RW8=<=I*_'-?D;>A*/UWKPW_?76K!O[]5.+Z\4<?*
MMS,BG!R,A'7H>?RKT:/CKCXV^L<.X.ILFZ./K4MVEHIX:M^9HLYG]JA%^DVO
MSBS]DUN('QLGA?/3;(C9^F&-2U^/=IXP\3V'%GK>H0 <#;<SMC@C^.1O7CTZ
M=*U;/XI?$#3W)B\5ZQ("<E);MF3L< %20. , XQ7JT?'?+]L5P]CJ;ZNAC,/
M67R52G0_,TCG,&ES4)I]>6<9?FHGZWT5^6T/[0'Q2M]HA\0$*,966%)\XZY+
M@<_A^-=+:?M/?$:V"^<]E>E<9\VW1 V,==I'7_.<\>K1\<>%)V]O@LZPW=RP
MV&JI;?\ /K%R;W_E-%G&&LG*%:/?W8M+;M.[WZ+H?I)17Y\V'[6OC!"/[0T;
M2)5SR84E1L>G^L S[]*ZB#]K_:RK<>$_.4@;I(KPPD'." K1R COGCZ5ZU'Q
MAX$JZ3S+%8=Z75?+<:K7Z-TZ-6/XV\S99G@W_P O)1]:<_T3/MZBODFV_:V\
M*,JF\T:^MR?O+%*LS#UZQ1C]:Z"Q_:H^&]WCS4UBSSWGMHL#KR<3Y P,YQW%
M>Q0\2N!<0TH<2Y?%O95Y5<,_G[>E3MZ,TCF&#EMB(?.\>W=+NCZ6HKQ"#]HG
MX43.D;^(U@D<;MLMM,0H_P!IHUD4'VSG/&*ZFU^+?PZNXQ+%XKTM4./FFE,
M&<]?-5,=/I7L8?BOAC%6^K\0Y+6;M90S/!N3OM[OMKW?:US6.)P\OAKT7Z5(
M>7GYH]&HKE[;QMX0O0&M?$NBSANACU&V.?\ R)_.MJ+4]-F ,.H64H/0QW4#
MY_[Y<UZ]+&82NKT,5AJR[TJ]*HOOA)FJG"7PRB_22?Y,O44U9$?[CH_^ZP;^
M1-.KI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6GTS1?B:VN? WQ5>R16SKXHMVO\ PLUW,RJD<.OZ>DCQH6)W27=E#%$ &>8
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MY(H@IK_=/X?S%.IK_=/X?S%8OXI_X7^2,8_:_P +_0AHHHK,D*T7_P"0"/\
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MSSP2*M6'QO\ B=IJKY?BG4+C  S=2F4].IXP3QW]>E<+I/\ Q[:W_P!> _\
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MM^(6'MR\0U*J6ZQ&"RZM?U<L)S_=(UCF>.C_ ,OV_P#%"F^W]R_3\S]*;?\
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M_=/X?S%0U[.&\5?$7"V]EQ?F\DK:5ZE'%+3_ +"J-9_B;+,<=';%5?FXRO\
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MK5/#NH6>L:->S6&HV4L<UO<P.4=64YPV"-Z,!M=&RK#@BN3M_N#Z#^M;%O\
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MV?6W9I]2"BBBN*?POY?FB33U'_4:3_UZ-_Z%6*W4_4_SK:U'_4:3_P!>C?\
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M%L,DX"B62),DOQX4;JV!93<VX*??!GB!3_>!?*_\"Q7[E:]^R;\)?''[#?\
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MYQ_-$D-0O]X_A_(5-3 $,A\QMD:JTDK_ -R*)#)(WU5%8CW%93^)_P!=$!&
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M,_A?R_-$D+@Y)QQTSVS@<4VO#],\9>([G]I3QE\/YKY6\)Z7\,-(\1V.G"%
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MJMK;Z=Y;FXD)& "17R-;+N%4L^PU>M0@XYA@^),]ISQM6$L-BJ3H8S"XZO\
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M1;36]0,K,/-ET> M<6\62V\#:,XJ+XI?"3XB:#J'P-\-^!/#NO\ C#X*^!/
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M/$>NV7A;P[KWB?4A(=-\.:1?ZUJ A7=,;/3K>2ZN!$O\4ABC8(.[8KY2T_\
M;5\"3:/H7BGQ%\.?BKX,\!>(S9G3O'VM^'V;PTD5_.;:SO+^YMP[6=C/, !<
MR*L:@Y9A6F$RK,<PISJ8'!U<3"G5A1DZ?)?VTHNI&E"$I1G5JRIPE*-*C&I4
M:3:B$:<YJ\(N5G;2V]FTDFTVW;9)OR/KZF IYA$J[XG5XI5!P6BEC:*0 ^I1
MV ]ZX^3QO9IXO@\*II.K2V4_A%_&2^-8H5?PB--1%F%J=2!*F_>V;[2D2D[H
M@2/6O"4_:V\"7'A2'QG:^$?'5WI.M>+AX)\#1PZ:GVSXAZQYES#+-X:A)R]C
M UI<&2>;8NR/()R,YTLHS+%:X?!U:J?L%>#AOB?:JBFW-<LIJA6GR-J<*=*K
M4FHPISDB-.<E>,6]MK?:O;=K>S]+.]CS_P $>'OV@OV?-#\8_"SP-\,K#XD>
M'[[Q)X@U_P"%WC)=>M-,LM#'B6Y>\>R\86-Q(D_EZ5>2RR[[96^T1 (,GBMK
MQ+\'_BCXT\>:#?\ BNXTQI[_ /9T\9?#[Q;XLTA3;Z3:>-/$)C:W@L;0D3M8
MHV8C,%Y12QY-?85E/-=65G=/!<6#WEM%</87+B.ZM7D0,]K<1A@#/ <QRA0R
MA@<'%3X;:3_#SD%@!D=<C/7TR.>@KLJ\1XI8BKBXX3+Z6/JJNL5C:=.K+$8F
MM6I*A.O-U,14HPFY1=9PP].EAZE=RJU*4](QIUY*\E&/.TU*23O)M)7M=I/J
M[*UVVT]$OSP^$_P(\9Z5JGP?TG7_ (?:YITGPD6X>Y\6>(_B!/K/AA-2L;":
MPT?4O!6@0%R!>R-'/<03A(X8V='R17$R_!3XZZ_JG@&3Q=X,U[4?$OA7XUV'
MC'Q9XSNO&-N_A'4O#-OJMQ-;/X3\*PN(K5K>SDA$V^,2HR.3EF)/Z?$.0 22
M,9"%^0!QD(3D#W"XH^? .X@'Y1EP >VU06')_N@9/7%=,N-,Q6(JXAX?!2J5
M(<BE-XV;IN4\95JNE.6-<XPK3QU:53#N4L,Y0H2]ES45)W]9GS.5HW:MKS::
MR;L^9/5R;:O;2.FB/G+X8^ O$WAOQ!^U+J&J:7%:Q_$OQEJVJ>%;E#"\VKZ9
M<>'%L;5Y) /,B0W@9%C=EV\MC%?,'Q&\$>+?A9^QU\-?$$J6N@?&3X'^)(=:
M\)P3RB1;G6-;U2:Q.@B6$DS+JEK.A:)-P9D'!(X_0^Z\2:#8Z_HWA:^U>SM?
M$/B"&\N-%TF>4+=7]OIX#7TT*'D16JLK2$XX.0#7(Z3J>B?$Z#6K;6_!6HPV
M?A?Q2]E#:^+[!4AU#4-)??;>(=*C<[9[-7&^SNFR%8Y'-<^#SS'4,33Q]?"P
MGA(8K)\;BH1@X+$X; 82ODU/#Q]M4<:F&QN&GB<-BG&,XN7.KP490<PJRC+G
MDKPO3E-)6NJ<732O)VY91;C)--;ZI:&%\$? +?#;X8>'/#]V ^OW\<WBCQ==
M$9DO/%'B)SJ6JR2N?G<QSSO$FXDJB@# XKU6LW7M<TGPUI&H>(O$>I6VE:)I
MD(N-1U6[D5;6UA+!%DDDS@@L0H"Y.3C Q5ZWFAN[:VO;:6.:TN[>&ZMKA'7R
MIK>=!)#*KD@;9$(9<GH1G!KYC%UL1C*U?,,0I.6+Q-:<ZO*U3E7DU5J4X2MR
MWA&I"U-.\*<H:*+C?"HVU*3WE)Z]+W4FD_)-:=%8<_W3^'\Q4-6&1CE<8/!Y
M(  R.22< >^<5Y_HGQ!T/7O'?C?X=V4=VNN^ ;31;W6Y98P+*2'7HO.LA9S
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M%I!8O=:?/>SZ3;*IVV D,DDS6_[A&W9VYQ4_ZKY8LRC26+<I+&QJ5*$Z-/\
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M*Q.)Q-23E4Q.(KXBI*3O*4Z]6=63;ZMRDVWU>H4445J8!1110 4444 ?=O\
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M7 (^_+NSM+^TNK"^MXKNQO;>6TO+2=0\%U:SH8Y[>9.C12QLR.O=217EVC?
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MI2&'4;=X@D3ZE8G-M.7B#QO&=K%2";^I?LC:_P"(?AWK^DZEXD\%^%?B!/\
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M-R4K6LO:64;:.-[WU9]0:)<ZK>:+I-YKNF+HFN75A;SZOHJ3K=+I.H/&&N;
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MKK4)\*WVDO<VO@KRR/LOC^;33I,OBAN?+(:S2%>!OR'.<GGBO^&;/%EI\./
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M+T7YQ)E\$?E^3+=MT'U;^5;<'W5_W?ZBL2VZ#ZM_*MN#[J_[O]179A-EZO\
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MH02_? KZJCC2)$CC14C10B(@"JJJ,!5 X  X %.          P !P  .  .
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M)[]K#X'?LD?%OXK^*?CUJFM:5X7\<?#>+PC82Z'I<NJW,MU)>W$EW')'"RM
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MX/$P^OXK)\SAF^">+PWUYX!3^N4J#Q.,PF#PN8XRC0I4L5C:L5+F_H#^(_\
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M@33ZU-"T"_\ %GB#P]X3TNWEN]3\4:[I6@6%M "TT]QJE[%;*D2@$L^UW90
M<[:3E&*<IM1C%.4I-V48Q5Y-MZ)))MMZ)*Y4(3J2C3IQ<ZE2484X)-N<YM1A
M%)7;<I-)))MMV6I_;Q_P11^&DGP^_8*\!ZA=VGV34?'VK>(?&-TA4AI(;R^>
MVL)F) ),UK;I(#C&UEP>M%?HU\$/AW9_"3X+?#/X9V( M_ _@3PYX;!VJADE
MTS2K:WN9G"X'F37"RRR'JSLQ/)HK_/+B/,O[8S_.<TNW''9EC,33NV[4JE>;
MI+7I&ER)=DK'^SO!&1KAG@_AC(+)2RC(\LP-6UM:]#"4HXB6FEY5_:2;6C;;
M.&^-?_(6TS_KT;_T,UXE7MOQK_Y"VF?]>C?^AFO$J_F'B[_DHLT_["(_^H]
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M_H-9=:FA_P#(9T__ *Z/_P"@U&"_WS"?]A-#_P!.P"GLO\<?SB8\W_'Q<_\
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MGP^28'):M#"T(Y50R.:RNAQ??VN"PTUQ J-.B\WI>SC5]M[6G+)_:(G^,G[
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M0?&[Q#X\TO13HLZZ9+X>U'Q5%JMK/)JYE\F*:2P0RM 4++)^Z/.&KZ,^)/\
MP4Y^$?AOP%_P3WU/X.WNK>*O'_[,-S:GXF>&+S1I-+AN='DT*+2M8TW3=1N'
MEAGNI_WT5M*L>U3Y<IZL@]::X[IX^MB<%5SJI4J\0<3X2AA<6I2RNGEL,F]I
MDU9TJE-4H8>69M1H8F<U#FC[.,E!RB_G:,O"2MDN#P6:T.%Z-+#\'<"9CC<?
METJ=//ZV>5.)J=#B7#*O1K>VJXN&2*I/%X&G#VGLY>WG%U%3G'W'QI_P1O\
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M^OB;_P!#-5Y.WX_TJQ-_Q\7/_7Q-_P"AFJ\G;\?Z5RS^->L@?P?*/Z$=0O\
M>/X?R%35"_WC^'\A6!'V/^WOT&T445,_A?R_-$D+_>/X?R%-IS_>/X?R%-K)
M[_*/Y( J%_O'\/Y"IJA?[Q_#^0J'\4?^WOR C?[I_#^8J&IG^Z?P_F*AK$ J
MO5BJQ('4@?4@5S@+43]1]/ZFI P/0Y[<<_RS4;@EPH1RV/NB-R?R"D]Q2YH_
MS+[T3/X7_75#*A?[Q_#^0K432]5E ,.EZC,&^Z8K*XD!SZ;4/Y=:VK/P#XVU
M(@V7A77I@PRN--N1D <G+1@=O7/M5T\)BL1)K#X7$UW)+E5'#UJK?P[*G"3!
MPG*,>6,GMLF]EK_7?0YRVZ#ZM_*MN#[J_P"[_45DB"6VFDMIXWBG@E>*:*0;
M7CD3(9&4\@J000><@UK0?=7_ '?ZBML*G%V:::DTTU9IJ2333U33T:>PULO1
M&S;_ '!]!_6MBW^X/H/ZUCV_W!]!_6MBW^X/H/ZU]#A]_G^L3>.WW?\ I,3<
MAZ+]1_(5U>A:5J.N7]GI6E6DU[?WKK#!;P(SNS,P&YL [47J[MA5&3GM5'PK
MX;UGQ;JUIHFA64M]J%U(JI'&I*QJ0,RS/C$<2#EV8@ ?6OU(^#_P8T?X9Z:E
MQ,D5_P")KJ(&^U%E#"W+ %K6R+ F.)3PSC#2G))VXK]9\/N!,RXRQEJ:GA<I
MPTHK'9E*#Y(Z1E]7PJ=E6Q<XZJ*;A1BU4K-)PA4]+ X.IBI62<:49)SJ/9;>
M['O-[I;+>36B=+X.?!;3_A_90ZIJJ17WBFXC5I9R%>+3@RY,%ID8WC/[R;D[
MLA" ,GWNBBO[2R;)LNR#+Z&697AXX?"T(V223G5FTN>M7G;FJUJC7-.I+5O1
M6BHQ7UE*C3H05.G'EBOO;ZR;ZMVU?Z!1117J&@4444 %%%% !7XN_P#!:#]B
M&?\ :9^ Z_%3P'I@NOBW\$+2_P!=L+>V@#WOB;P>J?:->T ,B^9));QQMJ=J
MA)YAG50695/[14R2..:-XI426*5&CDCD57CDC=2KHZ,"KHZDJRL"K*2""#7L
M9!G>,X=SC YS@)6Q&!KQJJ+;Y*U-WC6P]2V].O2E.E/JHR;C:237S/&/"N6<
M:\-9MPQF\'+!9KA9T'4BDZN&KQ:J87&4&](U\)B(4Z])[.5-1E>,I)_Y?\<@
MD0.%92<AD=2CQNI*R1R(P#))&ZLCJP!5U*D9%/K]M?\ @L?_ ,$]+[]FKXEZ
MA^T'\,=#/_"B?B9K+3ZU9Z="[0?#WQI?LTUW!/$NX6VA:W,7N;&7B*&X-Q Q
M'R"OQ*Z]*_O?A_/<!Q+E.$SC+:BGAL533<&TZF'KQ25;"UTOAK4)MPFM%)<L
MXWA.#?\ D)QCPEF_ _$>9<-9W1=/&Y=6<8U5&4:.-PLFWAL?A7)+GPV+I6J4
MY+6+YZ4[5:<XQ****]D^8"BBB@ K1T?5]2\/:QI/B#1;N33]:T+4+;5=(U"(
M*TMCJ-E()K6ZC60-&SPRJKJKJR$C# @UG44I1C*+C)*49)QE&23C*+5FFGHT
MUHT]&M&.,I0E&<)2A.$E*$XMQE&46G&49)IQE%I.,DTTTFFFCT_XO_&KXJ?'
M_P 9-\0_C+XROO'GC5M+LM%;7]1MK*UN3I>G(([*S\K3X+:WV0(  WE[V/+,
M223YA116=&A1PU*GA\/1I8>A1@J=&A0IPI4:5..D84Z5-1A3A%:*,(J*6R1M
MBL5B<;B*^,QN(KXS%XFI*MB<5BJU3$8G$5IN\ZM>O6E.K6JS>LJE2<IR>K;"
MBBBM3 **** "BBB@ HHHH ***]!^$_PJ\=?''XD^$?A+\-=&N-=\:>-=5@TO
M2[.WC9TMHI'47>JWSJ"MOI^G0%KBZGD*HJJ 3EJSJU:5"E4KUZD*-&C3G5JU
M:DE&G2I4XN<ZDY/2,(13E*3T23;-L/AZ^+Q%#"86C5Q.*Q5:EA\-AZ,)5*U>
MO6G&G1HTJ<4Y3J5*DHPA"*;E*225V?>7_!*O]BV\_;!_:2T>77]-GE^#OPHN
M[+Q5\0KXJ5M=2O;>43Z'X421E*22ZC<1B6[C&YH[5-[  \_WC6MK;65M;V=G
M!%;6EI!%;6MM BQPV]O BQ0PQ1H J1Q1JJ(B@*JJ   *^1_V(?V1?!G[&/P'
M\-?"?PRD-YK8B35?'7B81*EUXF\5W<:MJ%[(^ YM8')M=/B8GRK6)#PSM7U_
M7\/>)7&<N,<_G6P\I+*,O4L)E=-W7/34KUL9*+VJ8N<5.S2E&C&C3EK!W_U:
M\#/#&'AGP=2PV,A3?$><RIYCG]:'++V==PMA\MIU%?FHY=2DZ=U)PJ8F>)K0
M?+5BE'+_ *I_]TT42_ZI_P#=-%?GA^T'SA\:_P#D+:9_UZ-_Z&:\2KVWXU_\
MA;3/^O1O_0S7B5?SWQ=_R46:?]A$?_4>@>%BOXM?_&ORB0-U/U/\ZC?H/K_0
MU(W4_4_SJ-^@^O\ 0U\V8OX/E']"*D;H?H?Y4M(W0_0_RK&?Q/Y?DC(@HHHJ
M32/P2^?Y(*A?[Q_#^0J:H7^\?P_D*B6\/7]40MI>GZH;11160BO43]1]/ZFI
M:B?J/I_4UF_AG_B?YH!E%%%92V?H_P @(X?];%_UT3_T(5<U3_C_ +C_ 'A_
MZ"*IP_ZV+_KHG_H0JYJG_'_<?[P_]!%.7\&I_P!?J7_INJ/H_5?E(SZKU8JO
M7)+>'K^J$0O]X_A_(4VG/]X_A_(4VLY;OU?YDS^%_+\T%0O]X_A_(5-4+_>/
MX?R%2]OG'\T9Q^U_A?Z#:1NA^A_E2TC=#]#_ "K*?Q/Y?DB2"FO]T_A_,4ZF
MO]T_A_,5)<=I^GZ,AI&Z'Z'^5+2-T/T/\JYR""BBBIG\+^7YH#3U'_4:3_UZ
M-_Z%6*W4_4_SK:U'_4:3_P!>C?\ H58K=3]3_.GB?X\O\%#_ -1Z0/=_]N_^
MD1&/]T_A_,5#4S_=/X?S%0UQSW7I^K 8_0?7^AJ*I7Z#Z_T-15 !11143V7K
M^C)G\+^7YHKTC=#]#_*EI&Z'Z'^51/XG\OR11!37^Z?P_F*=37^Z?P_F*Q?Q
M3_PO\D8Q^U_A?Z$-%%%9DA6B_P#R 1_V$V_]!K.K1?\ Y (_[";?^@T8?_E_
M_P!@]7_VTJ.T_P#"O_2XF-37^Z?P_F*=37^Z?P_F*YGM\X_FB2&H7^\?P_D*
MFJ%_O'\/Y"LI_$_E^2 ;1116<_A?R_-$S^%_+\T5Z***SG\3^7Y(H*KU8JO4
M=5Z/\X@5Z***P)G\+^7YH:_W3^'\Q4-3/]T_A_,5#6;^&?\ B?YHA?!+U_R-
MG2?^/;6_^O ?^ABL)ON+^'\C6[I/_'MK?_7@/_0Q6$WW%_#^1K2M_!P?_7NM
M_P"GY"?PQ_[>_,CIC]!]?Z&GTQ^@^O\ 0UQR^./R_-DD51/U'T_J:EJ)^H^G
M]368#**3('4@?C2\D9 )'J 3_+-1-KE>J[;K>ZT 1NA^A_E4%3J&ERL222,>
M,)&[')Z=!^G6K":3JTA BTK4I=V-OEV<S YX&,)]*SC&4W:$93?:"<G]T4V'
MIKZ:];?F93_>/X?R%-KM+/X>^-]2.;/PQK$Q;& +*8$YZ=5')QTKI;'X&?%B
M_(\KP3K<:-]V2>T>)3_WT,UUT<DSK%M_5<GS7$W>GL,NQE5/7O"C)?B5[&K-
M-0I59-VVIS?5?W?O[=3Q]NI^I_G25]#VW[+?QDNV^7P[! C<[KJ_@MR >Y1^
M3]!S76V7['/Q/N,?:9]%L<@9WW:SXZ?\\CS]!D\5[5#P_P"-\4OW'"F>R4D[
M.>7UZ$=OYJ\:45NMW8T6"Q<XQ4<-6OIO3DEHM=6DNJ/DNM30_P#D,Z?_ -='
M_P#0:^R;#]B;Q4^/[1\5Z-$"?F%O;W3L![%OE..O.<G/; KL])_8GM;2^MKV
M[\;W1\AMWDVUC%L8D8(W3#=@C\<\]>:]W+O"#Q$J8G#U'PY5HPA6I5)2Q&,R
MZC:,:D6_=EB^;17;7+?3:YO3RO'.R=!Q]Y.\I06B:_O7Z'YUS?\ 'Q<_]?$W
M_H9JO)V_'^E?I_;?L5> 0S/?Z[KMT7=W;RS#;Y+L6QE02,9X^GXUU=A^R)\(
MK(('L]4O-O7[3?NP;G/S  =>X%>K1\!/$"O)2J4LGPJN[^WS-3:3\L/0KK;S
M-?[&QSC9QI1V6M3M;72+_KN?DCD9QD9].]0OD$L0<=,[3Z>P]C7[16O[-WP;
MM"&7P=:2N!C?/+/(3[D;PN?HH]ZZRS^$/PTL0H@\%Z$0F"OG6,4X4CH0)@XS
M^%>QA_HX<43M]9SW(\/>U_91QV):[VYJ&'3\M5TUW-(Y#B&K2K48ZWTYY/;7
MI'\^GGI^&T-K=7 S;VMS/_UR@E?.?3"<_A6E;>&_$5XVRVT#6)F[;-/N2/SV
M8_,BOW<M_!_A2TQ]E\-Z';XZ>3I=G'CZ;816Y%:VL "PVT$*@8 BACC 'H J
M@8KW,/\ 1HG+_?.+E%=5A<HN^FTJN/6F_P!DUCP^_M8I?]NTK_G-'X6VWPC^
M)NH?-9^"=?N Q &RRDS@@8." <?A76V'[-OQFOP"O@K4K8D9Q=J(,>F2W3\:
M_:P #H /IQ17MX?Z-?#D+/%\0YW7=DFJ-+ X:+LK:*5#$27_ ($_\MXY!ATE
MS5ZS[M*$;[=XR\_O/Q]L/V0OC3=G,VD:79(>AGU6#?UQR@ (]?I76VO[#_Q)
MN,-=:YX>L<XW*6EN"!WYB)&0/S/Z?JK17NX;Z//A_1Y76>>8QQW]OF:II^JP
MN'P[5_*2-HY'@E:_MI>M2U__  &,3\VK#]A#4VS_ &IXWLTR/^7.RF./H)20
M<>^,UU6G_L'^'(6#:AXUU6ZYY2*SMXD[=,Y/KC)-??=%>YA_!#PSP]O^,=6(
M:ZXK,,RK7VWB\6HO;5<MGU5C6.49>O\ EQS?XJE1_AS6_ ^,[7]B#X41LKW=
MYX@NV'51>+!&WU5%/OT(_2NQT_\ 9&^"MC@/H%S? 8XN[Z9\GW*E3S]17TW1
M7NX;PQ\/<);V/!^0WCLZN I8A_-XA56]MVV;QR[ PTCA:/?6"E^,KL\4L/V=
MO@UII!M? VE @@AI/.F)([GS)6S^/^%=A9_##X>6!!MO!?AQ&'1VTJTE?T^]
M+&Y_6N[HKZ##<,\.8*WU3(<FPS6SH99@J37HX48VV-XT*$/AHTH^E."_)&/;
M>'M L\?9-%TJVQT\C3[6+&.F-D0QCMBM)T1(9 B*@$;X"J% ^4GH !UJ:HYO
M]5+_ -<W_P#037K1HTJ47&E2ITE9Z4X1@MNT4D:));)+T27Y'\^'C#_D=/%?
M_8PZM_Z63U2@^ZO^[_45=\8?\CIXK_[&'5O_ $LGJE!]U?\ =_J*_P KJO\
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M2I4G)J,80BY2;LDSE?#WA[Q!XP\0:-X2\):-J'B/Q3XBO[?2]"T+2[>2ZO\
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M3M9QRW%I:VU;E222UW;-(X;$2UC0JO\ [ARZV[KS1X-17U!;_LJ>/)E!EO\
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MT?Y 1P_ZV+_KHG_H0JYJG_'_ ''^\/\ T$53A_UL7_71/_0A5S5/^/\ N/\
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M&K?;V>"Q,D_FJ5OQUZ&L*55J5J<W?16A)W_#SOZ'F%(W0_0_RKVJU^ WC^<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@".
M7_5/_NFBB7_5/_NFB@##N[*QOY4FO+&SN98UV))- LC*N<[06R0,\TZ.VLXO
M]78V2=^+:/KZCCC\***R]A1YW/V-+GEK*?LX<[>UW*UWHEN^@K*][*_>RO\
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K_7HHH /M,O\ L_E_]>C[3+_L_E_]>BB@!&N)&4J=N",' _\ KT444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img149481191_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_1.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &Y ]\# 2(  A$! Q$!_\0
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MY>P:;IVMZ]HUAIM]?SV6GW]W#9VUS+<26MC>7"1M%;3.GU4/#_P^?LH8CAG
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M*;:E9-O]4_\ A_K^WY_SZ?LZ_P#AK/%O_P ]2C_A_K^WY_SZ?LZ_^&L\6_\
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M.$L'3FH5<8O9Y?.4\+1EI5K4XSA%WBVY.S_4/_A_K^WY_P ^G[.O_AK/%O\
M\]2C_A_K^WY_SZ?LZ_\ AK/%O_SU*_,_1?V;_CS\1-2UR;X5_L[_ !X\3:-:
M:_XDTR"QT7X>>,O'6I:+)X?O[2WU/0-<U;PYX.L;6ZU_PR-5T>Q\2.FC:*T%
M_?6CW&CZ3_:%K9CC/!'P@^+7Q,\2ZIX+^&_PN^(OQ!\8Z':7NH:UX3\$>"?$
MOBOQ+I%AINH6FDZC>ZIH6@Z9?ZII]II^J7]CIM[<W=K##:ZA>VEG.\=Q<PQN
MEP!X;.-63R3)X_5XQEB$\5*^&4KI>W<<6XT]4XWE+E;32;L-^,'C@IX>"XIX
MFG]<J2IX)QP,+8V4%%M812R^,Z[490FXPBYJ,XN48\UC]8_^'^O[?G_/I^SK
M_P"&L\6__/4H_P"'^O[?G_/I^SK_ .&L\6__ #U*_/3P?\"+.^^"_P"U;XT\
M:V_B[PU\0?V?-3^%.BVGA:[ABT9;36/%_C_5/!OBW2?&FB:MH[ZW!J>B#3G@
MAL(KK1;K3=5BN(]3BN=AM4\T\0? WXU^$O ^B_$[Q5\'_BEX9^&OB1=+?P[\
M0O$'P_\ %FC>!]>36[.74-%;1?%FHZ1;:!JBZO80S7VEM8ZA.+^SBEN;0RPQ
MLXBGP)X;5:M:BLARR,Z.*A@[5*M:"K5ZF#PN.A##N6)_?\V'QE&2]G=MN22]
MVYK6\6_'"A0PV)EQ=GTZ6(P%7,KTJ.&JO#82CF6.RFI4QBC@G]5Y<;EN)IOV
MW*K*#;]^Q^JW_#_7]OS_ )]/V=?_  UGBW_YZE'_  _U_;\_Y]/V=?\ PUGB
MW_YZE?E]X?\ V</VA_%OA'3/B!X5^ OQG\3> ]:DNH='\;>'_A=XXUGPCJTU
ME?7FEWL6F>)-.T*YT:_DM-3T[4-.NH[6]E:WOK&\M)0EQ:SQIQ-Q\._B!:>,
M-,^'EUX&\8VWC_6KGPU9Z-X&N/#.M0^,-6N_&=IIE_X/M=,\,R62ZU?W/BNQ
MUK1KWPU!:V4LNNVFK:9<:6MU#?VKRZP\/O#>I.K3IY)D\ZE#G]M"&(J2G1]D
M^6K[6,<4Y4_9R:C/G2Y&[2LSGJ>,GC=1IX>M6XJXEI4L5['ZK5J8.C"GB?K$
M>>A["<\"HUO;P7/2]FY>UC>4.979^N__  _U_;\_Y]/V=?\ PUGBW_YZE'_#
M_7]OS_GT_9U_\-9XM_\ GJ5^=W[(_P &?#GQS_:9^%GP8\?S>)-(\.^,/$E]
MHWB*3PY<V&D^)[.*QT;5M0EBL+G6M'UVQL;T7.G)!(U]HM^L2F56MO, *^B:
M7\,/V?/C#\)OCIXQ^%?A'XW?"37/@9X3T'Q_=Z]\4?BGX-^+7PU\3V&I>*M.
M\('X>76I>%_@3\&K[P3\0/$=QKD&J_#R>:Y\66GBB7PUX@\.SZ+IBW!\3Z)Q
MXK@GPZPN*>&J<*X>7)# 3K5Z:J2HT(YGBZV!P/M+XV-:;KXFA4I_N*-;V:2G
M5Y(-2/3P'BEXU9A@%CZ/B#C*?M*N<4<+A*SHQQ6+GD.787-<U]DXY9/"TEA<
M#BZ-:^+Q.&]LW.E0]K53@_LW_A_K^WY_SZ?LZ_\ AK/%O_SU*/\ A_K^WY_S
MZ?LZ_P#AK/%O_P ]2OROU7X"_'/0O %G\6-<^#'Q8T;X6ZC;Z;=Z?\2M5^'7
MC#3O %_:ZQ+'#I%S9^,KO1X?#MU;ZK-+%%ILT&HO'?2R1QVK2LZ@FJ_ 7XYZ
M%I/AK7M;^"_Q8T?0_&FKZ+X?\':UJOPZ\8:?I/BS7_$FGQ:MX=T/PUJ-WH\-
MGKNKZ]I4\.IZ+INES75[JFGS17MC!/;2)(>M< >&LK<N39-*]2=%6Q4W>M22
ME4I*V*UJ4XM.<%[T$TY))H\Z7C#XXPOS\3\3QY:%'$OFP-)6PU=N-#$.^ 5J
M%:47&E5?[NHU)0E)W/U0_P"'^O[?G_/I^SK_ .&L\6__ #U*/^'^O[?G_/I^
MSK_X:SQ;_P#/4K\H?B/\&/C#\';C2K3XN_"CXE?"R[UV&ZN=$MOB/X%\4>![
MC6+>Q>&*]GTJ'Q-I>ER:A#9R7%O'=2VBS);O/"DK(TJ!OH3X9_##X#V/[+7B
M+]H/XM^&_BYXUU2S^/V@_!K2O#?PZ^*?@WX7V$%AJ_P[U[QO+K>H7WB;X*_%
M^XU"\AN-":PCM+:'2X6ANUF:7?;%+C'$<">'5'#4<52X:P.-IXBO2P^'^IU)
M5?;5:U3V4(PJ3QM.A9334I2K1C'E:;NK'3@_%KQJQ.-Q. K\<YMEE;!82OC<
M8\RHPH?5</AJ,:]2=6C3RROB[NFX2A"GAISFIQ:CRR<C[:_X?Z_M^?\ /I^S
MK_X:SQ;_ //4H_X?Z_M^?\^G[.O_ (:SQ;_\]2OB_P 6_L_?#O5O#'P<^.7P
M&T[XM_$3X4?$/XJZ5\&_%WP=OKC1%^-?A#XK)I?AS69/A?H'C30O"FHZ/X^F
M^).G7^L7'PM\>Z+\(H#%+:-I?B7X<#6;"+3M>\&\'? /XW_$_0M;\9_"[X(_
M%_QYX)T._O[+5/$O@[X?>+O&>A:%/86=OJMUI^M^(_#N@3:1:W^GZ1>V5_?K
M<&Q>*SNK>_DMK>VN829H<#^&M:C*O+A_+L-"G/V-98NI5PTZ&)56I1EAJT*F
M*4H554IR479T:\7"KAJM>E.,W>*\5?''#8F&%AQCG>-JUJ2Q.&>74:&-IXO!
M2P]#$T\=AJE'+Y0JX>=&O3=2-UB<)452AC\/A<1"I27ZD_\ #_7]OS_GT_9U
M_P##6>+?_GJ4?\/]?V_/^?3]G7_PUGBW_P">I7Y6_#WX$?'#XN6&K:K\*?@U
M\5OB=I>@316^NZE\/?AYXN\:6&BW$T+W,,&K7GAO1]2M].FFMXI)XHKR2%Y(
M8WE12B,PA^&WP0^-/QE_MK_A4'PA^*'Q5_X1S^SO^$A_X5MX \5^.?[!_MC[
M=_9/]M?\(QI.J?V7_:G]EZG_ &=]N\C[;_9U]]F\W[)<>7T3\/\ PVI^W=3)
M<F@L*Z:Q+GB:D?J[K-*DJ_-BE[%U6TJ:J<KFVE&]SBI>,7CA6>$5'BGB:J\>
MJSP*I8*E4>-6'5\0\(HX!_6502;K.CS^S2;GRJY^K'_#_7]OS_GT_9U_\-9X
MM_\ GJ4?\/\ 7]OS_GT_9U_\-9XM_P#GJ5^4_P -O@A\:?C+_;7_  J#X0_%
M#XJ_\(Y_9W_"0_\ "MO 'BOQS_8/]L?;O[)_MK_A&-)U3^R_[4_LO4_[.^W>
M1]M_LZ^^S>;]DN/+/ OP0^-/Q1U;7= ^&?PA^*'Q$UWPO_R,VB^!? 'BOQ=J
MWAW_ $F6R_XGNF^'])U"\TC_ $R">T_XF$-O_I,,L'^MC= Y^'_AO3==5,DR
M>F\*J;Q*GB:D7AU5LZ3KJ6*3I*HI1=-U.7GNN6]T%+QC\;ZRPDJ/%/$U:./E
M5C@94L%2J+&RP[:KQPCC@&L3*BXM5E1YW3:DII:GZL?\/]?V_/\ GT_9U_\
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MBJN*_P"$Y0I*CAL;0^M)R?U6IST\1[.5N?\ 5[_A_K^WY_SZ?LZ_^&L\6_\
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MQ;_\]2C_ (?Z_M^?\^G[.O\ X:SQ;_\ /4K\5Z*/^(9<!_\ 1,X#_P "Q/\
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M(XMXBP]"I5JT:=:OA:%*E.MAYNG7HPJ5,#&$JM&<7"M33<Z<U*,TG='[+_\
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M^>I7XKT4?\0RX#_Z)G ?^!8G_P"7A_Q'?Q=_Z+K./_ <%_\ ,GE^?=G[4?\
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M WWP_M?#.BW%P\FA17OY^?\ #)/[5?\ T;+^T'_X9CXC_P#S-T?\,D_M5_\
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M?_AF/B/_ /,W7-5RW**E/$/^W<&\5BJD*U?%2Q%%25?ES&G4JX=4,7AYX?\
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M"EYJ,&DI?V#:G+9PS1V"WMHUTT0N82_Q_P#\,D_M5_\ 1LO[0?\ X9CXC_\
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ME@/_  LP_P#\L#_5[/\ _H1YQ_X;,;_\H\U]Y\^45]!_\,D_M5_]&R_M!_\
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MNC^U<K_Z&6 _\+,/_P#+ _U>S_\ Z$><?^&S&_\ RCS7WGJ6L?\ *.GX>?\
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MCOXCL]*236_"6D_#_1+3Q'&)-![+3HO &J?$[P1XMO?B7\,M3L/%_P#P3P\
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M\,D_M5_]&R_M!_\ AF/B/_\ ,W1_PR3^U7_T;+^T'_X9CXC_ /S-T?VKE?\
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MAE@/_"S#_P#RP/\ 5[/_ /H1YQ_X;,;_ /*/-?>?/E?TL?\ !MQ_R.G[:O\
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M9IMW]@U'4?"NJ:AXCM['Q#8V%]_H5[=Z1/>6]K=_Z-/)'-\E'UO)?^A/BO\
MP[/_ .8/ZN_*Q_9_%'_12X'_ ,1V/_SV)/\ AO/P)_T0C]LG_P 11^+_ /\
M*"C_ (;S\"?]$(_;)_\ $4?B_P#_ "@KTKP'\1?A]\4_#EMXQ^&/CKP=\1O"
M-[/=VMGXI\!^)]$\7^'+NYL)VM;ZWMM<\/WVHZ9//97*/;W<,5T\EO.C13*D
MBE1V-'UO)?\ H3XK_P .S_\ F#^KORL?V?Q1_P!%+@?_ !'8_P#SV/!/^&\_
M G_1"/VR?_$4?B__ /*"C_AO/P)_T0C]LG_Q%'XO_P#R@KWNBCZWDO\ T)\5
M_P"'9_\ S!_5WY6/[.XI_P"BEP/_ (CL?_GL>"?\-Y^!/^B$?MD_^(H_%_\
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MI76..-6=V55)!];R7_H3XK_P[/\ ^8/ZN_*Q_9W%/_12X'_Q'8__ #V/"_\
MAO/P)_T0C]LG_P 11^+_ /\ *"C_ (;S\"?]$(_;)_\ $4?B_P#_ "@KV;0M
M=T/Q3H>C>)O#.LZ5XC\-^(]*T[7?#WB'0M1M-7T/7=#U>TAU#2=9T;5M/FN+
M#5-*U2PN+>^T[4;&XGM+VTGAN;::6&5';5H^MY+_ -"?%?\ AV?_ ,P?U=^5
MC^SN*?\ HI<#_P"(['_Y['@G_#>?@3_HA'[9/_B*/Q?_ /E!1_PWGX$_Z(1^
MV3_XBC\7_P#Y05[W7/3^+?"EKXGT[P1=>)O#UMXSUC1]2\0Z3X1GUK38?$^J
M:!HUU8V6KZYIV@27*ZK>Z/I5[JFF6FI:G;6DME8W6HV-O=3Q2W=NDA];R7_H
M3XK_ ,.S_P#F#^KORL?V=Q3_ -%+@?\ Q'8__/8\E_X;S\"?]$(_;)_\11^+
M_P#\H*/^&\_ G_1"/VR?_$4?B_\ _*"O>Z*/K>2_]"?%?^'9_P#S!_5WY6/[
M.XI_Z*7 _P#B.Q_^>QX)_P -Y^!/^B$?MD_^(H_%_P#^4%'_  WGX$_Z(1^V
M3_XBC\7_ /Y05Z__ ,)/X:_X27_A#/\ A(=#_P"$P_L/_A)_^$4_M:P_X27_
M (1K[?\ V5_PD/\ 87VC^U/[#_M3_B6_VM]E^P?;_P#0_M'VC]W6Y1];R7_H
M3XK_ ,.S_P#F#^KORL?V=Q3_ -%+@?\ Q'8__/8\$_X;S\"?]$(_;)_\11^+
M_P#\H*/^&\_ G_1"/VR?_$4?B_\ _*"O7]<\3^&O#']C_P#"2>(=#\/?\)#K
MFG^&- _MS5K#2?[<\2ZMYW]E>'M'^WW%O_:>N:G]GG_L_2;+S[^\\B;[-;R>
M6^W<H^MY+_T)\5_X=G_\P?U=^5C^SN*?^BEP/_B.Q_\ GL>"?\-Y^!/^B$?M
MD_\ B*/Q?_\ E!1_PWGX$_Z(1^V3_P"(H_%__P"4%>P^(?$GAWPEI4^O>*]?
MT7PSH=M/86MSK/B'5+'1=*M[G5=0M=(TNWGU'4I[:SBGU+5;ZQTRPADF62\U
M"\M;*W62YN(8GUIIH;>&6XN)8X+>".2:>>:18H888E+RRRRN52..-%9Y)'8*
MB@LQ !-'UO)?^A/BO_#L_P#Y@_J[\K']G<4_]%+@?_$=C_\ /8\(_P"&\_ G
M_1"/VR?_ !%'XO\ _P H*/\ AO/P)_T0C]LG_P 11^+_ /\ *"O6M&\6^%/$
M7ABP\;^'_$WA[7?!FJZ/%XATOQ=HVM:;J?AC4M GM?ML&N6&OV5S/I5YH\UD
M1=Q:G;W<EE):G[0DYB^>LWPU\1_AYXTN(;3P=X\\&>++NX\*^&?'<%KX:\4:
M'KMQ/X(\:)>2^#O&4,.EWUU))X5\61Z=J$GAGQ"BMI&O)8WCZ7>72VLY0^MY
M+_T)\5_X=G_\P?U=^5C^SN*?^BEP/_B.Q_\ GL>;_P##>?@3_HA'[9/_ (BC
M\7__ )04?\-Y^!/^B$?MD_\ B*/Q?_\ E!7KEAXK\+ZIK^O^%-,\2:!J/BCP
MI!HUUXI\-V&L:==Z_P"&K;Q'%>7'AZXU_1[>YDU'1H->@T[4)M&EU&VMH]4B
ML;R2Q:=+6=DWZ/K>2_\ 0GQ7_AV?_P P?U=^5C^SN*?^BEP/_B.Q_P#GL>"?
M\-Y^!/\ HA'[9/\ XBC\7_\ Y04?\-Y^!/\ HA'[9/\ XBC\7_\ Y05[W11]
M;R7_ *$^*_\ #L__ )@_J[\K']G<4_\ 12X'_P 1V/\ \]CP3_AO/P)_T0C]
MLG_Q%'XO_P#R@H_X;S\"?]$(_;)_\11^+_\ \H*][HH^MY+_ -"?%?\ AV?_
M ,P?U=^5C^SN*?\ HI<#_P"(['_Y['@G_#>?@3_HA'[9/_B*/Q?_ /E!1_PW
MGX$_Z(1^V3_XBC\7_P#Y05[W6!IGBOPOK>L>)?#VC>)- U?7_!EYIVG^,-#T
MS6-.O]8\*7^L:19Z_I-CXETRUN9;W0KS5-"U"PUK3K;5(+6:]TB^L]2MDEL[
MF&9SZWDO_0GQ7_AV?_S!_5WY6/[.XI_Z*7 _^(['_P">QY'_ ,-Y^!/^B$?M
MD_\ B*/Q?_\ E!1_PWGX$_Z(1^V3_P"(H_%__P"4%=2WQR^"B?$U/@H_QA^%
MJ_&252\?PE;X@^$E^)LB#0G\4ET\!G5QXJ=1X9CD\1%ETH@:$CZOG^SU:X'J
M5'UO)?\ H3XK_P .S_\ F#^KORL?V?Q1_P!%+@?_ !'8_P#SV/!/^&\_ G_1
M"/VR?_$4?B__ /*"C_AO/P)_T0C]LG_Q%'XO_P#R@KV*Y\1^'K+7M(\*WFO:
M+:>)]?T[6M7T'PY<ZI8P:]K>D^&YM'M_$6J:1H\LZ:AJ6G:!<>(O#\&M7MG;
MS6VE3:YH\5]+ ^IV2SDOB/P]#XALO",VO:+#XLU+1=4\1Z=X8EU2QC\0ZAX>
MT2^TC3-:UZRT5YQJ5UHND:EX@T'3]4U2"VDL=/OM;TBTNYXKC4K*.8^MY+_T
M)\5_X=G_ /,']7?E8_L[BG_HI<#_ .(['_Y['CO_  WGX$_Z(1^V3_XBC\7_
M /Y04?\ #>?@3_HA'[9/_B*/Q?\ _E!7L/AWQ)X=\7Z-9>(_">OZ+XH\/:FL
MKZ=KOAW5+'6M&U!+>XFM)WLM4TV>YL;M8;JWGMI6@GD$=Q#-"Y62-U7:H^MY
M+_T)\5_X=G_\P?U=^5C^S^*/^BEP/_B.Q_\ GL>"?\-Y^!/^B$?MD_\ B*/Q
M?_\ E!1_PWGX$_Z(1^V3_P"(H_%__P"4%>]T4?6\E_Z$^*_\.S_^8/ZN_*Q_
M9W%/_12X'_Q'8_\ SV/!/^&\_ G_ $0C]LG_ ,11^+__ ,H*/^&\_ G_ $0C
M]LG_ ,11^+__ ,H*][HH^MY+_P!"?%?^'9__ #!_5WY6/[.XI_Z*7 _^(['_
M .>QX-_PWAX'V"3_ (4+^V7Y98H'_P"&4/C!L+J Q0-_PC^-P5E)7.0"#C!I
MO_#>?@3_ *(1^V3_ .(H_%__ .4%?1C?\@F'_L(W'_I-:UQOBOQ=X4\!^'=6
M\7^.?$_A[P9X2T&V^VZYXH\5ZUIOAWP[HUGYD</VO5M;U>YL]-TZV\V6*+S[
MRYAB\R2--^YU!/K>2_\ 0GQ7_AV?_P P?U=^5C^SN*?^BEP/_B.Q_P#GL>2_
M\-Y^!/\ HA'[9/\ XBC\7_\ Y04?\-Y^!/\ HA'[9/\ XBC\7_\ Y05ZUJGB
MWPIH8\.G6O$WA[2!XOUBT\/>$SJFM:;IX\4:_J%A>ZI8:'X=-W<P_P!MZQ?:
M9IFI:C::9IOVF]N;#3[V[A@>WM)Y(_'-,_:W_93UKQ;:^ -'_:;_ &>]6\=W
MVN#PQ9>"M,^,_P .+_Q;>>)6O#IX\/6OANU\22ZS<:X;\&Q&DQ63WYO ;86_
MG I1];R7_H3XK_P[/_Y@_J[\K']G\4?]%+@?_$=C_P#/8L_\-Y^!/^B$?MD_
M^(H_%_\ ^4%'_#>?@3_HA'[9/_B*/Q?_ /E!7J/BSQUX(\!6^CW?CGQCX5\%
MVGB'Q#I7A'0+KQ9XATCPY;ZYXLUZ22+0_#&CSZQ>6<6I^(=9EAECTK1;)I]2
MU&2*1+.VF9& ZJCZWDO_ $)\5_X=G_\ ,']7?E8_L[BG_HI<#_XCL?\ Y['@
MG_#>?@3_ *(1^V3_ .(H_%__ .4%'_#>?@3_ *(1^V3_ .(H_%__ .4%;>D?
MM#? 'Q!\0[OX1Z#\<?@_K?Q7L+S5M.OOACI'Q,\%ZE\0[+4-!BN)]<L;OP79
M:W-XDMKS1H;2ZFU:VFTU)M.BMKB2\2%(9"OL%'UO)?\ H3XK_P .S_\ F#^K
MORL?V?Q1_P!%+@?_ !'8_P#SV/!/^&\_ G_1"/VR?_$4?B__ /*"C_AO/P)_
MT0C]LG_Q%'XO_P#R@KU_0?$_AKQ5;ZA=^%_$.A^)+72=<UOPQJMSH.K6&L6^
MF>)?#.I7&C>)/#VH3:=<7$=GKGA_6+2[TG6])N6CO])U*UN+&_M[>Z@EB7<H
M^MY+_P!"?%?^'9__ #!_5WY6/[.XI_Z*7 _^(['_ .>QX)_PWGX$_P"B$?MD
M_P#B*/Q?_P#E!1_PWGX$_P"B$?MD_P#B*/Q?_P#E!7K&M>,?"/AN_P!'TKQ%
MXJ\-Z!JGB%-8DT#3=:US3-*O]<3P[IDNM>('T>SOKJ"XU--#T:";5M8:RCG&
MF:9#+?WI@M8WE%'1/B+\/O$MSX?LO#GCKP=X@O/%O@Z'XB^%;31/$^B:K<^)
MOA]<2:9%;^.O#\%A?3RZSX.GEUK1XH?$^G)<Z)+)JVF(E\S7]J)3ZWDO_0GQ
M7_AV?_S!_5WY6/[/XH_Z*7 _^(['_P">QYK_ ,-Y^!/^B$?MD_\ B*/Q?_\
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M5C^SN*?^BEP/_B.Q_P#GL>"?\-Y^!/\ HA'[9/\ XBC\7_\ Y04?\-Y^!/\
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M6WANP&J>(KC2;*^NH+G4H- TPC4=:FLXIH]*L"+R^:"W(DH^MY+_ -"?%?\
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MBG_HI<#_ .(['_Y['@G_  WGX$_Z(1^V3_XBC\7_ /Y05U/P,^-NA_&OXO\
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MB;1M+O\ 2+33_#OCFT^&O@K3O"EWK>I'P7;VUY<P>)-0_4C_ ((46WPTTO\
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MNH>%H-330[W4D6^N;&2Z42@ _,O_ ((+_'OXI?M-?\$B?V(OC)\:?%^N>/\
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M%G\*CQ[\%?#WAK0WO(=0\5Z)K$-AX=\2:+9Z3X2BD\,W]_>6/EGPG_X=K_\
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MUG7)+&+PIH&B/IM@.%\/?%SQA??%W]BOXM_#SQ+\<]'^'OQ__:>USPM::_\
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MO!)::=>^'-4L[K1[JQM9+6UDMK2>SDMX'MH'BC5H8RH-*W7^KZ=>BT^[M8_
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M9KCQC\ ?$?B31/"XFFN)KG6_ASX@^'VL216UTNIP1>P?"_\ X5I_PZ?^*/\
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M=0M=+_L#51<_VEJ5HUC'=P"PBNO/N5A]VHHH*[^?^27Z!1110 4444 %%%%
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MY8_"Z^.L:%<QMX5L[77K.?20.9?U\O\ -'ZM?VOJ?_/]<_\ ?UO\:/[7U/\
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M[^M_C1_:^I_\_P!<_P#?UO\ &LZB@#1_M?4_^?ZY_P"_K?XT?VOJ?_/]<_\
M?UO\:SJ* -]M3U :9%+]LN/,-]/&7\QMQ1;>W95SUVAF8@>I-4?[7U/_ )_K
MG_OZW^-#?\@F'_L(W'_I-:U\3_\ !0+Q/XE\&?L=_''Q/X/\0ZYX4\2Z3X?T
M:;2O$/AK5K_0M<TR:7Q=X=MI9M/U;2[BUO[*62VGFMY)+:XB=X)I8F)CD=2
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M<R_+3UM_FC]M_P"U]3_Y_KG_ +^M_C1_:^I_\_US_P!_6_QK\ O"G[6GQ_\
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M5?\ "DOVR_\ H^.P_P#$7OAW_P#-51_PI+]LO_H^.P_\1>^'?_S54?V9@O\
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MV7_T?'8?^(O?#O\ ^:JC^S,%_P!%%DW_ ((X@_\ G%_5GY7/[>S3_HB^)O\
MPJX._P#HL_JS\K_:M%?%7_"DOVR_^CX[#_Q%[X=__-51_P *2_;+_P"CX[#_
M ,1>^'?_ ,U5']F8+_HHLF_\$<0?_.+^K/RN?V]FG_1%\3?^%7!W_P!%G]6?
ME?[5HKXJ_P"%)?ME_P#1\=A_XB]\._\ YJJ/^%)?ME_]'QV'_B+WP[_^:JC^
MS,%_T463?^".(/\ YQ?U9^5S^WLT_P"B+XF_\*N#O_HL_JS\K_:M%?%7_"DO
MVR_^CX[#_P 1>^'?_P U5'_"DOVR_P#H^.P_\1>^'?\ \U5']F8+_HHLF_\
M!'$'_P XOZL_*Y_;V:?]$7Q-_P"%7!W_ -%G]6?E?[5KQJ3_ %DG^^W_ *$:
M\/\ ^%)?ME_]'QV'_B+WP[_^:JO*Y/@U^UWO?/[:-B3O;)_X9J\ C)R><?\
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MG-\2/&7]DZ)9V#Z[);WNOIK.W_PIK]KK_H]&Q_\ $:O /_S3T?\ "FOVNO\
MH]&Q_P#$:O /_P T]']F8+_HHLF_\$<0?_.+^K/RN?V[FG_1%<2_^%7!WE_U
M5GDONT\]#6OV+O@SXGN/A@/%:>(_%&C?"[]G_P :_LU6?AC6+_2GT'Q7\-_'
M^D>#=#\1?\)?'9Z)9ZE<:])I_@C3$M-1T'4_#UO:2W>HSI8&5[%K#RVX_P""
M=G@36I]:N?'/QU_:-^(TVI_LS_$G]DS36\7>(?A:J^%_A#\3=.TS3-6BT2'P
MS\(O#<%WXOTR'2X9-/\ &OBF/Q)XAU:9U_X36\\6PZ?HT.F>A?\ "FOVNO\
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M37[77_1Z-C_XC5X!_P#FGH_LS!?]%%DW_@CB#_YQ?U9^5S^W<T_Z(OB5;?\
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M=ZO<6U[X4U.\TZSL+GP;_P (_<ZUHNK]/_PIK]KK_H]&Q_\ $:O /_S3T?\
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MO^CT;'_Q&KP#_P#-/1_9F"_Z*+)O_!'$'_SB_JS\KG]O9I_T1?$W_A5P=_\
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M_P (H?B/X3M?$VI^(/\ A&/B7XDL_!?C@6#>'=1UG1--OKNRU0_8H^"7Q/\
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M7[77_1Z-C_XC5X!_^:>C^S,%_P!%%DW_ ((X@_\ G%_5GY7/[=S3_HBN)?\
MPJX.\G_T5G?7Y>E^PT;]EKX?:'^R=-^QS::QXQD^&4_P6U[X$OKMQJ&B/X['
MA'Q#X6U'PE>ZBNIQ>'H?#X\1Q:;J<\]K=GPP=,2^2&272)X%>VDS/"_[.OQ&
M\*Q:390?MG?M,ZIHVBZ='I=GH>J^&?V/?L/V.VT\Z?8I-=:9^R?IFM2-8((+
MB"0:JKRW%M%]N-Y;O<V\^%_PIK]KK_H]&Q_\1J\ _P#S3T?\*:_:Z_Z/1L?_
M !&KP#_\T]']F8+_ **+)O\ P1Q!_P#.+^K/RN?V[FFG_&%\3::?[WP=Y?\
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MGH_X4U^UU_T>C8_^(U> ?_FGH_LS!?\ 119-_P"".(/_ )Q?U9^5W_;N:/\
MYHOB7_PJX.\O^JL^_O;TO8UC]C'X=:A)XGU?1_&'Q+\&>/-:^/\ J/[27AWX
MF^%=5\*1>-/AQ\0];\%Z#\.O$-GX.76O!NM^%+_P7XD\#Z)/X;\0>#_B#X7\
M=:1JUIKFIW5W$^J67AJ_\/S^"OV-?AEX(\1_#OQI;>(?B!KGC7P)\4OBE\:=
M6\6^(-6\/W&K_$[XE_%_P-?_  Z\6^(_B#%IOA?2])"P^%KRSTWPYHG@73/
M_AWPW9Z#X?TK2M)M]"TR/27H?\*:_:Z_Z/1L?_$:O /_ ,T]'_"FOVNO^CT;
M'_Q&KP#_ /-/1_9F"_Z*+)O_  1Q!_\ .+^K/RN?V[FG_1%<2_\ A5P=Y?\
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M308[/Q%JGAZQN?B;XO\ &_BW1M"N9TT+Q3I>J7NHZI>]?_PIK]KK_H]&Q_\
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M7]6?E<_M[-/^B+XF_P#"K@[_ .BS^K/RO]B45\=_\*:_:Z_Z/1L?_$:O /\
M\T]'_"FOVNO^CT;'_P 1J\ __-/1_9F"_P"BBR;_ ,$<0?\ SB_JS\KG]O9I
M_P!$7Q-_X5<'?_19_5GY7^Q**^._^%-?M=?]'HV/_B-7@'_YIZ/^%-?M=?\
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M_P"H/I%?F%_P71_9T_:1_:9_8GT#P=^RG\(O^%Y?%[P7^T[^S?\ &2P^&O\
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M^"RGA7XQ_!CX-ZI\)?VTO^"7G[2O[1GCGXI?!*W^''@JV_9H_:-T[X$?&O\
MM3]D&_\ "C>.;WQ?XU^%/A31O%VI/\-/%/@;3]:\#^&-335;/3[:SM?%FJ:I
M;]I^Q)^SQ_P5+_:C\+?\$M?C]X2_91_9[_9&T3]@7_@E[\7C^R-^T /C#X+\
M?Z+^U7\3/VIOV*=#\"?L]OXB^&?A[P^/&GPG\*^$O$.MZ1\1OBGX=\>:3KMA
M+XHC\4SZ%?ZZ+^U%Z ?OO^SC_P %Q?\ @EA^UM=_%W3_ -GW]K/0O'NI? KX
M7>*OC3\2]+E^&OQL\'ZKI7PO\#P27/B[Q?H6F>._AKX8O_'ECX>MT274[;P!
M;^)]2MTNM/)LC_:>G_:M?]F#_@M3_P $O?VR_BU>? W]F[]KCP9\1/B=8?#*
M;XP7.A3>$_B?X)T__A [/2/#NO:M?0>+/B%X&\*>#KS7?#ND>)["]\5^";37
MY_''A)+#Q5'XE\.:5-X(\9QZ!_/Y\*?V$O\ @L'\9_CQ>?M(_M9_LK>)?"?Q
M!\5_\$J/VPOV1/'^K>)?VX?AQ\>=8\;_ +2_C/P)IJZ)\1++X>V/BOPY\$OV
M9?AE\;O$5R^E^"/@_P#LZ:1=>"_ &HZ+K6K_ !/OM-_M:S\2ZC]9? S_ ()G
M_M5>!O&__!OU?:O^SOX8B\/?L<?L+_M=?!7]L;2M0\?_  NT[P]X;\=_%O\
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M)/ _[6_QF^"'_!/WQU^PE\<_V1-?_:2^#_P>\9?"?4_$GQV\2?&[2/C1\/\
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M>C3>)[31]3\-6JW1>6^FW)#,W]H3X$_M$_M02_&_XF?\*)U;X7WNH? /X=_
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M\%?%B&'1/#>D_LV_$C1;&*"#QG!H$,^K^-[6*XO;-KVY;3K2<BWZ3P]^VO\
M!/5_AG\._B)J;^-]&U#XD:MXQ\,Z5\+=,^'GC3XE_&&T\7?#74]4T+XG>'KG
MX;?!_0_B#XJNE^'>N:/>:9XL\0Z7IM]X5TJ2?19KC6XX/$6@OJ/D>BW'QV^"
M?[07[9OBK2?V5?BS\7_#_P 8_'OPS\9?#CQ%X#\;_LW:/H&I0^%_V<_A9\/M
M0L=;3XE?'7P+XOT&6+Q?X5U:PFG_ .$.U!190KJ5E'J$,L$<WS7!^Q1\6?A[
MXG^%GQ>\4>%/B1\9-6U_3_VBW^.G@+]F?]HKQ-\!/&'A'Q_^T!\8V^/0\2>
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MUM>ZCJ-]=_9/#>KM'F?M<_LW?&CXG_&'XH^*? W@S^W-!\1_"G]@[PUHU_\
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M+6%MS=-]JU^'NC_L7?M$V>@V^C6_A"VTK3_C-^T#^TI\.?VC;.3QAX;:X?\
M9-^+?[1S_&33?&EK#::U=:=JU]<^#=(\6_#RR\/Q7$^N:?;_ !\U:Y\0>$]6
MM](O;/2@EMIJROO==]DM?G?[S[G_ &:/VW?!7Q_\->#]4U[PYJ/PI\3?$GXK
M_%WX7?#OP-K%Q?>)-8URZ^$=EJNO:O/J^HZ/H$.A^&-5_P"$5T>]U?4M(O\
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M= '8>"_^2B_&3_L,^#/_ %!](KU6O*O!?_)1?C)_V&?!G_J#Z17JM !1110
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MGT23PU)X2AMK\O+?V^I6Y6U4#73O;7;O&_X)GX=:]XZ\8R_LG?#']O#XU?\
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M_P#C-']G#_H(:;_X$/\ _&:S:* -+^SA_P!!#3?_  (?_P",T?V</^@AIO\
MX$/_ /&:S:* -+^SA_T$--_\"'_^,T?V</\ H(:;_P"!#_\ QFLVB@#2_LX?
M]!#3?_ A_P#XS1_9P_Z"&F_^!#__ !FLVB@#2_LX?]!#3?\ P(?_ .,T?V</
M^@AIO_@0_P#\9K-HH TO[.'_ $$--_\  A__ (S1_9P_Z"&F_P#@0_\ \9K-
MHH TO[.'_00TW_P(?_XS5ZPL0DEP?MU@^ZQODPD[,5WVLJ[V_=#")G<[=E!(
M!/%<_6CIG^MN?^P=J/\ Z1S4 +_9P_Z"&F_^!#__ !FC^SA_T$--_P# A_\
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M_P#C-']G#_H(:;_X$/\ _&:S:* -+^SA_P!!#3?_  (?_P",T?V</^@AIO\
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M;0M$N_$-SX1N-"_IG\F7_GE)_P!\-_A1Y,O_ #RD_P"^&_PH#EVU[=-[<O\
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M9OJ?S>>,_#UEX7U+6?AO+>?"3X7_ +'G@K_@H=\>?#OBO3_BO\,M3\>?LM^
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M+WX!ZE\._P!LG4?C[=^'M0_;$U#Q_P##2]_9[O\ 6;B:Z^*=[\ [KP1\,Y_
MMW\&+JV>2^N?A+<Z3)\5YOBI<>#G?PU-JS_$*3XJNVIM<$^D?&WPY9^*/CG^
MU/9_'#X^_ WX&?'<_%?PW#^SYJWC;]F[X@?%C]K/2OA6UMX<'P+UO]BW7?"O
MQ\\+ZQK&E7?B>#Q';WO@_P""WPO\17DOQ0;XDV7Q'T_6-6UO5K*3];O'W[(.
ME_$K7_%,GBOXR_M :C\,?''BCPQXO\6_ 2[\5>%M5^%FJZGX3NO#^I:?8Z??
MZ]X#U?XN>#?"]WK/AC1]9U;P7X!^*?A3PCJ-XFHV\VB?V5KVO:=J?UKY,O\
MSRD_[X;_  H%R_I\]]79J[UW]=#^:C]K:/X"+X/_ &Q(OV@I/#@_;5C_ &H_
M#+?""XUT./BU<_!IO&'P]N/AL_PGBN+C4-;M_@;+X%?Q1;^*;;0)F\%VNMCQ
MC#XKD'BV-K@_T+_$CX7?#OXP^&)/!/Q3\&>'OB!X.N-2T?5KSPKXKTZ#6?#N
MI7N@ZC;ZMI)U;1KQ9-/U:UM=1M+:[.GZE;W6GW$D*"YM9D&VO0/)E_YY2?\
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MX;_"CR9?^>4G_?#?X4%$=%2>3+_SRD_[X;_"CR9?^>4G_?#?X4 76_Y!,/\
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M_P">4G_?#?X4>3+_ ,\I/^^&_P * (ZT=,_UMS_V#M1_](YJI>3+_P \I/\
MOAO\*T--BD$MSF-Q_P 2_4!RC#DVDH Z=2> .YH RZ_'3PG\>OA#\!OA'^VM
M\'OBUX]\/>"/B_>_'O\ ;%\1>%_A/KFH06/Q*^(>D_&SQ]XR\8_"F[^%_@FY
M>+Q#\28O'.F>+=%L]"E\%V&M0W&O/?:!)+%JVEZE:VO['^3+_P \I/\ OAO\
M*/)E_P">4G_?#?X4":ZKS\][>G8^ ]'T[PEX;_81\+? #XN^#M<^(7B;1/V)
M_"&C_%#]GGP!=:3J?QIUSPC8_#72O OC:'PGX2'B'0M9U"]@OX]3TC2KO2+V
MWOKKQ!;1:;X:GNO$TFFV,_RM\-?B1H]Q\9_V;/#OPC_:V\!?\%"O %YKOAJ"
MW^&?C;P3\'_&GQ\_9F\-Z1\.O&MCJG[0B?%+X3:)X+O_  (=-N]4\&>!_%-M
M\8_AI!XEOY?$L_A6W\:6?C+7WTS5/VE\F7_GE)_WPW^%'DR_\\I/^^&_PH"V
MVNUOPL<_X;\3^&O&6CVWB+PAXAT/Q5X?O9;Z&SUWPWJUAKFCW<VF7]UI6I0V
MVIZ9<75E/+I^J65[IM]'%.[VE_:75G.([BWEC3<J3R9?^>4G_?#?X4>3+_SR
MD_[X;_"@9'14GDR_\\I/^^&_PH\F7_GE)_WPW^% $=%2>3+_ ,\I/^^&_P *
M/)E_YY2?]\-_A0!'14GDR_\ /*3_ +X;_"CR9?\ GE)_WPW^% $=%2>3+_SR
MD_[X;_"CR9?^>4G_ 'PW^% $=%2>3+_SRD_[X;_"CR9?^>4G_?#?X4 1T5)Y
M,O\ SRD_[X;_  H\F7_GE)_WPW^% $=%2>3+_P \I/\ OAO\*/)E_P">4G_?
M#?X4 1T5)Y,O_/*3_OAO\*/)E_YY2?\ ?#?X4 1UA> ?^2U>.O\ LEWPU_\
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M>)!8:YXDU_0- \.'5=*ATQ=(N)O$VJZFVA:WJ4VH>'+36]$BM .9>?\ 5O\
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M.H"RE@\M-H)33V_'U2_7\#^OC^TM1_Y_[W_P*G_^.4?VEJ/_ #_WO_@5/_\
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M*Z&L7XM]$O .9?E^-O\ -'ZV?VEJ/_/_ 'O_ (%3_P#QRC^TM1_Y_P"]_P#
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MT\/6.EV%QKD /F7WV_&WRZK8_7K^TM1_Y_[W_P "I_\ XY1_:6H_\_\ >_\
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M4?\ G_O?_ J?_P".4?VEJ/\ S_WO_@5/_P#'*I44 7?[2U'_ )_[W_P*G_\
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M_F:Z31[#7=;^ .FZ!8OJ2Z?HDOQ-%DJZ!I%K:SW0)M)J_6_X'[E?VEJ/_/\
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MQX;U>VTKQOIFG^,-+UGPG8G_ &Q_BGH_PY^)'_"<_$O]EOX:>,_A#^U)XO\
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M[L@[@Z7 3O;)^TWO/)YXGQS[4 ?,O[2?[-/@3]J7P=X4\$_$#5O%NCZ5X/\
MB;X)^*VF7'@Z_P!'T_4)_$7@.\N+W2+*^EUO0?$-M+HMS+<NNI6]O:6M]-&$
M%KJ-FP+M1'[*_P -V_:-\<_M-7-_XMO/&GQ#^"MI\!_$/AV?4],C\%'P5::T
MNMFXL;.TT6U\26VOW,ZFVGOCXHEM!:.PM].M[D)<K]2_:[+_ *!4'_@3>_\
MQ^C[79?] J#_ ,";W_X_0*R[(_*;X,_\$E?V?_@?\0/A!\1/#'Q2_:7UW4/@
M-XE\3ZY\)O#OCGXI:;XJ\%>"-'\8Z=J>G^(O OA[PO>^#DT_1O".IMJMQJ-X
M=)6Q\4WNJQV]]?>)[IXRK^A^"/\ @FY\#? 7PZ_9,^&6C^*OBO<Z#^QO\3=>
M^*WPQN]2USPA-J^N^(O$7B7Q%XIO;+QY/:^!;.SU/18M0\37\-K;^'[#PO?)
M9PVD<VHSSQS7%Q^BWVNR_P"@5!_X$WO_ ,?H^UV7_0*@_P# F]_^/T!9=OZT
M_P D?G!H/_!-SX8:?\=_#'QW\5_'+]K7XNW/@+QCK'CSX;_##XS?'K6?B/\
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M^UV7_0*@_P# F]_^/T?:[+_H%0?^!-[_ /'Z LNW]7O^9G45H_:[+_H%0?\
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M+_1_ OPW\&> [#P7HUEK&L236?AOP=H.OZG>ZI>7NI>([JX>-X^5\,_\$_?
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M#.HK1^UV7_0*@_\  F]_^/T?:[+_ *!4'_@3>_\ Q^@#.HK1^UV7_0*@_P#
MF]_^/T?:[+_H%0?^!-[_ /'Z ,ZBM'[79?\ 0*@_\";W_P"/T?:[+_H%0?\
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M_P"@FG_@)<__ !-9U% &C]EL/^@FG_@)<_\ Q-'V6P_Z":?^ ES_ /$UG44
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M"7/_ ,36=10!H_9;#_H)I_X"7/\ \31]EL/^@FG_ ("7/_Q-9U% &C]EL/\
MH)I_X"7/_P 31]EL/^@FG_@)<_\ Q-9U% &C]EL/^@FG_@)<_P#Q-'V6P_Z"
M:?\ @)<__$UG44 :/V6P_P"@FG_@)<__ !-'V6P_Z":?^ ES_P#$UG44 :/V
M6P_Z":?^ ES_ /$US'@F.&/XU^.1#<"Y!^%OPV+,(I(MI_X2SXI\8D )R.<C
MBM:L+P#_ ,EJ\=?]DN^&O_J6?%.@#L/!?_)1?C)_V&?!G_J#Z17JM>5>"_\
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M7J&JM;:QJFC>'M+>I\"O!OQ7\>WG_!&'PQ\%/C-_PH'XB7O[.7[5,ND?$_\
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M$)?!.H:+<Z??MX3OU">9]4D_-V5NG3?I\GV/VG\">-O#'Q+\$>#?B/X)U/\
MMKP9\0/"OA[QMX1UG[%J&F_VMX8\5Z19Z[H&I_V=J]I8:K8?;]*O[2Z^Q:G8
MV6H6OF^1>VEM<QRPIU5?SG^!/AJOPA^%'_!.W6_V;/"]MX6^-7QK_P""=W[0
M\FL^(_"MG'9>-/B3XWG_ &7/AIX_\"P>*=8LEAU'Q=+X<^($>EMX$M_$$VII
MX1M8X-*\.+IUD/)-BSC^ )T7P5+^R FB'6T_8=_:/C_;8D\$JYU%$E^"T[>$
MD_:<>0?;U^.LGQDBU9M,7XA$?%=_*^(9NP=(35< *6VF]OR3T^_[D?T45Y]?
M_%3P'IGQ/\._!J^UWR/B3XL\'^(_'OA_PY_9>LR?;_"?A+4]"T;Q#JW]L0Z=
M)H-K_9^I>)=%MOL-[JEMJ5W]M\ZQL[F"VNY8/P.UWX=:[\&='^!UC^R!X6'@
M_P"+_P :O^"5/QZU'6;_ ,"VOV/QQ\2OB/HVA? KQ%X;\6:KJEL8]2\3?%&Q
MU?7O$#^%O%&HS7?B2UO==NK#3;V&&[6W'G_Q=_X8U?Q+\1)?V/1X'CT>3_@C
MY^VY_P )Q;> ?[,,$&ICPSX%;1A\1FT4R6Q^.)M7OH_B9_PDMQ-\2=D/AH^-
M2(SH3R@N;R2U77O;;35ZZ]O,_IRHK\1O%'PT_9.^%?Q$_9V\/?M%^$/A-X/_
M &3+W]F#6->\/0_$K2-"TOX*Z_\ M1ZC-X5C\4>*O',^JV\'A#7_ (ZZW\+[
M6YF\->)/&KW?C;6;>/QC<>&KVYU?^U'KYK^&T7[.<?C7]FE?V^I-(@\"Q?L>
M_&Z+X<VO[33SPZ+)X2'[2_B;_A2R>+X_&86&3Q[!^S_'H1\'V_B@GQ,MW]KF
MTJ%O&$%G) #YO+\?\/E_>_ _H5_X61X+_P"%E?\ "H/[9_XN)_P@W_"R/^$>
M_L[5O^1+_M__ (1C^V?[6^P_V'_R'/\ 0?[._M/^UO\ EY^P_8_](KN*_F^T
M+Q3J_@3P58:]\:/ WC;X@VEE_P $W1IFM>#/%'C3QY\-?$E_\+-;_;%;P]X6
MF^(?C?3;2^\?>%?#>A_"K4M"UOXF:I?:?J&H6W@G3/$:^)=.OK=M4LYN/\/:
M?\)+WQ?^UMX0MOC!^S;\*_A/XV_94_9S\1>./%'[''P7\87O[+FB^)]&^/>N
M'Q5INK>'_#OBS4]&^.'A"QTF>P^&OQI^+NB2?#3PM=_#[Q%K&C>-M%^&6HZ9
MXOBMP7/Y+IUMNEW\^O3JN_\ 2KKGB&P\/?V/]OM]<N/[<US3_#UE_8?ACQ+X
MG\B_U/SOLUQK'_"-Z3JW_"/:''Y#_P!H>)]?_LSPUI.Z'^U=6L_M$'F;E?SV
M_#_Q!X8O++X=^%_!O@CX!Z5H?A?_ (*._LP27'Q(_9%\3>(M0_94^*.M:QX9
M\4L;KX7^";TW?A#X7>*/#OA33O!]M\6/"/@/7?%.FR>,-2;6=8\2:IKFHWDJ
M^8>"?&/PS\3?M _L<?$WP#H?[.OPC\=:[^V)J>C^,? '@:3QO\1/VP="T;Q+
MX-^*FG^+1^V%^T/KNNZ1JNE:UXO\?W$VB#X&?$+P-J6IRO;:4OA#XD^(]+\.
M^)-"L :E?IUMOZ>7F?T7^.?'_A+X;Z/:Z[XQU5M,L-0U_P /^%M,2VTW5=:U
M/5O$?BK5[70] T71]#T&QU/6]7U'4-1O(46VTW3[J2WM4NM2NQ!IMC?7=OU-
MY=V^GVEU?W<GDVEE;3W=U+L>3RK>VB>::3RXE>1]D:,VR-'=L8168@'XK^/<
M\MS^V%^PAHFJ.6\+-??M)^)K.UF"O9S_ !.\/_"FQT[P?)Y4@DC.IV?@?Q-\
M6KK3YA&EQ;PQW[PW4(\V&Z^+/@E#^RYONYOC=/HL/_!1I/C9\<)O&#6[:_/^
MTNVLR:E\0[+PM!K]MX62Y\9-^S-/\")?"\?AE=:M_P#AFVT^'+^"]7T][*6U
M\-ZG; [ZV\[?D_OUT7D]3]=O GQ*\&?$WX=>&/BQX%U6?Q%X#\9^%M/\9^&-
M8M=&UV"YUCPYJE@FIZ?>V^@7VF6OB-)[NRD22'2Y](AU8R.ML;$7)$-9'A+X
MR_#SQOXLOO F@:KJH\9Z7X \"_$_5O"^N^$/&?A'7-'\&?$F77H/!][K.G>+
M?#^B7.D:K?7/A?7K34?"NI1VOBSPW>:;-:>)M$T>Y>&*7\)/@#\// _PL^'7
M_!,+Q/X!\+:-X8\5?&C]DG]H>P^+/BK2K**S\3?$C3O^&=-(\=Z?IWCG7;<1
M:EXNT[P]XAT;2I?"=AXBN-3M/"=EIUEIOAV'3;&VAA3S;PL-0/@/P*+M-8?X
M3_\ # W_  1V/[2HT62^BD'[,PUWXG'XS/KC:1+#K9\!1^&!))\48]*<M-\,
ME\7Q:M%/X<?6H9 2EY=/TC^&NO9(_HXT+XG^!O$OC[Q]\,-$US[;XY^%]CX,
MU+QUH?\ 9NL6W]AV7Q!M-8OO"$W]IW>GP:/J?]KVN@:M+Y>CZAJ$MA]DV:G'
M923VR3=[7\R?C?0OV9O$FN?MK^'/V<E\%W/P,\1?'G_@E!HWV?X52V-O\+FN
M=5^.VLZ=XOM_AM/X9$7A>+1);R:\.HS>#)&T>/QE+XG82+K2ZJD?J7Q_^&7P
MMT/]H']I7X<?$CQO^RG^S1X&T?P1\-8/V4++XJ?LX:]XIU_PUX&C^'L5WXBU
MG]BB]\(?'7X06GA'XFZ9\:]2\8WVH^'/@YX.U?XFZOXNB\#7UU%K)'A.P@!<
MSM>RW:WLMWW\EOU/Z&J*_G;^.7PA\&^(/#/_  4X^(WCVQB^)'Q5^#_[+'[/
M&K^ ?BCXN\*ZAX<\8>%_&VD?L\W6NS?$GPMH&O%]>^%7CW6=?T+2=7U1[>2R
M\6:5+I]IH6HWS#3Y87_3?]K;Q]X<L?V0]&\0?$WP%IWQ,\/^-M0^!VB^+-%\
M1>/O$'PD^%]M%XX\6^$K/4?$OQE\?>%])\0W'A;X-:"]]+J?CW^T?#/B3POJ
MNBQ-X<\4Z+<^'-7U%X0=]^F_X:.^GY7/NVBOY=/"$WA2QNOVH]#AU[X(ZG^S
MC=?%C_@G]XH^/L'[*/@+Q'\,?V:KOX-W5Q\2O#?QLUSPKX9L_%WC*'7_ (9?
MV_X9\/\ AKXO?$7PIJ@\-^*](\.:\GB>TTZ'3?$.F6?5^*S\+_\ C-%?V5M0
M\$Z/^RR_[0O[&X^*>L>%?"VO^-_@5I7P4'A3Q>_Q8OH/"'P^\6>!SXC^ \/C
MA(1\2])\">*-)\&W7AI_'B7,Y\,_VXC N;R[]?77T[OU['],%<%X9^)_@;QC
MXP^)7@+PWKG]H^+/A#J_AW0?B)I/]FZQ9_\ "/:MXL\):1XZT"T^W7^GVNFZ
MM]O\*Z]I.J>?H=YJ=M:_:_L-[-;:C!<V</X32>&OAQH>@3W^A_&SX*_%;]D7
M4OVMOV:3^T1X3_9N^#'B#X1_L;?#OP7:>!_B3::Y/=WS_%CXL_"7Q-X.\5_$
M&[^ ^I?M#:+X>\41^$/#=IHR:K\7M%AM?%FJS77U_P#\$YX_@A'\9/V_U_9S
MF\/3_!\_&OX62>%'\&BU'@A3+\"O!<NL0^!1810Z7_PAEOK;ZC;^&3H:'PVV
MDQ6K>%I9_#1TF>0&I7MMKYWZ/:W3S[W1]BR_M<_ "'XDQ_"J7QIJ:>)9?'J?
M"I-:/P_^))^%W_"TI-+.K1_#1_C</"!^#,?Q"DC TR/P5)X]7Q,_B9XO!Z:8
M?%<L6BO])5^.?B+]H']F#X_?'>U^ VC_ !;_ &<?A%\$/@K^T-I7C;QS9:C\
M0?AMX1^(G[1G[3_ASQ[%XZM/"'@7X>W.K:=J'_"$:?\ %B6U\2_$WXF:SI%Y
MJWQB\?6\WA3P997VER^(/'-Y]T0^+?VUVFB6X_9^_9;BMVEC$\L/[8/Q9N)H
MX2X$LD4$G[#=LDTJ)N:.%[BW21P$::(,9%!IW\]>B]/7OY=]M3UR]^+_ ,--
M/^+&A? RZ\8:4OQ;\1^"-;^)&E^!(3<76N'P)X?U?3- U#Q1J,=K!-;Z)I4V
MM:K#IFC3ZU<:>?$=Y9:[#X>35&\,^(O[+#\7_AH/BW!\"%\8:5+\79_ &I_%
M,^!+<W%SK%IX TG7]#\+W/B;4S;P2V>D6<^O>(],T_2H=5NK.]UQ_P"TIM%M
M=0MM#UR;3OA^_P#AG\/OA[_P4H^"-_X(\&^'O#.I>/?V>_VNO&/C?5=)TRVM
MM7\7^*-7^)G[.][>:WXFU8(=1UR^5[N6VL9-2NKE=*TQ+71M+6STFRL[*"]I
M7PS^'WPZ_P""EOA*Y\#>#O#WA:\\=?LC_M.^.?&NH:/IEM:ZEXM\7^(/VB/V
M:[_5/$/B34E0W^M:G--<-!;W&HW%P=/TV*STC3A::3865E;@KORW2^^WW[^1
M]S> OB'X/^)V@-XF\$ZO_:^DQ:QKOAZ],VGZIHVIZ5XA\+ZO>:#XBT#7-!UV
MRTS7=!US1-8L+O3]3T?6M-L-1M)X2)K95>-G[2OB+]G5[NT_:H_;YT+3T\GP
M;;?$+X&:_%;0+MT^V^(GB;X#>%)_'8AB6%(+>^U#1;#X?Z[JT,4C/<WFK_VQ
M=1+=ZM/<WGV[0-:_BONT"BBB@84444 :+?\ ()A_["-Q_P"DUK7F/Q0^)W@C
MX,^ ?$WQ/^)&L2Z!X(\'V*:CXAUB'1]<U^:RM);NWL8GBT;PUINL:[J,LEW=
MV\$=MI>F7MT[R@K"5#$>G-_R"8?^PC<?^DUK7P-_P4M$S?L,_M#K;R117#>%
M='$$L\+W$,<Q\9>&A%)-!'-;/-$C[6DA2XMWD0%%FB+"103T3?9,]/T/]KSX
M':WK9\.7&H?$GP9K4GASQ1XKTZQ^+'P"^/WP7?Q#HW@JQAU7Q8?",OQ<^&/@
MFW\9:KH&DS#6-1\.^%)=9\0P:/%=ZM_99TZRO+F#W3P7XP\.?$/P=X3\?^#]
M1_M?PEXY\,Z%XP\+:M]DOM/_ +4\.>)M+M=:T34?L&J6MEJ=E]MTR]M;G[)J
M-E:7UMYODW=K;W"21)\+?&']GWXO^-=-'Q$^/_QB^'?C73O@AX-^+_C+P#X1
M^$OP1\1?"&VN/'OB#X5^*? T/B#QEK/BSXZ_&W4=;T[0?"WB/Q1!I'A_0U\)
MP2ZMK,>IZW>:Q#IEGIP^!OAKX2\"?LZ:+_P3T\=?#+X:WBZY\2?^"=WQ_P#$
M/Q=L_AO/JWA[XD_'2]\+_ ?X)?$/2]/U/Q/X:E@\3:QXQ;Q#/?V_@?5S/<ZO
MX3N=5CL_")TNV@L;2 %=K=?U[J[OJV?T#T5_,3\.+SX2WGQE^&]Y\,/%?[/?
MP?\ #WQ-_8U_:^T#QJ?V$/#'C_QYXH^&NF2^%? ]]X&A^)OQ=T&]N=2_:7^/
M_A71XKWX@-I,?PN\%_$_PIXCL=2NM<TKQ/!K7ACQ5=7K;58-$^"O[2'P_P#V
M9],_9T\66%M\*?@7JWC+]HO]ABS^).G^#M6^"5G\6_#&D^+]#^,7[.?@CQ<^
MEZ'^T0?AW??%OQ1XGN?#WQ6E^*'C+X7:?J>BM?\ A62PT2WMP7-Z==GV2?;[
M^W4_IHKYK\;_ +7?[/WPZ\;ZI\/_ !?XSU73M:\.ZAX-TGQAJUK\//B9KGP^
M^'^J_$*;3XO!>F?$SXKZ#X.U/X7?#/4?$(U?1;JQLO'WC'PY<_V=KFA:I/%#
MINMZ5=7GR#^PCX:^&6E?%WXF:S\%_CU^SEX]\%ZU\.?"3^(/AK^QS\ ?$'PL
M_9]T/Q3%KFJ)IOC/4];T_P",OQE^&%E\8M2T-9=#\3>$-+U#PYX[O/"EAX1U
MKQ/HCZ99:%?W/"?M,?M _LT_$;XE_$W]C ?%7]G7X#>!&\4>&O$?[8OQ+\;?
M$/X;?#SQ#XOU*6#P]J\WPL^'.@:OJVCW7C#X@^*=%T#PQX>^)OQ9UI=0T7X>
M>$()O!EC%KGQ $,'@('=VOHGTZW[)-/_ (;4_4#XM?$74/A9X1F\7V7PX\8_
M$NVL)Y'UO3O!FN_"3PY<^'=!M=,U+5-2\7:WJWQG^)WPF\(VOAS2(].2#4I8
M_$UQJD$E_:W*:5+ID&JZAINY\//&!^(/@3PAXZ_X1CQ1X+7QAX<TCQ+%X4\;
MV>FZ=XOT"#6;*'4+?3/$NG:1JVN:?IVM6T$\::AI\&K7ILKGS+6:47$4L:8?
MQA^&Z?%SP!J?P^N-:GT+3=>U7PB^O7%M:_;)-3\+Z-XQT#7_ !5X5:(W5F([
M?QKX;TO5/!UW>&25=/M==FOVLM1%L=/NO3:"@HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *T=,_UMS_V#M1_](YJSJT=,_UMS_V#M1_](YJ ,ZO)OA/\
M<_A1\<;?QE<_"OQE8^+4^'WCGQ'\-O&D,%GJNFWOA[QKX3OI=-US1;_3M;L-
M,OU^SW<,J6NHQ6TNDZM$C76D7]]:CSJ]9K^<'X6ZMXS^'/A;XD:?X%.H6L_[
M;G[0G[5W[)MGK&G6$[1^#OBZO[5/CG_A#/',U[&LEG8SZ9\'OB!\>/%U]J5U
M%)=./A!X6TY-,\4HMII>GA+=FM+K6_?HE;YL_>SX0_&KX7_'KPK=>-_A%XNL
M_&_A*T\2>(/";Z_IUGJEKIMQK?AB_?3=8CTV?5+"P_M;3H[I,V&NZ6+S0M:M
M'AU#1=2U#3YX;J2WXR^+?P^^'_B+PEX4\7>(/[)U_P <V/C34O"UA_96MW_]
MJ67P\T)?$WC";[5IFFWME9?V/HCK>^7J-S:3:AG[-I<=[=@VX_$GX:WW@+X$
M^,?@7XK\0W^D?#CX*_"W_@I'_P %!O!^I>+=>O?[+\#^ ['6O"/Q8\&^!+'Q
M%XFU.7^S] L=0U 6.@Z=J.O7]O;2WKP6\UX9YEW\-\/+;PO\7_'NB1P:18^/
M/"'Q$_:E_P""N%YI>E:CH3:KI_BS1O$7@JSOM$(T'5;%VU&VUBWN;*YL+>XL
M'-VD]M)%$_F1D@N;TOI^/+_G^'4_?#P)\5_!/Q+TWP;K?@F[US6M ^('PX\/
M?%?PCXC_ .$+\:Z;X:U;P3XKM[.[T"[_ .$CU?P]8:)8:Y?V5_:7_P#PA>IW
M]EXUM;"7[=>^'K:TCEF3T:OY5[RW^'#?LE1VOPT/@ZVT]O\ @C!X#M_%K?#\
MZ%##;_$T_%3PA'\2CKIT!?(B^($7C+^UCXU.IK_PD$?BA=0_M]?[5%R*^U/C
MSHWPA_96^,7[3/A'P?\ !G2G^#&O_L4? ;7_ (B_"GPIXM\2?"+POXLU75_V
MG/%7PMU?Q]\1_&'@NUU+6++2[#PAK<VH_&7QQ>:3K^J:_P##S1-?C\8C7]+E
MU*VN@%+1Z+2U]>_R^_MYG[.?$CXD>"_A%X+UKXA_$/6?^$>\'^'O[._MC6/[
M.U;5OL?]K:M8Z'I__$OT.QU/5+C[1JFI65K_ *+93^5Y_GS^7;QS31[FG>(;
M#5-7\1:);6^N17GABYT^TU*;4?#'B71](N9=3TRVU>V?P[K^KZ38Z#XNMHK2
MZBBU"]\)ZEK5GI&II<Z)JL]EK-G>6$'\L/BGP[\--4TC]NS1]-@_93\4>!D_
M9X_92^*3:;^S!\-QX;_9JTGQ;H?QDU_2?&_B;P/_ &AX@\5>%_'FH^!] N]0
M\*^+_C;X6B\-6EQ9IJFA:_X;\':UIOBK0H?K;Q__ ,*[_P"%R_%;/_"(_P##
M&/\ PUW^Q=_PMW^P/L/_  IO_A1/_##VF?\ "L/^$J_L;_BB?^&>_P#A8O\
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ME_D+V]#_ )_4O_!D/\S<HK#_ .$G\-?]##H?_@VL/_DBC_A)_#7_ $,.A_\
M@VL/_DBCV=3_ )]S_P# 9?Y![>A_S^I?^#(?YFY16'_PD_AK_H8=#_\ !M8?
M_)%'_"3^&O\ H8=#_P#!M8?_ "11[.I_S[G_ . R_P @]O0_Y_4O_!D/\S<H
MK#_X2?PU_P!##H?_ (-K#_Y(H_X2?PU_T,.A_P#@VL/_ )(H]G4_Y]S_ / 9
M?Y![>A_S^I?^#(?YFY16'_PD_AK_ *&'0_\ P;6'_P D4?\ "3^&O^AAT/\
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M&?\ A4:'_P#)U'_"Q_AY_P!#YX,_\*C0_P#Y.H^KXC_GQ6_\%3_^1#Z[@_\
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MVEZ7H_AS1=%T;3[*"TT^):]0KC/^%C_#S_H?/!G_ (5&A_\ R=1_PL?X>?\
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MXS_A8_P\_P"A\\&?^%1H?_R=1_PL?X>?]#YX,_\ "HT/_P"3J/J^(_Y\5O\
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M?\+'^'G_ $/G@S_PJ-#_ /DZC_A8_P //^A\\&?^%1H?_P G4?5\1_SXK?\
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MSP9_X5&A_P#R=1_PL?X>?]#YX,_\*C0__DZCZOB/^?%;_P %3_\ D0^NX/\
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M;WEEK/B7PKK5I+X6!_:V:?\ 0RS#_P +,1_\L\E]P?ZO9!_T(\G_ /#9@O\
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M*/LVM/XD/[:SC_H;9G_X7XK_ .6^2^X/]6>&7MP[D;_[I.7K:W?#^GW'[/\
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M^!?PO+(':?<%8^%LJ&P-P!&<#.<"J'_#&G[('_1J?[-O_AC/AA_\R]?4=O\
M\@W4?^NMA_Z%<5XW\<]1U#2/@E\8M6TF^O-,U33/A9\0=1TW4M.N9K+4-/U"
MR\):O<V=]8WEL\5Q:7EI<11W%M<V\D<T$\:2Q.DB*P/[:SC_ *&V9_\ A?BO
M_EODON#_ %7X:_Z)W(O_  TX#_YG\E]QP'_#&G[('_1J?[-O_AC/AA_\R]'_
M  QI^R!_T:G^S;_X8SX8?_,O7YF_![5M3\0?#_\ 9!U[]GS4?VZM=_:#UK4/
MV?\ 6/B;K?QAU']NV_\ @'J?@G4M%TN[_: U;Q??_M)7+_ #5= U#PG/XGG\
M'7/@"2\\1W/C*Y\'7GPOW1!+F/U/X5_M[?&7XH>)_AUXL\/_  ZUKQ)\+/B;
M\98/A_:^ ] _9*_:R@USP7\-=2\2ZCX-T_XS:W^U7J&FO^S]X@M-,O;.P\7>
M+O#&F^$](TC0_#&J:CIL'Q$U'5?"EQ=ZX?VUG'_0VS/_ ,+\5_\ +?)?<)<,
M\,Z?\8[D6MO^93@/[O\ U#]+KY69]O\ _#&G[('_ $:G^S;_ .&,^&'_ ,R]
M'_#&G[('_1J?[-O_ (8SX8?_ #+U^>=U^T#^U#\74_X)Z?&YM?\ !?@SX(?M
M ?M0Z/=P>!? ,'CC0?'FD^"=1^'_ ,9+GP-X5^)7C2;Q_<>'OBOH_B_0[*T\
M4^*]$M_AMX)TWPOXNTC1;&"/Q3#8PZ\FGX._:]^)<7P1^ %SHWQ,^!/P_P#%
M/Q#\/?$^^L/!OBKP7^T[^UY\</B!XBT+XA>,+#3M/\#_  7\%_$B?XUW?@;1
M_#OAG6=:\7_$RY\8?$B/0?)&E0^$=!\/Z3#<@_MK./\ H;9G_P"%^*_^6^2^
MX/\ 5GAGIP[D?_AIR_\ NV_YA_-?=Z'WS_PQI^R!_P!&I_LV_P#AC/AA_P#,
MO1_PQI^R!_T:G^S;_P"&,^&'_P R]?E]X(_:\_:-^('B/PC^T?:^)/!>A>&+
MW_@EU\2?VBM1^"DOA_QWJOA.X\;^%-62!+F&YC^*NE:?#?W'C*VL;ZWUZ?PO
M>:OI_P .FUCX=B>YU75(?B!IOHOBS]L7XP_!I_A;\5_C5I_@GQM<Z[^Q=\=/
MVC3X/^%O_"T_AUI6G7&FG]G>7PK\,;JSUSXP>.O OB_4(=>\:ZMIE_\ &+7_
M  !#K-MI<MM<>$_"W@ZV?Q1I/BP_MK./^AMF?_A?BO\ Y;Y+[@_U9X9_Z)W(
MU_W2,!_=M_S#^:^[R/OS_AC3]D#_ *-3_9M_\,9\,/\ YEZ/^&-/V0/^C4_V
M;?\ PQGPP_\ F7K3^$</[45AK%W:?'K5/@3XIT2]\*Z-J6FZW\(/#7CWP'>^
M'?&BW5S%XD\(:EH/C3QG\14\6^'C:3:==^'/'UEK?@^_N9;35;+5_AYIHFT^
M[;Y9AE7X^?$+]J7QK\5?&?QXTOX5?LW?$E_@MX)^&'P$\;?'/P7K<]]I7P^^
M&WCGQKX_U[3?V9[W1/BS\2O$?B&_\:V6F^%?#+7OB/1]!\+:8E[HWA:VUG7M
M;U2[/[:SC_H;9G_X7XK_ .6^2^X?^K'#6G_&.Y%_X:<OTV_ZA^FFW6WJ?2?_
M  QI^R!_T:G^S;_X8SX8?_,O1_PQI^R!_P!&I_LV_P#AC/AA_P#,O7YU7OQX
M\1Z!;?LC:=\+/B?^T'^TA:^%OVT_'OPA\0>%]1\*:S\$/C9KGAW2?V</B/XL
MT/X0_%:Q^/6L_!FS^(VN^![#4/"NOZAXW^(EQX?D\8G2],U_5?[8^(%K=:CJ
MLG[1OQ^^-%_XS_:F'_"*?'K]G6/PI_P2P_:6\=^&O#WBOQW\.XYAXZT358O[
M$^)?AA/@?\8_B=HVD^)O#ZLUCIOB2[U#1/%6GN&&G8M")V/[:SC_ *&V9_\
MA?BO_EODON%_JSPS_P!$[D>Z7_(HR_K:VJP]NWW:'Z(_\,:?L@?]&I_LV_\
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MC3]D#_HU/]FW_P ,9\,/_F7KZ2HH_MK./^AMF?\ X7XK_P"6^2^X/]5^&O\
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M>6E?L^_LNWGB']G7]M]?@)9^&_&?PZ_;RL?@'^REX4U_PX_A73O$7QI_:_\
MV/\ Q%JNJ^,OCU\5_ ,?ARVU#PS/\.+31_!'A7^R]*^(&A_#WXH?$R>YTVU_
MNHHH _/'P#_P3/\ V?/!GQ3_ &I/BUJ6H>/O&6J?MC?L]_!W]FGXV^#=9UZQ
MT[X?S_#GX.?#C5_A=IT/@RW\.Z1I'CWPSJ'B;PSKNIQ^([^Z^(>NW:7,D%QH
M%QHDT D?X;^ 7_!N]^R9^S]K'P_\0Z7^TC^WG\3M<^&?P=^//[/'A*]^-GQ]
M\,?$>ST7X#_'?X8Z?\,IOA'X;\-ZA\*K7PEX!\%_"Z.'6O&GPOL_AGH'@J]A
M\8^+-<_X3^_^('A*T\+>$O#?[Y44 ?F'\'O^"3W[.OP3\8_\$_O&_A7QG\:=
M0U7_ ()P_ _XF? +X'V_B#Q%X&N]/\5>#OBKX<TKPQXAU+XK1:;\.=)N=<\2
MV=AI%M-HUYX1N_ VEV]X\\E]HVHPM';Q>(V/_!#[X.>$OV3/@?\ LA?!O]M+
M_@I7^S?X1^ _B[XJ^*_#_P 0_P!F_P#:O?X,?$WQC'\8?&NO^/\ Q3X:^)G_
M  AO@.P^&?C30K'Q)KQG\*W5W\,[?Q5X9M=/AL=,\316VK^*T\1_M510!\N_
ML8_L@_![]A#]FWX;?LM_ N'Q,WP^^&UIK!AUKQQKK>*?'GC'Q)XI\0:KXN\:
M>.O'/B1K6PCUCQ9XR\6Z[K/B#6);'3M)T2RGOQI/AK0] \-:?I&AZ=]1444
M%>-2?ZR3_?;_ -"->RUY7)=V0=P=+@)WMD_:;WGD\\3XY]J /F7]I/\ 9I\"
M?M2^#O"G@GX@:MXMT?2O!_Q-\$_%;3+CP=?Z/I^H3^(O =Y<7ND65]+K>@^(
M;:71;F6Y==2M[>TM;Z:,(+74;-@7:B/V5_ANW[1OCG]IJYO_ !;>>-/B'\%;
M3X#^(?#L^IZ9'X*/@JTUI=;-Q8V=IHMKXDMM?N9U-M/?'Q1+:"T=A;Z=;W(2
MY7ZE^UV7_0*@_P# F]_^/T?:[+_H%0?^!-[_ /'Z!679'Y3?!G_@DK^S_P#
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MLO\ H%0?^!-[_P#'Z!F=16C]KLO^@5!_X$WO_P ?H^UV7_0*@_\  F]_^/T
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M;W_X_1]KLO\ H%0?^!-[_P#'Z!F=16C]KLO^@5!_X$WO_P ?H^UV7_0*@_\
M F]_^/T 9U%:/VNR_P"@5!_X$WO_ ,?H^UV7_0*@_P# F]_^/T 9U%:/VNR_
MZ!4'_@3>_P#Q^C[79?\ 0*@_\";W_P"/T 9U%:/VNR_Z!4'_ ($WO_Q^C[79
M?] J#_P)O?\ X_0!G45H_:[+_H%0?^!-[_\ 'Z/M=E_T"H/_  )O?_C] &=1
M6C]KLO\ H%0?^!-[_P#'Z/M=E_T"H/\ P)O?_C] &=16C]KLO^@5!_X$WO\
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MWAK1],T#0=(LD\NSTK1M&LH-.TO3;2,EC';6-C;06L"$G;%$BY.,T#UOY?\
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MI9\4Z .P\%_\E%^,G_89\&?^H/I%>JUY5X+_ .2B_&3_ +#/@S_U!](KU6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*Y+6QWOG4T!WMD?9
M+DX.3QG;7JE>-2?ZR3_?;_T(T 7OLMA_T$T_\!+G_P")H^RV'_033_P$N?\
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MLQ87RC4$*M)9EG^S7 V$-/M&TKEM^3R.%V\]15'[+8?]!-/_  $N?_B:+?\
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M_B:SJ* -'[+8?]!-/_ 2Y_\ B:/LMA_T$T_\!+G_ .)K.HH T?LMA_T$T_\
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MD]!S6-5VP_ULW_7E?_\ I'-0!)]EL/\ H)I_X"7/_P 31]EL/^@FG_@)<_\
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M)<__ !-'V6P_Z":?^ ES_P#$UG44 :/V6P_Z":?^ ES_ /$T?9;#_H)I_P"
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MXR?]AGP9_P"H/I%>JUY5X+_Y*+\9/^PSX,_]0?2*]5H **** "BBB@ HHHH
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MHA?7?A:\FT7^E#^S=1_Y\+W_ ,!9_P#XW1_9NH_\^%[_ . L_P#\;H&H_/\
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MSJ<$?B3XX6?Q#\,:UIFEZ<?"6E^(;^;7+.[\#36J:AI"V0_6W^R]2_Y\+O\
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MVFJW ._K_GK;\&^MO(_HYWO_ 'F_[Z/^-&]_[S?]]'_&OS2^$_QJ\7?M$_\
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MOCFPUG[5;^-8KSPQ]G\4ZE>ZI_9W@ZX\/:5+YWV*:QDTZ.*TC\+^$7BKX\_
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M7_VD[C_@FS\$]/\ $OPF^!VD_#'_ (1C]AF+_A+]"_:$\>^(O'?]C0_$_P"
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MASQ5HCSW&B>+/&(CM/$UZ I)_AVZVMU\S]M=[_WF_P"^C_C1O?\ O-_WT?\
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MB>"="\2Z/I.O>)?!?ASPYX-\3A;75] TA;:X:]O?JR@H=O?^\W_?1_QHWO\
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MQMYFB)?BRM?#5U'K&H7.H3V]YJGTY^V=XX_:1\#^,]*UGPKK'QN\!_L^Z?\
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M_P#"KOAKU.?^9L^*?K6Y6%X!_P"2U>.O^R7?#7_U+/BG0!V'@O\ Y*+\9/\
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M=-_\ T_^*H_M(_\ /CIO_@&G_P 50!FT5I?VD?\ GQTW_P  T_\ BJ/[2/\
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M?4O#MK_;OE66D6\&F:-'I_?>"/AOX+^''_"7_P#"&:-_8W_">>.=?^)'BO\
MXF.K:C_:OC3Q1]D_MW6?^)K?7WV'[=]AM?\ B7:;]CTFV\K_ $.QM]\F_P!*
M_M(_\^.F_P#@&G_Q5']I'_GQTW_P#3_XJ@=EV_K^DCYS\ _LQ_ [X83Z3<>!
MO!']AS:'\-+[X/Z6_P#PDOB_4_LOPZU+Q/>>,KWP[MUC7]02?SO$E_=ZE_:U
MPLVNQ^;]CBU..PCBM4U;#]GOX-Z=\#8/V:X? NG7'P0M_!)^'4?@'5;W6-;L
M3X.-HUDNDS:GK.HW^OW#Q0,#;ZG<:M+J]M<I#>V]_'>00SI[O_:1_P"?'3?_
M  #3_P"*H_M(_P#/CIO_ (!I_P#%4"LNR/D?P_\ L6_LX^'O$/B#Q;_PA6O>
M*O%'BWP!XI^%/BWQ!\3_ (I?%OXOZQXL^&?C+^Q_[?\  7BK4/BKXZ\97/B3
MPG,=#LSIVA:U)?:=H+7&LMH$&F-XB\0'4\[PI^PO^R_X0N_%U_9_#[6/$-]X
M[^&=[\&O%M[\1_BC\7/BU=ZS\*[[^SO,\ S7'Q2\=^,9H/#-K_9=I_9.FV;V
M\.B;KW^QA8?VGJ7VO[)_M(_\^.F_^ :?_%4?VD?^?'3?_ -/_BJ LNR^X^*;
M']@C]EBRL_%%G+X \1ZV?&G@33OACXEU'Q=\8?C7XWU_4OA_H^N:7XCT;PE_
MPDOC#XBZYXAL]%T76-'L+G1;2PU.U72(DGL=--KI]]?6MST_C']CG]GKQWX@
M\7>*O$'@_7T\0^-_%GA+X@:UJGAWXH_%GP9<6GQ"\#:+;>&O#?Q"\)KX-\<:
M#%X"^(%KX9M8O#%]XX\"Q^'/%6N^&GN?#^O:OJ>CWMY93_5_]I'_ )\=-_\
M -/_ (JC^TC_ ,^.F_\ @&G_ ,50%EV7W(\G^%WPF\ _!KPU/X4^'NC7.E:9
M?:YK/BC6+S5M?\2>,/$_B7Q/X@NC=ZSXE\7^-?&>K^(/&7C#Q#?N(8)M;\4:
M]J^J#3[/3M*CNDTS3-/M+;T:M+^TC_SXZ;_X!I_\51_:1_Y\=-_\ T_^*H&9
MM%:7]I'_ )\=-_\  -/_ (JC^TC_ ,^.F_\ @&G_ ,50!FT5I?VD?^?'3?\
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M1\Y^)OV8O@9XPTSXNZ-XA\"QWNE_':Y\'7GQ4LH?$'BO38?$T_P_TGP_H7A
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MM-TG7]7N_P"U]7L+W4X+:[A^KJTO[2/_ #XZ;_X!I_\ %4?VD?\ GQTW_P
MT_\ BJ!F;16E_:1_Y\=-_P# -/\ XJC^TC_SXZ;_ . :?_%4 9M%:7]I'_GQ
MTW_P#3_XJC^TC_SXZ;_X!I_\50!FT5I?VD?^?'3?_ -/_BJ/[2/_ #XZ;_X!
MI_\ %4 9M%:7]I'_ )\=-_\  -/_ (JC^TC_ ,^.F_\ @&G_ ,50!FU=L/\
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M?\(WX#UN'PS;ZIH7V2?6);'6/M4/@_PXG]J:]:ZIK,/]G;K?48FN[YKKV_\
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MHGAO6=7@.GIXCN+G0K#4]56ZT"WN9]7TN*ULI/M.K6=C;3R6UM--=0@'R#\
M?VS/&'Q6_:-\1> _$GA3PWHWP3^)&E?$'6?V2O'5@NKP:[\0;7X#^,T^''QB
M3Q&U]?W6GWKZKK5S:>-O !T_2_#%PO@)I9KNRUV%K/Q#=]W#^VGHGB(:S=^"
MOA#\:]4\!_VGX_\ "?A/X^R>#]!OO@GKWC/P%I^M"^@E_LGQM/\ %'2?"DWB
M?0=3\'V'C[Q'\.O#?@#7?$=FNFZ+XON5U;0;S4_'->_X)TZ%\.O#G[/NK_LP
M^(O&&C_%']FSQIX"U;P1'\5/C]^T!XB^&^I>"H/)\+_%KP6GA76?%GQ \*^
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M_P!O#P!?1"Y\4_"KXX?#&RUOX0>,_CE\,+SXA>'O ]A%\9? '@+1T\1>(Y/
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M 7X@:)I=SXTTSX;^,]5\->+]&@UC0+S5%M_ /BS2+BZTO4_#MK?"WU*W\4V
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M@]X1\$ZO+XFN/&?PHT3X0>+?#7P.MO@'JTWP\^'7A'P7\3[75/ GB#P5X?\
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M $'X+_PJH?\ RSS7WA_Q$[PU_P"CA\#?^)9D'_SP\U]Y]+_\(@G_ #_M_P"
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MX##_ ./T?\(@G_/^W_@,/_C]?-'_  \+_8E_Z.8^%7_A0+_\9H_X>%_L2_\
M1S'PJ_\ "@7_ .,T?VCE_P#T'X+_ ,*J'_RSS7WA_P 1.\-?^CA\#?\ B69!
M_P#/#S7WGTO_ ,(@G_/^W_@,/_C]'_"()_S_ +?^ P_^/U\T?\/"_P!B7_HY
MCX5?^% O_P 9H_X>%_L2_P#1S'PJ_P#"@7_XS1_:.7_]!^"_\*J'_P L\U]X
M?\1.\-?^CA\#?^)9D'_SP\U]Y]+_ /"()_S_ +?^ P_^/T?\(@G_ #_M_P"
MP_\ C]?-'_#PO]B7_HYCX5?^% O_ ,9H_P"'A?[$O_1S'PJ_\*!?_C-']HY?
M_P!!^"_\*J'_ ,L\U]X?\1.\-?\ HX? W_B69!_\\/-?>?2__"()_P _[?\
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M_/#S7WGTO_PB"?\ /^W_ (##_P"/T?\ "()_S_M_X##_ ./U\T?\/"_V)?\
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MW_")7/\ S]P?]\24?\(E<_\ /W!_WQ)7SC_P\+_8E_Z.8^%7_A0+_P#&:/\
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MYQ_X>%_L2_\ 1S'PJ_\ "@7_ .,T?\/"_P!B7_HYCX5?^% O_P 9H_M'+_\
MH/P7_A50_P#EGFOO#_B)WAK_ -'#X&_\2S(/_GAYK[SZ._X1*Y_Y^X/^^)*/
M^$2N?^?N#_OB2OG'_AX7^Q+_ -',?"K_ ,*!?_C-'_#PO]B7_HYCX5?^% O_
M ,9H_M'+_P#H/P7_ (54/_EGFOO#_B)WAK_T</@;_P 2S(/_ )X>:^\^CO\
MA$KG_G[@_P"^)*/^$2N?^?N#_OB2OG'_ (>%_L2_]',?"K_PH%_^,T?\/"_V
M)?\ HYCX5?\ A0+_ /&:/[1R_P#Z#\%_X54/_EGFOO#_ (B=X:_]'#X&_P#$
MLR#_ .>'FOO/H[_A$KG_ )^X/^^)*/\ A$KG_G[@_P"^)*^<?^'A?[$O_1S'
MPJ_\*!?_ (S1_P /"_V)?^CF/A5_X4"__&:/[1R__H/P7_A50_\ EGFOO#_B
M)WAK_P!'#X&_\2S(/_GAYK[SZ._X1*Y_Y^X/^^)*/^$2N?\ G[@_[XDKYQ_X
M>%_L2_\ 1S'PJ_\ "@7_ .,T?\/"_P!B7_HYCX5?^% O_P 9H_M'+_\ H/P7
M_A50_P#EGFOO#_B)WAK_ -'#X&_\2S(/_GAYK[SZ._X1*Y_Y^X/^^)*/^$2N
M?^?N#_OB2OG'_AX7^Q+_ -',?"K_ ,*!?_C-'_#PO]B7_HYCX5?^% O_ ,9H
M_M'+_P#H/P7_ (54/_EGFOO#_B)WAK_T</@;_P 2S(/_ )X>:^\^CO\ A$KG
M_G[@_P"^)*/^$2N?^?N#_OB2OG'_ (>%_L2_]',?"K_PH%_^,T?\/"_V)?\
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M;913WNHZEJ-[/!:6-C:0375W=316]O%)+(B']5_^"V'_ "?5J/\ V1KX9?\
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MP]..$AB/R9HK]MO@EX*^$?P\_:'_ &/?B'X%\*?"#Q-:_&KP-\;H[]? U_\
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M** "BBB@ HHHH *^O_V,?^1T^-7_ &:!^US_ .J#\<5\@5]?_L8_\CI\:O\
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M? PIUZWM*:J5<1&I%*,4N90PTTI)IOW9O;>Y_2GC)]"SQ9X_\5.,>.N'^(.
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M^;ZC_4/./^@C+?\ P=B?_F3^K/RN?\4]?&K_ **3PQ_\/?%'_P!!O]6?E?\
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M@;_H@!_\.K\9O_G@4?\ #K;]@;_H@!_\.K\9O_G@4?ZAYQ_T$9;_ .#L3_\
M,G]6?E<_XIZ^-7_12>&/_A[XH_\ H-_JS\K_ ,=5%?V*_P##K;]@;_H@!_\
M#J_&;_YX%'_#K;]@;_H@!_\ #J_&;_YX%'^H><?]!&6_^#L3_P#,G]6?E<_X
MIZ^-7_12>&/_ (>^*/\ Z#?ZL_*_\=5%?V*_\.MOV!O^B '_ ,.K\9O_ )X%
M'_#K;]@;_H@!_P##J_&;_P">!1_J'G'_ $$9;_X.Q/\ \R?U9^5S_BGKXU?]
M%)X8_P#A[XH_^@W^K/RO_'517]BO_#K;]@;_ *( ?_#J_&;_ .>!1_PZV_8&
M_P"B '_PZOQF_P#G@4?ZAYQ_T$9;_P"#L3_\R?U9^5S_ (IZ^-7_ $4GAC_X
M>^*/_H-_JS\K_P =5%?V*_\ #K;]@;_H@!_\.K\9O_G@4?\ #K;]@;_H@!_\
M.K\9O_G@4?ZAYQ_T$9;_ .#L3_\ ,G]6?E<_XIZ^-7_12>&/_A[XH_\ H-_J
MS\K_ ,=5%?V*_P##K;]@;_H@!_\ #J_&;_YX%'_#K;]@;_H@!_\ #J_&;_YX
M%'^H><?]!&6_^#L3_P#,G]6?E<_XIZ^-7_12>&/_ (>^*/\ Z#?ZL_*_\=5%
M?V*_\.MOV!O^B '_ ,.K\9O_ )X%'_#K;]@;_H@!_P##J_&;_P">!1_J'G'_
M $$9;_X.Q/\ \R?U9^5S_BGKXU?]%)X8_P#A[XH_^@W^K/RO_'517]BO_#K;
M]@;_ *( ?_#J_&;_ .>!1_PZV_8&_P"B '_PZOQF_P#G@4?ZAYQ_T$9;_P"#
ML3_\R?U9^5S_ (IZ^-7_ $4GAC_X>^*/_H-_JS\K_P U'PI_Y,X_:\_['S]E
MK_TX_&&OD&O[4-$_X)V_L7Z-X"\=>!M,^"IM?"GC;4O!FI>*=)_X6/\ %6;^
MU;WP?-KTOAN?[?<>-9=2L?[-DUS56\K3KNTBO/M>+]+E8+81<)_PZV_8&_Z(
M ?\ PZOQF_\ G@5T5N",VJ4\)".(R].AAY4IWK8FSE+%8FNG&V$=UR5HIMI/
MF4E:R3E]%G7T"_&',<MX1P=#B'PXC5R'A[$Y3C)5<YXEC3J8FMQ9Q/GL9X9P
MX1G*=%8/.L+3E*I&C-8BGB(*FZ<*=6K_ ">^*/C7\3?&?_"R_P#A)?$W]I?\
M+?\ &.B>/OB+_P 2;P_9_P#"1>+?#G_"3?V-JW^@:5:_V3]C_P"$P\1_Z!H7
M]F:9<?VC_I=G/]DL?LN]I'[2'QFT/7M \1V'B^%K_P -_#*'X,V5GJ/A?P?K
M/AS4?A9!!<01^!O%?A#6/#]_X4\<:#FX-U):^--%U]IM1MM-U6:234M)TN[L
M_P"J3_AUM^P-_P!$ /\ X=7XS?\ SP*/^'6W[ W_ $0 _P#AU?C-_P#/ J5P
M7Q I<ZQ^#4KWYEB\8I7YY5+W6%O=5)SJ7O?GE*7Q2;>,/H-_2-IXA8NGXA\&
MT\4JBK+$PXPXWCB%56.Q.9JJJT>%%4519EC<9F"FI<RQV*Q.+3^L5ZE2?\OW
MB?\ :\_:$\81:;:ZYXYLCI^B^!_&_P --#T?2? GPZ\-Z%H/@+XBZ-IV@>,/
M"N@:#X;\):3HVAZ3J>E:596]O!I5C9G1I$FO-#?3;V\O+FXS;;]J7XY6G@4_
M#N+QA8MH7_""WGPNCU6X\$> +OX@VWPSO[FXN+SX=V7Q8NO"TWQ2L? TZW=W
M8MX2L_&,&@+HUW=:$FGKHMS-8/\ U)_\.MOV!O\ H@!_\.K\9O\ YX%'_#K;
M]@;_ *( ?_#J_&;_ .>!5O@_B-RE)YEAG*4>64GC<<Y2BU"+C)_5KN/+"":;
M:M"*VC$ZY_0K^DY5KXC%5?%'ABIBL70EA<5B:G'/'LZ^)PLZ6&P\\-B*TN%W
M4K4)4,'A*,J-24J<J6$P]-Q<*%*,?Y?W_:\^/KZ-J>C'Q9X?5M=\ W'PM\1>
M)(_AA\*8OB#XI^'EUX43P3)X1\6_$Z/P0GQ&\5Z.GAFWT_3[:W\1>*=3-G+H
MOAW4K1X-5\.:#>Z=@^&OVEOC)X0TOX9Z3X?\1Z+8Q_!V^U:_^&VI2?#_ .'-
M_P")?"_]NW/B:]U;3;?Q=J7A.[\57WAV]U#QCXCU.7PMJVLW_AI=5U+^U8])
M34+2QN;7^I[_ (=;?L#?]$ /_AU?C-_\\"C_ (=;?L#?]$ /_AU?C-_\\"C_
M %/XCNI?VEAN9*R?UW'72YX5+)_5KI<].$[+3GIQEO&+$_H4_2;E6IXF7B?P
MN\12I^QI5WQQQXZU*E]<PF8^RIU7POSPI_VA@,#CN2,E'ZY@L)B;>WPU"</Y
M:O 7[47QN^&OAW0?"WA3Q5I*:5X1U'6-7\#3>(? 'PY\;:[\.M4U][:?6+_X
M9>*O&WA+Q#XH^&EU?7UI;ZM++X#UCP\RZ[$-?C*:TS7[>6ZQX\\7^(?#VG^%
MM<URZU71=,\7>,O'EK%?);W%\WB_X@V/A#3O&6N7FLR0MK.I76NVG@/PJMPF
MHZA=V\,VF/=6<-M=ZCJL][_7/_PZV_8&_P"B '_PZOQF_P#G@4?\.MOV!O\
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M\\"C_4/./^@C+?\ P=B?_F3^K/RN?\4]?&K_ **3PQ_\/?%'_P!!O]6?E?\
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M:O\ HI/#'_P]\4?_ $&_U9^5_P".JBO[%?\ AUM^P-_T0 _^'5^,W_SP*/\
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MNFZ3IMK::9IEI::?:6UM%_77_P .MOV!O^B '_PZOQF_^>!1_P .MOV!O^B
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MW/E0P?:+[4+B2[NY_)MXX;>'SKB:23RH(HH8]VR*-$"J/[!O^'6W[ W_ $0
M_P#AU?C-_P#/ H_X=;?L#?\ 1 #_ .'5^,W_ ,\"N>7 ^=S24\7@))--*6(Q
M<DFHQ@G9X1JZA&,%VC!16BBCYO$?0&\>L73C1Q7&7A]B:,9PJ1I8CB3B^M3C
M4IX:A@Z<XPJ<(2BIT\'A\/A822YHX;#T:$6J5*G!?QU45_8K_P .MOV!O^B
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M .'OBC_Z#?ZL_*_\=5%?V*_\.MOV!O\ H@!_\.K\9O\ YX%'_#K;]@;_ *(
M?_#J_&;_ .>!1_J'G'_01EO_ (.Q/_S)_5GY7/\ BGKXU?\ 12>&/_A[XH_^
M@W^K/RO_ !U45_8K_P .MOV!O^B '_PZOQF_^>!1_P .MOV!O^B '_PZOQF_
M^>!1_J'G'_01EO\ X.Q/_P R?U9^5S_BGKXU?]%)X8_^'OBC_P"@W^K/RO\
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MKPG<7\G@/QCXP^,%IH_P_P!<\;:5Y7PZ\7>)?A6ND^,8/U<_X)9? C]O!/\
M@HQ_P4>_;A_;(_8]\)_L=Z;^UM\-_P!DO3_ _@3PM\</A?\ '.6+6/A#X8\4
M^$?$]AXJ\6_#^ZLKC6/%EO;IHVI:CKD_A#1-"FL]5TW1M$U'77T2^OF /HR\
M_P""R?P ^&OQI_X*3>!?VF[&V_9]^$'_  3J\=?LD^ M<^.MYK'BOXB6?Q"U
M/]K3P8/$7AR>[\!^#/AI<:WX"MM UZ>P\,3W7]I>,=.NHKM_$6K:CX7TVTN8
MT]5^"7_!8K_@FA^T5\+?VB_C5\'_ -K7P#XH^%_[)MJNH?M ^+;W1_'7A&T\
M :9/%JDFF:M]B\:^$_#NJ^*M&\0RZ+JEAX2UCP58>)-,\8:Q:-H?A:[U?6)(
M;&3\,?V[O^"6'[;OQR\1?\%S)/!/P#MO&&A?MG?M&_\ !*+QI\ H+SXB_!JR
ML_BAX%_9QT_P]:?'>\N['Q)X^T__ (1JV\))9WT$^D^/X/#E]XIB5T\*V'B"
M.9/,]"_X*'?\$EOVM/VI/C-_P66OOA7\/O".B>$OVI/V;/\ @GXGP%U?Q/XD
M\$0^"/C/\5?V1OB)HWQ&\1?#/QAX7T[Q"/$NE6^J:5X.T[P%IVN>.-'\/>&H
MYM3T>6/73H.E7KVX!]0^"_\ @XM_9*^.?Q5_:+\-_LR7?@;XJ_!#]GS_ ()_
M^+_VVM8_:0\4>+OC'\.?#4&N^"?BF?AOX@^#WCOX76_[,OC?XU>!X-,L9M-\
M9W7C;2/ GCSQ#=Z#JNG3>'?A5XAM-0TW4;[ZX^+_ /P6S_X)L_LR6?[.6G_M
M1_M3?#?X2^/?VE/A7X!^+'@SPKI6F?%[X@:=#X8\?Z=H]SI'B+5]:TKX2Z;J
MW@;P-J5UJKQ^'/%WQH\)_"*36]-TS5]4N]"T1]!\36&A?AI\1?V,O^"KW[9'
MQL_X*-_M'?%[_@G=X0_97U?]HO\ X(J_$']B[X3_  Q\*_M0_ 'XM77B#XTQ
M?%+3]1\,>'O%?B[1M>\(:7I^O>)=%M+S4=.UF[T^/P#X<\$VWA#P_JOCS_A(
M[34=*L>^U']C'_@J%^R7\0/%'C'X$?\ !/7]GK]O+2OVR?\ @FY^QA^RK\4_
M"?QX^-GPG\-^#_V8/B9^SC\(+?X9^)]#^+'@7QA>-8_'WX'^*KW6#KGBGP9\
M*_%#2^,_^$:U*T.NZ(\'AV]\1@'[4?M0_P#!:G_@E[^QC\8/"OP&_:2_:X\&
M?#SXH>,?#GA3Q=H^AP>%/B=XYTJW\->.+N>U\*ZUXE\:?#KP/XM\#^"['5XX
M#JT,OC+Q)H)@\-3V/BR[6W\,:EI^KW/SAXZ_X+__ +%OA;]KG]JS]C&QURWC
M^)O[,G[._P 1?C,GBKQI!\3])^&'CWQ9\*?A-XW^.'Q%\$V_B#X;?!WXP^(-
M$\)> ?AAX0C\3^*/B1;>$O$M]JL=]=Z7\*OA[\4=<L;'2];_ "^_X*>?L;?\
M%P?VD?#G[1G['WA[X _#'XK?LQ>)?V6OV=-+_9HUO]G_ /:ATG]C']G_ ."/
MQ0^&_P ,M&'[1'@34?V=K'5;+XE?':V^*_Q T#4O#7[/WPW^.?CK6?V=?@UX
M3N?ASK.N:]+KUKXHO_#GJ7QQ_8A_X*&6_P >_P!OR+X:?L@GXB?"[]OS_@BY
MI_[+T_Q,F_:#^!WA*^^#G[0WP\_94^-?@_PU\,M2\ ZSXC.I^+[[QO\ $74?
M!O@B3Q+I&LVGPX\,Q^*(?%UWX^U#1].UNUT@ _4OXL_\%R/^";?[,7PF_9:^
M(?[6/[3OP[^$VN_M6? 3X?\ [07@+PCX+T3XZ?&2:\\#>//#6DZY8>*M/T[P
M[\#M'^*NF_#O5;R_OM,\#>,?BS\(/@_J?C5M"UV!?!^B>(_#GBWPQX;[[]IG
M_@LW_P $Q?V/Y?!:?M _M<>!O"5O\2OA!HWQZ^&VK>'O#WQ$^*7A[XC_  E\
M0^*;/P?H?B_X?>)?A-X-\<>'_&\&JZO?1W5EI7A?4]5UZ?PQ;ZGXW32CX+T?
M5M?LOPT\&?L6_P#!4[]@RY^&/Q8^ _\ P3_^$_[=.M?';_@C[^QQ^Q!\;OA7
MXP_:)^#GPE\7?LN_&+]G7X.:3X&\8:%JFL>.K[4? /Q<^"_C.[NUDUWP_P##
MKQ=,/'&O^&[U+_5_"^BZ%X7\0^._<OV)_P#@D)^T;^R?^U+^P3%XW\.>%OBY
M\,/V;/\ @D%\7OV8O'WQAT_6?"<_A>U_:/\ B5\;M7\?7W@;PAX:\6ZIIOQ+
MU'PW!X=\7>)/#.A^.)_ NCZ7JOA"/RM>A\,7NLW?A:U /Z0_@A\;/A9^TA\(
MOAS\>?@AXSTSXA?"7XL^$M'\<> /&.DQWUM:ZYX=URU2ZLYY=.U:TT[6M$U.
MWW/9:UX=\0:9I7B/PWK-M?Z#XATK2];TZ_T^V]2K\G_^"'/[-OQT_9"_X)7?
MLE?LX_M*>#Y? 'QL^&.@?$C3?&W@^7Q/X4\9/H;:S\:OB3XH\/VP\2>!_$'B
MGPKJ,4GA77-#NH1H^O7\-E#/'I\YM[NTN+2W_6"@ HHHH *\7KVBO%Z /R[_
M &W?V[_VAOV0/$FGRZ1^Q1_PMGX1:]XA\#^!_#/Q9_X:0\#^ _[:^(/CGSH;
M'PI_P@ESX/\ $WB?3?)OX);+^W=0$.B2;?M$UW:0LI.YX=_X*7?"WP=K7A7X
M4_MA:*?V5?VFO%VL:-IVE? *'4?$?Q[O;BR\7ZS<Z)X#U*U^('PH\!WO@VZ/
MBF[LYT-DMU'-H,OV>'6GM3>6C3[G_!2?X&?%/X_?![X4^%?A)X7_ .$LU[PU
M^TW\$_B%K5A_;?AW0?L7@_PCK&H77B'5_M7B;5]&L[G^SX)XI/[/M+B?5+O=
MML;*Y=648^G? #XM6G_!33XL?M*0>#-('@#5?V.=$^&'@/QUK.J:!<6I^)=K
MXWMM8N-#GT:RU27QOI]@;"!)M2U*/1K73[JT1[:WU":[\N A%Y7?:Z2TTL]W
MI;;U]3TCX1?\%'?V*/CQ\8)/@-\)OCQH?C#XJ"7Q+!:^'+;PYXZTVTUF7PC'
M=7&OKX;\4ZWX6TSPAXI^R65A?:K WAS7M474]%L;W6]*:]TBTN+V/$^$?_!3
M_P#81^.OQ \&_"SX6?M!:+XE\>_$""^F\)^'YO"/Q'\.R:E)IQU83Z?/?^*/
M!VBZ5I&M2KHE_-8:#K5]IVM:K;'3[K3+"\MM8TB6^_-7X1?L]?\ !2+QS^U7
M^QI\:_VI/A+J,FH? CQS\6[/XI_$J3]HKP7XITSQ;IGC3P;J6@^&/&'@?X%>
M'=3\/?#?X3>$]$M+?1=!U&S\$: WQ&\;7)7Q+XWLM1OK59HK?P(_8/\ VD?
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M^E^)-;T?X6^&K[Q-K'C_ .*7C&Q40^/_ !T=<CU;5K*Z/AKP]8>'_"5C8Z-
M V]-UKVW6F^FG5>OD?H!^T[^U/K'P,\??LY?![P)\-;'XG?%?]ICQGXJ\->#
M-+\1>.I?AKX+T;2? GAM?$GB_P 1^)?&%EX+^(NJP?V=;WFE+8Z1IG@S4[G5
M(Y[^2*>&XL+>SU+YST3_ (*B>%-8_8O^'7[6-W\-4\*:K\2/B[I/P2TOX?\
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MRO\ 'OXL>/M<_:=U7X8>-/#S3_M)?#/Q\O[-&B?'&U^'?QAUGX9>!?@IXK^
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M+O;TUT\O7M\NGOME>V>I6=IJ.G7=KJ&GZA:V][87]E<175G>V=U$D]K=VEU
M\D%S:W,$B36]Q"[Q31.DD;LC FS5:RLK/3;.TT[3K2UT_3]/M;>RL+"RMXK6
MSLK.UB2"UM+2U@2."VM;:"-(;>WA1(H8D2.-%10!9H&%%%% !1110 4444 %
M%%% !1110 5HZ9_K;G_L':C_ .D<U9U:.F?ZVY_[!VH_^D<U &=117R-^S?^
MQ?\ "S]EWQY^T!\1/A]XA^)NLZU^T?X[D^(/C>U\=^,CXETK2]8?4M?U0P>&
MK<:;87*0?:/$=\DFH^)+SQ+XFN;:*S@N_$%PD!\P ^N:^/Y_VM]-L/VT%_9
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M6@1A-Y6>COI;1]=U\O,^L_"'[>/A7Q?XR\>^#!X1U7PI=^"?VL/#O[,-M?\
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M!;G5/@[:VVH7=Q\4/ 6G>-O _A[4?BEX$A@TZ0OXG^&5KXNT@27VA0?:O/\
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M%_\ RRH_X3/XC_\ 1'-5_P#"T\%__+*O5:* /*O^$S^(_P#T1S5?_"T\%_\
MRRH_X3/XC_\ 1'-5_P#"T\%__+*O5:* /*O^$S^(_P#T1S5?_"T\%_\ RRH_
MX3/XC_\ 1'-5_P#"T\%__+*O5:* /*O^$S^(_P#T1S5?_"T\%_\ RRH_X3/X
MC_\ 1'-5_P#"T\%__+*O5:* /*O^$S^(_P#T1S5?_"T\%_\ RRH_X3/XC_\
M1'-5_P#"T\%__+*O5:* /*O^$S^(_P#T1S5?_"T\%_\ RRH_X3/XC_\ 1'-5
M_P#"T\%__+*O5:* /*O^$S^(_P#T1S5?_"T\%_\ RRH_X3/XC_\ 1'-5_P#"
MT\%__+*O5:* /*O^$S^(_P#T1S5?_"T\%_\ RRK@/.^*O_1)+K_PMO"/_P F
M5]*44 ?-?G?%7_HDEU_X6WA'_P"3*/.^*O\ T22Z_P#"V\(__)E?2E% 'S7Y
MWQ5_Z))=?^%MX1_^3*/.^*O_ $22Z_\ "V\(_P#R97TI10!\U^=\5?\ HDEU
M_P"%MX1_^3*/.^*O_1)+K_PMO"/_ ,F5]*44 ?-?G?%7_HDEU_X6WA'_ .3*
M/.^*O_1)+K_PMO"/_P F5]*44 ?-?G?%7_HDEU_X6WA'_P"3*/.^*O\ T22Z
M_P#"V\(__)E?2E% 'S7YWQ5_Z))=?^%MX1_^3*/.^*O_ $22Z_\ "V\(_P#R
M97TI10!\AZKX.\0Z[XF\*>--;_9UT'6/&/@1=>3P/XLU75_AWJ'B;P:GBJR@
MTWQ.GA37KLS:IX=7Q'IUK:V&O+I%U9C6+*V@M=0%Q!#'&O4>=\5?^B277_A;
M>$?_ ),KZ4HH ^0?!W@K7?AWI,N@_#_]G+P]X&T*?4]1UJ?1?!VJ_#KPSI,V
MLZQ<M>:OJTNG:+]ALY-3U2[=[K4;]X3=7UR[3W,LLK%CU7G?%7_HDEU_X6WA
M'_Y,KZ4HH ^:_.^*O_1)+K_PMO"/_P F4>=\5?\ HDEU_P"%MX1_^3*^E**
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M#YK\[XJ_]$DNO_"V\(__ "91YWQ5_P"B277_ (6WA'_Y,KZ4HH ^:_.^*O\
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M?_DROI2B@#YK\[XJ_P#1)+K_ ,+;PC_\F4>=\5?^B277_A;>$?\ Y,KZ4HH
M^:_.^*O_ $22Z_\ "V\(_P#R91YWQ5_Z))=?^%MX1_\ DROI2B@#YK\[XJ_]
M$DNO_"V\(_\ R91YWQ5_Z))=?^%MX1_^3*^E** /FOSOBK_T22Z_\+;PC_\
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M277_ (6WA'_Y,H\[XJ_]$DNO_"V\(_\ R97TI10!\U^=\5?^B277_A;>$?\
MY,K:^&GA_P :1^/O%_B[Q1X9C\+V6H^#_!GAS3;5]<TW6+NZNM$UKQOJ=_<,
;-+:6"WMDB\06$<1EF\V67SL1A(]S>]44 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img149481191_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $- L\# 2(  A$! Q$!_\0
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M_MF_#O\ X*A?M@>"?A_^UG^T?X%\&>&_B%I^G^'O"/@_XR^/?#?AK0K$>$]
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MXD#\3_\ YI*^/::652H)Y=@J+U9V/14499F/95!/M1_9N7?]"_ _^$F'\O\
MIWY(+ON_O9]B?\/#OV_O^CX/VM/_ !('XG__ #24?\/#OV_O^CX/VM/_ !('
MXG__ #25\>;AN9#E73&^-U*2)D9&Y& =<CD9 SVI:/[-RY?\R_ ]/^83#^5O
M^7?D@N^[^]GV%_P\._;^_P"CX/VM/_$@?B?_ /-)1_P\._;^_P"CX/VM/_$@
M?B?_ /-)7Q[11_9N7?\ 0OP/_A)A_+_IWY(+ON_O9]A?\/#OV_O^CX/VM/\
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MUI_XD#\3_P#YI*^/:*/[-R[_ *%^!_\ "3#^7_3OR07?=_>S["_X>'?M_?\
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M/UJ>.637F\,0^+XM)6S\,RI^YTV?6-.BTT2:G<1M>6<5Q,UI#YODM,WZ3?\
M#0'[5-KIL7C>77/$ \-32CR=8N/">D_\(Q*[RM L<<QTM;5D:9'A15E_UBE
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M[[O^O^&7W'<?\+1^*O\ T5GXL?\ AS_'G_S04?\ "T?BK_T5GXL?^'/\>?\
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M>D!SZ^G((Z?4#\^A[4>RI?\ /NG_ . 1_P O)?<%WW?]?\,ON.Y_X6C\5?\
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MG^//_F@H_P"%H_%7_HK/Q8_\.?X\_P#F@KAZ*/94O^?=/_P"/^7DON"[[O\
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M^[^]GV%_P\._;^_Z/@_:T_\ $@?B?_\ -)1_P\._;^_Z/@_:T_\ $@?B?_\
M-)7Q[11_9N7?]"_ _P#A)A_+_IWY(+ON_O9]A?\ #P[]O[_H^#]K3_Q('XG_
M /S24?\ #P[]O[_H^#]K3_Q('XG_ /S25\>T4?V;EW_0OP/_ (28?R_Z=^2"
M[[O[V?87_#P[]O[_ */@_:T_\2!^)_\ \TE'_#P[]O[_ */@_:T_\2!^)_\
M\TE?'M(6"]<_@K-_Z"#1_9N7?]"_ _\ A)A_+_IWY(+R[O[V?8?_  \._;^_
MZ/@_:T_\2!^)_P#\TE'_  \._;^_Z/@_:T_\2!^)_P#\TE?'2NC$J&&Y<94Y
M# 'H2IPP![$C![4^C^S<N7_,OP/3_F$P_E;_ )=^2"\N[^]GV%_P\._;^_Z/
M@_:T_P#$@?B?_P#-)1_P\._;^_Z/@_:T_P#$@?B?_P#-)7Q[11_9N7?]"_ _
M^$F'\O\ IWY(+ON_O9]A?\/#OV_O^CX/VM/_ !('XG__ #24?\/#OV_O^CX/
MVM/_ !('XG__ #25\>T4?V;EW_0OP/\ X28?R_Z=^2"[[O[V?87_  \._;^_
MZ/@_:T_\2!^)_P#\TE'_  \._;^_Z/@_:T_\2!^)_P#\TE?'A.!DY_ $G\@"
M?TI@EC+!-P#D$JC95F ZE58 D#N0"!WH_LW+O^A?@=/^H3#^7_3OR07EW?WL
M^QO^'AW[?W_1\'[6G_B0/Q/_ /FDH_X>'?M_?]'P?M:?^) _$_\ ^:2OCVBC
M^S<N_P"A?@?_  DP_E_T[\D%WW?WL^PO^'AW[?W_ $?!^UI_XD#\3_\ YI*/
M^'AW[?W_ $?!^UI_XD#\3_\ YI*^/:*/[-R[_H7X'_PDP_E_T[\D%WW?WL^P
MO^'AW[?W_1\'[6G_ (D#\3__ )I*/^'AW[?W_1\'[6G_ (D#\3__ )I*^/:*
M/[-R[_H7X'_PDP_E_P!._)!=]W][/L+_ (>'?M_?]'P?M:?^) _$_P#^:2C_
M (>'?M_?]'P?M:?^) _$_P#^:2OCVBC^S<N_Z%^!_P#"3#^7_3OR07?=_>S[
M"_X>'?M_?]'P?M:?^) _$_\ ^:2C_AX=^W]_T?!^UI_XD#\3_P#YI*^/:*/[
M-R[_ *%^!_\ "3#^7_3OR07?=_>S["_X>'?M_?\ 1\'[6G_B0/Q/_P#FDK^K
MO_@U,_:9_:/^.WQL_;"T?XX?'WXQ_&/2O#_PO^%VI:!IWQ0^(WBKQS9Z)J%[
MXJ\2VMY>Z3!XCU/4$T^YN[:&&"YEM1$T\44:2%@BX_B"K^P__@SW_P"2^_MM
M?]DB^$O_ *F/BFOC^/\  X&EP?GE2E@L)2J0H8;EJ4\-1A.-\?A(MQG&"E%N
M.C::NFULV73;YXZO?NS\5/\ @NE_REI_;9_[*=8?^H?X<K\FZ_63_@NE_P I
M:?VV?^RG6'_J'^'*_)NOI\@_Y$.2?]B?*_\ U!H$2W?J_P PHHHKUA!7HWPI
M^+7Q ^"/C2R^(7PQUR+PYXOTZSU"PL]5GT70O$$<5IJEN;6^B.F>(]-U;2I3
M- 2@EELGEA/SPO&_S5YS12:4DXR2E%IIQDE*+3T::=TTUHTTT^IE6HT<32J8
M?$4J5>A6A*E6HUJ<:M*K3FG&=.I3FI0J0G%N,H2BXR3:::9^WOQY_;2_:8T?
MX!_L*:UH'Q!T?1M?^.O@'Q^WQ+UF#X8?"VXG\0WL/Q-?PE87\UO/X.:"UEL=
M&G^RQQZ8M@DBJ'<F?$P^2?CS^QU\'_@M\9]#^!5W^UCH&I?$&]\?:9I'CW4-
M4^'FO:)X)^&7A#7M,BUB'Q%K_B&"YU$ZQXEC^TQ1W'A+P]9W(AENK6V2^>9I
M%B\D^*/QZ\+^.?A7^QOX$TS1]>M-3_9Q\.>)M&\77=\MB+'7+C6_B,OC&VE\
M.F"YEG:&+3U^S3?VA%:.+P@(K0_O![;)^V3\-W_X*)7?[8%QX"\1:M\/+WQ(
M=3C\,7RZ*OC+1HYO!T7AB+Q!IB2RWVA'Q+X=OE.NZ(D\SVS7-O;[YH92'3SJ
M5"I0B_8TU2M''5)1IPHQ=::KWPD)2E"5E[*<G"UDDHIZ+E?YQ@,HS3)J51Y3
ME[P$5A^,L97P^787*,/5S+&4L[G+AG"5\17PE>4:?]GXFO/!QBX0I0C3A4M2
M@Z$\+XW_ +&/A[P#\#]8^._P\\9_%75?#7A;XDZ)\.=<TSXS_!34_@]J6NKX
MFBNWT+QI\.Y+G5=4A\2>%[M[&83QW"V6HV<4MM+,@,AC'K]U_P $Z?A2OQ>;
M]FK3_P!J:YOOVBM;\!67C?P1X4;X2WL'@>_N;WP1'XWM?!WB3QL/$4C:1XDU
M"R\^.U^Q:5?:?;J+9[NY$\[6T7'_ !J_:J^#VO\ [.GQ+^!?A#QI^TY\8/$G
MCOXO^"/BJ/BC\?;_ $IGCAT!M52_\,V^A6_B+7)-'CMX;V*6/4+6>1=:OI)F
MEM--M;:V5I;#]MCX<VO_  4)\)?M=R>%?&A\!>']%\/:9=^&TCT;_A+9IM(^
M%2> [B2",ZB-*,<FJ*;R+S+]7-A@LJS_ +JDGCG3DU*HI1AB90;IT5*I*,,.
M\/":G35E*;K)VC3DTK2::3)C/C>K@L3*.(S&E6PV%X@Q&#E+!99"MCL10PV1
MU<CPV(IXG Q<:5?$U<VI.*H8+$3IT^6M*C*$&<S\*OV)_"&N?!/P)\;OC/\
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MY-7T:]TFT\5>&TU2&73'\2^%;B\CUO1%OD$!OK2(&2)MLB_3/QM_:G^$&O\
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M6C_6;AO_ **#)/\ PZX'_P"7^?Y]F')/^67_ ("_\C\6**_:?_B'A_X+"?\
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M6C_6;AO_ **#)/\ PZX'_P"7^?Y]F')/^67_ ("_\C\6**_:?_B'A_X+"?\
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MR_\  7_D?BQ17[3_ /$/#_P6$_Z-(?\ \.Y\'O\ YM:/^(>'_@L)_P!&D/\
M^'<^#W_S:T?ZS<-_]%!DG_AUP/\ \O\ /\^S#DG_ "R_\!?^1^+%?V'_ /!G
MO_R7W]MK_LD7PE_]3'Q37Y+_ /$/#_P6$_Z-(?\ \.Y\'O\ YM:_H/\ ^#:K
M]BG]IG]AG]K?]KCX;?M2?#9_ACXT\6?L\_"3QIX?T=O$?AKQ,-0\-'XB^-=%
M_M);WPOJFK6,(_M/3[NU-O/<1W(:$N8O+9';Y3CG.\FQW"6>8?!9MEN+KRP^
M'E&CA<=A:]5QCC\)*4E3I59S:BM9.UDMRH1DIQ;BTK[M-'[^_P#!/[_DJ_\
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MUKX^^(M$\)?$K4-/TCXE>(?!,_@3PVW@/3M;\'^,O%OAXZ%?:<?&=G?-X?\
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M5%%% PHHHH _.;_@K+_R8)\<_P#KY^%/_JY_AY7Z+I]Q?]U?Y"OSH_X*R_\
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M7%A.++6=&U*UFTW7O#^I"-)9-,US2;I4NM/O41U=5D5H+F%DNK*>ZM)8KB0
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MA6&,XDTE^%L%S$BZ]XY^)>NS[ +B<>-=4\,)<2%<2N;/P0WABRBCD8LWV>.
M01@[$0* * /4:*\P7X5:5; _V5XJ^).DL1A3%\1/%6K1Q\D_N[/Q-J.NV"<D
MD@6FT]P1Q68[?%CP1&DTDUM\6]!@\][Q4L[#PU\18+<,TD;V<5JUKX1\4301
M QFS6#PC<S@*T,MY<XAF /8J*YSPMXLT'QEI8U?P_?"[MEN)[*[ADAFL]0TO
M4;5@EYI6KZ;=QPW^E:I9N0EUI]_;P74)*,T?ER1N_1T %?F]X=_Y2V_%/_M'
M]\(/_5__ !8K](:_-[P[_P I;?BG_P!H_OA!_P"K_P#BQ7IY=_#S3_L65?\
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MBR'<,M\_?L\Z>-)^(NJ7!M6M[OQM\/-/\::JSF=);FYO_$5ZEE<3P2LRQO\
MV6MK&@0)F,!V4,Y+=5\>/A]X]T[6].^.'P6+2^/_  [9#3O$_A/EK;XA^$(G
M:8Z>+<R113:_I#%[C25=XY+^!IM.CGBN?[/>/Y+Q$SG.,I:S7!T,;G.$P;PM
M?-<KP4/:XZMETL-&CC<3E6#I66(QF"K16-C@:*C6Q^&IXC#X>G4QU3#4I='!
M6$PV#R"AB,/EF$IU<-C<?2Q"H4(SQ4\*\96JX?\ ?U4\35K8;#U:*<)U)7]G
M.G!NU,Z;XEVT>F_&+X&^*(K<M=7%_P")O!]S<1Q NMCJ^F)<Q1R29_U0N[<.
M%;A?WC+EC@_0E?,W@_\ :@^'&M>%M.U7QI-+X#\6QJ\>L^"-=T_4T\0Z/JD,
MDD$MLMB]@MV9) !+'%Y2W,,<Z07*I,&!T[WXZB_T<ZGX;\+>)+2QG?R[7Q%X
MJ\.ZUINB!"Q3[5N2U82(2&,<<]U9%MN7*GY#Z\*&-Q^$RZI' XNC36%A&G4Q
M5"MA92IUZE3%4E.EB:5*K2G"%>TJ,H^UA9J4(R3BO5P6=\.X6OFN*H9U@L5_
M:>(IYD\+A9PK5\.Z> P>!J*K3I3G.FYO"0E)UXT%"<G">L7([[XG?$G2OAKH
M']H7$4FJ:[J4O]G>%O#%GF35/$>M3 +;65G @:7R5=D>]N]AAM(,N[;VB23E
MOA%\+W\.^&->NO'$-GK?C#XEW\OB+X@_:K>&YLKBZO(REOH?D2QM#+IVC63+
M800NC1@"4+N0@FO\-/!_AC4M7E^(U]XJM_B)XSN87@BUAY8GMO#UFTC[M.T+
M3 %_LF#<Y61_)BEESG"^9(9/>&954LQ"JH+,S$!54#)))X  Y)/ ')IUJL<)
M1E@L.Y^TG.$L7B'&=.525-\U.A2A)1J0H4I^^W-1G6JJ$Y0@J=-+KP.%JYMB
MZ>=YBJ/L*5*M2R? 0J4L33H4<3#V>(QV*K4Y3H5<=BJ-Z"A2E4HX/"RJT85:
MLL3B)/R'P-X=NOAUXAN_!&GR33^ ;ZPEUKP;;W5R]Q/X6N(+F.+6?"MO+,7N
M)M"'VJVU/0Q-*[Z<DM]IBL;6"R5/7Z\2\+^++;XD?$K4=4\,7$6H^"OA]INH
M^&9/$-K+YNGZYXVU2[LY-8TW2KA T%_:^%K'3;>WU&]MY7@&K:D]A&[3:?>+
M'[;6..555HO$*V)G1ISQ"::G[22;C*K?7VTZ7LJE9OWG4G)U%[1S.[))85X2
MI' /FRZEBJ]' 2C)2H_5Z;C&4,*UI]3HXE8BAA5%NE&A2A'#OZNJ(4445Q'L
M%2_L+34[.XT^^A6XM+J,Q3PL2 Z'!QE2&4@@,K*058 @@@5Y]>>#O"_B+3+C
M3S;:E9R:1>R36^IK*RZE#=1Q^4TD%Q<^>LT+Q((F@G1X'C"DQ@[7'H\\RV\,
MT[ARD$4DSB.-Y9"L:%V$<48:21R%(6-%9W;"J"2!7-:+XBLO&7A&'Q#HT6IP
M66LZ;=364>JZ9>Z-J: B>%1<Z;J4-O>6DOF1DK'<0QL5*OC:P)NG5<:D8*I*
M$I-22C-QMRS@G.R:NHW2OI9M.Y%;#2GAZN)>'56E2O2G.5-3ASU:56<*#DTU
M&56-&I)1U<HTYV5DSYO^$&E^(I_$7CO4?%G@^ZT_2?">K6=MX$\1SZ_:ZK/X
MV@EL'O\ 7[^]\/V.EVLV@3:7J4PL+.*\N+V.[>-;FUV(FX^J>%= U#PUHEOI
M5CKGB+QA;ZUXKU+7=6O?'WB(RZ_IFGZ_>3ZC+::5<BPA']FZ%OAL]'TE1YL-
MFHA>[PI)L:-]N:Y69M7B@\/:CIO]FIH4FFQ1DZRMRTTVJP:T7+S0S6"R6XLQ
M\B,JR'YB2W2:A::S/?#2;:Z32/#\UI!>VNL6%TK:L-1@O4FN=*2RN+::S_L^
M>S1G>X#B0"25%5=H>O3S*K.K6J5*OMY5HU)J@Y.+E"E&6L*:45345*]M+Q47
M-RY[R?S_  W1H4,)A\-A/[*H8"MA,%4S&G3IXI4J^-C0C36(Q$ZM:KC98FI&
M2JXB%*JZ56O65.C06&C3PU-9[VSUFSU'2=,U2;3;K3=073Y[^PME26TN%B,I
M:S%W;M;SMM95D,:S(#*55]Q4BEKNB:1XA6Y\)^(=).KZ1K^D[-3L-5TR.]\-
MWL4=PA6VU#<BPR7US*BW#P1-&?,C1AD("9]5A+W[7M]9VVFZ#IRVE];ZM'>-
M'/)<8GCG-[:Q+&5M8%:-HF:1TD!=V3*H4MS7"7QL+2VLY[BQU&*&8ZI#?.;2
M$,Z2PE(WN#+,EW"K26\BQM'QME*D,!Q?NVHIR;=5.%:+I\T.5SLTX2FX\MY<
MTI/1Z+1-)^LI8BE.52G#V<<-*&)P%:EC%3JQKJC2G&:Q5*C2G&JO9_NJ$9*I
M%7<4ZJE,YKQ1#?2RVFEO8M'H-J=+N5N?#FL7-EJ::I87L0LX&MHHXU32H[=%
M%TAN6,T2_9S$R*IKE/B%;^,?&NC>)O"WPX\3-\.-<AC@TJ7QKJ_A<^)(-&DE
MMQ?1:CX9T6ZGM-+UR[7:UK,]_=-:6C2RR>3+<11(W4WGBW4/#NG>,=4\:Z3;
M66F>$Y-6U+2H_#(O?$VK:QX9LM/B,.HMH%G9K>#6)KF2ZCCT2RCNI',*F)V)
M!JK/KMS9>!=*\0ZA#J?B34EMM/O&?1="FT_6KBPU&XMI[(#0FGCN;.9;:X@B
MU"VN9$DMV@NUEC65"M72E"3A2BJE.4E)RFI3A4]GS.%-QY94YT^62<J<X7DE
M*T6[Q)Q6'Q-.G+%R>'Q%.CBL+3PM-JCBL++'16&Q>(C65:CB\'C'6I.GA\?@
M\1RTJC;C6I.,:R77^![WS]--M+=&]NX8[6XN+MHDMVOI+B+9+J MX_D@%Y<V
M\\TD"96"=I8U)4(3VU>?>"K**.XU*X2%(EMTBTV+RP463;/<WEP[(>2?.N%1
M7;#$(P(R"3Z#1CXPCBZJIWY7R/6UTY0BWLWU=_*]GJCER"I7J95A98A155>V
M@^2ZBU3K5(1:32LK1LK7324EH[(HHHKC/9/SB_X)[?\ (Q?M_P#_ &D%^-W_
M *C7PZK]':_.+_@GM_R,7[?_ /VD%^-W_J-?#JOT=KT\X_Y&-;_!AO\ U%H"
MCLO1?D?GE_P5>_Y1Y?M0?]B5I'_J;>%J^_=)_P"05IG_ &#[+_TFBKX"_P""
MKW_*/+]J#_L2M(_]3;PM7W[I/_(*TS_L'V7_ *314ZO_ ")<#_V-,U_]1,F#
MJ_1?G(T*9(K/'(B2-$SHZK*@0O&S*0LB"170LA(90Z,A( 96&07T5Y8SR3P_
M\%? V@WWB349=/\ ^$DO?%^V;Q)?>+1'K]_J-YY:0S3QSWB>1IEK=Q)&;G2-
M*M;+2?M$45S;6=M+YQFY=_A]9VGCS3/"E]JOBK4?AY?>&;G4M'\(WWB"ZGT*
MRUS0=3LDN+6XD;&N:MID]AJ%E-9Z)JNL:AHMD^G7!33PD\2Q:OQH^(WCSP!%
MX2C\"_#'5_B)-XDUMM)UB\TZX:"T\%Z<RP1?\))JR)9WDMS8VTUTLTUO"JS/
M!;7&S)!9+]A\-K_7KVRU_P"*.IV^OZ_I=LMKHEOX<DUCP]H>@":SMX=5O;%(
M-034+C5=8N(YGN;ZYN0MO8&WTVRMK=([J>^ .1\<>'+KX=S:'/\  _0=/T7Q
M-K&IW,^I>%=.T8V_@[Q-H^G6$5QK]YK=EIRV%A:>*(M-LK73_"VMOJ&E7%UK
M-QIFFZG=7VCFXMX?-?$WAGX7?$OQM\*Y/B'\:=2U'Q#>'5+GP_\ #QM0@\+:
M/XELKBWC36/"FN^'M#NH5O[^Q:: 3Z9JNIWE_'=6LB2075O%+$GT5!\.9M,\
M:VOB_1?&'BVUM5T:V\/7O@Z^UJ]U?PC<6$-[=ZC+J<.FZC-<36_BF>XG@MCK
MPNGE72[8:>(?+D=SC?##X"_#?X2+JW_")Z3(\NLZQ_;US=ZU)!J]]!JC0B":
MXL;^XMA>6BS@>:]O%,+>.9I'MHH/-E#@'L<44<,<<,2+'%$B11QJ,*D<:A41
M1V55 4#L!3Z** /@OXB^%_VO_'W[0^M^$H==TOPC^R7J&C:/8V^O>'8["/XH
M6/BB+P_)K4FLZ9>>9;W5CID'B6TM].?4'O+N5)6BL&\+WFEWMUJUK]/>"/A3
M8^&+*0>)?$.N_$[7[K3[;2K[Q)X[:QU&[FTZU6X1+&UL(+2WTS3[6;[5/)?"
MWM?M&ISRF74;FZ\NW6'U:B@#YL\7>/+'X;>'/VA?&VJV>I:G8:%JVEF:QTI?
M.U&87_A?PMI426<1#EI%EO8GV1I)(40B**639&WC?@GXL_$SXH^!K36;3X?Z
M;H_P-GL] L?#'C#4/$=L?&FI:AX9\9Z3X=:XF\-V3W*PZ3K5[IMW=V+7[Z5K
M%G9-&FJ:5:WA:W3ZUT_P5J-CXP\2ZZWB)+SPWXG>UO+OPA=Z#ITB0ZK::?8:
M<E[%K6\7<D)BTZ&464]O(D<Y=XY5& *OCWX?7OC'2;?P[I?B63P?X?GNGGU^
MST;1K![W54>^@U(_8=2D>-]#O6O(Y)WU&U@GN6GG:<%9U$E 'B?Q.^-.A:)\
M=/"OPHL/"S7_ ,0]3TBQO/#>JZC8P/X?FU/6[7QA)H\=[?!8YH_[%@\*:]=S
M!;^SOX[;4)6T>&^>2^B7ZTA,IBB,RHLQC0S+&2R+*5'F*C'DH'R%)Y( )KS[
MX>_#/1?AWH$6@6FI>(_%"P:A<:A%K'CK7+SQ=XC5YKB:Y@MSKNL/<:E):Z>]
MQ.NFQ2W#_8HYI(X&57(KT6@ HHHH ^:4\6?M0M\3->T8_"GP /AK%?W\?ACQ
M7-XSE@OK_3(+96M;O7+: 7][I5[<WA\B&PL] U2*6V#74]_I[K]E;JI-<^/;
M^(X=-B\"^ [?17TM;I]<?Q=J%YI\=\LMPD]A*5TFRUI;LJ+&2T6'P[/I\D$M
MZ]QJL,\$%K+[910!\WWDOQ@?XL^'YAX?^'A,'P^\2)(W_"3>)A"'FU[PWNQ,
M/">1DQ($BDB;Y2[[@RJ*QOB/:_%C7/&_P9TNXE\'>$;6\\5>*(9/$&@WVM^(
M?$-@C?#;QA]J.CV^H:%I6D65[/;>=!;ZEJ#WJ63L)TL+F0+%76^,_P!GWPWX
MU^*6D_%B^\2>--/UW1_#UIX8MM-T?Q!>:;H4FE6VM_V_*)[&SD@>6YO+U($N
M9FFVR6L*V[Q.-K)P/Q3_ &1-$^*/@/X;>#+CXI_%KPO?_"S3[ZS\-^,O#'BR
M[T[Q-<7.H:;!H\^I:Y>QL)-7NQI\<L2&YDVM)<SO.)TEFAE /J#P]X>TGPMH
M]EH6B6OV33K",I$C22SSRR2.TMQ=WEU.\ES>WUY.\ES>WMU++=7EU++<7$LD
MLC,?#OVI[KX?V_PBO(_B7=:?;>&[SQ9X"MMNJ7%W;6<^H1^,-&O;5'>RS*TE
MNEG/J$(8%(YK))SAH48>Z>']*;0=!T30VU'4-7;1M(TW2FU;5IEN-5U1M.LH
M;,ZCJ=PJ1K/J%Z83<WDRHBRW,LCA%#8$/B'POX<\6V"Z5XHT+2O$.FK<17:V
M&L6-OJ%HMW"LBP72P74<D:W$ ED\F95$D3,6C96P0 6-#UC2O$&D:=K6AW\6
MJ:1J5K'<Z?J$#M)#>6SC$<\<C@,ZO@G>PRW7G.:U:IZ?I]EI5G;Z=IMK#96-
MI'Y5M:VZ".&&/);:B#@#<S,?4DD\DU<H **** /SF_X*R_\ )@GQS_Z^?A3_
M .KG^'E?HNGW%_W5_D*_.C_@K+_R8)\<_P#KY^%/_JY_AY7Z+I]Q?]U?Y"O3
MJ_\ (FP'_8SS;_U%R475^B_.0ZOS6M_^4P&H_P#:.*P_]:6N*_2FOS6M_P#E
M,!J/_:.*P_\ 6EKBGEFV9?\ 8KQ7_I=$'M\X_FC]*:**\X^*M[J,7A&;2-&E
M%OK'B[4=,\':==,7 LG\17265[J&8F24/IVE'4+^(QL'$UM'CUKRQG+Z=:CX
MNZ[)K^JQF;X:^&]3DM_">BSQJUIXQU[2KDQW7C+5(B6CO=%TR_ADM?"-E*K6
M]Q<6T_B.:.1FT9K;N+CQUI]G=6)OK6?3M"O[J;3X?$VI7-A9:2=01O+MK8F6
MZ^T1_P!H3AK:PDN(8%N;E/(CS))")>GTG2M/T+2].T72K:.STS2;&UT[3[2%
M0L5O9V<*6]O"B@ !8XHU4<9.,GDFO%OCG\)=4^(/@?4=,\#W^E:#XJ74[77=
M/DUB.]E\/ZC?6A+-9:M!9NTMG;WYV&?4=/MGOH98TF19&+Y\#B3$9U@\KQ6-
MR+"?VCC<'0K8FGED9TJ57,*E)1G#"4ZE>+IKVRC4IN//0G*4X.GB(./)4]OA
M^AE&*S+#83.<3]0P>+K4L/4S"4*M2E@*=5N$\54A1DJC]BY0J*7)7@HQFIT)
MJ2E3]YHK\X?AA^T]JWPW\>Z[\,_VEO',<GCF\U31K*R\.Z)X,U,Z/X>6=&@E
MU^VU^WLTCA^'MQ&+$6>I:]+-J#W#W%S<S1O))%7Z.JRNJNC!E8!E92&5E89#
M*1D$$$$$$@@Y%>?P=QMDO&N"Q.)RR<J&,P&*K8/-LEQE;!?VQDV)I8C$8>-#
M-<'@\7BW@:U?ZM4JT:-><*SI?'3A.,X1[^*^#\WX0Q>'H9C"-?"8[#4L7E>;
MX2EC%E.;8:K0H5I5LLQ>+PN%^N4J/MX4JM6C"5+VGP3G"4)R6O+O'7@Z_EO(
M/'O@D16GC_0[5HTC+F"Q\9Z,A,L_A'Q$%9(YX;C#MH6I3[I_#VK/'>6SBTFU
M&TO/4:*^O/E3G_"WB33_ !=H&F>(M+\Y+74K?S#;W4?DWMC=1.\%]IM_!EOL
M^H:;>Q3V-]!N;R;JWFC#,%#'H*\G\-6S^&?B7XQ\/PI!'HOBNQMOB!ID42F,
MVVLF=-%\71LI)1EOIUT75]T:J?ME]J$DNYIE:O6* /.OB!XHU72DTCPSX42W
MF\;>,+B>QT(W2+-9Z-96J)+K?BO5(#+"TVF^'[66-Q;(^_4=4N=+TM=OVUI8
MG:#I7@WX6:1!876M6-C<ZO>O<:CK_B75;.WUCQ;XAN0K7>HZC?WDL#:AJ5RQ
M&R"+]U9VP@L;&WMK&WM[>/+\%6[ZWXU\?>-;SR9#;:B/ /AQ1&IDLM$\.;)M
M783=2^J^)KJ^>X48!ATS3E8L81M\Y^*UK-X=\<Q>+-3^&UK\5-*\7:/HWP[T
M6RDO-$CNO#NN7NHZ@1:2VWB26&PAT'Q0]Y:C4]5L&FO[233(EN+&ZMS"8_3R
MG T\QQ?U>I5=-NE.=."J8:E.O4CRVHPK8NM0PU*7*YU7*K52<:4H04ZLH1?B
MY_F=;*,!]<I4%52KTJ=:I*EC*]/"TI\U\14P^7X?%8VM'G4**C0H2<9UH5:K
MA0IU9Q]4\5_%SP!X+U$:3KFN-_::0"]OK#2M-U37[O1M+.T'6-?@T.RU"30M
M'3>A;4M56TM2&W)(RH[)TH\9>$6M=(OAXI\._8O$&/["NSK>FBWUK<54#2IC
M<B/4"695VVC2G<P7&X@5R'P:^'-I\,/ &A^&5LM*M]5CMO/U^YTN)]E]JMQ)
M+/,\U[<#[?J?V195L+>]OW>YDM;:'(B3;"GA/CGP)IG@?Q;XOGTWX,>'_&=E
M\9ETSP[H\UK+H.G0:)XE.DZF+RTUJUU62#^S=(U0P3Z_<ZSX:AN+Z>]BF%Y9
M2WPT^9_7PV6Y%C<7B,!A\3C%/#>T]CC*E;+Z='-(TZT*<YTJ6)J82GERC0=3
M&PC4QV.=6E1E0O"I.,U\_C,YXGR[+\)FN,P66^SQOL/K&7TL/FU7$9'.MAYU
M:=*M7P=+'5LWE/%1HY;.='+,M5"OB88EQJ4J<J4OLFLW6-'TOQ!I=]HNMZ?:
M:KI.IVTEI?Z??0I<6MW;RC#Q312 JP/#*>&1U61&5U5AF>#-'O\ P]X1\,Z#
MJNH'5=3T;0=*TR_U+=*XO;NRLH;>XN%><M<.DDL;,CSL9W3:\Q,I8UTM?,U8
M0IU:L*=15H0J3A"K%2C&K",FHU(QE:45-)22DN9)V>I]IAZE2K0H5:M&6'JU
M*-.I4H3E&<J%2<(RG1E.'NRE2DW!RC[LG%M:-'C_ (.O=5\&^(V^&?B&]NM4
MT^XM+C4_AQXBO6DFO+_1K(H-1\*ZU>/_ ,?.O>&!+"]G>,6GUKP]+!=7#2:C
MIVJSR^P5YE\6M*N;OPC-KFEVT5QXB\#W=OXU\/>9*]OF^T'?/>6?GQ@ND>KZ
M,^IZ-.N&CDAOW61&7BO0M/O8-3L++4;4EK;4+2VO;=F&&:"[A2>$D9."8Y%)
M&3@\9K,V+$LL<$<DTTB0PPH\LLLKK''%'&I>2221R%1$4%G=B%5022 ":\5\
M,63?%+5;7XB:]$[^$=.NFF^&/AVXP;.XCB9XX_B-JUMO:*\U+5!NE\)0W*,N
MA:,\6HPQQZMJ<LEIL_%B5[[2-%\%6]ZUG<_$'Q%8^&)G@91>?V"(KC5O%)M5
M8, [^'M-O[1I2K" 78EQN5:]/@@AMH8;>WBC@M[>*.""&)0D4,,2".**-% 5
M(XT5415 "J   !0!+114<LL<$;S3.L<4:EY)'(5451DLQ/  % $E%<T?%_AT
M$C^TDX](;G'_ *)H_P"$O\._]!)/^_-S_P#&: .(\<>&=1T;4F^)G@6T:3Q1
M801)XF\/V[F*V^(7ANTRTVFW,"JT;>*=,M_,F\)ZN4%PMPHT2\E?2;]UMO1]
M"UO3?$FC:9K^CW(N]+U>RM]0L;@*R&2WN8UD3?%(%DAE0'9-!*J2P3*\,J)(
MC*+5E?6VH0BXM':2!CA)#')&KXR"4\Q$+ $8W 8ST->8> T_X1OQ?X]\"+#/
M!IJ7=KXZ\->9('MAIWBV2[.N6%BF2T$.G^*+'4[IK<A8XDUFW6 "/*( >M5^
M;WAW_E+;\4_^T?WP@_\ 5_\ Q8K](:_-[P[_ ,I;?BG_ -H_OA!_ZO\ ^+%>
MGEW\/-/^Q95_]2<(3+[/^)?J4_\ @G]_R5?_ (*3_P#9]OBO_P!5)\):_2PD
M*"S$!0"220  !DDD\  <DG@"OS3_ ."?W_)5_P#@I/\ ]GV^*_\ U4GPEK[N
M^*VB:UXD^&7Q \/^'+F6TU_6?!_B+3='G@=8Y4U&\TJZ@M%CD8A8VEF=(A(6
M79OW;AC(US.$:N:QISJ1I0J4\MA*K+X:<9X+"1E4E;7E@FY/R3,,36J8?"8B
MO2H3Q-6AAJM:GAJ;2J8BI3I2G"A!M-*=6453BVFE*2T."U3]ISX+:;K%QX?M
MO%X\1ZU9S_9KO3O"&EZMXJEM9P6!BFET2RO+5'!5E9/M!8,"I 8$#Q/XG?M7
M^"/ OB/P=X]_LWXD3^&;7^U?#?CM(OAUXF$.F:)J:176G^)+FXN;.VBM+?0]
M:L((;Z69Q$NGZI=SN\?V;Y_H;X!>$X_!OPA^'^C2^#[3P3J]OX5T5/$&B01V
M8N(M<2QA35)K^YLB\=Y>W-VLMS<7#33NTDI#2,5KUF\L[34;2ZT^_M;>^L+Z
MVGL[VRNX8[FTO+2YB:&YM;JWF5X9[>XA=XIH94>.6-V1U96(.JKY/@L9.'U+
M%XNC2E6P]6<LPH1^L4VIT:E2FJ6"J4Z;E%NI1<:E=0DH352I:[^1E@^+LXRJ
MC7><Y3E>*Q-/"8_#TJ>08ZH\%7BZ6+HT*\L3G-"M7Y)Q5#%J>'PDJU)U:;P]
M!R<8^"C]H*UU"&P?PS\,/BWXB;5((KJPDB\&W6GZ;/;3Q>=!/_;%[(FG1Q2Q
MD.LDLRH4(=68,H:K>>'OB;\79X;+QOIEM\/?AY%<6UU>>';;5(]3\4^)A"1,
MEEJ-[8G[%IFFF4*+F.*5[J50T8B1MERGELW@?X]?LV7-U/\ !*SC^-GP3::6
MZC^"/B#6XM(\>_#R*3=-/:?"SQEJADL-9\,PL"-/\$^*)()=+C:.RT/5C!MM
MT?J/[=?P?L_#^MQ:^GB_X7_$&VTB]?3O ?Q4\(ZUX.UF\UI+24V^GV-Y=VLN
MA:BWVH*@ELM5FB=/W@*H21Z"RVM*4*W#^$I8^G-KV>*HU*F)QV%<G&SQ.!YE
M/ U*5^65>IAJN'4U.>%QE6,8U3P99]AJ4*F&X^SC$Y)6I1DZ^68O#X?+,DS-
M4HWDLNSF-.5/.L/B&G.G@J.8X?'2I2IT<RRG#3G/#OU3X9EM?^+GQ:\3VZ1I
MHF@IH?PXT01!/+/]A0FYU81,B &**_F\I!N;9@J/EQ7T17QI\'?CA^S[X ^&
M6A6&H?&/X?\ ]IO;2ZWXBDC\0V4\[ZWJ[MJ.I&6*%Y+AYXYIC;NNQY&DBVC<
M2 >N/[3&F^*BME\&_!/C'XGZA<$I!J-OH][X=\(6^<!;F^\2Z[!96RVP+*V8
M4<R*0(WW,M<./RS,*V+J\F"Q,,/05/#0KXBE+"T/9X:E"C&K4K8A4Z4/:*#J
MR<ZE[S>K/7R'B7A_!Y3AO;YSE]7,<PGB,SK9?@<33S+'+$9EB*F,GA:&!P'M
M\77>%>(CA(QI4)65**LD:VMZ%'X6^/&@>,;6*W-AX\T23PWXA@:VAD=-5TYX
MFT?5(GV&6-YD:"PN' P8X4+O@_+]#$!@58 J0000""",$$'@@C@@\$5\9>)+
M#QOH6L_#C7_'NLVVH>/?&?CO3-(M?#>@O.F@>']!6":YO[*T+A9=4N;23[*U
MQJ$ZHJLQ%M"Q>6YF^SJY<QA*-/ R=6%9K#NBJM/FY)K#U)4URMV<XTU^XC42
M49JE[MXI-^GPU6C4Q&>TXX2M@8RS"GCGA,0X>UH3S'"TJ\U5A!RC1JXB47C:
MN&YY3I3Q;]IRSG*$?'?%'P)^'?B>X-^EAJ'A?5RX<ZSX*U6\\+W[<$,DHTZ1
M+*X20D-(+BSE+LH9B3NSQM]^R[X-UQX8?%GC;XO^,-&C8&;PSK_Q(UL^'K]%
M  @U.RTK^RY=0MB!B2UN;E[:9?EGAD7(/TI16-/-,QHJ*IXS$0Y$U"2J-SIW
MM_#J.\Z=K)KDE&S5U9G;B.%^'<74J5,1DV7U'6:E7B\/!4L0T[WQ-&*C1Q%W
M\7MX5.9:2NM#*T/0]&\,Z1I^@>'=*T_1-$TFUCLM,TG2K2"QT^PM(AB.WM;2
MW2.&&-<D[4098LS99F)U:**X92E*4I2DY2DW*4I-N4I-W<I-W;;;;;;NWJSV
MZ=.%*$*5*$*=.G"-.G3IQ4(4X02C"$(12C&$8I1C&*2BDDDD@HHHI%A00""#
MR",$>H-%% '@VH>&;JUUKQ3:Z;K6J:1JM]X7DTGPO?K>Q7ECHMU<B[DLM8L?
M#FH?\2V_UJTN6C+"0!+R"VF@NF\EF(VK"#6-"\)^$[+Q!-K/B_7H_P"Q=(US
M5]+L++2-4OK]+98K_P 2ZG864T.DZ=;>8/M]Y:V):SB2;$8GC(%=+<S>'?&P
MUFVT'6=/N]8\-W\VB:G+87,4\^D:HL*32Z7J2Q%FAF2*X2802C?$TBRJ 2V[
MB-(L;7PGIEAIUQ;^--4NM!TV[@>[2YO]2U&Z*S++&]PC3(;G=*[1VL[+=011
M&...ZBC&!Z].4,9%5:4W&LHM5?9N4I.K&*BZB@ZBIRC5G%.;C^\C5NE'WGS?
M,UWB,FG+ YA2C/">WHU,)'%4*=%+"2O*&'GC%AY8VE]5H5%&C0E-86OA90K3
MDI48<G3K=QZ9%IOAE]>DU/4;DW$UI)XG4RW>K0:?.+F\9)+6*!;F.W201[I(
MXX_*" &;DF^]EK$;ZA/>7T'[D >';1+>2SMK<I;O'-#?S6D@%U%+)M:!?W#1
M1*45"X)K'TO6AK6BV.KS:1J.G0WEINNK?7]0-EJ^FQRDJZ7=E]KN;82%<!_*
MO%C*L' RNT<SJ6L+X<\>Z(ND> /%'BJR\5Z9?VNO>+['4K2[TSPC;Z':I<:-
M::CI-SJB7-X^MW4\MK:SZ1:37"NG^F.Z!:P=*45#EBTO:*,%""4[34*7+.49
M.2;;]Z,XP2B^:7*XWEVQQ-.M5Q$:E2FZJP]6OB)8G$498>5;#3JXV<\/&HJ-
M)Q]C1:HRPM;%3K5X?5Z"K_6(TH]3<:DFE6FD7&L9DU>_FCT;=X8TZZU&V2[G
MM99)KAHMDLL-DDBO+'/>@HDJ1I*QW/GRNXT&'PYX*\%V/C#QWXGU_7H?$EK9
MV?C.ZM4L=:\1ZC>75T]I!KVC>$K2UT];"VL[C[%F[CMX(&C@N;IQ(6:3J_%'
MBF+2=-T[P[X=N;KP]X@\07BZ7IEU:^'+KQ%IUI?E6N[NXU>RLR;:SM%A2X2:
M>ZNK5ED==V[MT'AO0M?OM>O]?U#6WN]$NK73;.UTZ;28+%X381.M_P#9)XY3
M/+8:E>%+@B<?*D(BC:19'9>E47AVL14=2,:=E2G5;:G&+C.*=/F=.JY3IIJ=
MZK3YTDE*I*'"L=#%TW@</]7<\7*=3&4<+&,*T:CC/#U/88WZK4Q6 A3PV/K0
MG23PU&K&$:E7FJTL#3K=OX:T^>QLYI+EOWE[<&Y2 *56TMQ%'#;VPRS%F6./
MS97."TLS_*,9/15YMX0\:>*O$/C3XF>&M:^&/B/P;H/@G5- L?"?C;5M3T"\
MT?XH6FJZ+'J6I:IX;L=+O[K5=+M?#]^[:)>Q:_:V-Q<7:>=:1R6Y9E])KR)5
M_K,IUG=.4YQLX2IV]G)T[*,XQERKDM"=K5(I5(RE&2D_IUELLHA1P$G3;IX;
M#5E*EBJ&,C*&,P]+&PE*MAJU>DJLH8B,J^']HJN$K.IA*]*A7HU*%,HHHJ0/
MSB_X)[?\C%^W_P#]I!?C=_ZC7PZK]':_.+_@GM_R,7[?_P#VD%^-W_J-?#JO
MT=KT\X_Y&-;_  8;_P!1: H[+T7Y'YY?\%7O^4>7[4'_ &)6D?\ J;>%J^_=
M)_Y!6F?]@^R_])HJ^ O^"KW_ "CR_:@_[$K2/_4V\+5]^Z3_ ,@K3/\ L'V7
M_I-%3J_\B7 _]C3-?_43)@ZOT7YR-"BBBO+&%%%% !1110 4444 %%%% !11
M10 4444 %%%% !17DK?%W2E^*'_"L?[$UIKH/%9OK:I:FR359] D\40P&Q%Q
M_:QTAM'AD5_$RV9T.+6A'H#W8U&01C3\4?$_PSX<\16/@>.^MM2^(6K:8NNZ
M-X(AF>/6M5T&'5(-.U36+2,02J]GI2R37%T_\*P%"%,B-0!Z/17 _$/XI?#[
MX3Z7I6M?$?Q9I'@_2M<\0Z;X4TB_UF9X+>_\2:PER^EZ- Z1R[KZ_%I<BUB(
M'FM$R*2Y53G^$?B-=^(O"VK^(-5\"^,O"]]H-K)-J&@ZIIFV^O)H-.%_-#X?
M:1[==77.ZTAE*6@FNU\L!0P<@'IU%<+X \;1?$+1+;Q=I-F\?A+7;+3-5\):
ME<-Y5YK&E7]DEPUY<Z<V9M. E8K!#<$3R0[9)8X7)C7NJ "BBB@ HHHH _.;
M_@K+_P F"?'/_KY^%/\ ZN?X>5^BZ?<7_=7^0K\Z/^"LO_)@GQS_ .OGX4_^
MKG^'E?HNGW%_W5_D*].K_P B; ?]C/-O_47)1=7Z+\Y#J_-:W_Y3 :C_ -HX
MK#_UI:XK]*:_-:W_ .4P&H_]HXK#_P!:6N*>6;9E_P!BO%?^ET0>WSC^:/TI
MKR;X@S2-XS^#5@S?Z)=^--8N9T[//IO@?Q-=6))Z9CN!O4'JP&.0*]9KRSXL
M31:5I7ASQ9-%(]OX/\9:!K-_+#&99K72+J6;0-7NE55:1H;2QUF6[NP@S]EM
MY7.%0D>6,]3HH!! ((((R".00>A![@T4 ?+/[5/PC\0?$7P9;Z]X(U]_#OC3
MP*;W6].=?#UIXGAUVQ2V\V^T*?1;IX8[Z[G%M&VC-.\T%K?$LUI<+,ZUY!^S
M#^V)\+O$EEX;^&/BWXUV7B_XJ:C-K?V.&[T#5M.U1H-*8R76EZ_?0:+9>'EU
M_3 ETUW%!]DCBM(D7#O#(Y_06OFKQ-\)G\+Z1\7O&6AR77BCQ#JG@CQ''X8T
M%=.T?2KBROY+?5M4EBM-8TK3HM8O=0U?4;B"'[==RW%W#;P06D&]0JU^3<0<
M+YME7&5+COAC$QP\<3E^(H<88#%1S/'8''X; 8:G4PF-H9?A\^R^A3S:%#"_
MV?AZ]/+<SG:I#FP\;U*I^HY!Q'E&9\*5N"^)L/.N\/C*5?A/'86>6X'&X'%X
MZO.EB,)7Q^(R+,*U3*W7Q*S#$8>IF&6TW&E5C'$J3I07THK*RAE(96 964@J
MRD9!!'!!'((X(Y%+7QE^QOXS\4ZSX.D\/^/_ (@Z3XI\8Z?I6A:@_AN&'64U
M_P )V$EJ;2XM=<NM;T_3[G4)6OH_+6>..2&%XWB60AE ^S:^UX1XEPW%_#N5
M\0X2C/"TLRH>UEA*M?!XFOA*L)RIU</7J8#$XK#JM3G!J=-5O:TKJGB*5"O&
MI1I_'<4\/XCA;/LQR+$UH8FI@*RIK%4J.*H4<33G"-2G7HT\90P]=TIPFN6?
ML_95+.="I6H2IUI^1>*YGMOB]\)/(W!M1TOXCZ?=E<C=91:=H6HJ),#!1+ZT
MM2H)'[QU(S@UZ[7E:RP:W\8G2(/,O@/P2\-U)M80VNK>-M1MIX8%9@%>[&D>
M'C-((RYAMK^ R;?M$>[U2OI#Y\\B^!4:)\,=#D69KB2[U+Q;?W,SG<\EW?>,
M=?NKH.QR2T4\KP#)RJQ*G 4 ;/Q,\/:[X@T32W\-+IL^M>'?%'A_Q796&K7$
M]E8ZJ^@WHNWTN6_MH+J33WOH]\,%Z;2ZCMYC&\UO)%OQD_"=;32(?&?@F F*
M3PCXWUXQV3Y$D.D^*[I_%^E7"Y_UEM<#6;J.&4?*9;6YA&# P'K5;X7$3PF(
MHXFFH2G1FIJ-1.4)6WA-)Q;C.+<9<LHRLWRRC*S7+C<)2Q^$Q&#K2J1IXBG*
MG*=*2C5A?6,Z<I1E%3A)*<>:$X\R7-"4;Q?A%O\ '6WDN=0T>?X;?$[_ (2;
MP]9PWOB_0K'0;&^'ANWN%E:VNO[8?5K31_$%K?K;W<NF#PS=ZMJ-Y!:S,VFP
M3*;<9!\4^)/BXWAGQ+X"\*,?!/AW4!XOTC7O%5Y+X=N?'-];Z3JMC8:9H&D/
M9W6I:9I=Q)J(>;Q#X@M;(?NPMEI5W$6NDT/B?X>UC3=>TSQ#X3\::OX0O/'>
MK>'_  +XBBM-*TG6K:ZBE^W)INL6<6J;#I.LZ;#)=6RW\#7,,T$D N--N'M(
M7'L/ACPYIGA'P]HWAC1DECTO0M/MM-LA<3-<7#0VT8C$EQ.P#37$Q#2SRD+Y
MDSNX50=H^FK5\HP6$P^/P."I/%XN*C2I5:V/J0PT70E3S/VL9>PBY+$R5++'
M3Q.*Y<#*I+&.6,5*K'XS#87B#,L?BLKS/,:T<!@)NI6KT,-E=&KC)QQ5*ODC
MH3@\3-1>$IRKYU&M@L%SYE"E#+U#+I5J$O.;+XX^!XK34!XPNI?AYX@T6*)M
M:\*>+@EIK43R_+&^B);M<0^+K*YE'E:??>%GU6.\D:. )%>O]D7YW'BG4==N
M-7U$S_%W3/C+J/C87/P_\/W%AXUTK0#X,75X8]!\_1?*_P"$,A\*WOAP27GB
MJ77MNLVUXU[]J>TU!+"W'K?Q1\9^!M,^*/PJBUJ_L!=>%M5UJ_UB[ETZXOH/
M"EOK_AJ^TW2;K6=5ALKFT\-IJM\]O!:2ZA=6(G)BEW>2HE'T>"& 92"I (((
M(((R""."".01P16T<3A<DH83&4\HQD)9OAXXJ+K8KEP\%0Q-:#P5)U,#.>)R
M[%*%+$8NC4K.K6PE;#8=UTHRQ6*YI8/'<2XG'Y?5X@RZHN'\7+ 2>&P7/BZD
ML3@L-5695XT<SITL%F^"E4K87 8FE05##X_#8S%+"OGC@<%3U&))]-OX9@#'
M-8W44HSP4D@='&3VVD\GMUKB_A-/+<?#'P#+,2TA\):$I<YS(L6G011R'/4R
M1HLA/0ELK\I%7/B/KO\ PC?@;Q1JZPSW-S#I-S;:?:6J>9<WNK:B!IVD65O'
MD;IKO4[NUMT&>#)D\ UL^&-*.A>&_#^B$*#H^B:5I;!#E-UA8P6K;#@97=$=
MIP,C' Z5\8?HQR'B&UM[KXG_  X>XC#/INC>/=0L68C]W>O#X=TQG0$9WBPU
M"]BR,$),_8FI?&NL:O8RP6]J9;*T=0XO(FP\\HSNBW@9B$8.2GWI/O9*K@9O
MQ(5=+UWX9^,I+MK6UT'Q:VBZGN8):/IWC>PF\.HUW(2!''!K<NB2QNQ""4)O
M(6O4I[>"Y3R[B&*>/(;9+&LBAAT8!@0".Q'/)]: .'\,ZMK4VF!S83ZK^_F'
MVN2_MXV.-O[O;-\^$S@'H<\=ZB\67^J2:-+%/I4EC#)- LDQO+><%=Q81E(O
MFP[*N3]WC!SG%=[!;P6R>5;PQP1Y+;(D6--S=3M4 9/<XR:KZEI\&J64]C<9
M$<ZXWKC?&ZD,DB9R-R, 1ZC(/!- 'SK1QD9X!(!/3 )Y/X#FO2O^%=MVU;_R
M4'_QZC_A7;?]!7/_ &Z#_P"/4 >BV4<<-G:Q18\N.WA5,="HC4 _B.3ZDYK@
M9V*?%S354#_2/AWK/G'C.+7Q)HIMP>YYNKG;CIEL]17;:7:W-E9PVES<I=&!
M%BCF6(Q,T:#"B12\@+*H"AE(R ,C.2?/]%GFUGXK>+[Y(=NF^%/#VA^$XKKS
M%<7>LZG-+XCUB)%4YB&GV4F@)+N'[R6Y90<P,  >HU^;WAW_ )2V_%/_ +1_
M?"#_ -7_ /%BOTAK\WO#O_*6WXI_]H_OA!_ZO_XL5Z>7?P\T_P"Q95_]2<(3
M+[/^)?J4_P#@G]_R5?\ X*3_ /9]OBO_ -5)\):_2VOS2_X)_?\ )5_^"D__
M &?;XK_]5)\):_2VGG/_ ",)_P#8/@/_ % PPX[+T7Y!1117EC"O&/VA?AS!
M\5?@W\0/!$FF6VK7.L^'+Z*PL[A4W3WD(2[AMH)BI>VDO7MEM/-C*L!-R=N:
M]GHK;#8BIA<10Q-%\M7#UJ=:F[M6G2FIQU33WBKV:=CCS# T,SP&-R[%1Y\-
MC\+B,'7C:+O1Q-*=&HDI*4;\LW:Z:3L[,\6^%_AWX5^(_!/A+Q1X?\#^#H(K
MS1;'9)'X8T6&\L[NTA6ROK&X=;(317FGWEO<65U&["2.>"1'PP->QDP6D!),
M-M:VT.23LA@MX(4ZG[L<4,4:_P"RD:+V45YM<?#B33M4U+6? ?B2\\$W6MWC
M:AKFFQV%IK7AC5=2E"+<:K)H5Z8C8:K<I&@N[S1K_3!>NOGW\-W<DS'A_$/P
M0\2?$%S8_$_XM>(]>\'.P-UX$\):38> -"UE%D#BU\1:AI]QJ7BC5=/<*%GT
MV/7[&QN@ +B"1"\;=\UA<57=6KF,J=!R<_9UJ>)Q&+IP;O*E3BJ?U>I4C=QI
MREB:%.HDI3E1<G&/B4)9EEN#AAL/P_#$X^-.%&6(PE;+<!E>(JPBHQQ5:<Z_
MU[#T)M*=:%/+\97P[E*G1ABU"-6I@^#]23XW?%@_$+3LS_#3X:QZAH7@[46B
M!MO%7BFZ(AUO7M-D+$3:9IR1K8V5W&/+N)(_.B)#L1]2UFZ-HVE>'M*T_0]"
MTZTTG1]*M8;'3M-L($MK.SM(%"1000QA41%4=AEF)9BS,Q.E7+C,1#$58JE"
M5+#4*:H8:E)J4X48N4KU)124JM6<IUJLDE%U*DN5*"BEZ&39=5R_#598NM#$
MYCCL1/'9EB:<90I5,75A3I^SP\)N4X87"T*5'"82$Y2FL/0INK*56524BBBB
MN0]<**** "BBB@ HHHH JVUC8V;W4EG9VMK)?7#7=[);6\,#WETRJC7-TT2*
MUQ<,B(C32EY"JJI;"@#S.]^&VJZC\5U^(5W\1?%;^%X_ G_"*6_PJCCT>W\)
MVOB#^W/[4/Q @U*WL(O$Z^(VL"=":W.L-I!L/G^Q>?ESZM12M9PE&4X2IS4X
M.G.=-J2ONZ<HN47=\T)7A*_O19JJTE#$TYPH5X8O#SPM>&*PV&QD949N#?(L
M52K*C5BZ<'2Q%'V>(H\O[JK"[OYEK'PZ;4[[2KV#Q'KMBNCZ@=3MK2QU*\L+
M>\N?*:)4UI+:;R]5M0KNQAGA4,Y#R%R!52+X>ZR_B*77;KQ5J,=N^FPV*Z';
M7$\ND1W$4TDAU5;6X VW[QOY#,'\LQ@[51FW#J_'OCKPK\,?!?BCXA^.=670
MO!W@O0]1\2>)M9>TO[]-,T72K=[N_O6L]+M;W4;H6]O&\AALK2YN9 NV*%V(
M4Z'ACQ+HOC+PWH'B[PW>_P!I>'O%&C:9XAT+4!;W5J+[2-8LH=0TZ\%M>PVU
MY;BYL[B&80W5O!<1!]DT4<@9!UK,ZRE[)5J;JJFI<KC2=54FW%2<;7<')./-
M*+3::O='E3X7H/"QQKP.,CETL34PL:Z>*6!>+4*>(J8:%=MTX8B-.5.M*C2J
M0JQI3C)Q5.?O<#X%TGP!I.I:_P"#=!O[:]UCPM>QZIKFCQ130QZ1<^*5GU&"
M>6)E,4KZBGGSY:YN\<@K#MC1?6^G2F+%&KO*L:+)+M$DBHH>0("$#N &?8"0
MNXG:"0,"O._B-\/)?B$G@U8O'GQ!\"'P?XZT#QN[^ -?CT%_%,>A-<%_!_BT
MR6-Z-6\%ZV+C9KFC 6YO5A@ N8C&#7+6K8B<7.=JTTWRPC:E%1<]%&-W"-HN
M\K**E)-I1O9>K@\'EL<3"G&I4P&'JQ@\3B\0ZN85W7CAXJK5JSC&.(KJK7@U
M24W4J4:,Z<)U:SIRJ3]'HHHH,@HHHH _.+_@GM_R,7[?_P#VD%^-W_J-?#JO
MT=K\XO\ @GM_R,7[?_\ VD%^-W_J-?#JOT=KT\X_Y&-;_!AO_46@*.R]%^1^
M>7_!5[_E'E^U!_V)6D?^IMX6K[]TG_D%:9_V#[+_ -)HJ^ O^"KW_*/+]J#_
M +$K2/\ U-O"U??ND_\ (*TS_L'V7_I-%3J_\B7 _P#8TS7_ -1,F#J_1?G(
MT****\L8445Y[X^^)7AWX?#0;/4Y)+CQ%XQU"ZT3P1X=MXYOMGBKQ#;:;=:J
M-%L[KR7L+&>6SLYY%N=5N+*R79M:X#LJL ='>^)]$L=:T_PY+?02:]J4?VFW
MT:WDCFU-=.#21R:Q/8H_VJ'1H;A%LY]4:+['#>3VUK)*LUQ&C9DWCWPO8W,E
MMK.K6'A]F\2_\(GIKZYJ%AIRZWKG]GPZB++2?/N@UU.\$S>5!M6YE:"8QPLB
MAF\?M]1?4OB5X;^+%Y\,;K1]&C^&U_HFJ>-M:FGL?%/A1+G4TU>Y\/7^@V]W
M<6U_X>>6UAO;G5[1;J"RNK;SY'^RB*ZCYJP\(Z%XD\=_$#XE>%M)U7Q-XMU!
M+/0]*NM5G_XMQ%9:&UAKFD7EM;ZM!+9QZI=7.I7*3ZYH%G=W]SISQ1/<"""W
MV@'T=IOC'0]7\3^(/">GW276J^&+?3)]96&6"5+*354EEM;2<1RM-!=F");@
MQ31(#!-$\;OEPG2S316\4L\\B0P01O--+(P2.**-2\DDCL0J(B*6=F("J"20
M!7SQ\/=+T+X8:]=>&(=#\0Z19Q>&K2\DU"\CDUZ/4+_4_$>NWET3K%E-J-_<
M$W,\PM(-142VMKY=M$RPQPPKZ9J7BG3?$&CZG9>'+2;Q7)>6NJ:6T=M!.FDQ
MW7V2:*2TU;4I#:Q6L8D(M[N&":34(M[*EMY@  !4;XEZ5J/A+5?%?A&%/$MK
M8ZQ;Z)82FZ.GZ1KES<ZAIFGI>Z7K:6VH6][HK/J:/%J]A!>VMQY%Q'!YCQMB
M]JWQ,\$:+#?F_P#$>CQWNG:O8^'+C3/[0MX[[_A)M5B:31] 2&X:!QJ&M,IC
MTA)5BCOW_P!2Y <KX1=GP]X8^ ^F?#36?#\OPVN;?3= T)?!^D33:@;&Q3Q%
MI%K>3>%M4LX[R"^M;=+H3P7<'&G230I=6UHRI#73:+\.;;3;?PWI\G@N\\0^
M$?#-IIE[:GQ;'X:U;QS?>(/#TETFAZIJ%U>%9;N;38+RXO=/N9[V#5;6_2,0
MI&LLJ4"Z_)?K_P  ]:\#>*[GQ?I5_?7NC_V%>:;XBU_P_<Z?]O74@LFAZE-8
M^>+I+6S&;A(TFD@\C_1I6>W$MP(Q/)V=?-W@+XA:1INA^+)4%U_:MY\4OB&=
M/T"YL+Z/5]6>#Q%=3WVFZ3;I$R7VK);).L,,$[VXN(Q]HGBMUEF3Z#TR];4=
M/M+]K6>R^UP)<+:W/E_:88Y1OC6X6)Y$2;RRIEB5W\IR8V8LIH&7J*** /C;
M5/VE=?UGQUXQT+P#HGARRT'X*^,4\*_&/4_B5XAA\*VI@UB.Q_L36?"-]:P:
MM!<V%N6U!M1DU=](\J=+2W<!9)Y(?L6*6*>*.>"2.:&:-)89HG62*6*10\<D
M<B$I)'(A#(ZDJRD,I((-5?[,TW==-_9]CNOHY(KUOLEONO(I2QECNCY>;B.0
MNYD28NKEVW [CGY)^(OA7P]X&^(OPMTO2/%^L_#3P/XG;QX?%'AO2=9N-*\$
MZG9V&D#6=0:ZW:KI[>#)X'\AM$U+PG/IZPW$]Y:75E-!>J\ !P.L>+=.3]OG
MP[HO]O ,/!]I82VJW-P;&.\E\->.)DTBXN$!TR'5)II+*[BT.XN$U.X#6U_%
M8R1B.<?7/C3X4^#O&UW)KU[ID5EXU@T&]\/Z'XZT[?:>*O#MI=-+.HTG5H&C
MN;>&.^D6^DM-YM+N:*,7<,Z(JBAKOA[X4>$_ LOA74?#_A6/PO-:7<MGX6N_
M[(A/B&]L[-KIA9_VQ<VXU+Q#<+"LPU2XO#J+792^N=024-<K\T>#=&U_Q#K%
MG=>,]?\ '@_9O\9);:9\.?!/BG56\/:MH%[86RSQQ^/-<EG@\7^*?#_C:;S;
M;PIHVJ:[<16B:7;66H1:[;>([0V@!T>@:GX9_::UFW\!>.-%\&^+K;X':@G_
M  M'2]033==@@^,5M:/:^&[C1H40QV)L]&NKOQA9ZO:NMQ8G7M(L(A;:E:7R
MVOT7\2-2M=.\ >/8(=1AL[^Q^'_B?48D%ZD5[:VT&C7\<.H#=*+B.**>,*MZ
MQ"K,F/-\P&LG_A7GPO\ $<>D:AX;LM(L;KPE.UKHFL^ -0CT&[TEH&+W.B&_
M\,RP+)ILXF==0T'4%NM.E\\S3V!N/*E7A?!/P.NKAKS4/C7<V/Q&UZS\0:I-
MX9U"?4M7NK6+PA<W@U70_#GB#2)8=-TC6I/#%W<75G:W%_I]]%?I;6>MS16^
MK2RK  5_V7O%FEZC^SYX)\10ZS!KVGW<GB"/3;[3KR'54U&,>*-:AL;73)+:
M61+MC#&D5G;6S-^Z14B0(H ^F <@'!&0#@]1GL?<=Z\0O/@W _C&?QUX:U.7
MX?:]%<6<,47AL)/X=\1:?!+'+?3>,O"MQ%;:-JFJZC$7L+?588H=>T6U@MY-
M.UY#+<VY]P&<<]>^!@9^F3CZ9/UH **** "BBB@#\YO^"LO_ "8)\<_^OGX4
M_P#JY_AY7Z+I]Q?]U?Y"OSH_X*R_\F"?'/\ Z^?A3_ZN?X>5^BZ?<7_=7^0K
MTZO_ ")L!_V,\V_]1<E%U?HOSD.K\UK?_E,!J/\ VCBL/_6EKBOTIK\UK?\
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MX+JUGAN;6YABN+:YMY$F@N()D62&>":-FCEAEC99(Y$9D=&5E8J0:E9592K
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MZO\ ^+%?I#7YO>'?^4MOQ3_[1_?"#_U?_P 6*]/+OX>:?]BRK_ZDX0F7V?\
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MA?39/A_JOQ&M+VSNAH-_HNL7<GAS3DU>YL9]:TB.ST.<ZG+>F46MC>>::?\
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M8*6<@D*N2-S$ D*,D@$XXIU !13!)&SO$LB-)&%,D8=2\8?)0N@.Y0X4E2P
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M?_:/[X0?^K_^+%?I#7YO>'?^4MOQ3_[1_?"#_P!7_P#%BO3R[^'FG_8LJ_\
MJ3A"9?9_Q+]2G_P3^_Y*O_P4G_[/M\5_^JD^$M?I;7YI?\$_O^2K_P#!2?\
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M+X>N$T^^\,O%HDU^J7"ZO<O?Q?IW11L!\,_"K]A_PW\,]1T2_/C&?4X=*O\
MX]WLFFZ=X;M?#]BR?'K_ (1U=5L]+8:KJM]I,'AR'P^+?2I3>WUY<PW;?;KJ
M22$22\GX*_X)[^'/!^G:+IR_$;5]1'A:X^%EOX9OKC2;ZYU"U\._"WQQ:>-K
M'1]1GUSQ9KT4\VKSV%E87D^A6_AK2+=8#>VOAY;N1F'Z)44 ?+&D?LSMH'Q5
MTCXI:3X]NH[JR^('Q:\9:EHMYX=M+JSU/3/BU8>%;34M AN4U*VGT^?2)_".
MGW-AK86Z:9)KFVN=-93%)'D^(OV5KO5/'OB/Q/HOQ.O= \,>,OB]\+?C3XJ\
M(/X3TO5[F^\5_#"3PZ(;/3_$US?P7.EZ%X@M_"VCIJ-I_9MY>V=S#+/IFHVL
M-Q+:-]>T4 ?&-W^R/=6OA/X<Z)X2^*-WX=U[X<ZS\9[_ $_Q#=^#M+URVO[#
MXW7/B2;Q'876A2:G81)=::OB ?V1J27[ 3V*S7UE>174UL/E'Q_^R;\<_"EE
M#\(/@]!J6O>#_%7A7]F/POXM\<:U+X#AT._7X(^(K$ZSJ^J6]SK%CXM\(7DW
MAC38O+T_P[HGC6SUR_E@2RN?#<D=[++^OE% 'RC\$OV7H/@S\1O&WCZS\<76
MH0>,H-5CN?"FE:##X5\.37NJ>))_$)\2ZUHVGZK=^'[SQ=;Q2C1QK?A[0?",
M5]8&:;5M/U#4)S>)XE_P[WLKGQ!X^\0:O\7-8UC4/''@CX@>!I]4O?"T$_B)
M['QYXYT7QM]NU[6+KQ!=PZU>>'QHMOX>TF"PTOP]I:Z,(D?3Q<0F:;]&Z* /
MD'6?V5KJ3XQ:S\<_"?Q+NO#GCO4O$-OJMH;_ ,*6'B/1++2I/AQI?PZU?1)M
M-EU739KQ[V#1M.UJQU1+ZSN-,OH#:/#J&FSW%K+K>'?V7['0O@'\,_@5/XUU
M#58/ASXH\&^*?^$JN=$TZ&]UZ\\(^/X?'XBNM)@E&GV*:E>Q?8I6M69;6)O/
MMXRZK&/JBB@#X-U/]A/PU?\ Q'\;>.$\=:M'IWC3QCXR^(<F@7=A?:B^D^,O
M&G@>Z\%7U[IT\_B5?#L=A:173ZE9QIX/BU])"^GMXF.GR& 9&F?\$_?#6E^)
M-(UJ#XC^(OL=A)\/=8N+8VE[]O'B_P"''@;3O!6B^(]%=O$C^%])<C1],UM(
M;SP;K6HZ?J5L4T[6K:UD\E/T)HH_K[@/S0TK_@G)I-AIGB^TU#XEVOB*]\80
M?"^#5+G7OAW;ZG;:E+\,KKQ%=1:QKAO/%T_B*X\3>(Y?$,MWJGB3P]XH\*ZI
M8ZG:0W.A3:7:23:<V]HO_!/C0=(\2:'X@N?BOXQ\3M%'\*I/%P\7?VIK5]XF
MU'X27CW7AZ[AG'BBTTFVCDC%I:2+XDT'QG?VD5A;SZ?JEM?F6[?]$:* /B'X
MT?L__$;XK_'/6K[2?%(\$?#;Q9^S-J_P@\7:Y#HNB^(=2U(^(/'$MYJVB:5;
M7^HVMUHFHMX<GNFM-?>RU/38'NV$MA<W<%N(MB']D'2=)\/2Z9X8\;ZAHVL:
M9\?H/V@?!>LW&AV>J6V@:]:^&+#P;!H.L:0][:KXHTAO#EO>6$]Q+?:7J9>^
M2YM;NSGLH&/V-13NW_7HOT0'Q.G[&>GOH_B:UO?B-K%WKGC?PM\?=(\7ZX-"
MT^VBU+Q#^T!J^@:OKWB.PTB.\-MI5KH+>'[2ST;04FN4DMB6OM2N+H27,V?X
M_P#V(=(\:^(5\86WQ#UK1O$MIXTO/%FESK9ZFFFVT.J_"SPS\+M6TF[M_#?B
MKPGK%XLUIX7L]:M+N+7[$6]Y+-9W=IJ6GL\,GW112 ^%_ W[$.C?#_XF^!/B
M!X?\?7NF0>!]-\.Z8--T/PW9^'-4\26&@>%+CPT- \4:UHVJ6VF^(O"MY<W!
MUX:?X@\,:OKVFW\4-OI7BFST^-;8?=%%% !1110!^<W_  5E_P"3!/CG_P!?
M/PI_]7/\/*_1=/N+_NK_ "%?G1_P5E_Y,$^.?_7S\*?_ %<_P\K]%T^XO^ZO
M\A7IU?\ D38#_L9YM_ZBY*+J_1?G(=7YK6__ "F U'_M'%8?^M+7%?I37YK6
M_P#RF U'_M'%8?\ K2UQ3RS;,O\ L5XK_P!+H@]OG'\T?I37S+\>/VF=$^!/
MB7X::!J7A?5O$=MXTUA1XOUK2[NT@L_A;X(;4]*\.#XA>*(9U>>XT+_A+/$/
MA[P^(K15G\S49[PN+?3KD5]-5\??$[]C/X>_&CQ9\5/%OQ.UGQ/K=U\0?!6E
M_#O0K31_$/BGPE9^"?"&FVMY.VG):^'?$ME9>*9;WQ5J%UXKN)=?LY;87D6G
MV:60@LFDN?+&>H:Q^TG\$- ^($_PMU?Q_I]GX\M;[3]+N= .GZY,]OJ^KZ+_
M ,)#HNC3ZA;Z7-I,.MZYHX-YH6C27ZZGK8!@TJTO+D&$>(R_MT?#BZ^'.J?%
M;0=*O;SP?I?@*^\=30:_<77A#Q6MGI7Q&M/A[JCS^&M8T;?#HMG-='4CX@2^
MGAE\O^SH[,W)D>'9T[]E"^%G9-XC^*=_XDU]/BM\#/BMJ_B"3PM9V$VMZI\%
M/#GAGPZEK<VL6L3I#)XK7PW'?WU^DSMIUU=R>1;7*Q*7XN3]A^YN?!^M>$[O
MXO7;-=_#OQ!\-]#U>V\$:=%=Z+I6J_%RT^+&EZA=6USKE[9:SJ>CW5M_8LID
MAL[+58&6]FM+9U>UD />)OVJ/@'!X?;Q+)\0[,V"^);CP>;*+1?$\_B;_A)+
M32QKESI(\&0:))XO:>'0V37)'70S;KHDD>KF;^SI8[EN-^+_ .V?\%/A5X*C
M\5VOB2R\<7VI>&_#WBOPUH7AJ6\NUUS1/%.MVNA:%?S:_9:;J.B^'K75KV>:
M+2Y_$%QIZ:E<V=U96?FW,,J1\FG[(?B2V\>W/QMLOC(L7QXO/$.HZA=>,;CX
M=V5QX-D\/:AX+TCP*OAM/AZOB>"2-K/2M"TR_@UL>+#?R:Q'<23K)I-RVD)Q
MMU^P(FF^!M=^'/@'XP:GX7\,>./!?@7PK\0CK/@O2_%>L:]?^ _$&H>(;+Q#
MH]\=7T2U\-RZM-J^IVFK:9'IVI6*VTT#Z5_9EU;FXF /I[1O&7P+\0>.?"WC
M71]6T;4/'WC;3_%WPT\,:G&NJ-JU_8> -7NM2\;>&HK66(1Z:GA_6K2676FN
MK:R<W<5K#+/,38Q'S/\ X:NMX?B7\4?"FK:#X+\.>!_A!K4^E^,?&OB+XL:7
MI_B&.RLO!FG>,]1U[3/AQ%X<N]5OM*L[/4HK=IFU> S&WO9X@RV[1M4^#O[/
MFH>#_P!IG]H+XP:BNIVGACQ'>:;:_##P]>WVG7>F:9=^(]*T75OB_P"+=%M+
M22:YTK_A-_%.DZ)'<VU^T5T9M!N[J.)+344!U]=_9'\%^(+7]HN2_FT>?Q%\
M?KG5I8_%MSX,T6[\0>!;?5? ND^!VL=,U*>4W^HVT,.F27ZQM>:=&S7L]KY:
M)NFD .NTO]J[]GO6SX2.E?$S2;V#QRVGKX9OHM.U\:7??VOK=SX;T1[G5GTA
M-,TB+7]=M+C2_#\VLW>GPZ_=Q[-'>]#QL\#?M<?LY1ZOK.AR?%30X[_0=*\:
MZYJ!EL]<CT]M&^'&1X[U/3-8?2ET?7+'PI(K0:U<Z)?:A%972/:2-]I1XE\F
M^+G[%Q^*WCOPCXKN_BE?V.B^$Y?A-<V'A.\\,_VO9Z5=?"OQ%%KP;PI)'XDT
MK3O#\7C$11V?B4W6B:[>[;>S?3+^QB@>UG^8= _93^/OC7Q3I'PT\76NH^"O
M@IX#^'/[3G@#0=:U9? &L7UM!\8[VTT[PI+HEUX:\1W&K>-#9Z''-?7EQXCT
M#P$;*%+?3;VWU/5VN-2< ^ZM _;'_9I\3ZMIFA:)\4],N]5U;5]'T*UM)=&\
M4V)AU/Q''#-X:@U274-"M8-$B\41W$+>%KS69;"R\3>8JZ%<Z@QQ6C<_M9?L
MZ6UKXRO+OXJ>'[:P\!V\EWXGO[B#5X=/@L(O$,?A*XU#2KZ335M/$VFVGB::
M+0+[4?#$VL65CJLB65W/!.P2N2U']E.QU&/XF12>-KR-/B3=?L_W%WY>AVX;
M3$^!#Z*T$$+#4@;I?$XT8>:TGE?V.]RTD"WIB4/XSIG_  3STC3]"O\ PT_Q
M/U&\TJSL8-%\#37OAVZU#5O#.A?\++\/_$F_L;^ZU7Q=J%AJ$M]<>'K/1F;P
MYI/@K3FMECO[[2M0OX8W !Z?H'[3_P"R]\-]'^%7@KP+?W</A3Q9XT\5?#CP
M_!H7ACQ0VF^#?$'AW2[SQCXCM/&D>J6,.J>$(K>VG.H.^N6\!-M?Q:FJKHRR
MWT'OWPU^,WPT^+\&I7/PZ\40^(X=)739;UDT[6=,;['K-L]YHVJ6D>M:=ITF
MHZ+K-I')<Z1K>G)=:1J<"/+8WMPBEAX+X@_9+N-3\8W_ (WT?XE2Z/JM_P#&
M_4?B^\%WX-TW7M/6RUSX20?"'6?"<ME?:I';WGG:-')J-CK%Y'-!;7LBVU[H
M6IV*O!+F? []F7XA?L]7VFZ;X,^(FCZOX/USQ%I<_C;19O#UYX>\/:#X7\.>
M'-9M8+;X=^#(]=U_3-!\2^,O$-YI=YXMO=,OM$\+6]K82'0/"&FNR0D J?&K
M]M.+X.?$7QKX,F\ :9K>E?#WP_\ #KQ%XAU.?XF:#X=\4ZK;_$35M4TNST_P
M%X"U#2IK[QIK%@VER.VG6NK6$M_//;6%F6O)XHW]0B_;$_9LN;#5=1L_BGI6
MHPZ-XFG\&7T&EZ3XFU74O^$IL[>^NM1T.RTC3=$N]5U6^TBVTV^N-<32K.]3
M1(;:275GLTVLW06/P"\*1?'/QI\<]7@T;Q#K?B?PYX"T#2+35?#&E75YX0?P
M/)XAD74-%U^Y-S?Q2ZL^O[IXK:*R%N]E"XDG9P8O*M-_9-U'PMHGPN/@?XH-
MH?CGX4:_\7M5T+Q3JG@JSU_1K_3?C1K>H:SXGTK5?"@U[2VEGM)+FP_LO5K;
M7[:X2XTM9;R&[M+VZL" =C)^U]\"(O%FH^&)/%DJV>F_"C2OC--XV72=4E\
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MIU*=2+M:4)PDI1:;73=-*"BI_LMU_P ^MS_X#S?_ !%'V6Z_Y];G_P !YO\
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MQN_]1KX=5^CM>GG'_(QK?X,-_P"HM 4=EZ+\C\\O^"KW_*/+]J#_ +$K2/\
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M.OZ?]V_6&ROM=DAC7]>GM+60(LEM;R+'.+F-7AC81W*DLMP@92$G#,S"5<2
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MKK1K>P\/ZCIOB*ZNKR^W0?M,EM;1*JQV\$:HK*JI%&BJK*JLJA5 56555@,
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M@?\ X67P'_\ G T?\._OB;_TDK_X*!_^%E\!_P#YP-'U/ ?]#C#_ /A)CO\
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MW_*_O7^?K_3T_2>BOS8_X=_?$W_I)7_P4#_\++X#_P#S@:/^'?WQ-_Z25_\
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M]J+_ ,33_:Q_^?#1[#)O^ACF'_AIH?\ SW"\OY5_X%Z?W?-_=YGZ845^9_\
MPZ8_9)_Z"?[47_B:?[6/_P ^&C_ATQ^R3_T$_P!J+_Q-/]K'_P"?#1[#)O\
MH8YA_P"&FA_\]PO+^5?^!>G]WS?W>9L?\%9%9OV!/CI@$XN/A2QP"<*/C/\
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M'U/ ?]#C#_\ A)CO_F?^K/RN7?\ *_O7^?K_ $]/TGHK\V/^'?WQ-_Z25_\
M!0/_ ,++X#__ #@:/^'?WQ-_Z25_\% __"R^ _\ \X&CZG@/^AQA_P#PDQW_
M ,S_ -6?E<N_Y7]Z_P _7^GI^D]%?FQ_P[^^)O\ TDK_ ."@?_A9? ?_ .<#
M1_P[^^)O_22O_@H'_P"%E\!__G T?4\!_P!#C#_^$F._^9_ZL_*Y=_RO[U_G
MZ_T]/TGK\WO#O_*6WXI_]H_OA!_ZO_XL5#_P[^^)O_22O_@H'_X67P'_ /G
MUZ9^SQ^Q/8? ?XN^,OCEKO[07[0?[0/Q&\9?#KP[\*Y-9^./B'P3JZ:%X+\,
M^(]:\5V&F:#:^#/ 7@B"V,NMZ_J5U=37:7LDIF !3&3M26!PE#'..8T\14KX
I.6'ITJ>&Q4&YSKX>=W*K2A!1C&G)N\KZ62;:N.[MI:S3W73^OZZ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img149481191_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_3.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #D K@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3QE/&P@Y34*V'<J52T/=****\L^("BBB@ HHHH **** "BBB@ HHHH ****
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M/#VK:?XGTNPW!'U%M,\XSV$1.%\Z>*0F(,5!= H.6 /YK_LU:IXEO_VF/A]
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M)RM]=C/W4[IGG7Q-^.G@[X:SPZ3=RR:MXENTW6F@::#<7K%LB,S1Q"25 [#
M5(Y)<?-L"_-7F]E\4_VA=<B^WZ5\&(;*RD^>UCUG5HK:2> Y,<GW_.3>,'$D
M,;#(^45P/[&_@!O$VB7?[0_CD-K7C+XCZC?:KH,^H()/[$\._:9(K#[)$X*P
M7<ZH5DF159(HHQ$0';/WA79F,<LR/%ULLIX.AFF*P<Y8?&XS%3K^P>*IOEQ%
M+"T:%6C^ZHU5.DJM24I5.5R2BFF^#()<0\99=A.(\3F^-X=RW-*,,;E&4991
MP2Q<,MQ"57!8C,\7C,-C'+%8G#RA7GAZ%.E2H*HJ;E4DI6^"O 7[0/B;P?XI
M^)GA[QY\)_&5M/;>(D\3ZI<>'(X->LM$L]?MK>*VW1QS)>SVKFR>99H('.6<
M!"0 ?K+P5\5OA_\ $*+=X5\26-]<J/WVESE[#6;<XRRSZ3?I;WZ;>0S>08P>
M-YKP3QMJ+_#C]JGX>>()&>/0?B_X:O? NJ2+\L$>OZ%(+[P^UPQP@:=+JXA1
MF^8A-HZ"NP^/VC_!/P[X3U?XA?$6'3O#DND1%[?Q1IMP=!\0/J4WR6%M#J6G
MO:W=W/<7)C2."XDFA8DEUV!B.K,:&58F66598+$X1YM@</6P^(R^<L3!XB$I
M8'$4)8'%2]I-PQ>&JQBZ6-IR]G*G)PJ2E=QP?0XSQ&-S7(<HQF'XAS#*>(Z^
M3QR3,\*\/C\7#,'1S+*)X/,\KI-1GB\#F6%CR5LGQ4)XJ->G"K1A!1@OP.U!
M='\2_%GX8R%E;PCXO?6-(A8_ZOPWXGA2[L51221&MY#?$$#&7/M7T;7\]OPS
M_;5\0?#/]I#QCXB\0^&O$'C'0_%W@_P[H%I?W&IZ>NLSQ:)<7D]I+%96\:1W
MZVMK.QEN8QYTXRC,74U^VOPK^.GPQ^,FCVVK>!O%&G:B\L$4MUI+SQP:QITD
MB@F"]T^1EGBD4Y&=I5@-RDC.,N)<AQV#KK&JDZ^$KX?"U*F*HQE*FL0Z%..(
M=6#2J4'/$*I*+K0@IMOD<K-GWN'X>XHX*H4\BXVX?S'A;'T\PS'"9;0S.%-X
M3'8*&(GB,"LHS;"U*^49Q3I8"M0I.66XW$NG.A5I5H4JE*I"/KM><?\ "N;%
M?B;_ ,++BO)EOI=!&AW-DX#PND;#R9HFR#%M0;70 AV^<G/%>CU@>*?%/AWP
M3X>U?Q7XLUBPT#P[H-C<:EJ^KZG<1VUE8V5K&TLTTTLA  5%.U1EW8A$5G8*
M?F*-:K1]I[*;C[:E.A422?/2J6YX.Z>CY4[JS32:9>,P6$QBP[Q=*-18/%4<
M=AW*4H^QQ6';=&LG&4=8<TE:5XM2::9E?$+X@^$_A=X0UKQSXUU6'1_#VAVK
M7%U<R9>:>0_+;6%C;)F:]U&^F*6UE96ZO-<3NJ(N-S#\N[SQOXW^(OQ,TKQ_
MJOAZ75/BMJ,<UM\$?A1<@76F?!CPW>J4'C7Q5!DVK_$76K1O/N;BX_=^&[)Y
M+*V9YBN.&O?BC\0?VS_B?8ZQX4\.7\G@/PYJ+M\)/#NI0-#IJRAC"?BYXVBD
M!A$NS=)X3TZZ#BUAVW80270<_H#HO@;PI^S%\,_%/C+4KU-6\9W.G3W&M^++
MT;[W4-5G0K;VMHTNZ6&PAN&5O+4[Y(XS-<%F V_0X++:>!^KXC,:/M\;B94U
MEF3N_/6E5:5+$8Z,?>I85.2<*+M4Q#T]RFI2/SO.N)<1GO\ :&!X>QLLOR+*
MX5Y\2\8P453PU+"QE/$Y=D-2:]GB<R<83A7QT>?#Y>KN+JXEP@O _P!FGX2P
M^)/BE\4-;^*]S8_$77M N].@M+VZ076G:?J\C7#:GY2O\MS=1.L</G2K\JH0
M$Y!'Z206=I:HL5M:VUO$H"K'!!%"BJ!@*J1JJ@       5\R_LE^%+S1/AD_
MB;5K<VVM?$/6M0\87\3@^;$M](([:-BW.QTA-S&.FRX4]P:^HJPXEQM3%YMB
M8.KSTL-[/"TXPM&A%X:E"C5=&E&U.G"=:$YI4TD[WN[W/0\-<FH95PGEE181
M4,3F4:V:5YUDYXV:S'$5L9AH8S$U+XC$5Z&&K4:+G7G*:Y.5VM8Y7Q'X6TK6
MK665K6*WU2UCFGTS5K9$AO["\$;&*XAN$ <E7"ED<LCKD,.<CR_]G+XLR_&#
MX>-KM\D::WH'B/7_  7X@\H!8IM7\,WIL;F[B0<)'=C9.J@D LV#C '3?&KX
MFZ'\(/AEXM\>:_<QP6VC:3=/:Q.ZK)?:E)"Z6-A;*2#)<7,Y541<D@' XKYY
M_P""?_@O6_"G[/6FZKXCAFM]9^(?B;Q+\1KB"X5HYXK?Q3?&]L8YHF ,<@M=
MC,A'&X'O2I853X<QN.Q"=Z>98'"Y?.3=W.5+%U<=3I7WIQA]7G52T4Y4GHV[
M]N(Q[I\<97E6"<?WN19MC\ZITTN6-..)RZAE5:ORK2M.M]<IX>4K2E2CB%=Q
MBDOMJBBBO /L@HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^,/V^KG08
M?V:?&46NZ=K%\;N;3K71Y]$BGDO-'UN><Q66L,]O#.\$%D'E,LS)L <*S+N!
M'V?7C'[0WAZ;Q/\ !;XB:1;7FIV-Q-X:U&6";2%A>^,UO \T<44=PDD,GF.H
M4HZ'/!7YPIKORJM&AF>7UYN2C2QF&J2<9.#2C6@VU.*DX[;J+=NC/JN!L=2R
MSC/A7,:_.J."XARC$U73KSP\U"ECJ$I-5J<*LZ:25Y.-.;<4X\KN?SS^!KHZ
M3X$N$N;ZU35K.ZU7P?X7@GO+348);Z&&35+J;7(9I]VGS7MHCWB3D"4J=HC)
M.#[[^RA\++WXS?'VTUWQ;XW\,6]]X/2UUX^&+;00(]>M(88H?L5CITFRRDTW
M3F1'EU3S6E>:XR(B:^1/ =I8:UJ^G> /$Z)X/\2ZS::AXGTW5=?TE=,:UU#P
MWI\MG'K&IO)$EMJ#7'E_Z0;A)#- 6B7EJ]/_ &>_$-G\.?C7\.?%EW\2K_3]
M.O?%3^'_ !%K=O 9[?5;2!AOL[&VVO)9:;J5U.B0VL,85E4MM*(H'[[G%"K5
MR[.986O".-JX:56$Z.'=92I5X2<Z5*K[.JG"K]6JQ<;JK*LI5%&,91E'_1GC
M7*\7B,@XYIY3C50SS&9-C\1A<1A<L^O+$8;%TZ\Z^&P-=8;%TY4,PIY?CL,H
MTVL3/&<U>FZ$)4ZU+^FQ$2-$CC14C151$10J(B@!550 %50     !@4ZHX98
MYXHIXF#Q31I+&XZ-'(H=&&>>5(///K4E?SF?Y>;>04444 %%%% !1110 444
M4 %%%% !1110 4452U+4M/T>PO-5U:]M=-TS3[:6\O[^^GBM;.SM8$,DUQ<W
M$S)%##$BEGDD954 DF@"[7XJ?MN?MU^/_''CU_V(OV$HCXS^/?B8/IGCSXAZ
M2WVCP[\(-%G_ '.HW,^K0[[6'688&<O.TH%CAO)$UTNQ<#XW?M=_'#]N/QEK
M7[,7_!/@SZ;X.M;N31?B_P#M6W4$T?ACP[8$M!JFE^"+K:IU#4VC,D45U:L9
M9V(-FRJDF[]"_P!CW]BSX1?L:^ SX8\ 6#ZGXJUH1WGCSXB:SB[\5>,]:?\
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M8RIPW2Q]2M.G# YAG%"KC:F0J2<91Q&>PP.5XKGC"GCIXAU*$?MOI'\5I8;
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M>5XZNZV8?V5F].I*GC,NQ%2I.E.>&J5I485:E%0PLZTXR]F "@*H 4
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M.VA&U0&N+EU'FW=W,<O/=7#R32NQ+-C 'HE%%(H**** "BBB@ HHHH ****
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MJVG6NIVLB-%#%<ZM&U]:2I<[$8;*XK0/VM?CY+XV\8^,I?&OA);?7O#GPX\
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MKW5-2D_>21"<@N+*WD9Q!$&VDEI6!9N/R1_:'^$MK^VM_P %3/!_@>\\R_\
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MM]HLI7CCG&YN I65E?II\K?H?5-%%% PHHHH **** "BBB@ HHHH *S-:_Y
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M8GZO"*Y:&%IQ2B>Q_#.34Y/ ?A<:S+'<:I!I%I:W]W"B1Q7EQ:1BW>\C1%5
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MQ$OGW-BC%I;FZD<>9!<!601Q,0S*I8YS7MUK=07D0GMW\R%F8(X!"OM.-RY
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M@K_A$O"&DW^F:YXTO!J-W)<^/8;.+Q'JL=OJ#27-BFIWC11!VA?=&B"NA?\
M8 L_%WA;3M1^(_Q+UGQ7\7;*;PCJ6B^.?$'A;PGJMOX9_P"$6T*?1+'0AX3G
MLW\.:Q9"QO;JWOY]0MY9[R<K>,QEC5B"][31>?X>?K;\?+5N_P#@HU\+3I^D
M:CX?^'_Q1\713^%+[QGXK'A_1=.NAX!T+2-8FT36KGQ+-)JD< .GW4#R :?)
M=K=6Q66%N=H/&7[=NBV?CKP1I?A7POX@E^&=S\0-7\+>-/B_JFF0KX(BC\.>
M#=9\3^(-*T>\COOMIUK3FT^.*0S6(MG>.>*)W89'4:7^P_X5L-$U_2Y?&FJO
M<^)OA1J/PMUB]L- T#1+9X-3UF;69M;M-'TNWM].LKF-IOLL-G!$MHL"*6#/
MEJY^?]@;PY<ZKIMA-\4?%K_"BR\0Z[XOE^% TW1%TF^\5>*?"^I^%_$.IS:^
ML(UL17\&J3WT5@LQMK2['[E A- ES=^JZ+3O_E\M-[JC8_\ !23X/7^B:QJE
MOX2^(%Q?6\OA23PUX=LK#2=1UGQMI7C74Y=)\/:IH,=CJL]NBW5Q$TDEIJ,]
MG=6]L\<LD?S;1O>!_P!LG5_B-\;OAS\-M!^$OC+2='\0:9\2;;Q[/XDM+*SU
M7P#XL\ :EIEC<:9JD4.H3QO;N;X*9[?SM\LL(4!0QK(\&_\ !/[PQX5T^UTR
M;QW/>6NB:WX$O_#)TKP+X,\+W.FZ5\/]3DU'2M*U"ZT*QMI]>FN8W6QO=3U-
MY;N2&%)0?.>1CZOX=_95L/"?Q<M?BYH7CS7K;43XL^(GB'6=&ET_2Y]/UC3_
M (C7-G?:AH3RR1FYM(=/OM/M9K.\MF6Z=4:.5BKD$#W]+]U?;RO_ )Z>:?1'
M??$3X_>$?AMXJF\):U8:U<ZC!\//$'Q):73[5)K8Z+X<=TO+<.TB-]OE9#Y$
M6W:X(RXKP/3/V]_A7K6K36.I^"?B%I/@6+4I?#NM?$O6M!M!X!TS6FT:[UQ-
M)U&[%Y+<$S:=97.]Q920I,(X'W&4$>A?M"?LOI\<M9TC7]+^)?B7X9ZS:^%_
M$/@?6[OP]IVCZHWB'P=XF0+J&D31ZQ#,MC(C^9+;ZA9A;F-Y&&< 8^:_AM^P
MKK$VO>/-$^)'C/Q%+\&D\?WNJZ%\- FCMIWBZ"/0+C0+/Q+J>K6\?]L6,ES;
M7UQ-<:5%-'!]KCAEVC8*!OFNK;7_ $6_97O_ %:_H"_MW_"[PEX<U"_O?A1\
M2_"&EG3;'7_A[IA\+:79/\3]!U6_-C;ZIX)LK*_$,WG-LOC;7GV.<V$T-TPQ
M(%KZ6^!WQOTCXWZ'X@U&S\,^*/!6M>$O$U[X3\4>$O&-G;V6O:-J]E%!<;9X
M[2YN[=[>YM[B.6VFCG.\!PRJ5Y^:X_V#K/4(["W\8_&+QGXPM?"%IHFB_"^W
MO=)T&Q3P#X9T741>QZ3 ;&"-M:FGM FD2:EJ9DNUL+>$*P?./J3X9?"/3/AE
MK'Q*UC3]6O\ 4Y?B5XRE\8W\5Y'"B:==2VD-H;.T,0#20*L(</+F0LQR<8H!
M<W6WZ_/I]W<]<HHHH*/G']J?X5:O\7OA'J_AGP[L'B.&ZL=2T8R.$0W-I<([
MQEB0%\R,$9/ (]:]B\!P>(;;P9X7MO%B6L?B2VT33[?64LI#+:B^@MTBF\F0
M@%U)0,3C[Q;'%=9179/'5IX"CETE!T</B:V)I2<7[6$Z\*<*D%*]E3E[*$W'
MEOSJ]^C\RGE6&I9OB<YA*K'$XO!8? UZ:DO85(86K5JT:LH<O,ZT/;3IJ?/9
M4VX\NMPHHHKC/3/!?C9^SG\./CI96K>)[&YTOQ3I&9?#?CKP]</I7BSP_<CF
M-[+4[?;+)!OP9+2<R0R*"H"%BU?,L<O[;'[/?^B&UL/VH/ %FI6TNT>/1OB3
M#;KC:MXK'[+>^1",!U:5I&3.,L0?T4HKV\'GN)P]"."Q-'#YGE\6W#!9A"56
M%'F=Y/"5X3IXK!N3UDL-6IPE+WIPFSY7,^$L#C<9/-<#B<=D.<U%%5<SR>M&
MA/%*"2A',<)5IUL!F2@DHQ>-PM6K""Y*=6$=#X9T']O;X6O<_P!E>/O#7C[X
M:ZW"@-[;>(_#-ZMA;N =RKJ:*L$@0C:65=N<$$@\>>_ G]H/X)/XK\??$+Q?
M\2?#.G:UX@U>X&GV]Y<N)8+$R&$+"RQOB%X+>V*1@_(6DX!)!_0'Q9X5T?Q9
MHNI:7JNDZ7J7VS3[RTA_M*QMKM8GN+>6)'7SXW*;&<,"I&",CFOAO]C[X"?"
M2V^&&HZ%KG@#POJNNZ)XU\2QZC)K&E6E_J,#RW[M!#)+<Q/-'$J*6@B+;%1A
MM&"*]S#8CAV>59I7A@<RP4IU,%AZ]'#8VCB4J-6=6HY4JF(P\*E*E*K1A"I&
M;K.7-!*<;/G^)S3!<:QXHX6P5;-LDS2G2IYSF."Q6-RS$8&/UW"4<)AHT\50
MP>,J0Q&)6'QN(K8>I1>%C3]G6DZ4[I4_?+C]K/X#1I(]GXZL=7,><1:3%-=R
MR$<D1)MC+G'0#KVKCG_:N7Q(3;?##X;>-/%]TTWD*\VF3Z9 ,DJ)U:Y18Y8@
M<'_7+D ^U?0&G?"CX9:2RMIO@#PA9NA!1X?#^F*Z$="KFV++C_9(KNH+>WM8
MEAMH(;>%.$B@C2*->WRI&JJ. .@KQ'B<AHZT,LQN)DMOKV.C&G?2W-3PF'I3
MDKWNE6CIU/KWEW&F+]W%<195EM-_%_8^33J8BVEU#$9GC,33IO>TGA9M=$?(
MUM\.OC9\5[J*\^)_B%/!?AD2K*GA;PY)_P 3&YB63<B7<X)CL9]JA)662Y+
MD[.16%\3]/T_PU\2O@_X!\(6R6$$<-\;I(@7E=;V2)(YKR7F2>6Z>TFWR2$Y
M<-M"C K[/U'4;+2;"\U34KF*SL-/MIKN\NIW"106\"-)+([,0 %12?4G  )(
M%?(7P?@N_BS\4?$/QEOK>2/0;)SI'A%)U(,EE:,RVLJYXWJS37?F)\K)=(I)
MQSWX',*]:.*QE:%+#Y?@,+6C1PV'IJCAGBL53E0H4U%7=6JU.<W.K.I44(R=
MU%GS6?9#@L(\MR;!5<5CL^XAS/ RQF9X[$2Q>8K*LLQ5''8[$3JM*&%PD?84
MZ,:.'IT*$ZM:$8TY33:^R@, #T&****^4/U;8**** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .-U/5[6SEU+4;T
MAK;2D$44;'*B<J&E;;W=E957@D'H>37YA_M3V?B:?Q3X0\=7VC2Z9X?OOM.D
M:=-,RK)<2NWVM6,.XR(K1+N4L!D 9QNQ7Z.:Q:"]U)-.G :WO/$<!N$/26!8
MUD*$_P"UL QT. ,&OR$^.?Q0\0?$3XR^*(=6O)8]!\(:U>Z!X=T16*65G%I\
MC6[W9@!"M=W6T,\C+N5244[37R6=UE["?M'-7J<E*$;7G5NIRE4D]53A3C&,
M8QLW*2=THGZ5P#@:]?-E5H*FH8?"U*F*G4<F_8U(*A"E1A&R]K4JR<Y3EI&$
M&[-M)]UIE[NLXL@DA5YSQG:!^G3M]3UK#\2WJI:2[C@E3D9Z#/OV'3V]\UC6
M.LP16RJ77Y5'\0 Z #OQTK@O%OB1Y4%K:*US=W4BVUI;1#=-<7,S".&&)5R6
M>5RJ*H&2Q&.,5\FZKDK):^F[NNWZ6/U>AE[57FY;)-MO1*VCZNR2W=W:WFW;
M[@_8!TZ:6Y^*7B,HPM;B\TS2(GQ\K36GGW$Z@^JB:+CWS]?TEKY__9F^&,GP
MK^$V@:)?H%UW4T;7O$#  '^TM259/);@'=;VXAA=3RLBR#M7T!7Z3E5"6&R_
M#4IIJ:I\\T]U*HW-I^:YK/S3/Y_XKQ]+,N(,RQ5!J5!UE1HS6TZ>&IPP\:D?
M[M14N>+ZJ284445Z!\\%%%% !1110 4444 %%%% !1110 4444 %%%% !7Y]
M?M)>,];7XG^/-'$K)HWPO_96\:?%;2=/F>=-/U?Q7>ZE>^'%DU*.WE@DN[&R
MT]<+")5\NZ;S%96Y'Z"UY7XL^$GASQ=XV\.^.;[<NH:-HNL^%]4LF@@N=.\5
M>%=:BD^T>'==M[A72?3HKR0ZA#'M/^D@[PR,10#_ ,OS/S(\/_M/?'O1+VU\
M>ZWXV\)M\+K3XQ_\*93P';^#V:_L])3X;6WB6'Q$VOIJ#W-S>6=_&52Q%L3/
M;R>6\O5QYEX/_;J_:)-UXHTK6M;\,74'B[P'\/\ QEX,\2ZAH>FVK>"+7QU\
M0K/P;<^(=6TG2M8U& :!I&FW9U6.TU"]M[F,Q!KU;=#(!^T:?#?P!'"EM'X,
M\,K;QZQ_PD"0#1K 0KKGV,Z=_:PB\C8-0^P'[&;K;YIMOW);R_EKF-(^ 7P1
MT"VU:ST3X3?#W2K77K&ZTS6K>Q\)Z+;1:KIM[,UQ=6%^D5FHN;.:=FE:VEW0
MAR65%-!-I::^N_9?K?M:^A^8'QE\;_$W2O$WPXO;S]HWPEX^M?#WP\^-4.L/
MH&D0:=X8\>W6D2>"&@L-1@M-8DM7UR.+4&9/[*OKHQ>5F NS35IW/[9'QM\-
MCQ'X L+'2]=\=?"#P/XB^+WC&UM]'E:'4?A=J/AB[N_AO#9PB9Y$N(]6-A;:
ME,LTLMQ C@B(L6K],H_@5\&(M'T'P]%\+? <>A^%IKBX\.:4GAC25L=$GN]G
MVJ73;=;41VDESY<?VAH@IFV()-P1<=7!X$\%VVJ7^MV_A3P]#K&JZ)!X:U/5
M(](L5O\ 4/#ULNVWT2]NA!YUSI4*_+'83.]LB_*L8'% -/NUJKZ]-$]>^FC/
MR9\&_'+X\_$?X-?&R\^(E[#:W/@OP+X+^+O@+Q9:1Z7H^K:9K]],]Y<Z'<66
M@ZSK%I+IMF@>RLWO+B"ZF22=+JR1@N/UE\!^(+CQ9X)\)^)[JU:RNO$'AW2-
M8N+1P5:VGU"Q@N982IY78\C  \@8%>7ZQ^S;\*KCP5K7@#PMX7T3X?>&_%.J
MV6H>+K/P9HFF:.?$EM:W0O)].OWMH(V$-[,D?G3+F5$5TCVB5\^[P00VL$-M
M;Q)#;V\4<,$,:A(XHHE"1QHHP%1$4*JC@  4#2:W=]-?6_Z?C\D2T444#"BB
MB@ HHHH **YW7O%GASPO-H<&OZO9:7-XEUFU\/:%'=S+$^IZS>[OLNGVH8@R
M7$VUMJ+Z<UT 926 925(# $$J3R P!R"1R <9H _(G6_VD_C(WCGXC6]W\2?
M!.J^&8OB]XC^"MK\(-,T.*#QQIN@3^%8;^/QQ-J\5\U\KZ'<7#SW4IL$LVMG
MB'VE'2N3\!>,_P!I"Z\(?L$6_C;P]X/T;P'??$;P[!_PE>A_$?5-:\4^(X&\
M*>*7TV/5=%FTBSBD6[BC$^H1G4KQ8;B.,$%@"/T>^'O[-?PM\!^*O'7CF/0]
M%U_QCX^U_5M:O_$^JZ)I,FN6MGJMI;V-WH5KJ:P-=MI7E6Y5XFE_>>:Z2AE"
M@>OKX.\()8Z#8+X=T-=/\)7$5UX;M!I]H+7P_<VL,MO#/I40C\O3YH()YHDD
MMQ&T<<LB@A6((2XM]>_YI]?3;T6NY^</[=_[3GQ<^$7B1/#_ ,(-<TO3]0\+
M_#FY^)_B*SU;1;"YLKG3H-7ETRV6]U34=5L9%M)GAGC:QTBSU&^=U$DD<<>Q
MCY9)^UW^T5;WU_\ %9/$7A/5/A]IGC;3_"$'PKLO# .IZRE_\/\ 5_$KS0^)
MUNS,EW_:^G00V:+9.S6\DD>"Q%?JKXQ^%7PN^(-[I>K>._ 7@[Q=?:.LD>D7
M_B30=+U>>RCN.7BM9KZWF*12D[O*!,;,=P7<<UE:YX>^#?@+P_/K6MZ#X*\/
M>'M$U33=5GNY],TVVLK#6&ECTK2[YL0A([X27R65M,0)5%QY:D(Q% -.[?-9
M:/[NZ_/7Y=O@G]EKQ_X^\<_M-P:OXU^+?ASXA/XG_9IT/QBOASPM91Z5:_#^
MZU7QKJGF^&=4LK>_O4GU+2P?L$]U=I:WS30.)($7 K]3J\Z\(?"SX6>"=3U/
MQ)X'\!^#O#&K^) 9=6UGP_H.F:7?:NMQ,]ZS7EW9V\4UTLMQ*]TPD=E:61Y2
M"[%CZ%YD?]]/O^7]Y?\ 6?W.OW^#\OWN.E TFEK_ %W_ !NQ]%%% PHHHH *
M*** "BBB@ HHHH *^=-6\):[\,_B#JGQ(\&Z?<:UX9\8>5_PL'PI9 &^@O[<
M;8/%6BQNP2:98BR:G9@QF2)%DC);=CZ+HKJPN*GA95+1C4I5Z;HXBA4O[.M2
M;4N5\K4HRA.,:E.<6I4ZD8R3T:?G9CEM+,84'*<Z&)P=>.*P.+I<OML+B(QE
M3YX*2<)PJ4JE2A7I33A6H5*E.25U*/*:;XX\*:K"LUMK=C$2%+07TRZ?<QL1
MS')!>&&3>ARK[0RA@<,1@GF/&7QK^%G@*R>]\3>-=$M556*6MI=#5-0G=02L
M,%CIHNKEY9#A(U,:J6(RRC)'7ZQX/\*^('$FN>'M'U61?NRWVGVUQ*O^[*\9
MD7\&%8VF_"[X<:/>_P!HZ9X&\*V>H!@POH=$T\788=&%PT#3 CU#@UM2>5IJ
M5:./<4[NC2EAXW7\JQ,HRY?\7U66GV;G-77$+BZ>%GDT9M66*KPQLU%_SO T
MY0YNK]G]?@K_ &['R5>W?Q,_:LU&"PM-%UOX;? NVNHY[N^UJ%K#Q%X\2&0.
MBI8[O-M--)4%(92"Y*2RLP7RZ^V/#^@:3X7T>PT'1+2*QTS3;=+>VMXE  5
M 7<CEY)#EG<\LQ/0  ;(      & !P !T '8"BJQV8O%PI8>C0A@\#A[NAA*
M4I37/))3KUZLO?Q&(J67/5FDDK0IPIP2B8Y/D%/+:^)S'%XJKFF<XV,88O,\
M1"%.2HP=Z>#P>'I_N\%@:4FY0P]-RE*;=6O5K56ZC****\T^@"BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M .+H^VR_W8_R;_XNBB@ ^VR_W8_R;_XNC[;+_=C_ ";_ .+HHH /MLO]V/\
M)O\ XNC[;+_=C_)O_BZ** #[;+_=C_)O_BZ/MLO]V/\ )O\ XNBB@ ^VR_W8
M_P F_P#BZ/MLO]V/\F_^+HHH /MLO]V/\F_^+H^VR_W8_P F_P#BZ** #[;+
M_=C_ ";_ .+H^VR_W8_R;_XNBB@ ^VR_W8_R;_XNC[;+_=C_ ";_ .+HHH /
MMLO]V/\ )O\ XNC[;+_=C_)O_BZ** #[;+_=C_)O_BZ/MLO]V/\ )O\ XNBB
M@ ^VR_W8_P F_P#BZ/MLO]V/\F_^+HHH /MLO]V/\F_^+H^VR_W8_P F_P#B
MZ** #[;+_=C_ ";_ .+H^VR_W8_R;_XNBB@ ^VR_W8_R;_XNC[;+_=C_ ";_
M .+HHH /MLO]V/\ )O\ XNC[;+_=C_)O_BZ** #[;+_=C_)O_BZ/MLO]V/\
M)O\ XNBB@ ^VR_W8_P F_P#BZ/MLO]V/\F_^+HHH /MLO]V/\F_^+H^VR_W8
M_P F_P#BZ** #[;+_=C_ ";_ .+H^VR_W8_R;_XNBB@ ^VR_W8_R;_XNC[;+
M_=C_ ";_ .+HHH /MLO]V/\ )O\ XNC[;+_=C_)O_BZ** #[;+_=C_)O_BZ/
MMLO]V/\ )O\ XNBB@ ^VR_W8_P F_P#BZ/MLO]V/\F_^+HHH /MLO]V/\F_^
M+H^VR_W8_P F_P#BZ** #[;+_=C_ ";_ .+H^VR_W8_R;_XNBB@ ^VR_W8_R
M;_XNC[;+_=C_ ";_ .+HHH /MLO]V/\ )O\ XNC[;+_=C_)O_BZ** #[;+_=
MC_)O_BZ/MLO]V/\ )O\ XNBB@ ^VR_W8_P F_P#BZ/MLO]V/\F_^+HHH /ML
MO]V/\F_^+H^VR_W8_P F_P#BZ** #[;+_=C_ ";_ .+H^VR_W8_R;_XNBB@
M^VR_W8_R;_XNC[;+_=C_ ";_ .+HHH /MLO]V/\ )O\ XNC[;+_=C_)O_BZ*
J* #[;+_=C_)O_BZ/MLO]V/\ )O\ XNBB@ ^VR_W8_P F_P#BZ*** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>img149481191_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_4.jpg
M_]C_X  02D9)1@ ! @$ D "0  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #U J # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK]/>HKS28Y; 6B )%'&0%'..<MDGEL\Y)K<J&X=$AD+R+&/+8EV8*%&.I)Z
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M2I4E<8)%6W\,^&Y(5MY/#^AR0)+<SI ^DV#0I/>\WDRQM;E%ENSS<R!0\_\
MRU+ULJL5]B]Y.3O9ZRM>UUM=)KK=?='*_P":UDEIIMWUUZGX@WNO_M ^"YO'
MNJ)^T/\ %KQ#)\.-"_9D\<Z1I>J7)DL-=U[XK:QI]EXPTO6/DS=^&I;:[EBL
MM"&(=*D*7 D)3%:47Q^^,]A=V'C+PG\4O%WC3X^>(O$_Q/T?QQ^S;?6]Q/X9
M\%^&_#VHW]MHM_I_AHQ*WAZ32M'M['68=8DDV>)'O&@CW$$']KY/#OA^43B7
M0]'D%S'9Q7(DTRR<7$6G,KZ?'.&@(ECL756LTDW+:LJM $(!J&V\*^&+/6[W
MQ-:>'-!M?$FI0I;ZCX@MM'T^#6[^WC $<%[JL5NM_=0Q@ )%/<2(@ "J,"AU
M4]X)[=DMDFG:.UU>Z:E?J@Y'_,_QT]->VA^ WAKQ==2?%FSUWPQ\</&?Q7UK
M7_ _PIC\5ZUK;W%Y>>$]8\1^.]'BU_0=.EDA5-+2)F?R=(*F;0C JOC<!3M
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M1M5L+*[U:UN;^2:./6(;=[>T=I(()) E?LG\,_@]\,_AG\/=+^'OA_0]"GT
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MWQQK/C7P#\1SJ'Q.UOXNZ5X;^+?BKPUX5\;:^_FZCJ'AO34LUT^.2X*K]L6
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MI<[I$@D18 6Y9,)T KXI\(EOB=XJ^'/AO5=0N;'6?B/K\]SXG\2VN)=8N7U
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M2U;X[?#OPCIWBK1M+^!'A/Q)JOP4\0&ZE\OQ9?\ Q3N=-U2&PTB2:58[^_\
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M!QL?C_K7PO\ $FG7/QA:^O\ X=VMSH.DZ&NO*KW3202W[H4>%A;DJR';'<[
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MQ1;QM'X ^)-WXCT>XM]9G\ 6<4^OQWOAF&!=5T@?:C/964ES,RW)@,Z@1R*
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MA/7[[Q/X>LX 2;=E_M2*VW72Y E54"+G"NPYK[&T32=+T71+"PT6QATZP%I
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M-) 9)HU#-IR5%R_O-[;-NW,W>_?7N[-/Y$\T=N6_;O96]7IU_P""?H1XH_9
M^ 'Q1L? =Q=VNK7.F>"=!M_#6B2>'O%-W:V6K>';#5(-5M=(UQ[)VCURPM-6
MLX;R**=L)<Q9)(!6O&OA?^Q?=_##]HN[^//B3Q_80^#?"4/BX^!_"5B)-,\/
M:1#XRM(;+4[J[T^X9-.T:>"")&N+JTGF_M*Z>2YN!"9& \L\->)?VF]&7X3>
M"[&+Q8;/X^V.G0OKD7A^UL[/X.ZGX)U@WNN_VC%;V\<&FV_CC0;>Z16EC(^U
MS1"(*S@UR/P \4_M,>+?CI\1='^.?BC4'\$OIWQ7M/'WP^UWP5J%IHNDZ#IS
M7UO\/K^Q\1R.NEVR7&GI:W,LJ)G43,53$JD@2FHR2J*W*]-VTW9I*SLVTX[K
MMHFF.\7RZ=5T2U6WZ-?+72Q^M/CO3/%WB#PEJ.G_  ^\7VG@GQ->QP'2O%=Q
MH-IXJMM.!ECDDF&C7=Q;6E_YUN'CC\R=44R+*-VT _,R_LN?$G7I#)\0?VL?
MC3K"N3YEKX&FL?AG:.K##QF+1Y-1)0\[?F!4$=<9KOOV1[W7]1_9R^%5WXD>
MYEU*3PW&%GOBYO;BQCNKF/3I[OS/G$TEDD)(;DIL;O7T=6#5FUV;7W,M:V?>
MSW?D_0^.[/\ 86^ #RBX\6Z;XL^)EQSNG^)/C/6_%$DF><2^;/;(XS_"4VGN
M#7L7A3]GOX'^!BK>$_A5X'T1E4*K6N@6+LH'3#7$4S C PP.1C@U[%12"R[+
M[BI;6%C9#;9V5I:+C&VVMH8!CIC$2(,8XQ7G7Q(^%FD?$VX\&G7+V\CT_P (
M^)(/$;:5"S?8M;FM@ODV>IHLD>^V1E\Q1\VUSG::]0HJ*E.%6#A4BIP;3<7L
M^62DKKJDTG;9VL[K0ZL)C,3@,13Q>#K3P^)I*HJ=:G93A[2G.E-Q;3Y9.G4G
M%27O1OS1:DDTBJ%554 *H"J!T  P /8 8KY9_:_TZ:Z^$DFH6<8-]I&OZ//'
M.<C[/:W%Q]GOF9@#MC>)E$A.%( #'I7U/6#XH\.Z9XN\/:QX:UB!;C3=:T^Y
MT^[B;O%<1E-RGJKQL1(C#E64$=*]?),?'*\WRW,)Q<J>#QF'K5(*UY4H5(^U
MBD[)\U/F7*VE*_*VD[GQ_&F13XGX3XBX?IU%2K9OE&.P6'JR;2I8FK0FL-5<
MDI.'L\0J<^>,92@X\\4Y)(_)#2_$?A3PC#IFGL-4M-9U>YN=!L8-(E$0OUMH
M61H]0#GRY&E>3;%_')N  "DM7T'\,#XOTS28-",FDZC?Z%JT5Q?6NHO+IU\]
MO?DR6;O,B/YHBC9;$,^T;X"BD@#/S*-,N_A]\4].\&^.;$:M::'JMQ-IU[%;
M>=J,UUIBR0:?*R=66[BE6>*5,&<P@DDBO0OC-%H7CBW\+:UK&I^(O"6E:+K]
M@VOP0KJ.BZGXIL&E_P!'MI)[.6*;RK*XW31Q$LTN\J" :_;,ZPN.JSJ4Z$:.
M9T,UC0QV6UW&4H2M2]G1HNK%3Q#5:I+$\W(E*DJN'O!JFVOX]X)S3ARA2P-?
M&U<;PIC.%)X[).*L-"4?K"YL5'%8O&4L#.IA\O3P>$AE*IPKU>3%U,-F+5>+
MQ--'V7=>*4O+2]T37?">KK%=PM;WDMND6HZ= LF0)P]L\MSYENVV: +$)5D5
M3M'-<[X3^(T6HO=> [;6[.Y\9Z/*;.?Q!J3_ &6QTWP^L8,&IK%>^5G5%MF2
MU6U8&1[F*2:4(A4EWAV\\2>(-.L(M&*Z%X3GBACANHI?(\1ZM9[ BMNG,@LA
M*O$DD^^Y;.])5)S67X3M_AWXK3X@:"VGH)Y=6,5TWV4W%U96\$26JM+J[$W#
MSS74,C2-YA8JV02,8^ G3P>&H8JG7H)U8RINC2H5U5C2Q;DH+VU.MS3;]E&K
M*KA*=64:BH_[1*])0?[I0JYSF>/RROE^-G]4J4L0L9C,9@98:KB,GC"-23PE
M;!^SIQC#%5<'3PV;8G#4YTJF,;R]2CBY5H_1&@PZ)8^'H[;P]<0ZC:S3F)]2
M29+R34-1E<"]N[JZ0N)KMSO+DME<   *!6+KNGSW7BZ;3K*[:RNM4\$FRLKI
M>6AN;&\FF24$<@C> & ) )('3'GL6F^!/!]O:1:/K=[X+6S#,-/TFY:_>[U
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M'TGP==:?XRTC2[*V@TZ :7XE%O;0H]YHTOW-0FDB4>9+ILY-PSDLT@EVY*@
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MTXS7HVG7@*ABRXZ=>_3 Z8/7GOT[T >F6DRG'<XQU_3ISDX.>:\>_:F\:O\
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M6WL;&WAM+.TACM[6VMXUB@MX(4"1111H J1HBA550  *L444 %%%% !1110
M4444 ?$'[57PG^WWVG_%.PL[NY&E6$EAXC6P5I+NR@A99]-\0P0H#)(VF3QK
M%<B(,YLY9&VD*:^:?"7Q#DN-#O\ Q)XMM;'Q%=>'HQ>W5W'<>9%!I43;1=Z?
MI<ZK"C3Q;3,=QD9V(*HPP/US=$D1XY$62.1622-U#HZ."K(ZL"K*RDAE((()
M!!!K\P/VC?V<[OPA+KWBWP5:3)X0U9)IM8BTY))I_#PN7#:A;2:>K%;C0+T_
M.\D:"73Y&9MVS97ZWP;G^&S+!0X:S*I3H8RG%4LEQU=S]DXN;?U&K*G.G6IJ
M;ERI4JC5>G"G25*56E2C6_E/Q;X&Q_#6>U/$?A["XK'9+BJSQ'&N29>J"Q:<
M:=*/]N82GBJ.)P-:=&%&4^;%4(K 8JK7Q<\33PF*Q53";MG\6] \#Z:FJI'J
M]AX/\264^H:9;:E:R->^']0N[=VMGM88A+(^DW<Q5A$ QMG*A4V'([+P#XO\
M-R64EWX0NK+29-4M()/$/B2\M;FZGNKC<9IVM=*6%U$JS,Z&6\:!L*"%.!7A
MFB>*- TWPC-IFNZ/#91'1432=?-S)J^F74"Q$V5Q;RW3RRV#%U!\DD%64HV.
M:]8M-9\!W^D:89-7T?2=:>VLH;S4=*O8K5EB6VB>6[EAAQ:S,4(+>=$Q\PL#
MG!KT<PRC#JC!8G+L74QBQ$55Q=)PQ.%J5*5+ECB8T.2JY2C&K5A.4ZU6;O%X
MBA*K.9XF1<6XZ>/Q']E<297A\FGE\Y8;)<4J^79K0PF*QM.L\LJX]5\'&$:D
M\)@\12IT,#A:"E&2P&/I8.C0MZGI<_@:UF;7I-6N;K6+_P"T6DNOWEO?3ZG:
MP2J8[6XMF:U\JW6*0C;"@.T$ /@9JM=^)9?#O@8+KOB.WUV[\,:M!K=CJ<-M
MJ*WL]M9W33HMR9+8*]PZ2%&4-E@@"9Z5R]C\2[22SG&A:K8_$32XO,M&72M.
M(U57A!5HUNHE2PFDC8;D6.(,S #.>D-O\2K?Q3K%KI>N:9KGA:QT&*"^ETS5
MM#E-YJUYTM+J5!^Z^Q6PPR)(KI--YGF*1@5X']DUJN)IXVI0Q5:EA4Y2;Q,>
M;ZO&4'&E##2PD,1%2=J*4:,:<5--OD4VOO7Q9AL'EF)R##XS*L%B,UG3C"+R
MVI&"S+EJ1GBJN9T\WK8"?)&=3%U74Q=3$5947",77=)/T3Q9\:?AVNDMK1MY
MO%]E?6MM$FGP:5>-+)=2RQ1QHTDMO&T3(96W'>I4K@@<9B6[U*2V#:%8>*OL
M-S N/".K6T5]I$D4\8)MWGNY8IK-!N"QB)957 92:P=0?P:U_9W^AZY8Z7JM
MU=^3>1:FL@TJ^W@NJWNGA1%;'S0F);,0.&PQ)ZUROP__ &E_!_CFW\4?8=5F
MTFX\(:YJ'AF^M-;&VSU'4]+0^:NBS$K+)"YP;9)&8M$RG=S7&L)&A*E#!8?%
M35:'[O!XZ4I3YJ+DZDH4(8:"J*,.2]>DE.$4IR>'<K'LK,*V8X7&XC-L5EU#
M^S:T'C,^R2%.&&C1S!488*EB,;7S"O+"RJXB.(4,#BFZ6(JSJ4:<<PC3YDW0
M_%_C.#7Y]-U[PH=*M/#D;Z)I6J7]W+>:=:::\R7+6]U)IZ75PUU!/%&H9XE0
MQ9#LHXKL==\/0>*];\.^)=<\727W]C0ZF]M#X:\FPM(UEMOF@EDMWEEE!!VJ
M)8UD)S\HYKF/#/CZRTK3[@ZE?V$>L^(;VXU>XM+<G4[B3[?)F.U,,#*$=0 '
MAESC//->9_%=+W5-+WZ+/_PAFK3O*=*U3[=;VDMU>J%:*U30K-HF#7#9#/,'
M9%4\Y.3[E; 2Q.*<?J=+!.,)4X3IP52G7J0AS3G0>*E.K"4\0G4=3"U:CN^;
MV5KH^)R[/:>599"NLZQ><*=:%;$4L15G0KY=A,35C2C1QZRJ%'#UZ=#+IJ@\
M/F.$PT7",J*Q"NI&WH.B6/@G1K?Q'I%U9Z6)]9U6:]L=<8-:F.(R$K%=.7FM
MKJ7@NMNCL[E3\O->5WGC2[\>W6L>,-89M#\(::?[*LM*9W_M*_L8F)O9<]4M
M-2E(@62/=)=0A(R%*FN4\1V^IW/@[4]!\:^)EF\4&V:*RG@.+*6?55!:[L(8
MB L5JJE[B9@]PT@PC*"0?HCX$_ #6_%$G@KQ'XTMDL/"'@^RMK?2M+ECF2[\
M:3VBAK?5-3@F8F/2TN=US!',IEN3(#NV#Y?IZ]7!Y33Q&:YK6A5J3A55+,6G
M[24+QK0P> A5BJN*Q&)A*G2IXNI#FPL/:RDH1A4</S'"X?-.**N6<,<,8:IA
MZ=&OAOK'#4;.A"HZ?U2MG>?8C"U*F%RO+LMK4\3BJV48>MR9G6>&C2E5G6PL
M*WOG[-OPWGT#1KOQWK]@EEXC\81PM::?Y8C_ + \-1 ?V7I,<>/W4C1;9[K^
M)W*EB3D#W#QWX'\._$;PMJWA#Q18QWVD:M;O#*C >;!)@^3=VTF-T-S;N1)#
M*I!5AC.TD&O\1?'WAKX4^ _%?Q%\77$UEX6\%:%?^(-:GM+:2[N(=-TR!IY_
MLUI"/,GEV)MBA3&YBJY49(3X;?$'PW\5O 7A+XD>$+F2[\,>--#L/$.B7$T?
MDSR:?J,*SVYGAW,89PC!9H6):*0,C<J:_!\US>6;9IB*^(J06*K15:.&C*_L
M<+!JC1A"+][V-*,8THR>LG%RDW-R;_N/AC@R7"O"6 HX#!XJ638/$/+JN;SH
M.-'&9U6IRQ^,E7K1BJ/U_%N=7&U*,6N2$TH0C2C!+\0?B3\+_$WP(\;3^&-=
M5[C2;B1YO#6O+&PMM6T[?E%WX")?6RD1W$!(.?F4%<XZ;PQK0PN6!5P#^0)&
M>>#R#@=3Q7[#?%/X6^%_BWX5O/"_B>T5TD5I-/U&-5%]I-\H/DWEG*1N1U;
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M)PE:HH.$YQCSJ\M%("&&001Z@@C\Q2US'HA1110 4444 %%%>"_&3]HWX?\
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M73K.BRV<RS2;E#VLTI"X<+S7Z%?M0?LVQ_M)Z;\,=(N_&&L>%],\ ?$_P_\
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M2*KK!-=E,@9!(!KZQT#PSX?\+62Z?X=T?3]'LU"@Q6%M%!YNP85YY$7S+B0
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MPK!XP\4WD][%IFN,\4@MO#AG=8M/M+=C(B7:PB6XPK,%( K\#KJVUKPUXO\
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MWL\!G526*I1I2483=+!9G3KTX5)+F_VNG)RU27\G^,W%N4\1?2DXVXIR[ /
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M# _ZXJ3AAMXHV\]O%JKOJ2.J6K;EO;>21);[4XIG<^7 AWR;8MGF&4LJI@#
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MO\>[&-/BGXBLI+/P'X(>07>F?!;P)=,);;0+ ,#%)XMU2+RIO%>M1J)))O\
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M=!5<9[+!X:>%X?S>I45&E',\+",<90]M#.(XR$'7I[WAJV72/B?X1\'FZO\
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M110 5@^*?#FG>+_#FM^&-7C,NFZ[IMUIEX@^]Y-U$T;,O^TA(=?]I16]2$@
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MO5:_>V'(KWOVV5MM]N_E:Q^&'[('PO\ %?@2?XB^(_'B>.M%T[2O@+XT\/\
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MCMH[Q=MCY7\'?L:? CP=?P:G'X;N?$%];.LD$GB:_DU>&*5#N22.VE5(@Z,
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MUMXUB@@B!)(2.-55023@#)-7J**!A1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
+!1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img149481191_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_5.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" UO" (# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:U.HH
MB:DJ7;2;: (Z*?M]J90 4Y:;2CO420[#J:W>DHI6$-HI=M.VU2 5:6A13MHJ
M@&T444$!112;J"K"T44R@84C4M%9L 6I5J)14JT(!:***8!12-2<T .HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)8ZBBD)Q0(6BDW4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5')4E1-0)C-IHIU%4B1M.
MW?6FT4FAH=3EIBTM(H?N]Z7=46XTH)HL K?UIC4ZHVH 7=2[OI4-*&-4D YL
M5!)4K=:KW#8!IF397GN/+6L74-8$(/S5)J5UY:MS7G?BC7#"K#=6$I6.:I.R
M-J^\5K&Q^>LMO&"[C\_ZUY'KWC QLPW_ *US?_";-O/[S]:\ZI4.!UK,^@4\
M6*Q^_P#K5B/Q0K?Q5X':^,BQ'S_K6K;^+"<?/^M<$ZUA?6#VP>(@W\5+_;P;
M^*O)K?Q.6Q\_ZUI0Z]N_BKDEBK&L:W,>D#7/]JI%UW_:KSC^W#_>_6GKKG^U
M4?7/,W50]'&N?[52+K6?XJ\X77/]JIH]<_VOUJ?KA?.>B?VQ_M4?VO[_ *UP
M2ZT?[U/&L?[5'UP/:'=?VP/6E_M<?WJX;^USZT]=7/\ >JEC"E4.Y_M;_:I#
MJH_O5Q?]L'^]2_VQ_M4_K?F/G.R_M3_:I?[6]ZXO^U_>D_M;_:J/K?F/F.V_
MM;_:I?[7]_UKB/[6_P!JE_MC_;I?6BN<[C^U_P#:_6D&K_[5<1_;'^W2KK'^
MU1];#F.W_M;_ &J/[6_VJXG^V/\ ;H_MC_;H^M!S':?VM_M4O]L?[5<3_;'^
MU1_;'^U3^M>8^8[;^V/]JD_MC_:KB&UC_:IG]L_[5'UOS)<CNCJX_O?K3&U<
M?WJX;^VO>D;6C_>J?KGF+G.Z_MC_ &J/[:_VJX)M:Y^]36UO_:I?7"N8[QM:
M"_Q5"VN#^]7"/K9_O?K4+:X?[WZT?6S&52QW4FM\_>IK:V/[WZUP$FN?[55Y
M=>//S?K5?6_,YG6L>B_\) !_%44GB15_CKS*3Q&54_-6?<>*2I/SUTPQ1A+$
MV/5)/%(7^/\ 6HU\7+G[_P"M>,77BXC/S_K5!?&3;OO_ *UTPQ1E]8N?0MGX
MJ5F'SUTVFZV)<?-7S?I'BPR2#Y_UKTSPSKAFV?-V]:[(U[G53JZGM5G>"11S
M6@LF5KD]'O/,0<]A701R;@*[H5+GK0E=%Y6IWWJ@C:IEK3F-R15J1>E,6I*N
M.Q+"FM3J*H0RGT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH:6Q>CJQ'5:-JL1FNF)UHF6I*C6I*ZHB844458@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M]VO;IGVU'X23L*-M'I2UU=#<D44ZD6EJ0"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*S,'4&ZUDK_K!6GJ'>LV/_6"O8HGGK<ZOPT#YR_6O?\ X?+_ *KZ"O O#/\
MKEKZ!^'Z_P"J_"O;HGU&7[H]\\,?ZE/I751GY?PKE?#?^I'X5U*U[=(^WH_"
M3KTHI%I:Z39DJTM(M+0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:U.IK4 )11100%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS)4-]/UHTV3,O6O7I1.>+U/5_!2_OD_"OHSP&OR1_05\Y>"&^>/ZU]'^ _\
M5Q_6O=HGU.7[H]HT#_4K]*W:P]#_ -6OTK<KU(;'VT/A$:F-4E1M6R*%6I5Z
M5$M2KTI,!:***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ $HHHH("BBB@
M:$W4UFI6I/XA04%%%% V1M0M#4+5F74>M/5J8M/6H+0V2LK4F^0UJR5D:E]T
MUA(F6QYWXI;]W)7S_P#$#_EI^->_^*F^1Z^?OB W^L_&O+K'R^.V/!?$W^N;
MZFN>@;YC6]XE;]XWUKGH?O'ZUY4T?%U/B-RQ?I716+=*YG3\[A71V/:O-K%P
M.ALVZ5K0]JR;%>E:\/W17A5CTZ1)NIZM3-M'0UY[.M,EW4QFIK25$TE"B:HE
MW4Y9*J^93EDK3E)+T;5*&JK&U65[5DT:)D\9JTOW:J1U:4TD;Q&R+561:MLW
M6JLO>A[%E9UIA&*D>F;JB-R!NWZT]5I-U/7[U$B5N2QK5J-:K1FK$;4D:DZT
M,V*0G@5'*U6@3(YI.M5)'J21^M5)'K1$R8CM4+,*:\E-W5HD(D'-2**8O:IE
MJDCED.44ZD6EK2QBQK=ZI7#;15QZHW74UU0.>H9%])P:Y;5)NM=#J#=:Y35&
M/->I21YM0P;R;YC4FDR?O!56Z;YC4ND_ZY?K7K4S**U/8/ [?O(^?2OI+P W
MR1_05\U^!5_>1_A7TG\/Q\L?X5ZU$^HP&Z/;=!_U:?2MM:P] _U:?2MS^&O6
MAL?:4_A%IE._AIM;(IBJM2+TIBT]>E)@A:***0PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-:G4UJ
M$HHHH("BBB@:$VTUEI]-;K04)1110-C:;MIU%68+<0+[8IZKQ2+3U%9LW0R1
M?EK%U1?W9K;F^[6'JS?NS7//8SJ;'F?BWY5DKY\^(#?-)]:^@/&#_*]?/7Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M72CT:9UMNWR"K"FJEJ?E%6EZ5JCL2T)5-25"O:I5Z4Q"T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1(R[KH:JP_ZS\:LW3=:IPM^\K:)U1.W\+M^^6OH+X=R?-%7SMX8?]\G->_\
MP]D_U==T#MIGU-X#D^6+\*]FT)_E6O#? 4GRQ?05[3H$GRI]*ZHGITSM;7[H
MJ['TK/LV^5:OQFM3H)EJ2HUJ2@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^['79$[H'>:?_JUK7C/RBL?3ONBMF'[M:G2B5:6D6EH&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_?+7T'\.E^:/\*\ \+?ZY:^@_AVOS1?A773.J!]*^!_]6GT%>Q:!]Q:\?\
M _\ JX_PKV#0?NI77$[(G=:;]P5M0_=K#TW[HK:@^[6IT$ZTM(M+0 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MULP?=K9'03K2TBTM, HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ_=&O'_&W^KD^E<DT<LD?-?CZ/YY/J:\1UQ?WA_&O</'WWI?QKQ'7O\ 6/\
M6N9HYFC#7[QI^33!][-.K"5C)V()C6;<]ZTINE9MSWK,2,NX/6H;=OWG'K4E
MU4%N?GK:)O$[OPJ?WL=?0_PY^_%7SOX7_P!8GX5]$_#G_EE75$Z(GTQX%_U<
M?X5['H/\'TKQ_P !K^[C^E>QZ#]U*Z(G7$[33ONBMF'[M8^G_<%;$/W:W1J2
MK2TBTM, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ?05[%H?W$^E=<3KB=MI_P!P5L0_=K'T_P"X*V(?NUOT-25:6D6EJ0"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ=3&:@
MHI-U.6@!U,I],;^M $,C5EWC?*:T)FX-9%\W!H PM0DZU@74GS&M;4GY-8,S
M\]:"!H;FIE7-5XV^:KD*T[@&RF[:L;:C9:H!JK4\:TU5]JF5>G% $L:U,HJ-
M%J5>U F.VTE.I&JA$34QJE:H6I,!C=Z93FIM38H****8!1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MBGT4 (O:GTBTM #::U*W>HVIH!&[U&U*QJ-C1N UJ8U*QJ)C18!&IC4ZFM2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'7J^BYVK73!G3 Z^R^Z/I6K']P5DV/W16K#]VMD;DJTM(M+5 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %-:G44 ,IDE2M5:9OEH J7#8K$O).M:5U)UK%O)
M.M &=</S5/=\QJ69LL?K4*_UJ )8QFK*K4<*^U6E6M@(MM)4C+[4JK00+&M6
M8X^E,CCZ5<CCH (XZLQTQ4IZT 6$J2H5;FI%:J =3&%/I&^]2N20,O%1,E62
M.*8RTP*ICYI?+JQY=.\NDQHJ^73&CJXT=1LG6D,J-'43+Q5QDJ)HZ *VWZ4[
M':I&CYHVT 0,M,VU,PIFT4 1.O%5I!5R3[M5)J (&ZU&]2-UJ-N] $3=Z;3F
M[TV@!K4QJ5J;2L 4444P'T44C&A (S4E,8TZ/[PJBRU#TJ9NE,AZ5)-]VLY&
M$C!UQOW+5XMX]_U<GXU[1KW^I>O%/'S?NY/QKCD<LCYG^(?^LE^IKP_7?]8W
MUKV[X@-^\DY[FO$=<_USUS2.>1C1]ZLQ_P!*KQU.O2N9F9'/]VLBZZFM6XK)
MNJ2 SYOO5/I_^L_&H)OO5-I[#S/QKH1O$](\'_\ 'Q'7TC\-_P#EE^%?-OA!
MOWR5](_#?[T7X5M$W1].^!_]7%]*]9T7[JUY/X'_ -7%]*]:T?M^%=$4;11U
MEC]T5JQ]JS+'[JUIQ_TK9'4B5:6D6EJA!1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?;Y8UJBD;=FVX"M2%>!658J>*UXQA:HTY295IU-6G5!(4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZD6HZD6F0+1110 4444 %%%% !1110 4H:DHH*0NZDHHH-;A1114&8444JT
M)2[C3J;MH :TAH69AWIK**;5@3+<-3_.:JZU*M $OG&G[C40%+0!,.:GC4<5
M77H*LQT :%NO2M6VX(K(MNU:]I5 :4/6K<9JI#UJTE9 3+2TBTM !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 FT4;12T4 %%%% !2-2U'(U %&\;@US6I-UK?O&X-<YJ#?>
MJD)G/7G>LN2M&\;YC6=)WIF8P+\U/J-<T]:=AH:S5$S5*RU"RTAC?,I-QI-I
MI"IIV&QP:I%8U#3MU*PD2[JC9J :1OO4"8A:DIVVEV^U (;DTZF[33J!A111
M0 JT]:CJ6J <M.6FK3EJ0)%I],6GT %2+4=2+0 ]:6D6EI=2Q]2+4=2+3(%H
MHHH **** "BBB@ HHHH ****!H****BY04444 %%%%!84O-&VDJR IC#K3Z*
M=@&JM3+4=2+2 ?\ PTVG?PT;:=@'I]ZK4/\ 6JJU8C-2] -*V[5JVW:LBW)K
M5M3TI7 U8>U6HZJPMTJTAI /6G4U:=0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@!K4<T-24 /HHHH **** "BBB@ JM-T-6:KW'2@#'O%
MX-8-]'G-=%=+P:Q;I.M ',7D/6LF:'@UTMU%UK'N(NM &%-'521>:U+A*SYN
M] %*1:BVU/(*9M]J (E2GK'4BI[5(%XH @9*@D6K;+52;J: *DE,5:?)2HM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M$SKH+C<1S5^%@PKG+.XSCFMRUDW8JB32C7@5)LIMOVJ?;4@1;:FCI&7;0M-
M6%-(U-5J>M,"/;R:D5:7;[4Y5H ;12M25(!29%+3* 'T4BTM !1110 4UNM.
MHH 913Z* "BBB@ HHHH **** "G+3:<M 6!J;2M24 2KVJ=:@7M4ZT +3EIM
M.6@#0MNU;-GVK&MNU;-GVIH#8M^U6EZ55M^U6EZ5#&@6EI%I:104444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 57G[58JM-UH I3?=K-NZTI1P:SKA?E- T8EYW
MK%O.];EXO6L.\[T",&\[UDS5JWW>LB;^M $#=Z%[4-TIRK0 M(S4-4;-0 ,U
M,9J8QIM #ZC:I*:PH @;O0M.9:2@"1%I_EYJ-) I%3K*.* *\EOGM5&:U]JV
MLAJ@DC#9IH#GIHMM1QOM:M*ZAX-9DB[6JB6;%C<=*Z.QGZ<UQMI)M[UO6-UT
MYJ@1V%K)G%7H^:Q;";=BMFW.Y: 8YEJ)OEJRR_+5>3BI$*C58C:J"M\U6X6H
M L@4-2H:1J &-24K4E !3*?3* '+2TBTM !1110 4444 %%%% !1110 4444
M %%%% !3EIM.6@!&I*5J2@"5>U3K4"]JG6@!:<M-IRT :%MVK9L^U8UMVK9L
M^U- ;%OVJTO2JMOVJTO2H8T"TM(M+2*"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "J\PJQ4,E %&9:S;E>M:LE9ESWH Q+SO6%>=ZWK[O7/WU &'>=ZRI5K7N
MNM9LJT 5-M&VI&[TV@"-JB?K4U1M0!"RTFVIJ90 FVFL*=NI&[T 1-WJM++M
MJ>;A0?>LB^N-N: )Y+P+WH74 .]<O?:MY>>:SO[>PWWJ /08]1#$<U86Z#=Z
MX"UUO<X^:NBT^]\W'- &O.NY:RKB/K6M&OF+52ZAXJD)F=&^UJT[&XVL.:R9
M%VM5BT8@U9)VNFW&['-=-9R;L5Q6ER?=KJ["3Y14@:S?=%5YNM3*WRU%+SF@
M"KSNJS":@9:EBXH O1T-4<;<4[=F@!**** "F[:=10 BTM%% !1110 4444
M%%%% !1110 4444 %%%% !3EIM.6@!&I*<1FFT 2KVJ=:@7M4ZT +3EIM2*M
M %ZV[5LV?:L:WXQ6S9]J: V+?M5I>E5;?M5I>E0QH%I:1:6D4%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M *Y:]>\*_=3Z4 >D:<W[D4^\^[46G_ZL5)=?<JD09$_WJ6V^]1-]ZGVZY:K
MW=-4\5T]E]T5SFFKTKI;+[HH OKU%29%,7[HI:D"4'(I&IJ]J?0!&OWC4J]J
M94BT +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3EIM.6
M@!&I*5J2I8$L=6%JO'5A:0#Z<O:FTY>U %^V[5MV?:L2V[5MV?:@#5B^Z*L?
MPU7B^Z*L?PT#0JTM(M+04%%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@,T )3EHVTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!3EIM.6@!&I*5J2I8$L=6%JO'5A:0#Z<O:FTY>U %^V[5MV?:L2V[5MV?:@#
M5B^Z*L?PU7B^Z*L?PT#0JTM(M+04%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[5OVW:L#3>U;]MVH LTUJ=36H$R2.IUJ".IUH!#J***!A1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 ]>U31U"O:IHZA@2444$T %
M68>HJNIJQ#TH TK?M6E!U%9MOVK2@ZBFRD:$/W:N)U_"J</W:N)U_"D,D6EI
M%I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'[M7$Z_A5.'[M7$Z_A2&2+2TBTM !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH&B]#]VKB=?PJG#]VKB=?PJ"B1:6D6EH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MNB@">FMWIU-;O0)DD=3K4$=3K0"'4444#"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "E6DI5H D6I5J):E6I8#Z<M-IRTT ]:L0]:KK5B
M'K3 T(.HK1M^U9T'45HV_:I8T7X?NU<3K^%4X?NU<3K^%(HD6EI%I: "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH :U,;K3VIC=: &M4$E3M4$E4@*-SWK'O.];%SWK
M'O.]#$C%NZR)^AK7NZR)^AJ&,S)JI2=ZNS52D[U($#5&U2-4;=ZI 1-4;=Z>
M]1M3 :U-I6IE $BTC4+VI9/NB@#'U/[IKSSQ-]UJ]#U/[IKSSQ-]QZ /+M>^
M\]8-O_K*W=<^\U8EM_K!]: .S\-_>6O7?#/W%KR+PW_K$KUWPS]Q:B^H'=6O
M^K%5[RK%K_JQ5:[K5"9G/]ZK-K]ZJS_>JS:_>IDG1:;T%;L/W1]*PM-Z"MV'
M[H^E $Y[4QN]//:F-WH$R2.IUJ".IUH!#J***!A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2K24JT 2+4JU$M2K4L!].6FTY:: >M6(>
MM5UJQ#UI@:$'45HV_:LZ#J*T;?M4L:+\/W:N)U_"J</W:N)U_"D42+2TBTM
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ.0T]FJ"1J *ERW!K$O&ZUJW+5DW'- &->?Q5S.J_P"K?Z5U%XO6N8UA?E-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "FM3J:U #&ZT]:8W6GK0
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MM [CUI:1:6@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2+2 >M+2+2T%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !2$9I:* (]M.6DIR]* %IK4ZFM0 T=Z>M,'>GK0 M%%% #6J
M%JF:H6H @DJA<-5^2L^XH HS-6?<<U>F[U1FZ4 95TO6LBX7K6W<+UK)NEP:
M ,F5:AJS,.34% ";:8RU)36I+02*\BU6D6KC=Z@D6F,HNM"K4S+Q2*M "*M5
M[I/EJ\JU7NE^6@#E-67Y6KS?Q-]YZ]+U9?E:O-O$R\M0!YOJ2_O#Q3M*C_>+
M2ZDO[PU+I2_O%H ]$\,+]VO4=#3]VOTKS3PO']RO4M#7Y%^E &RJ_*/I5.XX
MS5_;\HJC<]ZI"96J_:KR.*I1C)K1M%^84R3=T]>G%;4/W:R+%>E:\/W:EL![
M+3*D:FE:H!\?:I-M,C%2T )MIP7BDIR]* $VT;:=10 W;1MIU% #=M&VG44
M-VT;:=10 W;3J** "BBB@ HHHH **** "BBB@ HHIK4 .IZK4:]JG6@!1\M*
M.:*5: 'HM78%Z55CJW#]VG<#1M^*T+?I6=;]JT8.@I,5R['VS4M1QU)4%7'+
M2TBTM!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !36IU,DH CW5(E
M0[N:ECH DHHI-U "T44FZ@!:1J%Z4-0 G-1MWI],;O0!6F[UGW%:$W>L^XH
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M3@Z"@"['4H;Y:BCJ1:"QRTZD6EH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *CDJ2HY* (6J6.HFJ6.@"6F4^F4 /IE/
MHH 1:6BB@ J)N]2U$W>@"K-WK/N*T)N]9]Q0!GS=ZHS$5;FZ50F:@"G/T-8]
MUT-:=Q)UK*N9.M*P[F;<=:HR+5Z9LFJQ7/YTQ%;RZ%6K/ETC+BH KU%)4TG%
M5I&]ZL")J92M0M #JAN/NU-5>Z^[0!SFK_<:O,/%7\?XUZ;JWW6KS/Q5]YZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MBT%CUI:1:6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 -:F-UI[4QNM "5(HIJT]: $:H6J9JB:@"O,M9=VW6M6:LJ[7
M.: ,J9NM9ETW!K2G7K67==#0!@Z@W6L"[;+&MV^'6L.X7K5@9[+N_.@0BK*P
MY-3K;^U0!1,( Z54F4+6Q+;^U9EW'LS0!ES2;::MQ[U%=94FJ\<GS4 ;4$FX
M5>A^85E6;=*U8/NT 3$8JE??=JZQX%4;S[IH Y+6/NM7F'B889J]0UKA&KR[
MQ0?F>@@\^OO]=6QH*_O%K'O6_>FMGP__ *P4%GJGAI>$XKT/35_=BO/O#/W5
MKT33?]6OTH MR?=-4YZN2?=JG,1S5(3&P?>KH--[5S]OUKH--[4R3IK3[HJU
M56U^Z*M-]T4 -J:/[HJ&IDZ4 *],'>GR=J8.]2P)EJ5>E1+4J]*?0!:***8!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%2P%6EI%I:0#Z**
M*; <O:KUOVJBO:KUOVI :=OTK3@Z"LRWZ5IP=!0!=CJ1:CCJ1:"QZTM(M+0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD)Q1N
MH 6BBF[J '4444 %%%% #>:5>E)MI5Z4 +1110 UJ8U/:F-0 E2+4=2+0 -4
M#+4[5"S4 57Z53N&XJ[-T-4+AJ!=3/N&Z\UDWC<&M.:LRZ7@T#.=U XS7/7;
MX)KHM07K7-7O\5 %-KC%*MUCO5&5CS4#3'UH TY+OCK69=7&<\U&TQJO,2U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU*O2HU.VGK0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBEVU+ 2G444@';:=MI*?38"K5N'K55:MPKTI :5K6I!T%9MJM:=NO% %R.
MI%J..I%H+'K2TBTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MPH:EC^\*@"RG2AJ6/I2LM6!%4L=15+'0 ^BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBBI8!4BU'4BT@'KTIRTU>E.6J0#UJY;_UJFM7
M+?\ K3 T[?I6E;]JS;?I6E;]JH"W'4BU''4BUFRN@]:6D6EI#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!K5"W6
MIFJ%NM #EJ:H5J:@ J)JEJ)J $I-U+2'[PH >K4Y^E-6E;O0!0NNAK'NFZUK
MW1ZUC79^8T 9\S=>:HS-5J9NM4Y* *-SWK*N>]:EQWK+N>] &9-TJNU6)N]5
MVJN@#UIP.*93JR+&LW%1-4C4W;NK1$#.?:G+WIRQT\)2 @DK(U%OE-:\_"FL
M+5&^4T <AKC?*U>8>)G^9J]%UZ7Y6KR[Q+-\S4 <K-)^\/UKH_#DG[Q:Y":;
M]Z?K73>&7/F"@#V7PPVY4KO[)?W8KSSPNW[M*]%L#^Z_"@ G7VJA)]XUI3UG
M2+\QJD)DMKRU=%IO:N?M5YKH;'[HJ[&9OV_W15O^'-5+7[HJY_#291$U/C6D
M;K2K68%F/BE;[M)&U/JP(-M21TRI%H =1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1114L J1:CJ1:0#UZ4Y::O2G+5(!ZU<M_P"M4UJY
M;_UJP-.WZ5I6_:LVWZ5I6_:I MQU(M1Q]#4BU++'K2TBTM( HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :U0MUJ9
MJA;K0 Y:FJ%:FH *B:I:B:@!**;10!(M(U*M*PP* ,^[K%O.];MUUK!ON] &
M7-]ZJ<E6I/O&J<E %.>LRX^Z:T)VZUF7/>H H3=:@;O4\E158#:=2;:?MH*N
M,:E5<T'&ZG+02/5*-OTIZFFLU %&ZZ5SNK?=:NBNNIK!U&,L#0!P.O9VM7F'
MB-2S-7K>M6997XKSS7M-+9XH \T:$F;\:ZKPU"?,6H/['/F#BND\/:65=.*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !36IU-:@!C=:>M,;K3UH =36IU-:@!H[T]:8.]/
M6@!:*** &M435*U1-0!7N*QK[[IK9N*QK[O0!SEZO)K(N%ZUN7B\UES1YS4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MTK2M^U9L'05I6_:@"W'4BU''4BU+*Z#UI:1:6D,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:U.IK4 ,;K3UINVGK0 M
M-:G4UJ &CO3UJ->M/6@!U%%% #6J)JE:HFH KW%86H-UK=N*P-2[T 8<S?-5
M<OP:==-\QJHTE $VZHV:HO.I5>H ;(NZJ\D.:N;=U2K!NJP,22UR.E5VM?:N
M@:U&.E0R6HH P6MR.U1-#6U);"JTEOUXH RFCI/+J^T--\F@"NL=2K#4PBJ5
M8Z=P*WDT]8ZL^73ECI 1+'4JK3UCI^V@"/;[4JK3]M)0 4UJ=2;>:I$#:D5:
M%2IXXZ8"+'4BK3U6G;?:@!%Z4M+MI*$P'!O>GAJBIZT 2T4W=3J "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBBI8!4BU'4BT@'KTI]
M,7I3ZI 2+5JW[556K5OVIDLTX.@K2M^U9L'05I6_:@HMQU(M1QU(M2RN@]:6
MD6EI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!E.7I3:<O2@!::U.IK4 1TY:1NM)0!(&IU19-/6@ :HFJ>HFH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9F"U(O:F4JT 2TZF+3ZE@%.6E44X#%(L6BBBFB HHHJ@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *5:2E6@!ZU)4:U)0 4JTE*M $T=7+?I5.
M.KEOTH T[?\ AK0@K/M_X:T(*E@7(Z?3(Z?2 <M+2+2T%A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5"QJ:H&H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %*M)2K0 ]:DJ-:DH
M*5:2E6@":.KEOTJG'5RWZ4 :=O\ PUH05GV_\-:$%2P+D=/ID=/I .6EI%I:
M"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%2K2%<4+71<T9(M/J-:E6MD2.I5I*=28T2+3JC6I*0V%%%%4B0HHHI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4JTE*M #UJ2HUJ2@ I5I*5
M: )HZN6_2J<=7+?I0!IV_P##6A!6?;_PUH05+ N1T^F1T^D Y:6D6EH+"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*** "BBB@ HHHH 5:=35IU !2K24JT 31U<M^E4XZN6_2@#3M_X:T(*S[?\
MAK0@J6!<CI],CI](!RTM(M+06%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV_\ #6A!6?;_ ,-:$%2P+D=/ID=/I .6EI%I:"PHHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHI!4=2R*F4]J96L2"S#TJ5NG2HX1Q4[+\M1("NU"TDBTJT(L=1113("BBB@
MHHHH **** "I%J.I%H 6BBB@ HHHH **** "BBB@ IRTVE#4 .HI-U+0 4JT
ME% $\=7+?I5*,U=M^E &G;_PUH05GV_\-:$%2P+D=/ID=/I .6EI%I:"PHHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH :U0M4S5"W6@!5^]4RU!4ZTNH"U U2M4+=Z8!3EJ-:E7M0 \=ZCDI]-;O0!
MCZE]TUP/B)>&KT#4%^0UP_B"/Y6KSL3L85#RO75PSUP^J-RU=_X@CY>O/]87
MYFKY2O)IGER.=N/O&JC1;LU;F^]3(UW5YG,[G-(I-;9[4SR-M:OEBH)H\4G(
MQ945=M3+)4$F5S4>\USN1B7_ #,U%*NY342R5)33 SKJ'-8UU":Z.2/=5":W
MW5JF08D<>&K3M%(Q1]C^8\59AAVXXJFP-&V^Z*L,W%5(VVK3VDYK(VB$AS43
M4YN:2N:9J-JM))R:EDJE*WS&IH?$:Q+=NWS5U_A^,LZUR6GQF1A7?^'+/=LX
MK[G+^AZ-(]!\-QD*M=]8_P"K%<AH-OM5?I786IVK7U4=CMB75/%,D- ;CK36
M-1)&HQJ93VIE;16AFRW!]VIVJK"WO5AF^6LY#B0OUH6AZ%H13%HHHIDA1110
M 4444 %%%% !4BU'4BT +1110 4444 %%%% !1110 4444 *M.IJTZ@ HHIR
MT /CJ];]*J0_>JY#]V@#2MNU:$%9]O\ PUH05+ N1T^F1T^D Y:6D6EH+"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MVY%786JA'FKMOVH U+?^&M""L^W_ (:T(*E@7(Z?3(Z?2 <M+2+2T%A1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%7H.HJC']X5>@ZB@#3M^U7[>J-OTJ]'4L"W'4E1)TI_-(JXJTM(M+0,****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %1-4M1-0 JU)4:U)0 5$U/:HFH 2BBB@"5?NFB3
M[M*G2DD^[0!E:A]PURFI=ZZG4.AKF=07K5Q P6^_4L?2DE7YC0C8JY;&30DT
M.Y:Q-0L?,4\5O;@:@GB#UYM5&3B><:MH^[=\M<IJ&B\GY:]9O-/#9XK OM(W
M9^6O(J4[F=CRV;2=H/RU3DTL^E>BW&B]?EJE)H?^S7FRP]S-Q//9--/I4?V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "HFJ6HFH 5:DJ-:DH :U1-4K5$U "444JT
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M"1?O5)3%'(I]0 5(M1U(M6 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !3Z93Z '4H[TE*.] $T?WA5Z#J*HQ_>%7H.HH U;;M5V
M.J5MVJ['4L"TG7\*=34Z_A3J0QRTM(M+04%%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !435+434 *M25&M24 -:H
MFJ5JB:@".I$J.I$H F6H)_NU.M03_=H Q+]NM<UJ#=:Z2_[US6H=Z:!F1*WS
M&H:DE^\:CJB$%+Q244#W$:DI6I*!!36IU-:@!****".H4445184Y>E-IR]*R
M 6G+3:*K<I$F13:**9(4444 .W5(O:H:E7M0!*M/6F+3UH 6BE6AJ $IRTVG
M+4L"15IU(O2EI %2+4=2+5@+1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4^F4^@!U*.])2CO0!-']X5>@ZBJ,?WA5Z#J* -6V[5=
MCJE;=JNQU+ M)U_"G4U.OX4ZD,<M+2+2T%!1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIDA1112 1J2E:DH *:U.IK4 )1110+J%%%% PIR]*;3EZ4NH"T444P'4444
M%%%% #Z?3*?0!(M/6F+3U[4 +12[:2@ I5I*5:E@2K3J:M.I -7[QJ5>U1K]
MZI5JP%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M?3*?0 ZE'>DI1WH FC^\*O0=15&/[PJ]!U% &K;=JNQU2MNU78ZE@6DZ_A3J
M:G7\*=2&.6EI%I:"@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *B:I:B:@!5J2HUJ2@!K5$U2M434 1U(E1U(E $
MRU!/]VIUJ"?[M &+?]ZYK4/O&NEU#H:Y>_[U2 R9OO5#4T@PU1M3(&T444 (
MU)2M24 %-:G4UJ $HHHH%U"BBB@84Y>E-IR]*74!:***8#J*** "BBB@!]/I
ME/H D6I%[5&M/6@!]-HHH *5:2E6I8$JTZFK3J0!4BU'4BU8"T444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %/IE/H =2CO24H[T 3
M1_>%7H.HJC']X5>@ZB@#5MNU78ZI6W:KL=2P+2=?PIU-3K^%.I#'+2TBTM!0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 (U1,:D:HFH >OWJDJ)6J6@!&J-A4M1-0 W;3U6FU(M "GI56X:K=4[C
M[IH Q;YN#7/7G>M^^.W-<_>-UH RY%^:H6'%32M\QJ%JI$#=HIM/IK=:8#6I
MK4YJ8U !S2444 %%%% !1110 4Y>E-IR]*74!:***8#J*** "BBB@"1:>M,6
MGK0 M/5J910!)S3J8K4^D@%VTX+2+3QZ4F JTZD Q2T@"I%J.I%JD M%%%,
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I],I] #J4=Z2
ME'>@":/[PJ]!U%48_O"KT'44 :MMVJ['5*V[5=CJ6!:3K^%.IJ=?PIU(8Y:6
MD6EH*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@!K5 S<U.U5V^\: )(VJ:J\/WJG7I0 M1-4M1-0 E2+4=2+0 ZJ
MEU]TU;JC=T 8=^W6N?O/O5O7O\585WWH RVZFHV!J=OO&HFJD01TUNM/:F-U
MI@-:F-3VIC4 )1110 4444 %%%% !3EZ4VG+TI=0%HHHI@.HHHH **** )%I
MZTQ:>M "T444 .6I,'%,7M]:EI(!5[4]:CJ1:3 =11130"[:>M-I]" ****8
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3Z93Z '4H[T
ME*.] $T?WA5Z#J*HQ_>%7H.HH U;;M5V.J5MVJ['4L"TG7\*=34Z_A3J0QRT
MM(M+04%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% #6J%NM3-4+=: '1U-4*U-0 5$U2U$U "5(M1U(M #JI77W35V
MJ5U]TT 85\.M8-XO6MZ_[UA7GWJ ,J3[QJ)N]2R?>-1-5(@;36ZTZFMUI@-:
MF-3VIC4 )1110 4444 %%%% !3EZ4VG+TI=0%HHHI@.HHHH **** )%IZTQ:
M>M "T444 .7[U25&OWJDI(!Z]J>M,7M3UHD ZBBBA (&J1:C5>:E6A +1113
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH <M/IBT[=0 M
M*.])2CO0!-']X5>@ZBJ,?WA5Z#J* -6V[5=CJE;=JNQU+ M)U_"G4U.OX4ZD
M,<M+2+2T%!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 UJA;K4S5"W6@!RU-4*U-0 5$U2U$U "5(M1U(M #JI77W
M35VJ5U]TT 85_P!ZPKS[U;M_WK"O/O4 94GWC435+)]XU$U4B!M-;K3J:W6F
M UJ8U/:F-0 E%%% !1110 4444 %.7I3:<O2EU 6BBBF ZBBB@ HHHH D6GK
M3%IZT +1110 Y?O5)4:U)M-) /7M3UIB]J>M)@.HHHIH J1:CJ1:$ M%%%,
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I],I] #J4=Z2
ME'>@":/[PJ]!U%48_O"KT'44 :MMVJ['5*V[5=A[5+ M1BG[:;'4E(JPBTM(
MM+0,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4#5/4#4 )4BU'4BT .:HFJ5JB:@!*>O:F4
M]>U #JIW'W35RJ=Q0!A:A]TUS5\>M=+J'W37-7W\5- 9,I^8U'3Y?OFF50D%
M%%% PHHHH **** "BBB@ HHHH,Y!3EZ4VG+TI=1BT444P'4444 %%%% $JU*
MM1+4JT 24C4M% #**5J2@!R]*<M-7I3EJ6 ]:E6HEJ5:: >M+2+2TP"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "G+3:<M #EI:1:6@!]
M.6FTY: )HZT+?M6?'6A;]J -:U^Z*O1BJ%I6A'4L!]%*>U)2&.6EI%I:"@HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** "BBB@ HHHH *<M-IRT .6EI%I: 'TY:;3EH FCK0M^U9\=:%OVH
MU;?[HJ]'5&W^Z*O1U+ EHHHI .6EI%I:"PHHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** &M435*U1-0 ]?O5)4:_>J2@!K5$U2M434 )3U[4RGKVH &J
ME==#5UJI770T 8&H=ZYV\^\:Z+4.]<W>??-"W!F;+C-1T^7[YIE6)!1110,*
M*** "BBB@ HHHH ****" IR]*;3EZ4NH"T444P'4444 %%%% $JU*M1+4JT
M+1110 4^F4^@!Z]J>M,7M3UJ6 ZE6DI5IH!ZTM(M+3 **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *<M-IRT .6EI%I: 'TY:;3EH FCK0
MM^U9\=:%OVH U;?[HJ]'5&W^Z*O1U+ EHHHI .6EI%I:"PHHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :U1-4K5$U
M #U^]4E1K]ZI* &M435*U1-0 E/7M3*>O:@ :J5UT-76JE==#0!@:AWKG;P8
M8UT6H=ZYV\^\:%N!E2CDTRI)N]1U8N@4444 @HHHH&%%%% !1110 4444$!3
MEZ4VG+TI=0%HHHI@.HHHH **** )5J5:B6I5H 6BBB@ I],I] #U[4]:8O:G
MK4L!U*M)2K30#UI:1:6F 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4Y:;3EH <M+2+2T /IRTVG+0!-'6A;]JSXZT+?M0!JV_P!T5>CJ
MC;_=%7HZE@2T444@'+2TBTM!84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 -:HFJ5JB:@!Z_>J2HU^]4E #6J)JE:
MHFH 2GKVIE.6@!]4;M>*N;JIW;<4 <_J'>N>O.]=!J#=:YZZ;K30&;,*AJ69
MN3454 4444 %%%% !1110 4444 %%%%! 4Y>E-IR]*74!:***8#J*** "BBB
M@"5:E6HEJ5: %HHHH *?3*?0 ]>U/6F+VIZU+ =2K24JTT ]:6D6EI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %.6FTY: '+2TBTM #
MZ<M-IRT 31UH6_:L^.M"W[4 :MO]T5>CJC;_ '15Z.I8$M%%%(!RTM(M+06%
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA;]J -6W^Z*O1U1M_NBKT=2P):***0#EI:1:6@L**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"<4M-:@ W4ZF4^@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHI-U "T444 %%%% !1110 4444 %%%%
M!1110 444FZ@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** &M4;&I
M&J%NM #U:I:A6IJ &M435*U1-0 E2+4=/7M0 K?=-9UXORFM*LV\;Y35(#G-
M2[US=UU-='J1ZUSEUU-'4"BWWC24K4E, I=M)3EZ4"8A&*2E:DH(ZA1110,*
M*** "BBB@ IR]*;3EZ4NH"T444P'4444 %%%% $JU*M1+4JT +1110 4^F4^
M@!Z]J>M,7M3UJ6 ZE6DI5IH!ZTM(M+3 **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *<M-IRT .6EI%I: 'TY:;3EH FCK0M^U9\=:%OVH
M U;?[HJ]'5&W^Z*O1U+ EHHHI .6EI%I:"PHHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44F12T %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 44F11D4 +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% #6J%NM3-434 *M35&OWJDH
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M_NBKT=2P):***0#EI:1:6@L**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 QN]0M4[5$U $=*M&TTJT 2*U/W
M5%NI5:@"7(IM)NI: &[324^EVT 1T4YJ;0 4Y:;2[30 ]:=35IU ";J,BFTF
MZ@!^13&HW"AJ (Z7;3MM.VF@ 5:7;3J* &[:2E:DH 7;1MIU)NH 0C%)2L:2
M@ HHI-U #UZ4M-5J=0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !36IU-:@!C=:>M,;K3UH =4;]:D
MJ-^M #!]XU*G2HA]XU*G2@!U%(>U+0!%/]VL*_[UNS_=K"O^] '-WW\58\U;
M%]_%6/-5("L_>HZ>_>F4R HHHH ****![!1110(**:W6E6@D6BBB@T04W^*G
M44$C>:>M)10)CZ**=0)"KVJ1:8M/6@H<M/6D7M3J "BBB@ HHHH *D6FKTIR
MT#0]:E6HEJ9: 8^BBB@04444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 .6GTQ:?0 ^G+3:<M %B/[PK2MNU9L?WA6E;=J!=33AZU;CJ
MI#UJW'4LM$JC'-+2+2TA,<M+2+2T%!1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !12-3: 'T444 (U,(S4E% $.WVH
MQBI=M-910!&U)2M24 %.7M3:>M #UI6I ::TE  U-J-IJC\_WH L4Y357SJD
M604#L65I:A62I0<T"&TRIJ85YH 92K0U)0!(M.J-3S3UH 6BBB@!K4E*U)0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "-2;:=10 44
M44 -+4F[WI'-1%J )]U+P:@5^:E5N* !A43$4^22JDLPYYH FW4_>*SFN!ZT
MGVP>M &@\P'>JTMR!WJC+?=>:HW%]UYH OS7@'>JYO>>M8UQ?>]56ON>M '2
MK>^]3QWF>]<O'?>]6X;[WH Z>.Y![U:CF!KFH;[WJ_#>9QS0!MK)FG;O>L^*
MXSWJRDF: )Z&6A6IS4 , Q4E,I=U #J*;NHW4 .I-HI-U&Z@!=HINWVI=U)0
M *M(R^U/6AJ (]OM1M]J=10 JTZD7I2T (U)MIU% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UJ=36H 8
MW6GK4>>:D6@!U1OUJ2HWZT ,'WC4J=*B'WC4J=* '4444 13_=K"O^];L_W:
MPK_O0!S>H=*Q9OO5M:ATK%F^]5(3*S4VG-3:9(4444 %%%% !1110 UNM*M(
MW6E6@CJ+1110:H****"0IRTVG+0)BTZFTZ@41RTM(M+042+3UIBT]: %HHHH
M **** '+TIRTU>E.6@:'K4RU"M3+0-CZ***"0HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH <M/IBT^@!].6FTY: +$?WA6E;=JS8_
MO"M*V[4"ZFG#UJW'52'K5N.I9:)5I:1:6D)CEI:1:6@H**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_>%:5MVK-C^\*TK;M0+J:</6K<=5(>M6XZEEHE6EI%I:0F.6EI%I:"@HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "D:EI&H
M :6XI-U#4S)]* '[J3=[U'N]Z;N]Z )]W%.6JX:I5:@!U5+IL+5K=5.];Y30
M!S^J2[<UQNJ717=S74:RWRFN$UB4C=S0!E7M\1GFLQ]0.>M5[^8[FYK*DN#G
MK5) ;Z:A[TYM2P#S7/+=$=ZCFO" >:JP&[)JV.]+#JFYNM<=<:D5SS4ECJ1:
M0<T@/1+6Y\P#FM",EJYW1YO,Q746T>Y14 *H-31R%:D6WXJ-HRK5-P-&TN"&
M%;5K=8QS7+0R%6K2AN-N.:+@=.M_M7K36U;;WKG)K[:O6L^?5".]6@.R75\]
MZF74@>]<%'JIW?>J_%JG'6JL!U[:D/6E74O>N1;4_>A=4]Z=@.Q741ZT[^T!
MZUR*ZG_M4]=3_P!JBP'5_P!H>]']H#UKEO[2]Z;_ &G_ +5*P'7KJ(W#FK"W
MP]:XM=3]ZN0:EG'-.P'7QW0;O5J.3-<W:WV[O6O;W&[O2L!I!N*7=4"R BEW
M5-@)MU&ZH=U+NHL!/NHW5$KTX-2 ?NHW4W=2;O>@!^ZC=3=U-+4 2;J-U1;J
M7=]: )-U)N-"_-2[: $HHI-U! [=1NIFZDW>]!9)NHW5'N]Z-WO0!+NHR*C#
M4H;F@5R2BDR*6@8C4FZD9J;DT /W4;J9DT9- $M%(O2EH **3=1D4 ,VT]:-
MM &* %J)JD:HF:@!%J5.E1+]ZIEH 6BBB@""XK#U$_*:W+BL'4V^4T <UJ#=
M:QI6ZUJZ@QYK&F;DU2!C6--IK-[TF[WID#Z*3=1NH 6BD!S2T %%%% #6ZT+
M0QI-WUI7 ?2C[QIFZGK4@+M%&VEI5YXH+&[>M 6G;:-M! NT4444 .6EIH.*
M7=0!(K5(M1+4JU2 6BBBF 4444 .7I3EIJ]*<M T/6IEJ%:F6@;'T444$A11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 Y:?3%I] #
MZ<M-IRT 6(_O"M*V[5FQ_>%:5MVH%U-.'K5N.JD/6K<=2RT2K2TBTM(3'+2T
MBTM!04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !2-2TC4 ,:HZD:HZ &4QC3V[U&U "J:E6H5J9* 'U4O?NFK=4;YOE- '+
M:U]TUP6M=Z[O6&^4UPFM'[U6!QFHM\QK'D;DUL:A]XUD2?>-4@&;C56XD.TU
M.S55N>5- &-=S'<:ETV8[Q4%TOS4RUE\EJ) >E^'Y,A<UW6GL"JUY3HNJ"/;
MS7<:7K ;;S7.!V2H&6J\\?6HK:^$BCFIY) PH HGY34@FVBF3=:KR28H =<W
M/RGFLJXN#ZU8FDSFJ,GS9K2(!'<$-UJ['>''6LS&TT]9,5H!HM>'UI5NSZUG
M[Z56HN!J+='UJ1;L^M9:O4RM0!?^U'UIOVL^M4]U-W4 :*WA]:NV]X?6L-9*
MM0S8H ZRSO.G-;UE=[L<UQ5K<8Q6Y8W/3F@#KX9MV*LJV:Q[.?<!6G&WRU($
MU)NIN13: )U:EW^]1;O>D9J6X$^ZC=5<-3MWO56()MU-W4S=24@) U/6HU[5
M,M058>M._AIJTM A&IM.;M2;:"AK4E/VFF[30 E-W4_;2,M! BM4BM4:K3]N
MV@!]&[WIE)S06/+4@&:50:>!B@!FVC;4E% #0:&H:F-0 NZC=4;-[TB]J +&
M12TU.E.H :U1-4K5$U  OWJF6H5^]4RT +1110!6N6XK U%N#6Y<]ZP=0Z&@
M#G+[^*L2;[U;.H?>-8TWWJ *[=:*4?>-+3W("BBG+2 %I:** "BBFMWH :U)
M110 JU*M-6G+0 ZE'WC244%,=12+3UH)L)M-)3Z:W6@!**** )5J5:B6I5JD
M M%%%, I-U(U)0!*O2G+35IRT%(>M3+4*U,M ,?11102%%%% !1110 4444
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M2G+0-#UJ9:A6IEH&Q]%%%!(4444 %%%% !1110 4444 %%%% !1110 4444
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MI%I: "DR*&IM #LBEIE.6@!:*** "BBB@ HHHH **** "BBB@ HHHH ****
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MWFF@+JW!]:>LWR]:H+)[U(LE# T%FJ99JSUDI_G4@-))JF6X]ZR5FIWV@^M
M&M]I]Z&N/>LK[12^>:H#1\^CSJH":G"0U(%SS*7S*J*]2*QH2 EWFG;C3%!I
MX6JN JM2^9@TFVFG(J&P)/,H\RH&:A6J2R9I*;N--!S2-0 C/4$C4]JJ3-0
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M@ HHI&H ,BEIE.6@!:3(I&I* '9%+3*?0 4444 %%%% !1110 4444 %%%%
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MMMVJVM5+;M5M:12%HHHH&.6GKTIBT]>E "T444 %%%% !1110 4444 %%%%
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M&IM #Z*0'-+0 4444 %%%% !2-2T4 ,IRT;12T %-:G44 ,I])M%+0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%-:@!U%,I] !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)K4YZ5UUQ:[NU4CINX]*D#BM2M3Y9XKCM0LW\P\5Z]>:/NCZ5S-]X?+.?EH
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M:9;L&6K#8IW A5<&K<+ 54D;;FFK<;32 ULBEJC#<;JM+)F@!VVD9:<#FEH
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MJQH[S=WJPMQGO0!I>;3L[JH+(6JS$] $K+TI-M/WBFEQF@ 6G%JCW?6D+<T
M/9J831S0J[J #FEI^WVI"M #=WUHI&&#24 .I]1K3UH DI&IM% "-3:<U(M
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M?<O->H>']:,:KEJ /=K;7 $'S5%=>(E7^*O-&\4"./[_ .M8U]XP^;[_ .M
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M%&T4M% !1110 4444 %,I])MH 1:=2 8I: "BBB@ HHHH **** "FM3J3;0
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MCL,=JZ;^S?E'%']F^U4!D0V0XXJPMD/2M2.QQVJ=;/Y>E2!C?81Z5)'8^U;
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METACH I+#2^35ORZ7RQ2L!4\NG".K.RC93L V..IU3FE5:=2N FT4M&311<
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MH **** "GTRGT /7M3UIB]J>M2P'4JTE*M- /6EI%I:8!1110 4444 %%%%
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M3>: )5:G9XJ%6I^[I0@9,K4[=4.ZEW?6@$2-24@.:6@ HHHH **** "BBB@
MHHHH ?12K2TK -IU.6AJ8#:*1J%H 6BBB@ IP&*6B@=KA1114W"U@HHHI%#Z
M<M,7I4B]J %6I5IBTZ@"1>E'%)NI* %6I%IBT]:"4+11104%%%% !1110 44
M44 %%%% !1110 4444 %%%% !4<E25')0!DWG>N?U#H:Z"\[US^H=#28'-WW
M>LF;O6M?=ZR9N]" A_BIU-_BIU;$#E[5*M1+VJ5:3 =_%2TG\5+2%U'T444#
M"E6DI5H >M+2+2T %,:GTQJ &T^F4^@ICJ<M-IRT$DB]JD6HU[5(M "T444
M%%%% !3Z93Z 'KVIZTQ>U/6I8#J5:2E6F@'K2TBTM, HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ IRTVG+0 Y:6D6EH *<M-IRT 6H>U:
M=MVK,A[5IVW:I8&K;=JMK52V[5;6D4A:***!CEIZ]*8M/7I0 M%%% !1110
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M48LM-6X9: /1+/Q$1CYJV[/Q)T^>O*(KYE[UH6^K,N.: /8[/Q'T^:MJS\1
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M&Z@!^ZEW?6H]U&XT 6%:I%J*,\5(M #EZT;J2B@ (S12[:7;0 BTNV@#%+0
M444FZH+'K2TU6I^V@!FVG;?I3]OM2JOM5(!%6GK2[:55J6 4ZA5IVV@FXM)M
MI:4#- "4Y:0C%*M T+1110,**** "BBB@ HHHH **** "BBB@ HHHH ****
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MJD HV[J3=3E:@!-OM1M^M/I0M #-E*%J3;]*-OTH 93E:D:DH F5J=4*U*M
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M:.@@R)DJE(E:LT=4I(J ,R5/:J<B5K20]:J2P^U &5(M5)5-:DD/M562#VJ
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M4!Z/X7M0NSBO5_#\.%6O,?"Y'R5ZQX? VK0!U=K#\HJRT/RFEM<;14LA&VJ
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M-M+0 ]>U/6F+VIZU+ =2K244T!(M+3 U.!S3 6BBB@ HHI-U "TUJ7=2$YH
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M :ID96(H PGT4-_#3?[#']VND"J:>JK0!SR:"O\ =J=='5?X:W5V@=*CD9:
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MJ:N21TSR:!(K;344B<&M!;?=2/:DKTI(9@W,?6LNXCQFNFN+/KQ65=6?7BK
MY^20QU'_ &F8^]3WMJ1G K%N86&: -,Z\5_BJE=>(3M^]6/,KC-9UQOQWJ0+
M>H:T64_-7)ZE=F3/-7;I'-9<\+,30!B72>835![7VK>>UZ\5 ]KB@#":';5:
M3Y:V;B'K6=<0]:H#/:X*]ZEAU(KCFJUQ$5JHV5-9R Z>UU8\<UL6NL=/FKA8
MIBM:%K=$8YI)@>C66J9QS6[:ZAG'-><V-\>.:Z"RU#IS5@=O'>>]3?:L]ZYF
M#4.G-7([[WJ@-U9MW>I$:LB*\'K5J.Z]Z -6-AQ4P; K/CN!Q4WG+4@6_M&V
MI([SWK,:2A)#FFB&;\-Y[U>BO*YZ&7I5V.:A@C=6\XZTK7OO6-]I]Z=YU" T
M9+SWJI-=>]5GDJ%B6I@/ENCZU7:XW=Z:ZFHO+.ZI%L3+)N/6K,>*K1QFK"#%
M.PNI;C-/J"-JG5JS-1VT4UEZ\4^EV[JLBY7VTY%-3K#FGK": $C7%64 J)8Z
MF1: )56GJN*2.I:"QN<4OF$4;:C9: '?:"*>+O;WJHPJ(DT :BWOO4J7WO6-
MO-*LIH):.BCOO>K4=[[US4=P?6K,=T>*!HZ);C<.M.W;JQX;K/>KT4]*PRQY
M=&W;0L@H:05(!2-2%Z;NIV ":A:I&IA&:I 5Y(\U7DAJ^R<U&T= &6UO0MK6
M@8?:G+#BJ'T*T=KM[58CC"U)M"BHY),5)F6$FVU+]NV]ZRGN,56DNCZTK@;+
MZE[U6DU+/>L=K@GO3#(336H&HUYN[T+)NK.CR<5HV\9;%*P%J%2U:-O;[NU-
ML[4G'%;=K9].*8$4-CN[5933/:M.WMO:KR6X]* ,5=-]J=]EV]JVO) JM,H%
M &3(FVJ-Q)MS6G<XYK)N%W4 9=Q<'FL^2Z*GK6A<6Y;-49+-L].M-(3&K?E>
M]:%KJ1R.:R)+-L]*58V3%#!'7V>I=.:UX+_('-<3;3E>M:MO>XQS46&=5'>9
M[U.LV[O7-Q7WO5V&^'K3L.YO(P:IEQ65#>#UJTET/6F.Y<XJ-L5'YWO2>9FE
M<+"M24W=1NHL,:U-IS4VF0%%%% !112-0 M%-HH **913L*XK4E%%,+A13*-
MWO4A<?13-WO1N]Z N/HIN31DT!<EIK4W=[T,WO0%Q:9)2[O>FM2L%RNU.1L4
MK+3/NU8RPKT/-CO58R8J"6XQWJ6%BS)<>]5I+OWK/GO.O-49;WWJ4@-O[9[U
M7FO/EZUC_;O>HI+[WJ@+-U<]>:R;B;)I9KH-WJG))N-*P"2-FH6DVTYVXJM)
MFF!:CN/>KT,VZL-6*M5R";'>@#;C4-3S"*I0W0XYJPMT#WH 22W%5I+>KGG!
MN]-(W4 9[0^U"V_M5[R<U(L- %);7..*4VOM6I'#3C"#VI7%8PGMZC";2:UY
MK?.>*IRV^VF,@CJS&:@QMIZM@T 6/X33&[_2D5Z5N] %>2HJG9:9M% "QU:C
MJNM6(Z )5I:1:6@ I5I*5: '4445+ >O:GK3%[4]:?0!U%%%2 5(M1U(M6 M
M%%% !3*?3* "D:EI&J6 E%%%(!U,:GTC58$+4E.:FT %%%% !1110 4444 %
M2K452+UH F6D:A2>*=0! U*O:I-F:<L= "JOM4ZK[4U%J6@!-M12+4U1-0!5
MD7VJNR]:NNNZH6CXH ILII\>>*F\JG+#4LLLVS8K6MY<8K'C&W%78),8I ;L
M,U7X9NE8<,U:$$IXH U5DIU58FJRM "-43=ZGJ)A0!%4BTS;3UH 6BBB@"W1
M110 4444 %%%% !36IU-84 1TVGE:85H C:HFJ9EJ)EH CVTUEI]-9N*T0F1
M-24YN:3FF9B4JT;:2@I"M]VH7-2,U0M4@,)S4;=ZD:F-WH 93UXQ3*>!TH F
M4U*&J!:D5J %=JK2-4[5 ZU.H$#4U33V6F 8JT!,O:I:A4T_=0P%9:C9>:>6
MIA:D W;[4UEZT_=2,:HLB9::4J6BIL*Y!MI"M2,M&V@9%Y>:/+J95I=M %?R
MZ7RZF"\]*=M]J=@*CK4#+5R1*@9*0%9DJ%TJXR\5$T= %)HZ<L/M4YCJ6.*C
M<")+?I4OV7/:KL4-6%@Z<46 PYK/VK*N[+KQ76S6_M6;<6H]*=@.-N--W9XK
M+FT7=GBNY>S'I4#V2^E,#SNXT(\_+67<Z&>?EKTV;3U/:LVXTU>>*D#R^ZT4
M_P!VLJXT@KVKU"ZTL8/%8UWI(YXH \WN-/*YXK.N+4KGBN]O-+Z\5C76D]>*
M .(N+<\UG36I/:NTGTD^E49=)//RT"N<5-8D]JHR6#>E=Q)I/M5:32/:@9Q9
MLV7M2QPLI%=5)I/M5=M**]JFP7,ZU++6Q:S$8J*/3RO:K"0%>U4!?ANB.]6H
M[[WK+"E:<N:H#=AOO>K\-][US<;'BKD,Q6I Z6.^]ZM0WFYAS7-+<'UJW;7)
MW#F@#IHY-P%3+BL>WN^F35Q;H>M+4@T8WQ5A).*R4N!5J&;-6!IJ^:D&35:%
MMU6XUH*0JJ32^74RH*E6.E<+%7R/I2_9>^*NB,"I @I!8HK;[:7R<5?V"F-%
M038I;2*>M2M'3#'04F/6K$:U67Y:F1\4$EN-!BI=@JLDU2B:@"3RQ1MIOG>]
M&Z@!X:GAJ@W?2E5O>@"PK9I66HE:I5:@LB:.HC#5H\T;?K0!3\FF^55[93=E
M %0)BI%S4NP4FW;0!)&VW%6X[C;WJANVTC2F@#76ZIXN,BL=9CGK4T<QH(-4
M35(K9K-6:I5N,4%FCQ2[15%;L>M/6ZH N[13?+%1QS U,KB@!ODTR1-HJRN,
M5%-C% ,SYY-N:IR2$U;N(]QJLT-!!4D<U#R:M20U#MVT -6+-2"WS0K 58AP
MU !#;?,*V+&UZ<5!:Q@UMV,/3B@"[8VG XK8M[<+BJ]JNW%:$;4#L3(H6I5<
M569Z8TF*!%EI*I7$E#2U!)\U %6<[JK&'<U7'B+5)';^U4!G_8-W:E_LG/:M
MZ&V'I5C[,-O2@#DI-''I5&XTT1YXKL+B-54UB7S*N:D#FYH_+J);@K5J\;=F
MLY@=U %Z.Z/K5V&\/K6.N:L1L10!T%O?>]:$-[[UR\<Q6K"WI7O0!U<=X,=:
MF2X'K7*+J6&'-68=4]Z!W.H60-3JQ;>^W8YK3AFW4")BM)MJ1>13&H ;12;J
M-U-%6#=244C&F0Q:*9N]Z7F@0E%%%*X(*8WUI6J-FI%6%_&DS[TVG*M58!,^
M]+D4;?I33Q18!V11D5&6H#4!8DW-1N]:8O.:<JT!87(IRTW;2?=H E*\5!)Q
M0\X454FN!@U-P&S28K.NI^#S2W%UUYK*N;K@\T -N;KWK,FNCS27%P1FL^20
MFJ N?:C4;71P:J;Z3)I,"=IRU*KYJ!5-3QK2 D6AH\T]:?5 46AJ-CM-79*I
MS+4@)]J*]ZECOCZU0D4TQ-V: -Z&\SWJY#-GO7/0R$5?BN-K"@#<C8&I0P6L
MB.\]ZD^V>] &IYP%2K,#WK!:]]ZDCOOFZT ;>%:JTT8JO'>>]$ET#F@"O* &
M-5]WS4^:3=4.10!,LG2I-U0+FI%S0!)2;:3=[TNZ@ 5:GC^[4&ZI%:@+DZTM
M,62GT %*M-+4Y30 ZBBEVT .7M3UJ+=4JFET =112[:D!*D6HZ%:K EHJ/=1
MNH DIE&[ZTFZ@!:1J3=]**E@%%%+MI +2-2U&S58 U1-3MU,)H ,FG4@%+0
M444H&:+ )13]OM2;: &TY:7;[4]8Z $7M4ZKG%"Q5/'%0 U4IWEU,L=.V^U.
MP$.WI2U(R^U-V4@(F:HVJ9E]JC9* &4FVG;:<JT[ -6/CI2[*E6G;:3*17VU
M)&V*&6F\U R]"]:5NW3FL>)JOP2=*: VH6JTK5G6\F[%7HZH"6FM3]M-;BH
MBI=U-+<TF[WH DW45'N]Z* -"BBB@ HHHH **** "BBB@!&J-JD:HVH 8W6H
MVJ2F-WH @:HVZ5*]1M57 913J1J8K#6IC4]@:8U R-N],J6FT 1-32*E:DH
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MG+D5/Y='ET 1JYIWF'UIWET>70!"S&GQN=PI_ETY8Z 'K(?6G^8?6FJE/VT
M)NIRK0%Y'2I56@ 5:DVTJK4BK0!#Y1I=IJ?;]*&6@"#::5:EVT;:!6!:E6F!
M1D5)0,:W6E6EHH D6EIBT^@!M2+3:E6@L<M+3:*"6.IFWWIRT_;5"(N?6DYJ
M;;366@!G-+2;12U(#**5J:WWJE@2*U+NJ'=2%J: >S5&S4E%,!-U+0JT\+0
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MMVWN,*O-4(Z*.:G^=[UDQW7O3OM0]:E@:$D_R]:S+BXQWI)+H;>M9=Q<]>:
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M]N1VJ)HS0 Y9*D63I4&W;2[C0!:$G%.W?6JPDIPDI6 GW?6A6YJ#S*59.:+
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M%E=DI-OTJPRTQEJR"+::*DVT4 7****@L**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *3UI::3
M0 QEIFWYJEI-M601[?I1M^E2[?:C;[5!97\ND*U.R\TQEH A9:;M]JF*TW;1
M<$,VT;:?MHVT[@T-HIVVD;BKN0,INVG[32;34H!NVD9:DVTA6F!&!BEI=M)4
MH!E-;%.IK+3; C:HFJ9EYJ)EIH!E-VU)MHVT , Q2T[;1MH 85IM2[:;M]J
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M TDDJQ')66LU3I-0!K1R5.K!JRXY_>KMO-G% $SP[ATJA=6_M6NN"M07$8-
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MU9EK(O.]6!DW3=:S)FY-:-TW)K+F;DT 1LU&ZF'K2[J )D:K<+=*SU:K,4E
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M)0 FVBEHH%<?1110,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTYJ2@FPFTT;:6B@+!M^M)MJ2BI8$9%)4C4FVE8!NVEI=M&TU8"4JT;:-IIZ
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M/2HVTT<\5T'V<4UK8>E5<=CFFTWVJ-M.]JZ5K4>E1M9CTIB.<.G?[--_L_\
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M'Y(]*3R_E-34R@"+;MHI6I* "G+TIM+NH "*2EW4E !29%+3=M #J<M-IRT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[4UJ &;:6BB@"1:=48:EW>] #Z*:&IU !1110 W;366I*:U $#4VGLM-VF@
M#4X/3=M&V@!_F4N[ZU%3EZ4 2[J56J*C)H GR*6H-U*)#ZT 34QF%1-(:B:2
M@"=L4QHU-1;Z<)* $:W4]JB:R#=JMJV:E7!H R)--'I52325;^&NCVCTIOEK
MZ4 <K)H:G^&JSZ"/[M=DT*^E,^RJ>U '$MH(/\-5)O#H_NUWS6J^E1M9J>U
M'G4GAC=_#^E0MX5_V?TKT@Z>I[4?V>GI0!YK_P (K_L_I3E\+_[%>D?V;'_=
MH_LV/T_2@#SG_A%_]C]*7_A%_P#9_2O1?[.3TI6T]/2@#SC_ (1G_9_2F_\
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MBBB@ HHHH ***1J %HINZG4 %%%% !1110 4444 %%(3BDW4 .HHHH ****
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M*-HH CHI^WVHV^U #**?M]J-OM0 RBG[?:DH 1:6BB@ HHHH **** "BBB@
MHHR** $:DVFG44 -VFBG4UNM #6I*5J2@!-M+110 4H.*=2-0 9%,:GJ#0RT
M 5V;FI(VIC)3T6M.@KDH;BEW4W;THV^]9D@S5$S4YE-0M06/W4NX^]14O\5
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MZ7<: )**CW4;C0 K+2;:;1N- #Z0J*;N-% !M%/$8Q3*>K4 'EBCRQ3MU+0
MSRQ3MHI:* "DW4QFIM $NZDW4Q:1N]  S5&RYI>:D44 0>6<U(J&I544NT>M
M $:K2_A3^/6CB@".BGMBFL: $IVVFY%.#4 .VTC+S3MU+0!$RTFWZU+M%&V@
M!FVEIVT4M "+TI:** "F4^B@"&E7K2L*;0 ]6I=U1TN30 _=1NIF31DT /W4
M;J9DT9- #]U&ZF9-&30 _=06IF30M #J?3*?0 4444 %%%% !1110 UJ2GT4
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:@".FTK4E !3E[4VE6@"0-^%+NJ.B@!V13EJ.G+0!)12+2T %%%% !1136H
M7(I:93Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img149481191_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_6.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #= G # 2(  A$! Q$!_\0
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M2=6K[?F]H\/AJ=*=7%P<<3_A\S_P45/3X[6W_AN?AQ_\S%'_  ^9_P""BO\
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MBB\>9-(\C=68FO+O^'S/_!17_HNUM_X;GX<?_,Q7Q-^TI_R<)\:?^RC>(_\
MTJKQ.N?+^#N$IX# 3GPQD$ISP6$G.4LHP$I2G+#TI2E)N@VW*3;;>K;=]V=F
M<>)GB+2S?-:5/CSC"G3IYECH4Z<.),XC"$(8JK&$(1CC%&,(Q2C&*2C&*LDE
MH?J+_P /F?\ @HK_ -%VMO\ PW/PX_\ F8H_X?,_\%%?^B[6W_AN?AQ_\S%?
MEU179_J7PA_T2W#W_AGR_P#^9_+\^[/-_P"(G^)/_1?\9_\ B39S_P#-GE^?
M=GZB_P##YG_@HK_T7:V_\-S\./\ YF*/^'S/_!17_HNUM_X;GX<?_,Q7Y=44
M?ZE\(?\ 1+</?^&?+_\ YG\OS[L/^(G^)/\ T7_&?_B39S_\V>7Y]V?J+_P^
M9_X**_\ 1=K;_P -S\./_F8H_P"'S/\ P45_Z+M;?^&Y^''_ ,S%?EU11_J7
MPA_T2W#W_AGR_P#^9_+\^[#_ (B?XD_]%_QG_P")-G/_ ,V>7Y]V?J+_ ,/F
M?^"BO_1=K;_PW/PX_P#F8H_X?,_\%%?^B[6W_AN?AQ_\S%?EU11_J7PA_P!$
MMP]_X9\O_P#F?R_/NP_XB?XD_P#1?\9_^)-G/_S9Y?GW9^HO_#YG_@HK_P!%
MVMO_  W/PX_^9BC_ (?,_P#!17_HNUM_X;GX<?\ S,5^75-;[K8Z[3_*C_4O
MA#_HEN'O_#/E_P#\S^7Y]V'_ !$_Q)_Z+_C/_P 2;.?_ )L\OS[L_4O_ (?*
M?\%&]R)_PO!?,D"F./\ X5G\/?-E#\QF*/\ X17?*L@(,9C5A(""A8$&F'_@
MLQ_P46!(;XZVZL"05;X<?#I64C@AE;PN"I!X((!!X(S70CP=?:E^VA_P3RO-
M.\*7%]X>\1?#+]DO4(;BRT(W6C:S:Z1HNDV7BB]E:WM9+.[CTZ^L-1AUZ:Y#
M&WFM;EK\J%9CK6_[/?[-_CC7?@[IFI> ?B9J_B[]JOQ9^T7/#\4O#GC.YT_P
M?X /@OQCXDC\/ZOH_A&'1YM+URQBM8+2;Q+8:C?6=M8Z6/M=M*LDPV_)RP_
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M8P01R".#3T_X++?\%&)&VQ_'.*5R"0D7PU^'<CD*,L0B>%F8A1EF(&%4%C@
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M (?,_P#!17_HNUM_X;GX<?\ S,5^75%'^I?"'_1+</?^&?+_ /YG\OS[L/\
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M)-IW2O>UG9)IO_6R=:G!\K;OU25[=K^O]=#V"BO'/^$UUS_GI;?^ Z_XT?\
M":ZY_P ]+;_P'7_&N3_6/+^V(_\ !<?_ )89_6J?:?W+_/\ JS\K^QT5XY_P
MFNN?\]+;_P !U_QH_P"$UUS_ )Z6W_@.O^-'^L>7]L1_X+C_ /+ ^M4^T_N7
M^?\ 5GY7]CHKQS_A-=<_YZ6W_@.O^-'_  FNN?\ /2V_\!U_QH_UCR_MB/\
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MS#_B3[)?^B[S3I_S(L)Y?]3+U_'NK?YX/_#/GQ]_Z(=\7O\ PW'B[_Y4T?\
M#/GQ]_Z(=\7O_#<>+O\ Y4U_H??\)IK?]^U_\!D_QH_X336_[]K_ . R?XT?
M\32Q_P"B8A_X6U/+_ISZ_AYA_P 2?9+_ -%WFG3_ )D6$\O^IEZ_CW5O\\'_
M (9\^/O_ $0[XO?^&X\7?_*FC_AGSX^_]$.^+W_AN/%W_P J:_T/O^$TUO\
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M[B5T,+%1PU%X!.EAH\U.?+AZ?]K\E&*E",N6E&*YH1DE=1:_@>\,Q_MW^#/
MNH?#'PEI'[3'ASX>:K!J5K?^#](\)^,[71I[768_)UBUC1=&-S9VVJ1$IJ%O
M8W-M#=JS^>C[WW8-SX2_;*O+FYO;OP9^T/<7=YX&M_AC=7,O@SQDTUQ\.;2P
MCTNU\#RO_9&7\-6^FPPV,6G']VMM$D><"O[_ /\ X336_P"_:_\ @,G^-'_"
M::W_ '[7_P !D_QIKZ3&!C.I4CP;@HU*LG.K.-6,9U9RY'.=22PRE.<G%.4I
MMRERPNW964OHI4)TZ-&?B9Q'*EAX0I8>E++HRI8>E334*="F\V<*5."G44(4
MU&,5.:BDIL_S[_&WPZ_:U^).KVWB#X@_#KX\^,M=M-&TGP[;:SKW@3Q==ZE#
MH>@V_P!DT73%NQHT<K6VEVN+>S\PO+%"J)YK!$QWOBJ__;_\<^#8_AWXRM/V
MG_$W@:.*P@_X1?5_"WC*XTR:#2E5=-@O<:*EWJ,%@$3[+#J%U=11%$(3**1_
M>G_PFFM_W[7_ ,!D_P :/^$TUO\ OVO_ (#)_C0_I,8&2PZEP;@FL(U+"IU8
MM8:2Y;2PZ>&M0:Y='2Y6K1[!'Z*5"+Q<H^)G$<99A%PS!QRZ*>.@_BCC6LV3
MQ47S3O&O[1/FEI[Q_!/K-S^WUXB\-^'/!VO6/[3VK^%?"%UI%]X8T*^\+>-)
M;'1KSP_@:#<V_P#Q)EGFET7 _LHWL]TMB54VZQE5(Q]-T;]MW1]0U'5=(\-_
MM)Z7J>L>.[?XHZKJ%AX4\;VUWJ/Q(M5OTM_'%Y/%I2O-XDA35=3C6_8[C'?W
M:,C+,PK^_#_A--;_ +]K_P" R?XT?\)IK?\ ?M?_  &3_&IC]);+X1E"/!>!
MC"3<IPC4BH2E*49SE**PJC)RFN:3:;E)1E*[5RY?15ISJ0K3\3^)9U:<:<(5
M9X!2J0A3A[*G"%1YNYQC3I2G3A&+2A3<H12C*Q_!G<:S_P %![KQS8_$VX@_
M:?E^(&F:1<>']/\ %A\)>+4U*ST&\8/=Z+#%'H*:>-+NY )KJR:R:"XG GF5
MY0'KEO%F@?MK^/&\1/XU\+?M'>*CXNU3P]K?B@:WX/\ &=ZFNZOX2MKZR\+7
M]_$^D")IO#MGJ>HVNC+"D,-A!?7,4$2)(17]^O\ PFFM_P!^U_\  9/\:/\
MA--;_OVO_@,G^-%/Z2V74I0E3X*P%.5.$*<)4YPA*%.G4C5A3A*.%3C3A57M
M80BU&%11J12FKA5^BM"O"I3K^*'$U:G6JU*]:G6P/M85J]:E]7K5ZL9YO*-2
MM5H.5"I5FI5*E%RI2DZ<N4_@\L/$O_!1/2QXH&G2_M4V?_":W/V[Q88_#7C)
MGUR^_LV+1S?74DVB220WS:3!!IKWEDUK<R6<,4#RLL:XS=-O/V_='\!GX7:5
M9?M/V'PY.EZCH9\&6_A;QFNB-HFKNTNJZ,T3:*UPVE:A*[2W6GFX-I)*S2>4
M'8L?[U?^$TUO^_:_^ R?XT?\)IK?]^U_\!D_QJ/^)DLK_P"B'RWXZ53>G_$H
MQY*-3_=/CHP<H4I_%3@^6#C%M&B^BW):_P#$5.*K^SK4;_5)?P<34A6Q-'_D
M<?PL16BJN(I_!6J14ZD92Y6OX'?%T/[=GC[PCI7@#QOHO[2OBKP3H@L!I7AC
M6O"/C&[TNT&E0-:Z6&4Z,MQ>#3K9W@L1?W%V+2)BL&P&O(_^&?/C[_T0[XO?
M^&X\7?\ RIK_ $/O^$TUO^_:_P#@,G^-'_"::W_?M?\ P&3_ !KHH?2>PV&@
MZ>'X1PV'IN4IN%#$.E!SFTYS<:>'C%SD[N4FN:3LY-NYQXGZ)6 QM2-;&^(N
M>8RK&G3I1JXK*:.(J1I4TE3I*I6S2<U3IIR4()J,5=12NK?YX/\ PSY\??\
MHAWQ>_\ #<>+O_E31_PSY\??^B'?%[_PW'B[_P"5-?Z'W_"::W_?M?\ P&3_
M !H_X336_P"_:_\ @,G^-;?\32Q_Z)B'_A;4\O\ ISZ_AYG-_P 2?9+_ -%W
MFG3_ )D6$\O^IEZ_CW5O\\'_ (9\^/O_ $0[XO?^&X\7?_*FC_AGSX^_]$.^
M+W_AN/%W_P J:_T/O^$TUO\ OVO_ (#)_C1_PFFM_P!^U_\  9/\:/\ B:6/
M_1,0_P#"VIY?].?7\/,/^)/LE_Z+O-.G_,BPGE_U,O7\>ZM_G@_\,^?'W_HA
MWQ>_\-QXN_\ E31_PSY\??\ HAWQ>_\ #<>+O_E37^A]_P )IK?]^U_\!D_Q
MH_X336_[]K_X#)_C1_Q-+'_HF(?^%M3R_P"G/K^'F'_$GV2_]%WFG3_F183R
M_P"IEZ_CW5O\\'_AGSX^_P#1#OB]_P"&X\7?_*FN@\)?L_\ QZB\7^#Y9?@C
M\6XHHO%WA:6663X=>+4CBBBU_3I))9';20J1QHK/([$*B*68@ FO]![_ (33
M6_[]K_X#)_C1_P )IK?]^U_\!D_QJ9_2DC*$H_ZLP7-%QO\ 7:FEU9O^#Z_A
MYET_H@Y-3J4Y_P"O69ODG"=GD6%UY91E:_\ :76S_'NK?P2_M$_ ?XY7_P >
MOC#?6'P8^*U[97?Q!\0W%I>6GP_\57-K<P2768YK>>'2WBFB<<I)&S(PY4D5
MXW_PSY\??^B'?%[_ ,-QXN_^5-?Z'W_"::W_ '[7_P !D_QH_P"$TUO^_:_^
M R?XUGA_I00P^'P^'7#49*A0HT%)XRHG)4:<*:DU[&R;46VMKM&^-^B/DV,Q
MF+QCXXS.F\7BJ^)<%D>%DH.O5=5P4O[13DH\[BG9-I7W:M_G@_\ #/GQ]_Z(
M=\7O_#<>+O\ Y4T?\,^?'W_HAWQ>_P##<>+O_E37^A]_PFFM_P!^U_\  9/\
M:/\ A--;_OVO_@,G^-;?\32Q_P"B8A_X6U/+_ISZ_AYG+_Q)]DO_ $7>:=/^
M9%A/+_J9>OX]U;_/!_X9\^/O_1#OB]_X;CQ=_P#*FC_AGSX^_P#1#OB]_P"&
MX\7?_*FO]#[_ (336_[]K_X#)_C1_P )IK?]^U_\!D_QH_XFEC_T3$/_  MJ
M>7_3GU_#S#_B3[)?^B[S3I_S(L)Y?]3+U_'NK?YX/_#/GQ]_Z(=\7O\ PW'B
M[_Y4T?\ #/GQ]_Z(=\7O_#<>+O\ Y4U_H??\)IK?]^U_\!D_QH_X336_[]K_
M . R?XT?\32Q_P"B8A_X6U/+_ISZ_AYA_P 2?9+_ -%WFG3_ )D6$\O^IEZ_
MCW5O\\'_ (9\^/O_ $0[XO?^&X\7?_*FC_AGSX^_]$.^+W_AN/%W_P J:_T/
MO^$TUO\ OVO_ (#)_C1_PFFM_P!^U_\  9/\:/\ B:6/_1,0_P#"VIY?].?7
M\/,/^)/LE_Z+O-.G_,BPGE_U,O7\>ZM_G@_\,^?'W_HAWQ>_\-QXN_\ E31_
MPSY\??\ HAWQ>_\ #<>+O_E37^A]_P )IK?]^U_\!D_QH_X336_[]K_X#)_C
M1_Q-+'_HF(?^%M3R_P"G/K^'F'_$GV2_]%WFG3_F183R_P"IEZ_CW5OX+_#.
MI_\ !03P7X(G^&OA&']J3PW\/[BWU"TD\(Z3X9\:VVD+::L'&IVML@T9KFRM
MK\2R?:H+*YMHI/,DRHWMGNKSQW^V[;_ _P"'/P'\%_#C]H/P#X1\&:%XST+Q
M)#X=\*^-+:'Q];^,==;6)WU>%=%$MH+6%Y=.9+.XC-W;2N+AW4E:_N6_X336
M_P"_:_\ @,G^-'_"::W_ '[7_P !D_QKSZGTC\JJSC4J<$8"4XXKZ[?VJ7/B
M_95:/UBJHX9*M65.O649UE.4934XM5$I+V:'T8*N'I3HT?%/B:%.I@/[+Y?[
M/A+V67/$87%2P6&E+-7+"X:5;"4'4I89TH5(4_934J4Y0?\ !1IMS^WUH_P\
MF^$FE6/[3NG_  QN-,NM$F\"VOA7QE'X?DT6]G2ZN]&:W.BF<:5<7,:7#Z<M
MPMF)U$J0H^6.EXC\1?\ !1#QAX<D\'^*3^U-K_A:>TTJQN=!U'PQXQDT^[M-
M#N;6]T6*]2/1(I+XZ5=V-E<6$UY+//;2VL)CE 7!_O%_X336_P"_:_\ @,G^
M-'_"::W_ '[7_P !D_QJ_P#B9/+.=5/]2,N]HJSQ"J7I^T6(DX.5=3^J<RK2
M<(MU;^T;A!N3<5;-?1;DJ7L%XJ<5*B\-#!NBL))4OJ<$XPPCIK..1X6$9U(Q
MP_+[&*G448)3:?\ "38^-O\ @I#IFK^)?$&G7W[5EEKGC)[*7Q5JMOX7\7)>
MZ[<:=8C2[&]OI3H)_P")C;:<!9)J=N(-1: !9+IV :L3PAJ7_!0+X?\ AR^\
M(>"(/VH_"_AC4[K5[[4-$TGPUXUBL[J[\01/!K\[F71YKA&UR&62/5UAGCCU
M$.S7:2NQ:O[T?^$TUO\ OVO_ (#)_C1_PFFM_P!^U_\  9/\:7_$R.5<LH?Z
MC99R3]CSP_=<LO81Y*'-'ZI:7L(.4*-T_90?+#EBVAKZ+M13A47BMQ8JE/V_
MLZBPT_:4_K<X5<6H36<\T5BJL54Q*BU]8J14ZO/*S7^>GH/P5_:4\+:QHWB#
MPU\(/C7H.N^'=1L-7T'5]*\ >,;/4-'U32[B*ZTW4-/N8]*#V]U8W,,4]M*A
MS')&IY P>IN_!G[8U_K7CWQ)?>"?VAKSQ#\4XKZ#XE:W<>#?&DFI>.H-4U2T
MUO48?$UTVD[]2CO=8L+'4[A9-H>]M+>88:-:_P! /_A--;_OVO\ X#)_C1_P
MFFM_W[7_ ,!D_P :Z9?2?P\Y\\^$\/.?*H<\L2Y3Y%.%50YGAV^55(*HHWLI
MQA.W,DUP4_HD9?2I^RI>(F=TJ7.ZOLJ>4484_:.DZ$JG)#-%'VCHU*M&4[<S
MI3G3;Y)N)_!)XPE_;V^(/A[1/"?CG3OVG/%?AGPW=:;?Z'HFL^%?&=Q8:??Z
M/&D.D7P1-&BDN[S3(HXTL+J_DNY[4(IAD5@&K-\5:7^W%XYMO&5GXST#]I;Q
M3:?$77]#\5>/K;7/"WC>^@\9>)O#-DNF^'=>\11R:4%U'5-$T]5L]-N9?FMK
M=0B@@9K^^W_A--;_ +]K_P" R?XT?\)IK?\ ?M?_  &3_&L8?26R^ER*GP7@
M*:IR<Z:IU(05.<JE*M*5-1PJY)2K4:=5N-G*K2I5'>=.+755^BK3KNHZ_B?Q
M+6=:$:=9UL![5U:<*-7#1IU'/-Y.I"&&Q.)P\82O&-"O7HQ2IUIQ?^>#_P ,
M^?'W_HAWQ>_\-QXN_P#E31_PSY\??^B'?%[_ ,-QXN_^5-?Z'W_"::W_ '[7
M_P !D_QH_P"$TUO^_:_^ R?XUU_\32Q_Z)B'_A;4\O\ ISZ_AYGG?\2?9+_T
M7>:=/^9%A/+_ *F7K^/=6_SP?^&?/C[_ -$.^+W_ (;CQ=_\J:/^&?/C[_T0
M[XO?^&X\7?\ RIK_ $/O^$TUO^_:_P#@,G^-'_"::W_?M?\ P&3_ !H_XFEC
M_P!$Q#_PMJ>7_3GU_#S#_B3[)?\ HN\TZ?\ ,BPGE_U,O7\>ZM_G@_\ #/GQ
M]_Z(=\7O_#<>+O\ Y4T?\,^?'W_HAWQ>_P##<>+O_E37^A]_PFFM_P!^U_\
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MF !-?W&+XUUI6!)M' /*FV !'H2K*P_ BNZ\/^)+?6<PO&+>]C7>T6=R2*"
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M]^W_ ,*/(G_YXR_]^W_PKYU_X9>^$O\ SS\<_P#AQO%__P LJ/\ AE[X2_\
M//QS_P"'&\7_ /RRH^O\:_\ 1+\._P#B98[_ .@OU_I:G]E^'?\ T6?%7_BO
M\N_^F"?17D3_ //&7_OV_P#A2-%*HRT<BCU9& _,@5\[?\,O?"7_ )Y^.?\
MPXWB_P#^650S_LV^&]-C:[\ >+/'W@KQ'"I>PU4>+]9UNV^T*,Q1W]AJ]Q=0
M3V3N MQ&BI(T;,%<&E+,N,Z:<Y\)Y/5A%.4J>"XNJUL7-)7<</2QG#&786I5
M>JA"OCL+3E)I2K07O%1R?P_JRC2I<<9[0J5&HPJYCP)1H8&G*3LIXJM@.,<V
MQE*BGK4GALMQM6,;N&'J-<K^BZ*\F^#WC?6/&/A_5+3Q3!!;>,O!FO7GA/Q6
MEHH6SGU*Q57BO[502$BO[5XKDQ#B)W9!D#)]9KWLKS+#9OE^$S+!^T^KXNDJ
MD(UJ;I5Z4E*4*M"O2=W2Q&'K0J4,12;;IUJ<X7?+<^8SG*,9D.:X[)\>J7UK
M 5G1J2H5%6P]:,HQJT,3AJT4HUL+BL/4I8G"UDDJN'JTZB24K!1117>>8%%%
M% !1110 4444 %%%%   3P!D^@J7R)O^>,O_ '[?_"OFSQ3=^*/BE\1=9^&O
MA[Q%J'A#P;X*LM/F\<ZUHS)#KVL:GJ\1N++0=-NG#_8[06F9;NX1=[Y>,X(C
M8V!^R_\ "HC,S>.[B4\R3O\ $3Q8CROCEV2/45C4L>2J*%!Z"OD?[?SC'U\6
MN'\APV88+!XO$8"IF&9YV\GH8G%X.K+#XR& I8?*<YKUZ6%Q,*N%JXBO3PD)
M8BC6C05:$/:2^[_U7R#+,/@9<4\3XO*\PS# X3,Z659-P['/\1A,#F%"&*R^
MIF=;%9YD&&PM?&X.K1QM#"X:KCJD<)B*$\2\/4J>Q7T7Y$__ #QE_P"_;_X4
M>1/_ ,\9?^_;_P"%?.O_  R]\)?^>?CG_P .-XO_ /EE1_PR]\)?^>?CG_PX
MWB__ .655]?XU_Z)?AW_ ,3+'?\ T%^O]+6/[+\._P#HL^*O_%?Y=_\ 3!/H
MKR)_^>,O_?M_\*/(G_YXR_\ ?M_\*^=?^&7OA+_SS\<_^'&\7_\ RRH_X9>^
M$O\ SS\<_P#AQO%__P LJ/K_ !K_ -$OP[_XF6._^@OU_I:G]E^'?_19\5?^
M*_R[_P"F"?17D3_\\9?^_;_X4>1/_P \9?\ OV_^%?.O_#+WPE_YY^.?_#C>
M+_\ Y94?\,O?"7_GGXY_\.-XO_\ EE1]?XU_Z)?AW_Q,L=_]!?K_ $M3^R_#
MO_HL^*O_ !7^7?\ TP3Z*\B?_GC+_P!^W_PH\B?_ )XR_P#?M_\ "OG7_AE[
MX2_\\_'/_AQO%_\ \LJ/^&7OA+_SS\<_^'&\7_\ RRH^O\:_]$OP[_XF6._^
M@OU_I:G]E^'?_19\5?\ BO\ +O\ Z8)]%>1/_P \9?\ OV_^%'D3_P#/&7_O
MV_\ A7SK_P ,O?"7_GGXY_\ #C>+_P#Y94?\,O?"7_GGXY_\.-XO_P#EE1]?
MXU_Z)?AW_P 3+'?_ $%^O]+4_LOP[_Z+/BK_ ,5_EW_TP3Z*\B?_ )XR_P#?
MM_\ "F,CI]]67_>4K_,"OGC_ (9>^$O_ #S\<_\ AQO%_P#\LJY?Q5X'UKX%
MZ9+X^^&OB3Q'?>'M">*Z\6> ?$NK76O6&HZ$98TO;K2KR_:6]L]3L8F,Z2-,
MR&-#D !U?#$Y_P 2970JX_-^&,%#+,+"5;'5\GXBJ9KC,+A::YJ^*6 Q60Y/
M]8I8>FIUJT*&*GB72A+V&'KU$J<NG!\,<(YSB:&69%QEF%3.,;4AA\NPV?<*
M4LDP&,QE5J&'P3S/!\3Y]]5KXJJX4,/4Q.#IX-5JD/K.+PM+FK1^K:*I:;J-
MKJ^FZ=JUB_F66J6-KJ%I)_?M[R%)XF_%'%7@"2 .I( ^IXK[&$X580J4Y*<*
MD8SISBU*,X32E"46M'&46G%K1IIH^!J4ZE&I4I582IU:4Y4ZM.:<9TZD).,X
M3B]8RA).,D]4TTP +' !)/0 $G\A4GD3_P#/&7_OV_\ A7RY-%XA^.GC'Q=I
M47B?5O"WPL\#ZH?#<\7ANX^Q:SXR\011++?M<:D!YMOHUGO$*QVY61Y0PRK
MN=G_ (9>^$W\2>.F;NQ^(WBX%CW8@:E@$GD@<#MQ7R-+B#.\S=:OD'#^$QN6
M4\1B,+2S#-,]EE"QT\)7GAJ];!8;#9-G-6>$5>E5I4L1B?JCK\GMJ-*>'G3J
MU/NZW"O#F3JAA^*.*L=EV<5<+A<97RK)>&89Z\MIXW#TL7AL/F.+Q?$'#]&G
MCY86O1K5L+A%C8X;VBHXBO3Q4*M"G]%>1/\ \\9?^_;_ .%'D3_\\9?^_;_X
M5\Z_\,O?"7_GGXY_\.-XO_\ EE1_PR]\)?\ GGXY_P##C>+_ /Y95I]?XU_Z
M)?AW_P 3+'?_ $%^O]+7'^R_#O\ Z+/BK_Q7^7?_ $P3Z*\B?_GC+_W[?_"C
MR)_^>,O_ '[?_"OG7_AE[X2_\\_'/_AQO%__ ,LJ/^&7OA+_ ,\_'/\ X<;Q
M?_\ +*CZ_P :_P#1+\._^)ECO_H+]?Z6I_9?AW_T6?%7_BO\N_\ I@GT5Y$_
M_/&7_OV_^%'D3_\ /&7_ +]O_A7SK_PR]\)?^>?CG_PXWB__ .65'_#+WPE_
MYY^.?_#C>+__ )94?7^-?^B7X=_\3+'?_07Z_P!+4_LOP[_Z+/BK_P 5_EW_
M -,$^BO(G_YXR_\ ?M_\*/(G_P">,O\ W[?_  KYU_X9>^$O_//QS_X<;Q?_
M /+*C_AE[X2_\\_'/_AQO%__ ,LJ/K_&O_1+\._^)ECO_H+]?Z6I_9?AW_T6
M?%7_ (K_ "[_ .F"?17D3_\ /&7_ +]O_A1Y$_\ SQE_[]O_ (5\Z_\ #+WP
ME_YY^.?_  XWB_\ ^65'_#+WPE_YY^.?_#C>+_\ Y94?7^-?^B7X=_\ $RQW
M_P!!?K_2U/[+\._^BSXJ_P#%?Y=_],$^BO(G_P">,O\ W[?_  IC*R'#*RGT
M8$'\B!7SQ_PR]\)?^>?CG_PXWB__ .65<KXH\,:U^S]:0^._!'B3Q#JW@;3;
MRUC\:^!O$^J7&M0QZ+=7$=O+K&AZC>M)>VM[IHD$THEED66%2H'4'#%<0<0Y
M50J8_.N&L%1RK#1=7'8K*.(:F:XG!8:%G6QD\#BLAR=UL-AJ?-6Q/U?$5<3&
MC"<J.&KRCR/IP?"W"N=XFEE?#O%^88C.L9-4<MP6>\*TLDPF88R;Y</E]+,<
M'Q+GZH8O&57&AA'B\+0P<L1.G"OC,-"7M%]7UKZ#,\.LZ8Z'!:\@B/NDTBQ.
M#]4<CV.#VK#M[B&[M[:[MV\RVN[>"[MWQC?;W4*3P.1V+Q2(Q';.*U]&_P"0
MOI?_ &$+/_THCK[G"ROB,-.$DU[:C*,HNZ?OQ<91:T:V::]4? J,H5%&2<91
MFHRBTU*,HRLTT]4TU9IZIFCXM_Y&"_\ K;_^DL%?@YX_G\<>,OBY^W#8>&[7
M]MOQ5\4/#/Q=NO#7P0N_@_\ $+QMH_P@\&:B?AYX6O?#>GZQ8R^(;7X<V&EV
M/B&[.J>([76])GM)].EO!-%*\R@_O'XM_P"1@O\ ZV__ *2P5X_X-\ >#?!>
MN?$G6O"T31:Q\2_&?_";^/,ZB+TS^*9='T_1Q,+8$MI:2:9IEFJ61 #;&F7.
M\FNZM65#'9A+EYI.M5C%:I76)C-\S33Y6HM-+XK\KT;'-VJ5/\<K?^!W_0_/
M/XA_'WX_Q>%?C7X:\3:-X2ATKX ']ESPE\0/%WA?QCXB\-^._$WQ'^(\OPIU
M;76\.-I&FM8Z9H-I=^(+N/4)1?*NLV$EQI<=O'9W,C5T<O[6/[1>H>++#3?#
M/PO^$D_AGQ/^U#\1/V6?"E[K?C7Q-9ZU'K7@V+Q5>6OCW7[2S\-WMHFAFU\*
M7=O?:/97,^IW%TR2VQ6*4 ?76L_ ;X5>+;7XK0W^GSW]K\:/$O@7Q-\0FL]:
M<KJ.O?#!?#T/A5[66#S%TX:;_P (MHZ7MK$2;AX)5GV-,X$EC^S_ /##3KC0
M[JUTB^2;P[\9/$GQ[TMFU2=A#\3/%D&O6VMZM("O[VRN(O$NKK%IC$00&>,J
MQ\I<Y^WPO)9T%S+6UI<J;H4XR:2J;^WC)ZZ<C2LM(J;JRT^_;5+L[[I_)]#X
MEUW]NWXAVO@;PC<V7@[X:V/Q NI?CE:^+=*O-<\6^(X9;_X(^,M1\&7$7@?P
MEX1\.:IXZU?2_%-W917J^(]2TC3M'\.0S&TU&XEOF@@FT_#'[9/QP^*^GZGX
MA^$OPM\!7&C>'?V:?!G[0&K:9XD\0Z^GB36=0\26&MW-YX#\+VMEI'D27L4^
MA746GW^J/8BX-Q;PR6ZS[D'ONL?L<_L]WT@O9;3Q%H-S9?\ "?QZQJ6@?$+6
M/"UWJFA?%7Q/+XR\:>%?%-[IMW9R7?A36_$DAU.+3)WMGMI8HQ97B(K!NT\!
M?L_^"_@EI%_-\#]'T_2_$4?P[T#X?^&E\6:IJNI^&4T7PA+?WGA'3M4%E')J
M+:9:7&I3QW5S9^;?7%DR(OF.@=QU<%R>Y0_>.3MSIJ%I5+V;51RLH-)/6RUW
M87C_ "_I^KZ?CTU,KX&?M P_'GQ%XJN/"6GV<OPU\.>#/AA>0>*8YII+G4O'
MWCGP\/%VN^&XD*+;BS\*:%J.A6MU.C23'6IM2LYUA:T"GZ3KY^_9>^ ]E^SK
M\']$^&UJVDW6KMJOB+Q9XKO/#UG=V>A7GBWQ=J]UKNN#0+.^>74+7P]9W5VU
MGH-G>NT]GID$,#! NQ?H&N2O[+VLU1_AI\L&[WDHI+F=^LFG+LKZ(3M?3;^M
M?F%%-=DC>.*1TCEE5FAB=U2694&YVBC8AY51?F<QJP1?F8@<TZLA!1110 44
M44 %%%% !1110 4444 ?/WQ3 /QB_9K!&1_PDOCTX/(R/".0?P/3TKZ'6WN'
M0RI!,\8ZR+$[(,=<N%*C'N:^8_CAJ9T3XC? 76A;O>'1[[XHZJ+2+F6Z.G^!
M)[L6\8')>8PB-0.<MQS7Y]:!H7@7Q;^S-X _:L_:/^-?Q]L_BK\<=,D\7^'/
M&/PI\1_$6[T3X37NN07^O>&?#?AGX>^!H;GP]%H7@O3+>WL-4/BG1]5&I75E
M=I?7:S700?-<,4/:YWQ[)RDDN*,LII0@ZDY2GP1PI))03C[J4).3O==(R;L?
M<\4*_#OAIK_S2.:JRU?_ "</CB[MVMN?LW17YU>'/VK_ (D:YK'PA\'_  PM
M?AU\8_#-_P#LT0_'SXA_'GQ/J/B#P9;W_AKPSKUIX6\4:QH7A#3;*:>35]<D
MBU'4M-TZ;R(+6^0Q7GEV9!%7P[^V?\8KW1OA!\5/$WP5\$:#\!_VB_%EMX'^
M$&MVGCK4]1^(FD:YXJMM>D^%^H_$[0#8QZ/;Z)XVN="DBO(O#%W<ZCX>2ZMV
MN@[;L?7_ %.OVAZ<\5*]I-+EDU-2:A-J#BI6B[Q5U?XCE>NFW]??UMO^!^C]
M.56<A45F9CM55!8LQZ   DGV'-?F/X>_X*,Z?J/B+]FS2-<\$:;H6F_%CP1X
MRUGXQ:U)JU^MO\&/&WAZT\:?V-X,'VF%$U Z]K'PU\?:6)M2:VNHSI%J\<;&
MZ(KY9\??M+_M5_$?0_VD/$.KV/AKX?\ P[O_ /@GWIWQH\,>$O#7BKQ.GC#P
MLWBO6M<D\)Z_IEX;&S%MXVUNWM--M=?!U"*STJP$)TR0W1N ^D,OQ$I-3Y*2
M5M9SCK>JZ5HI-W?-%NVFG*[VG#F%!M]O7Y]O3^D?NZ002"""#@@\$$=01V(I
M.O2OA+X!_M"?&"Z^(_PS^!_QP^''@[PI?_$+]GZS^+GPXUWP=XRU7Q5?W&E>
M'(='TS7M&^(4>JV5M';>)PE]:ZB+S1I;K3KF26XA:4S1,S;/Q@^/WQ;'Q.\<
M_!?X#?#3PAXXU;X;_"BR^(_Q0U;QGXSO_";6=EXL&L0>&?"W@:/3K2Z-[XNU
M&TTJZU-;[5GMM$L$>SBN)?-E)7%X6JJGLWR+W/:<_/#V?L^;EY^?FY;<WN6O
M?F]W<3BT[:;7WZ?.Q]KM%(@8O&ZA7,;%D90L@&2C$@8<#DJ?FQSBF5^)GPS_
M &G_ !!\*_A]\(/%TW@/QG\4_&NB_P#!-SP)\3;L_P#";^+-6NM9O+WQMHFB
M7D6M^%XUU&TOGTV:\DUOQ!XX@BOO%7]D6=Y:VT<\3*A^@?"G[>OBK7OAQJ6M
MV/@SX1_$KQUK'Q-^'?PH^$R?!SXFW>J?#WQMXH^)/VM;2/Q)/XDLK'QKX 'A
M)[*=_$]MKVBP7-W;[)=$$V6"[3R^O&[BE**DH<SE"*;;2O9S=H^\FV[67,W9
M1DTW%_?;MUM^K^>Y^F5* 20 "23@ <DD] !W)K\S?'O[;OQD^%5K\1/ _C?X
M*^ [CX]^!M;^"D>DZ)X9\;ZU-\+?&_A/XW^)V\(Z'KNG>(M0L(_$&CW^AZTD
MEKK6F:G9':L37-N[P.AK2\??M&_M-WMQ\8_A;X1^#GPPUOQK\$OA3!XB^.EY
MIWQ$\1Z39V>K^--!U;5_#OA?X.W%WIZ7FJ>(8/#<%OKEUJ7B0V.FQ7=S;V,$
M@E.]86#K:-^SC%V?,ZM.W*U3:G?F^%^UII-V3E-13O=)6?\ P[7E_FOO/T@9
M65BK*5920RL"&4@X((.""#P0>0:2OQF\/_\ !0#6/AU\/?@W\-=!A^&&K>*O
M"'[+7P=^)7Q$\0?'3XD:]X;O/$]]XJ\*?:['PIX+ETS3]8O=:\:7\&E7MYJ&
MK^()8M)BN;FP2>622[=E^EOAE^V+\0OCS\5?!/A3X.?##PE_PKW6_@E\._CG
MXK\5_$/Q%KNC^)= T/QIJU_H6H^%]-\/Z78RV]_XETG5-/GBMI;J6#3;B&)Y
MYF5)8<N>!Q$$Y.,5!)OG<X17*K.+=Y:<Z:<%N[Z#Y7:]M-_ENG\T?0?P8_Y'
M?]HS_LKDG_IBTVOH"O /@SC_ (3C]HW&2/\ A;LN"< D?V%IN,@<9QUQQFO?
MZ^'X(_Y)VC_V-.)?_6FS@^V\1O\ DJJW_8CX.U_[LW( HHHKZP^'"BBB@ HH
MHH **** "E'4?4?SI*5>H^H_G0!\^?"@$_%C]HCC)_X2;P@!W/\ R+K8 []>
M@KZ(DM[B$!I8)HE;[IDB= WT+* ?PK\KOC_X^\;>%?$OB_P+X \17_@C7/C_
M /M/_ _X(7/Q TJ*WEU;P-X?\5:+=7'B'6M&:\CEM+?7+G2[&XTG1+RXBE2T
MU*^@N%BD>-5K1CT3X#?L_?M)_"/P7X*^.?QR\">-=7\9Z+X2\7^%_'MW\4/B
MA\/_ (RVOBVQN8],T&ZU_P 4K?>&-!\9RW<)U+3-9\/ZAIHAN(9K.?3FCE")
M\YP-AG/A^<W)J4L^XTE",:<IWC2XOSM2E-Q=X1<GRQ:C+57FH1M)_=>(BOQ+
M#6__ !BW -E:^W ?#7W>6F_;<_3JBOS%\*_MO_'+Q#\.[?XB2? KP$8_B!\9
M=1^ 'P-\+:=XYULZYXI\?Z7XF\1Z1>:]XTN[VP33?#G@2#1?#5_X@DELGN=;
M*026J0%Y(<]3<?ME?%'P'XVB^&OQF^$?@W0?%&@_$7X/:'X^UWP7XNU;6/ ]
MO\,OCA>:]X9\(?$7PO=ZK:6NJ&XT[QYH\7AOQ%HVO10""":6_MI&01 _7/!5
MTY)J%XW3BJM-R]UQC*R4KNTI1BVKKF?*KM.WP_*_Z?E?\+JY^B-.".0S!6*I
MC<P4X7=PNXXPNX\#.,]J_,KP5_P4#UWXBW^K^$_"/PRT%?B+<_M/Q_!#X>Z)
MK>LZTFC>)_AO-;ZW?P_&;4;NQM7O+;33I?A7Q-J1M[&.6R:WT^$).S3YKYX^
M&/QC_;!\2P?L-ZW>6O@KQO\ $GQKXN_:PTB&TF\<>*-$\%ZMH6B?:+.#7?B6
M8[*":[3PA<6;6>AZ=I.GW5RUE]BN(6COGO&-+ 5_>YW"FXWTE.-W^ZJU4UK;
MEM2<7)O1NZ3496.5];+_ (9N_IIO_P $_;JG*CMNVJS;5+MM4G:B]6; .%'=
MC@#N:^>_V<_C1K/QD^'FO>(O&?A;3?!'C'P+X^\?_#7QWH>B:O-K_AZW\1?#
MO6+G2=6OO#VK7$,%W>Z)?"W%Y8&\@BO$BD$5P@E5J^!/%W[2/QW^,<W[(?Q"
MTWP!I'@;X!?$S]L'X;:3X/\ $>A^/M7_ .%BZGX8L_$VIZ;!-\1_#,<5KI'_
M  CGCB*REEM]'LKN\-LDEE'K$#>:VW.GA:DYS@W&'(^64G*-N;EE)1C[WON2
MA)KE;NE?LF<KO;JK=>__  -?D?K^RLAVNK(V <,"IPP!4X(!P000>X((X--K
M\=+;]NG7/A7\/OAQ8^'?!7@?PY:^-O$'[0=__P )C\>?B3\07^'PU/P/\7/$
M?AVW\"6/C^#2-6N[+QEXMDB?4]%LO$LVG>&-!TT_88;C['9Q ?2S_M3_ !I\
M?^*=-\ ? /X-^ -<\::/\&_"/QB^*2?$;XD/9>&/#<?CAKQ?#7@?PKK_ (,@
MU6W\3:[JPT^ZNH]=5QX=M+*6T>YE,CR*MRP->+U45&\USSJ4X)*$N24I-SM%
M<UH[O5I;R5URO\7OY.UWV_KR/O6G*CMN*JS!%W.54G:N<;FP#M7/&3@9XS7Y
MN^ _VXO'?QF\9_#W1_A1\*O"D?A/7/@E9_&_XAZ]X^\5:K8ZIX(T[3?&NO\
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M%S<W=C9_'CPEX&^'=Y\*!86C/)':R:M;>(+C3Q:6\2"]>&X<?/&Q'[N>+?\
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MB[U[2B=-UB>0E]1LB;>Z,L7RUCZ!^SU\!O"FE:]H7ACX,_#+P_HOBJ[TN_\
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MBDVWQ!DJ22NVWF6&LDDKMMO9:MLG^$__ "2WX;_]B-X7_P#31:UZ'#_K8O\
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M<ZE:VD,LK_: 9#]R45?UO$:?O-FW;DA9MN,N9KEM*2<(.,FFXN*Y6K!S/O\
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M42YZO(WRHHY)Z5\WQG7J5.$>*O:332X;SY[1BD_[)QBOHDKN[OW;;=V[GUG
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MPW_@R?\ \J#ZK4[P^]_Y?U9^5_&Z*]D_X0K0?^>-Q_X%3?\ Q5'_  A6@_\
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M&Z*]D_X0K0?^>-Q_X%3?_%4?\(5H/_/&X_\  J;_ .*H_P!7,P_GPW_@R?\
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ML[J)9[6[L[J">2"YM;F%TF@N(7>*:)UDC9E8$V/^%I_%S_HW?Q/_ .%%HO\
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M  *F_P#BJ/\ A"M!_P">-Q_X%3?_ !5'^KF8?SX;_P &3_\ E0?5:G>'WO\
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MQ#/J/A?5+BWN+WPEXG@A^Q:QIA4%H;^WO+6#]'/^$*T'_GC<?^!4W_Q5<O\
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MUC$?]!%?_P '5/+^]Y(/JV&_Z!Z'_@JG_P#(^2^XT_[:U?\ Z"5[_P"!$O\
M\51_;6K_ /02O?\ P(E_^*K,HH^L8C_H(K_^#JGE_>\D'U;#?] ]#_P53_\
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M]!^+>A7-U$1<#0[KPAJ%UJ>JV:MY5V-*A65'"@5^]ZJJ*J* JJ J@#   P
M*\>_: ^%7A[XW?!KXC_"GQ786VI>'O'O@[Q!X4U>RNXUEM[BPUW3+C3KA)8V
M&'0)/O*G@[>:BECL0L3"M4K59)U%*HG4G:49.TU9.R3BVE9:=-BZN P[PTJ-
M.A2C)4^6G)4X<RE%+EE>UV[I-W>NSW.4UK0?!/[4'PJ\*^.=(ODU?0O'?A30
M?%_AG5ED,D5]I'B#2K76-'NP03@S6=Y;RAE(>-F(!!!Q\UZ?XO\ %7P<O(_
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M(2S"^;8Q^]2PTJ=*C@Z6L5SK!THJA"G!VM5Q*Q%9:*-64K)ZOQ3_ &W/BO\
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M -GWX-Z5:0V ^'_A[43;J(WOM8LDU34;J11A[BZO;SSIY99FS(^7VAF(557
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M&QD)#"6\V:1NB)&C,QX4$\5\D>*?VK+WQ*T^B?"#P5>>(&F#0CQ%XAMY[/2
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M?#'-;V_^LF5^SYXI13_M.C[%-1;O!+DN[J35]F?YD?B_]L3]O/\ ;:_;V_:
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MH0J]NTE?T&>%M!LO#.@Z7HEA;Q6MKI]G;VL,$*+'%%'#$L:1QH@"HB(JHJ*
MJJJ@ 8K\'_\ @B/\)_&?Q,TCXV_\%*?CGIL]O\9OV[_',GQ(TRPU!7:;P/\
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M^'VM^"_#%O\ &+Q!$S? SX:_$/PCXK\?^-IM$B^(/Q5\7ZI=2>*M.N/#FF>
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MNGVP:YNKJ2*-OLUK$AEN)-L<09F%?E$G[,_Q(\(Z7^P=K\'Q4_:$^(5WH'Q
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MG1]36*5K36?!'[+>FWD<8US6)4$UK=?$23_B7::0\FGE607%>3ZS\-?VK_\
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M:>._"NO>%+B_M$BEO;2WUO3I]/N+NR@F=$GGMHYS*D;'864!R 2:^4)/V%/
M#>(/$GB >+_$P?Q%XJ^#/BN/3GMK"33M#NOA-=>';O5+718=Z_9(/B5<^$?#
M=QXL(.Z.ZTF&ZMA+,\CM\??M<7G@'3OC+\;O%WB'6O WBK5O"6@^")9/ASX]
M\>>*_A!\8_#MG8^';74;76/V5_$VEZRVB>(GUFXD%PELWAG4]0G\=I?Z-++%
M&L<1Z+P9XY^+?_#0/C?P'X2^-'B33XO'W[47C74=<\.:IX>\*:QXLT+POX:_
M9"\!_$GP]X8LK+4K>9]$3Q-JUNNAW5U+ OF?V-?W6G%=4N-4G;]WIT*T*2E2
MK."E3=62E!Q7NJC4DDUSR=ER/F<8QE9*+DI,\6KB</.I)5J'-R5?91<)J4FI
M*I",G'W8J[YER\[G'>23BK_1-C^PNFGWEE+!\=?'2Z=X7\'_ ! \"_#K2&\,
M>$;BU\)>'?B%XF;Q9J=GJGV^&]@\:"*_DET^1=7M+:*_T"5M,FBCE O:?X<_
M86L/!-JUYX!^,/BKP!XQU9/&>F^+/$7@WPKX;T31]1\->.M175-5T#PGX*MY
M#HWP[72[T2WGA?4-!GGET2^N[N\:WOY)5$?Q)8?MB?M2:CX&\5^*4^('@*SU
MC6O!NJZB?#C7'@W7_$/PD\1CXQ>&?!&E"V\%Z1X>M=6L;33M/U:ZT?6M/^)6
MJ/<7E_"E]I_VEI,5[IK?QR^,?AKXQ>+/@-XS_:(TWP+X8\)>-_&5LW[07B'P
M9X%L+J[;3_A;X&\=>&?A_>V=_;Q>$+:ZO+[Q-KMS'<+!%JFKZ1X?%E9EKD73
M'1TL<G).M2=N=R27-=0Y92;2HM27-43Y?><I-RL]S&-7+]'&A7BG;E=U&SFU
M9J]5<K:A9NZ22Y7K[J]7U;_@GOX#N+T:UI/C:]L_$EQ??$&/4-?\4^!O!7Q&
MN+WP[\0_%)\6WNEP6WC.UOK:R\0:+JAG.A>,H1)?1B[OS>:=>"?RX_N_1-)M
M?#^B:-H-DSFRT32M.T:R,PMTE:UTRSALK8R):PVMJ)## A=+6VM[=6R(;>&,
M+&OX%^#O'?Q8^,/B;X<^)]7^.VJ:?XT^)C?L':Z(=,TK0H;&P?7K[QO;ZYXK
M\.^&)AY<MI-/;22/;7<$^BO=ZPD&HQS):V,:??7P$\;>./BS\6/#WASQIXG?
MQ5??L[W_ ,:Y?$'B2VTZTT!O$.J7OB-_ '@)/$6CZ08=+BO9O"=UK.JI';P"
MT>^T7[;%$DS$KEB:%?E_>UHS]G%R:Y6G&\5+=QBG%S:IKWM&TU&SL;X;$4%.
M]'#S@ZKC&+<U:24N1>ZG+EDH+VDERVLM9=7]%>%O^3GOC!_V2_X7_P#I5JE?
M2ND?\A;3/^O^T_\ 1\=?-7A;_DY[XP?]DO\ A?\ ^E6J5]*Z1_R%M,_Z_P"T
M_P#1\=?"\$?[MF/_ &6O%W_K69F?=\;?[Q@/^R,X._\ 61RDT/%7_(>O_K!_
MZ30U\=>,/V3/V8?BGXZ\0>+_ !#X'TK6/%E[>:=_PGMCHWBC6],TWQ+?VL,3
M::/B1X0T#6;31?$EV;6*$1CQ3I=Y+<6<44;"2!5%?8OBK_D/7_U@_P#2:&OP
M*E\>WW[.?[4'[97Q8TB6X"?'CXI^,O@/96]L'G"_'/2/ ?PXO/@Y?F!,D7ES
M!K5]I=NF"9X[6Y.4\O-??5*=2ICLQ]E5G3J1KUW#D<ESMXFSBY1::2C>6SNX
MI6N[GP,:U.E@,L56C"M"6'H<W/ROV:CAXVG%2BTVY.,7K&RDW?H_U,UW]G']
MGWXD>)X/B!>>%].U;4H)-$LKY_#GB;5]/\,:]-X&DCA\.6?BWP]X=U>V\->*
M9?"$EK#;:5!K]A?R:/\ 98;:)85MXT2X/V7O@0/B%>?$]OA]82^*K_4M1URY
MBGO]6G\+-XCU?39-'U;Q2G@F:^?PE#XIU32YI['4/$4.CIJUW;SSK/=.99"W
MX]_!'Q9XI^ /P6\(_L_>!O'FH^&-5NOVD?VTY_$,VA:EX'\/:[K3^ O&.F3:
MQ>6OQ#^*,Z^!?#FFQ>)]=OM0U:TNH=0U_6[>:UM=)MXHX+RY3TWX:?M"?M)?
M'KP7HOB&Q^.,_P /[C0OV,IOC/JI\.>%_"VI+XG^(^@>/O'?AR&_U![R.Y@A
M\/ZI9^&X5U_3]-9%OG$;Z?<V(5VD4\+B(\SCBG[*,G24I2JQO!RE%>Y%3M&3
MIM<J;7NK7>RI8S#SY5+!159J-5QC&DU[1*#=IRY+RA&I&5VDVFVEJG+] ;']
ME3]E'P=HOCK2!X5T+3]&\0>&8? WBB+7/&FL7":!X)O]2BU>T\%:+<:QKDLG
M@3PM=:G:PWEGX?T"32-/FFMXS!;L(5"^E^+?@!\'/B&WB&\\5^#K+7I/&'AC
MPQX7U>[DO]162?0_"-\=8\)OIMQ:W<;:7J.B:@_]H:7KFE/:ZI#.5ECO.!7Y
M%>/;_5?VD/%?@6#Q3KJ:%IGB[X\?\$[=7\0:/X;T3PJ]EKUQ\1? 'B/Q'?VN
MN1:YH^JKX@M+'4D$N@6FM"^MK,90121EA74?"3]K/]H_Q!XN\/ZYJ.M:-H>F
MZ[X]^,7@76_A]XKUSX:V?A/P'X7\ Z;XNA\-WFA>!-"G?XO1>(O#K^&M)U?Q
M)'J-C]CUG1]4NOL5M910V/GDL+B7%36(DYQ7-)3G-<K<(5$HRNW*3Y7VMR0U
MNU8AB\)SNB\+!4Y.*CR4XN\74G3<IJR48J3T3;;4I-*RU_0VW_8N_9NL-!.A
MV?@C4+"(>-9?B0=>M_''C6V\81^-[K1(?#FI>(U\;IKZ>*(KW6=#@33M=(U8
M1:S;[AJ27!=B>S^'_P"S;\&/A1=Z-J?PV\$V?AC4O#.G>/=/\-RPZAK%U:Z7
M#\2]8TCQ'XQC2SN;^6&2+6]?T'2-3N0P\R*6VD%I);BYG\S\=?$7Q[^*'CKX
M!?&KP3X^^-WC&+QC+\.?AA\3K?7/#6I_#+7/"!TR[^*>E:)KNN>"OB+X%DEC
MT+PGJ4-S;P+X%\<:?:>(].BLY9KB^N89+V"/U'QO^US\4_#?Q<TEO"7Q9O?$
M_@WPY^TK\&O@!=:?/>_#+3=!UK0?$)\'Z/XL:]\-WLH^(WC'Q?=RZ[>ZY;^/
M?#-M8>#+$?95M[6\LK2ZF9/"XN5X/$.>LTTYU.65HT]I-<KYU6<5?M):\UAQ
MQF#BU-86,;*G9QC3YXWG.]TGS14/8QE==>7:US]&_P!G_P"#%K\&9_B7JWB/
M7O"FM_%3X[?$;5/B1XXU7PWHZ^%M/U2_M=(T_1].TK1- N=5U>^^Q>'=$L$>
M>2:^N[E[J_OKNX:..:)5^DJ_!?PK\4?'GPA2Z\2:%XNO/BUXLT/Q]_P4*UJT
MTKQ?'HOB+6-"U#P7X>AN-(M+66QLX]?TG3A$XU?5=+BFA;5-,TT6D06SPH[O
MQ_\ M)?&WP!X;UC1/ /[3&E?&2^\4_!'X,_$]?B(F@>$M17X2>-/&?QR^'7@
M2\T\Q>'W.E2>%/%^D>)M4M]&\)ZX1K^GC3KK&H2&1)XE/!5:M1/VL).;C%2<
M9Q6DE2M90:C&"4;)M76D$VK#IYC0HP4/8S@HQ<^6,H2>L%5>LIIRE*4I7?1_
M$T?M;17Y&?$KXO?M"_#G4_BU\(++XW6VOZEX7^+GP7L=&\6^);GP)X \?ZOX
M3^(O@/4_%'B3P+X8\2Z[:Q_#O3/$\6IZ1-<>&-1\3VT,#:)]JTG?=:JUF\OV
MY^R+\4[CXO\ P-T#Q5?Z]KWB75[+6_%GA37-7\3:%I.@:U+JOAGQ!?:9/:WT
M/A^\O_#FJ3Z?%'#8R^(?#UW+HVO36\FI6:P"=K>+EJ8:=.DJW-"4&X)<O/>U
M2FJD)-2A&R:=M7>^FNMNVCBX5:KH\DH349MJ7*TG"?).*<9.[B]?1INUU?0_
M:0$EEX:\&>)WBEETOP?\1O#&NZZ\*-*]GHZ7#076H.B*S&"S\Q9)V"G:ASQQ
M7NUGKFC:K:P:EINK:;>V%]&MS:74%[;/%/!, \<B,)>C*P.#@@Y! ((JW<6]
MO=P36MW!#=6MQ$\-Q;7$:303PR*5DBFBD#))&ZDJR.I5@<$5X=/^S1\%)YI9
MU\%Q6IF=I&ALM5UBTME=R68Q6\-\L42DDX2-511PJ@ "OB<5@,^P&=9AFN24
M,IS"CF^'R^&,PF9X_%Y74PV)RZ%:C"OAL3A<LS6->CB,/5A"I0J4*,J52@JL
M*U55I4Z?V^&Q^18_)LORO.J^:Y?5RG$8^>$Q66X#"9G3Q&&S&="M4H8G#XG,
MLKG0JX>O1G.G7I5ZT:M.NZ4Z--T8U*GM_P!LL_\ G\L__ NW_P#CE'VRS_Y_
M+/\ \"[?_P".5X7_ ,,Q_!;_ *%2;_P>ZY_\L*/^&8_@M_T*DW_@]US_ .6%
M5]<XX_Z)_AC_ ,2S,_+_ *H_U_K>?J?!?_0_XE_\17+?_HN_JS\K^[+?6J9*
M7]JI/!*WD"Y'H<2BF_;+,];VS_\  NW_ /CE>%_\,Q_!;_H5)O\ P>ZY_P#+
M"C_AF/X+?]"I-_X/=<_^6%'USCC_ *)_AC_Q+,S\O^J/]?ZW7U/@K_H?\2:_
M]4KEO_T7?U9^5_=/MEG_ ,_EG_X%V_\ \<KYW_:4UK3;OP+!X&LKN"^\4>-]
M?T#2M#T>SFCN;V?9JEO/=WK0PF1TL[*"-I;B9PJ*H.&R"*U/^&8_@M_T*DW_
M (/=<_\ EA78>#?@W\-O >H/JOA7PK:66KR1F'^TY9;O4;^.)L;H[>>^GN'M
MU?HY@\MG7Y68KD'@S3"\8Y]E^,R7%Y=P[E>#S3#U,#C<=A\\S',\30P>)A[+
M%/"X*IP]EM*KB94)U(4'5QE*G2JRC5FJL:?LJG?EF*X1R+,,'G.%S#B#,\7E
M>(I8[!X*ODF7Y9AZ^,PTXUL*L5C8<09C4I8:%>,)UU2P=6I5IPE2@Z4JBK0]
M'MXF@MK:!B"T%M;0.1R"T,$<3$'N"R$@^E2U)Y,O_/*3_OAO\*/)E_YY2?\
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M&K^-]7BN2MY"/[.)\F.:OI_]@3_@EEX7_9ZU;6OCS\;?%FN?M#?M;_$M4O\
MXJ?M#?$@+?\ BW7+N8+++H?A:WFWP>"? MA(6M])\,Z*MM"MHD8N]Q_<Q_L9
M!;PVL20V\:11( JHBA5  P, 8%<TJU+#Q=+"MRG)6J8IJTI7WA16].D^KTJ3
M7QM1?LUU1HU,3)5,4E&G%\U/"IIQ6SC.JUI4J+=)>Y3DO<3DO:/,T/0-,\/6
M,.GZ7:Q6T$**BB-%7(50HSM X   '8# P  #7=!TSQ%83:=JEK%=6\R,I61
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M)D?#<I\SY>2,LRQ5>,IWMRQE1J4ZR;LG2G"HO=DF^<^"LB1?!GX:RR,J1Q^
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MW3[=A=7MS:SWS7WDVH,PCMGE7:$+#Z]^(?\ R3_QS_V)_B3_ --%W7E?PU\
M^$/&GPQ^ 6L>)]%M]8O_ (>V>B^+_!\MR\A31O$R:+=:7#K$4*N(I;NVL]0N
MDM6G606\LHGB"S(CCY52A'C_  4IIRC'A3'R<5;WK9SEK47=K2323>Z3;2;T
M/I)1G/@3'0IR4)RXIP,8R=_=OD^/7,K:WBG=+JU;2]U^87AWX]>,_AQ^RO\
M&SX)Z'XR^)T'B?X/_$?X7^#]'^*?Q/TW5-,^)=O\"/C-K^DV<OQ,OX_$QN]1
MEO= U"?Q5HRZ[>^?!9-+I;*4%M&J_5'QC^$OPX_9X\/^-[SP#\8_B%X-\2>)
M_P!GKX[6MA\/M=^)'B_QL_Q2N_#?@.[U:+QYI\WBK7-7U+P[XC\&R.FI-KOA
M672K&Y_M*.*2W4Q6NS[0\2?!_P"&GC#Q)JOBWQ1X/TG7=<UWP%>_"_7KC4HC
M<0:YX"O]035;CPUJ]HS>1?V(U&-;NW,Z--:2Y:VDB+'/G/A/]D?]GKP3'XC3
M0?AY;B3Q3X0U+X?ZI=ZOK6O^(;Z+P+J]O+:ZEX2TB\UW4]0GT71+RWF>*>UT
MUK<S((Q+)((HPOW3Q5)OF2J0DY.=2,5!QJRE&"ESMN*LIQE4BN1V<WRJ$O??
MPL<%B(V3E3J*,53IRE*:E1A&4FO9Z-^]!JG+WKM0]YSBU!?GW/\ &CX_ZI\/
MOV ++Q/\'O&_P[\/ZK\7O@5!JGQ+?XP^$_$3^-[-_"&M2R:?JNA>'=4D\2WU
MOXF5/M\]MK*30F6%$U%'N#&:^@_VI_VE]-U;X&ZKX<\"6/Q<\->*?BAX\T#X
M,:7<#P%XGT+QO8V>OR2WGC3Q7X+TM5BU759?"W@W3]8U,7NF,C6TBPR)(CE6
M'V1??"+X=:EH?P[\-WOAFTGT7X3ZSX>\0?#ZP:2<1>&]8\*64^G>'[VU*R!Y
M)--L[F>")9VD5ED)<,:VM8\">%?$'C'P=X_UG2EU#Q9\/X=?A\':K//<$Z%_
MPE%B-,UV>TMQ(+?[5?Z=NL6NGC::.VDEBB9%D?.;Q%%SA-T;*$IS48-J+?,Y
MPYN>51M-\L9ZI))N,7L]%A<3&G4@J]_:*$6YV;4>6,9M.$(6<5S.-DFW:\E9
M'XP:]\4/$OCO]EOX>_"?[#\4_%_C+X6_MG_#SX*Z]X8N_%NO_"/XF_$SX?7<
MGB;6? 3:[XENM6T;6-';Q5X2:R6\OM2U6--1FT&::YFEDFR?TC_9>^'$O@2P
M\8W%W\#_ ![\$;O4[RRMQIGCCX[ZC\<'URUL[>66.^T^[N_%OBFV\/K;S7$M
MM-;Q-9SWA5991+&D17J_B1^R[\#/BUJFOZWX[\$IJFL>*)O!=UKFIVNKZOI%
M]>WWP\-]_P (9J/VG2[RUFAU'04U*^@M+V!X[C[-<20/(T> -KX5? /X9_!:
M?7+KX?Z=KEA-X@MK:WU1M8\6^)?$RRQ6+7$ML(8]?U/4$M&5[F4R/;+$\H*B
M4L$7%5<12G2E""G!RDYN-I.+E+D<E=5HPY>92<;T9.UK<NBBJ&$KTZ\*E1TY
MQA'D4ER\W+%2C%^]2E.[7+S6K15[Z7NY\_\ LP?\DL7_ +&WQC_Z?[ZF_'[_
M (_?@I_V5W1O_2*ZIW[,'_)+%_[&WQC_ .G^^IOQ^_X_?@I_V5W1OULKK%?C
M*_Y-'E'_ &)^&/\ U.RH_:)?\G:SC_L;\2?^J_,CR/\ X*+:;KFK_LQ:II_A
MN26WUVX^*GP*72[V+2)=>&F7@^+WA P:K/H\3Q-J%KIDH6^NK5I[>*6""1);
MFWC+2I\O_M&^!/CMHOQ723XH_$JP^+R77[&'[:%KH<WAKX/_ /"OH]"NGTWX
M9B>WNGT_Q'XI75;C6,0BQM9&LY8S93B!+HR2>5^LWB3PUH_BJQ&F:W;RW-FE
MS'=+'#=7%HWGP$M"YDMWC<B-]LJ*3M$L<;XR@KC&^#?@!R&?3=1=@K(K/K^L
MNRH^S=&I>\8B-O*@W1YV/]G@WJVP[OUZGC*U!1A"A2J0C*K)RG44)MU84X6B
M_85)045"^DUS7LU8_+:>691BH2JXW,\PPE>:I15+#952QE&,*4G-2=2>=8#G
ME/F:<)8>U.RE&<F[1_+G2/!_QBT'4?\ @GY=_'/QV_C7X+MI'@J?X=77ACX7
MV_@?4OA;\?AX!AB^&=M\2KVUU/Q%?:KX*NTFN-)34(DT4#Q'%:1Z[ +*Y:->
M&O?C3\#_ (,_L.>,_P!G?XS^$?%,GQSU:V^,?A;QKX-@^&WB+7=;U'XOZMJW
MB35O#7Q&UO6+/2I+>/1]9NK[P]K6A?$"2]>VLXK6-3<6ATUHX_U^;X-?#YXQ
M"^EZ@\(\O;"^O:R\*>45,.R)KQD7R3'%Y.%S'Y$)7!0EDF^"_P .KAB]SHUY
M<NUN]HSW&M:M.[6D@99;4O+=.YM949HY+<L8G1BKJ0S9T6857RJI@X-1G&?[
MK%*C>4)U)QT6#E%7]HU.R3DXQE=/FO4LER&/,Z6?9LI2A*G>KPYAJON3ITX3
M5Y<4*3UIWA>7N\TE9JS7Y#>,?'?Q)T'2OB%%XU^+_P 5-$^/7P_^&GP%B_9/
M\(^!Y=6N_"GQ0U*_^'WAB6^U!;*RTB\T?X@3^*OB)-JGAKQB^LWC+H^D0R7%
ML;'8+QOIK]ECXV_#CP'X_P#VF? /Q(\6:;X0^)/BW]JK7=0L/">H66M1W6HS
MZWX*^']G%)ILD>ER6EQ9W6K07MG;7"W/DM);NA==N3]N1_!7X<PK:I#HUW"E
MBABL4BUG58TLHF4QM%9JETHM(FC9XVCMO*4I)(F & 5!\$_AK]J2^.@R/>1R
MI.MU+J>H2S^=&Y=9&E>X:1FW-(268D^=+V9=DSQLZD'"6#@KQ2;ABE%W7L]O
M]D=HW@Y.+;;E.3YE=EPRG)*<U4CG^:R:ES1C/AW#N-O>5F_]9F^:TE%24?AA
M%.+LDN9_:;&/@[KX/4:MX8'_ )7+2O<[+_CRL?\ KRL__2:*O#/VFSGX.Z\3
M_P!!;PQ_Z?+05[G9?\>5E_UY6G_I/%7Q6"_Y+CB'_LFN%?\ U8\6'T.,_P"2
M,R#_ +*/BG_U7<)EFBBBOK3Y8**** "BBB@ K1TC_D+:9_U_VG_H^.LZND\*
MV+WFKP2 ?NK,BYE;' *?ZI<]-S28(!ZA6/:NC"4Y5L5AZ<%>4J]*WRG%MOR2
M3;?1)LY\74C2PN(J3=HQHU&__ 6DEYMM)+JVD>L7]C;ZC;26ETF^*0=1PR,/
MNR(W\+H>5/X$$$@^5ZEX3U.Q=F@C:^MQDK)",R@=A)"/F# =60,G&<C.![!1
M7WV/RO#8])U5*%6*M&K3LI6_EDFFI1[)JZN^5J[/@,!FF)P#:I.,Z4G>5*:;
MBWMS1::<96T;3L]+IV5O SI^H X-A> CJ#!("/PQ2?V?J'_/C=_]^'_PKWVB
MO)_U8I?]!=3_ ,%1_P#D_7^EKZ_^L]7_ *!*?_@V7_R)X%_9^H?\^-W_ -^'
M_P */[/U#_GQN_\ OP_^%>^T4O\ 5BE_T%U/_!4?_D_7^EJ?ZSU?^@2G_P"#
M9?\ R)X%_9^H?\^-W_WX?_"C^S]0_P"?&[_[\/\ X5[[11_JQ2_Z"ZG_ (*C
M_P#)^O\ 2U/]9ZO_ $"4_P#P;+_Y$\"_L_4/^?&[_P"_#_X4?V?J'_/C=_\
M?A_\*]]HH_U8I?\ 074_\%1_^3]?Z6I_K/5_Z!*?_@V7_P B>!?V?J'_ #XW
M?_?A_P#"C^S]0_Y\;O\ [\/_ (5[[11_JQ2_Z"ZG_@J/_P GZ_TM3_6>K_T"
M4_\ P;+_ .1/ O[/U#_GQN_^_#_X4?V?J'_/C=_]^'_PKWVBC_5BE_T%U/\
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MBGG@MHGGN9HK>",9DFGD2**,$@ O)(51020,L0,D#J:/]6*7_074_P#!4?\
MY/U_I:G^L]7_ *!*?_@V7_R)X/\ V?J'_/C=_P#?A_\ "C^S]0_Y\;O_ +\/
M_A7OH((R#D'D$="/6BC_ %8I?]!=3_P5'_Y/U_I:G^L]7_H$I_\ @V7_ ,B>
M!?V?J'_/C=_]^'_PH_L_4/\ GQN_^_#_ .%>^T4?ZL4O^@NI_P""H_\ R?K_
M $M3_6>K_P! E/\ \&R_^1/GJ[T6XOK2ZL;K3;J:UO;:>TN86@?;+;W,30S1
ML,='C=E/7K7S+X?\.?'[X0V;>$/#G@6R^*7@VRGN&\+WDFO0>&-=TG39I7G3
M2]4&H026]V+5Y'C@FMP2T87<RJ%CC_1^BO#S7P[PN:5\)C:>=9IE.8X*%>CA
M\QRN.#CB%AL4Z,L3A:M+'X;'X'$8>K4P]"KR8C"573J4H5*,J<^:4O<RKQ#Q
M664,7@JN397FN78V="M7R_,Y8R6'>)PJJQP^*I5<#B<!C</B*4*]>ESX?%TE
M4I5ITZT:D>51_/\ _P"$Q_:-_P"C;O\ S)6@_P#R%1_PF/[1O_1MW_F2M!_^
M0J_0"BN#_B&N8_\ 1Q>+_P#PAX)\O^J3\G]_D=W_ !$G ?\ 1O.$?_"WC3_Z
M*S\__P#A,?VC?^C;O_,E:#_\A4?\)C^T;_T;=_YDK0?_ )"K] **/^(:YC_T
M<7B__P (>"?+_JD_)_?Y!_Q$G ?]&\X1_P#"WC3_ .BL_/\ _P"$Q_:-_P"C
M;O\ S)6@_P#R%52^U?\ :=\06L^D:;\'=*\"W%]&]M_PDVK^,++7X-+24;'N
MH=-TRU2>>YB0L\"L'C,@7>I7-?H714S\,L;5A*G6\0^,:E*I%PJ0CA^$L-*<
M))*45B,'PSA\51<E=>TP]>C6A?FIU822DJAXF82E*-2CX?\ "%.K"2G3G*OQ
M9B%"<7>,G0Q?$N(PM9)I-T\10K49_#4ISBW%_)GP[^'+?#OP=HWA*QAO[U=-
MBE>ZOYK>19=0U&\GDN]0O77!V?:+N:5TCR?+C*)D[<UF_%3X8:A\1?"K:1:O
M>:-KFG:C8Z]X:UD6DDO]FZYI<PGLY98PI9[65@8;M%^9H6;&[&UOL6BO8J>'
MN3U,F?#[E*.4?4(9;'"0C*"A@Z=*-&G3IU85E6ISI0A%TZT9JM"I&-6,U4BI
M'CT_$'.*><+/XQB\V6/EF3Q4Y1FYXR=5UJE2I2E2=&<*LY252C*FZ,X2E3E!
MTY.)^?4'B7]IJPB2SU'X$Z9XBO+=5CGUK2/'6G:5I^HN@VM=06&HVCW=L)B-
MYCD*[2Q"HHPHE_X3']HW_HV[_P R5H/_ ,A5^@%%>0O#/'Q2C#Q$XPC"*2C&
M6%X/K2459)2JU^%JM>HTE9U*U6I4DWS3G*5V_7?B5@I-RGX>\(2DW>4EB>+Z
M2<GNU2H<3TJ---ZJ%*E3IQVA",4DOS__ .$Q_:-_Z-N_\R5H/_R%1_PF/[1O
M_1MW_F2M!_\ D*OT HI_\0US'_HXO%__ (0\$^7_ %2?D_O\A?\ $2<!_P!&
M\X1_\+>-/_HK/S__ .$Q_:-_Z-N_\R5H/_R%1_PF/[1O_1MW_F2M!_\ D*OT
M HH_XAKF/_1Q>+__  AX)\O^J3\G]_D'_$2<!_T;SA'_ ,+>-/\ Z*S\Y-4\
M&?&SXPW>CZ1X]\'67PX\ Z=J]CK6L:5::PGB/7_$D^ESI=6%@+RQA2TLM/%S
M&LEPV$F< +B1=R5]/?V??#A=/NE4 !56W<*J@855&. H  'H*]]HKT<H\/,)
ME53&8F6;YEF>89@Z'UW,LRCA9XJM3PL9QPM",,'1P6"P^&PZJUY4J&%PE"FJ
ME>M6FIUJM2<_.S;Q!Q>:PP>'CE&6Y9@, J_U/+LM>*AA:-3%2IRQ6(E/&5\9
MC,1B<1[&A&K7Q6+KU/94*%&#A2HTX1\"_L_4/^?&[_[\/_A1_9^H?\^-W_WX
M?_"O?:*]K_5BE_T%U/\ P5'_ .3]?Z6OC?ZSU?\ H$I_^#9?_(G@7]GZA_SX
MW?\ WX?_  H_L_4/^?&[_P"_#_X5[[11_JQ2_P"@NI_X*C_\GZ_TM3_6>K_T
M"4__  ;+_P"1/ O[/U#_ )\;O_OP_P#A1_9^H?\ /C=_]^'_ ,*]]HH_U8I?
M]!=3_P %1_\ D_7^EJ?ZSU?^@2G_ .#9?_(GC%AX8U>^=<VSVD)/S370,>T9
MZK&<2.>N HQD8++UKU32M*MM)MA;VXRQ^::9@-\S_P!YL= .BJ.%'')R3IT5
MZN RG"X!N<.:I6:M[6I:\4]U"*244^KUDUHY6T/+QV;8K'KDJ.-.BFG[*FFD
MVMG.3;E)IZI:16_+?4****]0\L**** "BBB@ HHHH **** "BBB@ K'\07>H
MV.AZM=Z/;6]YJ]OI]Y+I=K=R216ESJ*6\C64%W+$K2Q6TMR(TN)(U:2.)G=
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M'7(4 MK7B@=<8)/D''N><5]>7/P0^'DOB>R\6IH5G!K%G(9(;B*",$.Q&XY
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MGC.]^'6G> M%T34(;J*\^*0G\,WVOQV37?@:>TMM(UZ]TZ[U""X-?]CKQ/\
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, !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img149481191_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_7.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &0!)P# 2(  A$! Q$!_\0
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M^$GTO^]/_P!^3_\ %4?\)/I?]Z?_ +\G_P"*KSBB@#T?_A)]+_O3_P#?D_\
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MZYDU.Q0:8;#7K-[8OJ_VB'329[420B\62(K(JL-#QI^U;^SS\#-%\$V_Q?\
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M#/&OB5(GG.CZ1=7?VLQ1F0.\8NK.VCE"^5)GRW<_(3C% 'V]_P )/I?]Z?\
M[\G_ .*H_P"$GTO^]/\ ]^3_ /%5\6>(?VN?V;/"GCH?#/Q#\8?".E^/6U#3
M=*'A:XN+MM5&HZO,UOIEJT,5I(BR7DR-'#ND"EE.6 YKF=9_;I_9&\/>+I/
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M)=:7<W*IH]A%'/+)=WBW=M;2+"D=M.Y=4<;8G(Z5F?#/]K_]F?XR>,9_A_\
M##XR>#_&7C.VMK^\F\/:3<W9OUM=+FBM[^=5N;.WBECMIIXHY&BD?F1=NX'-
M 'VQ_P )/I?]Z?\ [\G_ .*H_P"$GTO^]/\ ]^3_ /%5^=?[-/Q?\9>)_B=^
MT1\(?B'J9U77?A7XYM;3P]J!M+2S.I^%+_P_H6IK=B*TBA0K;:AK#Z?O,>6-
MOEF+$Y^S: /1_P#A)]+_ +T__?D__%4?\)/I?]Z?_OR?_BJ\XHH ]'_X2?2_
M[T__ 'Y/_P 51_PD^E_WI_\ OR?_ (JO.** /1_^$GTO^]/_ -^3_P#%4?\
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MZA::;&;>&>>VB<I->1O)NF3$:N1N8!2 ?1O_  EW_3E_Y&_^UT?\)=_TY?\
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M +\G_P".4 <;179?\(B__/ZO_?D__'*/^$1?_G]7_OR?_CE '&T5V7_"(O\
M\_J_]^3_ /'*/^$1?_G]7_OR?_CE '&T5V7_  B+_P#/ZO\ WY/_ ,<H_P"$
M1?\ Y_5_[\G_ ..4 <;7Y??\%7]%UG7?V?\ P7::)I.IZQ=1_'/X,W4EMI5A
M=:A<1VUO\3/"4UQ</#:132)!!"CRS2LHCBC1W=E521^N@\)./^7U/^_&?YR&
MC_A$G_Y_4_\  ?\ ^SH _)C_ (*.Z+K&L?LG^"K#2=)U+5+Z+XE?"R:2RTZP
MNKV[CA@@U 3RO;VT4LR1PDCS9&0+'D;R,BOFSXE>,? OP@_;H^''Q%^,/@3Q
M#K/@:/\ 98MM M]?M/!^O>)K/P[XB;Q#I%T)KBSTC3-1GDF-E%<VQ@6WDD7S
M]Q0!25_?K_A$G_Y_4_\  ?\ ^SH_X1)_^?U/_ ?_ .SH _F UGPKXC\7_ ?]
ML[XE^"?!?B32OA=\3?CEX/U;X<>'WT34K2]U"T3QKX8NKG7;7P[-;1ZI86\]
MH%#17%A;-$EL[21H 37N/[0/COQ7HGBO]G?P-\2?B!\4O@+\$G^"=C>6?CCX
M5>"I_%7B76_%-IH7AOS])U:%/"/C5],AL+J66V$=SI=@\P9]DDGELR_T'?\
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M:V+O$3&2REE)_*S]I_QSXZ^)FC_M*6?Q!\>?'KPM\4?[>71_"/P!^'W@4/\
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M9S>*5FM)XP\L"I^[R&VE2?T^_P"$9TO^[-_W]'_Q-'_",Z7_ '9O^_H_^)H
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M[LW_ ']'_P 35RRT>ST^5IK<2!VC,1WON&QF1SQM'.47GZT :E%%% !1110
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MI0$20W5DTQ$0 /WKJO=7=I8PM<7MU;VENF-\]U-';PKD@#=+*R(N20!EADD
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M*** "BBB@ K^6G_@V7_YRA_]GM:W_P"[-7]2U?RT_P#!LO\ \Y0_^SVM;_\
M=FKZO*/^28XO],@_]64R'\</2?\ [:?U+4445\H6%%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MEO=S07 =&TOV5_\ @J5\;/%NJ?'R#X^^)?@C<:]\-_#USJ&@?!WP3\)_C?\
M#WQU8ZA)KMGI&G1ZSXM^)>SP-XHM +R)[J3PE>S*,O)YL<<$Q0 _H)=TC1I)
M&5$16=W=@J(B@LS,S$!54 EF)  !).!0CI(JNC*Z.JNCHP971@"K*P)#*P(*
ML"0000<5^!^H_M6?MK2^%]2\(?M*Z7\"&\'_ +3?[-?[3'BOX8O\'EUVT\3^
M $^'_P '-9\626'C:^U?Q-JUAK=[<P7EG:6]_P"%8?L:W44TWFB$QL/I'X+?
MM6^+/#WP.^,6GSV_AE8_V:OV9?V7?$OA*YU*2Y6?6;CQK\"-/\5ZQ)XCEEOD
M\^&WU"!(XI+7[*RP.WGR/(P>@#]7A(A<QAT+J,L@8%P,XR5!R!GC)&,T^OY7
M_!G_  4)_:Q^&?B+]N']L/XI:G\,O$?P5^'?PAT+Q-X,^'7AK0_&,_B72I]3
M\<> O""-<$ZA<VE]:PW>L7&HS0:;&UW/;%HX"92 ?M7_ ()I_P#!3_QS^U=\
M4M;^$GQ$N_"?CC4VT,>)](\8?"_X(_'CX3>$M%LGCOYAHNN2_&G2[234]7C3
M3WC:;1IFM6DN(2H*DT ?M_>ZCI^FQ^=J-]9V$)( EO;J"UC).<#S)WC7)P<#
M.>#20:EIUS%'/;:A97$$K;(IH+J"6*5\$[8Y(Y&1VP"=JL3@'C@U^/OQR^$G
M@3]L?]NCQ)\ ?VCUN/$'P6^'?@'P_K/AGX3:AJTFE^&OB+JWB+1M/U+4M=O8
M+&YL=:O[GPG=HUE VG7]O! -6F2ZCF=XF3Y\^.7P=\/?LF:7%\//V1?&EQXB
MU=_C=H^K^#/@;JNM-J'@[X5W!\%OIX\/V;Q2V^IVND3R23>)+RPU;7;K4)IK
MZ>2WD6)X8T /Z$J*_"2Z_P""@?[6WP5\ ?M$>!_CMI'P+\8?M)?"*7P?J.BW
M7POT_P 3^'_ALW@SQ_XEA\):-XBU72O%WB"?Q%J;>'[N'5=7UO3=(OO[3U&P
MM%M-)LVOI8DE^=/A7_P5^_::\;:%\4/AG8O\!?B/^T-X-^+G[/O@#PYK?A7X
M>_%OP)\-/$5C\<E\42>6N@?$2_T_Q;'J'A[^Q+6WN+N6Y@L+J6X>6T$T)4J
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MW.57<[$*HSEF( !) J2OY(-8_P""K'Q"_:'_ &?/BQX/^)][X>\9ZMX(\4?
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MGHIS>):V:S><VFFX&+:/RQ*(OG*>8_I5 !1110 4444 %%%% !1110 4444
M%%%% %/4+-=1L;RP>>ZM4O;:>U:YL9VMKR!9XVC,UK<*"T%Q&&WPS*"T<@5P
M,BO"/A#^R_\ !SX(?";4_@GX$\-B#X?ZWK?C/Q%K&EZE)%?2:GK'C_Q!J'BC
MQ3>WTQMXEN)M2UK5+V]E=XBQDE+.SMEC]!T4 ?E7XJ_X)"?LW^)K7PE;6OQ*
M_:@\&2>%- N/"DM_X#^..K^%]1\7^%+G7M1\13>&?'5W9Z8S^)M!>_U.=#IM
MV%MS:)!;E2(@QW?'_P#P2G^ GCV/P5HL?Q2_:A\!?#GP)H7AWPQI/P9^&?QQ
MUGP;\'KS0/#3G[)I.L^ ;'37TK4K&^@)LM6MY D=_8DVTBJE?IO10!^9/Q;_
M ."3?[+OQ>\60^)[W5OC/X$L;KPYX<\)>,O GPN^)EYX)^'7Q1\/>$]'L_#^
M@Z9\4/"5CILMCXSMM/T6R3388]1;8EI-<PHJQS%1Z3XD_P""=7[.WB+P9\5O
M!,2>._#%G\7?%^B^.M9UKPAXNET#Q/X:\3:#X6\/^#M/U'P+K5M8M/X7E70O
M#=C;2FV25Y&EO7WJ+EE7[MHH _)=_P#@C/\ LI7.C>(;#4_&'[1NM:_XIU3X
M8ZWKWQ$UCXS:E?\ Q(U'6/A-XM'C3PQJ=QXOETO[?)?7.M@-KMPX:35;;-O(
M8P=]>J2_\$TOA%;?$3P[\1/"GQA_:F^',N@ZE::S>^#?AU\<M;\)_#SQCK,$
MB3WNK>./"5A8?8_$NH:[=B:]U^ZNY%DU2\O+RXF.^X<U^BE% 'G/Q,^%'@;X
MP_#G7_A5\1M%@\4>"O$VEQ:3K6F:FL=S]LMX);>XMYI&GCE1KN"[M+:\BN&C
M9DNX8YP-ZC'P_P#"S_@EQ\!?AEXTB\::A\1OVD?B^=.M[J#PWX3^.7QFU7XE
M^!_!K7<$UL]SX0\,ZMIT=IH-W'%*H@N+5]T1M[8C/DK7Z344 ?'GCC]AGX#_
M !#^'G@+X7^)K'Q-=>$_AS\>O#/[1WAZVBUXQ7+?$?PGK5]K^E/J5P;-Q>Z%
M_:&H7!NM(:.-9X2D1G4+N/RWX/\ ^"/?[(OP]\1:#K!\6_'?7%TCXFZC\2_!
M?ACQM\8+S7/"_AKQEJMCK-M=IX2T&[TR.#2[22VUK5I%T^S.0T\LF\_-G]9Z
M_(;_ (*:^(=>T/\ :$_X)&6FCZYJVD6?B#_@H3I6D:_;:;J5Y86VM:2WP-^+
MUTVF:O#:SQ1:CIYN;>"X-G>+-;&>"&4Q^9&C  ^M?&O[%7P.\4?!S2/@[K*:
M_#X*\+>(=)\8:6TFO;+B+6?#^IZ?K6FRZC=O; 76GI?:7:-=VC)&MQ;B:$R(
M)"P_"^P_X)L?M=>+OVI_"VJ'PQ9VWP3\/?M7Z'^T2_Q%A^/NC:]\)+G3/"GC
MA_$]IHWAG]EZWLHY/#'C;5+:=H[SQQ'XDNY$U!([Z33791$?UK_X*4? GQU^
MT#X"^''A;PC>WFH:'IOC"XUGQKX T?XB>*OACK?C_2[&&RN[/3M+\5>"9K;Q
M%#/I=W:G4FL+2Z@M]41?[/OV:SN)E/BW_!/C1/AS\,/C3\1_AYX>\*_M(_"+
MQ%JNB:/J=]\.OC=K7B'Q5X8UD6-M?/+K/P\U_P 5^+O$.J&&V-PTNJPP6.F0
M_P"D6 <3 +Y8![]X5_X)Z_!/P)\;+3XD^!/C/^T?X*N+36[SQ0OP5\+?'+5-
M&^"T]_J-Q+>:G-=?"RTLDTV>WU'4+NXO[]&<"XOKF6>1B\A)^O?B;\,O OQ:
MMM)\,>+Y[J1M$U+3O$EG9Z?J:V5\+C3[R"YM)YEV2R26S7-F@<% LFUTW@DX
M_GF_:>\:?$?X2_\ !8+X>?&K2O%>JQ?#'0=0TCP'\8M%U+Q'J]OX5T/X8ZMH
M=IKVI>*+?1%EETB;6;?6K+2K*&6>VMF%O>3J+U QCDP- _:1\9^ ?^"A?[57
M[66M^(-:\3_"Z]_9STC7_@GX5;7=37PG?^#!XGUZ/0=4N=-2;^S[&>[U];VT
MU+4;2UN+I-.A#">?REA4 _<OQ;^PK^S[XX^$/C?X*>)=$UG4?!WCGXKZ[\;K
MJ>35U.OZ!\3M;UAM?3Q9X3U=[1Y-!U30M787_ARZMXGN-(N8XY8)2Z UP/PR
M_P"";/P!^&GA7Q9X:;Q#\8_B->^-+JTN-=\<?%?XD7GCKX@S0V$(M[+38O%>
MH6$=[%I=K;K#;PV6UXTAMK:-<"%:_,S]E[_@M)\1OB;K'B/2?B)X,^#FH3WG
MP8\=?%[PI_PJGQQKOBBTT&?P-X<D\0ZCX8\>7&I>']$?1DN3+:V6DW-LNI7%
MX8KYI5@:!!)SOP"_X+>>+_B7\2_'/PTOKC]FGQU>M\"O&OQF\%7OP;^)6O>*
MVTG4O"?B;P_X:'@3Q?%J'A;14T[57N-;D^VB'^T'MYK":..211N(!^VNK_L@
M_![6_&7Q%\=WT'B0Z]\4/AE:?"7Q2T6N-':/X1L]1?4X4L+;[*19ZC]JD8M>
MAY"T?R>4.M4O&?[(GP<\5?LR:-^R9JM[XOTCX7:/X9T7P?HEWHWBE](\:65E
MH-J++29[/Q,ELTT>K6ZE9$O([82?:%215# "OAK]F+]L[]M'5/C)\(_!O[7/
MPG^"_P ._#'[0GAN]NOAJOP]\=^(?$OB&S\4Z:=<U*]T;5;'5_"^A1168\.:
M*=06Z6[NIS<W!@\E8E66O;O'?BSQQ\0/VP_B9X,\.WTUBG[-OP(MO&&B6"7$
MJVGB#Q+\7]$\0VFE/J%D!]GO!HE]X5@GM3<1S^2]PYC52S;@#$^#O_!+K]GO
MX6^,=+U?4/C)^T[\<[[P?:01>'O"G[07Q[U7XL^'_"4L4,*:?JNC>'M9T^./
M2=4L;5/*T^_B*26\$\RQ_+*:XCX9?\$F_P!C+X=^*O"5QHWQ'^-OB?5? ?C?
M7?'/@#P]XO\ C?/XFLO!'B+7M&U'2-17PGH\]@G]BVJ6.IW\D%I:!?(FGDF#
MG<P/Y/?"CXF?!/P1\9OV:?$OP[\1_M"S_M/^//VO%^%GQOT_Q3XU\6Z_X=3P
MUXCU/QC=ZM:7W@_5_&&H^'=%TFXNM(TR30M3T_2H[JUT@0I;I:1SR6]4O@'\
M'_VMO@KXY^%GQ9^/_P ,]&MO%'Q[UWXM>&_#WB[3OVB/BSJ_B#P;XKO?"_CJ
MW\+ZUJOPPO+2U\&) \%OI<'V/S)[6W\]+Z&-KI%) /V\\-_\$T?V?[?XG>)/
MBGXI^*_[1?QIOK[3_&>@3^$_C)\;]2^(_P /_#%CXRTRXT?Q-8:%X4U2Q^R:
M$)=/N#;F*.3]TD, =6$0!Z7X,_\ !/7X5_"#Q#J_B+PI\;OVH_$WAS5]'OO#
M]M\-_&/QVUGQ5\*-!TFY> 1V/AGP7-8QZ;H\&E0VT5EI4=NY6PLU-O&I6OYB
MK%_VNOV"4\?Z1\1K?XD-\1/CO\*/AS\./%UMK/Q \9^(K_XF^(/AW+X@N?VC
MOB%\)=#UF]ET_0+G6?#/B2VO/!4GAX:$-4U*&UMYWTJ.WAG3]3M9_:PT+]I?
M]GK]G#]GKPC8_&GX':)XJ^//P'^ 'QCA\;BY\)_%!_!GCKP[K_V&Q.MZ=K][
MK&B:OXWTC1DUN'7[#6K?5X&C,MO=YED>@#]4;_\ 8K_9Q\;:/?Z:+G7K_35^
M&EC\';Y].\6(Y@\*:5\4+?XQ06\LT5M((M43Q?:Q2RW;89M,W61B"GS1K?$;
M]BW]GKXS?$7Q=\5O%UGJNL>*?B!X%\*>"KZ:UUV,:?;Z3X,OM:U7POK.@V@M
MIAI^OZ3J.MW>H66LQ2R217<-G/&BO;*3\A:A^Q'^S[^R'XHT;X@?##XY_$OX
M:ZWXE\&^,_ ?_"#>,/B=XR^(FE_%[[-X3\2^)%T>QL_&OB358M$\06D]FNNG
MQ#HUJFLM9Z.VGM=_8II8S\^1?'75_P!G?_@G?_P33_:HO]2\0Z]JFFWW[/GP
MDUBREU2_NV\22?M*>*O"'PD&HZXDUTPU2319-<;4XKB^%Q+;S!IXF24[J /U
M'_9I_8X\,?LQ:CXFO_#WQJ_:8^)Z>)I8G.F?'/XSZW\3M(T".$3+':^%[#5+
M2WCT2T5)M@M[<L@6&!1Q$M>2_%W_ ()@_L[?&3XS:]\;M>\1?&KPYX@\76OV
M;QMX8\"_$V]\+_#_ ,;N+6&RCO?%OA.VT^6UUR_AM+:TMX;J[F9XXK2V11MA
M4#]&** /@GX0?\$Y/V?/@5\8? ?QN^&U]\3=#\7^ O@UX?\ @-!9KXYN&\->
M*?AWX4?7Y_#>G>.-%CL88_$UUH=YXEU74-,NKN9%M+^5+J*%9$RW>_M$_L2_
M S]J#XA? WXG_%"Q\1R>+_V>_%]IXS^'U]X?UTZ-&+ZUU"SU*73-=B6TN&U;
M0-1N;"T&IZ4TD$5Y%$L<C@ $?7-% 'RAXQ_8P^!OCK]I+P#^U3X@TG69_BA\
M-O!U[X+\,10ZJ(?"D=C?:BVHR:I>>'S:O'=>((@[V%OJWVB.:'3'>R"&-B:\
MOA_X)T_"G3?C*?C'X9^+7[37@OS=3FU:[^%'@WXUZSX?^".H7MPI2X>_^&UI
M8_V5<K/&4CF5Y?WD<42,<(*^_P"B@#\_=#_X)S?"KPK\;9?C;X/^+W[3_@Z:
MX\0S^*+SX4^&/C=K6C_ ^^UJ\OCJ.HW=Y\-+6P72IVU2Z9GU'?,6N]S"1CG-
M>AZ)^Q!\#_#=M\*(=#C\7:9=?!OQMXA\<^$M7M/$;PZS/?>*-9U[7]9T;7=0
M2T675O#%UJWB*]O#HKB*#SH;)R[-;*S?7]% 'R9^U/\ L:_"S]K?2?"UGX[U
MWXE^"==\$:C>:GX2\?\ P>\;77P\^(7A^YU"S_L[4!I?BNPM;F^M(K[3S+97
M4<(036UQ<1.2LK"OE[QS_P $?_V8_&_PP^'/PKA\=?M(^!=*^&WB?5O'%IXE
M^''QHU3PAXY\5^-M;N=.OM1\8>//$]CICW7BCQ)/J&FQ:@=6NXH[K[;-=7!<
MO.Q'ZJ44 ?./[-7[->B_LR>$M2\(:)\5/CM\5[;4K^*_;6?CW\4-5^*?B2S:
M*.2-;73]9U:WMY[2Q82EGMD4JS)&V?D%?1U%% !1110 4444 %%%% !1110
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MW_$#_P 2,\._G_R2'I^- ']U]%?PCR_\'P_PLC<I_P .[OB <=_^&C?#@_\
M>0&NO\(?\'KOPJ\5W+VW_# 'CS3F3;AG_:%\/7 .XD9POPGAQC&>30!_<317
M\=VG_P#!WC\)[R-9)OV+_&%H&&0'^..A2'WZ?#5.G'_UCQ7L_AG_ (.C_AEX
MFM8;JW_9'\8Q+-]T#XN:-,.I'#?\(%%GI_=';&>M ']55%?S=Z5_P<3>#-8C
M1K3]E?Q3OD"E(Y/BII2DEB  2O@=L<]?E.*]]\*_\%J-)\16*7EU^SAKND^8
M-RQ?\++L+TE< YW#P7:CH?[IH _<>BORAT3_ (*DZ1K5GI6H1_!/6[>SU">Y
MAGN9/&M@T.GBVF$)DF;_ (1U&D5N7PB @*1R<$]8?^"CECO"#X3NVZ401'_A
M/8,RSLADBA4?\(D?WDD0\P#. ,C=F@#],J*_-V#_ (*$">,JOP=NS?I;"[GT
MY?'-NT]M 69 \['PLJJ,JV=NXX&<&L6#_@I3I"WT5IJOPGN=+CGFAA@N7\<V
MT\<[3.$'DJ/"\1<KD$@E,[EYYR #]/**^.?A%^US:?%CQSIO@ZU\!W.D0ZE/
MJ$$6LOXBAU")6L-&U/6"?LB:/:,_F+ICVY'VA?+>57RX4JWV-0 4444 %%%%
M !1110 4444 %%%% !1110!XI\:_@%\/OV@-,\-Z)\1X=6U#0_#7B&T\2Q:)
M9:D;/2M7U"P>*>PCU^R,,T6JV=E>06]_:VTP58;ZWAN%8/&M9?QT_9J^&?[0
MUOX?B\?1:Y!<^%Y-0;1M5\-:LVAZM:0:O';P:O9+?1V\\GV'5;:UBM=0ME"I
M<VX,4F5/'O\ 10!^:_@7_@EC^SSX \>VWCW3/&G[0&JR:09KGPEX0\2?%O4=
M8\!> M:FD28^)O WA:;3DM/#?B59Q-.FL63BX6:[NY.L[59^&G_!,#X$> ?%
MWB7QIXD^(?[1GQWU7Q)HE_X?$'[0_P 8M4^+&F>'=.U"YENIE\*V.MZ?&FAR
MQR3RK;R6[-Y,<C(%.23^C]% 'YJ?"[_@E7^S9\+-4UO5+3Q'\</&HU#P;XT\
M ^'=,^)'Q1OO&.C_  T\*?$#P]>^%O$^D_##3[W3HX_!EO?:%?/8>7I[&-8(
M+5&1T@52?%O_ ()6_LX_&'5-%U#6/%?QX\*6>G_#SP]\+]?\-_#[XK:AX2\+
M?$7PEX5T'2_#.A6GQ)T2TTZ6W\7SZ?HNDPV,,]^0$AN+U$C5;EE'Z5T4 ?G1
M9_\ !+O]F*PN-3^S2?$V/1];^&\7POUSPH/'<_\ PB>MZ);>(K?Q39:KJNAC
M3Q:WOB>PU:SLGLM;ES-;PV5I$D?[A&'J?[-7[&7A?]F+5_$.K>'OC;^T[\3E
M\0P06YTGXY_&K6_B=HFBQV\DTB?\([INJ6EO%I#-YY20PEM\<<2G_5@U]B44
M ?'G[37[$7PB_:DO]!\0^*M;^)OPZ\=^&+6[L-"^)OP4\;W7PV^(^FZ;?O;/
M?Z7;>+--M+G4(M/O7L[-KFU0K',;2W+ ^4N.;^&G_!/+]GSX7Z186.FMX_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_EI_X-E_^<H?_9[6M_\ NS5_4M7\M/\ P;+_ /.4/_L]K6__ '9J^KRC_DF.
M+_3(/_5E,A_'#TG_ .VG]2U%%%?*%A1110!_,3_P=T_\H<?&G_9?O@5_Z?-4
MK_*4.>W7^=?ZM?\ P=T_\H<?&OK_ ,+]^!6/<_V[J?%?Y2@SSNQT_+U_SR*
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M+U5W&XCK^U-?@9^Q!>Z?<?M*_#V.VO'G=(?%01/E50&\ ^)6(8%$8[5';)R
M3P,U^^= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM/&OP8^&^C?%;QG;W5E=06MOX-UVX\0VUAJ5M=2P);W2N_AC56<02RLB0AF
M#*3\\> O^"G7[,OQ#_9[^.W[2FAZCXJ3X?\ [/,GBH>/;>]\)>(K3Q(T/A6?
M5(9;C0_#MQI<.LZY#K$>DW5UH#Z58WB:U:^7<::UU#(CM\;_ /!4>]UWX"_%
M7P9\3_ GA.]UB]_:V\+:A^R=\2M<TR"1KG0M#U.PO-!\%7<LL,3NBQZY\0[]
MXIFD@-J\9GA=G! ^3_BI\#?$WP$_:6^!_P"RIX1\-ZQJN@_M<6/[+EG\3HXX
M[B3P[9^ OV;O!5E\/OB3J+$+);6NJ:U+XKBOM4811RZY=^9=W]P\R;R ?TQ>
M%O%NC^+=!\.Z_IUPL<'B;0-+\2:=9W3"#4/[,U>S@OK26>RF\NZ@?R+F(2QR
MPH\,I:*15D4J-E=3TUI9H5U"Q::WC,T\2W=N98(@&)EFC$FZ*,!6)=PJ@*QS
MP<?R1W_AKP]I%SKVL3_$G]K"T_X*+Z1\31+X0^&5C\0/B#;?#6>+2R?#^BVU
MK\,8?$R>&[CX>_\ "NXH+N]B70O[+;Q2HO)+)[[_ $NOJSQ?^R_?:I^S%^U]
M\3KO]H#XP_#+XA^-OC#;M)XRO_B-XLBT+PUX6\/:KX;UL>%='T^;7K>Q\,Z7
MK6_4M'N]0TXP>7:W\A-M.L B< _HQ@U+3KJU:^MK^RN+)-^Z\@NH)K5?+_UF
MZXCD:)?+_CRXV_Q8IZW]BT,=PMY:-;RDB*=;B$PR$9R(Y0Y1R-K9"L2-IST-
M?Q7Q?$[]I'6_V-_B+X"^''ASQ6GA#P9\=O@\?%'Q4\*?M)^/O%WA[QUX'UVY
M\43>)Y[/XF'3[:Z\#V6A6EJB>,[?2&NK?39KNW6[:4VL)/T+\#_A[\8/BU^S
M;K/PTU#XK>*K7X4^/OC=X=T;2-9^&7[0?C/Q_P",?#.F?\(S=3ZC:6WQ,672
MO$=@+C4+6YD>&"YB5?-*?,%&0#^LNTO;*_B\ZQN[6]A#%#-:7$5S$'&"5\R%
MW3< 02N<C(R.:M5^0'["7PUD_9R_:Q_:/_9Y\*ZQ\3]?^%UOX*\+_%#2K_XF
M>/\ Q3\0KRV\3^(=<N-"U/3]*U/Q1>7]Q9:='8Z+:3)IUK.EM#+-/*L*O,[-
M^O\ 0!^=?QN_X*6?!'X(?&.[^!VI^'/B7XO\;Z=_9ZZG!X%\">+?%=KILVIP
M6MU9V]]=>']!U2WMKB6UO(;E89IHY&@W2A2BLP_0RTN%O+2UNT22-+JWAN%C
ME1HY46>-9522-PKI(H8*Z,JLK JP!!%?RP_MB_#_ /9GLOVCOVT?&%SXQ_:X
M\/?M@>+==^'-[\*_"O@[7O&_@W0O$FIZ3X.\.Z7:3?#?P_H?BNVL_B'IR6L'
MEZW=II]J++4OM5E)%,R-*WZX?%WXH_\ !3[P;#\.-/\ V<OV4_@!\;M#N/A[
MHUWXQ\2_%7]HS5OA%K^G^,6EN8KK2(/#]E\-O%L=Y:1:='I]R^IOJ$,LEY<7
M,#6P\D2R 'Z;45^-/[ O[6W[</QA_;9_;'^ '[8_PY^%?P?;X,?"W]G7Q?X+
M^&_PL\8+\3-,TP_$M?'K:KK-U\1;CPQX3U35IM:7P]9.=&N]+$&B&W9;6>47
M,A7]EJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH QO$6NZ?X7\
M/ZYXEU9Y8]+\/Z1J6MZB\$,EQ.MCI5G-?71@MX5>:XF\B"3RH(4>6:3;'&C.
MRJ?S!^"G_!7#X!?&?XP>!?A)#X/^*7@B?XKMXK_X57XE\;^"/%?AW1_&B>#T
MLI-5>!M:\/:8FFEX]3T]K*.[N2UZUSLM?-:-Z^A/VEM7_::\,ZU-XK^'K>#+
MSX*^'?!M]K/CK0]8L["^\1:Q+I<6HWNIZ=I-K<V-Q+=2ZAIT,%G96J3(+B[E
M$0 +DG^>S]B/XMZC^WK^W9H7[4G[1&C>.?@SX ^"][XX\)?LL?LVGP6?#D=G
MI4[V]F_CKQ7Y=UICVUWJ=II^A7EGIDVE7T5K+;7$4%ZP+2$ _HT_:?\ VI1^
MS18:?JUU\,O%7CK2KBPO-1U+4M!D:WLM"MK-RLCZE<G3KV&!2HWAY9(5P0.<
MBO@33/\ @N7^S#JGP(^%/QOA\(_$K9\=/'VN?#KX0^#8_#/B"?7/&^M>&]$N
MO$.L76GO%X>)CT>VTW3]39-6:T?3Y[FPFM(KAK@%%PO^"MOQG\5_&C]A._\
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M)_Y*5_P2K_[2:?!K_P!0#XIU^N5?D;_P5)_Y*5_P2K_[2:?!K_U /BG7ZY4
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MT+PSX8UR\^(TG@CPEXM76?&3736FK7G]M6HT*V?S=)T[0VO;]/,MK9'FE1:
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MQL_"/GEM7G\,:=?VVEWNLB%4*)9V^H7EK:NTDB2&2=-J,IW#\Y/@):?M%_\
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M\7C3GV7&\QW3;& D7 _6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** /R#_P""^G'_  1O_P""A!]/V?\ 6?\ T^:%7^,M"V(3D9S^GL?\_P"%
M?[-/_!?3_E#?_P %"/\ LW_6?_3WH5?XRD7,0SW_ %/&/UH 2Z?Y .AX_$<]
MOY_A7<_#+2#J.OPR,H9(&5L8)YY';IU'->?W+$OM[#&/7D=*^B?A!I8@C2[=
M<-,P.?; Z=,].1[]LYH ^S?"ULD20IM &T =<;L #!_P Z"OHCP?I8F9))DR
M@.%P,]>A'Y<5XEX5M1/]G53G(7('4=,Y_ ]N/Z?5/A>T6.*W7;]W;D8ZXQST
MY/KZ?K0!Z?X:L([>1) @"J <=,_,.W?TQTKU_3([F_FM;2V5WN+N1((D52<;
MV52<#T!.3VQ[9KS31B#(#D;5VC:>.A7VQZY[^HXX^Q/@#X8ANKZ[\6ZA$&L=
M+0K9HZ_+)<X(5AGK@R+[C'<XR;!N?2W@;14\"^&=.T"W(?4+J-+S5W8[@FY4
M<Q[3G'/F#''3IVKTC2=#TB8/XMUT26FD6!8S,^52382=L>XJ"6$;%1Z#BN7T
M:UFU23[1,"LFHW&7(SB*U5\MC/0>6['@<],UP_Q1\?C6;V#P5I3&'0])55NW
MB8C[3<(JJY?:<GDR C('7(K](Q.?8C(^',#PKCL/2S6EC<+/-,7A,?.M+^RZ
MN+I6R=8&<)QJ86KA*,GC:E!-T*E7$)5:3MI^08/A?"<2<7YCQOEF*KY'5RW&
MT\DP.-RNGAZ?]MT,#6C+B!YE2J4IT\90Q^(C'+J6)DEB:5+"2E0JQO8UM7^+
M-YXGU@Z=HZ16'ARP8QQB)$,LP3@-(ZJA&22>6;M[U5U+4)M5N(;2W$CI@%I7
M!VD#)(&21CCU^E<WX2TB".&1X;<LL[#<2.<# )!)_P!D=/RKT!+81S("JP1J
MO!/!Q@]< ^GKGGTK\W/U_P#K^KF#?Z;";=8W17 4JZXRO3!)R.<^G'\Z^7=9
M:7X?>,TU".21="U-BMRB$A(9&*?. IVC #DG@]Z^K-8O8K:)HXB-KD_,>2WK
M@\@#G'8_D!7R?\6KA]3A-A&@R9  XSE200"#U')SUX]* /[H_P#@D%=K?_\
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MHY9)TLXKGR_-CMUEEDD$2N$#.QVY)K;EBBGBDAFC26&5&CEBD4.DD;@JZ.K
MAE9200000<5^1'_#C3_@GM_T*7QQ_P#$K/VE/_GH4?\ #C3_ ()[?]"E\<?_
M !*S]I3_ .>A0!^M<.E:9;P6]M;V%G#;VDPN;6"*WB2*WN 6(FA15"QR@NQW
MJ V6)SS4S6-F]P]VUK UU);?8I+@Q(9GM"YD-LTA&YH-[%_+)*;B3C-?D=_P
MXT_X)[?]"E\<?_$K/VE/_GH4?\.-/^">W_0I?''_ ,2L_:4_^>A0!^FWQ&^&
M>@?$KP9/X#U=[VQ\/7<UC]MM-(NI-.%YI]I,LD^D7!MR@DTS4( ]G?V;AH+J
MUEDAF1XW93V>CZ3I^@:1I6A:3;1V>EZ+IMCI.FVD2JD5KI^FVL5G9VT:J%58
MX+:&.)%50H50   !7Y+?\.-/^">W_0I?''_Q*S]I3_YZ%'_#C3_@GM_T*7QQ
M_P#$K/VE/_GH4 ?KW17Y"?\ #C3_ ()[?]"E\<?_ !*S]I3_ .>A1_PXT_X)
M[?\ 0I?''_Q*S]I3_P">A0!^O=%?D)_PXT_X)[?]"E\<?_$K/VE/_GH5Y!_P
M1S^'VC?!CX^_\%;O@;X-U/QC<_#?X2_MC^ ?#OP^T;QEXY\6^/[OPWHNH_LX
M?##Q#>:=9:UXSUC7-8^RS:QJM_?-$]ZR>;<.0 ,  '[M4444 %%%% !1110
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MC49[MGNIKZ:Y:22ZEN7:>2=G>9C(6) /J^BBB@ HHHH **** "BBB@ HHHH
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MI7B#2A?7MCX-\"Z+XH\/KK.EW$FKV;37=[8^,=5D-O%"'CD@BS+(7& #Y/\
MVAO^"N_[45Y<7_B/PYJ>G_ +POX7_97\#?&[P?J6O>!/'/B[0?B_XM\1>"_!
M?B37=,@?P>MXXTS0M8U[4=%;2Y);75+CRHY+>66.&:0_0?[=O_!8GXF?#?\
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MPP\9:]*LVL^)?!FB:QJ<J A9+R\M$EF=0Q) +DGDD^]>OUX)^R_\*O$'P1^
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M +LU?5Y1_P DQQ?Z9!_ZLID/XX>D_P#VT_J6HHHKY0L**** /YA?^#NXD?\
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MVBPW$B:?JUU\8])TF>]MU=A'/)I\N@S26K2(%<Q-*Y4MMW'&:Q/^%F?M??\
M1K_@[_P^FB__ #.4 ?6TL44\4D,T<<T,T;Q2Q2HLD4L4BE)(Y(W!1XW0E71@
M59258$$BDAABMXHH((HX((8TBAAA18HHHHU"1QQ1H%2.-% 5$4!54 *  !7Q
MQK7QB_:RT'1]6UW4/V8?"2V&BZ;?ZM?-%\<='EE6STZUEO+EHXE\.;I)!#"Y
M2,<NP"CDUE^#_CS^U+XY\.:9XIT#]F3PK+I.KVT=W927/QMTBUG:&5%D0R02
M>'-T;%74E3TZ4 ?;]%?(W_"S/VOO^C7_  =_X?31?_F<JW8?$C]K.:^LH=0_
M9I\(V5A+=VT5[>1_&[1[J2TM))D6YN4ME\/(UP\$)>58%=6E9!&&4MD 'U=1
M4<32-%&TR".5D4R1JV]4<@%D#@ ,%.1N  .,XJ2@ HHHH **** "BBB@ HHH
MH _(7_@OD<?\$<?^"@Y'_1O^M?\ I[T*O\8)NI^I_G7^S]_P7QQ_PYR_X*#Y
MZ?\ #/\ K7_I[T.O\8+!9L#DEL#\30![I\(-)$\LMT5R-XP3VQ@=?P_#OGM]
MK>%M.#RQ=Q&%/(Q^7'./Y_6OG7X3Z4+;2X6*X,@#'(Z\G'3^F.1[U]?^ [&W
MFU'3H+MQ;VUU?6EO<SG/[B"6>..27@$_(C,>AZ8QZS*2C&4FFU%.345=M)7=
MDM6^R6KV6HF[)OLKGI_AZ,+)$,8QCI@C.1T[\_K7KEM+(PAMH\F>9UCC0<DL
MW0#W/';OSFNT^-'PH\,_"G6?#47A?7#K^D:]H-IJD5_L<()IHC+)$I:"'=LR
MF2 ?O#GJ:N?!GP-K7C76I->MK99]*\.?Z3=@LNYFC(<*JLX9\K&_0'TZU&05
M)<3T,+7R3#XO'?7*-6O0HT\-56)=.ASNNY8=Q]K%TE3G*<7'FC&+=CS<3G.5
MX' 1S/'X[#X# 2G2I?6L;4CA:4:M>LJ%&G.=5QC"=6M*-*"DU><DEN?4_A+3
MQX>\-:'X9@3;J>MO'/>LN?,6([VRY!R%PJ#TY'UKZ#N?$5OX5\*ZEJJ.JK:6
M[V5B#A092 "PSU)$O!.>G08&/ _#-Q<[M2\2:E$T,\TJZ3HEO*K*X ,>YD5O
M3R9 .1UX]15^.>NFPTC0?"T,H5BJSW6#\SNV<[\8YP@SG'(Q7V6+B\FX<PV!
M<73S#B&I3S+&J2<:M'*L+*<,OPTDTG%8JNJN,E%[PA0;1\O@91XBXOQ>:1DJ
MF5<*4JF3Y=*,E.EB,\QD*=7-L;3E%N,OJ6%=#+J<HM\M2IBDG\2.5\/71U2[
MO-:O)"TUQ++/)N8G.XE@ 2<GJ0 ?UKLM/OF,KRF1L$D*F>0,X'&>.V.?KT%>
M,Q:RFEZ: GWC'R1GG(&/R/-7_#NOSSQ.22S&0D#OU;&,\8YYR>WTKY(^[/I?
M2=4=5$I8 )G<&XR!DY./;@'GZ]*H7_B!+JZ#,2$7Y0I.0#SR,DYQD8X[5P U
MHPV>X,%RGS <'/Y^F <5Q=]K+-.3'/M8 G:QP".?I^IR: /6KW5HR,139D<X
M([D>G7@>G7->?^+-2+QB!&)(3+*#P"5&<\\YYZ^]>*ZOXRU&TO)WAEXCW8W'
M*\$GC!X_/H/>OGGQI\8/%D9NFAN(D50PWMN) 7([-SQ0!_I+?\$.CG_@EU^S
M&?67XWGKGK^T9\73U_&OUBK\8/\ @WKU2]UK_@D!^R+JFHR&6\NS\?GFD/\
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MV%@>@_(48'H/R%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7\M/_!LO_SE#_[/:UO_ -V:OZEJ_EI_X-E_^<H?_9[6M_\ NS5]7E'_ "3'
M%_ID'_JRF0_CAZ3_ /;3^I:BBBOE"PHHHH _F"_X.\?^4-GC;_LO_P "?_3[
MJ=?YDGP=TG%A'<%>9I"V<=BJD<GL.WXD5_IP?\'=:&3_ ((Y>,8QU?\ :"^
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MR*[2XC(!^95/&.,8SQ@_CQ7E7CG5#)!)$K9$<9&/1BI.#SQU)_\ KUYSJOQ
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M'//?@'(_ <5DW,[%'DD<ENH )P3GZC^7%<5J&L);I(C#:YW;![^N>N./\>*
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M_);]EO\ Y2S?\%5/^Q _8._]5?X]K]:: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KX\^$?_)S/[07_7?3/_35X>K[#KX\^$?_ "<S^T%_UWTS_P!-
M7AZ@#[#HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K^6G_
M (-E_P#G*'_V>UK?_NS5_4M7\M/_  ;+_P#.4/\ [/:UO_W9J^KRC_DF.+_3
M(/\ U93(?QP])_\ MI_4M1117RA84444 ?S1?\'9-I]N_P""1?B2VP"'_:%^
M!)(/3"ZWJK<_E7^<-X3L?*@MT7 "  C'08 Q[\?Y'2O])G_@ZDA6?_@DYXE1
MAD#X]_!%QQW76-4Y]NO6O\X?PW BHI7)8*HQ@]6^4Y'J.N>: /8/#B&1%506
M^8#GKCH..HSCM7L?A_2FU/5M-TN,X:YF0/CD1QC&YCCH,XY)[UY5X:B,0)56
M9]I  !.YB,J!SUSTQWSV-?1?@72YM/CDU.Y4KJ%PI2",Y#0Q-CYO4,2JD<="
M>?4 ]5OI1>7\&G6KXM-/2.UA 'RC&"WH "7;GU/>O:?&FH1>%/@TD,+A);^]
MBMV;H7!>U##'4@B3W'6O&],@2U(FF7,F]2^23G)!^8G'3\N._;7^-NM&Y\#^
M$K-&4QC4Y3*JX*_*++;G Y((/7F@#B-,N&ATYF9@ 4+J"/O$C< .>,Y[=N3S
M5CPFTLUU++)@$R$@D9!!;C'IQQUZ#CK7,7-T5L+:)6 9E10,X^4@=,=?Y^F*
MUM"U%;."3/$B] #SR.N3@]3SVSVZ4 >FWVN-:;H%;#,VWU'_ -;CU)KC-8UR
M0SH!*%*1A25(!';&,Y!P".?6L"XOI[F<NS$#>IP#DGYAE1GVXKF/$6IPV]Y/
MR5!C5PK?>WDMQS@]0,X]^YY\?$/FSO+H?R8',:OS]I@J:_\ 2WJ?HN4P5+PN
MXUQ/*^;$\5\%Y>I6T45A.(\=)7OJV\/![-I+L8?B/6&_TL9.6! ;=SW_ !.#
MT(.?ICCY9\67+7UY!8H<&YN54$<EF+$GCOP,<<^AX(KU+7M8:4RG?@MG@'^$
M9S_^NO![K4@_B_0X]X9#>CH<YPLGMQZ?GTYKV#\Z/J><6^@>%)6!54L]/;;D
MA<-L(4 $?+EB.._XUXU\/C)?B2\D7)N[AI^3SB1@PS^9],],8XJ;XP^*#:Z)
M8:/;RD3ZO<1Q.BG#+#'LE/3Y@"$9<=^E:?P]MQ!:642C&[RP !NPO /7/K@?
MAQ0!_0#_ ,$&K)HO^"G/[+DKA?E'QI"8&"-_[.WQ;Z]\8[_3U%?Z(=?YY_\
MP0Q98?\ @I]^RG!@[Y%^-7TPO[.?Q=/(Z#H!P!]37^AA0 4444 %?A!\5/\
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M_#5&FE>XO&+SW;^=(\AY+L02<GJ< 8R1_C]K^ 8A%ON"1@*%7)&#P?R_SGV
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M)W4Y0*/);YB<@>O?L5_L2W/[2/P:\7_&[6?C1X>^$7@#P5J5KI>I:KKD-A)
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M:VN@^']+TF;4BP^RQ"ZFEC4?:O[4'[,7@K]J7P':^#O%>HZ]X=U#1=6M-?\
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MD_M"?_._K]/M8_:/^.OA_P#;J^'G@S5+G]IBRUGXR_M$GX7>(5U;P!XCT[X
MCX<S_#/Q#XMTF[\ ^+I-6;0Y+^74-$T*2XU?3=+MIU,FIV+2.C3,_P"\7[(_
MQ%\0?$7X/:6_C.:.[\<^$[RY\)>,[R)%2&[\0:<D4]S/"J\"-H;NW QU96[Y
MJ_;3_N_=_P '^KORL'\;_P#PVY\-O^B6_M7?^(D_M"?_ #OZ_H)\(_\ !<K]
MB'2O"GAC2[W0/VO8KS3?#VBV%W&/V)/VH7$=U9Z;;6\Z!T^&11PDL;J'4E6
MRI((-?MI@>@_(48'H/R%1.<IVO;2^WG;_(#\;/\ A^S^PQ_T!/VOO_$(OVH_
M_G8T?\/V?V&/^@)^U]_XA%^U'_\ .QK]D\#T'Y"C ]!^0J /QL_X?L_L,?\
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MFR?L,_\ HCXP5^Q-?@Y^P7\>O@O^T?\ \%</^"D/Q*^ OQ0\$_%WP!/^SO\
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M(5OX2UC6-6N?$>H3'3O$&JVXM&U&]FFN+X:8\,=FL;2$0A!$JJ!M'B_PZLO
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M";0=$N+^SU>_N$MKJ'3;**ZO60 /E72;:CJU>]][M?=M^%NP'[+K(CDA'1B
MK$*P8A6&5)P3PPY4]".13Z^'_ANWC;P#XN^!GA[6==GUBW\1> ]=MO$L,FHS
M:O*M[HT&@VN@(+R9FDO)-.CN+J+4=5=4EU"4BZN$61\#[@JT[]+?\,G^H'V)
M^P9_R<]X _ZX^(O_ $P:A7]&E?SE_L&?\G/> /\ KCXB_P#3!J%?T:5S5_C7
M^%?FP"BBBL0"BBB@ HHHH _(;_@OA_RAR_X*#8_Z(!K/_I[T*O\ ' \!?#7Q
M_P#$?4I+3P'X3UCQ7>69$MQ;:1;?:)8DSG<Z[TP,<]:_V/\ _@OC_P H<?\
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MFH6"8W%8&CC#O& ,XWW;Y., G\_DGQ/&$\!(YSL6ZVXZC.8AZ]<\9_"OI[X
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M "4K_@E7_P!I-/@U_P"H!\4Z_7*OR-_X*D_\E*_X)5_]I-/@U_Z@'Q3K]<J
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MNG7_ )#6A_\ ZJ_QG=!GBLM=TB[N&*P0WT$TK==L:2*S$#CM7^S#_P %\O\
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MLDT;3QJ<8:2$,9$!R.64#D>HJQ0 4444 %%%% 'Y&_\ !4G_ )*5_P $J_\
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M?_G*'_V>UK?_ +LU?5Y1_P DQQ?Z9!_ZLID/XX>D_P#VT_J6HHHKY0L****
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M0 4444 %%%5S=VJW"VC7-NMTZ[UMC-&+ADY.]82WF%< G<%(X//% %BBBB@
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MW_A+_"?_ $-'AW_P=Z;_ /)-'_"7^$_^AH\._P#@[TW_ .2: .BHKG?^$O\
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M *#.E?\ @QM/_CU']NZ)_P!!G2O_  8VG_QZBZ[K^O\ AU]X&K165_;NB?\
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MH^-.NR.0%;&.GY?3/^>:^90<R@^LF?\ QZMRSH8ON#\/Y"I*CB^X/P_D*DH
M_P!=S_@U^_Y08_L/?]W+?^M@?M 5^^E?@7_P:_?\H,?V'O\ NY;_ -; _: K
M]]* "BBB@ HHHH _"W]FS4M1F_X+3_MFZ?-?WLMA;_"S1G@L9+J=[2!S;_#[
M+PVS2&&-CN;YD13\S<_,<_NE7X0?LT?\IL_VT_\ LE6C?^D_P\K]WZ "HYIH
M;>*2>XEC@@B4O+--(L44:*,L\DCE415')9B !U-25GZKI=CK6FWNDZE EU8:
MA;R6MW;R ,DT$J[9(V5@5(8<$$$>HH ^?_C5\7-<M/A!X]\0_L_/X5^)7C?1
MM!U>738-.\0Z/J>EZ3?6]E)(E[K(LM5BD^RV38N)[>&=+ETC*1J79 ?!_P!A
M7]H3Q/XK_9-\._%7]I_QWX(T3Q5)XAU31_%'B6\U:V\+^#HM5C>UBCLM+N_$
M=[#]GM)+AYDTVVO+N2[=,(6DD!->Y_#W]E+X,_!?PIX\\.?!SP9H_@?_ (3O
M2M9M-3?3+.VMTGN]4LI;;[3.EM#;^85D=';<<L$QN'4>2?#;]A;X5S_LT+^S
M7^T;X)\"?'?P3)XPN_%UWX<\:^&;'6O#-SJ"W45WI%U)H^I&^MGN],F1Y+:=
MLO'(Q9 IY(!\;?\ !1SXQ_"+Q_\ %O\ X)7Z-X$^*GPX\:ZO#_P4K^#M[+I7
MA+QQX8\1ZE%9Q> _BA')=R6.CZI>726T<DL:/.T0B1Y$5G#.H/[<U_.M^VM^
MP5^Q=^S)\=_^"6OCW]GO]F#X*?!OQI??\%'/A%X?N_%'P\\ Z#X8UNYT2\\#
M_$JYNM*FO],M()Y+&XN+.UFEMV<QO);Q,1E!7]%- !1110 4444 ?FY^W[]W
MP1_UPU#_ -*8:_-*OTM_;]^[X(_ZX:A_Z4PU^:5?\V'T^_\ E*?Q'_P<-?\
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M#.EW=7$4?V9/L\<.7W?J1_PY%_X)7?\ 1G7@'_PH?B-_\VE<5^SK_P II_\
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MNK]:** /R7_X<4_\$E/^C(_A;_X,O'?_ ,UU'_#BG_@DI_T9'\+?_!EX[_\
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M<GCN<?Y_*O\ 9A_X+X\_\$<?^"@_./\ C'_6>?\ N-Z%7^,_9Y\L[3D -UR
M>WZ?X=: ,BY7;)D9YYSVR/0UZY\.]9^4V<C\I@*"<DCZ=NIP>GTKS*>'S 22
M,@Y!'7T Y&/2I-"U!],U&&4<#>%;MP<C^O?M[T ?8MA<[3&^[T!.3R.A^N/3
M\J]G\%7R^;-8[SY5X@9#D_?7CCN.7XP?Y5\\:-?1W5M#,C!MZ@X'N/;CN?\
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MI_RG<^ /_9OVI?\ IF\?U^[]?A!\5/\ E.Y\ ?\ LW[4O_3-X_H _=^BBB@
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M@#NJP3G!Y#NR&8_]\@9[8Z]J -C3G_M#P%:R;SYVD7SQ.QRQ\NYE=E'J,+$
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MN+.*,;AZN$QG$.=8K"UX>SK8?$9EC*U"K!M/DJ4IUI0G&Z3Y9)K1:!1117Z
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MV'L=/^,EO_6O_C_7[YU^!?\ P:__ /*#']A[_NY;_P!:_P#V@*_?2@ HHHH
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MDHH _?3_ (-?O^4YW[#W_=RW_K'_ .T!7^NY7^1'_P &OW_*<[]AW_NY;/\
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MK+:L*.+5",YP52/L,9@\9'E;<=:F#KXBG&5T_<E)36[C9ILHHHKW#A"BBB@
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MI2UWT5NK&\58/,<77QN+X6R.IB<1/VE::JYU!2E:*ORPS516D=DDO+>_A_\
MPFOQ?_Z)EI?_ (4=S_\ *BO8-*N+ZZTZSN-2M([&^FMXI+JTBE,Z6\SHK21+
M*R1L_EN2N2BDXS@5H45]KP]P[FV35\15S'C/B'B:%:E&G3P^<8?A^C2PTHRY
MG6I/)\ERRJZDE[C56I4@H_#!/4\7,,QPF,ITX8;)LORR4).4JF#J9A4G53BD
MH3^N8W$Q44[R7)&,F]V^I1117UAY(4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5_+3_P;+_\
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M '[Z?\&OW_*<[]A[_NY;_P!8_P#V@*_UW*_R(_\ @U^_Y3G?L/?]W+?^L?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!T _K*HH I:;;FTTZPM&+EK:RM;<F1@TA,,$<9+L  SDK\S  %LD  U=HHH
M^-OVT/V+O"/[:GA+X:>'/$GQ*^*_PCUGX1?%;0?C+X \?_!G7],\-^-O#WC;
MP[I>M:1IM[9:GJNBZ[;)$EIKU]N066\N8R)%"LK?*W_#K3XC?])4?^"FW_AZ
M_ W_ ,Z^OURHH _(W_AUI\1O^DJ/_!3;_P /7X&_^=?1_P .M/B-_P!)4?\
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M"QLI?"?P=^*NM^"O#%S=Q7?P\OI)-7N-*TZ"35+A)8X;B[+R0V\"$1C] _\
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MT^(W_25'_@IM_P"'K\#?_.OK]<J* /R-_P"'6GQ&_P"DJ/\ P4V_\/7X&_\
MG7T?\.M/B-_TE1_X*;?^'K\#?_.OK]<J* /R-_X=:?$;_I*C_P %-O\ P]?@
M;_YU]'_#K3XC?])4?^"FW_AZ_ W_ ,Z^OURKQSX]?'+P3^SE\+O$GQ<^(47B
M"?POX8A26^MO"VC3>(=?NGE++!:Z7H]O)%/?WEQ(!#;V\3AY972-<LPH _/#
M_AUI\1O^DJ/_  4V_P##U^!O_G7T?\.M/B-_TE1_X*;?^'K\#?\ SKZTOAY_
MP6)_9M\=>*?"'AC6?A3^UO\ !Z+Q_<V.G>#/%?QT_9U\4_"[P3XEUO5Q&VA^
M'='\3:_=+8W^OZ]$[SZ+I5N9+G48;:ZDMU98'K]+?A]X\T#XF^#M$\<^%WNY
M-!U^*ZFT][ZV-G=,EI?W6G3>=;,SF(BYLY@H+'<@5^C8 !^+/[1W_!/7XO\
MPE_9Y^//Q4\-_P#!4S_@I3<>(?AG\&/BC\0=!@U/XS>"I]-GUKP9X'USQ'I<
M.H01?#2"6:RDOM-@2[BBGADD@:1$EC8AQF_LL?L ?&3XT_LS?L]_&#Q5_P %
M2_\ @I-;>)OBG\%/A?\ $/Q#;Z3\9?!=OI<&M^,O!6B^(=4ATZ";X:W$T%C'
M?:A.EI#+<3R1P"-'ED8%C^W/Q%\">'_BE\/O'?PR\617,_A7XB^#?$_@3Q-!
M97+V5Y-X?\7:)?>']9BM+R(&2TN9-.U"Y2"YC!>"4I*@+(*K?"[X<^&?@_\
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M8IH7?[\N['0[J7RKZSTJYF:VDA\N[M[.:5K1@@FBV3(SFV($8D3!B("!APM
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M_P"(;C_@D5_T;?<_^%UXK_\ D^C_ (AM_P#@D5_T;?<_^%WXK_\ EA7[LT4
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MM_!9L\\,X\MK1I+A"TL<R_(UN2RR#Y2A'%<-<_%;P5I?Q5T/X)R7BV_C+6/
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M<^!O!]Q%X@N(KO7HI_#.BRQZU=P(D<-SJR263+J-Q#'%&D4UX)I(TC148!5
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img149481191_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img149481191_8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $( G # 2(  A$! Q$!_\0
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MJ7MWF^#R#%X2-&O1RNOA*L^;B7*<+5A#$2E#$8B$DI82MAL57]@_X2GXY?\
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M#+JV(QD:F'S+*LWPE>A.BITZ.!_M"7+@Z]*HO=_[,_: _P"AW^#O_AK?&O\
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M1PKJQRY595\92@\,L-A:^:8'#8C&^T6%IU:[<JD84<1*A]?_ -F?M ?]#O\
M!W_PUOC7_P"?#1_9G[0'_0[_  =_\-;XU_\ GPU\2_"?]N3XR^)M%^ 7Q/\
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M'%XG%0Q=7$3<L+1PN$R_&8BM5C0KSG"DH8:EB*M6C3E]:?V9^T!_T._P=_\
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M5,35HYAB)X2.99?+%X155ALKQF*I0E*->IAJ?/4P^'JR5%?=G]F?M ?]#O\
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M@\51HX&A&ABL54HPP6#IT*N,CC,RQ.'R[#U)XK$X2GB/JK^S/V@/^AW^#O\
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MFZW8_%+[;;V6LZ99W\>AZ)IWA_2+)=,U\W6K75UY=X1_X)T_$/0X/BZ_]M?
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MQ6VE^+-#CBOI-/MH[75[;4[=C /J[_A!?C-_T7=?_#7>%_\ Y.H_X07XS?\
M1=U_\-=X7_\ DZNO$\1YIB,5B<2LYRVC'%5ZU:>%I8"K]33KO&\\'AZF55*=
M5..8XN-2==5:M=U%4KU*M6%.<?.P/!608++\#@'PQGF)E@,+A<-2S"OF^&69
M-8592Z=2.-H\0TJV'E&>2Y=.E3P<L/A\*J$J.$HT,/5JTJGRMH'[ -_X"^'O
M@WP-\,_VD?B;X:E\*K\4],U.^\1^'O WQ&T#X@>&OBKX^U'XAZC:^/OA_P",
M-'O?!FM>*=$UO4)AHWCFWTRPUG[--J%G?QWFF:C/IPI77_!,KX02_#]_AA:>
M,_'=AX07]FK2?V<K2%'T2XU*WMM%^*;?%^S\;275QI;V-UJ4GBXH+WPU+I8\
M(W.CB31/[)CTN7[*OUM_P@OQF_Z+NO\ X:[PO_\ )U'_  @OQF_Z+NO_ (:[
MPO\ _)U9_P"L.<\[J+B+"QJ2Q3QLZD,)6IU*F*=:IB%6JU(93&=65.K6JRHJ
MI*4:"J5(45"$W&6W^IO#+IJC+@O,)T8Y?'*J="KF.&JT*.7K#4,'+"T*-3B*
M=+#TZV'PV'ABO80IRQDL/2J8J5:K3A->/?"']DG6/AY\;8/CYXR^./BWXI^-
MT^$=]\&Y+#4/"'@3P9X0LO#,OBO2_%FGOX<\->"M'TJVT*YMKZPN?[08RZ@V
ML2Z@TLTEO%965K#U'Q<_9GN?&WQ+TCXW?"_XK^+/@9\8M/\ "I\ ZOXI\-:/
MX9\5:%XW\"IJ%SJ]AX<\<>"_%VG7^DZR?#^L7E[J7AC6;6;3-9T274=5@AO9
M;/4)K8=S_P (+\9O^B[K_P"&N\+_ /R=1_P@OQF_Z+NO_AKO"_\ \G5R2S'&
M3Q4<9+.,O]M'#O!\OU&JL,\([WPT\$LI6#J4/?;]E.A*%U%J-X0:]&GDF6T\
MOEED.&<Z6&GC5F7.\VH2QT,Q3@UCJ6:2XCEF='%^XD\12Q<*K3J1<W&K44_!
M=)_86\*6&CZ8^J?$?QQXJ^(EU^T9\./VF/B1\4_$<6A7'B7XD^,_AK]EM]#T
M*]L;#3]/T/PWX-LM(LK/0=$T#P[86EOX?TJW$=D9+J:ZNI][QC^QMX<\8_%3
MQ1\4[GQQXALK[Q1\8/V:/B_/I%OI^DR6-IJ'[-4-[#HNB03RQFY?3_%0O6;6
M;B5C=69C4:>R FO7/^$%^,W_ $7=?_#7>%__ ).H_P"$%^,W_1=U_P##7>%_
M_DZM/[7S+VDJO]OX;GE!TF_J^*M&E*KA*WLH1_LOEITH3P6$]E2IQC3HT\/"
MC2C"DN1Y+AW)%1A07!^/]E3JPKI/&8!RE7CA\?A7B*M1Y\ZE;$5*.:9A]8KU
MIU*N)K8JMB<1.KB)*JOG@?L-0Z'8^#]4^'/QI\;?#WXH> /B%\?/&GA?XD6&
M@^$M;8:'^T7XZO\ QWX^^'WB#PCKVG7GA_Q!X9_M&?2FTJ6X2WU6PU#P[I&K
MPWJW"W45Q[K^S7\!8?V<_AW>^ D\=^*?B3=:IX[\>?$'5_&/C--+3Q%JVN?$
M'Q)?>*-9EU#^Q[2QT]V&HZA<"-K>SMD$15%AC1%0:7_""_&;_HNZ_P#AKO"_
M_P G4?\ ""_&;_HNZ_\ AKO"_P#\G5GBLQQF-PT\+BLZP56C4K?6)IX3$1J2
MJ>UQ%=)UX95&O[*-;&8JK##JK["%2O6G"FI5&WKE^297E>-IYA@.%LUPV)HX
M7ZG2<<QP<J$*'U? X1M82IQ!/">WGA<MR_#U,7[!XNK0P6'I5*TX4J<5\J^"
M_P!BOX[_  LTK7/#'PH_;?\ '7@CP9J7C3X@>-M-\-M\$_@OXD_L.^^(GC'7
M/&^KVL.KZ_H=WJ=];P:QKUX;8WLSL(@J$!?E'4?$+]A;1OB?XJ\6_$_Q;\5?
M&5S\:)9OAK+\'?BA::;H5IJ7P 3X:-#J-O;_  ^T=(&TQ[;QOXBGU[5/B9;Z
MFLMOXTT[76\-7T4.C:7I<-M]!?\ ""_&;_HNZ_\ AKO"_P#\G4?\(+\9O^B[
MK_X:[PO_ /)U=#SO,G7EBHYSE=+$SYO:XBAE4</7KJ=6C6J+$U:&2TZF*56I
M0A[:.(E55:'M:553I5ZT*G%'A3(UA(X"?#&?U\#3]FZ&"Q?$$\;@\&Z6'Q&%
MH/ X7%\4UJ& >&HXJJL,\%3H/#5(T*V'=.OA<)4H_!OAW]BKXE?$OQ7^UEI7
MQ*^*'Q(\!?!;XO?M&WNO^(?A3H]GX(FT3XO^!;/P9\-88]4TWQ'-:ZMXL\"Z
M7XQU/1]3T#QGIVEWME>:UI.E+:(--\^6^O/=?%O[$TU_XZ\?>(_AK\=OB!\&
MO"GQ<\1:?XM^)W@OP=X<^'VH7%_XFM].TO1=7USP)XS\2>&M5\2?#6_\5:-H
MFE67B%]#FN8I+BVDU72X=+U.ZN+I_??^$%^,W_1=U_\ #7>%_P#Y.H_X07XS
M?]%W7_PUWA?_ .3JTJY_F-2I&<,WRRC3A0IX=8>& K2P[5.E@J7M:M*KE56-
M?$R^H827UFM[3$0="G&E4A"G3C''#\'Y+0HSIU.&\^Q-6IBZN+EC*N<8:&,C
M*KB,QK^PH8C#<0T9X7!1>;YA!X#"NC@ZL<5B)5Z%6I7JSJ>4^)OV//#GB7P3
M^UQX(E\;>(;2T_:VOQ?:]?16.F37?@O;\,?!WPQ6+0UFC:/4O] \'6VJO+JW
MF.]_?7,9_<)$HY;QG^Q->:GXV\:^+?AK\>_'OP;M?BQ#X9/Q9TGPOX5^'6N7
M6OZQX9\.Z?X03Q9X.\1>+/#>KZO\-O%NK>%M*TW2-6U;09)X9GL++5H+&VUJ
M#^T']_\ ^$%^,W_1=U_\-=X7_P#DZC_A!?C-_P!%W7_PUWA?_P"3JYJ6;9A1
M^#/,$X\J@X5<'6KTI15+ 48JI2K934I5.2&6X%P<X2<*F%IUH-5;SEW8CAW)
M\4OWO"F:QE[1U55P^987"5X5)XC-<54E2Q&%XAHUZ7M*N>9M[54JD8U:6.KX
M>HIX=PI+S'6OV1/#NL:9^UEI9\:^)8(?VK_ GA[P'KDTEOI]Y=^#K/P[\*'^
M%%OJ.DW%Q&7U:_NM/?\ MBZ;5_,1]1#( ('*UQGBC]B2]NM<\1:I\-_VAOBG
M\';+XF>"/ O@/XU:=X,L?",]SX]LO 'AJ+P9I'B/0-=UG1[[6/AIXWG\(Q+X
M=N_$OA6X63[!;Z;/;6EOJFEV>HI] _\ ""_&;_HNZ_\ AKO"_P#\G4?\(+\9
MO^B[K_X:[PO_ /)U%+-LPHN\,\P37)2IN%3"5ZU.4*%'!4**G2K954IU/94\
MOP3IN<).%7"TJ\6J\54;K\/9/B8VJ<)YI%JK7KQJ4,QPF&KTZN)Q698S$RI8
MC#<0TJ]+ZQ6SG-8UXTJD(U</CL3@YJ6$J>P/G;7/V&?*\4^+;_X6_'KXD_![
MP5\2=7T;Q%\1_!WAK1_ ^O:KJGB+3M)T?P_JGB#PC\1/&'A_7/&?@36/%VB^
M'])M_%5[I]]?R7U]!<:W9_V?J]_>7<OT;\>/@II?QV^$&N?"#4M=U/P[IFMW
M7@RY?6=-BMK[4K;_ (0SQEX<\8VL:)J"R6\WVZX\.06-U),&=8+J::,B=481
M_P#""_&;_HNZ_P#AKO"__P G4?\ ""_&;_HNZ_\ AKO"_P#\G5G4S#&5:V!Q
M%3.L$Z^75*57"U_JN(C6C5H>Q5*I6JQRM3Q52FL/1C&>*E7ER4E"[CH]J.39
M;A\/FN#H\+9I#"9U2KT,PPKS#!2PTZ&*^L?6*&'H3S^5++Z-5XS$SG2R^&%@
MZE6=11]IRR/FGQ[_ ,$]/AWXXUS]K;73XV\6:--^U?X"'@:^L;6'3;G2_AI_
M:EEI</CG7?!EE<QF-]3^(6H>'O#&L^)QJ!DAN-1T"SDC"JSBM[QY^Q=>ZUXY
M\8>-_AC\=_''P7N/BGI'A?3/BS:^'/"?P[\3S>);WPEH$/A+3/%OA;5O&GAS
M6K_X=^-G\+6]KHEUKF@/);S1:?I.H?V6NKZ;#J#>\?\ ""_&;_HNZ_\ AKO"
M_P#\G4?\(+\9O^B[K_X:[PO_ /)U=$<ZS1>S3S_"5(TJ4:$*=?"5\11]E"E@
M*,83HU\JJ4JJC#+<#*+J0FU6PT,2G]8<JLN.?"^0S]LUP?F5&I7Q$L74K83,
M<)@L0L34Q&:8F=6EB<)Q#1Q%"4ZF=YK":H5*<987&5L$T\&J="/RO\0?^"?%
MIXN\0_&6]\-?'WXF^ /#?[0G@7P_X(^+^C:;HO@/Q!XC\0P>&? 8^'5A=Z/\
M1/$WA[4?%?AB'4_#L<$?B32].N&M=4N7U&ZLFTB?5;R1CXA_\$_?^$_\,/\
M#V3]H'XB:?\ ##Q-\-? 'PS^)GP^O/#?@+Q=H?B&Q\!>%[7P?'XB\!GQEH>N
M3?!SQ/X@T*V2#6]1\$F.*2\BL]:M+:VU^RAU6OJC_A!?C-_T7=?_  UWA?\
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M_P"0_P#XNO+\GU/YFC)]3^9H]C#S^\/[1Q7\T/\ P!?U_P ._*WJ'_"56/\
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M9M+96M\TG^9[>&J2JT*=2=G*46VTK*]VMOD%%%%0;A1110 4444 %?E[X_\
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M&GBC6=2U[5_$/B2YW7NNWYU#5YKC4/[-;5+FZBT2RN)Y6TS18]/TT22"U$C
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M^"=!\<>-?C!'\<-5U;PIX=;4O$N@>#?$W[)TO[,ANO#6G-K.K*GPVTKPA?\
MQK;3EN+VX4>(+3Q\]T=GVHR(?GW3=.^+L7@CQD_QL\6?%G1];\+?M0_'SQ79
MV'Q&^&?BKXE>#OBYXCU'X3>'9?#G@M;;X6>//*\(^!-,UW6-<MOA?X?M-0N]
M(OY;2PTOP]>7GB?2);B4#FU:M_ETOKW5]OENS]XJ*XSX<7VMZI\// >I^)O#
M?_"&^(]1\&>%[[Q!X0^TF\_X176[O0[&XU7PW]K)8W7]AW\EQIGVDLQG^R^:
M22V:[.@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH ***_.W]J#Q%I5U\<_AU\/_"WB[Q1X3^+-Z/ /B8^-M5\4^)]
M$^&GPV\#Z'X\DN[ZRTG0[6:#PWXU^(WQCEMKOP#<^&);;5)SX5\S6_$EQI&B
MZ3I5EXCVH4G6GR)M)1<I2Y>91BMY22:?*MW:\GM&,IN,7G5J*G'FT>JBDWRW
M;=DEH[MO9.RZR<8IM?HE7SK\:/\ DH/[/W_8X?$'_P!4WX^KY?\ V*-5\:7W
MB^VCO+WQY>1R? /PM>?'J'QA<^*;N#2/VGCXSUV'Q+IR+XI8KI7B)=.&J1:W
MH_AQ(-(AT2S\(2_98+%]!DN?H'XQS^*3\9/@1;SZ7X?3P@NO^/)++5XM>U&7
MQ)-JQ^#WCH2VESX<?PY#I=MIJQF9DU&+Q1=W3R)$C:9&LKR1=$:+HXIT^:,N
M6G5;>B_Y<STLV]7O%)MN+4M$]./$U%4P4YV:YI4U;?\ Y>PZI??=*SNGJ=C1
M115'SX4444 %%%% !1110 4JLRLK*2K*0RL"058'(((Y!!&01R#244 9VD:1
MI/A[2[;1- TRPT31;*2]FL])TJUAL--M9=2OKC4]1EM[*V2.WADOM2N[N_O'
MC16N+RYGN)2TLKL=1)9(PZI(Z+(NV14=E$B_W7 (#+[-D>U,KD?&_CSPK\.-
M!N/%'C/4;G2= M"_VS4K?0O$6OI91Q6\]W-<WMOX:TG6;VTL;>UMIY[G4+FV
MBL;:.(F>YC+(& .S$\P#@32@2(L;@2. Z(,*CC.&11PJG( X  IRW-RGE[+B
M=?*5EBVRR+Y2M]Y8\,-BM_$%P#W!KE_"OBK0?&WA_3?%/AB\GU#0=8A^TZ9?
M7&E:QHKWEL6(2Y33]>T_2]4CMY@/,MYI[**.YA9+BW:6"1)&Z&@!\DDDKF25
MWD<X!>1F=R , %F))P.!D\#@4RBB@ HHHH **** "BBB@ HHHH ]%\&?\>EU
M_P!=Q_Z M=G7&>#/^/2Z_P"NX_\ 0%KLZXZO\27R_P#24?38+_=:/^%_^E2"
MBBBLSJ"BBB@ HHHH *IW.HZ?9+=/>7UG:)8V;:C>O<W4$"V>GH)2]]=-*Z"W
MLT$$Y:YE*0*(927'EOMN5^:/QD^ GBE_C!\>?&OA?P-X@\1>'_&OA_\ 9#\0
M^)HGU'_A(&^(,7PM^//BCQ/\2O VBZ=XCUQX(EM_AW#I_P!G\'VT6E^'-7^V
M#2K>WEN]:U'S #]);.\M-1M+:_T^ZMKZQO(([FTO+.>*YM+JVF020W%M<0,\
M,\$L;*\<L3M'(A#*Q!!KQ+P)_P ER^/G_7C\(_\ U']?K)_9B\+>(/"O@+Q+
M'K>AW?A2P\0_%CXI^,?!OA&^6"VN_"W@;Q5XRU/6/#>E7&EVLDMIH,LMM<OJ
MK>'[:0KHQU/[#-';W<-Q:P5?@_9^)K'XQ_M!0^*]?TOQ%J3'X6S07ND>')?#
M%M!ILF@:W]CL)+&;7_$3W-S;8D,VH_;;=;KS55;"W$.Z7:FO<Q#NM*4=-;O]
M_1VTMIUNUY7,Y_%25G\;UTLOW<]];Z]+)[:VTO\ 2U<SX.\&^%_A_P"&M(\'
M>"]$L?#OAG0;2.PTC1M.1DM+&TA&V.&(.\DC*B@*&DD=\  L0 !TU%8F@UHT
M9D=D1GC),;,H+1EE*,48@E2R$J2I!*DJ>"13!!"#&1#$#$SM$1&@,32!A(T>
M!\C.'<.5P6#,&)W',M% !@>@[?H<C\CR/0T444 %9NLZ-I'B/2-3T#7]+T_6
M]#UJPN]*UC1]5LX-0TS5=,OX'M;[3]0L;J.6VO+*\MI9(+FUN(I(9X9'CD1D
M8@Z5% #(HXX8XX842**)$CBCC4*D<<:A41%4 *B* JJ     ,"GT44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+G[9WQXUW]FW]FO
MXJ_%OPCX.U_X@^-_#GAFZ3P+X,\-:'J/B'5-=\9ZH1IGAJ!]-TNWNKMM+M=4
MN8-1UNY$7E6NDV=W)+(GRY^HZPO$.CV&M:=-::A"LT+*05;."#P0<$<'H?;(
M[T ?DM_P16_:N^,/[2_[)]E9?M!:3XVC^+?PTU>Y\/ZEXS\8:#JVE)\3_#>H
M23ZIX:\9:9J%_:P6NK316\MSX?UIK"206]YI$4LRH;Q-WZ?:I\9/A'HGBQ?
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M\/W\VA:-XGU2.]DL<S=M;M.VSV>UFO+J]GW^7W'\4/V3/$_Q0\*?L_:%XO\
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M[(GC.[USPY<:9%X:TI]3\/&"TM(K'Q19NUR![K>S=FG]]DGOY+?7\3$\5_\
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M[M1R0_EC_P" K_(?UBO_ ,_JO_@R?EY^2^XT?MTW_01UG_P<:E_\D4?;IO\
MH(ZS_P"#C4O_ )(K.HHY(?RQ_P# 5_D+ZQ7_ .?];_P9/_Y+R7W%N.\O1-<O
M)JNL/#(T)MXO[6U$&$)"$E!83Y?S90T@))V@A>,5-]NF_P"@CK/_ (.-2_\
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MDTT3'$UI1C.&(J2C**E&4:TI1E&23C*,E)J46K.,DVFK-.UC1^W3?]!'6?\
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M>W&FW=M>FTDE2&>UU&SN["YB+[[>\MKBVE5)H9$7RWXT?\E!_9^_['#X@_\
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MM;QI#!;V\:0P011J%CBABC58XXT4!41%554 * !BOEZU_P"2R_'?_KE\'?\
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M-3U/2=?\1PPZHGWP[F1W=OO.S.<DDY8DGD\GD]3R:](_X1*P])/^_K?XT?\
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MRJ0K$'T@DDDDY))))ZDGDD_6DHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS-1T71M7\K^UM)TS5/($BP_VC86M[Y*RA1*(OM,4OEB0*HD"8#A5W9P,:=%
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M5T:ZUB6WDDU;3+G3=-UB73X=(T'3Y-$BMM#DN;N^TF'7;[]5J*">57OO?O\
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ML5Y_SZ7/_?B7_P"(K:Z[K[T>#[.I_P ^Y_\ @,O\BM15G[%>?\^ES_WXE_\
MB*/L5Y_SZ7/_ 'XE_P#B*+KNOO0>SJ?\^Y_^ R_R*U%6?L5Y_P ^ES_WXE_^
M(H^Q7G_/I<_]^)?_ (BBZ[K[T'LZG_/N?_@,O\BM15G[%>?\^ES_ -^)?_B*
M/L5Y_P ^ES_WXE_^(HNNZ^]![.I_S[G_ . R_P BM15G[%>?\^ES_P!^)?\
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MRV"74$$P?3]<TC4=.E)B"/+:N\+20M'(_P"8WBW]AGXP7?B>_G\+ZE\.=/\
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M/U"J-8HD5U2*-5D9WD5455D>0YD=P  S2$DNS9+$_,30!^9WC#]LSXAWNO\
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MM+:**"WAC58XHHTC10J@  O4444 %%%% !1110 4444 %%%% !1110 4444
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MP!5@0001D$$<$$<@C@BEJ.**."*.&%%BAAC2**-%"I''&H1$11@*J* JJ!@
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MB+]EK2KGX[>&OCCXG^*7Q2\:O\/M?^(/BOX7> /$VI^';CPE\._$?Q/\-_\
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MVBZ'86^F:580M*\DK16=C:P6\;2.\A2,%W9B20#<HHHH **** "N'^)?C?\
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MW@SQOXON[CQ3X'/@76-"=- T271];TG2]4\: 'ZP4444 %%%% !1110 45\
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M_P""<5_\V!_PT?\ L\?]%Y^#'_AT? __ ,O*/^&C_P!GC_HO/P8_\.CX'_\
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MUY&T4;),I12"BC_5?+_^?V,_\&4/_F</]?,X_P"@;+?_  3BO_FP[7_AH_\
M9X_Z+S\&/_#H^!__ )>4?\-'_L\?]%Y^#'_AT? __P O***/]5\O_P"?V,_\
M&4/_ )G#_7S./^@;+?\ P3BO_FP/^&C_ -GC_HO/P8_\.CX'_P#EY1_PT?\
ML\?]%Y^#'_AT? __ ,O***/]5\O_ .?V,_\ !E#_ .9P_P!?,X_Z!LM_\$XK
M_P"; _X:/_9X_P"B\_!C_P .CX'_ /EY1_PT?^SQ_P!%Y^#'_AT? _\ \O**
M*/\ 5?+_ /G]C/\ P90_^9P_U\SC_H&RW_P3BO\ YL#_ (:/_9X_Z+S\&/\
MPZ/@?_Y>4?\ #1_[/'_1>?@Q_P"'1\#_ /R\HHH_U7R__G]C/_!E#_YG#_7S
M./\ H&RW_P $XK_YL#_AH_\ 9X_Z+S\&/_#H^!__ )>4?\-'_L\?]%Y^#'_A
MT? __P O***/]5\O_P"?V,_\&4/_ )G#_7S./^@;+?\ P3BO_FP/^&C_ -GC
M_HO/P8_\.CX'_P#EY1_PT?\ L\?]%Y^#'_AT? __ ,O***/]5\O_ .?V,_\
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MC/\ P90_^9P_U\SC_H&RW_P3BO\ YL#_ (:/_9X_Z+S\&/\ PZ/@?_Y>4?\
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M  T?^SQ_T7GX,?\ AT? _P#\O***/]5\O_Y_8S_P90_^9P_U\SC_ *!LM_\
M!.*_^;"W8?M ? ?5+VUT[3/C9\(]1U"]FCMK*PL/B1X-O+V[N)6"Q6]K:V^L
MR3W$TC$+'%%&\CL0%4DXKURBBOGLZRVAEM2A"A.K-583E+VLH2:<9)*W)3II
K*SUNF?9<,9WB\ZH8JIBJ>'IRH5:<(+#PJ034X.3<O:5:K;NM+-*W1G__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>asnd-20250331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2025-05-01T14:03:38.7020+00:00 -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ascendispharma.com/20250331" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2024" xmlns:asnd="http://ascendispharma.com/20250331" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" namespace="http://xbrl.sec.gov/country/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" namespace="http://fasb.org/srt/2024"/>
  <xsd:import schemaLocation="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd" namespace="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" namespace="http://www.xbrl.org/dtr/type/2024-01-31"/>
  <xsd:import schemaLocation="https://www.xbrl.org/2023/calculation-1.1.xsd" namespace="https://xbrl.org/2023/calculation-1.1"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/CoverPage" id="CoverPage">
        <link:definition>100000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" id="StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss">
        <link:definition>100010 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" id="StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" id="ConsolidatedStatementsOfFinancialPosition">
        <link:definition>100030 - Statement - Consolidated Statements of Financial Position</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" id="ConsolidatedStatementsOfChangesInEquity">
        <link:definition>100040 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements" id="ConsolidatedCashFlowStatements">
        <link:definition>100050 - Statement - Consolidated Cash Flow Statements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/GeneralInformation" id="GeneralInformation">
        <link:definition>100060 - Disclosure - General Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" id="DisclosureSummaryOfMaterialAccountingPolicies">
        <link:definition>100070 - Disclosure - Summary of Material Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/SignificantAccountingJudgementsAndEstimates" id="SignificantAccountingJudgementsAndEstimates">
        <link:definition>100080 - Disclosure - Significant Accounting Judgements and Estimates</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/SignificantEventsInTheReportingPeriod" id="SignificantEventsInTheReportingPeriod">
        <link:definition>100090 - Disclosure - Significant Events in the Reporting Period</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/Revenue" id="Revenue">
        <link:definition>100100 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/SegmentInformation" id="SegmentInformation">
        <link:definition>100110 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPayment1" id="DisclosureSharebasedPayment1">
        <link:definition>100120 - Disclosure - Share-based Payment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/ShareCapital" id="ShareCapital">
        <link:definition>100130 - Disclosure - Share Capital</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/TreasuryShares" id="TreasuryShares">
        <link:definition>100140 - Disclosure - Treasury Shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" id="DisclosureFinancialAssetsAndLiabilities">
        <link:definition>100150 - Disclosure - Financial Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/SubsequentEvents" id="SubsequentEvents">
        <link:definition>100160 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" id="DisclosureSummaryOfMaterialAccountingPoliciesPolicies">
        <link:definition>100170 - Disclosure - Summary of Material Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/RevenueTables" id="RevenueTables">
        <link:definition>100180 - Disclosure - Revenue (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentTables" id="DisclosureSharebasedPaymentTables">
        <link:definition>100190 - Disclosure - Share-based Payment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesTables" id="TreasurySharesTables">
        <link:definition>100200 - Disclosure - Treasury Shares (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" id="DisclosureFinancialAssetsAndLiabilitiesTables">
        <link:definition>100210 - Disclosure - Financial Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" id="DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100220 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" id="DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail">
        <link:definition>100230 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail" id="DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail">
        <link:definition>100240 - Disclosure - Significant Events in the Reporting Period - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail" id="DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail">
        <link:definition>100250 - Disclosure - Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail" id="DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail">
        <link:definition>100260 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail" id="DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail">
        <link:definition>100270 - Disclosure - Revenue - Schedule of Revenue From Sale of Commercial Products (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail" id="RevenueAdditionalInformationDetail">
        <link:definition>100280 - Disclosure - Revenue - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail" id="SegmentInformationAdditionalInformationDetail">
        <link:definition>100290 - Disclosure - Segment Information - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails" id="DisclosureSharebasedPaymentAdditionalInformationDetails">
        <link:definition>100300 - Disclosure - Share-based Payment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail" id="DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail">
        <link:definition>100310 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail" id="DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail">
        <link:definition>100320 - Disclosure - Share-based Payment - Summary Of Share Based Payment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail" id="ShareCapitalAdditionalInformationDetail">
        <link:definition>100330 - Disclosure - Share Capital - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail" id="TreasurySharesSummaryOfHoldingOfTreasurySharesDetail">
        <link:definition>100340 - Disclosure - Treasury Shares - Summary of Holding of Treasury Shares (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail" id="DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail">
        <link:definition>100350 - Disclosure - Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" id="DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail" id="DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail">
        <link:definition>100370 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail" id="DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail">
        <link:definition>100380 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail" id="DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail">
        <link:definition>100390 - Disclosure - Financial Assets and Liabilities - Liquidity Risk Management (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" id="DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" xlink:type="simple"/>
        <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:href="asnd-20250331.xsd#StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" xlink:href="asnd-20250331.xsd#ConsolidatedStatementsOfFinancialPosition" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements" xlink:href="asnd-20250331.xsd#ConsolidatedCashFlowStatements" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail" xlink:href="asnd-20250331.xsd#DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/CoverPage" xlink:href="asnd-20250331.xsd#CoverPage" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:href="asnd-20250331.xsd#StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" xlink:href="asnd-20250331.xsd#ConsolidatedStatementsOfChangesInEquity" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/GeneralInformation" xlink:href="asnd-20250331.xsd#GeneralInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" xlink:href="asnd-20250331.xsd#DisclosureSummaryOfMaterialAccountingPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/SignificantAccountingJudgementsAndEstimates" xlink:href="asnd-20250331.xsd#SignificantAccountingJudgementsAndEstimates" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/SignificantEventsInTheReportingPeriod" xlink:href="asnd-20250331.xsd#SignificantEventsInTheReportingPeriod" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/Revenue" xlink:href="asnd-20250331.xsd#Revenue" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/SegmentInformation" xlink:href="asnd-20250331.xsd#SegmentInformation" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPayment1" xlink:href="asnd-20250331.xsd#DisclosureSharebasedPayment1" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/ShareCapital" xlink:href="asnd-20250331.xsd#ShareCapital" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/TreasuryShares" xlink:href="asnd-20250331.xsd#TreasuryShares" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" xlink:href="asnd-20250331.xsd#DisclosureFinancialAssetsAndLiabilities" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/SubsequentEvents" xlink:href="asnd-20250331.xsd#SubsequentEvents" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" xlink:href="asnd-20250331.xsd#DisclosureSummaryOfMaterialAccountingPoliciesPolicies" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/RevenueTables" xlink:href="asnd-20250331.xsd#RevenueTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentTables" xlink:href="asnd-20250331.xsd#DisclosureSharebasedPaymentTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesTables" xlink:href="asnd-20250331.xsd#TreasurySharesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" xlink:href="asnd-20250331.xsd#DisclosureFinancialAssetsAndLiabilitiesTables" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:href="asnd-20250331.xsd#DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:href="asnd-20250331.xsd#DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail" xlink:href="asnd-20250331.xsd#DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail" xlink:href="asnd-20250331.xsd#DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail" xlink:href="asnd-20250331.xsd#DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail" xlink:href="asnd-20250331.xsd#RevenueAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail" xlink:href="asnd-20250331.xsd#SegmentInformationAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails" xlink:href="asnd-20250331.xsd#DisclosureSharebasedPaymentAdditionalInformationDetails" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail" xlink:href="asnd-20250331.xsd#DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail" xlink:href="asnd-20250331.xsd#DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail" xlink:href="asnd-20250331.xsd#ShareCapitalAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail" xlink:href="asnd-20250331.xsd#TreasurySharesSummaryOfHoldingOfTreasurySharesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail" xlink:href="asnd-20250331.xsd#DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:href="asnd-20250331.xsd#DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail" xlink:href="asnd-20250331.xsd#DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail" xlink:href="asnd-20250331.xsd#DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail" xlink:href="asnd-20250331.xsd#DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail" xlink:type="simple"/>
        <link:roleRef roleURI="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="asnd-20250331.xsd#DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesOfNominalValue" xlink:label="asnd_TreasurySharesOfNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleDebtCurrentAbstract" xlink:label="asnd_ConvertibleDebtCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsDomain" xlink:label="ifrs-full_PerformanceObligationsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RSUNetSettlementMember" xlink:label="asnd_RSUNetSettlementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CollaborationsAndLicenseAgreementsMember" xlink:label="asnd_CollaborationsAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain" xlink:label="ifrs-full_HedgingInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate" xlink:label="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfRevenueToCommercialProductsExplanatory" xlink:label="asnd_DisclosureOfRevenueToCommercialProductsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory" xlink:label="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NovoNordiskMember" xlink:label="asnd_NovoNordiskMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_StockRepurchaseProgramAuthorizedAmount" xlink:label="asnd_StockRepurchaseProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BoardMembersOfGroupMember" xlink:label="asnd_BoardMembersOfGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RevenueFromRenderingOfServicesAndClinicalSupply" xlink:label="asnd_RevenueFromRenderingOfServicesAndClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RepurchaseOfSharesValue" xlink:label="asnd_RepurchaseOfSharesValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfGeneralInformationAbstract" xlink:label="asnd_DisclosureOfGeneralInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="ifrs-full_RestrictedShareUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodTable" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VisenPharmaceuticalsMember" xlink:label="asnd_VisenPharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="ifrs-full_UnobservableInputsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_OtherCurrentLiabilitiesAbstract" xlink:label="asnd_OtherCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares" xlink:label="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentTermOfCustomers" xlink:label="asnd_PaymentTermOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_EmployeesAndConsultantsMember" xlink:label="asnd_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ProfitLossMember" xlink:label="asnd_ProfitLossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareRepurchaseProgramAndRSUNetSettlementMember" xlink:label="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareRepurchaseProgramMember" xlink:label="asnd_ShareRepurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodTextBlock" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentForRepurchaseOfShares" xlink:label="asnd_PaymentForRepurchaseOfShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ClassificationOfRelatedPartyDomain" xlink:label="asnd_ClassificationOfRelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RevenueTable" xlink:label="asnd_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceOfEntity" xlink:label="asnd_SharePriceOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ClassificationOfRelatedPartyAxis" xlink:label="asnd_ClassificationOfRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndDebenturesIssued" xlink:label="ifrs-full_NotesAndDebenturesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NewShareRepurchaseProgramMember" xlink:label="asnd_NewShareRepurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShortTermBorrowingOther" xlink:label="asnd_ShortTermBorrowingOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeMember" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BasicAndDilutedEarningsLossPerShares" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncomeStatementMember" xlink:label="asnd_IncomeStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharesAgreementDescription" xlink:label="asnd_SharesAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestOfWorldMember" xlink:label="asnd_RestOfWorldMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ChangesInWorkingCapitalAbstract" xlink:label="asnd_ChangesInWorkingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyEightMember" xlink:label="asnd_TwoThousandAndTwentyEightMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CostsOfCapitalIncreaseDecrease" xlink:label="asnd_CostsOfCapitalIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NetSettlementUnderStockIncentivePrograms" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="ifrs-full_MeasurementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharesAuthorizedToRepurchase" xlink:label="asnd_SharesAuthorizedToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at fair value, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities at fair value, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets by category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical areas [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Detailed Information About Marketable Securities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure detailed information about marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Addresses, Address Type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) investing activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Repayments of borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repayments of borrowings, classified as financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Repayment of borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) financing activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold percentage of sale price per share for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Percentage Of Sale Price Per Share For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings threshold percentage of sale price per share for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy Carrying Amount [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueHierarchyCarryingAmountMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value hierarchy carrying amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment ending period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Ending Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentEndingPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment ending period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reasonably possible decrease in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of reasonably possible decrease in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CounterpartiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparties [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Tax income (expense)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total tax expense (income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax expense (income)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes (expenses)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of income taxes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of cash flows [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Duration Of Marketable Securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of marketable securities explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for non-cash items:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to reconcile profit (loss) [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settled during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Other Equity Instruments Settled In Share Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments settled in share based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Settled during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested at the balance sheet date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments vested in sharebased payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average exercise price of other equity instruments vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesOfNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Of Nominal Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesOfNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares of nominal value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesOfNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">March 31, 2025 (Nominal values)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesOfNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">January 1, 2025 (Nominal values)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Other Equity Instruments Transferred In Share Based Payment Arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments transferred in share based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Holding In Percentage Of Total Outstanding Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares holding in percentage of total outstanding shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">March 31, 2025 (Holding in % of total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">January 1, 2025 (Holding in % of total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For Non Cash Consideration Regarding Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustments for non cash consideration regarding revenue.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Non-cash consideration relating to revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible debt current abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Debt Current [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleDebtCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes, matures in April 2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-adjusting events after reporting period [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing of transfer of goods or services [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of share-based payment arrangements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained earnings [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Third party investors.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Third Party Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ThirdPartyInvestorsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Third Party Investors [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion price per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Price Per Share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion price per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other comprehensive income that will be reclassified to profit or loss, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Other comprehensive income/(loss), net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income/(loss) for the period, net of tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Non-current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share Based Compensation Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for share-based payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Historical volatility for shares, measurement input [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparties [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total selling, general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, general and administrative expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in prepaid expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of reasonably possible increase in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of reasonably possible increase in unobservable input, liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of equity [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Categories of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of share capital [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for increase (decrease) in trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Inventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in associates reported in separate financial statements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentsInAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments in associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of number and weighted average exercise prices of other equity instruments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Weighted Average Exercise Prices and Movements in Warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units and Performance Stock Unit [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units and performance stock unit.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customer [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for increase (decrease) in deferred income including contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from contracts with customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromContractsWithCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized as revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-adjusting events after reporting period [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-adjusting events after reporting period [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow of Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange rate for percentage of net sales to royalty payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Rate For Percentage Of Net Sales To Royalty Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net revenue from sales interest payment in percentage in exchange for funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Intangible assets and goodwill at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Intangible assets and goodwill at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible assets and goodwill</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold trading days for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Trading Days For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings Threshold Trading Days For Redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Financial Assets And Liabilities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Financial Assets And Liabilities [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares authorised</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Treasury Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Information About Treasury Shares Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of information about treasury shares explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares holding in percentage transferred under stock incentive programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Holding In Percentage Transferred under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Holding in % total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proportion of ownership interest in associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Present ownership percentage</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Duration Of Marketable Securities Noncurrent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Noncurrent Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of Marketable securities noncurrent explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of share capital [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested at the balance sheet date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of other equity instruments vested in share-based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PerformanceObligationsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance obligations [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, plant and equipment at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, plant and equipment at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments granted in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in share capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) in number of ordinary shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease In treasury shares acquired from third parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Treasury Shares Acquired From Third Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Acquired from third-parties (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CostOfSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of sales</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operating activities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfWarrantsOutstanding_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Warrants outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to acquire or redeem entity's shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payments to acquire or redeem entity's shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Acquisition of treasury shares, net of transaction costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of other provisions [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Components of equity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of equity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RSUNetSettlementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RSU Net Settlement [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RSUNetSettlementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">RSU net settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RSUNetSettlementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSU Net Settlement [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forfeited during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of events after reporting period [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Preparation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of basis of preparation of financial statements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationsAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborations and license agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationsAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborations And License Agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationsAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaborations and license agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about financial instruments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales rebates and product returns in U.S. market [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Rebates And Product Returns In U.S. Market [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales rebates and product returns in U.S. market.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Maturity Analysis For Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity Analysis For Financial Liabilities [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maturity analysis for financial liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of entity's revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PercentageOfEntitysRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Perentage of sale to commercial products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Borrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings (excluding lease liabilities)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of share capital, reserves and other equity interest [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from sale of goods</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueFromSaleOfGoods_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from commercial products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in inventories</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyFundingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty funding liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HedgingInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hedging instruments [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total issued capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued capital</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basic earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total basic earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic earnings/(loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares used for calculation (basic and diluted)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average number of ordinary shares used in calculating basic earnings per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Financial assets at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Financial assets at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Transfered</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value transfered.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Cash Gain Recognized On Ownership Interest In Associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non cash gain recognized on ownership interest in associate.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-cash gain recognized</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquidity risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LiquidityRiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liquidity risk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of liabilities [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Forfeited during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments forfeited in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within 1 year [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotLaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Not later than one year [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of share-based payment arrangements [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of share-based payment arrangements [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Financial Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of financial liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bottom of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bottom of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of classes of share capital [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Presentation of leases for lessee [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharePremiumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Premium [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_AsiaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asia [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale or issue of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transfer under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities by category</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through share-based payment transactions, equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based payment (Note 7)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Holding In Percentage Acquired From Third Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares holding in percentage acquired from third parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired from third parties (Holding in % of total outstanding shares)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, award type.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share based Payment Arrangement, Award type [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Events In The Reporting Period LineItems</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant events in the reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Finance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reversal of finance expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Share Based Payment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased payment arrangement, restricted stock unit, activity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reversal of finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of shares outstanding at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of shares outstanding at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ordinary shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deduting offering expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Royalty Funding Liabilities Excluding Offering Expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from royalty funding liabilities excluding offering expenses.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segment Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of entity's operating segments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialProductsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue From Sale of Commercial Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialProductsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Revenue To Commercial Products Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialProductsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of revenue to commercial products explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings in arrears default payment start date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings In Arrears Default Payment Start Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings in arrears default payment start date.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Not Included In Diluted Earnings Per Share [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities not included in diluted earnings per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of voluntary change in accounting policy [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of share-based payment arrangements [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income statement [Axis].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial assets measured at amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets at amortised cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of financial liabilities [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial liabilities [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of Operating Segments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change to Presentation of Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of reclassifications or changes in presentation [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major customers [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major customers [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial assets at amortised cost, class [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial instruments [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase/(decrease) in cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty six [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySixMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty six.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of initial application of standards or interpretations [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">New and Amended Standards and Interpretations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New and Amended IFRS Accounting Standards and Interpretations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Attributable to owners of the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss), attributable to owners of parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Attributable to owners of the Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive income, attributable to owners of parent</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments outstanding in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NovoNordiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novo Nordisk.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NovoNordiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novo Nordisk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NovoNordiskMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novo Nordisk [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StockRepurchaseProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program Authorized Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StockRepurchaseProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock repurchase program authorized amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_StockRepurchaseProgramAuthorizedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share repurchase program authorized amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statements, Captions [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment beginning period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPaymentBeginningPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty payment beginning period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to Prior Periods Estimates and Assumptions [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Adjustment [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible notes current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Notes Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible notes current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleNotesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Convertible notes current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfWarrantActivityLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure Of Warrant Activity [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BoardMembersOfGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Board members of group.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BoardMembersOfGroupMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Board members of group [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Acquired From Third Parties</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares acquired from third parties.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesAcquiredFromThirdParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquired from third parties (Nominal values)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Effect of exchange rate changes on balances held in foreign currencies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effect of exchange rate changes on cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of treasury shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of treasury shares (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PurchaseOfTreasuryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of treasury shares (Note 9)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BalancesWithBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balances with banks</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BalancesWithBanks_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank deposits</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities (excluding indirect tax, and employee related payables)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromRenderingOfServicesAndClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Rendering Of Services and Clinical Supply</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromRenderingOfServicesAndClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue from rendering of services and clinical supply.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueFromRenderingOfServicesAndClinicalSupply_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rendering of services and clinical supply</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principal amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotionalAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notional amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Europe [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_EuropeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Europe [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of detailed information about financial instruments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of detailed information about financial instruments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RepurchaseOfSharesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase of Shares Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RepurchaseOfSharesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Repurchase of shares value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RepurchaseOfSharesValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repurchase of shares, value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax assets, current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policies [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of comprehensive income [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion rate per note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Rate Per Note</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConversionRatePerNote_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion rate per note.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Significant Accounting Judgements and Estimates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of accounting judgements and estimates [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of related parties [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Convertible Senior Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfGeneralInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of general information.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfGeneralInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of General Information [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (decrease) through transactions with owners, equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capital increase (Note 8)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MajorCustomersDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Major customers [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted share units [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RestrictedShareUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve of exchange differences on translation [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Currency Translation Reserve [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of operating segments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Events In The Reporting Period Table</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant Events In The Reporting Period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AtFairValueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At fair value [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current provisions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentProvisions_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VisenPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Visen Pharmaceuticals [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VisenPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Visen Pharmaceuticals [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VisenPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Visen Pharmaceuticals Member</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VisenPharmaceuticalsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">VISEN [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">American depository shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmericanDepositorySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">American depository shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AddressTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Address Type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial instruments [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherNoncurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherNoncurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other non-current receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of risks [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_UnobservableInputsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unobservable inputs [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding received in exchange of royalty payments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty pharma united states yorvipath.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Pharma United States Yorvipath [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Pharma U.S. Yorvipath [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current portion of non-current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LongtermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current portion of non-current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of risks [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfRisksAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of risks [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Diluted earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total diluted earnings (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Diluted earnings/(loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Duration Of Marketable Securities Current</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Duration Of Marketable Securities Current Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Weighted average duration of marketable securities current.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade and other payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trade payables, accrued expenses and other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Top of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TopOfRangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Top of range [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Holding of Treasury Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of treasury shares [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of vesting rights for share-based payment arrangement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage of vesting rights for share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of vesting rights</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Not Included In Diluted Earnings Per Share [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antidilutive securities not Included In diluted earnings per share.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">After 5 years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Later than three years and not later than five years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net gains (losses) on disposals of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains (losses) on disposals of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reversal of (gain)/loss on disposal of property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Other current liabilities abstract.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Current Liabilities [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_OtherCurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingOfSharesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Shares [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_VestingOfSharesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Ordinary Share Related to Repurchase of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of ordinary share Related to repurchase of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of ordinary share Related to repurchase of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and development expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share based compensation costs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Expense from share-based payment transactions with employees</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentPrepayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current prepayments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentTermOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment Term Of Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentTermOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Term Of Customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentTermOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment term of customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">"Right-to-use" licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence fee income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LicenceFeeIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Licenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Profit/(loss) before tax</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from borrowings, classified as financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net proceeds from borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GrossProfit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross profit</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of antidilutive instruments [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Pharma.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Pharma [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_HedgingInstrumentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hedging instruments [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issued capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Capital [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock unit program member.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Unit Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Treasury shares transferred under stock incentive program nominal value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares Transferred Under Stock Incentive Program Nominal Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Nominal values)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_PerformanceObligationsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance obligations [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Balance of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance of equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Equity_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of summary of significant accounting policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Types of interest rates [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfInterestRatesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of interest rates [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentContractLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current contract liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Later than one year [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employees and consultants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employees and Consultants [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EmployeesAndConsultantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employees and consultants [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit loss.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ProfitLossMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings Interest Rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings, interest rate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EventsAfterReportingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Events After Reporting Period [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EventsAfterReportingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Events after reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_EventsAfterReportingPeriodMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Events After Reporting Period [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings condition for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Condition For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsConditionForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings condition for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit or loss [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TreasurySharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Treasury Shares [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Convertible Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FairValueOfConvertibleNotes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of convertible notes.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current financial assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentFinancialAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current assets</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables (excluding indirect tax receivables)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary of Significant Accounting Policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Funding Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Royalty Funding Liabilities Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of royalty funding liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Repurchase Program and RSU Net Settlement [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program and RSU Net Settlement [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share repurchase program and RSU net settlement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Applied For Valuation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceAppliedForValuation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share price applied for valuation.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of the purchase price were royalty payment will cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Multiple Of Purchase Price, Were Royalty Payment Will Cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Multiple of purchase price, were royalty payment will cease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecuritiesExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of performance obligations [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Repurchase Program [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share repurchase program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShareRepurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Repuchase Program [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible Senior Notes and Derivative Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description Of Accounting Policy For Convertible Notes And Derivative Liabilities [Policy Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Description of accounting policy for convertible notes and derivative liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Significant Events In the Reporting Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Events In The Reporting Period [Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant Events In The Reporting Period Text Block.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Senior Notes [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ConvertibleSeniorNotesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Convertible senior notes [Member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at fair value through profit or loss, category [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities measured at fair value through profit or loss [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of operating segments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of liabilities [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Financial Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of financial borrowings.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares in entity held by entity or by its subsidiaries or associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stocks non-diluted basis</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Shares held</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of reportable segment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of reportable operating segments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfReportableOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of reportable operating segments.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share-based payment arrangement, award type.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Award type [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of classes of share capital [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income Or Expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remeasurement recognized in finance (income) or expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Performance Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PerformanceStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Performance stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiple of the purchase price were royalty payment will cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Multiple of the Purchase Price, were Royalty Payment will cease</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Multiple of the purchase price, were royalty payment will cease.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentForRepurchaseOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment for repurchase of shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentForRepurchaseOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment For Repurchase Of Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentForRepurchaseOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment for repurchase of shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Revenue to Commercial Customers Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of revenue to commercial customers explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Attributable to Commercial Products</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherCurrentReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other current receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShorttermBorrowings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Summary Of Significant Accounting Policy Explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of significant accounting policy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Summary of Material Accounting Policies</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reserve of share-based payments [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Reserve [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of treasury shares [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of non-current financial assets [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classified in the statement of financial position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two thousand and twenty five [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFiveMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty five.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfCommercialCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of commercial customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfCommercialCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of commercial customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfCommercialCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of commercial customers</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Purchase of intangible assets and property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase of intangible assets and property, plant and equipment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of intangible assets and property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty four [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty four.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Measurement Input [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceMeasurementInputMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share price measurement input [member].</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of non-current financial liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Classified in the statement of financial position</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of changes in equity [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of revenue [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ClassificationOfRelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Classification Of Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ClassificationOfRelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classification Of Related Party [Domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from exercise of warrants</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DerivativesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Three [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty three.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share of profit (loss) of associates accounted for using equity method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share of profit/(loss) of associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Share of (profit)/loss of associates</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Within 1 to 5 years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Later than one year and not later than five years [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value Hierarchy</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Summary of Fair Value Hierarchy [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of summary of fair value hierarchy.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrant1 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_Warrant1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. SKYTROFA.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">United States Skytrofa [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. SKYTROFA [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">SKYTROFA [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RevenueTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue table.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CondensedIncomeStatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Condensed Income Statement [Table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue from external customers (geographical)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of geographical areas [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue (geographical)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Trade Payables And Other Payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of trade payables and other payables.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Granted during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments granted in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Granted</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in treasury shares transferred under stock incentive program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Treasury Shares Transferred Under Stock Incentive Program</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transferred under stock incentive programs (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration partners and license agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration partners and license agreements [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration Partners and License Agreements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds From Issuance Of Notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from issue of bonds, notes and debentures</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for decrease (increase) in trade and other receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Funding received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Funding received in exchange of royalty payments</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Funding received in exchange.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_FundingReceivedInExchange_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding received in exchange</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of maturity analysis for derivative financial liabilities [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Withholding Taxes Under Stock Incentive Programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of withholding taxes under stock incentive programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of withholding taxes under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings threshold consecutive trading days for redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Threshold Consecutive Trading Days For Redemption</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings threshold consecutive trading days for redemption.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non-current liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charge</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Impairment loss recognised in profit or loss, property, plant and equipment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Financial Liabilities at Fair Value Settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settled</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Derivative financial liabilities at fair value settled.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of financial position [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Significant events in the reporting period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Events in the Reporting Period [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Share nominal value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Par value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ParValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Nominal value per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and cash equivalents</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents at January 1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents at March 31</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock units.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestrictedStockUnitsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of summary of significant accounting policies [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Summary Of Significant Accounting Policies [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Line items representing the disclosure of summary of significant accounting policies.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of operating segments [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity and liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity and liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfProvisionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of other provisions [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current derivative financial liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for amortisation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Liabilities at beginning of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Liabilities at end of period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss) from operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating profit/(loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price Of Entity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share price of entity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharePriceOfEntity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share price</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ClassificationOfRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Classification Of Related Party [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ClassificationOfRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classification Of Related Party [Axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Categories of related parties [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand and Twenty seven.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand and Twenty seven [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentySevenMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2027</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of employee compensation costs [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of employees compensation costs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotesAndDebenturesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Notes and debentures issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NotesAndDebenturesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Convertible senior notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of antidilutive instruments [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of fair value measurement of liabilities [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General Information</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of general information about financial statements [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Levels of fair value hierarchy [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty Pharma U.S. Skytrofa [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty Pharma United States Skytrofa.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Pharma United States Skytrofa [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive income</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComprehensiveIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total comprehensive income/(loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NewShareRepurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Share Repurchase Program [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NewShareRepurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">New share repurchase program.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NewShareRepurchaseProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">New share repurchase program [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance income received</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance income received, classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. YORVIPATH [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">United States Yorvipath [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">U.S. YORVIPATH.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_UnitedStatesYorvipathMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">YORVIPATH [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermBorrowingOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short Term Borrowing, Other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermBorrowingOther_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Short term borrowing, other</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ShortTermBorrowingOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of shares issued</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentInformationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Information [Line Items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Convertible notes</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Potential Conversion Of Convertible Senior Notes Into Number Of Ordinary Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Potential conversion of convertible senior notes into number of ordinary shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial assets [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sharebased Payment Arrangement, Award type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Payment Arrangement, Award type [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of non-adjusting events after reporting period [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net gains (losses) on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gains (losses) on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gains (losses) on change in fair value of derivatives</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice As Buyout Amount</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments for depreciation expense</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of changes in accounting estimates [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Treasury Shares Outstanding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of treasury shares outstanding.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">March 31, 2025 (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NumberOfTreasurySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">January 1, 2025 (Holding)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange differences on translating foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other comprehensive income, net of tax, exchange differences on translation of foreign operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Distributable equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Distributable equity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DistributableEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Distributable equity.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise price of outstanding share options</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Additions</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in derivative financial liabilities fair value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Derivative Financial Liabilities Fair Value</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in derivative financial liabilities fair value.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted earnings / (loss) per share</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basic And Diluted Earnings Loss Per Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Basic And Diluted Earnings Loss Per Shares</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Finance expenses paid</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance costs paid, classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying amount of equity method investment</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments accounted for using equity method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total investments accounted for using equity method</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable securities1</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_MarketableSecurities1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net profit/(loss) for the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit (loss)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net profit/(loss) for the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net profit/(loss) for the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical areas [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GeographicalAreasAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Geographical areas [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows generated from/(used in) operations</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Exercised during the period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vested at the reporting date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of other equity instruments exercised or vested in share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Specified by vesting year</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current tax liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CurrentTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyConversionOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Currency Conversion Option [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ForeignCurrencyConversionOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Foreign Currency Conversion Option.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goods or services transferred at point in time [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel">Income taxes refund (paid)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income taxes paid (refund), classified as operating activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income taxes received/(paid)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_BorrowingsMaturity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings, maturity</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Levels of fair value hierarchy [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MaturityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Holding Of Treasury Shares [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of holding of treasury shares.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income statement.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_IncomeStatementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial liabilities at amortised cost, Total</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities measured at amortized cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at amortised cost</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Movements in Level 3 Fair Value Measurements</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of Movements in Level Three Fair Value Measurements [Table Text Block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of movements in level 3 fair value measurements.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of segment revenues by destination of major customers explanatory.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of segment revenues by destination of major customers explanatory</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MaturityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maturity [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NorthAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">North America [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_NorthAmericaMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">North America [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharesAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Agreement Description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharesAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares agreement description.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharesAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares agreement description</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goods or services transferred over time [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Level 1 of fair value hierarchy [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2009/role/netLabel">Net cash flows from (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash flows from (used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash flows from/(used in) financing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestOfWorldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rest of world.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestOfWorldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rest of world [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RestOfWorldMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rest of World [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_UnobservableInputsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unobservable inputs [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Borrowings redemption period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Borrowings Redemption Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_BorrowingsRedemptionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Borrowings redemption period.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in working capital:</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes in working capital [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ChangesInWorkingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Changes in working capital.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total financial liabilities at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial liabilities measured at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial liabilities at fair value through profit or loss</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Undiscounted Cashflow Of Financial Lease Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual undiscounted cashflow of Financial lease liabilities.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Eight [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty eight.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_TwoThousandAndTwentyEightMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2028</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange rate for percentage of revenue to royalty payment.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue interest payment in percentage in exchange for funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue interest payment in percentage in exchange for funding</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/label">DENMARK</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_DK_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Denmark [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Description of vesting requirements for share-based payment arrangement</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of vesting</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalties and milestones.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalties and Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_RoyaltiesAndMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties And Milestones [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade receivables from associate</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeReceivables_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Trade receivables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of transactions between related parties [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_RangeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FixedInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed interest rate [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_FixedInterestRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fixed interest rate [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Revenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CostsOfCapitalIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Cost of capital increase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CostsOfCapitalIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Costs of capital increase (decrease)</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CostsOfCapitalIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs of capital increase (decrease).</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Items that may be reclassified subsequently to profit or (loss):</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net settlement under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Net settlement under stock incentive programs.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net settlement under stock incentive programs</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets and Liabilities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of financial instruments [text block]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TypesOfInterestRatesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Types of interest rates [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of marketable securities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from sales or maturity of financial instruments, classified as investing activities</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MeasurementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement [domain]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharesAuthorizedToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares authorized to repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharesAuthorizedToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Authorized To Repurchase</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_SharesAuthorizedToRepurchase_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Shares authorized to repurchase.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of terms and conditions of share-based payment arrangement [line items]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Level 3 of fair value hierarchy [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_MeasurementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Classes of financial assets [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reconciliation of changes in fair value measurement, liabilities [abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trade payables and accrued expenses</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current trade payables</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial customers [Member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial Customers.</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="asnd_CommercialCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial customers [member]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure of classes of share capital [table]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Timing of transfer of goods or services [axis]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subclassifications of assets, liabilities and equities [abstract]</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="ifrs-full_GeographicalAreasDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForProvisions" xlink:to="ifrs-full_AdjustmentsForProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueHierarchyCarryingAmountMember" xlink:to="asnd_FairValueHierarchyCarryingAmountMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPaymentEndingPeriod" xlink:to="asnd_RoyaltyPaymentEndingPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="ifrs-full_CounterpartiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentContractLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesOfNominalValue" xlink:to="asnd_TreasurySharesOfNominalValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="asnd_ConvertibleDebtCurrentAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ThirdPartyInvestorsMember" xlink:to="asnd_ThirdPartyInvestorsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConversionPricePerShare" xlink:to="asnd_ConversionPricePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialLiabilities" xlink:to="ifrs-full_NoncurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ComponentsOfEquityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_VestingMember" xlink:to="asnd_VestingMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentsInAssociates" xlink:to="ifrs-full_InvestmentsInAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleSeniorNotes" xlink:to="asnd_ConvertibleSeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromContractsWithCustomers" xlink:to="ifrs-full_RevenueFromContractsWithCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" xlink:to="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsAndGoodwill" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:to="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" xlink:to="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="ifrs-full_PerformanceObligationsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" xlink:to="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_BorrowingsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfWarrantsOutstanding" xlink:to="asnd_NumberOfWarrantsOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentFinancialAssets" xlink:to="ifrs-full_NoncurrentFinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RSUNetSettlementMember" xlink:to="asnd_RSUNetSettlementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CollaborationsAndLicenseAgreementsMember" xlink:to="asnd_CollaborationsAndLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" xlink:to="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PercentageOfEntitysRevenue" xlink:to="ifrs-full_PercentageOfEntitysRevenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Borrowings" xlink:to="ifrs-full_Borrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_AssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueFromSaleOfGoods" xlink:to="ifrs-full_RevenueFromSaleOfGoods_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativeFinancialLiabilities" xlink:to="ifrs-full_DerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyFundingLiabilities" xlink:to="asnd_RoyaltyFundingLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HedgingInstrumentsDomain" xlink:to="ifrs-full_HedgingInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssets" xlink:to="ifrs-full_FinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate" xlink:to="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiquidityRiskMember" xlink:to="ifrs-full_LiquidityRiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="ifrs-full_ClassesOfLiabilitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotLaterThanOneYearMember" xlink:to="ifrs-full_NotLaterThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="ifrs-full_PresentationOfLeasesForLesseeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_AsiaMember" xlink:to="srt_AsiaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SaleOrIssueOfTreasuryShares" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties" xlink:to="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SignificantEventsInTheReportingPeriodLineitems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesOutstanding" xlink:to="ifrs-full_NumberOfSharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfRevenueToCommercialProductsExplanatory" xlink:to="asnd_DisclosureOfRevenueToCommercialProductsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCost" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory" xlink:to="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentySixMember" xlink:to="asnd_TwoThousandAndTwentySixMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LeaseLiabilities" xlink:to="ifrs-full_LeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NovoNordiskMember" xlink:to="asnd_NovoNordiskMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_StockRepurchaseProgramAuthorizedAmount" xlink:to="asnd_StockRepurchaseProgramAuthorizedAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPaymentBeginningPeriod" xlink:to="asnd_RoyaltyPaymentBeginningPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="asnd_ConvertibleNotesCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_DisclosureOfWarrantActivityLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BoardMembersOfGroupMember" xlink:to="asnd_BoardMembersOfGroupMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesAcquiredFromThirdParties" xlink:to="asnd_TreasurySharesAcquiredFromThirdParties_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfTreasuryShares" xlink:to="ifrs-full_PurchaseOfTreasuryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BalancesWithBanks" xlink:to="ifrs-full_BalancesWithBanks_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherFinancialLiabilities" xlink:to="ifrs-full_OtherFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RevenueFromRenderingOfServicesAndClinicalSupply" xlink:to="asnd_RevenueFromRenderingOfServicesAndClinicalSupply_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotionalAmount" xlink:to="ifrs-full_NotionalAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_EuropeMember" xlink:to="srt_EuropeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RepurchaseOfSharesValue" xlink:to="asnd_RepurchaseOfSharesValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxAssetsCurrent" xlink:to="ifrs-full_CurrentTaxAssetsCurrent_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConversionRatePerNote" xlink:to="asnd_ConversionRatePerNote_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTradeReceivables" xlink:to="ifrs-full_CurrentTradeReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" xlink:to="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfGeneralInformationAbstract" xlink:to="asnd_DisclosureOfGeneralInformationAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="ifrs-full_MajorCustomersDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedShareUnitsMember" xlink:to="ifrs-full_RestrictedShareUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="asnd_SignificantEventsInTheReportingPeriodTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AtFairValueMember" xlink:to="ifrs-full_AtFairValueMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentProvisions" xlink:to="ifrs-full_CurrentProvisions_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_VisenPharmaceuticalsMember" xlink:to="asnd_VisenPharmaceuticalsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmericanDepositorySharesMember" xlink:to="asnd_AmericanDepositorySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherNoncurrentReceivables" xlink:to="ifrs-full_OtherNoncurrentReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_TypesOfRisksDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="ifrs-full_UnobservableInputsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:to="asnd_RoyaltyPharmaUnitedStatesYorvipathMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LongtermBorrowings" xlink:to="ifrs-full_LongtermBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherPayables" xlink:to="ifrs-full_TradeAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" xlink:to="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="asnd_OtherCurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingOfSharesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares" xlink:to="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentPrepayments" xlink:to="ifrs-full_CurrentPrepayments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PaymentTermOfCustomers" xlink:to="asnd_PaymentTermOfCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LicenceFeeIncome" xlink:to="ifrs-full_LicenceFeeIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossBeforeTax_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPharmaMember" xlink:to="asnd_RoyaltyPharmaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PerformanceStockUnitProgramMember" xlink:to="asnd_PerformanceStockUnitProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentContractLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearMember" xlink:to="ifrs-full_LaterThanOneYearMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EmployeesAndConsultantsMember" xlink:to="asnd_EmployeesAndConsultantsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ProfitLossMember" xlink:to="asnd_ProfitLossMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsInterestRate" xlink:to="ifrs-full_BorrowingsInterestRate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_EventsAfterReportingPeriodMember" xlink:to="asnd_EventsAfterReportingPeriodMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsConditionForRedemption" xlink:to="asnd_BorrowingsConditionForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TreasurySharesMember" xlink:to="ifrs-full_TreasurySharesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FairValueOfConvertibleNotes" xlink:to="asnd_FairValueOfConvertibleNotes_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentFinancialAssets" xlink:to="ifrs-full_CurrentFinancialAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherReceivables" xlink:to="ifrs-full_OtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_SummaryOfSignificantAccountingPoliciesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" xlink:to="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember" xlink:to="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharePriceAppliedForValuation" xlink:to="asnd_SharePriceAppliedForValuation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MarketableSecuritiesExplanatory" xlink:to="asnd_MarketableSecuritiesExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShareRepurchaseProgramMember" xlink:to="asnd_ShareRepurchaseProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" xlink:to="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SignificantEventsInTheReportingPeriodTextBlock" xlink:to="asnd_SignificantEventsInTheReportingPeriodTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ConvertibleSeniorNotesMember" xlink:to="asnd_ConvertibleSeniorNotesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DeferredTaxLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfReportableOperatingSegments" xlink:to="asnd_NumberOfReportableOperatingSegments_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PerformanceStockUnitsMember" xlink:to="asnd_PerformanceStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" xlink:to="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PaymentForRepurchaseOfShares" xlink:to="asnd_PaymentForRepurchaseOfShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" xlink:to="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherCurrentReceivables" xlink:to="ifrs-full_OtherCurrentReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShorttermBorrowings" xlink:to="ifrs-full_ShorttermBorrowings_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfTreasurySharesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyFiveMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfCommercialCustomers" xlink:to="asnd_NumberOfCommercialCustomers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" xlink:to="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyFourMember" xlink:to="asnd_TwoThousandAndTwentyFourMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharePriceMeasurementInputMember" xlink:to="asnd_SharePriceMeasurementInputMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_ClassificationOfRelatedPartyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromExerciseOfWarrants" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DerivativesMember" xlink:to="ifrs-full_DerivativesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyThreeMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:to="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_Warrant1Member" xlink:to="asnd_Warrant1Member_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UnitedStatesSkytrofaMember" xlink:to="asnd_UnitedStatesSkytrofaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RevenueTable" xlink:to="asnd_RevenueTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="srt_CondensedIncomeStatementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_FundingReceivedInExchange" xlink:to="asnd_FundingReceivedInExchange_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" xlink:to="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilities" xlink:to="ifrs-full_FinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:to="asnd_SignificantEventsInTheReportingPeriodAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RestrictedStockUnitsMember" xlink:to="asnd_RestrictedStockUnitsMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfProvisionsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharePriceOfEntity" xlink:to="asnd_SharePriceOfEntity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ClassificationOfRelatedPartyAxis" xlink:to="asnd_ClassificationOfRelatedPartyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentySevenMember" xlink:to="asnd_TwoThousandAndTwentySevenMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="asnd_DisclosureOfEmployeeCompensationCostsAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NotesAndDebenturesIssued" xlink:to="ifrs-full_NotesAndDebenturesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" xlink:to="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ComprehensiveIncome_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NewShareRepurchaseProgramMember" xlink:to="asnd_NewShareRepurchaseProgramMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_UnitedStatesYorvipathMember" xlink:to="asnd_UnitedStatesYorvipathMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ShortTermBorrowingOther" xlink:to="asnd_ShortTermBorrowingOther_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeMember" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NumberOfTreasurySharesOutstanding" xlink:to="asnd_NumberOfTreasurySharesOutstanding_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DistributableEquity" xlink:to="asnd_DistributableEquity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BasicAndDilutedEarningsLossPerShares" xlink:to="asnd_BasicAndDilutedEarningsLossPerShares_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_MarketableSecurities1" xlink:to="asnd_MarketableSecurities1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_CashFlowsFromUsedInOperations_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentTaxLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ForeignCurrencyConversionOptionMember" xlink:to="asnd_ForeignCurrencyConversionOptionMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BorrowingsMaturity" xlink:to="ifrs-full_BorrowingsMaturity_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_IncomeStatementMember" xlink:to="asnd_IncomeStatementMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:to="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:to="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_MaturityDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NorthAmericaMember" xlink:to="srt_NorthAmericaMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharesAgreementDescription" xlink:to="asnd_SharesAgreementDescription_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level1OfFairValueHierarchyMember" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RestOfWorldMember" xlink:to="asnd_RestOfWorldMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_BorrowingsRedemptionPeriod" xlink:to="asnd_BorrowingsRedemptionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="asnd_ChangesInWorkingCapitalAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_TwoThousandAndTwentyEightMember" xlink:to="asnd_TwoThousandAndTwentyEightMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_DK" xlink:to="country_DK_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_RoyaltiesAndMilestonesMember" xlink:to="asnd_RoyaltiesAndMilestonesMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeReceivables" xlink:to="ifrs-full_TradeReceivables_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_RangeDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FixedInterestRateMember" xlink:to="ifrs-full_FixedInterestRateMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CostsOfCapitalIncreaseDecrease" xlink:to="asnd_CostsOfCapitalIncreaseDecrease_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_NetSettlementUnderStockIncentivePrograms" xlink:to="asnd_NetSettlementUnderStockIncentivePrograms_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_TypesOfInterestRatesDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementDomain" xlink:to="ifrs-full_MeasurementDomain_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_SharesAuthorizedToRepurchase" xlink:to="asnd_SharesAuthorizedToRepurchase_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="asnd_CommercialCustomersMember" xlink:to="asnd_CommercialCustomersMember_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/CoverPage" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="3.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentInformationTable" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:label="ifrs-full_StatementOfComprehensiveIncomeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:label="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_11"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BasicAndDilutedEarningsLossPerShares" xlink:label="asnd_BasicAndDilutedEarningsLossPerShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfComprehensiveIncomeAbstract" xlink:to="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossBeforeTax" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossAttributableToOwnersOfParent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="asnd_BasicAndDilutedEarningsLossPerShares" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_StatementOfComprehensiveIncomeAbstract" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncome" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="srt_CondensedIncomeStatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="asnd_NumberOfWarrantsOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="ifrs-full_OrdinarySharesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleDebtCurrentAbstract" xlink:label="asnd_ConvertibleDebtCurrentAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AssetsAbstract" xlink:label="ifrs-full_AssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_OtherCurrentLiabilitiesAbstract" xlink:label="asnd_OtherCurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShortTermBorrowingOther" xlink:label="asnd_ShortTermBorrowingOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilitiesAbstract" xlink:label="ifrs-full_EquityAndLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_IssuedCapital" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="ifrs-full_ShorttermBorrowings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_Inventories" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="asnd_ConvertibleDebtCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="asnd_ShortTermBorrowingOther" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_LongtermBorrowings" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="asnd_DistributableEquity" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTradeReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="asnd_OtherCurrentLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentContractLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentContractLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_Equity" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ConvertibleDebtCurrentAbstract" xlink:to="asnd_ConvertibleNotesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AssetsAbstract" xlink:to="ifrs-full_Assets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_DeferredTaxLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_OtherCurrentReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_OtherNoncurrentReceivables" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_Liabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentPrepayments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentTaxLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAndLiabilitiesAbstract" xlink:to="ifrs-full_EquityAndLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="asnd_MarketableSecurities1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentProvisions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_OtherCurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NetSettlementUnderStockIncentivePrograms" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CostsOfCapitalIncreaseDecrease" xlink:label="asnd_CostsOfCapitalIncreaseDecrease"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_10"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_IssuedCapitalMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_TreasurySharesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_PurchaseOfTreasuryShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_NetSettlementUnderStockIncentivePrograms" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_CostsOfCapitalIncreaseDecrease" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ChangesInWorkingCapitalAbstract" xlink:label="asnd_ChangesInWorkingCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BalancesWithBanks" xlink:label="ifrs-full_BalancesWithBanks"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_9"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_FinanceIncome" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="asnd_ChangesInWorkingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_FinanceCosts" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_AdjustmentsForProvisions" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_BalancesWithBanks" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ChangesInWorkingCapitalAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/GeneralInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfGeneralInformationAbstract" xlink:label="asnd_DisclosureOfGeneralInformationAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfGeneralInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/SignificantAccountingJudgementsAndEstimates" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:label="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" xlink:label="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract" xlink:to="ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/SignificantEventsInTheReportingPeriod" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodTextBlock" xlink:label="asnd_SignificantEventsInTheReportingPeriodTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:to="asnd_SignificantEventsInTheReportingPeriodTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/Revenue" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfRevenueExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfRevenueExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/SegmentInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPayment1" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ShareCapital" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" xlink:label="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/TreasuryShares" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" xlink:label="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:label="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/SubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_SummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" xlink:label="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" xlink:label="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory" xlink:label="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/RevenueTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" xlink:label="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" xlink:label="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfRevenueToCommercialProductsExplanatory" xlink:label="asnd_DisclosureOfRevenueToCommercialProductsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="asnd_DisclosureOfRevenueToCommercialProductsExplanatory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTreasurySharesExplanatory" xlink:label="ifrs-full_DisclosureOfTreasurySharesExplanatory"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfTreasurySharesAbstract" xlink:to="ifrs-full_DisclosureOfTreasurySharesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:label="ifrs-full_PresentationOfLeasesForLesseeAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" xlink:label="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" xlink:label="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" xlink:label="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" xlink:label="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" xlink:label="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PresentationOfLeasesForLesseeAbstract" xlink:to="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConversionPricePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConvertibleSeniorNotes" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_BorrowingsMaturity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_CurrentProvisions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_Revenue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodTable" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="ifrs-full_RestrictedShareUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:label="asnd_SignificantEventsInTheReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VisenPharmaceuticalsMember" xlink:label="asnd_VisenPharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareRepurchaseProgramMember" xlink:label="asnd_ShareRepurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharesAgreementDescription" xlink:label="asnd_SharesAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RSUNetSettlementMember" xlink:label="asnd_RSUNetSettlementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NewShareRepurchaseProgramMember" xlink:label="asnd_NewShareRepurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_StockRepurchaseProgramAuthorizedAmount" xlink:label="asnd_StockRepurchaseProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareRepurchaseProgramAndRSUNetSettlementMember" xlink:label="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RepurchaseOfSharesValue" xlink:label="asnd_RepurchaseOfSharesValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentForRepurchaseOfShares" xlink:label="asnd_PaymentForRepurchaseOfShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharesAuthorizedToRepurchase" xlink:label="asnd_SharesAuthorizedToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares" xlink:label="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate" xlink:label="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceOfEntity" xlink:label="asnd_SharePriceOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_ThirdPartyInvestorsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="asnd_EventsAfterReportingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_RestrictedShareUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodAbstract" xlink:to="asnd_SignificantEventsInTheReportingPeriodTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_VisenPharmaceuticalsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_ShareRepurchaseProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SharesAgreementDescription" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_RSUNetSettlementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_NumberOfSharesAuthorised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_CounterpartiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesYorvipathMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_NewShareRepurchaseProgramMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_StockRepurchaseProgramAuthorizedAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_MajorCustomersAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_RepurchaseOfSharesValue" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_PaymentForRepurchaseOfShares" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SharesAuthorizedToRepurchase" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="asnd_SignificantEventsInTheReportingPeriodLineitems" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_ParValuePerShare" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SharePriceOfEntity" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_Equity" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RevenueFromRenderingOfServicesAndClinicalSupply" xlink:label="asnd_RevenueFromRenderingOfServicesAndClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestOfWorldMember" xlink:label="asnd_RestOfWorldMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_3"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_EuropeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_NorthAmericaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_RevenueFromRenderingOfServicesAndClinicalSupply" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="asnd_RestOfWorldMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_LicenceFeeIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_CN" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_AsiaMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_DK" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesSkytrofaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesYorvipathMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_MajorCustomersAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsDomain" xlink:label="ifrs-full_PerformanceObligationsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RevenueTable" xlink:label="asnd_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentTermOfCustomers" xlink:label="asnd_PaymentTermOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CollaborationsAndLicenseAgreementsMember" xlink:label="asnd_CollaborationsAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_RoyaltiesAndMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract" xlink:to="asnd_RevenueTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_PaymentTermOfCustomers" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_MajorCustomersAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CollaborationsAndLicenseAgreementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_NumberOfCommercialCustomers" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_PerformanceObligationsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_DisclosureOfPerformanceObligationsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_NumberOfReportableOperatingSegments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncomeStatementMember" xlink:label="asnd_IncomeStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ClassificationOfRelatedPartyDomain" xlink:label="asnd_ClassificationOfRelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_EmployeesAndConsultantsMember" xlink:label="asnd_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ClassificationOfRelatedPartyAxis" xlink:label="asnd_ClassificationOfRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ProfitLossMember" xlink:label="asnd_ProfitLossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BoardMembersOfGroupMember" xlink:label="asnd_BoardMembersOfGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_EmployeesAndConsultantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ClassificationOfRelatedPartyAxis" xlink:to="asnd_ClassificationOfRelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_IncomeStatementMember" xlink:to="asnd_ProfitLossMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_IncomeStatementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitProgramMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_BoardMembersOfGroupMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_MaturityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ClassificationOfRelatedPartyAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:label="asnd_DisclosureOfEmployeeCompensationCostsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_4"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_10"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfEmployeeCompensationCostsAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_DisclosureOfWarrantActivityLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019_10" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeMember" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyEightMember" xlink:label="asnd_TwoThousandAndTwentyEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFourMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_VestingOfSharesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySixMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySevenMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyEightMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesOfNominalValue" xlink:label="asnd_TreasurySharesOfNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesOfNominalValue" xlink:label="asnd_TreasurySharesOfNominalValue_3"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding_7"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_11"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesOfNominalValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesAcquiredFromThirdParties" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesOfNominalValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding_7" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_ConvertibleSeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CurrentFinancialAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentFinancialLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain" xlink:label="ifrs-full_HedgingInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="ifrs-full_UnobservableInputsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsDomain" xlink:to="asnd_ForeignCurrencyConversionOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="ifrs-full_DerivativesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_LiquidityRiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="asnd_SharePriceMeasurementInputMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesSkytrofaMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesYorvipathMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_HedgingInstrumentsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_UnobservableInputsAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionRatePerNote" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionPricePerShare" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_RangeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsRedemptionPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsConditionForRedemption" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsMaturity" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfConvertibleNotes" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_SharePriceAppliedForValuation" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchange" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentBeginningPeriod" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentEndingPeriod" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="ifrs-full_MeasurementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndDebenturesIssued" xlink:label="ifrs-full_NotesAndDebenturesIssued"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_MeasurementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MarketableSecuritiesExplanatory" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementDomain" xlink:to="asnd_FairValueHierarchyCarryingAmountMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementDomain" xlink:to="ifrs-full_AtFairValueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotesAndDebenturesIssued" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyFundingLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities_5"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_BorrowingsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ConvertibleSeniorNotes" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_NotLaterThanOneYearMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_Borrowings" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_LeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_FinancialLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
        </link:presentationLink>
        <link:presentationLink xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NovoNordiskMember" xlink:label="asnd_NovoNordiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="asnd_EventsAfterReportingPeriodMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_NovoNordiskMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/CoverPage">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementTable" xlink:label="srt_CondensedIncomeStatementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:label="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CondensedIncomeStatementsCaptionsLineItems" xlink:label="srt_CondensedIncomeStatementsCaptionsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" xlink:label="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfWarrantsOutstanding" xlink:label="asnd_NumberOfWarrantsOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="srt_CondensedIncomeStatementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_CondensedIncomeStatementsCaptionsLineItems" xlink:to="asnd_NumberOfWarrantsOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" xlink:to="ifrs-full_OrdinarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="srt_CondensedIncomeStatementsCaptionsLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="srt_CondensedIncomeStatementTable" xlink:to="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TreasurySharesMember" xlink:label="ifrs-full_TreasurySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" xlink:label="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReserveOfSharebasedPaymentsMember" xlink:label="ifrs-full_ReserveOfSharebasedPaymentsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PurchaseOfTreasuryShares" xlink:label="ifrs-full_PurchaseOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SaleOrIssueOfTreasuryShares" xlink:label="ifrs-full_SaleOrIssueOfTreasuryShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NetSettlementUnderStockIncentivePrograms" xlink:label="asnd_NetSettlementUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" xlink:label="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CostsOfCapitalIncreaseDecrease" xlink:label="asnd_CostsOfCapitalIncreaseDecrease"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_IssuedCapitalMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_SharePremiumMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_TreasurySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ComprehensiveIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_ReserveOfSharebasedPaymentsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_PurchaseOfTreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="ifrs-full_RetainedEarningsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_SaleOrIssueOfTreasuryShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_NetSettlementUnderStockIncentivePrograms" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="asnd_CostsOfCapitalIncreaseDecrease" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:label="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_NoncurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConversionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentDerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_NoncurrentLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_CurrentLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="ifrs-full_BorrowingsMaturity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:label="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SalesRebatesAndProductReturnsInUSMarketMember" xlink:label="asnd_SalesRebatesAndProductReturnsInUSMarketMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfOtherProvisionsDomain" xlink:label="ifrs-full_ClassesOfOtherProvisionsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfOtherProvisionsDomain" xlink:to="asnd_SalesRebatesAndProductReturnsInUSMarketMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfOtherProvisionsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_CurrentProvisions" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:label="asnd_SignificantEventsInTheReportingPeriodLineitems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SignificantEventsInTheReportingPeriodTable" xlink:label="asnd_SignificantEventsInTheReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ThirdPartyInvestorsMember" xlink:label="asnd_ThirdPartyInvestorsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CounterpartiesDomain" xlink:label="ifrs-full_CounterpartiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" xlink:label="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RestrictedShareUnitsMember" xlink:label="ifrs-full_RestrictedShareUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VisenPharmaceuticalsMember" xlink:label="asnd_VisenPharmaceuticalsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:label="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareRepurchaseProgramMember" xlink:label="asnd_ShareRepurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharesAgreementDescription" xlink:label="asnd_SharesAgreementDescription"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RSUNetSettlementMember" xlink:label="asnd_RSUNetSettlementMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NewShareRepurchaseProgramMember" xlink:label="asnd_NewShareRepurchaseProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_StockRepurchaseProgramAuthorizedAmount" xlink:label="asnd_StockRepurchaseProgramAuthorizedAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareRepurchaseProgramAndRSUNetSettlementMember" xlink:label="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RepurchaseOfSharesValue" xlink:label="asnd_RepurchaseOfSharesValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentForRepurchaseOfShares" xlink:label="asnd_PaymentForRepurchaseOfShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharesAuthorizedToRepurchase" xlink:label="asnd_SharesAuthorizedToRepurchase"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares" xlink:label="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProportionOfOwnershipInterestInAssociate" xlink:label="ifrs-full_ProportionOfOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentAccountedForUsingEquityMethod" xlink:label="ifrs-full_InvestmentAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate" xlink:label="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceOfEntity" xlink:label="asnd_SharePriceOfEntity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SignificantEventsInTheReportingPeriodTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_ThirdPartyInvestorsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="asnd_EventsAfterReportingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" xlink:to="ifrs-full_RestrictedShareUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_VisenPharmaceuticalsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_ShareRepurchaseProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SharesAgreementDescription" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_RSUNetSettlementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_CounterpartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesYorvipathMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_NewShareRepurchaseProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_StockRepurchaseProgramAuthorizedAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CounterpartiesDomain" xlink:to="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_RepurchaseOfSharesValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_TypesOfAntidilutiveInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_PaymentForRepurchaseOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SharesAuthorizedToRepurchase" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SignificantEventsInTheReportingPeriodTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_ParValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_ProportionOfOwnershipInterestInAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_InvestmentAccountedForUsingEquityMethod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="asnd_SharePriceOfEntity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SignificantEventsInTheReportingPeriodLineitems" xlink:to="ifrs-full_Equity" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember" xlink:label="srt_EuropeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredOverTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredOverTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:label="ifrs-full_DisclosureOfGeographicalAreasAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:label="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NorthAmericaMember" xlink:label="srt_NorthAmericaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" xlink:label="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CollaborationPartnersAndLicenseAgreementsMember" xlink:label="asnd_CollaborationPartnersAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RevenueFromRenderingOfServicesAndClinicalSupply" xlink:label="asnd_RevenueFromRenderingOfServicesAndClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestOfWorldMember" xlink:label="asnd_RestOfWorldMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_CN" xlink:label="country_CN"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_AsiaMember" xlink:label="srt_AsiaMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_EuropeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_GoodsOrServicesTransferredOverTimeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfGeographicalAreasAbstract" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_NorthAmericaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TimingOfTransferOfGoodsOrServicesDomain" xlink:to="ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CollaborationPartnersAndLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_RevenueFromRenderingOfServicesAndClinicalSupply" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="asnd_RestOfWorldMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_TimingOfTransferOfGoodsOrServicesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_LicenceFeeIncome" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_CN" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="srt_AsiaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfGeographicalAreasAbstract" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasDomain" xlink:label="ifrs-full_GeographicalAreasDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_DK" xlink:label="country_DK"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_GeographicalAreasDomain" xlink:to="country_DK" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_GeographicalAreasAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_Revenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_GeographicalAreasAxis" xlink:to="ifrs-full_GeographicalAreasDomain" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:label="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_RevenueFromSaleOfGoods" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesSkytrofaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesYorvipathMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable" xlink:to="srt_MajorCustomersAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:label="ifrs-full_DisclosureOfPerformanceObligationsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RevenueTable" xlink:label="asnd_RevenueTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsDomain" xlink:label="ifrs-full_PerformanceObligationsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltiesAndMilestonesMember" xlink:label="asnd_RoyaltiesAndMilestonesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MajorCustomersDomain" xlink:label="ifrs-full_MajorCustomersDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CommercialCustomersMember" xlink:label="asnd_CommercialCustomersMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsAxis" xlink:label="ifrs-full_PerformanceObligationsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PerformanceObligationsDomain" xlink:label="ifrs-full_PerformanceObligationsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentTermOfCustomers" xlink:label="asnd_PaymentTermOfCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_CollaborationsAndLicenseAgreementsMember" xlink:label="asnd_CollaborationsAndLicenseAgreementsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfCommercialCustomers" xlink:label="asnd_NumberOfCommercialCustomers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfEntitysRevenue" xlink:label="ifrs-full_PercentageOfEntitysRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromContractsWithCustomers" xlink:label="ifrs-full_RevenueFromContractsWithCustomers"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_RevenueTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_PerformanceObligationsDomain" xlink:to="asnd_RoyaltiesAndMilestonesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MajorCustomersAxis" xlink:to="ifrs-full_MajorCustomersDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CommercialCustomersMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_PerformanceObligationsAxis" xlink:to="ifrs-full_PerformanceObligationsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_PaymentTermOfCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_MajorCustomersAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MajorCustomersDomain" xlink:to="asnd_CollaborationsAndLicenseAgreementsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="asnd_NumberOfCommercialCustomers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_PercentageOfEntitysRevenue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_RevenueTable" xlink:to="ifrs-full_PerformanceObligationsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfPerformanceObligationsLineItems" xlink:to="ifrs-full_RevenueFromContractsWithCustomers" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfReportableOperatingSegments" xlink:label="asnd_NumberOfReportableOperatingSegments"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="asnd_NumberOfReportableOperatingSegments" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncomeStatementAxis" xlink:label="asnd_IncomeStatementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncomeStatementMember" xlink:label="asnd_IncomeStatementMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncomeStatementMember" xlink:label="asnd_IncomeStatementMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ClassificationOfRelatedPartyDomain" xlink:label="asnd_ClassificationOfRelatedPartyDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_EmployeesAndConsultantsMember" xlink:label="asnd_EmployeesAndConsultantsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ClassificationOfRelatedPartyAxis" xlink:label="asnd_ClassificationOfRelatedPartyAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ClassificationOfRelatedPartyDomain" xlink:label="asnd_ClassificationOfRelatedPartyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ProfitLossMember" xlink:label="asnd_ProfitLossMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearMember" xlink:label="ifrs-full_LaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PerformanceStockUnitProgramMember" xlink:label="asnd_PerformanceStockUnitProgramMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BoardMembersOfGroupMember" xlink:label="asnd_BoardMembersOfGroupMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" xlink:label="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" xlink:label="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ExercisePriceOfOutstandingShareOptions2019" xlink:label="ifrs-full_ExercisePriceOfOutstandingShareOptions2019"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_IncomeStatementAxis" xlink:to="asnd_IncomeStatementMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_EmployeesAndConsultantsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ClassificationOfRelatedPartyAxis" xlink:to="asnd_ClassificationOfRelatedPartyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_ClassificationOfRelatedPartyAxis" xlink:to="asnd_ClassificationOfRelatedPartyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_IncomeStatementMember" xlink:to="asnd_ProfitLossMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_IncomeStatementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitProgramMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_ClassificationOfRelatedPartyDomain" xlink:to="asnd_BoardMembersOfGroupMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_MaturityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="asnd_ClassificationOfRelatedPartyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_ExercisePriceOfOutstandingShareOptions2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfWarrantActivityLineItems" xlink:label="asnd_DisclosureOfWarrantActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_Warrant1Member" xlink:label="asnd_Warrant1Member"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" xlink:label="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" xlink:label="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsDomain" xlink:to="asnd_Warrant1Member" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfWarrantActivityLineItems" xlink:to="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:label="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyThreeMember" xlink:label="asnd_TwoThousandAndTwentyThreeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:label="asnd_ShareBasedPaymentArrangementAwardTypeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VestingOfSharesAxis" xlink:label="asnd_VestingOfSharesAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_VestingMember" xlink:label="asnd_VestingMember_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharebasedPaymentArrangementAwardTypeMember" xlink:label="asnd_SharebasedPaymentArrangementAwardTypeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyFourMember" xlink:label="asnd_TwoThousandAndTwentyFourMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestrictedStockUnitsMember" xlink:label="asnd_RestrictedStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyFiveMember" xlink:label="asnd_TwoThousandAndTwentyFiveMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PerformanceStockUnitsMember" xlink:label="asnd_PerformanceStockUnitsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentySixMember" xlink:label="asnd_TwoThousandAndTwentySixMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" xlink:label="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" xlink:label="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentySevenMember" xlink:label="asnd_TwoThousandAndTwentySevenMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TwoThousandAndTwentyEightMember" xlink:label="asnd_TwoThousandAndTwentyEightMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyThreeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_ShareBasedPaymentArrangementAwardTypeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_ShareBasedPaymentArrangementAwardTypeAxis" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="asnd_VestingOfSharesAxis" xlink:to="asnd_VestingMember_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_SharebasedPaymentArrangementAwardTypeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFourMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" xlink:to="asnd_VestingOfSharesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyFiveMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_PerformanceStockUnitsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySixMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementAwardTypeDomain" xlink:to="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentySevenMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_VestingMember" xlink:to="asnd_TwoThousandAndTwentyEightMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfShareCapitalDomain" xlink:label="ifrs-full_ClassesOfShareCapitalDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NumberOfSharesOutstanding" xlink:label="ifrs-full_NumberOfSharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" xlink:label="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfShareCapitalDomain" xlink:to="ifrs-full_OrdinarySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail">
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DisclosureOfHoldingOfTreasurySharesTable" xlink:label="asnd_DisclosureOfHoldingOfTreasurySharesTable"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesOfNominalValue" xlink:label="asnd_TreasurySharesOfNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" xlink:label="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NumberOfTreasurySharesOutstanding" xlink:label="asnd_NumberOfTreasurySharesOutstanding"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" xlink:label="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" xlink:label="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" xlink:label="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties" xlink:label="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" xlink:label="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_DisclosureOfHoldingOfTreasurySharesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesOfNominalValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesAcquiredFromThirdParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_NumberOfTreasurySharesOutstanding" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" xlink:to="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeReceivables" xlink:label="ifrs-full_TradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsAxis" xlink:label="ifrs-full_ClassesOfFinancialAssetsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfFinancialLiabilitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialAssets" xlink:label="ifrs-full_NoncurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:label="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentFinancialLiabilities" xlink:label="ifrs-full_NoncurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCostMember" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialAssetsDomain" xlink:label="ifrs-full_ClassesOfFinancialAssetsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherReceivables" xlink:label="ifrs-full_OtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialAssets" xlink:label="ifrs-full_CurrentFinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentFinancialLiabilities" xlink:label="ifrs-full_CurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssets" xlink:label="ifrs-full_FinancialAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_TradeReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialAssetsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_NoncurrentFinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialAssetsDomain" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfFinancialAssetsAxis" xlink:to="ifrs-full_ClassesOfFinancialAssetsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_OtherReceivables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract" xlink:to="ifrs-full_CurrentFinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" xlink:to="ifrs-full_CurrentFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_CashAndCashEquivalents" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_LeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_TradeAndOtherPayablesToTradeSuppliers" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAbstract" xlink:to="ifrs-full_FinancialAssets" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAbstract" xlink:to="ifrs-full_FinancialLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityDomain" xlink:label="ifrs-full_ComponentsOfEquityDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmericanDepositorySharesMember" xlink:label="asnd_AmericanDepositorySharesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain" xlink:label="ifrs-full_HedgingInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ForeignCurrencyConversionOptionMember" xlink:label="asnd_ForeignCurrencyConversionOptionMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativesMember" xlink:label="ifrs-full_DerivativesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotesMember" xlink:label="asnd_ConvertibleSeniorNotesMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LiquidityRiskMember" xlink:label="ifrs-full_LiquidityRiskMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="ifrs-full_UnobservableInputsDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfRisksDomain" xlink:label="ifrs-full_TypesOfRisksDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsAxis" xlink:label="ifrs-full_HedgingInstrumentsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_HedgingInstrumentsDomain" xlink:label="ifrs-full_HedgingInstrumentsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TypesOfInterestRatesDomain" xlink:label="ifrs-full_TypesOfInterestRatesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ClassesOfLiabilitiesDomain" xlink:label="ifrs-full_ClassesOfLiabilitiesDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaMember" xlink:label="asnd_RoyaltyPharmaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RangeDomain" xlink:label="ifrs-full_RangeDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_UnobservableInputsDomain" xlink:label="ifrs-full_UnobservableInputsDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FixedInterestRateMember" xlink:label="ifrs-full_FixedInterestRateMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceMeasurementInputMember" xlink:label="asnd_SharePriceMeasurementInputMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesSkytrofaMember" xlink:label="asnd_UnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" xlink:label="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsInterestRate" xlink:label="ifrs-full_BorrowingsInterestRate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_UnitedStatesYorvipathMember" xlink:label="asnd_UnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsInArrearsDefaultPaymentStartDate" xlink:label="asnd_BorrowingsInArrearsDefaultPaymentStartDate"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPharmaUnitedStatesYorvipathMember" xlink:label="asnd_RoyaltyPharmaUnitedStatesYorvipathMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConversionRatePerNote" xlink:label="asnd_ConversionRatePerNote"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotionalAmount" xlink:label="ifrs-full_NotionalAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConversionPricePerShare" xlink:label="asnd_ConversionPricePerShare"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsRedemptionPeriod" xlink:label="asnd_BorrowingsRedemptionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsConditionForRedemption" xlink:label="asnd_BorrowingsConditionForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" xlink:label="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" xlink:label="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" xlink:label="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsMaturity" xlink:label="ifrs-full_BorrowingsMaturity"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FairValueOfConvertibleNotes" xlink:label="asnd_FairValueOfConvertibleNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_SharePriceAppliedForValuation" xlink:label="asnd_SharePriceAppliedForValuation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" xlink:label="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FundingReceivedInExchange" xlink:label="asnd_FundingReceivedInExchange"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FundingReceivedInExchangeOfRoyaltyPayments" xlink:label="asnd_FundingReceivedInExchangeOfRoyaltyPayments"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" xlink:label="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" xlink:label="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" xlink:label="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPaymentBeginningPeriod" xlink:label="asnd_RoyaltyPaymentBeginningPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyPaymentEndingPeriod" xlink:label="asnd_RoyaltyPaymentEndingPeriod"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" xlink:label="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ComponentsOfEquityDomain" xlink:to="asnd_AmericanDepositorySharesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfRisksAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_HedgingInstrumentsDomain" xlink:to="asnd_ForeignCurrencyConversionOptionMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfLiabilitiesDomain" xlink:to="ifrs-full_DerivativesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsDomain" xlink:to="asnd_ConvertibleSeniorNotesMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfRisksDomain" xlink:to="ifrs-full_LiquidityRiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfRisksAxis" xlink:to="ifrs-full_TypesOfRisksDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_HedgingInstrumentsAxis" xlink:to="ifrs-full_HedgingInstrumentsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_TypesOfInterestRatesAxis" xlink:to="ifrs-full_TypesOfInterestRatesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_BottomOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_TypesOfInterestRatesDomain" xlink:to="ifrs-full_FixedInterestRateMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_TypesOfInterestRatesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_UnobservableInputsDomain" xlink:to="asnd_SharePriceMeasurementInputMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesSkytrofaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_RangeDomain" xlink:to="ifrs-full_TopOfRangeMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsInterestRate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_UnitedStatesYorvipathMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_HedgingInstrumentsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsInArrearsDefaultPaymentStartDate" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_UnobservableInputsAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionRatePerNote" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotionalAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConversionPricePerShare" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_RangeAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsRedemptionPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsConditionForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdTradingDaysForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_BorrowingsMaturity" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FairValueOfConvertibleNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_SharePriceAppliedForValuation" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchange" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_FundingReceivedInExchangeOfRoyaltyPayments" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentBeginningPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyPaymentEndingPeriod" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MarketableSecuritiesExplanatory" xlink:label="asnd_MarketableSecuritiesExplanatory"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level1OfFairValueHierarchyMember" xlink:label="ifrs-full_Level1OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="ifrs-full_MeasurementDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_FairValueHierarchyCarryingAmountMember" xlink:label="asnd_FairValueHierarchyCarryingAmountMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MeasurementDomain" xlink:label="ifrs-full_MeasurementDomain_default"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialAssetsAtAmortisedCost" xlink:label="ifrs-full_FinancialAssetsAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotesAndDebenturesIssued" xlink:label="ifrs-full_NotesAndDebenturesIssued"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCost" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCost"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_MeasurementAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_MarketableSecuritiesExplanatory" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level1OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MeasurementDomain" xlink:to="asnd_FairValueHierarchyCarryingAmountMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementDomain_default" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialAssetsAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MeasurementDomain" xlink:to="ifrs-full_AtFairValueMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_NotesAndDebenturesIssued" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="asnd_RoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCost" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:label="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:label="ifrs-full_LevelsOfFairValueHierarchyDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DerivativeFinancialLiabilities" xlink:label="ifrs-full_DerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" xlink:label="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" xlink:label="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems" xlink:to="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_LevelsOfFairValueHierarchyDomain" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="ifrs-full_DerivativeFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract" xlink:to="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:label="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_BorrowingsAbstract" xlink:label="ifrs-full_BorrowingsAbstract"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleSeniorNotes" xlink:label="asnd_ConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" xlink:label="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_MaturityDomain" xlink:label="ifrs-full_MaturityDomain"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NotLaterThanOneYearMember" xlink:label="ifrs-full_NotLaterThanOneYearMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RoyaltyFundingLiabilities" xlink:label="asnd_RoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Borrowings" xlink:label="ifrs-full_Borrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" xlink:label="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LeaseLiabilities" xlink:label="ifrs-full_LeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherPayables" xlink:label="ifrs-full_TradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherFinancialLiabilities" xlink:label="ifrs-full_OtherFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinancialLiabilities" xlink:label="ifrs-full_FinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" xlink:label="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" xlink:label="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" xlink:label="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems" xlink:to="ifrs-full_BorrowingsAbstract" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesDomain" xlink:to="ifrs-full_FinancialLiabilitiesAtAmortisedCostMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_MaturityAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_MaturityAxis" xlink:to="ifrs-full_MaturityDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_NotLaterThanOneYearMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_RoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_Borrowings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_MaturityDomain" xlink:to="ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_LeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_TradeAndOtherPayables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_OtherFinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="ifrs-full_FinancialLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_BorrowingsAbstract" xlink:to="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" priority="2" use="optional"/>
        </link:definitionLink>
        <link:definitionLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_EventsAfterReportingPeriodMember" xlink:label="asnd_EventsAfterReportingPeriodMember"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:label="ifrs-full_CategoriesOfRelatedPartiesDomain"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_NovoNordiskMember" xlink:label="asnd_NovoNordiskMember"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" xlink:to="asnd_EventsAfterReportingPeriodMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesDomain" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ifrs-full_CategoriesOfRelatedPartiesDomain" xlink:to="asnd_NovoNordiskMember" priority="2" use="optional"/>
          <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" priority="2" use="optional"/>
        </link:definitionLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:to="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:to="ifrs-full_ProfitLoss" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:to="ifrs-full_ComprehensiveIncome" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_Revenue" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_GrossProfit" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_CostOfSales" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ResearchAndDevelopmentExpense" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ComprehensiveIncome" xlink:to="ifrs-full_ProfitLoss" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLossBeforeTax" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_FinanceCosts" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossBeforeTax" xlink:to="ifrs-full_ProfitLossFromOperatingActivities" order="3" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax" xlink:label="ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation" xlink:label="ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossAttributableToOwnersOfParent" xlink:label="ifrs-full_ProfitLossAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent" xlink:label="ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ComprehensiveIncome" xlink:label="ifrs-full_ComprehensiveIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossBeforeTax" xlink:label="ifrs-full_ProfitLossBeforeTax"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_NoncurrentAssets" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="asnd_ConvertibleNotesCurrent" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="ifrs-full_ShorttermBorrowings" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="asnd_ShortTermBorrowingOther" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_IntangibleAssetsAndGoodwill" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_IssuedCapital" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTradeReceivables" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_LongtermBorrowings" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Liabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_NoncurrentLiabilities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_CurrentAssets" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_OtherCurrentFinancialLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="asnd_ConvertibleNotesCurrent" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentContractLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_PropertyPlantAndEquipment" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Equity" xlink:to="asnd_DistributableEquity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_OtherCurrentReceivables" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentContractLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_Equity" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_CurrentLiabilities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_InvestmentsInAssociates" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentPrepayments" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_DeferredTaxLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_OtherCurrentLiabilities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_OtherNoncurrentReceivables" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="asnd_MarketableSecurities1" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentTaxLiabilities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_OtherCurrentFinancialLiabilities" xlink:to="ifrs-full_CurrentProvisions" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentTaxAssetsCurrent" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_Inventories" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CashAndCashEquivalents" order="8" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ConvertibleNotesCurrent" xlink:label="asnd_ConvertibleNotesCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShorttermBorrowings" xlink:label="ifrs-full_ShorttermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentFinancialLiabilities" xlink:label="ifrs-full_OtherCurrentFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_ShortTermBorrowingOther" xlink:label="asnd_ShortTermBorrowingOther"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IntangibleAssetsAndGoodwill" xlink:label="ifrs-full_IntangibleAssetsAndGoodwill"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTradeReceivables" xlink:label="ifrs-full_CurrentTradeReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LongtermBorrowings" xlink:label="ifrs-full_LongtermBorrowings"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentContractLiabilities" xlink:label="ifrs-full_CurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_DistributableEquity" xlink:label="asnd_DistributableEquity"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentReceivables" xlink:label="ifrs-full_OtherCurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_NoncurrentContractLiabilities" xlink:label="ifrs-full_NoncurrentContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers" xlink:label="ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_InvestmentsInAssociates" xlink:label="ifrs-full_InvestmentsInAssociates"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentPrepayments" xlink:label="ifrs-full_CurrentPrepayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_DeferredTaxLiabilities" xlink:label="ifrs-full_DeferredTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherCurrentLiabilities" xlink:label="ifrs-full_OtherCurrentLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_OtherNoncurrentReceivables" xlink:label="ifrs-full_OtherNoncurrentReceivables"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_MarketableSecurities1" xlink:label="asnd_MarketableSecurities1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxLiabilities" xlink:label="ifrs-full_CurrentTaxLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentProvisions" xlink:label="ifrs-full_CurrentProvisions"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CurrentTaxAssetsCurrent" xlink:label="ifrs-full_CurrentTaxAssetsCurrent"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" order="0" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" order="0" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" order="1" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" order="2" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperations" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" order="3" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" order="4" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" order="5" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments" order="6" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_ProceedsFromExerciseOfWarrants" order="7" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense" order="8" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" order="9" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" order="10" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense" order="11" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_FinanceIncome" order="12" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_ProfitLoss" order="13" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_FinanceCosts" order="14" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" order="15" weight="-1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_IncomeTaxExpenseContinuingOperations" order="16" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperations" xlink:to="ifrs-full_AdjustmentsForProvisions" order="17" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" xlink:label="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInOperations" xlink:label="ifrs-full_CashFlowsFromUsedInOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities" xlink:label="ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_PaymentsToAcquireOrRedeemEntitysShares" xlink:label="ifrs-full_PaymentsToAcquireOrRedeemEntitysShares"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities" xlink:label="ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" xlink:label="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities" xlink:label="ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities" xlink:label="ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment" xlink:label="ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProceedsFromExerciseOfWarrants" xlink:label="ifrs-full_ProceedsFromExerciseOfWarrants"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" xlink:label="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod" xlink:label="ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment" xlink:label="ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_IncomeTaxExpenseContinuingOperations" xlink:label="ifrs-full_IncomeTaxExpenseContinuingOperations"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_AdjustmentsForProvisions" xlink:label="ifrs-full_AdjustmentsForProvisions"/>
        </link:calculationLink>
        <link:calculationLink xlink:type="extended" xlink:role="http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail">
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_LicenceFeeIncome" order="1" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="asnd_RevenueFromRenderingOfServicesAndClinicalSupply" order="2" weight="1" use="optional"/>
          <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_RevenueFromSaleOfGoods" order="5" weight="1" use="optional"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_LicenceFeeIncome" xlink:label="ifrs-full_LicenceFeeIncome"/>
          <link:loc xlink:type="locator" xlink:href="asnd-20250331.xsd#asnd_RevenueFromRenderingOfServicesAndClinicalSupply" xlink:label="asnd_RevenueFromRenderingOfServicesAndClinicalSupply"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd#ifrs-full_RevenueFromSaleOfGoods" xlink:label="ifrs-full_RevenueFromSaleOfGoods"/>
        </link:calculationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" name="DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RoyaltyPaymentEndingPeriod" name="RoyaltyPaymentEndingPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TreasurySharesOfNominalValue" name="TreasurySharesOfNominalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_RevenueFromRenderingOfServicesAndClinicalSupply" name="RevenueFromRenderingOfServicesAndClinicalSupply" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesLineItems" name="DisclosureOfHoldingOfTreasurySharesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SignificantEventsInTheReportingPeriodAbstract" name="SignificantEventsInTheReportingPeriodAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_FundingReceivedInExchangeOfRoyaltyPayments" name="FundingReceivedInExchangeOfRoyaltyPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable" name="SharebasedPaymentArrangementRestrictedStockUnitActivityTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RepurchaseOfSharesValue" name="RepurchaseOfSharesValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfRevenueToCommercialCustomersExplanatory" name="DisclosureOfRevenueToCommercialCustomersExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_UnitedStatesYorvipathMember" name="UnitedStatesYorvipathMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltiesAndMilestonesMember" name="RoyaltiesAndMilestonesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_OtherCurrentLiabilitiesAbstract" name="OtherCurrentLiabilitiesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" name="TreasurySharesTransferredUnderStockIncentiveProgramNominalValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_EmployeesAndConsultantsMember" name="EmployeesAndConsultantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BoardMembersOfGroupMember" name="BoardMembersOfGroupMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" name="DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfCommercialCustomers" name="NumberOfCommercialCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" name="TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ConvertibleNotesCurrent" name="ConvertibleNotesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TwoThousandAndTwentyFourMember" name="TwoThousandAndTwentyFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfRevenueToCommercialProductsExplanatory" name="DisclosureOfRevenueToCommercialProductsExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RestOfWorldMember" name="RestOfWorldMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" name="AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" name="IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" name="DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharesAuthorizedToRepurchase" name="SharesAuthorizedToRepurchase" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SalesRebatesAndProductReturnsInUSMarketMember" name="SalesRebatesAndProductReturnsInUSMarketMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" name="DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TwoThousandAndTwentyEightMember" name="TwoThousandAndTwentyEightMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ChangesInWorkingCapitalAbstract" name="ChangesInWorkingCapitalAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CommercialCustomersMember" name="CommercialCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SignificantEventsInTheReportingPeriodTextBlock" name="SignificantEventsInTheReportingPeriodTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SignificantEventsInTheReportingPeriodLineitems" name="SignificantEventsInTheReportingPeriodLineitems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms" name="PaymentOfWithholdingTaxesUnderStockIncentivePrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfTreasurySharesAbstract" name="DisclosureOfTreasurySharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" name="BorrowingsThresholdPercentageOfSalePricePerShareForRedemption" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement" name="PercentageOfVestingRightsForShareBasedPaymentArrangement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" name="WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_StockRepurchaseProgramAuthorizedAmount" name="StockRepurchaseProgramAuthorizedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ConvertibleSeniorNotes" name="ConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" name="AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_FairValueOfConvertibleNotes" name="FairValueOfConvertibleNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_CollaborationsAndLicenseAgreementsMember" name="CollaborationsAndLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPharmaMember" name="RoyaltyPharmaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TwoThousandAndTwentyFiveMember" name="TwoThousandAndTwentyFiveMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" name="DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AdjustmentsForNonCashConsiderationRegardingRevenue" name="AdjustmentsForNonCashConsiderationRegardingRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" name="ExchangeRateForPercentageOfNetSalesToRoyaltyPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" name="SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RestrictedStockUnitsMember" name="RestrictedStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" name="ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_NovoNordiskMember" name="NovoNordiskMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption" name="BorrowingsThresholdConsecutiveTradingDaysForRedemption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" name="ContractualUndiscountedCashflowOfFinancialLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_RSUNetSettlementMember" name="RSUNetSettlementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConversionPricePerShare" name="ConversionPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementAwardTypeDomain" name="SharebasedPaymentArrangementAwardTypeDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsConditionForRedemption" name="BorrowingsConditionForRedemption" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NumberOfTreasurySharesOutstanding" name="NumberOfTreasurySharesOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RestrictedStockUnitsAndPerformanceStockUnitMember" name="RestrictedStockUnitsAndPerformanceStockUnitMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DistributableEquity" name="DistributableEquity" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ThirdPartyInvestorsMember" name="ThirdPartyInvestorsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" name="NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NumberOfWarrantsOutstanding" name="NumberOfWarrantsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharePriceAppliedForValuation" name="SharePriceAppliedForValuation" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RoyaltyPaymentBeginningPeriod" name="RoyaltyPaymentBeginningPeriod" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfWarrantActivityLineItems" name="DisclosureOfWarrantActivityLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_FundingReceivedInExchange" name="FundingReceivedInExchange" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfInformationAboutTreasurySharesExplanatory" name="DisclosureOfInformationAboutTreasurySharesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares" name="TreasurySharesHoldingInPercentageOfTotalOutstandingShares" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfFinancialBorrowings" name="ContractualUndiscountedCashflowOfFinancialBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfGeneralInformationAbstract" name="DisclosureOfGeneralInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementAwardTypeMember" name="SharebasedPaymentArrangementAwardTypeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BasicAndDilutedEarningsLossPerShares" name="BasicAndDilutedEarningsLossPerShares" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ProfitLossMember" name="ProfitLossMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CollaborationPartnersAndLicenseAgreementsMember" name="CollaborationPartnersAndLicenseAgreementsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_EventsAfterReportingPeriodMember" name="EventsAfterReportingPeriodMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SignificantEventsInTheReportingPeriodTable" name="SignificantEventsInTheReportingPeriodTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_CostsOfCapitalIncreaseDecrease" name="CostsOfCapitalIncreaseDecrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_DisclosureOfEmployeeCompensationCostsAbstract" name="DisclosureOfEmployeeCompensationCostsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" name="AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" name="DisclosureOfSummaryOfFairValueHierarchyTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock" name="MaturityAnalysisForFinancialLiabilitiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" name="DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharePriceMeasurementInputMember" name="SharePriceMeasurementInputMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NumberOfReportableOperatingSegments" name="NumberOfReportableOperatingSegments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ForeignCurrencyConversionOptionMember" name="ForeignCurrencyConversionOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SummaryOfSignificantAccountingPoliciesAbstract" name="SummaryOfSignificantAccountingPoliciesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ClassificationOfRelatedPartyDomain" name="ClassificationOfRelatedPartyDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_UnitedStatesSkytrofaMember" name="UnitedStatesSkytrofaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" name="MultipleOfPurchasePriceWereRoyaltyPaymentWillCease" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_SharePriceOfEntity" name="SharePriceOfEntity" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" name="AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount" type="xbrli:decimalItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_BorrowingsRedemptionPeriod" name="BorrowingsRedemptionPeriod" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesTable" name="DisclosureOfHoldingOfTreasurySharesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" name="SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" name="DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TwoThousandAndTwentyThreeMember" name="TwoThousandAndTwentyThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConvertibleSeniorNotesMember" name="ConvertibleSeniorNotesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable" name="DisclosureOfSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" name="DisclosureOfFinancialAssetsAndLiabilitiesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RoyaltyFundingLiabilities" name="RoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_FairValueHierarchyCarryingAmountMember" name="FairValueHierarchyCarryingAmountMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory" name="WeightedAverageDurationOfMarketableSecuritiesExplanatory" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" name="DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate" name="NonCashGainRecognizedOnOwnershipInterestInAssociate" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ShareRepurchaseProgramMember" name="ShareRepurchaseProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes" name="ContractualUndiscountedCashflowOfConvertibleSeniorNotes" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_MarketableSecurities1" name="MarketableSecurities1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_RoyaltyPharmaUnitedStatesYorvipathMember" name="RoyaltyPharmaUnitedStatesYorvipathMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncomeStatementAxis" name="IncomeStatementAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsThresholdTradingDaysForRedemption" name="BorrowingsThresholdTradingDaysForRedemption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" name="ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_ShortTermBorrowingOther" name="ShortTermBorrowingOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" name="IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfFinancialLiabilities" name="ContractualUndiscountedCashflowOfFinancialLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_AmericanDepositorySharesMember" name="AmericanDepositorySharesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncomeStatementMember" name="IncomeStatementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PerformanceStockUnitsMember" name="PerformanceStockUnitsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_BorrowingsInArrearsDefaultPaymentStartDate" name="BorrowingsInArrearsDefaultPaymentStartDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_MarketableSecuritiesExplanatory" name="MarketableSecuritiesExplanatory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_Warrant1Member" name="Warrant1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NetSettlementUnderStockIncentivePrograms" name="NetSettlementUnderStockIncentivePrograms" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares" name="NumberOfOrdinaryShareRelatedToRepurchaseOfShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ClassificationOfRelatedPartyAxis" name="ClassificationOfRelatedPartyAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ShareRepurchaseProgramAndRSUNetSettlementMember" name="ShareRepurchaseProgramAndRSUNetSettlementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConvertibleDebtCurrentAbstract" name="ConvertibleDebtCurrentAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ConversionRatePerNote" name="ConversionRatePerNote" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_PerformanceStockUnitProgramMember" name="PerformanceStockUnitProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" name="IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ShareBasedPaymentArrangementAwardTypeAxis" name="ShareBasedPaymentArrangementAwardTypeAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PaymentForRepurchaseOfShares" name="PaymentForRepurchaseOfShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_DisclosureOfHoldingOfTreasurySharesAbstract" name="DisclosureOfHoldingOfTreasurySharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_SharesAgreementDescription" name="SharesAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueSettled" name="DerivativeFinancialLiabilitiesAtFairValueSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TwoThousandAndTwentySevenMember" name="TwoThousandAndTwentySevenMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment" name="ExchangeRateForPercentageOfRevenueToRoyaltyPayment" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_VisenPharmaceuticalsMember" name="VisenPharmaceuticalsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_RoyaltyPharmaUnitedStatesSkytrofaMember" name="RoyaltyPharmaUnitedStatesSkytrofaMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" name="PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered" name="DerivativeFinancialLiabilitiesAtFairValueTransfered" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_VestingMember" name="VestingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties" name="TreasurySharesHoldingInPercentageAcquiredFromThirdParties" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" name="PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="asnd_TreasurySharesAcquiredFromThirdParties" name="TreasurySharesAcquiredFromThirdParties" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="asnd_TwoThousandAndTwentySixMember" name="TwoThousandAndTwentySixMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_VestingOfSharesAxis" name="VestingOfSharesAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_NewShareRepurchaseProgramMember" name="NewShareRepurchaseProgramMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_PaymentTermOfCustomers" name="PaymentTermOfCustomers" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_RevenueTable" name="RevenueTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" name="MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory" name="DisclosureOfRoyaltyFundingLiabilitiesExplanatory" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" name="ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Ascendis Pharma A/S<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001612042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>Profit or loss [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">&#8364; 100,954<span></span>
</td>
<td class="nump">&#8364; 95,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">Cost of sales</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">17,517<span></span>
</td>
<td class="nump">7,569<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">Gross profit</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">83,437<span></span>
</td>
<td class="nump">88,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">86,603<span></span>
</td>
<td class="nump">70,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">101,046<span></span>
</td>
<td class="nump">66,783<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">Operating profit/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(104,212)<span></span>
</td>
<td class="num">(49,145)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of profit/(loss) of associates</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">26,579<span></span>
</td>
<td class="num">(5,796)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Finance income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">28,854<span></span>
</td>
<td class="nump">3,575<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Finance expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">44,786<span></span>
</td>
<td class="nump">77,161<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossBeforeTax', window );">Profit/(loss) before tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(93,565)<span></span>
</td>
<td class="num">(128,527)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Income taxes (expenses)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,061)<span></span>
</td>
<td class="num">(2,508)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(94,626)<span></span>
</td>
<td class="num">(131,035)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossAttributableToOwnersOfParent', window );">Attributable to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (94,626)<span></span>
</td>
<td class="num">&#8364; (131,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">Basic earnings/(loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1.58)<span></span>
</td>
<td class="num">&#8364; (2.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">Diluted earnings/(loss) per share</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (1.58)<span></span>
</td>
<td class="num">&#8364; (2.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">Number of shares used for calculation (basic and diluted)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">60,018,550<span></span>
</td>
<td class="nump">56,883,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfComprehensiveIncomeAbstract', window );"><strong>Statement of comprehensive income [abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (94,626)<span></span>
</td>
<td class="num">&#8364; (131,035)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract', window );"><strong>Items that may be reclassified subsequently to profit or (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation', window );">Exchange differences on translating foreign operations</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss) for the period, net of tax</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(75)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(94,701)<span></span>
</td>
<td class="num">(130,972)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent', window );">Attributable to owners of the Company</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">&#8364; (94,701)<span></span>
</td>
<td class="num">&#8364; (130,972)<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,017,157</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,031,498</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">575,000</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible senior notes which can potentially be converted into </span><span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,456,785</span><span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_b_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 91<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_91_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossAttributableToOwnersOfParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81B<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81B_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossAttributableToOwnersOfParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) before tax expense or income. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2024-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2024-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfWarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">6,017,157<span></span>
</td>
<td class="nump">6,031,498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares', window );">Convertible notes</a></td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedIncomeStatementsCaptionsLineItems', window );"><strong>Condensed Income Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfWarrantsOutstanding', window );">Warrants outstanding</a></td>
<td class="nump">3,456,785<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfWarrantsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfWarrantsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential conversion of convertible senior notes into number of ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedIncomeStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedIncomeStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Financial Position - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>Non-current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsAndGoodwill', window );">Intangible assets</a></td>
<td class="nump">&#8364; 3,909<span></span>
</td>
<td class="nump">&#8364; 4,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Property, plant and equipment</a></td>
<td class="nump">92,447<span></span>
</td>
<td class="nump">98,714<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentsInAssociates', window );">Investments in associates</a></td>
<td class="nump">40,938<span></span>
</td>
<td class="nump">13,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherNoncurrentReceivables', window );">Other receivables</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">139,951<span></span>
</td>
<td class="nump">118,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventories</a></td>
<td class="nump">293,071<span></span>
</td>
<td class="nump">295,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTradeReceivables', window );">Trade receivables</a></td>
<td class="nump">66,685<span></span>
</td>
<td class="nump">166,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxAssetsCurrent', window );">Income tax receivables</a></td>
<td class="nump">1,614<span></span>
</td>
<td class="nump">1,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentReceivables', window );">Other receivables</a></td>
<td class="nump">8,522<span></span>
</td>
<td class="nump">9,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentPrepayments', window );">Prepayments</a></td>
<td class="nump">33,672<span></span>
</td>
<td class="nump">28,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">517,923<span></span>
</td>
<td class="nump">559,543<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">921,487<span></span>
</td>
<td class="nump">1,060,861<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">Total assets</a></td>
<td class="nump">1,061,438<span></span>
</td>
<td class="nump">1,179,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Share capital</a></td>
<td class="nump">8,187<span></span>
</td>
<td class="nump">8,149<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DistributableEquity', window );">Distributable equity</a></td>
<td class="num">(197,994)<span></span>
</td>
<td class="num">(113,855)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Total equity</a></td>
<td class="num">(189,807)<span></span>
</td>
<td class="num">(105,706)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>Non-current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LongtermBorrowings', window );">Borrowings</a></td>
<td class="nump">357,312<span></span>
</td>
<td class="nump">365,080<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">692<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">7,733<span></span>
</td>
<td class="nump">7,258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">365,737<span></span>
</td>
<td class="nump">377,338<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleDebtCurrentAbstract', window );"><strong>Convertible notes, matures in April 2028</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShorttermBorrowings', window );">Borrowings</a></td>
<td class="nump">449,562<span></span>
</td>
<td class="nump">458,207<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">174,581<span></span>
</td>
<td class="nump">150,670<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleNotesCurrent', window );">Convertible notes current</a></td>
<td class="nump">624,143<span></span>
</td>
<td class="nump">608,877<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_OtherCurrentLiabilitiesAbstract', window );"><strong>Other current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShortTermBorrowingOther', window );">Borrowings</a></td>
<td class="nump">40,398<span></span>
</td>
<td class="nump">33,329<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentContractLiabilities', window );">Contract liabilities</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers', window );">Trade payables and accrued expenses</a></td>
<td class="nump">84,370<span></span>
</td>
<td class="nump">96,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">38,062<span></span>
</td>
<td class="nump">67,956<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentTaxLiabilities', window );">Income tax payables</a></td>
<td class="nump">1,573<span></span>
</td>
<td class="nump">1,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">95,772<span></span>
</td>
<td class="nump">99,149<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherCurrentFinancialLiabilities', window );">Other current liabilities</a></td>
<td class="nump">261,365<span></span>
</td>
<td class="nump">298,986<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">885,508<span></span>
</td>
<td class="nump">907,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,251,245<span></span>
</td>
<td class="nump">1,285,201<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">Total equity and liabilities</a></td>
<td class="nump">&#8364; 1,061,438<span></span>
</td>
<td class="nump">&#8364; 1,179,495<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleDebtCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible debt current abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleDebtCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleNotesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible notes current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleNotesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DistributableEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Distributable equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DistributableEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_OtherCurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other current liabilities abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_OtherCurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShortTermBorrowingOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short term borrowing, other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShortTermBorrowingOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentPrepayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current prepayments. [Refer: Prepayments]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentPrepayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of current tax assets. [Refer: Current tax assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph n<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_n&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentTradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables. [Refer: Trade receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentTradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph g<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_g_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph o<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_o&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 56<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_56&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsAndGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsAndGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentsInAssociates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentsInAssociates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LongtermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The non-current portion of non-current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LongtermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current contract liabilities. [Refer: Contract liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 105<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_105&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherNoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current other receivables. [Refer: Other receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherNoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShorttermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShorttermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 70<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_70&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Share Capital [member]</div></th>
<th class="th"><div>Share Premium [member]</div></th>
<th class="th"><div>Treasury Shares [member]</div></th>
<th class="th"><div>Foreign Currency Translation Reserve [member]</div></th>
<th class="th"><div>Accumulated Deficit [member]</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2023</a></td>
<td class="num">&#8364; (145,697)<span></span>
</td>
<td class="nump">&#8364; 7,749<span></span>
</td>
<td class="nump">&#8364; 2,123,074<span></span>
</td>
<td class="num">&#8364; (146)<span></span>
</td>
<td class="nump">&#8364; 721<span></span>
</td>
<td class="num">&#8364; (2,277,095)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="num">(131,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(131,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(130,972)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="num">(131,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment (Note 7)</a></td>
<td class="nump">17,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Transfer under stock incentive programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Capital increase (Note 8)</a></td>
<td class="nump">21,209<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="nump">21,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Mar. 31, 2024</a></td>
<td class="num">(238,179)<span></span>
</td>
<td class="nump">7,818<span></span>
</td>
<td class="nump">2,144,214<span></span>
</td>
<td class="num">(118)<span></span>
</td>
<td class="nump">784<span></span>
</td>
<td class="num">(2,390,877)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Dec. 31, 2024</a></td>
<td class="num">(105,706)<span></span>
</td>
<td class="nump">8,149<span></span>
</td>
<td class="nump">2,444,175<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="num">(2,559,700)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="num">(94,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(94,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComprehensiveIncome', window );">Total comprehensive income/(loss)</a></td>
<td class="num">(94,701)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(75)<span></span>
</td>
<td class="num">(94,626)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based payment (Note 7)</a></td>
<td class="nump">25,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,558<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfTreasuryShares', window );">Acquisition of treasury shares (Note 9)</a></td>
<td class="num">(17,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17,380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SaleOrIssueOfTreasuryShares', window );">Transfer under stock incentive programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NetSettlementUnderStockIncentivePrograms', window );">Net settlement under stock incentive programs</a></td>
<td class="num">(11,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,396)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners', window );">Capital increase (Note 8)</a></td>
<td class="nump">13,834<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="nump">13,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity at Mar. 31, 2025</a></td>
<td class="num">&#8364; (189,807)<span></span>
</td>
<td class="nump">&#8364; 8,187<span></span>
</td>
<td class="nump">&#8364; 2,457,971<span></span>
</td>
<td class="num">&#8364; (80)<span></span>
</td>
<td class="nump">&#8364; 1,708<span></span>
</td>
<td class="num">&#8364; (2,657,593)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NetSettlementUnderStockIncentivePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net settlement under stock incentive programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NetSettlementUnderStockIncentivePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComprehensiveIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ix<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_ix&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComprehensiveIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from transactions with owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82A<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82A&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SaleOrIssueOfTreasuryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SaleOrIssueOfTreasuryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Cash Flow Statements - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Net profit/(loss) for the period</a></td>
<td class="num">&#8364; (94,626)<span></span>
</td>
<td class="num">&#8364; (131,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">Reversal of finance income</a></td>
<td class="num">(28,854)<span></span>
</td>
<td class="num">(3,575)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Reversal of finance expenses</a></td>
<td class="nump">44,786<span></span>
</td>
<td class="nump">77,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment', window );">Reversal of (gain)/loss on disposal of property, plant and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxExpenseContinuingOperations', window );">Reversal of income taxes</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments for non-cash items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AdjustmentsForNonCashConsiderationRegardingRevenue', window );">Non-cash consideration relating to revenue</a></td>
<td class="num">(1,402)<span></span>
</td>
<td class="num">(24,770)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod', window );">Share of (profit)/loss of associates</a></td>
<td class="num">(26,579)<span></span>
</td>
<td class="nump">5,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based payment</a></td>
<td class="nump">25,558<span></span>
</td>
<td class="nump">17,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">4,426<span></span>
</td>
<td class="nump">4,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment of property, plant and equipment</a></td>
<td class="nump">7,508<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ChangesInWorkingCapitalAbstract', window );"><strong>Changes in working capital:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Inventories</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="num">(23,750)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables', window );">Receivables</a></td>
<td class="nump">98,032<span></span>
</td>
<td class="num">(11,286)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses', window );">Prepayments</a></td>
<td class="num">(5,521)<span></span>
</td>
<td class="num">(3,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities', window );">Contract liabilities</a></td>
<td class="num">(4,054)<span></span>
</td>
<td class="num">(950)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="num">(40,767)<span></span>
</td>
<td class="num">(19,025)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForProvisions', window );">Provisions</a></td>
<td class="nump">260<span></span>
</td>
<td class="nump">7,076<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperations', window );">Cash flows generated from/(used in) operations</a></td>
<td class="num">(17,515)<span></span>
</td>
<td class="num">(104,087)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities', window );">Finance income received</a></td>
<td class="nump">4,208<span></span>
</td>
<td class="nump">3,588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities', window );">Finance expenses paid</a></td>
<td class="num">(954)<span></span>
</td>
<td class="num">(877)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities', window );">Income taxes received/(paid)</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(206)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Cash flows from/(used in) operating activities</a></td>
<td class="num">(14,313)<span></span>
</td>
<td class="num">(101,582)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment', window );">Acquisition of intangible assets and property, plant and equipment</a></td>
<td class="num">(703)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities', window );">Settlement of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,354<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Cash flows from/(used in) investing activities</a></td>
<td class="num">(703)<span></span>
</td>
<td class="nump">7,155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities', window );">Repayment of borrowings</a></td>
<td class="num">(3,066)<span></span>
</td>
<td class="num">(2,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromExerciseOfWarrants', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">13,834<span></span>
</td>
<td class="nump">21,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares', window );">Acquisition of treasury shares, net of transaction costs</a></td>
<td class="num">(17,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms', window );">Payment of withholding taxes under stock incentive programs</a></td>
<td class="num">(11,396)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Cash flows from/(used in) financing activities</a></td>
<td class="num">(18,024)<span></span>
</td>
<td class="nump">18,423<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">Increase/(decrease) in cash and cash equivalents</a></td>
<td class="num">(33,040)<span></span>
</td>
<td class="num">(76,004)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at January 1</a></td>
<td class="nump">559,543<span></span>
</td>
<td class="nump">392,164<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">Effect of exchange rate changes on balances held in foreign currencies</a></td>
<td class="num">(8,580)<span></span>
</td>
<td class="nump">4,079<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BalancesWithBanks', window );">Bank deposits</a></td>
<td class="nump">517,923<span></span>
</td>
<td class="nump">320,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents at March 31</a></td>
<td class="nump">&#8364; 517,923<span></span>
</td>
<td class="nump">&#8364; 320,239<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AdjustmentsForNonCashConsiderationRegardingRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for non cash consideration regarding revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AdjustmentsForNonCashConsiderationRegardingRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ChangesInWorkingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ChangesInWorkingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of withholding taxes under stock incentive programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase of intangible assets and property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BalancesWithBanks">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash balances held at banks.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BalancesWithBanks</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash from (used in) the entity's operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section A Statement of cash flows for an entity other than a financial institution<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS07_IE_A_TI<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 31<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_31&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxExpenseContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 26<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -Subparagraph b<br> -Clause viii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=26&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35_b_viii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_h&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 81<br> -Subparagraph c<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81_c_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_g&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxExpenseContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 14<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_14_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsToAcquireOrRedeemEntitysShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire or redeem entity's shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsToAcquireOrRedeemEntitysShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the exercise of share purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfGeneralInformationAbstract', window );"><strong>Disclosure of General Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General Information</a></td>
<td class="text"><p id="notes" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">te 1&#8212;General Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Ascendis Pharma A/S, together with its subsidiaries, is a global biopharmaceutical company focused on applying its innovative TransCon technology platform to make a meaningful difference for patients. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Ascendis Pharma A/S and its subsidiaries.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The address of the Company&#8217;s registered office is Tuborg Boulevard 12, DK-2900, Hellerup, Denmark. The Company&#8217;s registration number in Denmark is 29918791.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#8220;ADSs&#8221;), representing the Company&#8217;s ordinary shares, under the symbol &#8220;ASND&#8221; in the United States on the Nasdaq Global Select Market.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s Board of Directors (the &#8220;Board&#8221;) approved these unaudited condensed consolidated interim financial statements on May 1, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfGeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of general information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfGeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract', window );"><strong>Disclosure of voluntary change in accounting policy [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory', window );">Summary of Material Accounting Policies</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 2&#8212;Summary of Material Accounting Policies</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements for the year ended December 31, 2024 and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#8220;IASB&#8221;) and as adopted by the European Union (the &#8220;EU&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New and Amended IFRS Accounting Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, the IASB amended IAS 21, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to help entities determine whether a currency is exchangeable into another currency and which spot exchange rate to use when it is not. These new requirements apply for annual reporting periods beginning on or after January 1, 2025. The Company does not expect these amendments to have a material impact on its operations or financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New IFRS Accounting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discontinued operations.</span></div></div></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unaudited condensed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of significant accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgements and Estimates<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract', window );"><strong>Disclosure of voluntary change in accounting policy [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory', window );">Significant Accounting Judgements and Estimates</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 3&#8212;Significant Accounting Judgements and Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the application of the Company&#8217;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unaudited condensed consolidated interim financial statements do not include all disclosures for significant accounting judgements, estimates and assumptions, that are required in the annual consolidated financial statements, and therefore should be read in conjunction with the Company&#8217;s audited consolidated financial statements as of and for the year ended December 31, 2024.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#8217;s ongoing revisions of critical accounting estimates and underlying assumptions have not revealed any material impact in any of the periods presented in the unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">There have been no changes to the application of significant accounting judgements or estimation uncertainties regarding accounting estimates compared to December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events in the Reporting Period<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodAbstract', window );"><strong>Significant Events in the Reporting Period [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodTextBlock', window );">Significant Events In the Reporting Period</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 4&#8212;Significant Events in the Reporting Period</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">VISEN Pharmaceuticals Initial Public Offering</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 20, 2025, VISEN Pharmaceuticals (&#8220;VISEN&#8221;) announced the pricing of its initial public offering (&#8220;IPO&#8221;) on the Hong Kong Stock Exchange. The IPO closed on March 21, 2025, and VISEN&#8217;s shares began trading under the stock code 2561.HK.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company&#8217;s investment in VISEN is accounted for using the equity method in the consolidated financial statements as the Company has determined that it has significant influence over the investment. Following the IPO, the Company owned </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% in VISEN. As a result, a non-cash gain of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">33.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million was recognized in the consolidated statement of profit or loss as part of share of profit/(loss) of associates. The IPO did not change the accounting treatment of VISEN. As of March 31, 2025, VISEN&#8217;s share price was HK$</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, reflecting a total market value of the Company&#8217;s equity position of approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">260</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. As of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the carrying amount of VISEN using the equity method was &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28.4</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The management and existing shareholders of VISEN, including Ascendis Pharma, have entered into customary lock-up agreements restricting the sale of VISEN shares for six months following the IPO; </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">additionally, certain significant shareholders of VISEN, including the Company, are subject to an additional lock-up obligation during the period commencing on the date that is six months after the IPO and ending on the date that is 12 months after the IPO during which such shareholders may not sell shares of VISEN to an extent that would cause such shareholder to cease being a controlling shareholder of VISEN pursuant to applicable listing rules.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Share Repurchase Program</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On February 12, 2025, the Company announced that the Board has authorized the Company to repurchase up to $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">18.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of the Company&#8217;s ADSs, each of which represents one ordinary share of Ascendis Pharma A/S (the &#8220;Share Repurchase Program&#8221;). On March 4, 2025, the Share Repurchase Program was fully executed in compliance with Rules 10b-18 and 10b5-1 of the Securities Exchange Act of 1934, as amended.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, the Company was authorized to repurchase up to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,726,015</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> of the Company's ADSs.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The holding of treasury shares is disclosed in Note 9, &#8220;Treasury Shares.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Impairment on Property, Plant and Equipment</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> includes an impairment charge of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">7.5</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, related to change in activities at one of our sites in the U.S. and is included as part of research and development expenses, and selling general and administrative expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Equity Development</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of March 31, 2025, the unaudited condensed consolidated interim statements of financial position presented a negative balance of equity of &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">189.8</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company, holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Based on its current operating plan, the Company believes that the existing capital resources as of March 31, 2025, will be sufficient to meet projected cash requirements for at least twelve months from the date of this report. However, the Company&#8217;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">s operating plan may change as a result of many factors that are currently unknown, and the Company may need to seek additional funds sooner than planned. Further details regarding borrowings including maturity analysis are provided in Note 10, &#8220;Financial Assets and Liabilities.&#8221;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SignificantEventsInTheReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant events in the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SignificantEventsInTheReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SignificantEventsInTheReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant Events In The Reporting Period Text Block.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SignificantEventsInTheReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueExplanatory', window );">Revenue</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 5&#8212;Revenue</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss with the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,499</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rendering of services and clinical supply</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,524</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,402</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,770</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">95,894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified per geographical area</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,686</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,681</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rest of world</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,940</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,646</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">95,894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">(1)</span><div style="width:100%;display:inline;"><span style="font-size:9pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025, Denmark, the country of domicile, contributed with &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue. For the three months ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue was attributable to Denmark.</span></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Revenue from Commercial Products</span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sale of commercial products were as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue from commercial products</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SKYTROFA&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,340</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,005</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">YORVIPATH&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,688</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue from commercial products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">96,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">66,499</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In the U.S., the Company has established an integrated organization to commercialize the Company&#8217;s approved Endocrinology Rare Disease products, SKYTROFA</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and YORVIPATH</span><span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#174;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. In Europe, the Company is expanding its presence by building integrated organizations in select countries (&#8220;Europe Direct&#8221;), where the Company has launched SKYTROFA and YORVIPATH. Beyond the U.S. and Europe Direct, SKYTROFA and YORVIPATH may also be sold through exclusive distribution agreements with geographic market leaders (&#8220;International Markets&#8221;) and under certain strategic collaboration agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">YORVIPATH and SKYTROFA is approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and authorized by the European Commission (&#8220;EC&#8221;) and other regulatory agencies. The Company began selling YORVIPATH in Europe in the first quarter of 2024 and in the U.S. in December 2024. The Company began selling SKYTROFA in the U.S. in the fourth quarter of 2021 and in Europe in the third quarter of 2023.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Other Revenue</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Other revenue is attributable to collaborations and license agreements, and relates to Novo Nordisk A/S (&#8220;Novo Nordisk&#8221;), Eyconis, Inc. (&#8220;Eyconis&#8221;), Teijin Limited (&#8220;Teijin&#8221;) and VISEN. Under the collaborations and license agreements, the Company provides various research and development services and clinical supply. Costs associated with these activities are presented as cost of sales in the unaudited condensed consolidated statement of profit or loss.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue from royalties or milestones has been recognized under the collaborations and license agreements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>Disclosure of operating segments [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">Segment Information</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 6&#8212;Segment Information</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company is managed and operated as </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">one</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 5 &#8220;Revenue.&#8221; Revenue is specified on geographical areas according to the location of the customer.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">Share-based Payment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 7&#8212;Share-based Payment</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a Restricted Stock Unit (&#8220;RSU&#8221;) program adopted in December 2021, and a Performance Stock Unit (&#8220;PSU&#8221;) program adopted in February 2023, which are all classified as equity-settled share-based payment transactions.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based Compensation Costs</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Share-based compensation costs are determined using the grant date fair value and are recognized over the vesting period as research and development expenses, selling, general and administrative expenses, or cost of sales. For the three months ended March 31, 2025 and 2024, share-based compensation costs recognized in the unaudited condensed consolidated interim statement of profit or loss were &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">25.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">17.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million, respectively.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Restricted Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">RSUs are granted by the Board to members of senior management, other employees and members of the Board (the &#8220;RSU-holders&#8221;), as stipulated in the program. In addition, RSUs may be granted to select consultants.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One RSU represents a right for the RSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting, if the vesting conditions are met. RSUs granted vest over three years with 1/3 of the RSUs vesting on each anniversary date from the date of grant, and require RSU-holders to be employed, appointed as member of the Board, or retained as a consultant (the &#8220;service conditions&#8221;).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Performance Stock Unit Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">PSUs are granted by the Board to certain members of senior management (the &#8220;PSU-holders&#8221;), as stipulated in the program. In addition, PSUs may be granted to other employees, select consultants and members of the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">100</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%, nor will it result in additional grants. </span></span><span style="font-size:10pt;font-family:Times New Roman;"></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">RSU and PSU Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number of outstanding RSUs and PSUs:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.423%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.164%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.164%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.244%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">993,807</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,667</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,150,474</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">634,589</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,583</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708,172</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settled during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,056</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,772</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">321,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,688</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,448</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,221,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">165,258</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,386,446</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by vesting year</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">583,076</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">669,735</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">427,429</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,066</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481,495</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,683</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,533</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235,216</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,221,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">165,258</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,386,446</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrant Program</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants. Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">. The exercise price is fixed at the fair market value of the Company&#8217;s ordinary shares at the time of grant as determined by the Board.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Warrant Activity</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number and weighted average exercise prices of, and movements in warrants:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,204,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,663</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,078</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,017,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">96.26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,057,771</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92.31</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The exercise prices of outstanding warrants under the Company&#8217;s warrant programs range from &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">11.98</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">145.50</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">depending on the grant dates.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract', window );"><strong>Disclosure of classes of share capital [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory', window );">Share Capital</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 8&#8212;Share Capital</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The share capital of Ascendis Pharma A/S consists of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,970,565</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> fully paid shares at a nominal value of DKK </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all in the same share class, and which includes </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">597,055</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares represented by ADSs held by Ascendis Pharma A/S. For the three months ended March 31, 2025, the share capital was increased with </span><span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;">281,078</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> number of shares.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share capital, reserves and other equity interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfTreasurySharesAbstract', window );"><strong>Disclosure of treasury shares [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfInformationAboutTreasurySharesExplanatory', window );">Treasury Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 9&#8212;Treasury Shares</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in the holding of treasury shares was as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.423%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.164%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.164%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.245%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>values</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845,887</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired from third parties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">80</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">597,055</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfInformationAboutTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of information about treasury shares explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfInformationAboutTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfTreasurySharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfTreasurySharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract', window );"><strong>Subclassifications of assets, liabilities and equities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">Financial Assets and Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 10&#8212;Financial Assets and Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:11pt;font-family:'Calibri',sans-serif;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial assets and liabilities comprise the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets by category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,280</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables (excluding indirect tax receivables)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517,923</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">559,543</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">589,109</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">589,109</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,657</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,317</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">586,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">727,470</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">589,109</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities by category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">449,562</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303,347</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,379</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,030</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,370</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,394</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities (excluding indirect tax, and employee related payables)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">935,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">953,321</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,110,093</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,103,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">357,312</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365,080</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">752,781</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">738,911</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,110,093</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,103,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Borrowings</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Convertible Senior Notes</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In March 2022, the Company issued an aggregate principal amount of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">575.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of fixed rate </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% convertible notes. The net proceeds from the offering of the convertible notes were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">557.9</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">503.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting the initial purchasers&#8217; discounts and commissions and offering expenses. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 1, 2028</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes accrue interest at a rate of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.25</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#8217;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6.0118</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ADSs per $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,000</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> principal amount of convertible notes, which represents an initial conversion price of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166.34</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#8217;s option at any time, and from time to time, on or after </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">April 7, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">but only if the last reported sale price per ADS exceeds </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">130</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% of the conversion price on (i) each of at least </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">20</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> trading days, whether or not consecutive, during the </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">30</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</span></span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Royalty Funding Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Company has entered into capped synthetic royalty funding agreements with Royalty Pharma (the &#8220;Purchaser&#8221;), which is presented as part of borrowings, and represents the Company&#8217;s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">YORVIPATH Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2024, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Yorvipath Agreement&#8221;) with the Purchaser. The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">134.2</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Royalty Pharma Yorvipath Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Yorvipath Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net revenue from sales of YORVIPATH in the U.S. (the &#8220;Yorvipath Revenue Payments&#8221;). The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times if the Purchaser receives Yorvipath Revenue Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2029</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Yorvipath Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to September 30, 2028, and the Company has paid the Purchaser, Yorvipath Revenue Payments equal to the Yorvipath Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">SKYTROFA Agreement</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In September 2023, the Company entered into a $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million capped synthetic royalty funding agreement (the &#8220;Royalty Pharma Skytrofa Agreement&#8221;) with the Purchaser. The net proceeds were $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">146.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (&#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">136.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million) after deducting offering expenses.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Under the terms of the Royalty Pharma Skytrofa Agreement, the Company received an upfront payment of $</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million (the &#8220;Skytrofa Purchase Price&#8221;) in exchange for a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">9.15</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">January 1, 2025</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> (the &#8220;Skytrofa Revenue Payments&#8221;). The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.925</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times, or </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times if the Purchaser receives Skytrofa Revenue Payments in that amount by </span><span style="font-size:10pt;font-family:Times New Roman;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">December 31, 2031</span></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Royalty Pharma Skytrofa Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.925</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser, Skytrofa Revenue Payments equal to the Skytrofa Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.65</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Derivative Liabilities</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Fair value cannot be measured based on quoted prices in active markets or other observable inputs, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#8217;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#8217;s share price (</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.7</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49.6</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">%</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> as of March 31, 2025 and December 31, 2024, respectively).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For additional description of fair values, refer to the following section &#8220;Fair Value Measurement.&#8221;</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Sensitivity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">On March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15.0</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% relative decrease in volatility indicates the opposite impact.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Similarly, on March 31, 2025</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, all other inputs and assumptions held constant, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% increase in the share price, will increase the fair value of derivative liabilities by approximately &#8364;</span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35.3</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million and indicates a decrease in profit or loss and equity before tax. Similarly, a </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">10</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">% decrease in the share price indicates the opposite impact.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Fair Value Measurement</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value of lease liabilities are not disclosed. Fair value compared to carrying amount of convertible notes, royalty funding liabilities and derivative liabilities, and their level in the fair value hierarchy is summarized in the following table, where:</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 1 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 2 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Level 3 </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">inputs are unobservable inputs for the asset or liability</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span></p><div style="font-size:10pt;font-family:Times New Roman;">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value level</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(1-3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">449,562</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433,666</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303,347</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308,018</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,379</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">752,909</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">741,684</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">763,586</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">743,961</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement recognized in finance (income) or expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,911</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,995</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">197,291</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Maturity Analysis</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><div style="font-size:10pt;font-family:Times New Roman;"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&lt; 1 year</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1-5 years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&gt;5 years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,585</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">991,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,031,221</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">752,909</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,607</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,250</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,986</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,240</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,240</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,240</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">142,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,049,243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">35,250</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,227,447</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">935,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Borrowings (excluding lease liabilities)&#8221; comprise convertible notes and royalty funding liabilities. Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>Disclosure of non-adjusting events after reporting period [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">Subsequent Events</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Note 11&#8212;Subsequent Events</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">No events have occurred after the balance sheet date that would influence the evaluation of these unaudited condensed consolidated interim financial statements.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2024-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2024-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of Preparation</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">Basis of Preparation</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#8220;Interim Financial Reporting.&#8221; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#8220;IFRS&#8221;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements for the year ended December 31, 2024 and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#8220;IASB&#8221;) and as adopted by the European Union (the &#8220;EU&#8221;).</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations', window );">New and Amended IFRS Accounting Standards and Interpretations</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New and Amended IFRS Accounting Standards and Interpretations</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In August 2023, the IASB amended IAS 21, </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8220;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">&#8221;</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> to help entities determine whether a currency is exchangeable into another currency and which spot exchange rate to use when it is not. These new requirements apply for annual reporting periods beginning on or after January 1, 2025. The Company does not expect these amendments to have a material impact on its operations or financial statements.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">New IFRS Accounting Standards Not Yet Effective</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;">IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221;</span></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In April 2024, the IASB issued IFRS 18, &#8220;Presentation and Disclosure in Financial Statements&#8221; (&#8220;IFRS 18&#8221;), which replaces IAS 1, &#8220;Presentation in Financial Statements.&#8221; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:</span></p><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Operating activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Investing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Financing activities;</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Income taxes; and</span></div></div><div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#8226;</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Discontinued operations.</span></div></div><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.</span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The unaudited condensed </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">consolidated financial statements are not expected to be affected by other new or amended standards.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenue [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory', window );">Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss with the following amounts:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Commercial products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,499</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rendering of services and clinical supply</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,524</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,625</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Licenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,402</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,770</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">95,894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified per geographical area</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Europe </span><span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;">(1)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">21,328</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,567</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">North America</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,686</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">92,681</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Rest of world</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">5,940</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,646</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">100,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">95,894</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">For the three months ended March 31, 2025, Denmark, the country of domicile, contributed with &#8364;</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2.4</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> million of revenue. For the three months ended March 31, 2024</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, </span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">no</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> revenue was attributable to Denmark.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfRevenueToCommercialProductsExplanatory', window );">Schedule of Revenue From Sale of Commercial Products</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">Revenue from sale of commercial products were as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Three Months Ended<br/>March 31,</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Revenue from commercial products</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">SKYTROFA&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">51,340</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">65,005</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">YORVIPATH&#174;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">44,688</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,494</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total revenue from commercial products</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">96,028</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">66,499</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfRevenueToCommercialProductsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of revenue to commercial products explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfRevenueToCommercialProductsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of segment revenues by destination of major customers explanatory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock', window );">Summary of Share Based Payment</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number of outstanding RSUs and PSUs:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.423%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.164%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.164%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.244%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Restricted Stock Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Performance Stock Units</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">993,807</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">156,667</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,150,474</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">634,589</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">73,583</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">708,172</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Settled during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">60,056</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,716</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">75,772</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">321,392</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46,588</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">25,760</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,688</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">28,448</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,221,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">165,258</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,386,446</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Specified by vesting year</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2026</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">583,076</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">86,659</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">669,735</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2027</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">427,429</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,066</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">481,495</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2028</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">210,683</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">24,533</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">235,216</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,221,188</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">165,258</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,386,446</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory', window );">Summary of Weighted Average Exercise Prices and Movements in Warrants</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies the number and weighted average exercise prices of, and movements in warrants:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Warrants</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Weighted<br/>Average<br/>Exercise Price</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Outstanding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,204,122</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93.25</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Granted during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">148,663</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">126.98</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Exercised during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">281,078</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">46.66</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Forfeited during the period</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">54,550</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">95.24</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">6,017,157</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">96.26</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Vested at March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">5,057,771</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">92.31</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sharebased payment arrangement, restricted stock unit, activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfTreasurySharesAbstract', window );"><strong>Disclosure of treasury shares [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTreasurySharesExplanatory', window );">Summary of Holding of Treasury Shares</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The development in the holding of treasury shares was as follows:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:57.423%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.164%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.164%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:11.245%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Nominal<br/>values</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Holding in<br/>% of total<br/>outstanding<br/>shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(Number)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Treasury shares</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">113</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">845,887</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1.4</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Acquired from third parties</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">16</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">119,148</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Transferred under stock incentive programs</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">49</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">(</span><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">367,980</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-kerning:none;min-width:fit-content;">)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">80</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">597,055</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1.0</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;">%</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfTreasurySharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfTreasurySharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTreasurySharesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of treasury shares. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTreasurySharesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PresentationOfLeasesForLesseeAbstract', window );"><strong>Presentation of leases for lessee [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory', window );">Schedule of Financial Assets and Financial Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The financial assets and liabilities comprise the following:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31,<br/>2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31,<br/>2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets by category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade receivables</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">66,685</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">166,280</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other receivables (excluding indirect tax receivables)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">4,501</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,964</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Cash and cash equivalents</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">517,923</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">559,543</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial assets measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">589,109</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">589,109</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,657</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">2,317</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">586,452</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">727,470</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial assets</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">589,109</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">729,787</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities by category</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">449,562</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303,347</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,379</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">93,030</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables and accrued expenses</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">84,370</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">96,394</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Other liabilities (excluding indirect tax, and employee related payables)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,870</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">311</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">935,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">953,321</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,110,093</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,103,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Classified in the statement of financial position</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Non-current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">357,312</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">365,080</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Current liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">752,781</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">738,911</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,110,093</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,103,991</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock', window );">Summary of Fair Value Hierarchy</a></td>
<td class="text">
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">December 31, 2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Fair value level</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(1-3)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Convertible senior notes</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">449,562</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">433,666</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">458,207</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">438,288</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Royalty funding liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">303,347</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">308,018</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,379</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">305,673</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at amortized cost</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">752,909</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">741,684</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">763,586</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">743,961</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities measured at fair value through profit or loss</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock', window );">Movements in Level 3 Fair Value Measurements</a></td>
<td class="text"><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table specifies movements in level 3 fair value measurements:</span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:66.967%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1.16%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:13.357%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">2024</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Derivative liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">January 1</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">150,670</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">143,296</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Remeasurement recognized in finance (income) or expense</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">23,911</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">53,995</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">174,581</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">197,291</span></p></td>
         <td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock', window );">Summary of Maturity Analysis For Financial Liabilities</a></td>
<td class="text"><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position as of </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> </span></p>
       <table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;">
        <tr style="visibility:collapse;">
         <td style="width:44.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.04%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
         <td style="width:8.42%;box-sizing:content-box;"></td>
         <td style="width:1%;box-sizing:content-box;"></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&lt; 1 year</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1-5 years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">&gt;5 years</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total<br/>contractual<br/>cash-flows</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Carrying<br/>amount</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"> </span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">(EUR&#8217;000)</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Financial liabilities</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">March 31, 2025</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Borrowings (excluding lease liabilities)</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">39,585</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">991,636</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">1,031,221</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">752,909</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Lease liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">15,129</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">57,607</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">35,250</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">107,986</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">94,363</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">Trade payables, accrued expenses and other liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,240</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#8212;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,240</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">88,240</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
        <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">Total financial liabilities</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">142,954</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,049,243</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">35,250</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">1,227,447</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
         <td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;">935,512</span></p></td>
         <td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-kerning:none;min-width:fit-content;">&#160;</span></p></td>
        </tr>
       </table><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">&#8220;Borrowings (excluding lease liabilities)&#8221; comprise convertible notes and royalty funding liabilities. Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Financial Assets And Liabilities [text block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of movements in level 3 fair value measurements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of summary of fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maturity analysis for financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PresentationOfLeasesForLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PresentationOfLeasesForLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Material Accounting Policies - Additional Information (Detail) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity</a></td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember', window );">American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Disclosure of summary of significant accounting policies [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionPricePerShare', window );">Conversion Price Per Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items representing the disclosure of summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Judgements and Estimates - Additional Information (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems', window );"><strong>Disclosure of changes in accounting estimates [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentProvisions', window );">Provisions</a></td>
<td class="nump">&#8364; 95,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 99,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">&#8364; 100,954<span></span>
</td>
<td class="nump">&#8364; 95,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph l<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_l&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Events in the Reporting Period - Additional Information (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 21, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Feb. 12, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>kr / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodLineitems', window );"><strong>Significant Events In The Reporting Period LineItems</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Nominal value per share | kr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharePriceOfEntity', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (189,807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">&#8364; (105,706)<span></span>
</td>
<td class="num">&#8364; (238,179)<span></span>
</td>
<td class="num">&#8364; (145,697)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CounterpartiesAxis=asnd_ShareRepurchaseProgramMember', window );">Share Repuchase Program [member] | American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodLineitems', window );"><strong>Significant Events In The Reporting Period LineItems</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PaymentForRepurchaseOfShares', window );">Payment for repurchase of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 18,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharesAuthorizedToRepurchase', window );">Shares authorized to repurchase | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,726,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_VisenPharmaceuticalsMember', window );">VISEN [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SignificantEventsInTheReportingPeriodLineitems', window );"><strong>Significant Events In The Reporting Period LineItems</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharesAgreementDescription', window );">Shares agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">additionally, certain significant shareholders of VISEN, including the Company, are subject to an additional lock-up obligation during the period commencing on the date that is six months after the IPO and ending on the date that is 12 months after the IPO during which such shareholders may not sell shares of VISEN to an extent that would cause such shareholder to cease being a controlling shareholder of VISEN pursuant to applicable listing rules.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProportionOfOwnershipInterestInAssociate', window );">Present ownership percentage</a></td>
<td class="nump">39.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_InvestmentAccountedForUsingEquityMethod', window );">Carrying amount of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 28,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate', window );">Non-cash gain recognized</a></td>
<td class="nump">&#8364; 33,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 260,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non cash gain recognized on ownership interest in associate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PaymentForRepurchaseOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment for repurchase of shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PaymentForRepurchaseOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharePriceOfEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price of entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharePriceOfEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharesAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares agreement description.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharesAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharesAuthorizedToRepurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares authorized to repurchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharesAuthorizedToRepurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SignificantEventsInTheReportingPeriodLineitems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Significant events in the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SignificantEventsInTheReportingPeriodLineitems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_73_e_v&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 98<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_98_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_InvestmentAccountedForUsingEquityMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B16<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B16&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_InvestmentAccountedForUsingEquityMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProportionOfOwnershipInterestInAssociate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 27<br> -IssueDate 2024-01-01<br> -Paragraph 16<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=27&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_16_b_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph 21<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_21_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProportionOfOwnershipInterestInAssociate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=asnd_ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=asnd_ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_VisenPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_VisenPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Commercial products</a></td>
<td class="nump">&#8364; 96,028<span></span>
</td>
<td class="nump">&#8364; 66,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RevenueFromRenderingOfServicesAndClinicalSupply', window );">Rendering of services and clinical supply</a></td>
<td class="nump">3,524<span></span>
</td>
<td class="nump">4,625<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LicenceFeeIncome', window );">Licenses</a></td>
<td class="nump">1,402<span></span>
</td>
<td class="nump">24,770<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">100,954<span></span>
</td>
<td class="nump">95,894<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">100,954<span></span>
</td>
<td class="nump">95,894<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember', window );">Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">21,328<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">21,328<span></span>
</td>
<td class="nump">1,567<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember', window );">North America [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">73,686<span></span>
</td>
<td class="nump">92,681<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">73,686<span></span>
</td>
<td class="nump">92,681<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=asnd_RestOfWorldMember', window );">Rest of world [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">5,940<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeographicalAreasAbstract', window );"><strong>Revenue (geographical)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Total revenue</a></td>
<td class="nump">&#8364; 5,940<span></span>
</td>
<td class="nump">&#8364; 1,646<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RevenueFromRenderingOfServicesAndClinicalSupply">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from rendering of services and clinical supply.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RevenueFromRenderingOfServicesAndClinicalSupply</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LicenceFeeIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income arising from licence fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LicenceFeeIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=srt_NorthAmericaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=asnd_RestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=asnd_RestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail) - EUR (&#8364;)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">&#8364; 100,954,000<span></span>
</td>
<td class="nump">&#8364; 95,894,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GeographicalAreasAxis=country_DK', window );">Denmark [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Revenue</a></td>
<td class="nump">&#8364; 2,400,000<span></span>
</td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2024-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2024-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GeographicalAreasAxis=country_DK">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GeographicalAreasAxis=country_DK</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Schedule of Revenue From Sale of Commercial Products (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from commercial products</a></td>
<td class="nump">&#8364; 96,028<span></span>
</td>
<td class="nump">&#8364; 66,499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember', window );">SKYTROFA [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from commercial products</a></td>
<td class="nump">51,340<span></span>
</td>
<td class="nump">65,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesYorvipathMember', window );">YORVIPATH [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromSaleOfGoods', window );">Revenue from commercial products</a></td>
<td class="nump">&#8364; 44,688<span></span>
</td>
<td class="nump">&#8364; 1,494<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromSaleOfGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue arising from the sale of goods. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromSaleOfGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesSkytrofaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesYorvipathMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_UnitedStatesYorvipathMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MajorCustomersAxis=asnd_CollaborationsAndLicenseAgreementsMember', window );">Collaborations and license agreements [Member] | Royalties And Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems', window );"><strong>Disclosure of performance obligations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueFromContractsWithCustomers', window );">Recognized as revenue</a></td>
<td class="nump">&#8364; 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfPerformanceObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfPerformanceObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueFromContractsWithCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity&#8217;s ordinary activities in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2024-01-01<br> -Paragraph 113<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_113_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueFromContractsWithCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MajorCustomersAxis=asnd_CollaborationsAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MajorCustomersAxis=asnd_CollaborationsAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PerformanceObligationsAxis=asnd_RoyaltiesAndMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems', window );"><strong>Disclosure of operating segments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfReportableOperatingSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfReportableOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of reportable operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfReportableOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment - Additional Information (Details)<br> &#8364; / shares in Units, &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>kr / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Share nominal value | kr / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">kr 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member', window );">Warrants [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 11.98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member', window );">Warrants [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019', window );">Exercise price of outstanding share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 145.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitProgramMember', window );">Performance Stock Unit Program [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement', window );">Description of vesting</a></td>
<td class="text">In addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitProgramMember', window );">Performance Stock Unit Program [Member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement', window );">Percentage of vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncomeStatementAxis=asnd_ProfitLossMember', window );">Profit Loss [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share based compensation costs | &#8364;</a></td>
<td class="nump">&#8364; 25.6<span></span>
</td>
<td class="nump">&#8364; 17.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting rights for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_a&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExercisePriceOfOutstandingShareOptions2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exercise price of outstanding share options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExercisePriceOfOutstandingShareOptions2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncomeStatementAxis=asnd_ProfitLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncomeStatementAxis=asnd_ProfitLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment - Schedule of Warrant Activity (Detail) - Warrants [member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>&#8364; / shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfWarrantActivityLineItems', window );"><strong>Disclosure Of Warrant Activity [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">6,204,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the period</a></td>
<td class="nump">148,663<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Exercised during the period</a></td>
<td class="num">(281,078)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(54,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">6,017,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement', window );">Vested at the balance sheet date</a></td>
<td class="nump">5,057,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Beginning balance</a></td>
<td class="nump">&#8364; 93.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019', window );">Granted during the period</a></td>
<td class="nump">126.98<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019', window );">Exercised during the period</a></td>
<td class="nump">46.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019', window );">Forfeited during the period</a></td>
<td class="nump">95.24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019', window );">Ending balance</a></td>
<td class="nump">96.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement', window );">Vested at the balance sheet date</a></td>
<td class="nump">&#8364; 92.31<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfWarrantActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure Of Warrant Activity [line items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfWarrantActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of other equity instruments vested in share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price of other equity instruments vested in share-based payment arrangement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=asnd_Warrant1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payment - Summary Of Share Based Payment (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2025</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">993,807<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the period</a></td>
<td class="nump">634,589<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Settled during the period</a></td>
<td class="num">(60,056)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the period</a></td>
<td class="num">(321,392)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(25,760)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">1,221,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">583,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">427,429<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember', window );">Restricted Stock Units [Member] | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">210,683<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">156,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the period</a></td>
<td class="nump">73,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Settled during the period</a></td>
<td class="num">(15,716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the period</a></td>
<td class="num">(46,588)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(2,688)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">165,258<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">86,659<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">54,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember', window );">Performance Stock Units [Member] | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">24,533<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Beginning balance</a></td>
<td class="nump">1,150,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Granted during the period</a></td>
<td class="nump">708,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement', window );">Settled during the period</a></td>
<td class="num">(75,772)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement', window );">Transferred during the period</a></td>
<td class="num">(367,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Forfeited during the period</a></td>
<td class="num">(28,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement', window );">Ending balance</a></td>
<td class="nump">1,386,446<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">669,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2027</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">481,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember', window );">Restricted Stock Units and Performance Stock Unit [Member] | 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems', window );"><strong>Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement', window );">Vested at the reporting date</a></td>
<td class="nump">235,216<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of other equity instruments settled in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of other equity instruments transferred in share based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based payment arrangement, restricted stock unit, activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentySevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentyEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_VestingOfSharesAxis=asnd_TwoThousandAndTwentyEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_PerformanceStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ShareBasedPaymentArrangementAwardTypeAxis=asnd_RestrictedStockUnitsAndPerformanceStockUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Capital - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>kr / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued</a></td>
<td class="nump">60,970,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Share nominal value | kr / shares</a></td>
<td class="nump">kr 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued', window );">Increase in share capital</a></td>
<td class="nump">281,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesOutstanding', window );">Number of shares outstanding</a></td>
<td class="nump">597,055<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iv&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Treasury Shares - Summary of Holding of Treasury Shares (Detail)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DisclosureOfHoldingOfTreasurySharesLineItems', window );"><strong>Disclosure Of Holding Of Treasury Shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesOfNominalValue', window );">January 1, 2025 (Nominal values) | &#8364;</a></td>
<td class="nump">&#8364; 113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesAcquiredFromThirdParties', window );">Acquired from third parties (Nominal values) | &#8364;</a></td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue', window );">Transferred under stock incentive programs (Nominal values) | &#8364;</a></td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesOfNominalValue', window );">March 31, 2025 (Nominal values) | &#8364;</a></td>
<td class="nump">&#8364; 80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfTreasurySharesOutstanding', window );">January 1, 2025 (Holding) | shares</a></td>
<td class="nump">845,887<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties', window );">Acquired from third-parties (Holding) | shares</a></td>
<td class="nump">119,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram', window );">Transferred under stock incentive programs (Holding) | shares</a></td>
<td class="num">(367,980)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_NumberOfTreasurySharesOutstanding', window );">March 31, 2025 (Holding) | shares</a></td>
<td class="nump">597,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares', window );">January 1, 2025 (Holding in % of total outstanding shares)</a></td>
<td class="nump">1.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties', window );">Acquired from third parties (Holding in % of total outstanding shares)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms', window );">Transferred under stock incentive programs (Holding in % total outstanding shares)</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares', window );">March 31, 2025 (Holding in % of total outstanding shares)</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DisclosureOfHoldingOfTreasurySharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of holding of treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DisclosureOfHoldingOfTreasurySharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease In treasury shares acquired from third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in treasury shares transferred under stock incentive program.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_NumberOfTreasurySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_NumberOfTreasurySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesAcquiredFromThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares acquired from third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesAcquiredFromThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares holding in percentage acquired from third parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares holding in percentage of total outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares holding in percentage transferred under stock incentive programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesOfNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesOfNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury shares transferred under stock incentive program nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">&#8364; 517,923<span></span>
</td>
<td class="nump">&#8364; 559,543<span></span>
</td>
<td class="nump">&#8364; 320,239<span></span>
</td>
<td class="nump">&#8364; 392,164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssets', window );">Total financial assets</a></td>
<td class="nump">589,109<span></span>
</td>
<td class="nump">729,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract', window );"><strong>Classified in the statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialAssets', window );">Non-current assets</a></td>
<td class="nump">2,657<span></span>
</td>
<td class="nump">2,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialAssets', window );">Current assets</a></td>
<td class="nump">586,452<span></span>
</td>
<td class="nump">727,470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">107,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">174,581<span></span>
</td>
<td class="nump">150,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,110,093<span></span>
</td>
<td class="nump">1,103,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract', window );"><strong>Classified in the statement of financial position</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentFinancialLiabilities', window );">Non-current liabilities</a></td>
<td class="nump">357,312<span></span>
</td>
<td class="nump">365,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentFinancialLiabilities', window );">Current liabilities</a></td>
<td class="nump">752,781<span></span>
</td>
<td class="nump">738,911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">449,562<span></span>
</td>
<td class="nump">458,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">303,347<span></span>
</td>
<td class="nump">305,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">94,363<span></span>
</td>
<td class="nump">93,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers', window );">Trade payables and accrued expenses</a></td>
<td class="nump">84,370<span></span>
</td>
<td class="nump">96,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other liabilities (excluding indirect tax, and employee related payables)</a></td>
<td class="nump">3,870<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities measured at amortized cost</a></td>
<td class="nump">935,512<span></span>
</td>
<td class="nump">953,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">935,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member] | Financial liabilities at fair value, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract', window );"><strong>Financial liabilities by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">174,581<span></span>
</td>
<td class="nump">150,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember', window );">Financial assets at amortised cost, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialAssetsAbstract', window );"><strong>Financial assets by category</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeReceivables', window );">Trade receivables</a></td>
<td class="nump">66,685<span></span>
</td>
<td class="nump">166,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherReceivables', window );">Other receivables (excluding indirect tax receivables)</a></td>
<td class="nump">4,501<span></span>
</td>
<td class="nump">3,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">517,923<span></span>
</td>
<td class="nump">559,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialAssetsAtAmortisedCost', window );">Financial assets measured at amortized cost</a></td>
<td class="nump">&#8364; 589,109<span></span>
</td>
<td class="nump">&#8364; 729,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2024-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose the entity&#8217;s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35H<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35H&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35M<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35M&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35N<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35N&amp;doctype=Standard<br> -URIDate 2024-03-27<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 35I<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_35I&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialAssetsAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph f<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_f&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialAssetsAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as &#8216;an accounting mismatch&#8217;) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity&#8217;s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial assets. [Refer: Financial assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current financial liabilities. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount receivable by the entity that it does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayablesToTradeSuppliers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of payment due to suppliers for goods and services used in the entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayablesToTradeSuppliers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount due from customers for goods and services sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialAssetsAxis=ifrs-full_FinancialAssetsAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Additional Information (Detail)<br> &#8364; / shares in Units, $ / shares in Units, &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 03, 2024 </div>
<div>USD ($) </div>
<div>Multiple</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>EUR (&#8364;) </div>
<div>XBB</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>XBB</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>EUR (&#8364;) </div>
<div>XBB </div>
<div>Multiple</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>XBB </div>
<div>Multiple</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>EUR (&#8364;) </div>
<div>Days </div>
<div>&#8364; / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>EUR (&#8364;) </div>
<div>&#8364; / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 174,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 150,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_SharePriceAppliedForValuation', window );">Share price | &#8364; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 49.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 49.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesSkytrofaMember', window );">Royalty Pharma U.S. Skytrofa [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchange', window );">Funding received in exchange of royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments', window );">Funding received in exchange of royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses', window );">Net proceeds after deduting offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 136,300<span></span>
</td>
<td class="nump">$ 146,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment', window );">Net revenue from sales interest payment in percentage in exchange for funding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="nump">9.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentBeginningPeriod', window );">Royalty payment beginning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan.  01,  2025<span></span>
</td>
<td class="text">Jan.  01,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentEndingPeriod', window );">Royalty payment ending period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2031<span></span>
</td>
<td class="text">Dec. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesSkytrofaMember', window );">Royalty Pharma U.S. Skytrofa [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesSkytrofaMember', window );">Royalty Pharma U.S. Skytrofa [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="nump">1.925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesYorvipathMember', window );">Royalty Pharma U.S. Yorvipath [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchange', window );">Funding received in exchange of royalty payments</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments', window );">Funding received in exchange of royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses', window );">Net proceeds after deduting offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 134,200<span></span>
</td>
<td class="nump">$ 148,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment', window );">Net revenue from sales interest payment in percentage in exchange for funding</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyPaymentEndingPeriod', window );">Royalty payment ending period</a></td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount', window );">Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount | XBB</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesYorvipathMember', window );">Royalty Pharma U.S. Yorvipath [member] | Bottom of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="nump">1.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesYorvipathMember', window );">Royalty Pharma U.S. Yorvipath [member] | Top of range [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease', window );">Multiple of the purchase price were royalty payment will cease | Multiple</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Historical volatility for shares, measurement input [member] | Derivatives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=asnd_SharePriceMeasurementInputMember', window );">Share Price Measurement Input [Member] | Derivatives [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue', window );">Increase decrease in derivative financial liabilities fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 35,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible increase in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities', window );">Percentage of reasonably possible decrease in unobservable input, liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember', window );">Foreign Currency Conversion Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue', window );">Increase decrease in derivative financial liabilities fair value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember', window );">American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionPricePerShare', window );">Conversion price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConversionRatePerNote', window );">Conversion rate per note | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.0118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 575,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsRedemptionPeriod', window );">Borrowings redemption period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">April 7, 2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsConditionForRedemption', window );">Borrowings condition for redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption', window );">Borrowings threshold percentage of sale price per share for redemption</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdTradingDaysForRedemption', window );">Borrowings threshold trading days for redemption | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption', window );">Borrowings threshold consecutive trading days for redemption | Days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures', window );">Proceeds from issue of bonds, notes and debentures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 503,300<span></span>
</td>
<td class="nump">$ 557,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsMaturity', window );">Borrowings, maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">April 1, 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember', window );">Convertible Senior Notes [Member] | American depository shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotionalAmount', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember', window );">Fixed interest rate [member] | Convertible Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsInterestRate', window );">Borrowings Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsConditionForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings condition for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsConditionForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsRedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings redemption period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsRedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings threshold consecutive trading days for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings threshold percentage of sale price per share for redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_BorrowingsThresholdTradingDaysForRedemption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Borrowings Threshold Trading Days For Redemption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_BorrowingsThresholdTradingDaysForRedemption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion price per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConversionRatePerNote">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion rate per note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConversionRatePerNote</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exchange rate for percentage of net sales to royalty payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FundingReceivedInExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received in exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FundingReceivedInExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_FundingReceivedInExchangeOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Funding received in exchange of royalty payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_FundingReceivedInExchangeOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in derivative financial liabilities fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Multiple of purchase price, were royalty payment will cease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from royalty funding liabilities excluding offering expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyPaymentBeginningPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment beginning period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyPaymentBeginningPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyPaymentEndingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty payment ending period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyPaymentEndingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_SharePriceAppliedForValuation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share price applied for valuation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_SharePriceAppliedForValuation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest rate on borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maturity of borrowings. [Refer: Borrowings]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 7<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_7&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal or face amount of a financial instrument, used to calculate payments made on that instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2024-01-01<br> -Paragraph 93<br> -Subparagraph h<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_93_h_ii&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-2022:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of bonds, notes and debentures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesSkytrofaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesSkytrofaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesYorvipathMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=asnd_RoyaltyPharmaUnitedStatesYorvipathMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=ifrs-full_DerivativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=asnd_SharePriceMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=asnd_SharePriceMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_HedgingInstrumentsAxis=asnd_ForeignCurrencyConversionOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=asnd_AmericanDepositorySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfFinancialInstrumentsAxis=asnd_ConvertibleSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfInterestRatesAxis=ifrs-full_FixedInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">&#8364; 174,581<span></span>
</td>
<td class="nump">&#8364; 150,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">174,581<span></span>
</td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">&#8364; 197,291<span></span>
</td>
<td class="nump">&#8364; 143,296<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember', window );">Carrying amount [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities measured at amortized cost</a></td>
<td class="nump">752,909<span></span>
</td>
<td class="nump">763,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">174,581<span></span>
</td>
<td class="nump">150,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember', window );">Carrying amount [member] | Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndDebenturesIssued', window );">Convertible senior notes</a></td>
<td class="nump">449,562<span></span>
</td>
<td class="nump">458,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">303,347<span></span>
</td>
<td class="nump">305,379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">174,581<span></span>
</td>
<td class="nump">150,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost', window );">Financial liabilities measured at amortized cost</a></td>
<td class="nump">741,684<span></span>
</td>
<td class="nump">743,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss', window );">Financial liabilities measured at fair value through profit or loss</a></td>
<td class="nump">174,581<span></span>
</td>
<td class="nump">150,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember', window );">Fair value [member] | Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Disclosure of detailed information about financial instruments [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NotesAndDebenturesIssued', window );">Convertible senior notes</a></td>
<td class="nump">433,666<span></span>
</td>
<td class="nump">438,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">308,018<span></span>
</td>
<td class="nump">305,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Derivative liabilities</a></td>
<td class="nump">&#8364; 174,581<span></span>
</td>
<td class="nump">&#8364; 150,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtAmortisedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_g&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtAmortisedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as &#8216;an accounting mismatch&#8217;) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity&#8217;s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 8<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_8_e&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NotesAndDebenturesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of notes and debentures issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NotesAndDebenturesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=asnd_FairValueHierarchyCarryingAmountMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract', window );"><strong>Reconciliation of changes in fair value measurement, liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Beginning balance</a></td>
<td class="nump">&#8364; 150,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Ending balance</a></td>
<td class="nump">174,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract', window );"><strong>Reconciliation of changes in fair value measurement, liabilities [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Beginning balance</a></td>
<td class="nump">150,670<span></span>
</td>
<td class="nump">&#8364; 143,296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense', window );">Remeasurement recognized in finance (income) or expense</a></td>
<td class="nump">23,911<span></span>
</td>
<td class="nump">53,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DerivativeFinancialLiabilities', window );">Ending balance</a></td>
<td class="nump">&#8364; 174,581<span></span>
</td>
<td class="nump">&#8364; 197,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Assets and Liabilities - Liquidity Risk Management (Detail) - EUR (&#8364;)<br> &#8364; in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">&#8364; 1,031,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">107,986<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">88,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,110,093<span></span>
</td>
<td class="nump">&#8364; 1,103,991<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ContractualUndiscountedCashflowOfFinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,227,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember', window );">Financial liabilities at amortised cost, class [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_ConvertibleSeniorNotes', window );">Convertible senior notes</a></td>
<td class="nump">449,562<span></span>
</td>
<td class="nump">458,207<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_asnd_RoyaltyFundingLiabilities', window );">Royalty funding liabilities</a></td>
<td class="nump">303,347<span></span>
</td>
<td class="nump">305,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">752,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">94,363<span></span>
</td>
<td class="nump">93,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">88,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherFinancialLiabilities', window );">Other liabilities (excluding indirect tax, and employee related payables)</a></td>
<td class="nump">3,870<span></span>
</td>
<td class="nump">&#8364; 311<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">935,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember', window );">Within 1 year [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">39,585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">15,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">88,240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">142,954<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember', window );">Within 1 to 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">991,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">57,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">1,049,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember', window );">After 5 years [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BorrowingsAbstract', window );"><strong>Borrowings [abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Borrowings', window );">Borrowings (excluding lease liabilities)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">35,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherPayables', window );">Trade payables, accrued expenses and other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinancialLiabilities', window );">Total financial liabilities</a></td>
<td class="nump">&#8364; 35,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ContractualUndiscountedCashflowOfFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual undiscounted cashflow of financial liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ContractualUndiscountedCashflowOfFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_ConvertibleSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible senior notes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_ConvertibleSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_asnd_RoyaltyFundingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty funding liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">asnd_RoyaltyFundingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>asnd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Borrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of outstanding funds that the entity is obligated to repay.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Borrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BorrowingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BorrowingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity&#8217;s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity&#8217;s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity&#8217;s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity&#8217;s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity&#8217;s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity&#8217;s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2024-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2024-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph m<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_m&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of trade payables and other payables. [Refer: Trade payables; Other payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2024-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2024-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2024-03-27<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtAmortisedCostMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_NotLaterThanOneYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MaturityAxis=ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>53
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( .>!H5I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( .>!H5I0H=7$\@   "L"   1
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MNIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#
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M"CS<_N\-L,+$CN'MB[\!4$L#!!0    ( .>!H5IIZ._RQ0(  *8(   8
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M%>%94WJ>IS<5'$]9RDI)<MB@U#LYQ6M"-$6QZ2A>F4)TSQ66-=/,\$,"A)Z
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MPA#@=+@%MIAAC)%C[X4[:F(_-<_%$C:Y"&$*ABIMY:-C1X-[AYU^=#9G!;J
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M!@V&1HDBH@.'-JD"Y#@(V9'?&PX2Z/8)=+4)_,H7H$U-5SFSWA2T:=X"ON(
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M_WY%^8SH+L1C'?VC2+/_ 5!+ P04    " #G@:%:GE>8O]D'  #9(0  &
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M;NKF\)F\F:N*OGM<>Z6S"T6?F)V[OG&^-NN^).E[B=I(XZQO.;W59MX/#C8
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M]CPXWO>X[DX+YJC6U:#1$,E2F+H;V]-VEEW4+?S7O1Z$%'W-A88,$X)ZO='
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M7 N@4], O%\J&*^ZH0F:COT7_P=02P,$%     @ YX&A6N5B^OQ^ @  = 4
M !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULC91+<],P$,>_RHZ9Z0GB
M1])2VL0S35L&#NUTV@$.# ?%7L>BLN1*ZZ1\>U:R8\+09KC8>NS^]B']-=\:
M^^AJ1(+G1FFWB&JB]BR.75%C(]S$M*AYIS*V$<13NXY=:U&4P:E1<98D)W$C
MI([R>5B[L_G<=*2DQCL+KFL:87\M49GM(DJCW<*]7-?D%^)\WHHU/B!]:>\L
MS^*14LH&M9-&@\5J$5VD9\N9MP\&7R5NW=X8?"4K8Q[]Y'.YB!*?$"HLR!,$
M_S9XB4IY$*?Q-#"C,:1WW!_OZ!]#[5S+2CB\-.J;+*E>1*<1E%B)3M&]V7["
MH9YCSRN,<N$+V][VY$,$1>?(-(,S9]!(W?_%\]"'/8?3Y!6';'#(0MY]H)#E
ME2"1SZW9@O763/.#4&KPYN2D]H?R0)9W)?M1_M"M'#YUJ FN-_QU\Y@8ZS?C
M8D L>T3V"F(*-T93[>!:EUC^[1]S.F-.V2ZG9780>"/L!*;I6\B2[/@ ;SK6
M. V\Z2N\*^D*95QG$4P%VNAWHOS)K95Z#1B*!E$16KYDK;%AN44K30G?Q<J1
MY9OSXZ6V]%%G+T?U:CISK2AP$;%<'-H-1OG1F_0D.3]0TVRL:7:(_G_G=AAQ
M:P@A38_>G&9I=OX/$&[-KCNUV'#KBJ*S%LNA5U0CRT$)72#TST<IF$>U(!9B
MITJ0NE+,*S#8XD:H3@0E\B'PBD/HM.A*2<PL#-\=[?J1,TIZF$=P*-E )34'
MDD*!(]YH?%:3E[H8[RFA0;L.>G<,[33UHAA7QR?EHE?2'_/^/>);N);:@<**
M79/)^^,(;*_Q?D*F#;I:&6*5AF'-SR):;\#[E>$&#Q,?8'QH\]]02P,$%
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MO$JC962U-*:"U"?>;O1RITL?[J:;/$&_-7Z HK;WK<CD@Q(SI4PGW-8)6^@
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MPY;CXJ>,>!-LR9\/9C8$6_!EAI<!Y8@ S^<6:WA]0PK:[TF3_P!02P,$%
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M"'SEN%=':S">;(1X-IO'=&9[AA#FF&B#P.CO!>\PSPT0T?BSP[1[DT;Q>'U
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M0ED%7%]):?8_-L#A>3;["U!+ P04    " #G@:%:;!MIR\\"  #O!0  &0
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M($W>5ZQ8::$)'#/>/K;URSD8("L;_ $1VLAF&]G'>$*J"&:LSF1=82>#TXZ
M-C:UJ5^=YMMP'*ZONP['RE]7#/JFL9D*AP#PM5UI68C<-LNV->C#O0$&C\97
MW>)W/C@JS 7$?\69(MYI:!>:',W,Q6;=](%-_>N9+KO(VA73F5VZ(T"Q/W%
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MGC\I;P3-BL,)2RH$38K+D&"Y"%()Y.\K2L7+C7*P/04T_Q]02P,$%     @
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M.-ZC_Y&+5V)>L" +%OU%0[F9&6,#A&2%LT@NV>Y/4@IR-5[ (I'_!;O2UC)
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MA(ITS#S*_BL,^2P<7R&9]E_4!]_%'*.BTT;R 6P5<"K"GSP/=3@#),D50#(
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MSPPHYV#/*RG-R7 !QH<K_P=02P,$%     @ YX&A6N>9I>F!!0  .B(  !D
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MK.^RS>]R-R%>V)MF<5[^19OMM;[OH.DZUUFR&VP4)%&Z_1]^VRW$W@!CIWD
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M)?A"D/)0U&@']228]+...];Q(*N^ FF^N0.'\8QWSC7V^G'B#B<^+,_:^V)
M^FZDY8AWXA('81R/^UDF'<ODT!0[Z5+L45R3W=3"$QS$_5S8VSS'WE]+L$>!
MMO9^RZQ1-)[L.TZ\53GP0?GU.!R\@Q-.QEX8[J'Q-S3^D]++%*;GIH(IKG3R
MZ\9$*EVCS!=+>=R+:8UAO,7IG7HXV(.YJ1AX\"T??MS^'[(UC/UMY#VXF]J
MAXO#$]+1TA^&'CP>?5-%\' 9V9.>3PQNV$.H\^$/2'>K$2M!+)IV4Z*4UTS9
MGJQ;[5K:<]O(;;;;?ECC+RB3J("Y%O5.QYI V!;33A2OFK;NCBO=)#;#7+?E
M(,P&_7W.N5I/C(&NT4_^ U!+ P04    " #G@:%:N@X/4-@&  "3,   &0
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MSFI;?AAX@SYM?-)4AB'!8B"P'L.VU<D4R\AQQ(1:0%6B\AS1#5"/:=]Q WO
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M7VZ8*JZB,E"_KSF7/VZJ4^/M_R$L_@=02P,$%     @ YX&A6IDV3?*1$0
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M^F_YL?D K;2@FH5J-JHYJ.:BFH=J/JH%J!92FIK-C9OBZ"\M\JJ]S'KL'9/
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MA_[\^0A./G_RL>=\.07Y!6 )^#'G2ZF=RI&E=+QIJU:8QW:]B0WMB.V>B'.
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MU5]_.6_7I%9E<_1GW>^)^2=02P$"% ,4    " #G@:%:1L=-2)4   #-
M$               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    (
M .>!H5I0H=7$\@   "L"   1              "  <,   !D;V-0<F]P<R]C
M;W)E+GAM;%!+ 0(4 Q0    ( .>!H5J97)PC$ 8  )PG   3
M  "  >0!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ YX&A6FGH
M[_+% @  I@@  !@              ("!)0@  'AL+W=O<FMS:&5E=',O<VAE
M970Q+GAM;%!+ 0(4 Q0    ( .>!H5I?+*:)R08  -(8   8
M  " @2 +  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"% ,4    " #G
M@:%:<DFU "8#  "H"P  &               @($?$@  >&PO=V]R:W-H965T
M<R]S:&5E=#,N>&UL4$L! A0#%     @ YX&A6A9-^L!O!@  K1X  !@
M         ("!>Q4  'AL+W=O<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0
M   ( .>!H5KF' !: 08  )8D   8              " @2 <  !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #G@:%:GE>8O]D'  #9(0
M&               @(%7(@  >&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!
M A0#%     @ YX&A6M.47X4Q!   ) D  !@              ("!9BH  'AL
M+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( .>!H5JO%O^,EP8
M -H1   8              " @<TN  !X;"]W;W)K<VAE971S+W-H965T."YX
M;6Q02P$"% ,4    " #G@:%:NT&@1WP$  !?"P  &               @(&:
M-0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%     @ YX&A6M=(
M#+DN"   KQ,  !D              ("!3#H  'AL+W=O<FMS:&5E=',O<VAE
M970Q,"YX;6Q02P$"% ,4    " #G@:%::4M2L#<&  #E#@  &0
M    @(&Q0@  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+ 0(4 Q0    (
M .>!H5J<FM>THP(   4&   9              " @1])  !X;"]W;W)K<VAE
M971S+W-H965T,3(N>&UL4$L! A0#%     @ YX&A6MC37\TE"   :Q0  !D
M             ("!^4L  'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"
M% ,4    " #G@:%:%M: 7,,"   &!@  &0              @(%55   >&PO
M=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( .>!H5JY6M[7R0(
M .T%   9              " @4]7  !X;"]W;W)K<VAE971S+W-H965T,34N
M>&UL4$L! A0#%     @ YX&A6LY)^Q@S#P  O2\  !D              ("!
M3UH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4    " #G@:%:
MY6+Z_'X"  !T!0  &0              @(&Y:0  >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;%!+ 0(4 Q0    ( .>!H5J2=8Y&I 8  %L2   9
M      " @6YL  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL4$L! A0#%
M  @ YX&A6AI3#-/U P  +0D  !D              ("!27,  'AL+W=O<FMS
M:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #G@:%:DB1#+"0$  "J"0
M&0              @(%U=P  >&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+
M 0(4 Q0    ( .>!H5IL&VG+SP(  .\%   9              " @=![  !X
M;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @ YX&A6CN&'ON\
M!@  :!(  !D              ("!UGX  'AL+W=O<FMS:&5E=',O<VAE970R
M,BYX;6Q02P$"% ,4    " #G@:%:6'OLE_8"   %"@  &0
M@(')A0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( .>!
MH5ILZ18ZR (  .4'   9              " @?:(  !X;"]W;W)K<VAE971S
M+W-H965T,C0N>&UL4$L! A0#%     @ YX&A6O)FT0[K!@  $30  !D
M         ("!]8L  'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"% ,4
M    " #G@:%:XYM[Y&0$  "E%0  &0              @($7DP  >&PO=V]R
M:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .>!H5IVL-S#M (  #4(
M   9              " @;*7  !X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M4$L! A0#%     @ YX&A6HN,7@4; P  20L  !D              ("!G9H
M 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4    " #G@:%:7(EI
M=7<"  ">!0  &0              @('OG0  >&PO=V]R:W-H965T<R]S:&5E
M=#(Y+GAM;%!+ 0(4 Q0    ( .>!H5KD03\_, (  ,0$   9
M  " @9V@  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL4$L! A0#%     @
MYX&A6N>9I>F!!0  .B(  !D              ("!!*,  'AL+W=O<FMS:&5E
M=',O<VAE970S,2YX;6Q02P$"% ,4    " #G@:%:=)UEK$T#  "F"@  &0
M            @(&\J   >&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4
M Q0    ( .>!H5K'AI-DJ 4   ,E   9              " @4"L  !X;"]W
M;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ YX&A6D,W1)O$ @
MS <  !D              ("!'[(  'AL+W=O<FMS:&5E=',O<VAE970S-"YX
M;6Q02P$"% ,4    " #G@:%: M@SL7X#  #T"P  &0              @($:
MM0  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0    ( .>!H5JZ
M#@]0V 8  ),P   9              " @<^X  !X;"]W;W)K<VAE971S+W-H
M965T,S8N>&UL4$L! A0#%     @ YX&A6IDV3?*1$0  2.T  !D
M     ("!WK\  'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q02P$"% ,4
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M  #3%P  #0              @ %3X   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   ( .>!H5J7BKL<P    !,"   +              "  ?3C  !?<F5L<R\N
M<F5L<U!+ 0(4 Q0    ( .>!H5IHP9.8@@,   ,;   /              "
M =WD  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #G@:%:/&'U&HT!  !/
M&   &@              @ &,Z   >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    " #G@:%:F,0A):(!  "F&   $P              @ %1
LZ@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ,  P  <-   D[      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>126</ContextCount>
  <ElementCount>206</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>47</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss</Role>
      <ShortName>Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Financial Position</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition</Role>
      <ShortName>Consolidated Statements of Financial Position</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Cash Flow Statements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements</Role>
      <ShortName>Consolidated Cash Flow Statements</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Disclosure - General Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/GeneralInformation</Role>
      <ShortName>General Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Summary of Material Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies</Role>
      <ShortName>Summary of Material Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Significant Accounting Judgements and Estimates</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/SignificantAccountingJudgementsAndEstimates</Role>
      <ShortName>Significant Accounting Judgements and Estimates</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Significant Events in the Reporting Period</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/SignificantEventsInTheReportingPeriod</Role>
      <ShortName>Significant Events in the Reporting Period</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Share-based Payment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPayment1</Role>
      <ShortName>Share-based Payment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Share Capital</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/ShareCapital</Role>
      <ShortName>Share Capital</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Treasury Shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/TreasuryShares</Role>
      <ShortName>Treasury Shares</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities</Role>
      <ShortName>Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Summary of Material Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Material Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/RevenueTables</Role>
      <ShortName>Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20250331/taxonomy/role/Revenue</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Share-based Payment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentTables</Role>
      <ShortName>Share-based Payment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPayment1</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Treasury Shares (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesTables</Role>
      <ShortName>Treasury Shares (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20250331/taxonomy/role/TreasuryShares</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Summary of Material Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail</Role>
      <ShortName>Significant Accounting Judgements and Estimates - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Significant Events in the Reporting Period - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail</Role>
      <ShortName>Significant Events in the Reporting Period - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail</Role>
      <ShortName>Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail</Role>
      <ShortName>Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Revenue - Schedule of Revenue From Sale of Commercial Products (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail</Role>
      <ShortName>Revenue - Schedule of Revenue From Sale of Commercial Products (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Revenue - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail</Role>
      <ShortName>Revenue - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Segment Information - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail</Role>
      <ShortName>Segment Information - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Share-based Payment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails</Role>
      <ShortName>Share-based Payment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail</Role>
      <ShortName>Share-based Payment - Schedule of Warrant Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Share-based Payment - Summary Of Share Based Payment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail</Role>
      <ShortName>Share-based Payment - Summary Of Share Based Payment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Share Capital - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail</Role>
      <ShortName>Share Capital - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Treasury Shares - Summary of Holding of Treasury Shares (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail</Role>
      <ShortName>Treasury Shares - Summary of Holding of Treasury Shares (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail</Role>
      <ShortName>Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail</Role>
      <ShortName>Financial Assets and Liabilities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail</Role>
      <ShortName>Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail</Role>
      <ShortName>Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="asnd-20250331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Financial Assets and Liabilities - Liquidity Risk Management (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail</Role>
      <ShortName>Financial Assets and Liabilities - Liquidity Risk Management (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="asnd-20250331.htm">asnd-20250331.htm</File>
    <File>asnd-20250331.xsd</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img149481191_0.jpg</File>
    <File>img149481191_1.jpg</File>
    <File>img149481191_2.jpg</File>
    <File>img149481191_3.jpg</File>
    <File>img149481191_4.jpg</File>
    <File>img149481191_5.jpg</File>
    <File>img149481191_6.jpg</File>
    <File>img149481191_7.jpg</File>
    <File>img149481191_8.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="392">https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>59
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "asnd-20250331.htm": {
   "nsprefix": "asnd",
   "nsuri": "http://ascendispharma.com/20250331",
   "dts": {
    "inline": {
     "local": [
      "asnd-20250331.htm"
     ]
    },
    "schema": {
     "local": [
      "asnd-20250331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/rol_full_ifrs-dim_2024-03-27.xsd",
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/full_ifrs-cor_2024-03-27.xsd",
      "https://xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "definitionLink": {
     "remote": [
      "https://xbrl.ifrs.org/taxonomy/2024-03-27/full_ifrs/dimensions/dim_full_ifrs_2024-03-27_role-995000.xml"
     ]
    }
   },
   "keyStandard": 144,
   "keyCustom": 62,
   "axisStandard": 20,
   "axisCustom": 4,
   "memberStandard": 22,
   "memberCustom": 23,
   "hidden": {
    "total": 5,
    "http://xbrl.sec.gov/dei/2024": 5
   },
   "contextCount": 126,
   "entityCount": 1,
   "segmentCount": 47,
   "elementCount": 460,
   "unitCount": 12,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full": 392,
    "http://xbrl.sec.gov/dei/2024": 8
   },
   "report": {
    "R1": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/CoverPage",
     "longName": "100000 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss",
     "longName": "100010 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)",
     "shortName": "Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical",
     "longName": "100020 - Statement - Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)",
     "shortName": "Condensed Consolidated Statements of Profit or (Loss) and Other Comprehensive Income or (Loss) (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:NumberOfWarrantsOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:NumberOfWarrantsOutstanding",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "link:footnote",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
     "longName": "100030 - Statement - Consolidated Statements of Financial Position",
     "shortName": "Consolidated Statements of Financial Position",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:IntangibleAssetsAndGoodwill",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
     "longName": "100040 - Statement - Consolidated Statements of Changes in Equity",
     "shortName": "Consolidated Statements of Changes in Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "C_17a14604-dfe5-4082-bab4-5778ed12841c",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_c4e71d44-6541-42a1-b85a-412e5d5807d3",
      "name": "ifrs-full:Equity",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements",
     "longName": "100050 - Statement - Consolidated Cash Flow Statements",
     "shortName": "Consolidated Cash Flow Statements",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/GeneralInformation",
     "longName": "100060 - Disclosure - General Information",
     "shortName": "General Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies",
     "longName": "100070 - Disclosure - Summary of Material Accounting Policies",
     "shortName": "Summary of Material Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/SignificantAccountingJudgementsAndEstimates",
     "longName": "100080 - Disclosure - Significant Accounting Judgements and Estimates",
     "shortName": "Significant Accounting Judgements and Estimates",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/SignificantEventsInTheReportingPeriod",
     "longName": "100090 - Disclosure - Significant Events in the Reporting Period",
     "shortName": "Significant Events in the Reporting Period",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:SignificantEventsInTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:SignificantEventsInTheReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/Revenue",
     "longName": "100100 - Disclosure - Revenue",
     "shortName": "Revenue",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfRevenueExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/SegmentInformation",
     "longName": "100110 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPayment1",
     "longName": "100120 - Disclosure - Share-based Payment",
     "shortName": "Share-based Payment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/ShareCapital",
     "longName": "100130 - Disclosure - Share Capital",
     "shortName": "Share Capital",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/TreasuryShares",
     "longName": "100140 - Disclosure - Treasury Shares",
     "shortName": "Treasury Shares",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities",
     "longName": "100150 - Disclosure - Financial Assets and Liabilities",
     "shortName": "Financial Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/SubsequentEvents",
     "longName": "100160 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies",
     "longName": "100170 - Disclosure - Summary of Material Accounting Policies (Policies)",
     "shortName": "Summary of Material Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "18",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/RevenueTables",
     "longName": "100180 - Disclosure - Revenue (Tables)",
     "shortName": "Revenue (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentTables",
     "longName": "100190 - Disclosure - Share-based Payment (Tables)",
     "shortName": "Share-based Payment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesTables",
     "longName": "100200 - Disclosure - Treasury Shares (Tables)",
     "shortName": "Treasury Shares (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:DisclosureOfTreasurySharesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables",
     "longName": "100210 - Disclosure - Financial Assets and Liabilities (Tables)",
     "shortName": "Financial Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
     "longName": "100220 - Disclosure - Summary of Material Accounting Policies - Additional Information (Detail)",
     "shortName": "Summary of Material Accounting Policies - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "C_08de1782-376b-48ac-8b33-acaf2bd1c052",
      "name": "ifrs-full:BorrowingsMaturity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail",
     "longName": "100230 - Disclosure - Significant Accounting Judgements and Estimates - Additional Information (Detail)",
     "shortName": "Significant Accounting Judgements and Estimates - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:CurrentProvisions",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R25": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
     "longName": "100240 - Disclosure - Significant Events in the Reporting Period - Additional Information (Detail)",
     "shortName": "Significant Events in the Reporting Period - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "asnd:SignificantEventsInTheReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
     "longName": "100250 - Disclosure - Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)",
     "shortName": "Revenue - Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:RevenueFromRenderingOfServicesAndClinicalSupply",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R27": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
     "longName": "100260 - Disclosure - Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)",
     "shortName": "Revenue - Schedule of Revenue Recognized in Consolidated Statements of Profit or Loss (Parenthetical) (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "parenthetical",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_da6b292e-7c16-4b6b-be4d-1a791f59c406",
      "name": "ifrs-full:Revenue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "div",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
     "longName": "100270 - Disclosure - Revenue - Schedule of Revenue From Sale of Commercial Products (Detail)",
     "shortName": "Revenue - Schedule of Revenue From Sale of Commercial Products (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_6f20e6a7-a161-4a7a-8def-bd1f1b851f84",
      "name": "ifrs-full:RevenueFromSaleOfGoods",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfRevenueToCommercialProductsExplanatory",
       "div",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail",
     "longName": "100280 - Disclosure - Revenue - Additional Information (Detail)",
     "shortName": "Revenue - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "C_d39182d1-57bd-4617-8a6a-98d8b663a8a6",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d39182d1-57bd-4617-8a6a-98d8b663a8a6",
      "name": "ifrs-full:RevenueFromContractsWithCustomers",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfRevenueExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail",
     "longName": "100290 - Disclosure - Segment Information - Additional Information (Detail)",
     "shortName": "Segment Information - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:NumberOfReportableOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_cfea5658-1faf-4539-ad78-6f615eb69073",
      "name": "asnd:NumberOfReportableOperatingSegments",
      "unitRef": "U_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
     "longName": "100300 - Disclosure - Share-based Payment - Additional Information (Details)",
     "shortName": "Share-based Payment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "31",
     "firstAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:ParValuePerShare",
      "unitRef": "U_DkkPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_d979433b-7c92-4bed-ad15-dbb8a17d94f5",
      "name": "ifrs-full:ExercisePriceOfOutstandingShareOptions2019",
      "unitRef": "U_EurPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R32": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
     "longName": "100310 - Disclosure - Share-based Payment - Schedule of Warrant Activity (Detail)",
     "shortName": "Share-based Payment - Schedule of Warrant Activity (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "32",
     "firstAnchor": {
      "contextRef": "C_4ffe96aa-eccd-4c58-806f-aeb003cfacb4",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_4ffe96aa-eccd-4c58-806f-aeb003cfacb4",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail",
     "longName": "100320 - Disclosure - Share-based Payment - Summary Of Share Based Payment (Detail)",
     "shortName": "Share-based Payment - Summary Of Share Based Payment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "C_084e81ae-053b-4124-8ea0-cf00fb92aefd",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_084e81ae-053b-4124-8ea0-cf00fb92aefd",
      "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
      "unitRef": "U_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail",
     "longName": "100330 - Disclosure - Share Capital - Additional Information (Detail)",
     "shortName": "Share Capital - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:NumberOfSharesIssued",
      "unitRef": "U_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail",
     "longName": "100340 - Disclosure - Treasury Shares - Summary of Holding of Treasury Shares (Detail)",
     "shortName": "Treasury Shares - Summary of Holding of Treasury Shares (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "C_8d9f98d0-af51-4f11-9756-1b080f1adc54",
      "name": "asnd:TreasurySharesOfNominalValue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_8d9f98d0-af51-4f11-9756-1b080f1adc54",
      "name": "asnd:TreasurySharesOfNominalValue",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfTreasurySharesExplanatory",
       "div",
       "asnd:DisclosureOfInformationAboutTreasurySharesExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
     "longName": "100350 - Disclosure - Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Detail)",
     "shortName": "Financial Assets and Liabilities - Schedule of Financial Assets and Financial Liabilities (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:FinancialAssets",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
     "longName": "100360 - Disclosure - Financial Assets and Liabilities - Additional Information (Detail)",
     "shortName": "Financial Assets and Liabilities - Additional Information (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "asnd:SharePriceAppliedForValuation",
      "unitRef": "U_EurPerShare",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail",
     "longName": "100370 - Disclosure - Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Detail)",
     "shortName": "Financial Assets and Liabilities - Summary of Fair Value Hierarchy (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_41b6f38d-a596-4e87-b38c-e28360d02d02",
      "name": "ifrs-full:FinancialLiabilitiesAtAmortisedCost",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
     "longName": "100380 - Disclosure - Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Detail)",
     "shortName": "Financial Assets and Liabilities - Movements in Level 3 Fair Value Measurements (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "C_8d9f98d0-af51-4f11-9756-1b080f1adc54",
      "name": "ifrs-full:DerivativeFinancialLiabilities",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
       "div",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "C_a7a008d3-7a3d-4804-83b9-58bcf05b742c",
      "name": "asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
     "longName": "100390 - Disclosure - Financial Assets and Liabilities - Liquidity Risk Management (Detail)",
     "shortName": "Financial Assets and Liabilities - Liquidity Risk Management (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:Borrowings",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_7ebbd176-7e24-4431-8904-088669448bc7",
      "name": "ifrs-full:Borrowings",
      "unitRef": "U_EUR",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock",
       "div",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "asnd-20250331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Adjustments for amortisation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Adjustments for decrease (increase) in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInPrepaidExpenses",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayments",
        "label": "Adjustments for decrease (increase) in prepaid expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the decrease (increase) in prepaid expenses to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Current prepaid expenses; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables",
        "label": "Adjustments for decrease (increase) in trade and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Adjustments for depreciation expense"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of property, plant and equipment",
        "label": "Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for impairment loss (reversal of impairment loss) on property, plant and equipment recognised in profit or loss to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Adjustments for impairment loss (reversal of impairment loss) recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total adjustments for increase (decrease) in deferred income including contract liabilities",
        "label": "Adjustments for increase (decrease) in deferred income including contract liabilities",
        "terseLabel": "Contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for the increase (decrease) in deferred income including contract liabilities to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Deferred income including contract liabilities; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r214"
     ]
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade and other payables",
        "terseLabel": "Trade payables, accrued expenses and other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r216"
     ]
    },
    "asnd_AdjustmentsForNonCashConsiderationRegardingRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "AdjustmentsForNonCashConsiderationRegardingRevenue",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments For Non Cash Consideration Regarding Revenue",
        "documentation": "Adjustments for non cash consideration regarding revenue.",
        "negatedLabel": "Non-cash consideration relating to revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForProvisions",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for provisions",
        "terseLabel": "Provisions"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments for non-cash items:",
        "label": "Adjustments to reconcile profit (loss) [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share Based Compensation Expense",
        "terseLabel": "Share-based payment",
        "label": "Adjustments for share-based payments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r215"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmericanDepositorySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "AmericanDepositorySharesMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "American depository shares [member]",
        "documentation": "American depository shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount",
        "label": "Amount Multiplied to Purchase Price Minus Revenue Interest Payments Paid to Purchaser on Effective Date of Buy-out Notice As Buyout Amount",
        "documentation": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice as buyout amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount",
        "documentation": "Amount multiplied to purchase price minus revenue interest payments paid to purchaser on effective date of buy-out notice provided on or prior to period as buyout amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Not Included In Diluted Earnings Per Share [Axis]",
        "documentation": "Antidilutive securities not included in diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Not Included In Diluted Earnings Per Share [Member]",
        "documentation": "Antidilutive securities not Included In diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "srt_AsiaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "AsiaMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Asia [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "periodStartLabel": "Assets at beginning of period",
        "periodEndLabel": "Assets at end of period",
        "label": "Assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r94",
      "r95",
      "r97",
      "r150",
      "r154"
     ]
    },
    "ifrs-full_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value [member]",
        "label": "At fair value [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r83",
      "r94"
     ]
    },
    "ifrs-full_BalancesWithBanks": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BalancesWithBanks",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balances with banks",
        "terseLabel": "Bank deposits"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash balances held at banks."
       }
      }
     },
     "auth_ref": [
      "r218"
     ]
    },
    "asnd_BasicAndDilutedEarningsLossPerShares": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "BasicAndDilutedEarningsLossPerShares",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic and diluted earnings / (loss) per share",
        "label": "Basic And Diluted Earnings Loss Per Shares",
        "documentation": "Basic And Diluted Earnings Loss Per Shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic earnings (loss) per share",
        "totalLabel": "Total basic earnings (loss) per share",
        "terseLabel": "Basic earnings/(loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "asnd_BoardMembersOfGroupMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "BoardMembersOfGroupMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Board members of group.",
        "label": "Board members of group [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Borrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Borrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings",
        "totalLabel": "Total borrowings",
        "terseLabel": "Borrowings (excluding lease liabilities)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of outstanding funds that the entity is obligated to repay."
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_BorrowingsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Borrowings [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsConditionForRedemption": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "BorrowingsConditionForRedemption",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings condition for redemption",
        "label": "Borrowings Condition For Redemption",
        "documentation": "Borrowings condition for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsInArrearsDefaultPaymentStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "BorrowingsInArrearsDefaultPaymentStartDate",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings in arrears default payment start date",
        "label": "Borrowings In Arrears Default Payment Start Date",
        "documentation": "Borrowings in arrears default payment start date."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BorrowingsInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsInterestRate",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings Interest Rate",
        "label": "Borrowings, interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "The interest rate on borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ifrs-full_BorrowingsMaturity": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BorrowingsMaturity",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Borrowings, maturity"
       }
      },
      "en": {
       "role": {
        "documentation": "The maturity of borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "asnd_BorrowingsRedemptionPeriod": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "BorrowingsRedemptionPeriod",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings redemption period",
        "label": "Borrowings Redemption Period",
        "documentation": "Borrowings redemption period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdConsecutiveTradingDaysForRedemption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "BorrowingsThresholdConsecutiveTradingDaysForRedemption",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold consecutive trading days for redemption",
        "label": "Borrowings Threshold Consecutive Trading Days For Redemption",
        "documentation": "Borrowings threshold consecutive trading days for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdPercentageOfSalePricePerShareForRedemption": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "BorrowingsThresholdPercentageOfSalePricePerShareForRedemption",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold percentage of sale price per share for redemption",
        "label": "Borrowings Threshold Percentage Of Sale Price Per Share For Redemption",
        "documentation": "Borrowings threshold percentage of sale price per share for redemption."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_BorrowingsThresholdTradingDaysForRedemption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "BorrowingsThresholdTradingDaysForRedemption",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings threshold trading days for redemption",
        "label": "Borrowings Threshold Trading Days For Redemption",
        "documentation": "Borrowings Threshold Trading Days For Redemption."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Bottom of range [member]",
        "terseLabel": "Bottom of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r99",
      "r110",
      "r119",
      "r185",
      "r187",
      "r223"
     ]
    },
    "country_CN": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "CN",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "China [member]",
        "label": "CHINA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents",
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents at January 1",
        "periodEndLabel": "Cash and cash equivalents at March 31"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r74",
      "r90"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) financing activities",
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Cash flows from/(used in) financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r75"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financing activities",
        "label": "Cash flows from (used in) financing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) investing activities",
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Cash flows from/(used in) investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents, from continuing and discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r75"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investing activities",
        "label": "Cash flows from (used in) investing activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) operating activities",
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Cash flows from/(used in) operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities, from continuing and discontinued operations. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r68",
      "r75"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating activities",
        "label": "Cash flows from (used in) operating activities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CashFlowsFromUsedInOperations",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net cash flows from (used in) operations",
        "label": "Cash flows from (used in) operations",
        "totalLabel": "Cash flows generated from/(used in) operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash from (used in) the entity's operations."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181"
     ]
    },
    "ifrs-full_CategoriesOfFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial assets by category",
        "label": "Categories of financial assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities by category",
        "label": "Categories of financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Categories of financial liabilities [axis]",
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ifrs-full_CategoriesOfNoncurrentFinancialAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfNoncurrentFinancialAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of non-current financial assets [abstract]",
        "terseLabel": "Classified in the statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfNoncurrentFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfNoncurrentFinancialLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of non-current financial liabilities [abstract]",
        "terseLabel": "Classified in the statement of financial position"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "asnd_ChangesInWorkingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ChangesInWorkingCapitalAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in working capital:",
        "label": "Changes in working capital [abstract]",
        "documentation": "Changes in working capital."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ClassesOfFinancialAssetsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r138",
      "r139",
      "r161",
      "r162"
     ]
    },
    "ifrs-full_ClassesOfFinancialAssetsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialAssetsDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial assets [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r116",
      "r138",
      "r139",
      "r161",
      "r162"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r133",
      "r134",
      "r135"
     ]
    },
    "ifrs-full_ClassesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r131",
      "r133",
      "r134",
      "r135"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r161",
      "r162"
     ]
    },
    "ifrs-full_ClassesOfFinancialLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfFinancialLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of financial liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated classes financial liabilities. It also represents the standard value for the 'Classes of financial liabilities' axis if no other member is used. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r138",
      "r139",
      "r161",
      "r162"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfLiabilitiesDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ifrs-full_ClassesOfOtherProvisionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfOtherProvisionsDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ClassesOfShareCapitalDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "asnd_ClassificationOfRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ClassificationOfRelatedPartyAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification Of Related Party [Axis]",
        "label": "Classification Of Related Party [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ClassificationOfRelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ClassificationOfRelatedPartyDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification Of Related Party [Domain]",
        "label": "Classification Of Related Party [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CollaborationPartnersAndLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "CollaborationPartnersAndLicenseAgreementsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration partners and license agreements [Member]",
        "label": "Collaboration partners and license agreements [Member]",
        "documentation": "Collaboration Partners and License Agreements."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CollaborationsAndLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "CollaborationsAndLicenseAgreementsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborations and license agreements [Member]",
        "label": "Collaborations And License Agreements [Member]",
        "documentation": "Collaborations and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_CommercialCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "CommercialCustomersMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commercial customers [Member]",
        "documentation": "Commercial Customers.",
        "terseLabel": "Commercial customers [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of equity [axis]",
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComponentsOfEquityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfEquityDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComponentsOfOtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTaxAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Items that may be reclassified subsequently to profit or (loss):",
        "label": "Components of other comprehensive income that will be reclassified to profit or loss, net of tax [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComprehensiveIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncome",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive income",
        "totalLabel": "Total comprehensive income/(loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r32",
      "r79",
      "r81",
      "r88",
      "r182"
     ]
    },
    "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ComprehensiveIncomeAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Attributable to owners of the Company",
        "label": "Comprehensive income, attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r34"
     ]
    },
    "srt_CondensedIncomeStatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statement [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CondensedIncomeStatementsCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CondensedIncomeStatementsCaptionsLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Income Statements, Captions [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ContractualUndiscountedCashflowOfConvertibleSeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible senior notes",
        "label": "Contractual Undiscounted Cashflow Of Convertible Senior Notes",
        "documentation": "Convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ContractualUndiscountedCashflowOfFinancialBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Contractual Undiscounted Cashflow Of Financial Borrowings",
        "documentation": "Contractual undiscounted cashflow of financial borrowings."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ContractualUndiscountedCashflowOfFinancialLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Contractual Undiscounted Cashflow Of Financial Lease Liabilities",
        "documentation": "Contractual undiscounted cashflow of Financial lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ContractualUndiscountedCashflowOfFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Contractual Undiscounted Cashflow Of Financial Liabilities",
        "documentation": "Contractual undiscounted cashflow of financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ContractualUndiscountedCashflowOfRoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty funding liabilities",
        "label": "Contractual Undiscounted Cashflow of Royalty Funding Liabilities",
        "documentation": "Contractual undiscounted cashflow of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ContractualUndiscountedCashflowOfTradePayablesAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables",
        "label": "Contractual Undiscounted Cashflow Of Trade Payables And Other Payables",
        "documentation": "Contractual undiscounted cashflow of trade payables and other payables."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConversionPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ConversionPricePerShare",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion price per share",
        "label": "Conversion Price Per Share",
        "documentation": "Conversion price per share."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConversionRatePerNote": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ConversionRatePerNote",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion rate per note",
        "label": "Conversion Rate Per Note",
        "documentation": "Conversion rate per note."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleDebtCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ConvertibleDebtCurrentAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt current abstract.",
        "label": "Convertible Debt Current [Abstract]",
        "terseLabel": "Convertible notes, matures in April 2028"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleNotesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ConvertibleNotesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible notes current.",
        "label": "Convertible Notes Current",
        "terseLabel": "Convertible notes current",
        "totalLabel": "Convertible notes current"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleSeniorNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ConvertibleSeniorNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible Senior Notes",
        "terseLabel": "Convertible senior notes",
        "label": "Convertible Senior Notes",
        "documentation": "Convertible senior notes."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ConvertibleSeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ConvertibleSeniorNotesMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Senior Notes [Member]",
        "documentation": "Convertible senior notes [Member]."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of sales",
        "terseLabel": "Cost of sales",
        "label": "Cost of sales"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r41"
     ]
    },
    "asnd_CostsOfCapitalIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "CostsOfCapitalIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cost of capital increase",
        "label": "Costs of capital increase (decrease)",
        "documentation": "Costs of capital increase (decrease)."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "ifrs-full_CounterpartiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CounterpartiesDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r84",
      "r182"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets",
        "label": "Current assets [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current contract liabilities",
        "terseLabel": "Contract liabilities",
        "label": "Current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "asnd_ConvertibleNotesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "terseLabel": "Derivative liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_CurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "totalLabel": "Total current financial assets",
        "label": "Current financial assets",
        "terseLabel": "Current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_CurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current financial liabilities",
        "label": "Current financial liabilities",
        "terseLabel": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current lease liabilities",
        "terseLabel": "Current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "negatedLabel": "Current liabilities",
        "label": "Current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r86",
      "r182"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities",
        "label": "Current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentPrepayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentPrepayments",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current prepayments",
        "terseLabel": "Prepayments",
        "label": "Current prepayments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current prepayments. [Refer: Prepayments]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_CurrentProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentProvisions",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "totalLabel": "Total current provisions",
        "terseLabel": "Provisions",
        "label": "Current provisions",
        "periodStartLabel": "Beginning balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "ifrs-full_CurrentTaxAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax receivables",
        "label": "Current tax assets, current"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of current tax assets. [Refer: Current tax assets]"
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_CurrentTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current tax liabilities",
        "terseLabel": "Income tax payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current tax for current and prior periods to the extent unpaid. Current tax is the amount of income taxes payable (recoverable) in respect of the taxable profit (tax loss) for a period."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "ifrs-full_CurrentTradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "CurrentTradeReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade receivables",
        "label": "Current trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables. [Refer: Trade receivables]"
       }
      }
     },
     "auth_ref": [
      "r167",
      "r169"
     ]
    },
    "country_DK": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "DK",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "DENMARK",
        "terseLabel": "Denmark [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities",
        "terseLabel": "Deferred tax liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r17",
      "r47"
     ]
    },
    "ifrs-full_DerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Derivative liabilities",
        "label": "Derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities classified as derivative instruments. [Refer: Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Liabilities at Fair Value Remeasurement Recognized in Financial Income Or Expense",
        "documentation": "Derivative financial liabilities at fair value remeasurement recognized in financial income or expense.",
        "terseLabel": "Remeasurement recognized in finance (income) or expense"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueSettled": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueSettled",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Liabilities at Fair Value Settled",
        "terseLabel": "Settled",
        "documentation": "Derivative financial liabilities at fair value settled."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DerivativeFinancialLiabilitiesAtFairValueTransfered": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DerivativeFinancialLiabilitiesAtFairValueTransfered",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transfered",
        "label": "Derivative Financial Liabilities at Fair Value Transfered",
        "documentation": "Derivative financial liabilities at fair value transfered."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DerivativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DerivativesMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivatives [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for financial instruments or other contracts within the scope of IFRS 9 with all three of the following characteristics: (a) Their value changes in response to the change in a specified interest rate, financial instrument price, commodity price, foreign exchange rate, index of prices or rates, credit rating or credit index, or other variable, provided in the case of a non-financial variable that the variable is not specific to a party to the contract (sometimes called the \u2018underlying\u2019); (b) They require no initial net investment or an initial net investment that is smaller than would be required for other types of contracts that would be expected to have a similar response to changes in market factors; (c) They are settled at a future date. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r183",
      "r186",
      "r194",
      "r200"
     ]
    },
    "asnd_DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DescriptionOfAccountingPolicyForConvertibleNotesAndDerivativeLiabilitiesPolicyTextBlock",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible Senior Notes and Derivative Liabilities",
        "label": "Description Of Accounting Policy For Convertible Notes And Derivative Liabilities [Policy Text Block]",
        "documentation": "Description of accounting policy for convertible notes and derivative liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfInitialApplicationOfStandardsOrInterpretations": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfInitialApplicationOfStandardsOrInterpretations",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of initial application of standards or interpretations [text block]",
        "verboseLabel": "New and Amended Standards and Interpretations",
        "terseLabel": "New and Amended IFRS Accounting Standards and Interpretations"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the initial application of an IFRS. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Description of vesting requirements for share-based payment arrangement",
        "terseLabel": "Description of vesting"
       }
      },
      "en": {
       "role": {
        "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Types of share-based payment arrangements [domain]]"
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted earnings (loss) per share",
        "totalLabel": "Total diluted earnings (loss) per share",
        "terseLabel": "Diluted earnings/(loss) per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59"
     ]
    },
    "asnd_DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureDetailedInformationAboutMarketableSecuritiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Marketable securities",
        "label": "Disclosure Detailed Information About Marketable Securities [Text Block]",
        "documentation": "Disclosure detailed information about marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/SignificantAccountingJudgementsAndEstimates"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Accounting Judgements and Estimates",
        "label": "Disclosure of accounting judgements and estimates [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Preparation",
        "label": "Disclosure of basis of preparation of financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfChangesInAccountingEstimatesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfChangesInAccountingEstimatesTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of changes in accounting estimates [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the changes in accounting estimates."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "asnd_DisclosureOfEmployeeCompensationCostsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfEmployeeCompensationCostsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of employee compensation costs [abstract]",
        "documentation": "Disclosure of employees compensation costs."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Disclosure of entity's operating segments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r160"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Disclosure of events after reporting period [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFairValueMeasurementOfLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFairValueMeasurementOfLiabilitiesTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of fair value measurement of liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "asnd_DisclosureOfFinancialAssetsAndLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfFinancialAssetsAndLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Financial Assets And Liabilities [text block]",
        "documentation": "Disclosure Of Financial Assets And Liabilities [text block]",
        "terseLabel": "Schedule of Financial Assets and Financial Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Assets and Liabilities",
        "label": "Disclosure of financial instruments [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r147"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [line items]",
        "label": "Disclosure of detailed information about financial instruments [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of detailed information about financial instruments [table]",
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r133",
      "r140"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/GeneralInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Information",
        "label": "Disclosure of general information about financial statements [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "asnd_DisclosureOfGeneralInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfGeneralInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of general information.",
        "label": "Disclosure of General Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfGeographicalAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfGeographicalAreasAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from external customers (geographical)",
        "label": "Disclosure of geographical areas [abstract]",
        "verboseLabel": "Revenue (geographical)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfHoldingOfTreasurySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Abstract]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfHoldingOfTreasurySharesLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Line Items]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfHoldingOfTreasurySharesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfHoldingOfTreasurySharesTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Holding Of Treasury Shares [Table]",
        "documentation": "Disclosure of holding of treasury shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfInformationAboutTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfInformationAboutTreasurySharesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasuryShares"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Shares",
        "label": "Disclosure Of Information About Treasury Shares Explanatory",
        "documentation": "Disclosure of information about treasury shares explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of maturity analysis for derivative financial liabilities [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "asnd_DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movements in Level 3 Fair Value Measurements",
        "label": "Disclosure of Movements in Level Three Fair Value Measurements [Table Text Block]",
        "documentation": "Disclosure of movements in level 3 fair value measurements."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]",
        "verboseLabel": "Summary of Weighted Average Exercise Prices and Movements in Warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [line items]",
        "label": "Disclosure of operating segments [line items]",
        "verboseLabel": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of operating segments [table]",
        "label": "Disclosure of operating segments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to operating segments."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ifrs-full_DisclosureOfPerformanceObligationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfPerformanceObligationsLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of performance obligations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfReclassificationsOrChangesInPresentationExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfReclassificationsOrChangesInPresentationExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change to Presentation of Borrowings",
        "label": "Disclosure of reclassifications or changes in presentation [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of reclassifications or changes in the presentation of items in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ifrs-full_DisclosureOfRevenueExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfRevenueExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/Revenue"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Disclosure of revenue [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue."
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "asnd_DisclosureOfRevenueToCommercialCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfRevenueToCommercialCustomersExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of Revenue to Commercial Customers Explanatory",
        "documentation": "Disclosure of revenue to commercial customers explanatory.",
        "terseLabel": "Schedule of Revenue Attributable to Commercial Products"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfRevenueToCommercialProductsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfRevenueToCommercialProductsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue From Sale of Commercial Products",
        "label": "Disclosure Of Revenue To Commercial Products Explanatory",
        "documentation": "Disclosure of revenue to commercial products explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfRoyaltyFundingLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfRoyaltyFundingLiabilitiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Funding Liabilities",
        "label": "Disclosure Of Royalty Funding Liabilities Explanatory",
        "documentation": "Disclosure of royalty funding liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of segment revenues by destination of major customers explanatory.",
        "label": "Disclosure of segment revenues by destination of major customers explanatory",
        "terseLabel": "Schedule of Revenue Recognized in Unaudited Condensed Consolidated Interim Statements of Profit or Loss"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapital"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Capital",
        "label": "Disclosure of share capital, reserves and other equity interest [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share capital, reserves and other equity interest."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPayment1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "Share-based Payment"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "asnd_DisclosureOfSummaryOfFairValueHierarchyTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfSummaryOfFairValueHierarchyTableTextBlock",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Fair Value Hierarchy",
        "label": "Disclosure of Summary of Fair Value Hierarchy [Table Text Block]",
        "documentation": "Disclosure of summary of fair value hierarchy."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of summary of significant accounting policies [abstract]",
        "documentation": "Disclosure of summary of significant accounting policies [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of summary of significant accounting policies [line items]",
        "label": "Disclosure Of Summary Of Significant Accounting Policies [line items]",
        "documentation": "Line items representing the disclosure of summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of summary of significant accounting policies [table]",
        "label": "Disclosure of summary of significant accounting policies [table]",
        "documentation": "Disclosure of summary of significant accounting policies [table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Disclosure Of Summary Of Significant Accounting Policy Explanatory",
        "documentation": "Disclosure of summary of significant accounting policy.",
        "verboseLabel": "Summary of Material Accounting Policies"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]",
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of transactions between related parties [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to transactions between related parties."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "asnd_DisclosureOfTreasurySharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfTreasurySharesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of treasury shares.",
        "label": "Disclosure of treasury shares [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTreasurySharesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfTreasurySharesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Holding of Treasury Shares",
        "label": "Disclosure of treasury shares [text block]"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r204"
     ]
    },
    "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of voluntary change in accounting policy [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DisclosureOfWarrantActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DisclosureOfWarrantActivityLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure Of Warrant Activity [line items]",
        "label": "Disclosure Of Warrant Activity [line items]",
        "documentation": "Disclosure Of Warrant Activity [line items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_DistributableEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "DistributableEquity",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributable equity",
        "label": "Distributable equity",
        "documentation": "Distributable equity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on balances held in foreign currencies",
        "label": "Effect of exchange rate changes on cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r70",
      "r71"
     ]
    },
    "asnd_EmployeesAndConsultantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "EmployeesAndConsultantsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employees and consultants.",
        "label": "Employees and Consultants [Member]",
        "terseLabel": "Employees and consultants [member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r203"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Balance of equity",
        "terseLabel": "Balance of equity",
        "totalLabel": "Total equity",
        "periodStartLabel": "Equity",
        "periodEndLabel": "Equity",
        "label": "Equity",
        "verboseLabel": "Equity"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r24",
      "r78",
      "r80",
      "r94",
      "r95",
      "r97"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity and liabilities",
        "label": "Equity and liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_EquityAndLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "EquityAndLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity and liabilities",
        "label": "Equity and liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_EventsAfterReportingPeriodMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "EventsAfterReportingPeriodMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Events After Reporting Period [Member]",
        "documentation": "Events after reporting period.",
        "terseLabel": "Events After Reporting Period [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExchangeRateForPercentageOfNetSalesToRoyaltyPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ExchangeRateForPercentageOfNetSalesToRoyaltyPayment",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate for percentage of net sales to royalty payment.",
        "label": "Exchange Rate For Percentage Of Net Sales To Royalty Payment",
        "terseLabel": "Net revenue from sales interest payment in percentage in exchange for funding"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ExchangeRateForPercentageOfRevenueToRoyaltyPayment": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ExchangeRateForPercentageOfRevenueToRoyaltyPayment",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate for percentage of revenue to royalty payment.",
        "label": "Revenue interest payment in percentage in exchange for funding",
        "terseLabel": "Revenue interest payment in percentage in exchange for funding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ExercisePriceOfOutstandingShareOptions2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExercisePriceOfOutstandingShareOptions2019",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price of outstanding share options"
       }
      },
      "en": {
       "role": {
        "documentation": "The exercise price of outstanding share options."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share based compensation costs",
        "label": "Expense from share-based payment transactions with employees"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "asnd_FairValueHierarchyCarryingAmountMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "FairValueHierarchyCarryingAmountMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount [member]",
        "label": "Fair Value Hierarchy Carrying Amount [member]",
        "documentation": "Fair value hierarchy carrying amount."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FairValueOfConvertibleNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "FairValueOfConvertibleNotes",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value of Convertible Notes",
        "label": "Fair Value of Convertible Notes",
        "documentation": "Fair value of convertible notes."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": -1.0,
       "order": 2.0
      },
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance costs",
        "verboseLabel": "Finance expenses",
        "terseLabel": "Reversal of finance expenses",
        "label": "Finance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_FinanceCostsPaidClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceCostsPaidClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Finance expenses paid",
        "label": "Finance costs paid, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for finance costs paid, classified as operating activities. [Refer: Finance costs]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Reversal of finance income",
        "terseLabel": "Finance income",
        "label": "Finance income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_FinanceIncomeReceivedClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinanceIncomeReceivedClassifiedAsOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finance income received",
        "label": "Finance income received, classified as operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from finance income received, classified as operating activities. [Refer: Finance income]"
       }
      }
     },
     "auth_ref": [
      "r217"
     ]
    },
    "ifrs-full_FinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "terseLabel": "Financial assets",
        "periodStartLabel": "Financial assets at beginning of period",
        "periodEndLabel": "Financial assets at end of period",
        "label": "Financial assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Classes of financial instruments [domain]; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r127",
      "r131",
      "r132",
      "r134",
      "r193"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCost",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial assets measured at amortized cost",
        "label": "Financial assets at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial assets at amortised cost. The amortised cost is the amount at which financial assets are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount, and adjusted for any impairment. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "ifrs-full_FinancialAssetsAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialAssetsAtAmortisedCostMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial assets at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial assets measured at amortised cost class. [Refer: Financial assets at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_FinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities",
        "label": "Financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Classes of financial instruments [domain]; Financial assets; Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCost",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Financial liabilities at amortised cost, Total",
        "terseLabel": "Financial liabilities measured at amortized cost",
        "label": "Financial liabilities at amortised cost"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities at amortised cost. The amortised cost is the amount at which financial liabilities are measured at initial recognition minus principal repayments, plus or minus the cumulative amortisation using the effective interest method of any difference between that initial amount and the maturity amount. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtAmortisedCostMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtAmortisedCostMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial liabilities at amortised cost, class [member]",
        "label": "Financial liabilities at amortised cost, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at amortised cost class. [Refer: Financial liabilities at amortised cost]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value, class [member]",
        "terseLabel": "Financial liabilities at fair value, class [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities measured at fair value class. [Refer: Financial liabilities; At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r145"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLoss",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial liabilities at fair value through profit or loss",
        "terseLabel": "Financial liabilities measured at fair value through profit or loss",
        "label": "Financial liabilities at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that meet either of the following conditions: (a) they meet the definition of held for trading; or (b) upon initial recognition they are designated by the entity as at fair value through profit or loss. An entity may use this designation only when permitted by paragraph 4.3.5 of IFRS 9 (embedded derivatives) or when doing so results in more relevant information, because either: (a) it eliminates or significantly reduces a measurement or recognition inconsistency (sometimes referred to as \u2018an accounting mismatch\u2019) that would otherwise arise from measuring assets or liabilities or recognising the gains and losses on them on different bases; or (b) a group of financial liabilities or financial assets and financial liabilities is managed and its performance is evaluated on a fair value basis, in accordance with a documented risk management or investment strategy, and information about the group is provided internally on that basis to the entity\u2019s key management personnel (as defined in IAS 24). [Refer: At fair value [member]; Key management personnel of entity or parent [member]; Derivatives [member]; Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossCategoryMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss, category [member]",
        "terseLabel": "Financial liabilities measured at fair value through profit or loss [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss category. [Refer: Financial liabilities at fair value through profit or loss]"
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ifrs-full_FixedInterestRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "FixedInterestRateMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed interest rate [Member]",
        "label": "Fixed interest rate [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "asnd_ForeignCurrencyConversionOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ForeignCurrencyConversionOptionMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Conversion Option [Member]",
        "documentation": "Foreign Currency Conversion Option."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FundingReceivedInExchange": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "FundingReceivedInExchange",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funding received",
        "verboseLabel": "Funding received in exchange of royalty payments",
        "documentation": "Funding received in exchange.",
        "terseLabel": "Funding received in exchange"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_FundingReceivedInExchangeOfRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "FundingReceivedInExchangeOfRoyaltyPayments",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Funding received in exchange of royalty payments",
        "documentation": "Funding received in exchange of royalty payments.",
        "terseLabel": "Funding received in exchange of royalty payments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net gains (losses) on change in fair value of derivatives",
        "terseLabel": "Gains (losses) on change in fair value of derivatives",
        "label": "Gains (losses) on change in fair value of derivatives"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) resulting from change in the fair value of derivatives recognised in profit or loss. [Refer: Derivatives [member]]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_GainsLossesOnDisposalsOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GainsLossesOnDisposalsOfPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net gains (losses) on disposals of property, plant and equipment",
        "label": "Gains (losses) on disposals of property, plant and equipment",
        "negatedLabel": "Reversal of (gain)/loss on disposal of property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) on disposals of property, plant and equipment. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ifrs-full_GeographicalAreasAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical areas [axis]",
        "label": "Geographical areas [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r173",
      "r188",
      "r191"
     ]
    },
    "ifrs-full_GeographicalAreasDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GeographicalAreasDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical areas [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated geographical areas. It also represents the standard value for the 'Geographical areas' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r173",
      "r188",
      "r191"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredAtPointInTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredAtPointInTimeMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred at point in time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers at a point in time. [Refer: Performance obligations satisfied at point in time [member]]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_GoodsOrServicesTransferredOverTimeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GoodsOrServicesTransferredOverTimeMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goods or services transferred over time [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for goods or services transferred to customers over time. [Refer: Performance obligations satisfied over time [member]]"
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Gross profit",
        "label": "Gross profit",
        "totalLabel": "Gross profit"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r165"
     ]
    },
    "ifrs-full_HedgingInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HedgingInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r126"
     ]
    },
    "ifrs-full_HedgingInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HedgingInstrumentsDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Hedging instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for hedging instruments. A hedging instrument can be a designated: (a) derivative measured at fair value through profit or loss, except for some written options (see paragraph B6.2.4 of IFRS 9); (b) non-derivative financial asset or non-derivative financial liability measured at fair value through profit or loss, unless it is a financial liability designated as at fair value through profit or loss for which the amount of its change in fair value that is attributable to changes in the credit risk of that liability is presented in other comprehensive income in accordance with paragraph 5.7.7 of IFRS 9. For a hedge of foreign currency risk, the foreign currency risk component of a non-derivative financial asset or a non-derivative financial liability may be designated as a hedging instrument provided that it is not an investment in an equity instrument for which an entity has elected to present changes in fair value in other comprehensive income in accordance with paragraph 5.7.5 of IFRS 9. This member also represents the standard value for the 'Hedging instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r126"
     ]
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Historical volatility for shares, measurement input [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r184"
     ]
    },
    "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charge",
        "label": "Impairment loss recognised in profit or loss, property, plant and equipment",
        "negatedLabel": "Impairment loss recognised in profit or loss, property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r39",
      "r48"
     ]
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit or loss [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncomeStatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "IncomeStatementAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement [Axis].",
        "label": "Income Statement [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncomeStatementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "IncomeStatementMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income statement.",
        "label": "Income Statement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeTaxExpenseContinuingOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxExpenseContinuingOperations",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 0.0
      },
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax income (expense)",
        "totalLabel": "Total tax expense (income)",
        "label": "Tax expense (income)",
        "negatedLabel": "Income taxes (expenses)",
        "terseLabel": "Reversal of income taxes"
       }
      },
      "en": {
       "role": {
        "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]"
       }
      }
     },
     "auth_ref": [
      "r37",
      "r44",
      "r45",
      "r46",
      "r54",
      "r92",
      "r149"
     ]
    },
    "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Income taxes refund (paid)",
        "label": "Income taxes paid (refund), classified as operating activities",
        "negatedLabel": "Income taxes received/(paid)"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]"
       }
      }
     },
     "auth_ref": [
      "r72",
      "r176"
     ]
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "Increase/(decrease) in cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "asnd_IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additions",
        "terseLabel": "Increase decrease in derivative financial liabilities fair value",
        "label": "Increase Decrease In Derivative Financial Liabilities Fair Value",
        "documentation": "Increase decrease in derivative financial liabilities fair value."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInNumberOfOrdinarySharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseInNumberOfOrdinarySharesIssued",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in share capital",
        "label": "Increase (decrease) in number of ordinary shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the number of ordinary shares issued. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "asnd_IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease In treasury shares acquired from third parties.",
        "label": "Increase Decrease In Treasury Shares Acquired From Third Parties",
        "verboseLabel": "Acquired from third-parties (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in treasury shares transferred under stock incentive program.",
        "label": "Increase Decrease In Treasury Shares Transferred Under Stock Incentive Program",
        "terseLabel": "Transferred under stock incentive programs (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based payment (Note 7)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTransactionsWithOwners": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IncreaseDecreaseThroughTransactionsWithOwners",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through transactions with owners, equity",
        "terseLabel": "Capital increase (Note 8)"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from transactions with owners."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_IntangibleAssetsAndGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IntangibleAssetsAndGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total intangible assets and goodwill",
        "periodEndLabel": "Intangible assets and goodwill at end of period",
        "periodStartLabel": "Intangible assets and goodwill at beginning of period",
        "label": "Intangible assets and goodwill",
        "terseLabel": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current inventories",
        "terseLabel": "Inventories",
        "label": "Current inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r51",
      "r167"
     ]
    },
    "ifrs-full_InvestmentAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentAccountedForUsingEquityMethod",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying amount of equity method investment",
        "label": "Investments accounted for using equity method",
        "totalLabel": "Total investments accounted for using equity method"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r93",
      "r151"
     ]
    },
    "ifrs-full_InvestmentsInAssociates": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "InvestmentsInAssociates",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments in associates reported in separate financial statements",
        "terseLabel": "Investments in associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of investments in associates in an entity's separate financial statements. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total issued capital",
        "terseLabel": "Share capital",
        "label": "Issued capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital [member]",
        "terseLabel": "Share Capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_LaterThanOneYearAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 to 5 years [member]",
        "label": "Later than one year and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r199"
     ]
    },
    "ifrs-full_LaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanOneYearMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than one year."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "ifrs-full_LaterThanThreeYearsAndNotLaterThanFiveYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LaterThanThreeYearsAndNotLaterThanFiveYearsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After 5 years [member]",
        "label": "Later than three years and not later than five years [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of later than three years and not later than five years."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r197",
      "r199"
     ]
    },
    "ifrs-full_LeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Lease liabilities",
        "totalLabel": "Total lease liabilities",
        "terseLabel": "Lease liabilities",
        "label": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_Level1OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level1OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1 [member]",
        "label": "Level 1 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r62",
      "r63",
      "r95"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3 [member]",
        "label": "Level 3 of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r63",
      "r95"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r95"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r95"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Liabilities",
        "totalLabel": "Total liabilities",
        "periodStartLabel": "Liabilities at beginning of period",
        "periodEndLabel": "Liabilities at end of period",
        "label": "Liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r94",
      "r95",
      "r97",
      "r150",
      "r155"
     ]
    },
    "ifrs-full_LicenceFeeIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LicenceFeeIncome",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "\"Right-to-use\" licenses",
        "label": "Licence fee income",
        "verboseLabel": "Licenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income arising from licence fees."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_LiquidityRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LiquidityRiskMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity risk [member]",
        "label": "Liquidity risk [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities that are settled by delivering cash or another financial asset. [Refer: Financial assets; Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r192"
     ]
    },
    "ifrs-full_LongtermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "LongtermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current portion of non-current borrowings",
        "terseLabel": "Borrowings",
        "label": "Non-current portion of non-current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The non-current portion of non-current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Major customers [axis]",
        "label": "Major customers [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "ifrs-full_MajorCustomersDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MajorCustomersDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major customers [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for customers. It also represents the standard value for the 'Major customers' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r159"
     ]
    },
    "asnd_MarketableSecurities1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "MarketableSecurities1",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable securities1",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MarketableSecuritiesExplanatory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "MarketableSecuritiesExplanatory",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities Explanatory",
        "documentation": "Marketable securities explanatory.",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MaturityAnalysisForFinancialLiabilitiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "MaturityAnalysisForFinancialLiabilitiesTextBlock",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of Maturity Analysis For Financial Liabilities",
        "label": "Maturity Analysis For Financial Liabilities [Text Block]",
        "documentation": "Maturity analysis for financial liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_MaturityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r115",
      "r125",
      "r137",
      "r174",
      "r196"
     ]
    },
    "ifrs-full_MaturityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MaturityDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r115",
      "r125",
      "r174",
      "r196",
      "r198"
     ]
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r94"
     ]
    },
    "ifrs-full_MeasurementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "MeasurementDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r94"
     ]
    },
    "asnd_MultipleOfPurchasePriceWereRoyaltyPaymentWillCease": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "MultipleOfPurchasePriceWereRoyaltyPaymentWillCease",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of the purchase price were royalty payment will cease",
        "label": "Multiple Of Purchase Price, Were Royalty Payment Will Cease",
        "documentation": "Multiple of purchase price, were royalty payment will cease."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "MultipleOfThePurchasePriceWereRoyaltyPaymentWillCease",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Multiple of the purchase price were royalty payment will cease",
        "label": "Multiple of the Purchase Price, were Royalty Payment will cease",
        "documentation": "Multiple of the purchase price, were royalty payment will cease."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NetSettlementUnderStockIncentivePrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NetSettlementUnderStockIncentivePrograms",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net settlement under stock incentive programs",
        "documentation": "Net settlement under stock incentive programs.",
        "terseLabel": "Net settlement under stock incentive programs"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NewShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NewShareRepurchaseProgramMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Share Repurchase Program [Member]",
        "documentation": "New share repurchase program.",
        "terseLabel": "New share repurchase program [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NonCashGainRecognizedOnOwnershipInterestInAssociate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NonCashGainRecognizedOnOwnershipInterestInAssociate",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non Cash Gain Recognized On Ownership Interest In Associate",
        "documentation": "Non cash gain recognized on ownership interest in associate.",
        "terseLabel": "Non-cash gain recognized"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-adjusting events after reporting period [axis]",
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current assets",
        "label": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r21",
      "r85",
      "r182"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "Non-current assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current contract liabilities",
        "terseLabel": "Contract liabilities",
        "label": "Non-current contract liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current contract liabilities. [Refer: Contract liabilities]"
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_NoncurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Liabilities",
        "terseLabel": "Derivative liabilities",
        "label": "Non-current derivative financial liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "ifrs-full_NoncurrentFinancialAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentFinancialAssets",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current financial assets",
        "label": "Non-current financial assets",
        "terseLabel": "Non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial assets. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_NoncurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current financial liabilities",
        "label": "Non-current financial liabilities",
        "terseLabel": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current financial liabilities. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSummaryOfMaterialAccountingPoliciesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities",
        "label": "Non-current lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total non-current liabilities",
        "label": "Non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r22",
      "r87",
      "r182"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current liabilities",
        "label": "Non-current liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_NorthAmericaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NorthAmericaMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "North America [member]",
        "label": "North America [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NotLaterThanOneYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotLaterThanOneYearMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Within 1 year [member]",
        "label": "Not later than one year [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a time band of not later than one year."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r106",
      "r107",
      "r115",
      "r196",
      "r199"
     ]
    },
    "ifrs-full_NotesAndDebenturesIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotesAndDebenturesIssued",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes and debentures issued",
        "terseLabel": "Convertible senior notes"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of notes and debentures issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "ifrs-full_NotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NotionalAmount",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Principal amount",
        "label": "Notional amount"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "asnd_NovoNordiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NovoNordiskMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novo Nordisk.",
        "label": "Novo Nordisk [member]",
        "terseLabel": "Novo Nordisk [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfCommercialCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NumberOfCommercialCustomers",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of commercial customers.",
        "label": "Number of commercial customers",
        "terseLabel": "Number of commercial customers"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the period",
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "verboseLabel": "Granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r221"
     ]
    },
    "asnd_NumberOfOrdinaryShareRelatedToRepurchaseOfShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NumberOfOrdinaryShareRelatedToRepurchaseOfShares",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Ordinary Share Related to Repurchase of Shares",
        "documentation": "Number of ordinary share Related to repurchase of shares.",
        "terseLabel": "Number of ordinary share Related to repurchase of shares"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Exercised during the period",
        "terseLabel": "Vested at the reporting date",
        "label": "Number of other equity instruments exercised or vested in share-based payment arrangement",
        "verboseLabel": "Specified by vesting year"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited during the period",
        "label": "Number of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Number of other equity instruments outstanding in share-based payment arrangement",
        "negatedPeriodStartLabel": "Beginning balance",
        "negatedPeriodEndLabel": "Ending balance"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "asnd_NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settled during the period",
        "label": "Number Of Other Equity Instruments Settled In Share Based Payment Arrangement",
        "documentation": "Number of other equity instruments settled in share based payment arrangement.",
        "negatedLabel": "Settled during the period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transferred during the period",
        "label": "Number Of Other Equity Instruments Transferred In Share Based Payment Arrangement",
        "documentation": "Number of other equity instruments transferred in share based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested at the balance sheet date",
        "label": "Number of other equity instruments vested in share-based payment arrangement",
        "documentation": "Number of other equity instruments vested in share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfReportableOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NumberOfReportableOperatingSegments",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/SegmentInformationAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segment",
        "label": "Number of reportable operating segments",
        "documentation": "Number of reportable operating segments."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total number of shares issued",
        "terseLabel": "Number of shares issued",
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "ifrs-full_NumberOfSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "NumberOfSharesOutstanding",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares outstanding",
        "periodStartLabel": "Number of shares outstanding at beginning of period",
        "periodEndLabel": "Number of shares outstanding at end of period"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "asnd_NumberOfTreasurySharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NumberOfTreasurySharesOutstanding",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number Of Treasury Shares Outstanding",
        "documentation": "Number of treasury shares outstanding.",
        "periodEndLabel": "March 31, 2025 (Holding)",
        "periodStartLabel": "January 1, 2025 (Holding)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_NumberOfWarrantsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "NumberOfWarrantsOutstanding",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants outstanding.",
        "label": "Number of warrants outstanding",
        "terseLabel": "Warrants outstanding",
        "negatedLabel": "Warrants outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations",
        "terseLabel": "Exchange differences on translating foreign operations",
        "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r23",
      "r38"
     ]
    },
    "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax",
        "verboseLabel": "Other comprehensive income/(loss), net of tax",
        "totalLabel": "Other comprehensive income/(loss) for the period, net of tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r171",
      "r172"
     ]
    },
    "ifrs-full_OtherCurrentFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current financial liabilities",
        "totalLabel": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Other financial liabilities; Current financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r91"
     ]
    },
    "ifrs-full_OtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current liabilities that the entity does not separately disclose in the same statement or note. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "asnd_OtherCurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "OtherCurrentLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other current liabilities abstract.",
        "label": "Other Current Liabilities [Abstract]",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_OtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_OtherFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherFinancialLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other financial liabilities",
        "terseLabel": "Other liabilities (excluding indirect tax, and employee related payables)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of financial liabilities that the entity does not separately disclose in the same statement or note. [Refer: Financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "ifrs-full_OtherNoncurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherNoncurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other non-current receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current other receivables. [Refer: Other receivables]"
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_OtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "OtherReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other receivables",
        "terseLabel": "Other receivables (excluding indirect tax receivables)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/ShareCapitalAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share nominal value",
        "label": "Par value per share",
        "terseLabel": "Nominal value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "asnd_PaymentForRepurchaseOfShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "PaymentForRepurchaseOfShares",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for repurchase of shares",
        "label": "Payment For Repurchase Of Shares",
        "documentation": "Payment for repurchase of shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PaymentOfWithholdingTaxesUnderStockIncentivePrograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "PaymentOfWithholdingTaxesUnderStockIncentivePrograms",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment Of Withholding Taxes Under Stock Incentive Programs",
        "documentation": "Payment of withholding taxes under stock incentive programs.",
        "negatedLabel": "Payment of withholding taxes under stock incentive programs"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PaymentTermOfCustomers": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "PaymentTermOfCustomers",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Term Of Customers",
        "label": "Payment Term Of Customers",
        "documentation": "Payment term of customers."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PaymentsToAcquireOrRedeemEntitysShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PaymentsToAcquireOrRedeemEntitysShares",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to acquire or redeem entity's shares",
        "negatedLabel": "Payments to acquire or redeem entity's shares",
        "negatedTerseLabel": "Acquisition of treasury shares, net of transaction costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to acquire or redeem entity's shares."
       }
      }
     },
     "auth_ref": [
      "r177"
     ]
    },
    "ifrs-full_PercentageOfEntitysRevenue": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfEntitysRevenue",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of entity's revenue",
        "terseLabel": "Perentage of sale to commercial products"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of the entity's revenue. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r224"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible decrease in unobservable input, liabilities",
        "label": "Percentage of reasonably possible decrease in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible decrease in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "ifrs-full_PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of reasonably possible increase in unobservable input, liabilities",
        "label": "Percentage of reasonably possible increase in unobservable input, liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The percentage of a reasonably possible increase in an unobservable input used in fair value measurement of liabilities."
       }
      }
     },
     "auth_ref": [
      "r219"
     ]
    },
    "asnd_PercentageOfVestingRightsForShareBasedPaymentArrangement": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "PercentageOfVestingRightsForShareBasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting rights for share-based payment arrangement.",
        "label": "Percentage of vesting rights for share-based payment arrangement",
        "terseLabel": "Percentage of vesting rights"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PerformanceObligationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PerformanceObligationsAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance obligations [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "ifrs-full_PerformanceObligationsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PerformanceObligationsDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance obligations [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "asnd_PerformanceStockUnitProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "PerformanceStockUnitProgramMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance stock unit program member.",
        "label": "Performance Stock Unit Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PerformanceStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "PerformanceStockUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance Stock Units [Member]",
        "documentation": "Performance stock units."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Convertible notes",
        "label": "Potential Conversion Of Convertible Senior Notes Into Number Of Ordinary Shares",
        "documentation": "Potential conversion of convertible senior notes into number of ordinary shares."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PresentationOfLeasesForLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PresentationOfLeasesForLesseeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Presentation of leases for lessee [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from borrowings, classified as financing activities",
        "terseLabel": "Proceeds from borrowings",
        "verboseLabel": "Net proceeds from borrowings",
        "negatedLabel": "Net proceeds from borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "ifrs-full_ProceedsFromExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromExerciseOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from exercise of warrants",
        "terseLabel": "Net proceeds from exercise of warrants",
        "label": "Proceeds from exercise of warrants"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the exercise of share purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfBondsNotesAndDebentures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromIssueOfBondsNotesAndDebentures",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds From Issuance Of Notes",
        "label": "Proceeds from issue of bonds, notes and debentures"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of bonds, notes and debentures."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "asnd_ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds after deduting offering expenses",
        "label": "Proceeds From Royalty Funding Liabilities Excluding Offering Expenses",
        "documentation": "Proceeds from royalty funding liabilities excluding offering expenses."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Settlement of marketable securities",
        "label": "Proceeds from sales or maturity of financial instruments, classified as investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from sales or maturity of financial instruments, classified as investing activities. [Refer: Classes of financial instruments [domain]]"
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ComprehensiveIncome",
       "weight": 1.0,
       "order": 1.0
      },
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net profit/(loss) for the period",
        "label": "Profit (loss)",
        "verboseLabel": "Net profit/(loss) for the period",
        "totalLabel": "Net profit/(loss) for the period"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r2",
      "r31",
      "r69",
      "r79",
      "r81",
      "r150",
      "r153",
      "r182",
      "r190"
     ]
    },
    "ifrs-full_ProfitLossAttributableToOwnersOfParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossAttributableToOwnersOfParent",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Attributable to owners of the Company",
        "label": "Profit (loss), attributable to owners of parent"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_ProfitLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) before tax",
        "totalLabel": "Profit/(loss) before tax"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r122",
      "r164",
      "r165",
      "r201",
      "r202"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "Operating profit/(loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r175",
      "r210"
     ]
    },
    "asnd_ProfitLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ProfitLossMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss.",
        "label": "Profit Loss [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property, plant and equipment",
        "terseLabel": "Property, plant and equipment",
        "periodStartLabel": "Property, plant and equipment at beginning of period",
        "periodEndLabel": "Property, plant and equipment at end of period",
        "label": "Property, plant and equipment"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r49"
     ]
    },
    "ifrs-full_ProportionOfOwnershipInterestInAssociate": {
     "xbrltype": "percentItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ProportionOfOwnershipInterestInAssociate",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proportion of ownership interest in associate",
        "terseLabel": "Present ownership percentage"
       }
      },
      "en": {
       "role": {
        "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Total for all associates [member]]"
       }
      }
     },
     "auth_ref": [
      "r56",
      "r57",
      "r82"
     ]
    },
    "asnd_PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of intangible assets and property, plant and equipment",
        "documentation": "Purchase of intangible assets and property, plant and equipment.",
        "negatedLabel": "Acquisition of intangible assets and property, plant and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_PurchaseOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "PurchaseOfTreasuryShares",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of treasury shares",
        "negatedLabel": "Acquisition of treasury shares (Note 9)",
        "terseLabel": "Acquisition of treasury shares (Note 9)"
       }
      },
      "en": {
       "role": {
        "documentation": "The decrease in equity resulting from the purchase of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "asnd_RSUNetSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RSUNetSettlementMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "RSU Net Settlement [member]",
        "documentation": "RSU net settlement.",
        "terseLabel": "RSU Net Settlement [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r99",
      "r110",
      "r119",
      "r185",
      "r187",
      "r223"
     ]
    },
    "ifrs-full_RangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RangeDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r99",
      "r110",
      "r119",
      "r185",
      "r187",
      "r223"
     ]
    },
    "ifrs-full_ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReconciliationOfChangesInFairValueMeasurementLiabilitiesAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesMovementsInLevel3FairValueMeasurementsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of changes in fair value measurement, liabilities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RepaymentsOfBorrowingsClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RepaymentsOfBorrowingsClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of borrowings",
        "label": "Repayments of borrowings, classified as financing activities",
        "negatedLabel": "Repayment of borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow to settle borrowings, classified as financing activities. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r179"
     ]
    },
    "asnd_RepurchaseOfSharesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RepurchaseOfSharesValue",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase of Shares Value",
        "documentation": "Repurchase of shares value.",
        "terseLabel": "Repurchase of shares, value"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expense",
        "terseLabel": "Research and development expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfExchangeDifferencesOnTranslationMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of exchange differences on translation [member]",
        "terseLabel": "Foreign Currency Translation Reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r52",
      "r166"
     ]
    },
    "ifrs-full_ReserveOfSharebasedPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ReserveOfSharebasedPaymentsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reserve of share-based payments [member]",
        "terseLabel": "Share-based Payment Reserve [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity resulting from share-based payments."
       }
      }
     },
     "auth_ref": [
      "r166"
     ]
    },
    "asnd_RestOfWorldMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RestOfWorldMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rest of world.",
        "label": "Rest of world [member]",
        "terseLabel": "Rest of World [member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAdjustmentMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Prior Periods Estimates and Assumptions [Member]",
        "label": "Revision of Prior Period, Adjustment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RestatementDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revision of Prior Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RestrictedShareUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RestrictedShareUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted share units [member]",
        "terseLabel": "RSUs"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for restricted share units."
       }
      }
     },
     "auth_ref": [
      "r211"
     ]
    },
    "asnd_RestrictedStockUnitsAndPerformanceStockUnitMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RestrictedStockUnitsAndPerformanceStockUnitMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units and Performance Stock Unit [Member]",
        "documentation": "Restricted stock units and performance stock unit."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RestrictedStockUnitsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock units.",
        "label": "Restricted Stock Units [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings [member]",
        "terseLabel": "Accumulated Deficit [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r166"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInConsolidatedStatementsOfProfitOrLossParentheticalDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "totalLabel": "Total revenue",
        "terseLabel": "Revenue",
        "label": "Revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r89",
      "r122",
      "r148",
      "r152",
      "r156",
      "r157",
      "r159",
      "r164",
      "r165",
      "r182"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Operating Segments [abstract]",
        "label": "Revenue [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromContractsWithCustomers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromContractsWithCustomers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from contracts with customers",
        "terseLabel": "Recognized as revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102"
     ]
    },
    "asnd_RevenueFromRenderingOfServicesAndClinicalSupply": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RevenueFromRenderingOfServicesAndClinicalSupply",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue From Rendering Of Services and Clinical Supply",
        "documentation": "Revenue from rendering of services and clinical supply.",
        "terseLabel": "Rendering of services and clinical supply"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RevenueFromSaleOfGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "RevenueFromSaleOfGoods",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail": {
       "parentTag": "ifrs-full_Revenue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from sale of goods",
        "terseLabel": "Commercial products",
        "verboseLabel": "Revenue from commercial products"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue arising from the sale of goods. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "asnd_RevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RevenueTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [table]",
        "documentation": "Revenue table."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltiesAndMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RoyaltiesAndMilestonesMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/RevenueAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalties and milestones.",
        "label": "Royalties and Milestones [Member]",
        "terseLabel": "Royalties And Milestones [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyFundingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RoyaltyFundingLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesSummaryOfFairValueHierarchyDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Royalty funding liabilities",
        "documentation": "Royalty funding liabilities.",
        "terseLabel": "Royalty funding liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPaymentBeginningPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RoyaltyPaymentBeginningPeriod",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment beginning period.",
        "label": "Royalty payment beginning period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPaymentEndingPeriod": {
     "xbrltype": "dateItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RoyaltyPaymentEndingPeriod",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment ending period.",
        "label": "Royalty Payment Ending Period",
        "terseLabel": "Royalty payment ending period"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RoyaltyPharmaMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Pharma.",
        "label": "Royalty Pharma [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaUnitedStatesSkytrofaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RoyaltyPharmaUnitedStatesSkytrofaMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Pharma U.S. Skytrofa [member]",
        "documentation": "Royalty Pharma United States Skytrofa.",
        "label": "Royalty Pharma United States Skytrofa [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_RoyaltyPharmaUnitedStatesYorvipathMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "RoyaltyPharmaUnitedStatesYorvipathMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty pharma united states yorvipath.",
        "label": "Royalty Pharma United States Yorvipath [Member]",
        "terseLabel": "Royalty Pharma U.S. Yorvipath [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SaleOrIssueOfTreasuryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SaleOrIssueOfTreasuryShares",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale or issue of treasury shares",
        "terseLabel": "Transfer under stock incentive programs"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity resulting from the sale or issue of treasury shares. [Refer: Treasury shares]"
       }
      }
     },
     "auth_ref": [
      "r205"
     ]
    },
    "asnd_SalesRebatesAndProductReturnsInUSMarketMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SalesRebatesAndProductReturnsInUSMarketMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantAccountingJudgementsAndEstimatesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales rebates and product returns in U.S. market [member]",
        "label": "Sales Rebates And Product Returns In U.S. Market [Member]",
        "documentation": "Sales rebates and product returns in U.S. market."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total selling, general and administrative expense",
        "terseLabel": "Selling, general and administrative expenses",
        "label": "Selling, general and administrative expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "asnd_ShareBasedPaymentArrangementAwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ShareBasedPaymentArrangementAwardTypeAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, award type.",
        "label": "Share based Payment Arrangement, Award type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss": {
       "parentTag": "ifrs-full_ProfitLossBeforeTax",
       "weight": 1.0,
       "order": 0.0
      },
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperations",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedCashFlowStatements",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share of profit (loss) of associates accounted for using equity method",
        "terseLabel": "Share of profit/(loss) of associates",
        "negatedTerseLabel": "Share of (profit)/loss of associates"
       }
      },
      "en": {
       "role": {
        "documentation": "The entity's share of the profit (loss) of associates accounted for using the equity method. [Refer: Total for all associates [member]; Investments accounted for using equity method; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r210"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Premium [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "asnd_SharePriceAppliedForValuation": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharePriceAppliedForValuation",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share price",
        "label": "Share Price Applied For Valuation",
        "documentation": "Share price applied for valuation."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharePriceMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharePriceMeasurementInputMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Measurement Input [Member]",
        "documentation": "Share price measurement input [member]."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharePriceOfEntity": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharePriceOfEntity",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Price Of Entity",
        "documentation": "Share price of entity.",
        "terseLabel": "Share price"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ShareRepurchaseProgramAndRSUNetSettlementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ShareRepurchaseProgramAndRSUNetSettlementMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program and RSU Net Settlement [member]",
        "label": "Share Repurchase Program and RSU Net Settlement [member]",
        "documentation": "Share repurchase program and RSU net settlement."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ShareRepurchaseProgramMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Repurchase Program [member]",
        "documentation": "Share repurchase program.",
        "terseLabel": "Share Repuchase Program [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementAwardTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharebasedPaymentArrangementAwardTypeDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, award type.",
        "label": "Sharebased Payment Arrangement, Award type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementAwardTypeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharebasedPaymentArrangementAwardTypeMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sharebased Payment Arrangement, Award type",
        "label": "Sharebased Payment Arrangement, Award type [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement, restricted stock unit, activity.",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share Based Payment",
        "label": "Sharebased Payment Arrangement, Restricted Stock Unit, Activity [Text Block]",
        "documentation": "Sharebased payment arrangement, restricted stock unit, activity."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharesAgreementDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharesAgreementDescription",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares Agreement Description",
        "documentation": "Shares agreement description.",
        "terseLabel": "Shares agreement description"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SharesAuthorizedToRepurchase": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SharesAuthorizedToRepurchase",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares authorized to repurchase",
        "label": "Shares Authorized To Repurchase",
        "documentation": "Shares authorized to repurchase."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SharesInEntityHeldByEntityOrByItsSubsidiariesOrAssociates",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares in entity held by entity or by its subsidiaries or associates",
        "terseLabel": "Common stocks non-diluted basis",
        "verboseLabel": "Shares held"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares in the entity held by the entity or by its subsidiaries or associates. [Refer: Total for all associates [member]; Total for all subsidiaries [member]]"
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "asnd_ShortTermBorrowingOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ShortTermBorrowingOther",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short Term Borrowing, Other",
        "documentation": "Short term borrowing, other",
        "terseLabel": "Borrowings"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ShorttermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "ShorttermBorrowings",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "asnd_ConvertibleNotesCurrent",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Borrowings",
        "label": "Current borrowings"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current borrowings. [Refer: Borrowings]"
       }
      }
     },
     "auth_ref": [
      "r207"
     ]
    },
    "asnd_SignificantEventsInTheReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SignificantEventsInTheReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Significant events in the reporting period.",
        "label": "Significant Events in the Reporting Period [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodLineitems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SignificantEventsInTheReportingPeriodLineitems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events In The Reporting Period LineItems",
        "documentation": "Significant events in the reporting period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SignificantEventsInTheReportingPeriodTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Events In The Reporting Period Table",
        "documentation": "Significant Events In The Reporting Period."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SignificantEventsInTheReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SignificantEventsInTheReportingPeriodTextBlock",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/SignificantEventsInTheReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Significant Events In the Reporting Period",
        "label": "Significant Events In The Reporting Period [Text Block]",
        "documentation": "Significant Events In The Reporting Period Text Block."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of cash flows [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_StatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfComprehensiveIncomeAbstract",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of comprehensive income [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of financial position [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_StockRepurchaseProgramAuthorizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "StockRepurchaseProgramAuthorizedAmount",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Repurchase Program Authorized Amount",
        "documentation": "Stock repurchase program authorized amount.",
        "terseLabel": "Share repurchase program authorized amount"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "SubclassificationsOfAssetsLiabilitiesAndEquitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subclassifications of assets, liabilities and equities [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_SummaryOfSignificantAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary of Significant Accounting Policies [abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_ThirdPartyInvestorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "ThirdPartyInvestorsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third party investors.",
        "label": "Third Party Investors [Member]",
        "terseLabel": "Third Party Investors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_TimingOfTransferOfGoodsOrServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TimingOfTransferOfGoodsOrServicesDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueRecognizedInUnauditedCondensedConsolidatedInterimStatementsOfProfitOrLossDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Timing of transfer of goods or services [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all timings of the transfer of goods or services in contracts with customers. It also represents the standard value for the 'Timing of transfer of goods or services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r189"
     ]
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Top of range [member]",
        "terseLabel": "Top of range [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r99",
      "r110",
      "r119",
      "r185",
      "r187",
      "r223"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers",
     "crdr": "credit",
     "calculation": {
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_OtherCurrentFinancialLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade payables and accrued expenses",
        "label": "Current trade payables"
       }
      },
      "en": {
       "role": {
        "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]"
       }
      }
     },
     "auth_ref": [
      "r168",
      "r208"
     ]
    },
    "ifrs-full_TradeAndOtherPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayables",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesLiquidityRiskManagementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total trade and other payables",
        "terseLabel": "Trade payables",
        "label": "Trade and other payables",
        "verboseLabel": "Trade payables, accrued expenses and other liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeAndOtherPayablesToTradeSuppliers",
     "crdr": "credit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade payables",
        "terseLabel": "Trade payables and accrued expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "ifrs-full_TradeReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TradeReceivables",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesScheduleOfFinancialAssetsAndFinancialLiabilitiesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade receivables",
        "terseLabel": "Trade receivables from associate",
        "verboseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount due from customers for goods and services sold."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "asnd_TreasurySharesAcquiredFromThirdParties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TreasurySharesAcquiredFromThirdParties",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares Acquired From Third Parties",
        "documentation": "Treasury shares acquired from third parties.",
        "terseLabel": "Acquired from third parties (Nominal values)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageAcquiredFromThirdParties": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TreasurySharesHoldingInPercentageAcquiredFromThirdParties",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares Holding In Percentage Acquired From Third Parties",
        "documentation": "Treasury shares holding in percentage acquired from third parties.",
        "terseLabel": "Acquired from third parties (Holding in % of total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageOfTotalOutstandingShares": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TreasurySharesHoldingInPercentageOfTotalOutstandingShares",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares Holding In Percentage Of Total Outstanding Shares",
        "documentation": "Treasury shares holding in percentage of total outstanding shares.",
        "periodEndLabel": "March 31, 2025 (Holding in % of total outstanding shares)",
        "periodStartLabel": "January 1, 2025 (Holding in % of total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms": {
     "xbrltype": "percentItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury shares holding in percentage transferred under stock incentive programs.",
        "label": "Treasury Shares Holding In Percentage Transferred under stock incentive programs",
        "terseLabel": "Transferred under stock incentive programs (Holding in % total outstanding shares)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TreasurySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TreasurySharesMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/ConsolidatedStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "asnd_TreasurySharesOfNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TreasurySharesOfNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Treasury Shares Of Nominal Value",
        "documentation": "Treasury shares of nominal value.",
        "periodEndLabel": "March 31, 2025 (Nominal values)",
        "periodStartLabel": "January 1, 2025 (Nominal values)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TreasurySharesTransferredUnderStockIncentiveProgramNominalValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TreasurySharesTransferredUnderStockIncentiveProgramNominalValue",
     "crdr": "debit",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/TreasurySharesSummaryOfHoldingOfTreasurySharesDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury shares transferred under stock incentive program nominal value.",
        "label": "Treasury Shares Transferred Under Stock Incentive Program Nominal Value",
        "terseLabel": "Transferred under stock incentive programs (Nominal values)"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TwoThousandAndTwentyEightMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Two Thousand And Twenty Eight [member]",
        "documentation": "Two thousand and twenty eight.",
        "terseLabel": "2028"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TwoThousandAndTwentyFiveMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Two thousand and twenty five [Member]",
        "documentation": "Two thousand and twenty five."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TwoThousandAndTwentyFourMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Two Thousand And Twenty four [Member]",
        "documentation": "Two thousand and twenty four."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentySevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TwoThousandAndTwentySevenMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand and Twenty seven.",
        "label": "Two Thousand and Twenty seven [Member]",
        "terseLabel": "2027"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentySixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TwoThousandAndTwentySixMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Two Thousand And Twenty six [Member]",
        "documentation": "Two thousand and twenty six."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_TwoThousandAndTwentyThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "TwoThousandAndTwentyThreeMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Two Thousand And Twenty Three [Member]",
        "documentation": "Two thousand and twenty three."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_TypesOfAntidilutiveInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfAntidilutiveInstrumentsDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of antidilutive instruments [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for antidilutive instruments. Instruments are antidilutive when their conversion to ordinary shares would increase earnings per share or decrease loss per share from continuing operations. The calculation of diluted earnings per share does not assume conversion, exercise, or other issue of potential ordinary shares that would have an antidilutive effect on earnings per share. It also represents the standard value for the \u2018Types of antidilutive instruments' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "ifrs-full_TypesOfInterestRatesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of interest rates [axis]",
        "label": "Types of interest rates [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_TypesOfInterestRatesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfInterestRatesDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of interest rates [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]"
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "ifrs-full_TypesOfRisksAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of risks [axis]",
        "label": "Types of risks [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r123",
      "r129",
      "r130",
      "r163"
     ]
    },
    "ifrs-full_TypesOfRisksDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfRisksDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of risks [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r123",
      "r129",
      "r130",
      "r163"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Types of share-based payment arrangements [axis]",
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "asnd_UnitedStatesSkytrofaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "UnitedStatesSkytrofaMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. SKYTROFA.",
        "label": "United States Skytrofa [member]",
        "terseLabel": "U.S. SKYTROFA [member]",
        "verboseLabel": "SKYTROFA [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_UnitedStatesYorvipathMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "UnitedStatesYorvipathMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureRevenueScheduleOfRevenueFromSaleOfCommercialProductsDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. YORVIPATH [member]",
        "label": "United States Yorvipath [member]",
        "documentation": "U.S. YORVIPATH.",
        "verboseLabel": "YORVIPATH [member]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r220"
     ]
    },
    "ifrs-full_UnobservableInputsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "UnobservableInputsDomain",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [domain]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r220"
     ]
    },
    "asnd_VestingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "VestingMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting",
        "label": "Vesting [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_VestingOfSharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "VestingOfSharesAxis",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentSummaryOfShareBasedPaymentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting Of Shares [Axis]",
        "documentation": "Vesting of shares."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_VisenPharmaceuticalsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "VisenPharmaceuticalsMember",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSignificantEventsInTheReportingPeriodAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Visen Pharmaceuticals [Member]",
        "verboseLabel": "Visen Pharmaceuticals [Member]",
        "documentation": "Visen Pharmaceuticals Member",
        "terseLabel": "VISEN [member]"
       }
      }
     },
     "auth_ref": []
    },
    "asnd_Warrant1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "Warrant1Member",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentAdditionalInformationDetails",
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail",
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants [member]",
        "label": "Warrant1 [member]",
        "documentation": "Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesCurrentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities Current",
        "label": "Weighted Average Duration Of Marketable Securities Current Explanatory",
        "documentation": "Weighted average duration of marketable securities current."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities",
        "label": "Weighted Average Duration Of Marketable Securities Explanatory",
        "documentation": "Weighted average duration of marketable securities explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "asnd_WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory": {
     "xbrltype": "durationItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "WeightedAverageDurationOfMarketableSecuritiesNoncurrentExplanatory",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureFinancialAssetsAndLiabilitiesAdditionalInformationDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Duration Of Marketable Securities Noncurrent",
        "label": "Weighted Average Duration Of Marketable Securities Noncurrent Explanatory",
        "documentation": "Weighted average duration of Marketable securities noncurrent explanatory."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised during the period",
        "label": "Weighted average exercise price of other equity instruments exercised or vested in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited during the period",
        "label": "Weighted average exercise price of other equity instruments forfeited in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted during the period",
        "label": "Weighted average exercise price of other equity instruments granted in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) granted in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "ifrs-full_WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Weighted average exercise price of other equity instruments outstanding in share-based payment arrangement"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average exercise price of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r221"
     ]
    },
    "asnd_WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://ascendispharma.com/20250331",
     "localname": "WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/DisclosureSharebasedPaymentScheduleOfWarrantActivityDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested at the balance sheet date",
        "label": "Weighted average exercise price of other equity instruments vested in sharebased payment arrangement",
        "documentation": "Weighted average exercise price of other equity instruments vested in share-based payment arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://ascendispharma.com/20250331/taxonomy/role/StatementCondensedConsolidatedStatementsOfProfitOrLossAndOtherComprehensiveIncomeOrLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares used for calculation (basic and diluted)",
        "label": "Weighted average number of ordinary shares used in calculating basic earnings per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "41",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_41&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "l",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_l&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "m",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_m&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "n",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_n&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "54",
   "Subparagraph": "o",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_54_o&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "56",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_56&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "61",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_61&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "vi",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a_vi&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81A",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81A_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "81B",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_81B_b_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "91",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_91_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "98",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_98_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2024-03-27"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_79&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "c",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_c_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "81",
   "Subparagraph": "g",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2024-en-r&anchor=para_81_g_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e_v&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2024-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2024-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "52",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_52_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2024-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2024-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "26",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "Subparagraph": "b",
   "Clause": "viii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2024-en-r&anchor=para_35_b_viii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_16_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "27",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2024-en-r&anchor=para_17_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "130",
   "Subparagraph": "f",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_130_f_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "36",
   "IssueDate": "2024-01-01",
   "Paragraph": "134",
   "Subparagraph": "e",
   "Clause": "iiA",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2024-en-r&anchor=para_134_e_iiA&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2024-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2024-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2024-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2024-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2024-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2024-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2024-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "44H",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_44H_b_iii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2024-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "a",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_a_iv&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "21",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_21_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ix",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B13",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B16&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2024-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "105",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_105&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_113_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "119",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_119&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_120_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2024-01-01",
   "Paragraph": "97",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2024-en-r&anchor=para_97&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "109A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_109A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "124",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_124&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "125",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_125&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "127",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_127&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "128",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_128_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "132",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_132_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "C32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_C32&doctype=Appendix&subtype=C",
   "URIDate": "2024-03-27"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2024-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "21C",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_21C&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "23B",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_23B_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "24A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_24A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35H",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35H&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35M",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35M&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "36",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_36&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42E",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42E_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "42I",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_42I&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8_g&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B2",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B2_a&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2024-03-27"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_33&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2024-03-27"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.34&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "9",
   "IssueDate": "2024-01-01",
   "Paragraph": "7.2.42",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2024-en-r&anchor=para_7.2.42&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Note": "Effective 2025-01-01",
   "Name": "IAS",
   "Number": "21",
   "IssueDate": "2024-01-01",
   "Paragraph": "A19",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2024-en-r&anchor=para_A19_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_70&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "82A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_82A&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "138",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_138_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2024-01-01",
   "Paragraph": "147",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2024-en-r&anchor=para_147_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2024-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "14",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_14_f&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Section": "A Statement of cash flows for an entity other than a financial institution",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A_TI",
   "URIDate": "2024-03-27"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2024-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2024-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "94",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_94&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE60",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE60&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2024-03-27"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_b&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2024-01-01",
   "Paragraph": "B89",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2024-en-r&anchor=para_B89_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2024-01-01",
   "Paragraph": "96",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2024-en-r&anchor=para_96_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "35N",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_35N&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_6&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11_d&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B11",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B11&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35_f&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "B35",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_B35&doctype=Appendix&subtype=B",
   "URIDate": "2024-03-27"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG31A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "IG40B",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance",
   "URIDate": "2024-03-27"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "78",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_78&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2024-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2024-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2024-01-01",
   "Paragraph": "70",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2024-en-r&anchor=para_70_c&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "16",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_16&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h_ii&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2024-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2024-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2024-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2024-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "39",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_39&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2024-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2024-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2024-03-27"
  },
  "r224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2024-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2024-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2024-03-27"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>60
<FILENAME>0000950170-25-061850-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-25-061850-xbrl.zip
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MP ;-D0W6Q[\N/]-N?""7'NK54'^\G]2#'C;^5C='A);,0 -@$"BJ1H! 2>8
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MAR4EVA\=IGGFL)UDKM0RR9*G=F"90N(@I4C#) $5B@(IG '8V>"D#,X)E/&
M78*Z@S13378ZN0"YUB:3L25[C-\V[_XXFT[&0:_8^.CMC8]V:'PNSDAP'$'(
M1/*R'@,9D $28FP,(BIBX*K'LB^24D%)!X$.<7I" T) "<8!,E#"@+2SC&8@
MJ4LF3SLT>>>DD9$546M;SBV!<9&"$Z-%G-]%3&;9@?%=?'2+V6\G_KB>':_4
M#=,."9*GV H9)\A*Q4F_93Y.^ID%<5Q2?"Q ['F?Q^11B6N'MJ+BC"$*WP%'
M/ %413XCM54@<*P8EY1(+?(=EX/$4+X<BL/Q203+],U#IYSW8L@W4>&WD_''
MB5ZML78XFU'06X4BSFHJDK'R (R.*B=EG'T*$QC&.E^E^,U_\L,4&EA&'OX6
M3Z@G]NB:T;9'DIN.[(M;50A!JX.+=%880 F,#A93!91FACAEJ0L^MY'J;-[9
M&W,B3(N@79I]1!\KA4AA8A1]K',!>ZJ9M+D-TJ/YV$OG3*N[^Z'5#'.S9ER>
M]?Q3I\^GJ#>FR@A&%L)HI9&+4DD(, 8+X#A&7FOB(V?-5PN^SX .)UXWLT>)
MSW<Y*H)9*(-.RYXB32D=D 8&@&F\# Y$"9?=7*$S6K*"4<H@1*<DA$99 SCG
MR><2"(Q%)LX!$<%>Q=FOR-C=YC#5R"" H:33!!L!M-4^4E ,@4;$ ,RMYA8A
MK71VQ.8N@_BZ:6;>O= G]50/UW,$%33,2 R\ASB"GM= P3BSU,)[0Z0@#&<\
ML[Q5X/4?=>-';]L$*>MGT]KJ87](J5(4(D*!I!']J! ,R#CC!\R8H W3AKJ5
M1PCO/SQ_]6E"?7*41+Z;B,=\5)K)=&=O-AF??(^6]A39E$'40 FP3<A&,8DS
M=*M!A#B,F< >V9Q-:IE,\(VE^I=1&I_:?+P.$TS>C\8FK6II,_2O1R>SZ;7+
M_JUNIN.49S+\QS@M;\6;.WLUGBRI;.*U+;%J?]T;"[=84(<U8!*AZ( Y!XI%
M6V>4(:F55UQFEWHRS_F)/W=URA'_Y-]Y.YNTJO)F',5OAS/GW>O1R_3U!06*
MY+8=JX=F+?74+5AMN2 B#K0/@*+H%J2A#&!L&/.,64YP;@/]75=^'O79#_\<
MQY.MY\@%'@BA/AJF8H!BSX%N4RZ1YT*E!6KM\AVY'*8JJXD*:.H]0W%<)#<Z
MI:@B(!&+4Q!I@]9"2M_O6,V*9Q^KP3/-"0D\A;DM$X#R$*?TUGF -.(N#A0F
M)CO&^FBAFMO=R3^B/XUVN BR7O:TAY_'AT?C6:-';G?D#C_'6SM[5Y^NI=?5
M0D,H'0%"DTBC)8R3(&)4A$]C V1&4)QQ@"C/Y:T<AE5!2I$,:=4R@6D\L=(.
M@F"AA,BPH'1QVH^=7Z"5M=83"Q#$$% ? E 81:<M1("I8@*N/F5KE8.RZE6/
M# )Y<7+A*<,!&,F6\TAI(%#..&H-@X%D'(K-TUVN)M=5!VD]I!QP[A2@(G)7
MC9T!"+'@L"!,JXPG@K_K:9KJ7Q^7J+B3PR,]VA_Y5 $7^4F<RY]_^JK^U'[<
MF\BK09@%*R6(4PP"J-,2*,ZC7U3,*QFGZXZ'?$>I;\4W'6*9D5AA*3Q@W 5
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MK0E,]S#[)PMT6(W/XZG02T9/9S%"T>=I!R12%F@;D C8*Y]SS7!/%MW7NUR
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M,863;EBXKWY(,OOO/TF,X?/404B/SMIWZ/F/U0]1W,-9\OCQ;&?5R63<G$2
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M1;D6*K@Q,("(P5+( +3@%E"N C!0,6 0TR8HA@(D7\* =,@HK"B 3'A H<=
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M)IGQTG0436HA>V^!THE3O_63=FO:J_QY-KGX?,&CX64>C6]+HV]^7A&8],%
M@)R.$P'L:)P#> :LE)I#SACEK)OG?3DG)H_XQ&B+W51UD=LTHM=NL03)"D3G
MHHL%HC<"HJ7@$7(@!5@A#*BA.L(/L1&R$(+,0ZC1M<TK[A?OR@.BH8E_$);
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ME&NA@GD0B<?H^&B$L]X;@(5B@#)%@;:4 QRDU P2XH3_LO&%\,8X)#@0'E-
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MGP0','%8F'A;Q[/A[ Q@ F"B3X(#F#@$3'S(L4<SJR]:I&@QXT[-<  4 !0
M%,<,%+],ZGS<>!YXM",%_1PT/M1VW)1"M<G\E^]B$^M/$5 $4*1/@@,4.02*
MO/!^=C8;E6K&%BQ^CFGHAU, "P"+/@D.P.(@L<D$LINPI'5$J 1+6CTR@VM
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ME(E0"G&N0IF+J,MLJ"0L3B'_=C=%9!#A'!>9=JX\#89*[0[@;K\I_-?JU3I
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MG.BCKV'".G!GC498.H(X\Q)9Z23B1">L#(\TB=W4,.W$:6_RF\H_@?<.M4Q
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M1%JD$!,3'M..4 8E \(QT,;16BW01G\E>10*V*NL&B31'J.* D;V5Y)'H8"
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M:#QHIS/%<>]E9LFHD0O*(^:LBBGZY(38,]G1 >%\0 D'PNL36 #A=05X@?"
M\#K<X[]!<0_;]+]+QL4Z4D*]1TF%'"IRI3)[!H^B"$0X;R2Q&Z.[C&"4>(PS
M06>>Y9HQY!Q5*$A*HK4L9CZ^/^/>KN&?0)1YZ,$!=U,_F"0 = QT#'3<Z?A3
MY$ 3ITQJ(K"2<:48&:HS.>;(TR;*H^;Z.AM*:@,+42$>O2UL&)#3),>L6-)
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M^(IA%9S5!%EO4AD0+Y"E6B/K*,&4XB"UW<VN-_OC*\+( #,!A/6@39H[6KR
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M"8LO86Q7([ED!]/T7U&].;5B!F8-W--A-07N >[96V^SC]8'G'*P*G+8JK5
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M7@+HVP5^[BK0(]T,]'K3]PS!(! @$" 0X&,)*'L#S+ :V!V,?Z@QDFE'HRJ
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M?)G6NDQCMV['EC+(:^3]N(R[^+[G]7#4QN)KKN_"SG<GWBNYO7S*RT7^9=G
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MV?HKO@'&4D@> ^+:YC\\IL@JZU$,25-F,*>4;2P/>NNE8@H)'5-Q*AC*<:)
M-+L9(@KA):/[]@W$P'!HL7Z4]MP)V0'Y@+("^=R3?(@)A I+D?(R!Z8J!Z:&
MBH "$4)[K;4C&ZVWF#-OO*"($*H1SU]$AE."E"!6!NH(MG'_JY"2=S1;^?C(
M!U8J>]3A!/,]'ID_ 9W4T$G]L)W4@E#'G&<H1B,03\8@$P)'3--$9"!.J8U2
M)YCO :W4P$K 2J"NP$K[824;+'4J)N0L<9F5%$=6LH22M#)3$O6<&9CO :3T
M7=%O_H?-#_OWY>OY;=;6B.9_A^&GO_\U_U'YD6WR>\Y2/T.C83-%<13/8E'N
M+/OS6*\ZHQ</U+X%<H*E^.%Y&#;G(WOQ+(WBEW7)R"RH?\V:Z3!=+&^\_0YJ
MIK:>/F^E@,H5FV?.-G$T+(][35Z7C\]/!%,_["I,;5^ER3?XM9?WM;>1;T<+
MS0S1BG%!J?QA/6?P9XSG^2Y'*]D,Q^7Q4"NBK\CD2I]F>2]+PFVOF5V_'ZZ=
M<:L"W>KAY@A4[F$XGMDU"#*<,I^?""E9G%RN#'(T,.2BI)H1JV32?Y"'DOM5
M*_AE4E?3TYC_7\=8G>7/3YNJ;#L3JE]M[4\K1@85Q50,JI_C."O7GX/V^WXR
M&T_KB[)^'B9G0S\<Q4&+JO70S:;YZ,_#Z6GU'_]',\E71G8W.1\@7RHM"[X@
M?B8/C;BT&EE!!,(I*1RTTBGXC4(>*QTU-"+ERTQ_)UU^P3R@_'X-2<)XCN7W
MDX:\0AKB6[U\)S<S1@>4J\K'CXJ4LY8L4E,GU6TUCG?H009;6],[I<(BTF"Q
MY"B8LC=5B!%I@S5BB@BLA _>;-2B<:N54S@C4X[$L]\C#<JQ.\X_)9*PT5HF
M]QTJ?*FXKW_[Y8KFHB;ZHKT%X)LX?O+W\:33>KM0UNJS;2H[G6-:<0"JZ60)
M@R<KS^$:"73J058WV?HI\S]OX9(1^HU;.%3N^_+NOBF0]E+/AM-\%_Z[JL#F
MKSK5D[/JY>0L.W9^:$?5VWH29GYZ92^H-7_B.^YN9;$+KW'9*8B-I3A9A+/=
M(&X]13:D4D8J@O*841'<O3<A_7G8^-&DF=7Q35H\Z8?)Y5,N'_+5E^P1C>UT
M4E\\J6*FHO-\@FF=C?Q6ZB*_2UO*MW?IA-Y./;Y?&9I,R(6Y_*52G"_D57V.
M=:PR.*3):#3YW#Q;TY)5S#!'C"U>OYU-)\N8JCQ5N:UL0N7K*#NFD]GB*RN?
M]21[K8OO9\F,['D3GS7QW-9VNG+XYU%7>]R3K:MVGX;-T U'P^G%L^5);EJ.
MFU]8RA,C5;GRER+H<I<+2>4W^>7YDZ=?.YB<$'G70^]Z'#MAXL[W"\_Y]/9+
MO[ISLRWOG^_5'5C[_4Y2[]P@NWW*\)!S[.1^YMC=LV9I*94]"OXR67S TH4V
M$/QU'@B^*H'@7UW]].^K8/#PZGZW6I\NO*F'':$'M "T<,RTL*?QID +V]Y,
M23H#]'<%^@%# $-ZB2$<,*0K& +N([B/79/A$605N@DE^P7V'U_]_NX__H^F
M1#W/I[_S8.YC$WK_)NC#ED=[LI K2UE;EK"Z8#+'67@-NZ'T/  %<8*5@Y4?
MNUH^!G%""W=W ^[W__-_V7O7YC:2Y%SX^_D5'>-WSLY$H#AUOTCKC>#H8LO>
M'2DDS?KU)T==Q?:  !<-2.+^^I/5#1  04J\ &0#+,=Z1 !]S<K*Y\FLK,S_
M_OC^[>MC&$+%^[+;J!=B/IS-<;T0YYYN?.NKQ7Z 7.Z0&*,&>\0,%XA'RY&+
M>3N"=\$I,,T<;VQ'D(GB**U"EDB"N%46Z9"WP062B-.")'U]7='7X"1^L,/X
M-OW;>!R:;942(P/6UUIB96;NN>P*2!15?-(@(;BCS#*.*/4*<6XP<HQ2%%6T
M%&/F]!4;G96F26N%7"Y3S97A2*O@$ T^!:U3"(H\,$A(,<!8%)#H;3VO4HOZ
M 9S!_W[[_N]OWAU__/?B#1XNT)>"H*4@Z&-YE$):0HQ RK.(N$BY)($)2-J0
MJQ$8HXW8V&P817+*$F1D[E2!G8:_O$56F$"8)%ZSA_8H.1](W=/>M4^O0&@!
MHP)&15D+&-VZ<[IUFK/$D-39<R6$ :8H@I+CBA'GJ95A XR428(+CH2S G'O
M&3(Q420%C@(<2!GH]=6I=P-&9,#WHV#74\"BLM*Y1[EI:\6JMYZA5GC'_O".
M4B^TU M]W'JA7! 9I7&(*!80ESX@$YA$F-N("2%*9&*QQ2K6NR$C1@XPW0O/
M^&F4#RT853"JJ&O!J*U@5/).6"LM4C)WDL<T8Y3$"!OBI916.;*1#W2OFM8[
M6NJ5X#&;@E%]F?2W*7'=XZ*1VRX"^&;4UJ?]_>C#45?K^,7X%![KO#JQ316;
M+*:Z.8FA@D>MX:1/N0Q?J,:33W94_[,K!#T=KWBT\'RKUYGO6VPJ>P:N[F<X
M]=4HC/VD'L$+?SJOWMM)K%[63;1-O'"&!]4B7_B.Y44OS81F=@8&="D_>:2V
M)L#U->P^#"D,5:@NUMB+!&__1$<53(M7L\GX+*Y/BAKFQ%?X*]O%JIXVH+&Q
MB2,?*W=>N5D]['ZX>IXT\$/5Q&'TTWE%\1J>[Z<\0RA^WMT.IL($?F^_(\]_
M'E1?3G+QS<L3<VAG(Y]GY6*>K(_Y4?5K/!_#-XNIW?Z\=H?!-:=6I_:\ H0;
M5R[F*&J^QF0\^W0"+^Z'LZ;^'*M0-UV5X#SY[:=);&O_-UT5]$]Q#.]^=E+[
M*E<.CM-J&"V@S?)-WV0Z,VI%8H>Y##8<U"S>N'V:V0A.J#RHH,TBFV99?H(+
MMJ4\ ;SLI3L?K5K])V2\EZ.6I78QH/6*M06]O%""UT!OVB-?3F:?JN, EZU;
MX69I+D;G]<OCM;&PL^G)> (/?G&M3H_@[7-IW;II5L]^]6+MY#$</ZDF\=-L
MV-;;A3&#V0)J?U1]7%%I%S_9=FH,\_19OE6]F(7YKWSK5$^::?6/F9V "N5R
MM;GF27NG>HEC^>^7T<=3!\?D [YULZ70UB_0WFT\FX!&K]^.+&ZW_F33DWH2
M+AW*]D4O'Z$2]=M6,]YOMG#<>@7FWL[>M_/)T2T,U)O%U]?,7=/J'0@YCH I
M+6W?H/U^$F&"P7/ 6;^-/^?_3,!*_U$=__+A8FZN_K $F%?G\$0U7.;-R!\M
MYW'W[?*PC['^7U#UO]:G=<:UQ7'=UVMS_N]O/KSZ[:CZO;7A7?>,&[W&*L9E
MXU4'>)_/=E*/9TV58;8MD9G/#B"RX?@LGP?S>/(9+M9=UL.4SJ2E KIR-CP_
M@NLU@$NV:<9 32\:=<"=\KW!(?M<3S,&9P[:(7D^!O#5PWEY$N>JV,UBBL]&
M=A;:MP?9A/S\[5_M4F-[<6#+T_9M\JGP"C#<0 "JX;AYL@AUXXXK?:)_WVN
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MT],8C.4^ "DU'LX1W"(#Q!1)+N%PFD),5VSN>]6-;INK>)F=?EP!A!R9?[6
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M>S:G'[(U?;,PIN\Z6WJW?,T&!@O^^HY?S$T_*<W>] "^Z[+KG8N+%( L %D
ML@#D(P"D2#PR&SER(5'$@S=(:\>0X\PX%R4A3NX\0'PCR/Q^M/AF\,BD&AA]
M?9/AOMJ:@I$%(PM&%HQ\NAAY30_8A%507"&N!,_I,!YI2ATB"L#,T( YV>A9
MMOTX]8T@[."CUGL#7X\=V2X)M8]1+.UO:YUC>V+<>R'W0V4B](AF&Q3&L]S
ML'"1;7.1F\IWO]C(W:S+U?2$18D%DP%1 AC.K53(F2 1U1[S0+U.=B-;]Y[T
M9"?E /;#8[ZDCP=*.@I %8 JZEH :BL 9:.SEN;MI2(XQ"6WR# B$3:,8J]C
M"LS>&Z!V78Q &#7 0A2(>IISOA>R*Q!5U+5 U"X@*JD4$S8"49LABD>" '\B
M4I(YS$UP9+->SO9#O+NOA5!<K!TL2]Y-$6]80@$^6!##7Q8#!SPG3FH/GT/]
M^;IOV__ +_EN]6AF5S4=>R4P PHF&6@M YT'<B90HM$2&DC2 O\/^:&[\NKY
MBVOW!_26]_[6[>YEP?,;PTAD@2Z>YY^H'H7X]1E]GH;Q*PKU)+8S"80UG)V.
MGH>Z.1O:\V?YUPU=/Q*@M?G^\^!]]\7_SIIIG<X7C]*>BN(H/#\;-W5[[4D<
MVKS, S/E:W[O_"X7D^;K#>>!_(ZDOC$P]VNHM>V!>HWND\NR[:<A]$J5.;E8
MJ)G+M1X-ZQ$\TM1.IL_L;#I^OOX##'CW]1E 0;=F@VP"L3^SPR_VO'G^PR^7
M=7'=+F=56FKGAI9M5YGNWRUL,=TNSS,_M$V3I087F$NY_1<^Q\D/EZ>AN.*]
M?EA:P*5M7.3K1DV]DQX9N#O8/T!M8X1!1I&H! 4KN+GIZ#;YNG6:-"C-AL-G
M+^O&#\< ^(#KK^N1'?G:#M^,FND$'F@T;5Y]!3LQLM/QY/R'*@*@G\'I\&/L
M;@]V-X;CZ4V?N;79-Q@WHN]N!;:ZGK;M:?C;>!HK@N>KUQ<"KXZ;)DZ;"OA4
M]=?:NGI8K]:[Z>6KK'7)79GN*S<CEV[VIQ<P1&Y2_VG0V%&#&M#XM&2[ZU/
M!Q:I3GG+-F6@3J#)3CF'I+0"J*S4B<1[IZQ?J?W=6!R/PLI(7#\-=@!J^>@M
M*?2V!_WC2:S2A=;:I=8.E[*"03D]F]1-K*;YZ/%P./Z2+[RB+Q>\L:6-ER"H
M9>8MQLSM?7ZQ? &8YOEP!,1E/)L?TCTDP4#X?UP<#\(9VK,F/FOBF9W8:5S(
MM^/D[7D_7)FM\+ENZO8USI\M+G)=&D)W8RF/C%0_KH+4 @U:E/KE6R>3(R+O
M>NI=SV-'3-SY><M[_G+SE)?][O)^M5W;93?'K>;(]:*%^\/+\ ":!MTSR?-
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M98+#FIAE*?*0/,F_1MO$XC\6;K!/)NBQ5?'I< -E7724(VR2[?Q'YRE!'@@
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ME*)S+E0; !%[$  9[$@;*$O8&NZ [&A '*T3D&3@/LX$8Q*56,>-,@_WT ;
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MM[9D/4Y..11Z]4VJOER1OAXZ'SLYY7(*XRUR4ZY_J;74E.ND\Y0R4[3#0=K
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M+MB?[0&:"Z.L0,IPB;@&]=-1&Z12Y$EJ!M[:YNX24.PDO$916 8L65.4,US
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MVV1$?#=9-!H/C"QZC,=[+];NX<BBO5C.!T.*#U".F(R)O<F8,( &=]S_^6K
M;TG&LC!A::>MNFR:'F$3=;;(8:W^Y BT4MX8LM;(R7V6D\9F,S;;;63MS7C/
MCC)9Q^>#:.S8XS@:V#[S8GLZ8D-[%/J.XWE.& 4;:>V^&XSBP22RV7 *AA\'
MFR\83$*;>Y/!R(D<#_Z_S;1VS?M:1MQ)=4+\KN31<V!W=V33C8=>;^H8_^*C
M//Y[L79&5AEB-;+JKF75R)_XDWC@V0-G'-A^/)G8;#1T[4D\' ;A>.2!Y-H(
M?@U&0SZ<!+;+!Z[M3P<3>\JFL3UBW&?#012'XRV0#M]15OEN;S3QC:QZC,=_
M+];.R"I#K$96W;FL<D(63_R![8X'L>T'HY$]'<3<9CQVW%$0>0[;"(XYL>LQ
M/AS9S@"?X9YG@T$UL&&@H3MQW,'8G_Q0634:](:3/44B,K+*R"HCJPRQ&EEU
M UDU'DXCYMN3T93;OL="FTW&8]L=#IUP,G!YL)E4&$W#D(V=")/BX9EQ&-G,
M90-[ $)OQ)W 8]$62-7O:5<->M.1:V358SS^>[%V>].]B^:99!&,^\0#4ON^
MJRU7C8;U^R-O_'-G0G+)'\1V&/K^X7T:#!#$=P"">,&+Y)Q5R3DW&!![SFR,
MG;+7C/SAVRFW,4N&(S Q@ABLB]'(]ETWLJ=C%ZR4R)V$$\>/)H.-<,_-.CTT
M#&V;@7)'%HD[]GO#B;%('N5!WXNU,U+)$*N12K>42K$W]<-P/+''S UM?X(X
ML-A<(@K8E+%A&$[B#:ETL[X21BH9J62DDI%*AEB-5/IF+>Z 1],!2B5_Y('=
M$XWMJ3=R[,DPCIQA!!)JLID:=Z,N%M]'*@V=WFCL&*GT& _Z7JR=D4J&6(U4
MNJ54\EP>Q8/!Q/9&+L>&K;$]&0=3VQ\,I_%TX/JCN^J98:22D4I&*AV05-J+
MY7PPI/@ )8K!BC!8$0\DJ>*^L")BEA36.4MK;E5SV+'9W%H6.8QBY865YJ5)
MR7B0HM,8=,:@VY?4\:'GA[[K>_;4'SA@K<43>P(FDCT=>&[ 1[X;AY/[A(]X
M!2SPG\@!/PL&>$K\[V/Q#KB?B9 9J\^(+B.Z'@VQ&M%UK;8>X7@8Q-[0#@?3
MT/:',;>G8Y!%4W?*F<M&_G2X":5^AV@21G09T65$EQ%=AEB-Z+IN7,T9N%.&
M&$CCT<#V_<D4["\GL*.QXT>N'T?^@-\GN,3W$%TFUO9XN<%>K)T17898C>BZ
M:]'EQB!GIMRQH\F0(8:? P87_.D,H\ ?32>^YSOWB35A1)<1749T&>@) SUA
MZ/LJ61+P!PM2_E^*FW^H%[Q(0O@[2L[_ZZ_P/SN^_;+/U<)1CB9E8^#YP_%T
M/+!'S '9Z'B!/0E\U_;#J>=Z03"(G&A=-H8Q9\/1<&*[,0.S;CB8VBP:3^Q1
M/'*'/!A-G?&@TU#K15*&:8XY!!_C]_DY7\":E&^S=_R<IR 3.=<2\KU(-: ;
M/N,B?(;7/DOS\,M/%@?)N(0AJZ+F5R, U_O&HG1I8 1WWU'ZQ=7VY.KD\WG.
M00%(T_P";K6(/*QR"=(_I@0-M:96DEDIKJHU:&=J+%JK^J1%@YK@Y(";+(S5
M5:[D-WXG3A2."MYNIVR5U_(6,6?7 0;PL[H?UBIERY(_*?F2%:SB:KG%.:;G
M?MJ:&G2>E FI3ZLG:I!=.3_BQ:-1?SH:XYN_XM+C+.7:P=Y^??K3KY<][/;=
MT4T?O>ES@_Y@>./YFN_\=0?GW))?-KD^9L_68WWUG+/[%W23@Y5SWW'IMGSG
M/2YE8U+OI5+\PUP-/VSI[]?1X#G>\/L3^<T,Z7W8#<-5#FLQ#5?Y05S%-UQE
M7P["]](L-U?RX6F:/^(T6?L@+Q[>L>C*A]']R(?]6,C[I<^CE[]]^LO_FGCN
M^"D,?VRH=8\P?2\M/[MG_\#C+3^[6Y!?$W#XT5K^OB8A/$1KU"RG.>7FE#](
MLGP,RVEZ+^QO[X6_LZQFQ<IR33[(GG 7@S>RMZ2X'\SZ.P"M1<R;C@;#V'8C
M9V#[HW!@!]YP9(\&WA@QTP(/LX#6:AD9B_T@#NT1C\:V/YZ.[>ET.+9=-_3X
M=#H.!VQ@@-;,$372PDB+1T&*CT9:A(-@%#$6V).A'P+GQW8$S'=M9X18T1'W
MO7@#EI.%(^X/O=@.)MC"8(#]K">!8T^C(/+#8.C$@Q\&%NT/>B#^C+0P '*/
MV3+\Q%NIQ5;!PWR6P1=$F(<<T^GCUE&2A?F"'R- '/^ZY%G)]Y8=&\W@T)?3
M: :'IAD,!M%PY TBV_/\&.'<7)M%DRD(_1&;.M%T- HW,''8F#G.)!K88P8/
M^A/'MR>#8&H/)T$8.\-@['MAMP+E4J6@5:+9X6B?-$-[F^GGWA([^UB\%+SL
MCA0*;]";NGN*FF,.]H&OG9$QAA0?M8P!Z](;#N.1'4X#S_;YE-JZ@AT:!/Z0
M!PX;QQN^2NX/G-@#.]7Q!@-L!>O;S',F]F#H!-YTS.*QZQ^6C!F"C)D.C8S9
M6YO51#-_1-;9>U:$<VM@HIL_1&.0U0=B/7>7@7P?;!*OCX@15I376 _]\)&*
M;K?X=PYD=-7E/RR]Y2ZAC'QOZ@^QL14'J]GVHZ%C3[@SM%UGY,9!S-C0<3<Z
M 8>#V(M AQG["-? !IX]<:+0]L:C432,@I"-QH?8"7@7\6X4+?T0WF&0C8PL
M-++P@*C9R,(#DX4NF.1@H@]L'@]!%KKP/\%XX-ILRB:QZS-_' ?KLG#J\'#J
M3L&4AU]M/QS%=L!<$(@3%K%Q$ \]C_TH63@=][RID86'PSVN ]IU]VA5]V<U
M7P.\BE[U)*E@%N&U3.ZJ+I)J99UD+%V5B:[Q.I#Y=TJ+[Q2/+9IXWM #CN3Y
MHXGM.Y%C,W<X F4]F(:3J3]QQALPV]?&8U/+KU;_55YL8VRWPEX;/6CHM7H!
M\X<7E=9"D3*3BVD=@82":==9E)1A7L,XD14P^.48!8 %+P.FKPL=XZTM][JI
M%!5,H<Y8'24X%DPM0J\P_8OX/,/+907_$2AP>=P:=IF7"4E-1C_<YJ3=]=(J
MSUO/0CR=)_LTM?8)?S P>;[?][WO#0%WP^<F?<<_D*F:3S2?>!!3O?DGWC/;
M,"".>YSD^0AP=!YH9;9!6=NZ,VGUU'*M%6>% 5O;%YP>PTH,*SD\5N+:0^(C
M/P"CR# 2PT@,(WDHC.0OL^JI826&E1A68EC)+5G)Y[QBZ5^#XM?_PFL81:[5
MWZR<VW&:7Q@>8WB,X3&&Q]R8QSQG1;&"NXBML 4&.0U+V1>68ISIQIF^;VOX
M/26!._D!.*</E-'O(4;]/BSZ7F*A&LSZ'U$]^&I;_M8^G).'62EAP*P/W HU
MRVE.N3GE#YTLS7*:4VY.^4,G2[.<YI2;4_[0R=(LISGEYI0_=+)\#,MY'[!L
MQK%ZS[!LHCAT'XZ(X=R&U1C._="7TYQR0Y9[2)9F.<TI-Z?\H9.E64YSRLTI
M?^AD:9;3G')SRA\Z63Z&Y33-&?>WU.!97A0$6EA:1_QKF-;X?5;*6<G;N:HW
M3NHV6-^F4]9C@9W?#U[^/3IEQ>,X'D\\&SFT[8^'L3UQID,[F##7'P?P"]L
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M-GDOK,RB)\_A<7QMS=+?LB@IP[R&\:+GK)S':7[Q,;Y7$\OSQCW?WU.(12/
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MON6L@KFP(K(&?D]_A-R)]K2E:TC/]3DO<"$[$\"OBK1OJ81=@E_2=-7L#SR
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MT/JCALV*$W0I\*+,LXRG1JTU%'<+BFOE86A?[.\\5$ZS5*!BRG0,6;RB <9
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MPU3OQ9DJ"PS#$.B&\!%TZUK*RU+=EA2N:T)! T'&HK^72J4T!&H(]!X(]%0
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MAL%@"OM-A%=<5%IXS_J0G^?P/T6$#;Q.?CW3=[9_:&X7?B>AF0NO#2NQF8^
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M6WM*3*3@Z/BP8N"0HG9SRT?E*@J!RP;J+BM 9#4(\W&-+%! E6GD:]58#6^
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M$PQG[:B S8/6H.1LFTRM0[^VXH6MS[F8Y\1\XYJR(:*Y#,A2D#@IVG2M46W
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MC6<A6Y8R?M?-C$846N2+5'LK0S&M[&61%DY,=5M3TQZPP4IX(D$YUB6Z6[7
M=NA!13U+Q>>4W/U02Y[U@B_SRA@\UY]1#Y4%6.BV+P]LE]<<F3\/9=;362,=
MGJ%&IOH!-DY$>.;=:[ X8FZ=4;J9+,5LW4Y&57]MSYKXT[D81=D0Y.R<3@6F
M,,5]4/9%!;O(GNZ8CW7T[IDS<!SO6(PJ^KG_V8S[\CD.ZSGNH+=MW#7< U;)
M1O+AEP:GDOJX+RLAC%E3F:]T-:4W[,(<DH7^LDN-J&A@I/:1:-]]]!H5SN!;
M[GL1V=04D9DBLE81F=%%C2[Z?731TRO:;?ND@CRQWK?GNJ9OYJBW:MB"#LX
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MN&L ,_%RI@2R@OTGOHK/E0EL'BO: %#- JH9]>540;7\G4 $55ZL4L$;O4
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M9]BUEM9,D'Y6+P(<&Y10X$\E8A\F#(9:P E&)/4<7XM4A?"(UN]U-$.[YZF
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M0CR A#3/)*29A+3K02$^%)4*N2MHV)[UNDXBRB5H2? S2D  H0TTG*E8V;^
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M L1K0;'W+Y[& F$!I"M^P#8SX@6Y>[KM'#^^>-'NYKC5,? -:\ D_1Y TN_
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M85"Y=7>KZ;)K6.![=_@!EL^.,NH?FR9_KQWJU9O/E/I8S51GMIN?+S/R"3B
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M>D7B?94F*$D::0V_'444QV2_I]41&I^LBC]3,&JL4F(E_()X%#5@4, EWL;
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M@Z,!5OS?FAIB$!2%6D\I_X1X'<M3$?O#.EZJ!P,#^0*D4A;17U;2Q!>+$6\
M(UZF=?G9U&5X:Q+YBU0HB"68S@Q(I9*:#(A-:4KS@F0RZZ7:?)UZK^7^4-8
M2P)\K:)'ZLD9D:B&WU.GEHE7B)FOIE5OM5H_5(>ZK7JGU>DVN[U>H]EHN#VW
M_4.Q!/E7*><PSR"CC=' B$1W4,4XL+N9_E!0Q?2'L4;ZTJA5X;&?C:-NN08(
M!1#\\CO*!M-#=Q.J+]WL_=3I'2\#NOAPI8LLX(@P<*?>/Q'#V6LJRE,ND=%V
MLS^L*1L'PS=[QTYQ2)MCHV,>W'H['_EH7BR>D9T>U.S,__(IXE.TC5-TE0YJ
MNFX+7B9B$LCI5MG-;;Q47NLU6L7_ZVZ)UZ)]Y+(+B[^Y<8( US$>U3M1&8L,
MW87*.<Y3[:)ZH[<6H#OU1O<; .TV[@;H1K, T#\A.O?;6T9G/BY\7):/2Z=F
M#?F[#TJK^Y"# GK )DVFP.<;#LHW-)E>_P&:S LR'7$7+@KF]#_,067SB!6[
MYQ6YSMU0XIXL0\E&-] 2K+CUSGKYVZBW6]\I?]W.LOQM]]@ZXD/T_(+X&\>G
MU7GL\6G6F^NE<J/>8:G\1"9PEI1HW96*!3)CR5/Y*U?+W.KJ.H0/<+(Q<NA=
MZ1IF&_[+]?BS\BF<2J/>:BQA3\-]E$^S46_VV9?))ZQB)^SBS<5C3]B*8/_&
M"5O]E#X7J,H63EB-?O.X(P:'U6C#C1;+<AUN>FGJ$EZE,[P;>@YQCC>W##<O
M"6Y*X'!7OQ"3YU>,V=!L.H\CK%A$+RL?IN.98! P"K+PT%54,#7L\\_-L/16
MGK  O!Q/\!\V_TCG'&5!*%_>GK]5>46F$-O<Y,G7I60ERE)S3)TES%L;Q_+/
M%!ZE$&4__$-'9\+L$PS1UE61X$L-O XUG\7*@*82&5E/Q[H! $Z:U0$^GT]V
M/G^--AV  ON+0$O@I6X0J]EVL6DCYMU@Y[!R(S$\'G"*;!WB#5^]*GZ6XNUT
MPS[=K:30?:+XX9<NT/]%Q>AF?J+=*#C$&TRM/I_GT?B6P+^^.<_HNS:-ZZXL
M$RQ=6&[01#F:\$<J"*TG 3. 9[[JQG/G:3*-8E_I2:R;T,?S[YF025?.BI!]
ME"-_".=+B?,)(;#]S-N/^6>*'4FF?DS%G#!]F)Q+AUF0[+Z!O6_D,(OK7>X3
M%\*0-@!B*3MD &)VC/6>U]6HRI& 0EN-K+<!IY\^O#7!KA0K>'ZADT@4Q0KK
M;DW-!T4'.Q366I-JZ 6:U9*5'D_+&56%>."&N49<&PY<CH-%"=WIY15$*:<\
M! 4@;]R(]7W)FXAAD!E7K]I-H,RL"=!U3%PPIDE/8FDMKEA.L!4J%FCWD,MM
M:5!\V%1 0+L(HUG3>$MI,H?"XUB\$WD8 Y"]:P_4R4%@(]6+S9NP@6P4@MZ8
M)<4^-*A:^A1*7.1[+'R8L3N= A)QUIS&"60,HV^8RCVF= 1TJ51&,:"\]&[G
MN)Z9>*87DJT-J<H1XFMZ7!$]<O+@X"<UMYL]<6R'+(5/'^D^N8%8ZF[5H0Y8
M4UUSQ\KP_XT^F"K:2C=F@F4.*:9]>;UZ!R@)TRQVW?PZ-;>5SX\KUNU!#E6?
M<Z@XA^IEYE"=9VW(35H1R 1 L9D5\2@UKGZN@39RY(&4(:,;5(NP9N'2M 0<
M8O.-:TF>!D_K,UF=^;P$F<%>(W&"H#:06@'V$BI12E5)J3BP-:^TU;6D(-E0
M1%+? F#[XZQ(T5*'";H3%F]O4=*1S^0C3!JKIV36Y<7;CYD^[N5M<&K9NK+N
M!:8:"#IV:0A=N51;A;HXM!8=:XJ_8DWD):(L2:&E,J[.2@_%]>E"HVQ6E&V_
M+$M)R5M*08/=/=V*C[5=[S3[S^5CA8^U>A7RX;3KO0YL9+_;/FFV>NU>L\,^
M'(T3GZ<+1>?%^//MA4?3V71XM^I79*YDKEPJ7_KVHWA#K4X^:.W]9]O 1G-F
MN[=G'(@C, _N'0^^G45&"_I7KOH8%NRL9<%=5D[N;ZH;TO]FY>1N^V&5DP]%
ME\9B0NUNKJLJT.'@!]M+T2I@V#O'E.TC%\VR/]"XDN]RZ>#?T8%3NJ?,5$+C
M[=09^VL=?T[Y!C-K])6Y3Q4JXN9#KKLAX&+=#,T[\-4:?763P]3ZGDJ>UI?J
M"WQS]SV ]G_K=CDPV?>_OL$VA.$H=^&66DWIWC>V!E?!>[U4Z:+LORYNU*9*
M%TZI\*PIE"4?4"9+<\Q)ITL<LWIO5ZC<L%R8XH[B7T:Q?%CQ+ZX+6(%U+S6N
M:VXJX&);E^H:+D]V,W._<G@;ZXL4/<:%@B]WWANNN?")"J$65=BDE\J<*,YS
M7C/U0BSHC?#"[1$[6P1:JG@C6J>NH,K.Q<(YYLY&4?Q.0F$+6$V0RKX@[ZH[
M&?&HNWJ!UUQSJ==9\[LU0OUX4\$@4S^1"(-=<U%SL!4>(FI*!VM1SM(=+?G-
M[G'I2+='KNZK6"R_DUV^T.42^M9*E27L25U38B*3)UKK;CY]Y<7]8N[\NA@X
ML] 9K6W<D9V.K:(3Q?Z$;MB*IR#!/27OJ>XU"WNEZXY2-&[KF/HY%120K%RI
ML[;:DV&LO 2VO//F>NVUM>Z:!T-0T5.*T,6(MM*;K[,?IK^\0QH,_+ @%>H"
M0Y5G$76Q0]<X_0W;8U'P,CV(9S0AP5*:TO\1I:$O"D/K%IF+NCBGHUP.9G%$
MNY-?@F:KQWR#0AW7WOI':*4OE:U!H<@*5>==(.EB )1AK-]^E:0CU$Q!G[[6
M-HI1BVN:+;'#<XI]$G2[M 6L"%XH*;[8D1!&5Q0I3MQ%G:.S2P;:T?LU=JUG
M\T*46ZM=+U4G<\0@&E$TJFU<GZO:Y:;MH%C%6O?]EA*2SNF+M)Y<!P'5S"Q^
MAL%,IITH-KDMWOL;@Z]$7BT7]+N2 @[,4V,_5LF2==,NA6[-;.-)J_+EE^M^
MN!H4Q3?JU;Q1/^$;=;Y1?^"->G\W(NA&,\0 (._!]'UD\?L'*@DOLRRA[F.*
MH@"I!$)T>H/=4CR,A$/)C!&.H(P%F;L3VY=]E:"_HC6B^Z/9R /2!VP'EQ'P
MY8)D$ND')H!<]_U8F%*FV'^%P@_03PGS1I73E-L<23 P_*0NLA8&J7;BCNB.
MR<QF"G-#UVN>=8'Q#4-LN*IP@<&B[+RU'>&7JH#>);:+I4!!.H/^"')<CW,F
M,"KN&I5L?#%*$R :Z@NDFMP9)+O2[*:H$"\[[)#F1>YUJ'$T"O*)) .6&FAA
M3HE6QP<+,QS9@3?H'AG).:H(0-^9Q*P\7\V4[:"%&X<;;JB2]6,I>5J B)'9
MO,/K,GB_P@>FH4/F"RM84PK>#F0-PW"-"[?<XN#.[?RFXHCUBY?*%VO=;\4+
M@)]=]AD7DJ H=0E-^7+ -IUI\L+519[YG[L6J(E%:=@U0ZZ$UF 3:]BJ"1U>
MZR90CIC;R 4+&[JI ,R!5&YD.B/;BHX/&1H7>=,M!*[F$PF]'__2;)V<7<.7
MPY_<YAD2!ST9=]BR1VN],.AZ\1+$)E"B-;UQR),'.S$.A.^_ !NB=YA*<C2[
M92\Q1IS;\Z"-?]/AXUL.V5B;<L,D-UMTCO+W9F<<C'IXH,K<PU2WSW$T2@%@
M+@ ?*%R1TL7@>'\*<;*3Q?>X\)]\&8?7'O21JKC.$!.?J$=G&J*<0-_G%O:0
M>[P^E;J#;4/CS.=)>L6 0@ZL=]IV3Z3&CJ1-SF!W20NHB_<V3"(%M3-6B9>U
M'25M5P8!]11%L3^+ JD[C!9T4S^\C@*3Z^W!%&I).L/.I+-9JF\JYZ#52T7Z
M_CB5@?$_ CG\3,W'=&Q\/JI%AM.*?0<53I)&&T[E\*N^Q?##J3_PP>X!146E
MV(1!Z<]_?E,[^G#LZK1O_,7%EP_GM3;]&_06'R]@*"',-(K5^7.E-H=SG0A>
MS#OB&\@*K/L-,)/.U1^:"@'(^@I5?>H2&TJ3K$4[FN>JFOV,)3IMU&H^V2@"
MVSDQO(I&E$,IT],H^Q48?"/Y)ZK48*CBWX=I'./8FF]\['7['MN<Z6AY'7BB
M4KQ[\XWV3;=P:+^%B_QM.T>MN0?^S$<U"SM(1K=H5?NV,ZK6Y:A9KDZ]0F&+
MJW(*"UW* U>TC+P)GDDVB'WUE4!BA;=?&#N5#'NL6@$(XU$R)L )T@=+2>!E
M<Y";W-EUZ@VY8VC'$"Z7TN:U=3>DZ#"] Z8#\MRH2<-,31*I(KP%_3SOFZL[
M. ,6V0:ZF9Z5 /*&!)&.[L9,\73V1BYWJ(BA'R-6TU>IH;=I\XNX6%P9M8BF
M]BEXA.;2^UKNKVP8T*/J/PFFG"@5#?T\[,VPZH(AL@+KQC1:Y ,-,.15HWZB
M)=]&SD.4BVQ%+MG3XMJ+?:G= RH*0$:3/%?FREO"PVGL37 \L+?Q YCR"</,
MB=?2&4*5CVH$'"@<"ZM+:0V%5 @9>"&L"2]ZL4L[V:9@.P0R_0J#V/PGJ7-\
MZ32B;O'^0ZU9N$S&'Y^@??+?KA8SL#'^YF QC/$#J#ZH$NN_KA!A)I5J<HV^
MTS%\AEQ7,M&B6GM'R#M+;)4LYE(#9@&CRTWJBYYFG0JM^=8\HB7X1[PU=\1Y
M"+HF.FZI H8,0\^!>8,BZXA_R5C>1,'8 =4AC*YIX*M%"%.!HP!_?P/G+ K'
M@;G-/D^#J*QF\(G@$_%4)^+N$Z!UZ&\A?O&<?)3Q\*LC+J)X*.? Z+_(4 ;I
MK8.I2/YPZHLK+_RZB(C3X6\S;T"L;N4%LSJS^HY8/>=A>OI2SD'K3Q&@#<1_
M!E,@FDB X_<SC(8;*D<[+")=GA-9^E)2Q;M"G/WA**:/=-=A%_>K*$@I."(_
MWE^L<FJKY[#SL=KVAK6A055'2S?/W,D]:E3\R#>Y PFL3&9)!73XLK^;V$&T
M>J]1GJ#[D30R;;<FOE*I- 6=*,K9&K+D<3$V>L'S8R[(2Y?X&:?Y2A==4*EO
MJBO8$8S!4G#/3/QKJ2^_ IR^ +$WT%=?A?(,M# 3U_@UC&Y"[1_09G1=_(,,
MFF!AS?TT]/],P5X+)E$,K\RT4#4. A]50L\ZDVS1!;")5K]'%KV.!U&ER([\
M[MI3F\F51Q%D1F/!$:72 ?K/,+ D\WW0-;3U4+#Y7\WCN&KM(Z"B%-QP>D)T
M5RG]EV)^CYI1Q5/M^T=OZQP4.+#=#>/%, AZ56U@C1F'SK=A#<?T2=:Q1!&6
M@%[]/ATV[<4J1PBC,[<8=$-N!(I0]JA0;"PG0"_KI[JA;Z [EVRZ&Y^L,S'&
M*0T"R5Q:@76O.*G\\%JJQ)]H;R7Z82W@82SL1*ZZ34NQX20^;!2-89ZLL S"
ML+F,TIA% 3(8\S+$5V9$'BMKRI("0=HZA,&6&>-%TU J-4Z#W+.&60YWXNO*
M>3+(J;VOA=AQ9P/,VRN&C3YG"NWA*ZHJK!N5V@QY5[DV9WGM,<H97U^@%CVN
MJ)\4N=S<5ZZ[);!<%)M<' VW!4U (Z\=0;.IKO(')@PF$Q1N;BVOU@4N1CMY
MLZ)/NEIPF/V,20V^U<BP]F!8F)\YER92<KA((I((]CC2@2M>;VD:Q-$ 1BC.
M*+]$'BSNH*Z]2O%#4^@[62),M4Y(Z8APXD8E$S>:#4[<V./(O!=5"G&7B1O?
M[9.]Y^37^2(?.??O<MON@-;?Y=E]?O).]HR\@KPO5YGN<F5UJTL=@?$RW7M\
MZ<*7+M]#F:,HO/;F<F+".[Q@[!VC7>.%19N?BL M1TFA7[AH_BSY9G6\J,U2
M2Z9QE$ZF!=O#!DYAZI1A7WTWF6B+0\'?*6D&C7#C/U#,YGO#YE4BC(F-0E,3
M_>0#7X=0 ],B/UW^^)>3=N=,YTC!+_Z1.6AULPJ3EN.^;N9F=E;J8TU1L94"
M3 S2S+W?XX@ 8 XBZXZDD&KJB#&3B4<%MX=+@8!>0+D%U,JYZ)BG0S"7LT$,
MC_\GG7D#?$B'5I$WQUZK68>F8Y* ;94="FTN5"&C:C7*9!227+ 7 _!EN@*8
M4QT,6XTC+U*N1[J=>[IRSC":8K)O,1[%!J_4-H8KVI+HGR\_7>0-Y^ OUW1$
M;8A+'J&"TWWW]K+Y?P0:^"HQCU3+Z_1"_;+O0W$EYTE66J^]5%I/)[\'.IH5
M_9C((ZA\4+I,[OZT%]6Z;\HU9KCCQ%<ZM=!90,[)2H0>:284K>.E!%=";901
MW;/7^)_>V=J#-9S*6:;O9&5%=:^F7((LRY=5^5#ZDJVWY(EAFD1C3-I/2&?Z
M9PHK:YXXAE8F&\CM%U)ZL0J.1QT(1+=MLIW- <M312U=O:RO@B/<MFZMD)<F
M(R&';NA26L;4TWV:;'#[/%))+>M.JUW#^;A'ZAAK&Z:D7-H(24Q>QEL<RO+(
MLB-DL>'D0(ZC6!;*\=S]&3%*I>FY1_HE**43@!""&7AP!,-.^<178-V:L2G$
M!,^TYN_\BJUPJ4#,6&Q9VCSY01RU7[OM8SO$7:QZA(4;X+O /3/30PU_ [B2
M_6[NQ70*\F]BP/PRKV<=K<":D<1D"M-)3'Y\0-WS2NW*Z([3/2M*M<*8P)R6
M27%TH/8U=G@DQ-(\2WW00&V%=2?IK8\"6T6Q=YV@V QE;;((;X\QO6XR05/-
M1.SDEYSH,7DP-&H]6..L'GBI N(:/+RK0>TI36H6H;R-9C.,(,,6L<6>E*4:
M=@9!OXG!!"4ET"4^&<,PDU0Z9'*"]H>W6G,98OF14*9);'_0Z8=RAC7-/N+D
M[OA6UO5$SYR^,XF]$0 N8DKS &,&[RNT_XD7A9F\UD5;,%=UKN_&5TH</$8B
M5L@P8(MID\5TETSM]#LGG<&#)W..[/ 825J%S7FCTZZ,ME707N!(P!/9K;NM
M^;%D$5UH9;0MCM;A$@J6;N/L#FTT#]?]<-E[W1?GDPCOV:FA("I062ZVFQE(
M.G:@V*L4RT):@:4CL9<,0&.W&<N2Q.!:O2O<E!F.INI$OS[P80[Q5ZPB;&(6
MAE&LK_8P-7Y=<$*!7M2=QZH(F<PSE:.L%DV%'V&:@7"[6G->TCTRA2 ;854S
M6-%&VHT?M(Z!T77P%2S428J)54IJ:Y02(J?=Y)((S\6W6H!$G>@:W@"=^ E,
M0PJ6?*OER/ARXK2O0^U&<)HQ_B-/>#:4T?-8NSEU\>GN)3QRTTDY1ROF2.<6
M:D&PB;6.K:&RZIA;LUOY+AUA$:_+MQ?OK[Z(:[?N'J_9MP[L&VZ6W3@,:I;A
M<;E>Z%TJB*YL#8>QW^B<]4NM K"8V4*T=/WFTOXN,R<MT*J,!6^'D@D^CX9<
M7C$,*P*WCT^!7IN5UX)C).L41Q !0"B'2>8:.?N6<XBJ#Y>_97U!^<?PX!6?
M^'Q)<5(8DUJC,QJD5-EBPQ<WX!158(9O-TLC:[^2@:MCTU484[DU0WP;*1_F
M&=LTMU5M5V3:K@F)C0A(C3\8W11>\&+3^-^7:G,O-\>VFJ+N)&P;7B^IB1O0
M03^_C Q4 #M9P#IN"V!%#@U;^HR*(&] '&"ZSE*=/F+RIKO!5"E)EW2"L7%N
MQS%K+<F70LC<-\W<-?9/A=0]UH/WXGJW)#E6!(!U@A[?#Q&/=*+!,J@[Y /4
M+M"B%-"]ZO.C3$\4G2XKLN3XVU[;:;393[)!B^$SM'=GJ$J$,9J<=OGI;AQW
M>;N<3 &820]''Z=!H;;GEUA.=%Z.C)0?1O.I'W!B0!76O7P!M:RG&+0J6>VK
M>LD]],KQ6G/&U/8$%2/1+K!B==9,;Z%,Y<_--V#08<4H'<0/ZD:I68YX__LJ
MTP(.WL!8BQI"\GJMZ 7KIQ^]Q;?W'+?-[GM1L"[SP)T[_+C=T^^"7GJG="RQ
MB2?,_1]Z)-!]L'1+D>>'9A72N&:J9H@KJG$^ =I< #V]060+;2%=WU-8'"4=
M<\74ZAUF3%T,5 1G88(7W^B*R'9S6-Y-L.;&:4S1+^CXB?'YJ)@>5DK,1627
M,08O@NP'M=,#T6VSWHN9]!A98L+-J%1KS1;W'/@@[;UX!C3 )TW[*M 1I+YR
M4W)Y@IX_RUK,@*H[\W72[DK=Q+SE#)FMQ01=FEZ^3BSQGP#%!6SC]([%DNZ>
MHE$ 0(67]*NY7([V.U&Y4<H0U:4!E@DQ10E32'3SZ+40YV(SG6G&U(TH\95T
MX!OS4D-.^!FCQ9<J*]U(&F$XC1!^,?TNC15FZY>I2-Y&G0BJ$Y-U_=SBXC =
M+T)-+KI!1%Z3ME;<\Z$90J'7D$JDX5A82 1@=I@JLW C!'X+*4__*J%Q< )O
M4[R"K*[*QXENU4QT<SG1C1/=]B/1[>F3@7Z-KB/Q*W"3K[Z*\]=7+U/76>I&
MK$,P"+6LB]M#WYJD7HV43%ZHFE66DAZUU0'(PQN="=@=>:./$JU)R%*.1I0G
ML8-@#%'*E9X$\LC;89 JO&"[B>)@=(/"TG[$%!):5_(4(W^Q;V5!=%-9YG3L
M#9,TEK9UX$S&0["K4)TISQ$$+)9(Q=8K1I@K<93'8%W)F3?!LE8C[7'$.&K0
MPS$J65]CEIZ.!E)EE9&P]&03'O,&8,&I8V-HF8_4!HN:51[RI=L%H_[HP02C
M:T_I&NWV:]75!0X#8^[=7S9G?!.WH71%!F6JD_^9^M3W/NMI@[Z4C(,+;)7I
MD,0?Q:=UL/T:KJ> UESYU"T"?.PSY8]]Z@">U2Y=8?_1!BXFV\$GN9+9+I8Q
M=>GRK,VE#*SGLA"96U@\11)N8%]0<D>F8!"Z-3+=-R.GLX0,:)^96$I5."DQ
MJA&ZZQ*&=>!"%R: #*F^LL#\<!/6:=*NF" ZG)'ZH]%U@3>SJRXC(":]Z0[5
M8"0ETV*+ZG4[FY<,T56-_""PL=18@9XJ?]V%'7SH*[#NG'$+O'HC-Q3@LKW.
MM8MV[BUTY3G@=MV/]J_-?D? C +C"$[GXSC"$8MB%UDAEA,L_([->N%Q; Y(
M/EDS'AZU9(EE5VW?NZ>H/!C60,J:3^A2?:0FQ-'""W3[73!R@V@  X7 NC2"
M/CM+ZS+(Z&4+%&-)*0E_Q29@]CF[BE5!J,\+F,ASSR?G1$HX]$\0\"BQJ5,5
MM;"66.:_ $<Y &P$H]7C2<2BTPEX*H$#?>,GL:1:LX^]7KVTD0_:OYUM51EC
MD9]U52)L0)F].;9TS>=B]B67/;FD25?/1]YL !4\X_1&KY2O*V3-_%%-]_"#
M/9GX"3931$N:G&M&+H2PTX6IDS<:.\2LS(2$0(QQ:]1!3Y/---:P>1YSCVHE
M43DNM*S\&8H/WU9:&OA@/ %=O;QRHW$!J:F'Q5\-I>&W@.YZP596FOG8(^G'
M.M:*G%TRP/3D5$M)=%TMC'=X;&X!+K.)G@\QZA/&@B5/(M/"\\5& ]V)N3G;
MP@OZ()N]P$F9O^J*5QL-FV+X^+H25-GW5RV@&UWW;AU,##%F-I;^;  6D#X)
M%'Q4.G7()]BG%/@!#1@,C\B8>^-\35Z&7YK;D@V&$1+F -!@=RQP"0A\9<,K
M:$740@+4*JTLP4;52I7#LA]*Q?1SO',*BF?!)/-MW\FB6II=AGUKQB87 T-+
M@,AJI7^)[AZ54>FE'IRK' 3O4K7O8X\[N4'N&.$ !@BP)R*Y03UC#E"U7^HC
M#-^E@1&-+3(Z6GY+S?4%N_O9[/HJV._B/%-2L!?$0>W +Q\^UUQ"P7F25S^V
ME?PVN7 (9L@BLJG?,%%8/ Q"?SORC]<A>TSH&XZB8>R'LOSVD0_O+(U)U0@-
M--I$P(5>A3<*Y:U.:8 WO_FJ[;'S4L'E-] % ZTX+;*NA.BT,+Q)<$/4Q.V#
MD6J83TS6MJ3K \<*3TPWP![D?F*2^ZS@<]:RG%/F-R>K2$"%@6%"0>0G^57;
M>%5R.R30UO.I*(F[9?W2U+8DS6,@95C4,U<^0X5G2>]%]\7**DET8S-QZ[4H
MKUEC\\9UFX5DU1C,NC,1FDWX+D)8OT:.A^37@:G=9V^I#L_B^VBT'HW9U5&!
M=?\6@J6E2'?V4<>D^",=L%C6-['BAU=F#>( FYJ/30M#%)IK#I0N.$Z]3H'I
M@-O K/7A!<V!FN],0VJ4 -H_8&VU$FMJ<\[8=MJJRU17G0VE_P:#_Z$C?G7U
M*5I"]J>5^9F_8"]22MN@GJ2+XLM*&X*#15EV#^'/L95XR\-FI:Q'D4([UQ0\
MQ^-L'('9]^-H##8^G702:+8-O2 0+:0)%O1L-)(WV\@8X9+JVNU(<CYL%5AW
MB75L[?%,A\O.WAI+#S/1J LP[JM/,7V)'U.[O_B.<T?GC"14YFSZYN>6/T *
MKEK2N0<QI:#9@S@%+4J&$ZE6S-+"D=1>P_Q#&*9#0G,@"[B#1TSZ).VT4T6[
MP,@2QS2!%%U>,X0+/ ,8J !,/ECH[*#":\;/./#"KW$Z3X:9B"L\Q(>B NO^
M;4XV@M[_ M[GC&(\>D4&S*%5CKTT !U*13/*X$-]WDH,ZZ>S9A>P2:J6AWJ
MT6/$S#JL5]J9C"$TU$I*7_=8KF9&J\"Z[\UHU@(UO*4TWRS=5I:## UBH?:2
M(:WU$&R+^]:HX!F$;Y0*JRX,D@EGF:9A];<5Y";24(**'*W1Z!(*(H%_4Z2Y
M]I7'15;GH,'J!@TV.6B0@P8Y:-"$^$C_#\#/#[IW&H<,KDEXTG?SRT&$X1IW
M^-(%E:&MO?6W^0;+-^=K[X?R+GB_O"L4<?C\Y9V^&<I^<_'K9WV!;3S$VM=,
M3F-[_T^!!$#G;P<E%>=M:E>9ZFZ%R 8K\#"ZH9<%-ZQ&2MTG0J 88>#V.OE@
M":X/6Z[A)3'%EY4H51AA-;9@TW5E*58@OVFWY''RN7AT9=]L9)IV?F'O8$5N
MZH8XR&Y<7JJ#' C_!FA;B+4U+%\\/!2I,/--_1LJ;(X-)<V= _%NZ=*TD)%"
M/V$KLVN=_CGW, 1C@N8OF+ >Q9[9TU7( !J+Z6(>T1/311SY< YF^2%@:Z2*
M<NCW]U=O?\5,TD(NV'?E$G+SW&>1EFY_15K2F9QEDHQVUJ$4-,SL6PC ;6\0
M^&JJ+XF*B6AEFP_=9W>(M;S%()SM7RCO-Q874[ )223 C$-M7.57QNLF5KB9
MUDRX+OAV\R3S&]N5J)K,>:<SC>^ZAJ:ZXOG]_$.DO[.R?,)$XRY%C] TG5'K
MBL+%<>'"JA $+>>FZ>\YUID+\5(MSE$Z<Z#F/B5X/:=BIBMT&O7&#Y0X&*NI
M/\_J/J<)%O&B!5*<F<IVP= US#L-EF_Y57&7\H^BQ4_R'$QU/RA$Q_SN7T?B
M0J=(TMA7T5CW)A:_PTLI?GN>QL,I[9"9#$Q33T9?JH!6!&H1-CG,'C41:ZCX
MM!O%8,BAIZ;$=(6 39>(HAN&H *5*T9_=9OE6$I# T6.V8PHF?+Q5[>3?^T*
MA!],]A\"%N2%J!J]5.WC$Y8HP."Q9H,*2W6<C)F*8&052""K3[$QNK;WG,)%
M=%]?_+.M#_?^\Z>L0)PN9R7>83G&_\'_N4JBX5?Q]A:X(9Q([=//6'ELK -=
MZ.#S)UU(@EB&$A[>_<\;T>W7^PVZKJ#7=-&3V[GV,^FX@#2@:XA)'"D*7AE*
M.:*3@N_W^BVGV>\[0&EQ1*H15D!.L!_,;U=O1"'8^-B4%2\$M:*6'ZII)'-%
M%\=TW9[3[I\XO>[Z,3-6/<8%8TK #*_5*%P9I#3&_9"'3Y<D'^D03R 6W?[?
MQ+KM*]4Q3^D"$O%3JX,FRDU?2F0[@?0(E0VT1D(.@\@@J=EPUVXXOEX^+&8[
M!G!RL82@3C//8P@5[> P LVQV>FZ]7?_@V@'NCU,T*@?8AH%0/&VZ[BMKM/J
MMI<! B.Q@T!7VS=[K2^,+XR$TSG3K9-Z\X?"2[@:X'"P(3*32-[ZNOXA?0&_
M"Y!9D$VY1%B:HZ,]K263=)@J]+\#^@2PQAIL<&;74;QC IR8U<.V]Z?ZQ)@%
M(O!A@3A*]L ?EU9Y5D Q#.JRH@-K^6$'"PK#>O!*EH*9RX7P[5(B.*VZZQ)V
M?\VJ>@/'1$8BA_J4A[9ZN@FJAP\5EI3?*"-?T19H@;3N/;>Y_C4S 9WJ1_?,
MI46C<QQ#811>IB\+.NLZ2+*P<=W[6]]O+@^FY;-'W<#)&"*/M6TL4GS06/+Z
M(\6$1&-K#:@'LV:V.*78>%V@3Y^HEEN"T/)I,F(/S_N[__EKIU7'2GZQ'%,O
M*IJ5SOXP,>18%%7:B 3,#TL6PCK>R  L00Q\"H[86;.;(==+E6>@/IA*B=J6
M7A%FT;Q&W1W*52&;W1J6PP'=&%3E&6:^.6(4@723-3@SX0C[2\#D!U'-\@Y>
M6D3Q:@6?EOCL?7EW ^RKU<BL\OCG-7;W45$KI911;T3W1:;O1QR%(%Y7#?&Z
M65=6%=T3U*]'V7O#(IA,0?F36G?.)YS5\;"U?G1!J35S](93K*^1Z0$$CM2"
MIX;&"&P&? , 0-?'(_LD-@DBFF0:M+_Y)IZ,[%N#A>CUZMT?-C@L5BL4';4[
M^&RG?^R4YJ"UZ,)ZCQI4 ZN9E?\ULT1= 2#R:%[31^_'(#F#EQL-%R3VI2DV
M3\H(*?4JR3Q]"35<R%E,W])E$?MK2&HYA:K+ON"3:C7/M0<581WWYQ\?SHF8
M 8@R(*3"VW%@9=B]HZ*%=VP8".TOO0FD3- 9_-5V&OPH1Y2$\-G>?YY7N$OX
MR^6+I8N$C1A>Z@&10W!3G%]0@35?O2NA,!J94S\8@7EL'.W#:12.@)L"3_D>
M-C0:P=L &VY#1\^M "VQ908F(U*IRP5U\2[!L"Y:$J9R-_[Z]=?):Y(RV&4*
M3>8<I &R#4R?__([?B3,< G&^A>^U'G)S4"*'-%<Y8A<F!/D^M>D2EF8Q:K_
MY7:)@!>KS/#+NS?X2^/\>O"^XY@C";JN+@M&MSWG[W['[[J->K<KAK/7%-I>
M%$\G]5XG^X/U#XT\+,2'X\$W.TU3J.\H=\Z/?+*3,0D,GFC43]QL#%/L\:1C
M;UMTZ=P1/4QUJ4"\G<([K5[61,BMM[-)@*+S$XH]MW&,ZBD*9%!.=0J(%N 1
M&1F4:9(O5]L2Q5X^1&)%B6!^B$9I%-N8D&Q]U<5;#CNI9MA)B\-...R$PTXT
M@3]J5\&G.<JH-#0=V$A^O<Q;-:WK^3HJ7DG,]!8!YDE@=Z1RA4SC9C$V(*5,
M%AQ4J\4501'0[964KK:C3?ZQ!W8@# ZV([GXUGY$Y1F9=+V!5SP@ETF_=#(K
M!:MT3C 7),R29;2779OW84KJ#WRW$ $2H[=XIO+*"44O.)I"NG2X,!W5"_EB
MA325$37PP14D-H5\9M/QL-5(H>Z-*NA'A7@1_!KFRNBX UO]TIA<43SQ0AN3
MH_NOX_T5)KS^1RJ[FKP4T-H\<232?8TX0[J$_BIM?]>$2@+IA&]%^X9^[>%7
M@37_897X;223GD4*FY!0F>,AU9/ RP.=^QF1=8ET(0>@71%(D)EN&CHUY,Y"
M+NCV0>6DHP^8(AMYG=;*:D*'@;#WKM0U3^,YNG.,Y]7/:C+G5XR^TM42"';I
M*5,(>*$K3,%HHV]=N^.KXRCP(\,)@>GM;F_U*? :\8:T=L,XU(.+2MS2C;!I
MC&&S)+$!ENXGBK5?"OX_*H#K:VL!OO$UC&X".<JKIJR6#X[62!3FT$KJ )?Z
M9O\\NZ1ZF9+?QF1B7?L[0DJQ5@!F>^FV&?A(YECH.280AW >[V?A^ +4VV"$
MMF/B$08RN<%TY>)=97:#2KUP CTV7N[A0^9.?&6G\L[R^M49WEJDU+L7Z$N^
M\?&8FB#>&3NSFM2Q&LFS4D8BGS E'2W7Q+E/21D8*QK:/KL49*(S/W3I*TR@
MTQ?&2Y5"*5IG6<*CLRMTEF>5%<6Q_G1=Q06[LNOYTOU=N89+\9(T>YQ"AP U
M,9@IT%?G-KO>%-19,](J&1D!=[_N?ZW4H<TT1I3(*$?+<=A&9H=TNFG'L?9D
MH=ZB>:T0[E7@KFQPNJKY]M$RM]I9 /SR7 NYU\NSU<J_YMOEIX"'5_*GEFX_
M;$"7O837L>DF)$Q/46'G1UPHD,48/BN@Q$Q>@77G&08K^Z/16Q>UP?B(]650
M""M+ 98@J'0H^$8I483?\@=T::!,-N@I:7#7P6#(XXHT9*IY #ISJ/DMBC=5
MM(MURPG3'Y7R)W+D-0>P5"=PA1):[/CQJ$;M(C3T:_&.V>9.X=WU9P&$%57
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M V_X%=.'PE'-(,B8_N_L!@Z25A].M1*!OUB/*ZO(M#+=LHK1<%&1,+^BL]Z
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M;J/AG'2^'754S?-2+=%^2">F$@1E45"-?:@,R5D4/*$H..DX_1.6!'MR8$P
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MU!X;BDQ*/ME\L@^1'9F43$H^[#LG*Y-R1P875XM[XI8%7V(O5!=1**:_O*M
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M$3*^-IKVP N_XB-C;Y@IV#AT%/H)J)FX/!H1)N4)-865TR?'I%K"YDSC*)W
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MR1D5@\1H>87%:><CVLF(SR#?9399$-CRUNBXI$.+U@\926 P%-GV!)(BK;Q
MTOPS_Q*.@9^D&]OU'[\T(WPV>I']O+Y8+:D%-VA4_M5M]XMJ@;6U6^W\M\>"
MKG+@(*.7BG0BHP]DOBX]_.9I6"S(-DI;($-ROZ5S^'(!;HH DY2&+9,6_]Z$
M[4!-A=1-X=:['?VC\,=+'S1;J^Z:)=$7]!_M\D5'VQMXBYC>F$XG>J7?9B?C
MP$0#3 S218TN;^>DBVK]]!KTZ0A45LVF9)-'H;96U+YH64\-,ZUG@YFKKXLD
MCL;>5E%F==#O!)ELP'MCS$G=[=P39C*?=@%E'#&0P#CD\(67_^F%9.=8-\+:
MN3T"@KKUUAH(*OSVWA"T<1;?A4 ;Z(Y_=NLGS<Y#(6CS++^)0"UW+0*MLMJ+
M * =F'D7!7?$E0Q]V/-?,;3I91I1@-C:M0AXT"1T0Z>0QC9O KPX05?@'$XJ
MWH %EJ\1YCJ]3@'FZ)+@%EXD+S[Z)'Y8#1]; R&9SS$#!'-F5V//--IT.H6[
MVPQM.HU6 6V<%;@A=U?F!3('6AE+3(Q\-<1UV6,TFP$5\!QI,PZ,M%!Y0QU]
M%JG$K ->0=RA&Q.I$G3P@QB@ZS(E9_]_>U?6W+:QI=_G5Z \XUM.%4B)VBUE
M4J4X]E2J[B0U=F[EN0DTR(Y  !<+)>;7SW=.=P,-DK*U42+E?K LD4"OYWQG
M[U8#D0%MTW1!X@887052E*EBUQ9/C=QT!"HQ,7P<WC9K@KF98&,/O5UB+U(#
MX&=.DAK1<##:#RV<?VHC-I=5)<W,')?&W=/55G?16W0O/^]/I!YTWG'(B:A4
MA0U1\[XMN_[#%3]F:*4O9E."4XC&6@ZHS4OE4A[DK]#O@N.?A\$W\FU"2V(5
MU6;G(+' A/(OF3'PI,X;R ),9@:"'GP"AI"GH579OK2N8N[CHU6./K0LRJ];
M_^WH0"LVVTNA/H]R._,HSWP>I<^CO&<>Y2N1))0'9IS)UN3N!8Q9 8DE)8H1
MV+H!72?-"Y8F] 5*H$C53.ETN_.MA6&'3JCL8)"JJA[(E&?,8R@<4C'[R*5"
M1\/C@[.W?4A> L2UV,N(<<&;/^!"A_,Q-%#"C!4RZ2: S@Y/WVX/W1P-3X^A
M+Y^='+T_.#P].H6.[YYT<R5E@7&F[>H84.1%^LJJ$$=#4SAI6=I!1]WQ:'__
M[5*KV\(]I*5@?TP&1EM<PMES)G%N(C-9:C-*YPFN]]^8Q UZHNK0C9#-_/1$
MZXGVZ8@6;S0$XXW)A) PG<EY!I3'YEY)G8Y$UFX DLMA2M96,W<I]9;,W9"\
M9Z#(,N>@8I<YHHW<2F?\UA 5VN(?-RIMTS4T2RR-1!2M[7H1>/;P[+%9]M"D
M&6J?;U%K1U#G_;*HS3YC[9Y77),8ME3?9Q'6FGKIXIZ,/1EOG(PUG18<[6#$
MG;99_02FG#_=%B#44X45HV06JC&>0VF92)/'HF;CIJQT8()<AO<5 9[6/:UO
MFM:ULN)4??=4G&45^W:J[>DJG8IR/949!TBRB'24)II:]<CP55<79++[B;<
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M"V'N-*>^*S&3 0:G\CA(154'"RG*8?#'5%6!FA5E/I=\@?FUJ(*B5-@!K$W
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M*Y^OV<<BW6-:G0Z="4Q<^&X&I^H#'D]O@JKA]XP>N4$3_ZI_\L!D@02?GT.
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MYO$)"E;HQ]KBBE ]J]\=2-/MB8V0]5S@N#+U:ZC]):,@%*()9X3=+U!$3,=
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MQ2#G31CP<+XHK=::*A"$P8E(%UAQ!G8_![T"RE>JXQ>'+[Z;@T]2!GW(&QB
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M3L@!'HVN[:74T$J0LU;!.UX*_[ "-)_PFMRJ=>>\?5=R]3"4(!-&3)_R*"Q
MU5J:SW+EPYPBS<P"6GP+(!%/C@\#.L7K,,(7ZS5>)8OUQ0O;%.Z(Y<(WIO[Y
M,5DF *;7Y4J9B,?1>  [D?Z \^&@!SH>A.F :/"%#PF1XQ>+/>LUZJ^]ON:;
MXKI>GL0@WG74GMFRB^=PN0G3F# F:E@^$X;[>^]E?*#NX_N/_WD\(Q>NE.<0
M":*T/2HCBV+OQ4XK5*U"E0N B'")$ [^+\F$L^$2Q/$J\G:LN'L>D+L7.<YW
M.Y\;?8OU/60F.9%+S$X*+4;,/C9R#2V=R8[C,9;(R7E2GYG@2DMZBWPM&YL6
M-53,Q[_!SW0]4/!]FB$L= *_+;%Z57HH)ED5M3"_O+M'N:_ZT%JA> @CD$B*
M4WY5;@8Y?0&JL#F5CI9'((0,%'A\P_</-O+;*%Q["0##SY(D\AY2FE2U#!D<
MY6)]ZT0#@.+D-273!;<, ]^DA9\;#)D6.R>P4!5N1E ^<8PXA_=_2^ZZ=2+O
M*!<+5UVBU@AO<!![3SSG_I7/KV&)Q55?YL+K$*8PW\UPD%+NNUY R$DTC3NH
M[(=K_W<@L?F'T $#5*Z*F 0*J&6%%6O';G^/GXI*!8?[8I:1XV+1\9E(!=MU
MO SIK^]3N F177LP-@HA NN:$CU264JH59) ]&[FK%81=)JR4A%S$SZ%-]"4
M9BCF=@4/_BE$G*!I@/>1(Q=;K#1B.WGGHT=>!)ZW/7Q:W7R'=^3O&[)QW3)@
MM5F:;,((\F9F6_ Y#.[5!V7+.77$R:.</F(,CE#&<C4WE37*9>48=<C)974H
M(\.0-4:$K;;[ZR*I2?#'LS!P84=U2\EQ\9E#W77QE0"/&0X5S!B@<M)<_!8)
M)N@KL$&4C]D/E9?R<<,BLX.8?3!R[8HR1F%BYJ7'AJ%H]$O&)Z]-(I,K$Z C
M1*9FUM!]_-F0TV*).EX8<9RD&%W$B;<E/)G-,8OC="O6I^%(D6:!Q?3A)R_F
M41%9TK=(TH*5(!C9!9YPE'C$H -XPO@LC8:X0JK8VX(J),N3>5LQNF:_-$W"
MY!MD)@0EASB]8Y"AD/Y6-QM'(8CD5CR,('+>WB_4.Y%!Y0P^@VOR2Q=KQ#E(
M<$$^G,">^1/8A)S^ZQ>QOG+RH**>AD[DLA,D7JP_1V&ZTW)GIG01N[I1=_8C
MD#9=]ZE)%KX<U3+8N9 6L5<-H_%. W?7$LCN1.!TK6/GWH1;+W!\UK_2'$)N
M[F=LR-5;U"3YC1'^HCF3$9HW<G=QC#;8IQ69D%+H/0;</EA9"9M;4(O?62/6
M,QREJ#KWFVCJ 2'(':3]PVA9E&"!]'../9$75Y** \7_:.%+UC55E;UJ"L+)
MQE[65OB:%4_",5+H?*G1PH64_[R?\#9G6.F,:<$6E-HU\3T2>A2>.L%O0R45
M=- S(41V7D+I" 9? /@@!)"+=R%9I<;&7G(<C:JKK',7H:_GMNHI:4Q18Z,Z
M2L]N,SX#PLBKBDDD?]]O<@PX+W")_4;.[,1Y>4O/9;S=^>$>0Z !.FVZ65C5
M;(L#7OE)P?,@]S:B&'GW.'KRR.<%%@IYQ5LY/@T8#RTZ+$!&97S@0BPX41T(
M7H@Q.V;!RQ$'K@ &$Y@I )+@906LA )BRM1P',*L!HK8[1TEMI#>$L*,./[X
MN"#9><E^L8.Z!J/1/UUCY]^B(&(A9GF11N%N7#M+1L)*6&?,: OW4S[D@_2K
M5)6M#K9EZU$/7)PXGD_1CC*03^0\A&E25]YJU;8UIA&E=3])9? M?I?=Z-A-
MCEYZ!I_B.^GNS5V*E. Q"%$YD65A^&647M%,G[I:I"F>KE51WC)9+.34LXC;
MTGEA  $:XI,\_X28QH!/@;TG2_F2FD3A7PM_FXK!\ W>6@E/,N/@.O43#S(\
MW64HO#K$8%GA:R](8V[ZT4(Z<B?EJ2CQK>-)CT>+@#D6O2<,$(N+]6FZ7Z0)
M&! K2+1Z\ESL+H)%1.^@Y$5Z"9W%Y#&R]XTR4MC+:)M) 3D@4@(6&0#:@B09
M%JG'91$I,#'YP2N\%H$?% N)*(PC?"\/Z?X$MNJ B@7)750N>)A<K'?T>@U4
MV W;B>$%>-ZL^?0*IK(,GG@L4VIV_Y=-$]XKB?R0=TDK(31Z.%["]J?/=(OS
M!DVQU)RM#-1('9*T6LE>"-Z@/I2&V^]3%8W0SM-1B=1S6SA-%VM5!=\XZ+,<
M&I*(O%*4[ED 19/RH\"M"X%"L@%#8&1\FA?U$]-H((#00I;4]*7P*P( ,0HT
M?',4 BC3'ZLS81D-.-\__I:Z')=V%KA9,NT(<+DBPH'<]%-"<<BY4M=?QO?5
M:$%YR$A;YS^+"L!9%K-=L!-QSX'JK;O\@C6^$NP@M[614I1O:P<01(*:O6/!
M'YXB- 9OK@ QF\>46(Z06; YL8_20S-U_"^!2[X(^ @P37A9^^$S'.59\NX]
M#HA)3K."=>4UQY0DRPI^#7+F1Z+@AF1V2/"#F)JL!\:2Y:N_!CTT%!;(4V[O
M#O<9!S@"YW+F^AUJD#;:Y8^,C>QB/D89E2<D)R\W#$-?9_:0B,O(A,M-%*:/
M&W*R!#%TGPT#FF?"P$$TPC8FC ^<.1DCED7#P$'><L2$(]= 88MV=EY"E[%0
M!TW_^K.%]*\B$N^H_)L*%J]%&/.L33.X^:%-\[ANGG=2TV5:YPI-EVT"[NJ3
MJ! 2N?]B^5IQ[230#F8_"QQ_'WOQ91B=XX@8D>"95#:HT[F%;CEW<J]@["'C
M&;G9 .KP]XV[-ESL_7K.#S9HEC)46DX" 0TKBQ)'3SC/W3[WH&DGAI3#14"W
M19^>4V._/>!2R-MV<T;@KDYR5G:_29/B%WI*\L1\=O]:[9%$'0D%'2:5(NOL
M(!H[:';$*YN&6G*IZI=3N2W9%Y%A0N3^IXLGX#H/EAO,^L%FE?9CI)0=7(P#
M=$8C/%#&1*3D4C9'*FT9\J.SU!8<F[-$RN$?O0OE^?GV]IK1$HA8>2+7%]@;
M/TUPYGXS[9G@/%/BH!GA&F63J]:+ EH5"[PQEW[X3)NE?Z%@,MGNSTN2^PBG
M[.Q "\S Y<.;HK])8YH:][UT&C@9KZ.3N>QF_3T(6\!<*$K\[C 2R]>*2V)R
M.#X[>"[)[P8G=8H[!B,H#G!*TJY%=A,&#L5](<ID!^UL38ZKTI&N]0(9A,%)
MQA-A=KH[P!60K_CASA-F;'8)XWLP35&*A\#,'QJ"=;0 5>QU<73L,IK'($:A
M<N*(!EX*$!Z5T@^(O4RO)C][,0YN-TZT=58X3:#09YR[DA)$)8IVD+'TR5),
MEG@5(I5NBFJ9&.DCD4C>KWZ>WU_<V(&#F6W))TMNV.>L'#D4%?CC;HB<J"AR
M#O/R^R,4JI)77"><,2\$6)\SUR5_C<$?/2J6Q.E0Q[;%^NW&/H?ZF_X6JI^L
M1<OH39L8T]Q@TI3KQ.[O5E.$] E2<+* T2^,2:ORP&*';"<O_FW<8J.$:(83
MD+*XM/+)8+5"XZUZ>3)8O=#TI>"S<'. H7\)P@>(#L&*G0>[=.2N)9,CNQ70
M,[Z:Z-EXF=(+*?NDP5\C8F[D\R@ !0^=',Z ?^#45Y.'&^'+*4('F\T2,R=M
MR2KH*[799"IS8A>B&%.::2$7M<4AJP.[M-0B_D<8/7D[)]EHL?XRX&O*AV:O
M0"H+Y83V@I4=0&_=HO(/6(C(Z"/&@*&SQRAC8>?&:$K40NY.2=X?[G^0Q;06
MW[H*@T<RKNUI&$7A,_FP-!_RU*O*0)SD7S]D[(Y"1!E'ZZA&KK!=)C CLF4\
M)/V_4)11,HXM=9@?*T*-:6]I].>>GY)=[<*)P$L:0S/(6QQ1?\7@0 NEB# G
MR5M TBHPZJ@X*J&J>YK[NN0KY&L5)7MG2S)ZUOZ"O<<-83][PI'SB,_3B/=@
MOG:BWS!-H[K'*TC[]#(T_1'%:[+@@C7BO)%@#N4E.7N4\[?2"\&R1ORQRD 2
M\]>DF)(-GBG(X0IRA8)H9G*FH#A7D.GV'RU-\,9O>JQ.$*HX66_+ W?UT]?%
M[T@$\.6Q'^TT%".!Q8EX6^FE*,EI-6ML&>Z(.0=>A%'W6$*&FG/4'6'O&C=V
M](5/Y3 BR+E!16!N3>?]?8[Z\5/HNQRHL]0]XDCES*QP.=VIC$)^D )\#<5
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M"U0E7C)>W_%KI7@ <")&/WIB&\&)A<\Q^^\\*-GQ9 PQ@\XFFP*.*!@4>0D
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M^3%.(GKOD?,9XM9O$8WV':>X%82XLK@<6][-Y?XWE_LH!?9[3:VU;?,Z?&(
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MYY$S86ADMU *F6.9/3/BQ(2@U/]R3"+Y;=+8Z@.O6:[2$JR7ST)*GCHDF%T
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M047+Z/SE]HG=\>6W0'#\<#PY7D0N"+%BY4%Z5.MA4QP,*X=W7!0(:C))F,I
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MR&7G@]@<!P0 <5B$^/F4SP$"6%E;0 @&.V)\/JE16$LK_%$Q=WQ :W6K! \
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MGF[%!F 7\&:YJP9PS!"  -0*)BB/2C0>(&BU8-T&*,7? 6Z][VC7!BYZ^R!
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MQ?<07UM\5"Y"Q_L@P;<R5N4CZ$T'"'B5>IM./4VRYTP$"&S.G*@M5<7!LD$
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M[L4H>*:6F2W"%+%U?,G%EXP&2#9R<I>^/QI3 0+\0NR'4K@N(Z!N7\'"V#$
M0;@)$RR1X8><;%/!HGAC^^A @#E)&FT/#BD,'NXCYRB)8).-[V-O<2DK,!W7
MA#OCC[:\K[Q)8<;EQ*CB#0-(D)OPI$>-C8&VT?KZZ0DEKRA)?"0,/I2-!(C<
MK!!_7M8_7J7) <OQ,7*%2!9.L(QL(NZ0A@Q$=_]G&+UY)R<YB#$N&VYY9T_H
MNRE34DVQS9=(&XO&M_*S^@]R5T=B5.;R*+V9??(KPX/7GCO(NX0U2'TN8;J$
M;:R77RYN,ZTHRD6R8*CE'>4=1=Z'4?.#O&U)Q_?SUI<W81->OBEY[?GC 3X$
M#\>3XT4$G8]A'+^@;8A5NI@42\9TN?.2=41^C_]]0A&^;C[)G I<8CX_D4G"
M]Z+KNK:9=_Y\K2/7"YS<MY/;K-@CDI&=\1H C_O9R>H'"PJX209"! 93#[$T
MD/J_Z^_$DG?P3K1C-(J3AZ!T HB!U%T (/!97 (-]<IB;I"+&>*GF'CRJ'/K
M(\(\2"S0Z<ZW?1'#X-:)#Q^P%IPS!<PDUX'!\;5>IH^7@18=6>\R5Y3P/:B.
M DA,V8D+:27_,Y3@-5EH41E$+PGW64@H:9NPH!)]ZI"<A6!1'+-3KS'&(\KY
M1WQ?BR9:OI!B$C.[T//'Y[4(I;)R2+MHI"KJ.D3S](%;0(5N=$)ZJKCD1\K,
ME01-@VEJ5U89ES)_O,DBJYBB<X9Q,7/%6\L8&UVR6TJZLDFD3CV-2ASN,FM]
MH7T\S27KVX!NYT^#ND&))?IDX4"S)KTV44/56ZMWW^=/<XT@I!IS8X-\%H(-
M&;/G1@PMY*IIF2#EX0*SSC3NJ'PJPZRNR%.)L0PSFW\5 &-I@1LJ-W\\*7EZ
M,^ANUC?-D*&+8GSF7Q[;AAU1'',X2%T(T*B3-J]I.J#FBK .'%T:/SCK"VK(
MQ)1QK+/N'VY%,-6,L[TB4L7;>&Z3/K V<=ZF'R@]:Y*SHGY+0K7GWTBB(^,3
MAHY?,:?B=#JVV3ZP"('SV2 ]>8Y '[U+YD5_)K%'@W2" 8U(I5%2D ^28^YO
M5SILV8K5*N9F0',6$W5R#/_]2IN<UH.F)]0',F= KBUSK7)L_F/AI*G@ ,W<
MK1QOOU[Q)L6;=II8X>N8I_?:WE.DFWI6X'.>SB,KO+)-.ER!UGF:LZU)Z;7<
MO )K\[2-6;O<12I@@2ZKU@A1[/[(-=OSZO^OVP-R4Q\1JRS]Q>5*/@2? B=U
MB>7U-@Q<$E9-_A&'ON<2N8;>4^_X6K1?R!J&E&+YO$J[?T#$DGHZD!C+580<
M5?$^T?A!^PC>IT0U$C8.K/P98(;NQCOB&[S>;2(GB'=$O/X0AFZ\CEY1](;Y
MG+* HN9\@*#7-EI @'G.&O,3#)BJ0)3V @"!O]8*ME8K6%A5]H@7)RWORP_)
MZL>*!@-$-=NA97U")#\HV+^B/7V@]%L2"Z8"!+CQT$CO"W\T0+"DA_%HU U5
M,AT@X+D8]AY+N*0G8OYF"0$5# <(&'LD33(T:?8KG@T0[ X]8,?>NO02&9V8
M>#9 L)5BH[P6L=;L0=6 )ZP*'_)2%$)E@#,(X-F(Q=I5\AQZ08*U_R[",6^5
M:T7_1C7%\LUY(?IZ1 F^I._ O<5K$.;\FIY./K=$E.D2UB&(D_7N<QCYDFY;
MS4$ +P0]\BUZC]!#L,6RN9#F&P.M !.C[1_WX=O/U"0>9: 4/UR84/Z++[=/
MM>TQ?P"(6\VG^\LOP[+S5>R)V3CS1RB!BPK36='(M6JLFG^NJ:%UJVJQUK</
MS1^1USHT5NJI""U"\\>0OM&H=@OYMI>%Y(.;F6BXO:<;5HX%HDYI"Y%W[;:+
MJC!Q?+BH4AHAQ-VZ1==Z(00GM1(KF-IR7DHCRT\MUT%7FIL_%C7E?9Y5:B&)
M]SV)_EP3V/P+//1:+W#&>&LK]4H26)>*+:ZTV\Y6NA 6J/%(B"RU\R\$T?9F
M:LHO"T>@0C5M6M3[P!?(BLX:EY(UY2\D\;[M;=0EPC[0")*\+!B,OORR('QI
M*E*L/VBNZ?1VB$C3[-8'$B><!<#&_(N"_9_IR1T0K4%\C?SO+?+?S-]^]W\"
M?SO^ T!_^S5V]QJ[.X?8W6NLIW:L)U2YBN6@"W$13< )/A])M%\O[L2("Z87
M%Q:Q71VX@$PU5HWS$],,+R$[EY QK FZZ389/>5;-X)6F6 J& 10;ALOM;1_
M.5HI=M;' 02%Y2S4+8/WB2]"?(.2[P@%U5*X^CJNYE( $:+7%;$!O&+:I !5
MW%+EQ&LR^-40 3F)6$!G;!'OUV_G) IW_#P6U>@>]]4H+B[?6'WXN'*P7+2Y
M)D-(1 NQ.J#[:,\?===^QO/)OYF:B4C/G#9(.@G(4(%.K8/JC_%BL-9>.;NV
MSQZ@==4@9K8)$Z!(WEM6,':7BVMH]^TW8G84@V\A#[NNEX'Q$.Q"/(?\,+8Y
MUZY._(PB"EFP1>NOOK>G$*AL,=))MHN2T(Y7'LT*^.CY"-_I $E,,=+Q<(T2
M@UEUY=5K>+;6YM\!HO%:'?-:'=,N#Y32D&0*0 #9!YV_<S.SKVH-RY27=_S:
MH.BXWI7TQ",[P4B 1\(T91<Q_'($U.TKF!([!B (-V&"R:/6XUP "F]LGP7P
MNE2^&[#D7='?A\/M>=N4#0=(()C+;8E,OR];1\2J4%;)%(  ,O;!VS"@8F7\
MV4L.HD,TF0E%)];1;VK==46ZQD(LSA)?$$=3F+\1[^H[O#IR>F-$8G*2,Z[Y
MDU4+G:7>(KBA,,R:U(1F'.TZ)3.FIH:Z5?.4LNK,0K AJZ;$U8UF?7N,WS-=
M;6TAE6NZL&NI&CEK_&GR;(9[+<N+:4!)>GI['R[+J5&33!)=5A&D5N2E8369
M=0D@32HSPG,?"(,129"'33#Q PL(*EA<R0K8*14*ZWW6%9B@MO%MF15?-FUJ
M1S2S4@X#)?S.71-L6=Q4ZUY=40BUP@$?BR/GG=,V]E^=F(1O4MNF1(J(YRA&
M$%LN+0P<!AG@\7K71$H4$4V9_M.$H[=>'/@[9PJ70:9UJY4!HFN#OZK8NZ*S
MI>X"$P5>U4U>?PG+XBO]Y(W@@GYW(I=LC7-TAI/[V+6(K10?YN+<>+KEG7]V
MR*>2=^(PI-H(R]_/ZDZ7I39%)\L;UN].Q CA#^RA:V?D;6G>4+C]1E*(9.'Q
MXM&V ]I\)XZ]G;>E@D<E >HL)G"-69;W>7\\^>$9H?PYBU,_<:31=O() V)1
M= 64<P ^1==XV+%!^.@D*=&@%+D3S"# 0"CS)2K#;,>KTQ+0I "TF(DTQ@!$
MYB/F&M'FX 3K /T3.9$B2%HP'"!@8X5^ U7[S S4[5<'B+;['R<2MD%+)-1A
M8%-HB8.O?/>%:&JWFFWN<W&VE2(>YC;[R#E*V)%RDN5=WH186<F6QO3S(0K3
MDWAWXL$ 26H3GO0X2V,@0&"PS/B[XZ<(TP>E:''F0WT@0&#N4+R-O%,F%/^.
M%2$OV+^@?Z=>E-DIWH>1C)&)N6/'=>TS@#+^I=B-MS]<]B&P>PCX0KNU ![_
M_0\27!:C9ZS_$I]"FL18<7.)5X% LJ8'&/_Y3^]^E3!X[24@>F"Z&M$E]<#:
M69KG'VIK:E^NM:XS,-#.%9?MC+VE-];(X#I7''8Q^9>8K!N 9^W"5IF<2ZP(
MC,%SI:2V3HQ*ZU*1N7K62-.WAY>X4IBFYW\!=:W?E[P,#23/E<JNV4Y\;/ ,
MV_6<N*K5>*XX47LO+RF4#1OV7)&B<A[4^B +;.+SQXZUP"*1Z+2H7%00V9>P
M\&+5A5'%:$LS_\Q+_G:6Y35<#7/-5VPKTDO\'G-%59]/B(%=:/[H53XL3=?4
M_)'2XZO2=(XMLT1WUYLL4M66E8QLF3@[.SMGG2K?.R7K^WT&R7V>+(JY5-[1
MS3WK]/P^I2VU.39'[5^NQ-Q*2]4/4+@BNB5C;M;2^>L5AX8XM'0'<OS_;7Y5
M/R2)NY?6T;D_?;5-O#=B=9Y5"9!K7N54\RK'SO-CF4OMBC3>3W976O, $DM1
M+F*='%!TCQ6TY/P0Q$F4TC-FA("'H%5TJJWU>SSFPN1^&QZ)G9YRN]LP%M9E
M:;$ P(._9NJWNB<L\7))^@.Y^LA57@CMA0 C@[_Q0I%PUQ'1C)';"^LP_<KD
MT/@^C';(ZPM]NJM/#FU@GJPO?^FK9!I_8RWNFJU5 1+)9T2L<<A=O:'(V:.Z
M<:/;T4JS-/K_\DS0G3]P Z-:_ZLS0;/A0VD=X6V^/Q/4:SZRUE%N\MV9H'HB
MO/O+NS]9MYBTV'-;6:&W;T$Q65\3YJ[)7D-CS-CN6"4Z:^I0'T@^(;R4^YHX
M40(2U=JVOTDD'X,A:7@!+O/$LR76H6_4G'4_G#Z#5_0.:=;H[?6=,S8Z6PTP
M_#5#=8#V)")I]LC6-DU;C75;&))-#,V]!&1ELMM],%U46[.:]Q&K-1>^/("U
MIH]0+>B:2?^'8&!_SP_@[U?ZMX/Z5C;Y_!#^<3T$.X=@9)W/D?_K%?DCO #$
M:E[J1CW8IR8OX_3G RBP/H!*"BY6.CT>G>B<:_ML/L\(P=("YT^>>B2.EJT.
ML.QZVGP/-X<PC?$]7@7NYCL&_[S!,_BU9[6F '1'SK<15(LN,9P":@5[XD6%
M=E_OVK>G/08;#X:%4WF\1K.#BV:?;ENG_'G*^1PO)T<X; P<BM\UD^D#O,+O
MPY3?,$-G!N"+/9WP^XGUR^*2A/=F*,DQ,P:-?7Y%"9;!"V5&F'K?!,+&L@-T
MT)"U\I$,'X!&7KT?9B1RF3 HA= Z:YF*:IM*])<>@)=@//,HPHS%R!<9@JK0
M&PH,Z8J9 O@!FV.NC\'!WA,[E=G!LE,F=[#77+AY:6Y?_@;!1LRU^I7&8*55
M;M8A<?W8[;0:>JAM8W,-^K9F-NQ06O.*5)GE[QHS?NT !./5XMGZ2FS57K99
MXZ-+[6LC:^6LL6@N"[&VT?D'7%M]E;E7>*Y5G =X?Z^)%X.U]9HG>;;@?HQ1
M?]9%EGO223KQ@KG6%+?.*NWY?):0YV.[BTJ==\Z37LUY)^/LFG45[S&NLX&#
M;MFX;R,+*;R"<VT"T/::L]['/C+KID-L?9D833-([: ?Z/-M3J$5-^K\DQ/'
MH-"V">778QC'%_'E;WWFB?(RA$;)5Z$HN'5.7N+X*S?S93K^0T#?=O+#O KY
MTYXO9:67'&Y%\7K9'("1#^L($[<3G3.3*C<V1C$8(%#<,Y!V7!#/  @>&UK
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MJ8&5G>-?^M-H@XW_C8(8?^P/;N6EN^! 3\ HL,!Y.B<"?OYZVX:_% M X^&
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M1C#MN>#16,R/GH_P]0R0Q#8A'0_P *Z%HZZ%H^Q>7BD-2:9,!L .W*FS45Q
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MW@C^Q9USCMO (IS>_\XQ0<18D"'1'!V!T%D)(/M;3#';#XX7Q"0.',7KX/9
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M\UGNOH3Y?I]$2 B^F3Z#A9H^Y,GF*Q ((,"8 &WY*0T.;V3[#!^M@:WG3='
M).&4)AO&MGRHNT[L)6T&K$HU;7C7MV5Z&^3H4#X)_:INXBQ/"\Z-1+*9-&/Z
M%1FO8'-**J"J]NB[I(JJ ,*#RHZIA. Z[R-08'O?K:CTH/QCLLIR. 9ABG]A
MAU-LX)IF0;3<=7_?)$]QR.<7&\4/.[7^[B,)1XFL#]]8N@G1^_<E2-- W$=>
M$L&5G1Q3ABD-,*![&85CA1%E]+DB*V-^EW"3$T,DX;8:LV)/08KZ;?>JL__S
M68W5;H49KK5[YX%/<_(A61SPTM1,>4C>>>EY&L)?<S68U]:<%EG5=5)>FB66
MJRK?O?3N32K-GX(PSG!)\;:7ZS [)J >E=?[#G6R^MN;W.1.MQR^^PXT:$71
M_SM'A>_2B2NS.]%55PK,] :"Y'-S_"GS@"R&$T1\7!J(A@RC)B-(%#<WG\UN
M4 V?.:%U;.J*A,24F?Q82(O+4\RC"*+IG*"C0=QU'H*D<',%V2R]:CA!Q$>F
M(VGH,&XV@F1Q3JPQBS;K>0B28F16C16OL)V-(%EL$VHT=+ <3A#Q<;D@>NO
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MW_ W;_=TS$V?3_!2-RC9RICS-%3J+#5BWS8"2KL,=A<./V5'="#)+ '/Q]5
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M9ZCSU5.NV\BBC!&U1 A\;V@@2.K9V_<Z&ALB!'Z?Z<$=N[(:7ZYHL;?UOGF
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M#A-:F9]6)O:XWON226I'%O'PV(O83)LA&N(8YG?)ODT4=<_:'S=6*49A \[
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M!,2XK2%I0'9]YN!@\ WG@9801'A>BG?[[HVYS[2AL?C/!&!#8\H%801I<N0
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M'2'FH23+;FH?W&CD8<5^!XBN>\8^J38QT[)<S[ZM=9HRW;V9]);TVGW.6)6
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MF:&MPLC+JVTOV*6N] Z_W"<XY;$SWGIVS[?$.2!"Q8?Q' SLP:&9O"V8\I1
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M$U]+FW6!90:5+/V0P>*<' OM]*W*V30G3HXV"\&FPSG#S5G^&'QHCQX99-^
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M+^&*_%NV-Z\4+IX0VXJ&/&E&PU#^7[8R^=U$P[7;>??MFR8%6/[YY['U[."
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MM-?^=!M>J/*:]NYW>^CGA[Y\F\B1<)"D,4)"(U)LT YY57C?J,JBB->@E"9
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ML:U3RCZ#V3D.V=>B5I_>]C.>QT,"C2J"C>T0:F.IKC*\N-7[$ZZ>5DW])L;
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MYDX04. +H:]JS"QS%7.=)4.9$ 8*B"8'4]+)VI/V$R]2=;L*@HO:I&8/R9.
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MUEB)<E5NP5U%O:B2#963BT8?S$,8K,6'-;]VC\?&?:O(X3P% S_ X1%G'I>
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M5A:_ND>%\/&KWMNVLF/WGGG5 T8BZR>=;+R9_Y@XX4\^*]O''?50.6R4T8#
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M8MQ(P1%UY+?:R[<VLC65"H>$8R5>GR6AI'R\9 WOD-0(IW;<>,'V>HA6-B*
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MZOE%F&#DK7^N9($,;^]]J;C6H,-E4:U^77Y&^SI]Y0-D<N8(1]Q333:S%XJ
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M]=/0!\ Q>1 UWB194GD9CSJ(/Y1NHM[]=BP>MSJJG2 >R9DE$EJN9OP&<W/
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MY![.*G6=-![1Y40*.> Q*:L1-_]>%JQ8.^["DQ^DF2J2=4GO+OR'T7M"%J
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MB?#&NRJIO4M@J+;\/BM\%-QLQ1MCP6W;2HS,:FP=,,VT^KR?R5T> K83X*<
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MHKICE#NYV&KMPKNQ_="LTT.O52\AK\?)BU< 2>K-U8S+_]*=?YDO;4M)R"F
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M'>Q/*JU;5+Q:J,RQ:[X$$&3PQE#J#*89K@2)=Y=(GC17&T4B\$A7=F@$<SH
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M*.8/=%<-VWKZ$, +5#-F2TE_650 2PK@H 2P$Y$$YF'^*&'U"KT)P5?(3A'
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M9WJ?,<W(FAYIS3F?-ZXGJ5<8GR6_'/.WY"YN+812%HA21O WPYSI3D3VM+@
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M?6-/;:'9ONWZ482X;[F;GL8)WNN)4 YM%U3,&<B(5TIV'-(-I:E!TUV?>6=
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MN3/>HC L<HB804#^>1RE-EE!G-\BY^OK-MLU<W7G[<<,AJ/H:6AD9WI">LW
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MC)G4^ZAP:F\ PYE#^G /5& 5-@./BUD&<(.*F"JS:^)8X7!AR^:GQ13;OH&
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M!PKZW\I"K7>USQ(-QDA6;6U=\$_[!\/4D?,!&F^F3\<$$(Q=.4ZQZ6;M#!$
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M6^\EQKZ[/#=M/1__4+:  5&D$I M(O N2J(=NM=4\!<@ F@D+F!64)%MV&0
MO+6 :?11+V FJ?!A0  HUNFZ=6]UW0N8U&RU0%8O1[\U(ZV*+YR[/1.NY[V
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M)J9\;,Y$[KVWB/%I4:O@=OV54'F?3S3!%)OJ?CE.J0&NY; EV'091UQGJ,Y
M6V$2LDU070_70ML!TS$*!IR>& B']!OS<1"AR0D^XJ_43T>U;35DE\I?(=Q5
MQBAIDM6+"@/$Q6]D8X_IQ0$[\)[@@+@/6"ZTT;@C%#C(KFDP6$E,( RGX+?"
M+<-:QSGE D8B7SWZ$_Q1_#WL!9REX1)G>19A0];=3+O@:)X\,'0!8Y#MF?MR
M*)J=/!G%,20/,J@-DP7  35W)=[B#>U'^$Z+8N1:F="+KK0")+VZKZK .]?H
MY0U*T=K08R$4-.NZE;G%4B5*W)J0*]6RO:+R+>.E-(N30HLKA9&7@U?^R'.Y
MSY**%C&=G!**06D#[CK>*E=1/I<:36#O_D U8JY_X#-LY-.<OH;1<@S\(8>5
M'J%;6P^=.V# N#/][5YSBS'QFK%;@<O;,6?J<\C@NR]=FWN#)+H!A(D2 'UI
M"Q:#G((9K]"5]KLJ@S.<M:ZGM)7UCKH^EA/<R@O!&Z,5,"5*FLDUJ#=%SL#;
MA@?U&^<(J[;T3"%$59Z^(OH=3WRJ0^AUMGB<LH)F9"D^!<7C0/9+UA+0'#&-
M4V0(KK$<F-_!>4%*'&Q'X"#'I)"]<B1=MW,\QHS$;0&N71ZE&D]&2S>,UZC+
M'XS*5]_G_UJ<<6]OZO#R*637U1@%=>6HN2MIM$9K#IJ_Y";@#/AY<4U40YT1
MLAVF*[%K43?+B'E)Q;IO'M8&-_T_Y+U[5!-GW_<;I8J*& $!!2'U2!4AM8!4
M")DJ152*4:FB(*1*D4/$U"H28<BHR%E(+=7<X@U1$1 Y1.2D"(D0#FVI1H[1
M((0DK9QEID(8R62RQ[[/LY_>;^N]GK=]UMI[K_U'EFME!:^YKM_A^_E>,[ER
MM?8*JB>Q([FV'<ZC?2&N%;X<J-*.L,X[KP3RICK<LP5D*$QP%ICOPLJ(4S(>
M323H20NKVAYZ>#-J>PB,=H*9YZ=8UXR/#&ZOZRXY[D(Q'LJ.^KDG-G\P>=*Z
M?IM\1[9U;X[9]MQ?UO!][W&VW)Z.%^VO[A=3KV:IA(F6M:VMX@M,B\E*>"J?
M=QYT0AB?(H'?WVM0.1QA+Y6C'RDDS*.L>+<#T49!5*W!/DM 'G Y[T!K#.EN
MVJCTP8%X>=H']F+!FS4S<PA:^9=7^+!@]#@T9G-;3QI>WIT3X!8VTRO0&D8"
M,]XNI##_U]=@:Q4U531KB$*Y#A\J/XCR-8_0;NT^D(KN^(JW[EN)YL93*%)A
M"M+@S)M/A5<Z?(HX[NHYR>DN<[7[1 +#1''8^%$B"_; '=YK"R'=,O]94;!
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M=NH@9@=7*%N3[.!NS<,[G--L,H<B<=M0.[=0E>X>[]XDSTQ?>RV_EWXY7N5
M[^B1!#TL__!0I.9TCZ;V G^QI]4'CL'\V@X]R9'9#M3A8& S%T#]M:O0P!WH
M"00@LLZ!\+#GG;#5:.&M-Y0E]!613)@'>B&&Z9BYC32M;K.N5,5Z3O,X&1H1
MO^G2C8/A>X=KPY*P32N(=7)P%BSJ#8SX1G<&\6_^BOL3TX)+QQR[1 YXMQN_
M\?%)S3Z4K/IAL(/K\(*C51L7-A'-0%P9DT)_SUJ<1%^/RDH5X8I%;/S]':6<
MF!W=U[;UT,R5C'DO&::</:!9440M5YB/7XT05$!CR,UPF<BF730;L^R@ 47A
M,?U+NTXY."ECSHTYL_0DX\CL=F1MH7*TSU&V->W'4<\N\--=]?&WI.]=L8QM
M=\MOKN.W2LLJF@1&W&6<'P</U2&01#B;<V>B"3>UG84XR%)IJY2ZKP>;Z',"
MM:5[0/,R1M'P]-Z1?M.@73/3>VR7BUD9RYG]04'I0.4AGU5G;VHG]_]:)?SU
MM"SDS5.TS:[)>MQ.\Q)U08QV(P0H.Y,78#:Z;^AV@>#[ DT;^ECK'?GV2?DP
MU42Z_Q7+6B@57\6YJ?V,\%W"$5O+V@XJ;0?\I*W)]D,TVGADR)9*H*))2:YM
MSS'1?60B XPIX+8'NZ#S!$M$ZSAQ QJQ]BCW1\I[+O&AQ"KVXJ9,,F>N5N-"
M0/C+SD?]%/3<;=8TW1TNR$/B5#')--<\3GI+K6'J*:G5Z(PXQ<6%;5*33IBB
M6X+;<F"L4[N9$_=I%^9R'22A=C?0DX'P8^GYJ1P#;W3?@*_3I]V83=R=?I8L
MUZQKLMAA[MN[, O[1K,S;Y2\&'+=[9,OO:,(COQ(7O]+UVMZ)V:,VMDEU6T9
MJ"&*H(J _CYW2:UW6MU:/8E<M[K?"MF4I31>]=E3VIH"3L)6MRT=4Z7NC3,6
MJ7GA(IM[7:7'HRI]5VWO=.[;9,]R-]I^9)976;W_"V&AK\M8/?E[ACFKWP.R
MY3UODT#6=*<7F#4LQ);PE)3&#+O6311S+.X$8OJZH7^3[AK(1@"UX2,;EAKD
MOL^VX3S\#*ZYZ'AM5_KN+I 1AQ@]VC13EG6S676-NABUEE@EI1YI52VJ6DXQ
M@<(^GI+*TU7)*96"WAHUI7'B'-< %HS;%',,FX(=8>D%N@''3+U$9(T^U/H2
M9KP<B^B@+T77OFZI;2EWF+Z L4NQG0\JR]LG X.L6]V,,UH30W7GVD6+P;7P
M8'(=14DE$UTUYCKJIWQ9">X8("\,[Y\/]_"5$P:<U,R[@<$P-SVD8$L!&A80
MHK(!<_R\JN^)[ [US!>XY4P(+JN@L]#L.G;>:*XM(FA@7^AW?$ICJ!#$L*F6
MDHHO1P%F.^:I5N8'AGNVS+R\>F=(=CJ@)KTE-2PBCV>J:#A1:KR^IY=A*?[R
M_ >?OR?@ZDGVO5[#;(9CLFIZK%T-+$4K5.*QAX4<27,6>A\$B-[P#;>7/@MN
M^A4,1%Q;B^,-&VO]QQ(0G\_OP067$7Z+_&B6FIU22TV.-F;ON]M!VZ+2?C"E
M_N*; T'S5.7GYT'<XL<T  X<&+Q0T'&<9@]?4Q8FA3UU:1.8#?EQH$>Y%NT%
M[:#/F0&4;MN')N_(VM51*O"5.=;-8D4-Q.4$/+XA%C1H8,[1P*3VPYD_Q#N>
MRP^=YN[@_N?3,Z3?OTJH)#WIATA$IOMV(DD\<P7T*Y7_\8MCI#&:I9ZTQE)M
MITL""0=[FWXIN#AXWX#XS0?B9<"8TX!4MV4R;2J ],'-M'_[LO_QY^ZJ#U_-
MF?I^UK-9+VM(9A/!1<$N=C,_  JV;M[3.1/C\0P<*H,F1J$,BGQ&@.E)A_0D
M18^>9(6M(E;V/N:(*"Z,U<U'!HDF/!ZD98(;N\$SR,,!7D,\0SDM869FMY['
MS8?[;1"O7UY=+A[-MDMT]J7+7TJ;^2:!:]HB8ZR:?[DH2WQ9VU&V)$7FU]#O
MJBL7&>//]@ONDL=T:L8B,!2F$M"'!JJE/-R9*\<=T%1DE7IUL D"9/1N14Z?
MN\6YUN@F3"YUR=G68WUM%JS=^1"NNL(O=*F?='MU3S.]Z=?>"Z]9K.B=^$-N
MX2MOC:A03P)DP/24N(7WN_EQEV/VQ)0N<#NF@6K_!N@\T\Q,XX,FP"&:A![N
MAB%\+B(;:Q%3:#X1-Z0#3.,^3B'C+!:!]"=>QY:BY6<*WNS'ER#U@L;!.A&,
MU\I^1=.D#;*>T\%+>V@5FB_??K6$*]>3%K\"CC!2F,NX2[F/8V,>07*MBG$1
M7QQ1 Y#S41X+<>QMIMOT@'XW>CG?'&#EKI9-&AM(DO=UW.BTW'[_6I.\K$!N
M45/D>YOS=6=@^\I*@ZMG]*3]>I(SY G\:X" JBG@#?Y 3Q*7XBYHJ/9#J,$+
MB*"D":I>Y<&KU%'\L7*8_FPT^*-,Z0 E,TI/"N<E0U7&A4GC+ONKX&TW\M#D
M9MSD/FJ-^.WO*;'KC&;YFC5:/;E<Q*F05$3:VK>73)8Z>8NKTQM%IAP[S15=
M.13Z. Q?L! :N Y9 F'"]. 5B/ BS1_6-OAA.^_!S+%X.*X16$3_X 4:PH!Y
MS=1DLZ'LS!R5/6>2:33R:V2L+.5X;N\!W["M@I98US3ZXU(@E?12](-8PF)"
M?C-;<5F7GC0X,XCC-6B[3EBD)TFGI#H=&Q&V,C(45:WC]:XM4";34!S*)N%/
M;%=2[ADV\@PXHYH$A-V26@?=+,S$O-32N4$<]:>$EU 8<_R:3@+)=J+V2AN.
M7)Q!\RH;WAC<-N=*J<K#T</-?L($%:9  _GB*F&S=!GFT2[^DI&HF'6DHRY"
M.VN+]BAKO]C6$3OI0*@6M1)*Y:Z%F1=!@%W"H1[J<, .'K'^I J>2#PFD^#6
MM>(>EQ3:OI+1;'IJQ)D;GY*OGM%):P-B*L(FA.],2"[XL4Y8-6$+-;A1-)W$
M*(R="<W5XHIDGLCQ!4KO\=T:-7>P64"NVZCR&=6M_^F']2.I-T=BIY,*?7QB
MZK+Q7D9MVK,1?[Y)O(B=()J/D70%T1.)XGO>XU?9!"BN0(M#$;9J.I5+!K>B
MZ4KRQ6"WBCK=99<)(RR$ >Q!MPP(SIVVR%Y[F:7>7(+MN(EZ2ZSV"U0.M#XT
MMW4/W8P^3S9%(8_@2V9K P.+L<J)$>X,Q!J!7NM.ZDE0(!;^^X#)?OW%=;P<
M>3U@.7Y-^W40 6B*C&CI<Z!);$[STP+/(F>$:5/C.]LT,6@Y-%#J>0CU*AF"
MY*Y1$80#:[32O<BN3B^2WCPTG/VY:8-M?8FU-]R?I2'J249W):K06P*A:RXG
MIXJH4(,GS2L$<1J(:2UEJ;SX8RRUGF0^HB=5>C?9A$GZ';OFGBO>P;X=*5N,
M"K4+MY"ZA5,_BVL[:0Z+KF_(3VCSO?Y=9R\RY3.%D4=?:YE^>I)@5*"=4:C_
MI7.(UP,#5]9IMQ=*J.E1R'V\W4XY)K9TX>MR(*5P-5GK2TYJ7)(Y!NX^>+!J
MWC5MY.;,=-L"4T\3$=_;3[D#=)N8R?BDLY;!ROYW59OC9> ,_>X-Y]^O+LLM
MC:1(\.NR:ISQ//-5\.8-C1LOU7QP^I\?^SW;U"TM,\S?\R_U0D3\_3YOO/89
M-.1OGAX7%U;PO&_$+:.O3% XK*FQK)F>KC$)>/[\H+SI=5]07]\NI"&*%?4>
MVZ6YZ<DE3U/:MVXWOR5M$K_S8H@NN55758*QM)^CWDURX;B#DFG+"=$H.NEK
MJQ-@6X6JX)S*7OR\M8EBY/(@#+6[19F[5GCBS$#@1!HP)Z_^ 7+Y5H!WDL(?
MO18VYXJPH)^3_F.7"U!&FX\4:@I1*:S8C2+7J0V^=@/,U)_1!V'YJ)6'>ZO<
MOT5JQ%G5V*:2+D AU7O,)4>0(#TIH6K"O!_E2YZB27K2HXV@$WRY.EWYV+?T
M&'UEY R>;#7ZZ+NL"5T@)A-<FF'^OI7D_3[BS%3 0$]B3? 4<^F&W!_HJPAK
M'3_ 2PTV1?.UIIQIM7%1^Z342HX%E->CQK#/(X5I5!5@C6U'J#PP-!_[K(>@
MW;VC![I![],B(WC-8#*X+_H]WS.J2DM_?_J#VWBWH%+1..[:X-;:W <,<.NC
MD%9-+-J ^"GKA1+%0LZ@)U]9V,1( A:N11\8GL5BSJ@H*=SW*6:84Q$:(JV@
M.\._\!I'U27A_AMK$H^-1X]NGOQF,W_J5T(0N*7OKD5U MZOL.8N1"&)R%5W
M\Q3[ K[N*;Z"V\PT 5B4!6B(TC()"U4:LR0!TY)G7-O(*+@U" '2:3'J/J!Y
M4^RKR\BBCM5(:7(2N$K'*XIP/8PYW9$'-6PXE-S"R*!4^S\29_ )+Y"CFDB*
M?9&[A!"_K[E$>B^?9+P' AV$GPQ4?BE>0E\FE-2?]C!HM25W<]>CI5BTGC0O
ML>N*QBJL*<[!NR$@]^$-]%K@W4YLLW+^%]F#NPVN<IGV<IEVYI!.]&XU>.Q@
MIP;&3ZAX2T$7U"&/):XHNX0 S8(Y0B!\8BFG<S_JA]A]_O8>O,WMX*'<9;"P
M<=RL81-S^63?R6;1.LA\Q.U6K:+92&C+"?3F?=*NB@,26W=W[[6GT%"V-A#O
M9E9ZI]$M4%?EMDLP19F;7XHM1O/5[-1:81-[$>>URC<I$;%7&K;:Q RLK5=*
MYQ_@,%4425R.7R.^ H&2A:\FZWWVU-74MV/TC*(@XR-8X!#_[$EJ&U+S)F]*
M\NZ>8PF::X.Q3PF#EC$NLF]646:!SEK&&*6,<VT/W-HL3I4/$OD>!LP##\**
M\35%(%6&'59Y''38:;Q2LKO#95ZE;E]EO7NPS'E-)^;N6'4#"A<5?I%-'D<0
M[>=9:D4RS?(FRM D==>M@?T&9"W !?I'**1UPMNA^>-U.VY@N]!K=T"@9VJ4
M><'6'4E.QPXCQ0VBI4\WW$(%! ":8!3DVR&QJ;/->JV$:]93T'.\_[77G)_$
MPD\U"B'[J2[OW4'[OMY.<Q^A\&A.L,"O&KT*>ZI&%+A<,0\W:RL%U_#4@@;
M9$B^]D%8F7QTQK5YXJQ\HHF,^N)6:.^GR*YDX; FUPA-5TW8<( 6$:6Z$]Q1
MBJY\7I"PLZ*X$.]CFBI1!(YK*%;SG@^J9 G<-?C3 /&C"8MARGLB*_#KGE/4
M1+Z,NQ@17 2="H3CY^)41H)S@L7XRO#87<G7#W$FE)6V!C"0X=!2\75/KFUY
MQYBCR_>S7E-%B@Q1T/[6T>EWR3@8H?7D/ P2HP^T'V*DIU6E+,DFA45=H)JY
MG#,8!+\JOAT>^[-XD6ANN(7M&C%<S2\9]H\]772K)AT[J:(DQ^ZJB2MDYK_
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MTJ:3<O ]-$8YSCK033L#6VHZ=55U.Q#K%I%'@C]BEP3.!N-AJ7^/"SOYRNF
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M'NY'T+.P!L%,PK#Y2!7BG2JR!4$DIH615IO<*)0[R@;PQ./]\RI$\*3"D.:
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MHX)7OI)[;\JC(8]/G!@"X (Q2SCC84W!M@F)QOJ:052@4#Z*\[81R&12_ C
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M/Y/V B@NND,'M J31&N[Z^*U="P*MKUT0@588*9(]8.((C1 L:=]\B'/#'-
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MYZ.T,".)?]CC8CGSF>#Y?D6OK3_Q?M4D(="1C-M_.#2)^0\F'$1YWJFYI"N
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MRQX9!;J.T(_![IUOE+ST6KHC+30X^I'T'B,\E/W5=22*,:+'(R,TR%*O0\Z
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M[@O4-)9&,@-_#X?YKV;HTSU]98UQ4^WZ2"(E7#\7EVBX2/OXX9OP?R%&'3>
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M6(-@ZZ-Y*HE7&5\-3[MF23W^$1_\OEZ^D$Y:D%DTPG.$]Q:47V'O)!?$?1%
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MC2K>L A<[>8 )!S<AY>2DP*S6S,C)3Z=U:-H4]H=G!GB#!EGT(UTW"<C=;:
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MM<]=]YYS_SI_U%HL5MZJI][W>7Y#Y4T]DXL=3I'M!,M^;I'%$77*K8*\F?K
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MX(*PZ4RJDH/2YS98#':2^0,NXE7^J#Q9@H1+"'J( ]@H;'$+XG+[7"P47I9
MBMSH9VH-;V<Y7'CXIN1(<B73-=_*/'1I_W4=YF1H?B'A!9@_\TKM#'<%I.SH
MZ@P:8Y8331)DN0/6#'.^%1(">S^!T^3,S&]>\B"#VXB# I\SL@R\E*HDKIIP
MIY=$5(;%%%OT<0MI]92,@42[+5Z*$7!L)E^]EW;/&RK/8MZ>)QI."+ \ZZ>
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M\BSEU6Y:LZ)M';CP^FYDN9*1Q?^F7X>1VT/6';C!ST*;_#NEM,VA'K]*Z*X
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M.UQXRA7TBWQZ3LRAL8[USCU+"*[T&+ZJP]27=<<F&,5B0PJ/PW24:]C"6:8
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MS>K,/LT^F M9GX#/R=?RR!&@LH-H/E/E>&>^Q:.U8+:-9!(")^[G]KHXG0J
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M3"TB+$D>]MKWY-T?4,._7ESD_UE<:TKQS-W6HO].1;K]U%^EZB7C+TFZZ4H
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MW%:RL\(#Q+M%]1;.DE-J00)(=#;B&U*3T+7<%4%![ ?>8%S01ET6ZI3I#]:
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M8X!S3%=2)G![AQDCW/O(=F#Q.\]HA\<;/&)$>?5.PZWDI=YWI<$1,>QU-0E
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MB[DIPD6!(N$BE"%C7!!6\51$F=HF(A).E(^TT R8"CVA 3#"7-%-<&US1X;
M'/&.E0E3'R%T6@__#'S .% T[ ;ORE& 2Y#X;15=U19;_1.>3D7<3M .Q4X!
M1ZD6: )R'+Z,*U\=^>(TS700R6D<+VI7,!8B6KFT&4QB>W9M<OVMY-J.OG*6
M(1S2Q%X,IT-OJR+)JBF.N??M/7+=7JUO[Y36YIMXE=W!VFJ(ED6JYEYFFXP'
M?]V_'C&Z&XP:XZ3&2:8:P^)FH2GR]"!$RV#M+&<=@ U3HE;DX2PVKDZMR^;
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M1RB]\F67GO!#(>3DMVQ$TY&IX<,_"BWWGI\Y@!ZO0?Z" 4B:T/P$<NGAO-)
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MTCJ!1'5(@(9<"OE-T8K^9L9M25TM%HQ?&8?.(KRCV>^E4NH,;)\AP-1.<+)
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M@8*-WXEC^U9)"?R@RZ(9@M$A#[891\.G]=LB^WG$K*J &*1D-]BA5=E "^N
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MJ,*MZM)\U/-3>R3AP5EY8)P#6HKU[\A*$&@T<S0V\Q A3()0E!,E ^-?,*H
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M[5($<Z<8.<@5Q#4A-+E>=&"!IT]P@WLJ6IWMB^.(%N.(>O#-WO9);Z<*6/$
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M:(X" AV';?AW1,GSBK+$U\!*.N<2P0_$S>P56 I//8%#)8A5BU?%FE*?;?V
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M$H10K5N\JEJPTU/<Y07,V A<"):P'8\U[,+!724:X\U:&MSN0%>X*_(4$]%
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M_9 O"5A)<Y#(JGV@CW.^'+[#;P'+N7\;7[N:XI6>WCL28* .(\G:WF6_P[T
M2;V9-A,#G]#,V+]$O& ^%W&#,J212_&V55$=#'MX["[-0:$1%"#A]MTYPJC;
M(^.9 6Q>*M\E:^^0,(@;GM$P@JL"=C.>JQLY,H"UB&HNK[4JGC5],FA(-/W,
M$^TD<1IM7Y#\ P05 LN3U??-'T!7J^_=6>U-?>*/O23WH7&UZMR1V*2P7E;P
M=^-W(IF)2?WCJF5,T-$@L_!9[P7S#IBKX96H?""!A*U4=(IPT'RI'X^-7S/+
M?#'XE05AF?:TN@/]>.WGR&H06]*<Q+^[%7S^^ ZM@@AY=&'S,P.Z1N(B0B(B
MFOXZRN@\FE6[.G(NOO7\+94Y5?6E69R9S!2@.[!.\;3/+8-GS>X6XN]RL=),
MB;9!CA=%>VB>G0&X;<,::'=;/V*CC^#D! IRA&?U7MO>20):8BOR]8K9>(_P
M2N??Z5&Z&6M <O+$_7/F]:8&9N(,QE)M(F"2EK %2$G8!MG/E_B*5Z7XT.QT
M.ZYJT)@4]?K;;:SNV' )I6BA.W<*YX!\.8SL6$AMH/9XMC-V0PXW3SBP=*M?
MM43[6I^.P)0*T48_^NE^?"+O][IV@6AU',$.<3<U8AF[Z*$#95)7V[,W: YC
MW8"K7Y-NV7E*PX$[$SU>%27T(-I":F'&/=*9A5JW\454<O.0&[\3CC3BZ$QV
M!^819ZI7I\[[&@Z7J!L#9"Y8G6,Q#I] :VMW&LL1;1WGK+D!,=B:.$P>P[4/
M.7P>"A$>A0(Q]LF9K,L><*&&PZHDY*3_$IQVDG*/UOE>B$<77#@83TQE&\6O
MS/J9$+SA#KSV?A)@A40FZV'\0T9(2N6;$I![I+4OF,@=H54< I\7ZO VDX]>
M^IGS4E2;<P[VT]UUSN]YPMA6^^)NKN]W+Y^&R'XFVM ]3/<95@@9LK7LN[J0
M;YS^?JSC$3VLWTMX %3H6)))RB8DN'JA.[*X6XVF$@H8Z\"6JQ"F WO^_FN(
M[4!;/R_-1+&/]Z6NO^'%[]E!ZNW!+#7W8II[2MA302 GSE0=/.IH^!J^#=6,
M=8OV0!@ID$<!>W6.+/H!#::DV@%,K=-&XB,@QT+1UN-PE)0K56Y)\,J1640X
M7L>T=LE\KASLJ,8VY20\Z<_N-43"1Z$Q;:^,LBXF*6$)/ :Z&;X?-#OTWJ:I
M-8(N7JEZO1D/+_L,DI?=@8,^!UVO&+TG#:Y>< F4$0IB6=/IO?8-]] E<QQ6
M]>8G ]["P'1"'@,CCID=7;=<G3J*J9A0C[9<-G"VF%^JUS$VT<];I#A3MX-M
MZ4-KX9,:13NPCIX. 3(BB)6%$"7?C2_(Z_1KLZ,B@2EF_KQRW\+I*[=H:03A
M(^A8A2[[6+=4M'W(;X:U$%8&2]I%'H/D[ P=<SH$]-$\OZVK=],!I3KPR?PE
MAE,<_02T+PUFRC(O!X9+BL4.V(L::)>B$I=W]P7!!@JU]H_T']#I8R[ZW"5P
MP^]X)K"+Q*29%P(]UJ(*"L3-)O8EX9;Y!:MNWN]N8?!F+=LYD@=_V2U16DG5
M5K1Y/5!<M@^B6L1I 3GX)#E1YXEWI3%ZOY +0[04V^0?XBW8;?AC(=BAT*^[
MU-RG7K&(2B$H*5)@"W(&?YJ] 0DH[L(\XN69U\ 9G:I/X*M@!%'AQW8=%[O,
M4@IB_RP6Y^*VTEB2EDR,P:_K1GHV<%A!MJ#6!P,-Z[DG;JA'H\>)'P2X9V/Y
MS<P0<9VZ/YN'1S9&&+YLCL^:K@Z"^#^9[0?K+0K0_O<$9*GIYH,YRAKX\S?/
MU8>:898NVVE,>R26QV(XC,:,CO22H:B8ID:8^EWC$G3AZ/!PMF,WI\5J:AI4
M2!MI<3+Q!O=+AE]'.C+,V^6^A)6P469>!:Z\#MDNHHQ![0L\&5!@1H,M3T"C
M=L<5W?DTZNV4190=G: -\=?O)RI$0ZW;<#?$'R. J=J,A;FZ1&0C7AKHF,L8
MK472307!GF".]I3:8 %B+Z9V)UQ\!\[0R_)F6*+>\_5QHTG5D>K+B)^C05"@
M&?#=@V\6R.X]=:DR*M]3>]N9RM .U]6F.MP&F*FI1<(((\NT8Y(>=!B$F /A
MM%,:"V"VJKC&3V&L(0UZ4P'=Z8V'<%7ZB!EKVCJ88+8+68G/5=G!-SV*?#W?
M"W=OS,35GJFHN) 0>UY07UW^5@Q,C+T673&&T7<HS+MAGL8U[P&-'0US-'MF
M1RA;DF,!";,P0^4*IB^H<YIG7%\?IG%U]H)<=YBJ-4!6>?RXB!GT(HI$:^@C
M*4A9-<DKW\4/S(5\,BCU,+7A'%X#KJ+=B#WTZJHE'Y:-J]>XPYOO>$BK".U,
M^T3P]",=NA3GU@:>*^&2G!"F=0W(O-3\#R0*G]]<@I8%JB]_"\X4E_+OJ\<S
M^I)5UI#?\$_J1FY[[R9D$WS%>*A'Y^E?(1%Y0_CVZ.!ENL<-S:S'4$,>J#?$
MP4&@F"AO\)VTCOIZJ/D86Z:RA5;<')R3\1\G;RM_VY,Z.U(7__GD;[B=YN?F
M75"OC##"#H,P^:\:X43CE^8>YIIF]FKZ":?Y7#+BH\&Z(+N:X/JD*W!EUSOI
M!MKD5XI9ET2IR $:8\V58#MP6T%:X\"K; +0/$P^6/BIX]6*\(QYDOA][;BX
M4,ROF%I$@33X*F,;;:YY!\@J"MZL*<GV0CSTS TAW,N,K:^)U>Y@8MYTF23!
M2>Y\5,$W.?Q#%9L<NU_TY++J=8O@4,=YG?4:]>%[B4; W)NA6C9LWA:J)Q]T
MP>R%>@02:Z)D?A&%9KB/,S>2&>[ @:1*BJ0#)$:!V=PN3_:6B7X@1OU:9=L"
M[E*:']6^#*L?K\Q6_:!.Y?V6_8U>=Y4U==V(0<Y"&3EB;3#\)Z0PO( #C&%P
M13LTL8"[=K8^A?'Q@)\:)E:O&_"+)#^@XV^3&*XPX282!*86>@NH-4GGS!_T
MD8$H$2@J/UWQY01N.^/7192K>1?->-S$I0+YKK[@.X+Q -T'>FON<?+H=@98
MS$U43G[""GBG3GQ!R2ZH%^U$W.";-^  "> H9?@/!U.TD5:1< ]%VS9C/>YO
MMH;"V;/O="&)7_&73D^_#[$[H,XF9Y<_,*VU));$Q+G>&9M8K(& 0MY)>7#:
M \2G$4RX!M;J#/>@R_2]X)NR\SJOK Z%>DGSS))1^ID!86@M[=BOA,TIL:?O
M@>;GKWK;WXV;_:OL.BL;*AXD9%E)\(75JV")I@2M"Y!4G:6'67+-QLM2]4YS
M#=91!WXQ?E%V'TB*?7[]7I)RNO1:0U*FG-607%E>V/ Z5G6=2PK<T<0%DF/K
M2VZ;;LN$S(I,]E3??.#*F[KKS-]YAHL#<_%,74F7!<I6>U\QTDFQ%=-MVCT/
MS.A)L74S4*3$7Q82H9I%5'MYQC>#A\O:!8PE+:;[U)"5\^UVR4[J E^VS>AX
MK7:4-<IL/'<%&MP'!W"C&7V5#?PZF@IO W?,GH;(\Q?G* 5.3 D7LE]$(9Y5
M;KH$/CAX<,",(3%MTM6K2CX9D2V(<[<^[N?Q3U5&\R._2</5T:S]YQ%.1=;Y
MV?>OLW>&;3ST<4W1AZC_R[4L3/R''=J4FXJ?K90WU?WOCX0>AES818M51FFZ
MI>B+C* AX>%;M' =KJC2]?%=V(=8' KYU3_(,&3^B*NX=SPFY=B5IN/1$I<>
MOOGZW?'6DK*7X\JJO#_S1GN:;[@^"SM/:._-46TR<40;Z$'P3LTSRY9,5-O#
MB5IR0&>LPTW==#2)X=8VV/R/W[[KN3^Q>R1ZY,">Y;F"P5E3P(&'%\*XXTZG
MK]]6*J-'%O@H1E(RIV6^:URT=$+,/U9GW(-\T@*OT%X3GJRCU62[&7Z _.L@
MAJ2=B::GU=-"NW#;!W&N$YBF1!:RN6XREEK!XE-L8VBQA.+*E)3R<BBY;[)_
M@FC3F;VLPY+OARB7,@6E#'<8W?4]R76E",1VNP1H1-?J+3W1C<;MJ+Q5O6.
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M 4Y$L]Z<'D0\#)CV4<<O0$4GL!0F2<2K_7@7$S"@JDCDVF>V@_.9*^))./2
M;U!=%?8@_TD;?%Y/**BV;<O^XOF 2XIG&WKSI*#"?^&GJ$G!!MJER*]_'?D!
MXDS56>J;RJD1Y!0@[O=+, 2((F4[Q>%90J9%_&6J#=U=UFE2E1M\._&LCKT2
M%GP&A<SD"K,?T,3'6R'"!0JUF+UT GK*C1FEG9U*=UDZ\M6R.&_#K(* 35![
M5QM/927>BU&F!%)'&VYR)QQ:YEL<#42;^!C5B]%]9<I19?QG;_>FD=*6%_H]
MD7I#D7:WKK2Y+3TS3/+T#/%_/GAPL-XKW80G\ 6-#Q\V"HKDSW]]+M]^23XP
M(%]>NI84E^2VGSRMW5>TZ8I;B?W&):<OYFT\_-F*?[V2QCF3J<PIE[N+J/$M
MPU6Q@8D+(QRC50I^(=P/E7@XC%YB#/CKELM:_"FU*Z,/8X/#T%BZU*9Z1K\Y
MJ$R'+IFF9^C==/&>$7+,UXJY4*O\^J[K)[[_(;M6FO%T1ZTNHM<6KGRE]/S4
M&]G[W0^8CRV%!#8SE>K(AZ9F1\-G0XA==LH"JW,&37OW&7S55;!<F5JKBSPO
MVJ;F7FA \#NNDT/R(% L03O0R@A#TW,E7TUL2';ZV78\,S/:U*B?6H,TP.^-
M@?3O%>)D3"G&Q>Q"^T@1/4S? \89DB'']NO%O0XT9J@ 8LMF+HKM&3MH"BE@
M?3J93VAY[:\*! D%B7 &LP%F$0:%@:T9;-[VG+BF7Q[],I1^@Q#&+5>UFJT>
M"J;?@;T'X4'C%T@0]$4%5<MA 4V 9-2N2^0-=_@]O_E F5(A2-@F!'L+?:O<
M.JI=0?.]^IZ3EKHDCUSY[ECI&_VA-LBUBC?>#Y^SQG_5).<S/S?56LK9,OJ2
M?B2;XB)&=F!LA58:[$J$T I3QTBN&"-P49@,?:+0DO,?6W#J+*AJNA'W/M.8
M$FKT]Q?*G8T!/LF&%N(/*?;OW^G8OU/T(JX&*$[8^&B@V3AC@X3^KR_II%F$
M7I$?8)-4WII1*$YQR=)7R-BE@$/ST]R A5+>R95MNAD7U<0Q\P>BYB?]BRA=
MUIJ7--81(7^H(8S'9J[$I^"5H5V8+4*FXY16A\_O@]L,T? >L*Q3Y PQI9Q+
MK14%5,(F&M[P8[&.4JC[A6*%A$*.K/11G/KS(6RJ;_$D9X/]\*[9/H7->&;/
M5.SR$P%7JTL7XL(5U+?O<$T@:UJO!1SA9]VB=:XVP_2=&1J.4B(1-UE;E'AI
M,_ZRR&D B?$HH._4FAB*N#XJ$7;)J.G6[^1;$[]^V BGU:6T4IN2 L]=T5>=
M[ YTS \F:8/J"0-TM#&5\9N%HY"8&[!/IVN('#L';*3QI*IEX)O;V6"WKIN%
M.-;39CKZ)WUH9>T6C4^Q@9T/P-E4?:3_B$0ITX(_)WA0-L1'O[@^Z1+XZGE6
M\JOW&**)P]@CD %.+T;HGPR]0?8P%U$KO&"\D3@NPK&DBZCU@YT6T;)FFF%-
M#[&$EMP%-]-U3K6')579*.B8N^'U2?,JZ^;\!>7,P<?@G9NZL!^G8B*TV!>U
M^M02,,C@!=)%:XR.!68[QJCY$[@'0A]D21FVF-_QUM1>#&,P\&7"]H!S"^^B
M)]2I@[AM<.RK;$Q8ZQ#_G4FP/2 P]F7,Q*.8G(.QR9.U;Q=1 0W/E1CB7Q]#
M3@W7TRKV@RT5>JQ]0@)<:>P*!"Y1"\SKZ21@.?W </ *4IT*KHB HR!7 BL9
M-.I:N"M$.76XJUSD4RB@"!O\E8&,SM\JWU&^ZL]WZ@N+* '[DMD/)FEF"F=F
M24">06PWRRY5=M5RD;W7=>'YO.8([,6*6+1!Q;N1XNH.X[4SJVG<SD?)N \:
MAX01NOHHF>NZ 03_?:IOR":X.[J?'D_2LB_3O4 [0Q?$E/%>N.DP792ER!D(
M*\7GJ5U>01G=3 SMF9[7F0?[K2P.D% VP78'*2\4&H*$XQH+'\,L^UV=$/I
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M07*R0-RGF;"]G0^'_VF$E7G.JMS+7U2U7.Z:" OY/<ORNV+7"I[KB&;PDJ&
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M'^)ZHQ=8(!AY^/NYK'_,@^M_B)^E'_#]K:RT5[D#LV"!,!'\*RVQJJ@?W\$
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M/%%K&S1X9\.QX(FJ:?BM,PFE2_*XH$KD(CV&T8()R@ 3P%LJ=8'@XW?B)&'
M)@$,;N_O]N=/ O/>4J+P;4$%87TNHC\\1PDK\3.>TA*HIB&9IVW<LB^C%1&7
M(9; #YHT @QH4- 7 .%HFMN:1'Z_)!X<5&"1%<7G2%SI+H4K$?,3]+;/:%P'
M"X0P3\6OVAL-/?2E7;;_"K?&SD3+BM^J"\W^O1(DHB4/E%$V^YAG 5>:)"!X
M>?SGIHT=-9R\^K E3-0+KY'2.*NIATD97I(,0AA=Z\B[FZ1A@APQH":X9&IQ
M<=7Q[W"V?:#=H!N@ .5<_/;]<(*60#">7PMQ*<J0KHWH5 6&S3/#.,V(*5WG
M*^6;\($6_3W2/8[U:P^-1V_.ZE-I*TD.TL8;3JI7TJBZTVH6T@[V53S:496U
M>&YNJRNY^4V%A1HWLE/O:;K^'CRD/'(FV%G&,;^+PP6<WIA+_GU75!D[_:GQ
M27/'<-+M7(HP.7=9 C4'%/SH'=0\7L$UF6CM\*#$6"N#!6K,2NXZ1(:Z 3OD
M'X,HX2@8']R39/N0O'IU$J)#%YIB\@=[;  %:NUC74'D[]9%KD[)_<6B;V/%
M$RA?-?+* H3:)C[]^=Y7!A/% G&L PX8T>?48'9E# YYOH-3\R0+YV?0!8CF
M@'4LY_V=[V$( 7#&-D*:9"?)+W )9_%0CU<+<@[6&.2*B^M,"WC;(?AY9CR<
M!9+ !#<\P+% 6^L4+0(LP3B(9HNX1E'*9&H!<J27[(VALD!6 9G2!UJ=,.21
MGL0PDD:$C<PY>-CU/!/3F1A1CYYL_[Q)F]:V-I<\+/4+$!G" AWF)N=O1RLE
M(@(1AXD,42S.#Y\T82+)/#%7.0$15OKSNWR\SLL,Y2'%EY6[6F<85[]<:WK%
M G66%Y^=S'%X62%VW>_(^KA#M3+V&)E<4*3GI]+Y :?[;:*E(.B,+\2@-K[_
MHV'Z8.Y-?=$4;;&SUH?S3-O."5S@>SS]GOPE%5YX]&J0:__T2+5AC9CZQ?7)
MY3K5,PGBG^BJC(?T4_4(0;+2X$XZ"R3<%4K^@04+(L)(88<"C?+_1/('HX7H
M6@2U+!Z\146P!PLTF"7H'HP+Q<3O^4_)^\=+QL9NKDR>1%]1:[SH.\$4YT+=
M@,V!2:O;G&0<[5V/-C#2P)S0HADCC('AT(J@18T)A!H!?2QP(J1S-ATIC8.G
M]GT?'':AW->O]7FU&#2"\JLJ:E0U_/")D<L"A4#OXSGV8+S!0X.HUH#>!C \
M>LB(!4I!Q%0A)*=;T(((0T8)0AO%UM1!Z\4RE.0$ND_#?"!2:.I4T^<'U7B/
MP/W<UNTG&3IJGP0#SI4AOX /T^-":19T-6"3W- /D0'X*9,DQM @.W<&R/Y>
M$E!1.@^%I#O3UK1FY-T4:@PE\0DZC'\3\6#FJGU)>J-E\IC+_CAZ)MBV/-BT
MPHJG19XX;,OC5.;!_*QM:=2S7*6U..*<?M6/RRF_.3(]^<12^-G$HTC!TY_.
MW#M;*2CHRK5V;<VQ?[DETOTL0=FGS/S$D,4&<DC0E2E$&?MT^DW,6#_Q]M-/
M%]Y-+;="T_$BT+!G2"[F:(\".3\!X4X[[TTWS[$<0T*OS@=Y2U%<FHEQ$5_E
M@( AK.GX'DT:9D%>,M-O*V#@GU5[SO?*\V1Z1@9NP!I7>_'"[/8GL0>;^T7-
MG.I1I3LST%UZ]7#LH+?0;(_8!P+Z*!R/]>;O] 1+;L!X$+8(LYJO&]O$N?:O
M9D'U0?=NX%KC]09*KM8\NS.*"Z/>85_M2>9T9^0A!>!95Z<AQQ&F'106**-'
M ^%O!"FB2))RNQGE!<ZS6%K<N;Y9T0*[1(1H6+F7MT)I6MJ"J8VY\]NBME.N
M"P^H"8P<""^6?2U[ YHS<RC-'D )9;6W6(-\[&$IW7X"H50.OT#(3X;(>C%J
M!VT":M?N#5:\!&BNJ7/E$\;0<+VDQZ&'.T0-@B>.F%=ME_F9YEKIXKI5PQ,-
M1.UGD9/S2I_7QN]L&YIK%CVIJFI9OC\-W4[7:JIXY/<LT^[/)[ZN&N\N\-[/
M$ZDWJ@^'-JC/%)D]+';,LP.MDUZWG/YY^D0%#_#FY04PCYC;"A!&/0. 0PF8
MN;0!J"@T:,'UW;W\;6<B\24<C$7* )912RI[?)9TUW"B817%>1?(LHF?[!O\
M'2HGD=$2&1QYU>[VPRJ%[K*OT &\!$2,70XXD&H(2^ \R?.YY*@ 0H^";"9L
MV]+L-._0YD<4O[UK;RNU6ZQK_6K#]W%(:4?VA%AAGJE=-WR3FD).3M7-^A)K
M^WJ,?B%4:0M#8)S#]IR)+9_L"_FE#Q-4HM2.$'.DYYOGVYZKXDJF!G+2QLZ?
M9[># N041F@/FHEO@;&Y[BTY^=-+#HL1[#FYV:,QOC=RTZ.^V:=JHTX@">\@
MXG@5I_'-A_\9->1A*4=\DT'H6IR/36R0U94G(?H5$D&F]OT>3WP_B'V<>/']
M]]?ZB6C;=9J[*HEKY9A[$<+FIHQL9J2#T^;X.\>JA-H+YZCNSJK\O*89 1*_
M+RY8,J[7GYJZ4\;NOU^7M,9V<)Y+[?VP+W97 #W:6>8GC[Q<\KPUF07J12?A
MC_<H ,6S?<6",\9FE-@A%NCXG1*2S?7508_ZMZ7!K@7)2=LGWV193M*-%)+M
MK/6NC>5S85><LHC1V\\I\R1P/]]=W!#UUF0Y.?,Y29PI3I<B^U=1U 9@ EWA
MH<*5^37N="7RL:)C64$B%23)1H.4GR'GGM?RB5[X\ZMQQ'MY9^G/&)HI\@.Z
M)2N)*;B!:O5_2)G'0L4@0G =4R"L!J@E%&'B6[T$E_CCC16-&XYJI6@8.T?[
M1A'#A+ZL_Y[0C J1>^GQ]0]\T.G?]^V-P,G@-J6M'V7P9.J+B19,,M*(D4OG
MI6"PWISD(2Q&A/F9!9HKJ.H?39*PB-=$#"\8[2\Y3K483$.)-UZ(%AMT3^AY
MZ<>T'G;S4?QP.Z:Z[\YZ^U$]L]0KX;7>JC+T*H]\X^^_&9@S*[5<G9&YAF:]
MRK966BNOGUZ^Y97_&8YXH%W5O_?ZI_)*S#*7SY/&W/"S;7S7&ZW*\U16(3/)
MK9]>OX9+>5V5$<FX+*U\K='9)SE/ 4\7_ +=/D4[BS@QB92#)U\F[VQK$=YB
MQ %?&)NRV+2&(_#-WB ?D5;I[QE+HP>\-IHR(/N++)!YX&)(J,,E[T%BF%SZ
M-M=>ER!-!,$+)-<@_!Y@P:T+A3VB##138A[8)$7WLX5GPN+)1G*+1(*,%D1B
M5C>,=VZX1CJV_^Y=LMCW.]*VO(;ELPV521]"-61SMGG7=ID+&$Y=%@@G234$
MT.6!:(FH'2[D)_0Q8TL"6, +OG-E["<Z95'_S90_Y50SY3C&J*LM8O2>WM-;
M8:%AMTC,SSPS(A,+0QR1EI2=7A8H$RD!1)-_4#O(277E(?GM+% +&+L)Y0(<
M5FU%%$?-,.V4GU5I,JO]1T@D%9>Q+_/=G=*0<QW(&2>Q?O='3LAN96_'0ODR
M<VVK(EXKAP%;O0!Y F.-F'M6MR U J-V3UH7.GO57-BV4@V<6'=4T=E6(%-0
M>:76&W/"7PR!%?00OIU;!^-_=.%PBA-AG3A5$]GIK'KV?*Q(-<$F>(EJ1LG-
MZK-+Y5W"/Q!$SD'$@1C"PB%GP*L"#AM@ZE(46PG+7>.(H,B&JU^]X6G8*Y?Z
M@R+@&O7UNN1^F+7*D]P&6XHH7= #;]L!%)%738''%%%W@$).(S+;ET:%@MAH
M#W99EM!Y9Y;)E5DB;TEX+D!GZ? T3;.Z;FT?D:-061)9YKFV/[V<^TG$@<#9
M\-083#,+0AYEY%\'SE:N>]0B_IA$!=MQ,L>,(*VZ+F%$OTFZ$K%AZTU+[;M;
MYB]PZ;@",\W^EA#'@*YG_6\N_)P=0,V'$=#]O/A4C)#@(+A-OV*)/]5;9+KN
M%28@SHX$J2IE)TK<TJC ^KA[</')9@HD<>GB]$\6B"LH_\BO*^/&$DRIYJ3P
MB$YDI<>(NQ5ZAJCFN'(E2A42.%&A8NN*?6GTT%S;/IO:-=FM]K;*L)5C5?28
M1M]U/VLMYW5BC?_9!&:CQ8'\Z=J,NI&<"YRNIS.,38R0PP*6_B?J4E:&IY:Y
M599.?Q<SBOC]MA_<M-J'/HP<@?$R30 \-8GY@:(UF'40GM:/YF,*K*./1=D$
MN$_K[?"'-*_]^+*Q>/*!8Y;56-=IDC(5B*?P?6J?Z'YE%&)QZ"LX9?#VF=.W
MSQ@1?HDWE/=HTP/(._UA#S!-0]@B.>N9FU&H^V#^+E<B6! 6K'*CX&YC7 .\
M[T>_2[[1\;8W>:BF"T&W7W^-:U,+.OS.1RA41*;G5CU.M32]R-W*(=>J3D59
M@0<Y$?Q7-5Z(U>..M/QH\[:M#>:7C=5V0YA='A7PKKO7D>F_[E!GQVUK>%-(
MYZBS^F$C-5[3M-RS!)_DFM64HGL_BBRMG&4+J@ZF*M?975/;YV,/=7S,D7UP
M&B*2(D?-HY@D2#R@Z\1".>C&21L+BDE# Q[;SQ<W>V13WG-9,PS,=V^J*YCA
M;^%R^S^^)W(S$;7[']@F#H=X^.&W,)00[*,67]=QINX";$-9>S4NZRJY+5-W
M3BI T7C]5W!RY07-"&UOERB'.[O[G_FJ#&P+"\9?VH8[N*Y_ZIY=L%JP&^[R
M';I.ECKTW)I;I<^MYHTZW[U'M\XDB0H_K.*AK'B:MXA.5RT*5\A4?6^+*V2!
MWDDQW\8TC#4(K#+%U+!R;#!@W.U!L4)4GW/<H'9A0''QS\$U3%M]:^D:SC83
MS=LE'5%@^\RG4N%3>[2:1M\7CX'@YO>E8XG9]L<?OY,_<OV 2<@FG^O2\L^L
MK85R^G485Z## OXKKF]1(J92XK)LW/4E6PVITD,J-]P0RY_DSFA+GVWH:^[R
M#S7J,*W-&<RN*O+Q.\_6IU>J?Z8V9CC;YK0J;#E?G*?FK*1K^!=-0L4)E]$)
M03[P 2+\<Z6F6R;72. *-_FS;Q+S<]]4,8];^@VORY=[.LD_[..QX]^J/0O(
MV?;1=/C1\QR<#EPGMZ-ZI>(E#W%$<<H)TS-0O>$8_Q%^HMW0#@\BF)R;V/:L
M#!$SJ:>6=6*=>G<]+%2T'\QGTN715BUAD?( 2+;I;,)T?7G8R91\]E3'=ANV
M$):&N>GE.[ H0N%,7 &"B!I&6L>#1'&7\ZGMT5KA_OECQGR1!_5*:VVX(BCQ
M'PT2%9+4?A]C@1X\B"HR@AY"?EJ4.'-J>H42EAGUGO3Q=W6EQUKG+;3\FT&*
M5'[DX)_QQSN/QQS$7"#>]/9QE 37$9 E*AV3=Y;2JE*=@V*5')]]+#Q9,NR@
M_<LC='?AG$X6-B#_VZ+L#;=;DB2>#JJ@+M:7/%=8[)SV4>B4E +BLHI5DFJ=
MNXO3AL]+DK-;RPL"<<:5>5VY-)4AQ<3R*)?^:6)'Y!_$/\2#Z/;A2ZB$1=D'
M6!FE-^,[NF>C)+/X@<C^%)S7YH#&R.M)NGWYIE%$2U:8(&]"B^=3:F[F#9?;
M^$9VZ]\VH%T,WJ1Q(W3&F++K$)$F1C4TP XT1+&V;P9@Y,^[<;[]8 %$:!U@
MX$X1'%)*)!7C".MA'-?G+=Y.7(>=U&ML+^K:H(-]<D]&<R"O]Y#8K7,;2L"(
M !BJ*$4XZ3XI-@0V%T(<PH*/ #.\+9-F0REZ_!QPZH^!>[FS2<:ULQE;W[=N
MG5A\OQ'FI]WI(C@DY!8YE((=K/#0,\DPRDYNC2BL[K/Q>)*KUJ&(<SX;X]AI
M^_D]\%GN_6F /JPZ-*3<ZZLVEAFP31%^[6;U4S#)-<7]3O#'[K-&CZLR[BS*
MZ*QD&'4U6^FOZ"/ED>_1'$AI!&H<&N!+<U_+9YZ<I(>3PGCH+I3++! ?W2*(
MJ)7<=D]*"Y(?5G85&QD7M[0CMGE0;R(KN<73K6Z;?OY,T/B&X(!4NRPT ]J8
MF4, )[% QWHTX#H#**%R,CJC1]."?)<%N@C,DB-H1'!FRXCWBEK("+1_'_)8
MO[9F;I,I-/5**>;D&^OGGB\UK]-TU]]@\E%$B^T0\DXOK%UTP [G>I6,27O>
MBSH1U9 >&3CK(;&63()AY2B&&]QE\%6L /Z#?LJB+CFERWU[=OM2FDKNJX;2
M7-]'.XAKC!KD\1 PAS$?&=9;+,<H9:IL(/D9I2VC&1[M ]#,V7VOP692G+Z)
MOJ3G@I+=1,GLSPZZ\<UO"1I%A?FSCV$C&C,ED>'L1M/I-Y*1<=FHV[W>P[:E
M@L>XZ<G40LCN9)9:E99_]NI;EQ8/9R4M/:<E'L.MS.263XVZ/=7Y=KH-KGQY
M<=[=-VV,$3]DHI+>V;NY7ZN-L\TPM!#<5N*_031_Y9/1/[..L&./!C3 WI?"
MN01]!^-D3F7#:ZE)@ 512P@@P!U^$)V9R00V*XN/C\M19)J);[KN[/^<RF.>
M:1OWJO=+O//PSHT.\^;,_>A,2]='9(,M$X(X\QA=%*BFY"R%I2+%< A4X\Q/
MK2/P?#/ I!:^1-BYKZ%;2ZO3G*+[ [E^M1Y#1+5:VKQ%2)J:M,$5M%5SMMKS
MQXHK9DE#5"SY<-5V(V62^@QU%.CNDJ98]V%$=:4%32].0(D*D]][3@(G['C6
M'3=29I=LCKOC#3NF(",QNO&SBAQYL(792B2[*[3!WJ'F?O7A>5O%C"_0' '>
M_F*NUIYD$J87<S!$0BF-R8&<B):)ZV^+-F(^6PH-Q,&%]:QC?";I9J%5\'N[
M^IF"4;YI>7C[L[YE-@JJ.3F)W/K5XRM1"E95K57PR6 !9^=SUG-.RZ&##D[+
M*A99@HZ9M^>B-"^;!Z7V#_/FD(+?$'83O99"ECNRJ'DPGI:(_19RB\J*T.MC
M14'+3Y=MZYPM!+SSCM5=-9?)2J1;O$0.01O!"4@MA%P^5HTRNK0S!$[IX0K+
M.![D 7W8T*5$7B4ZA7L,^9)Q<;&V/6WCHVFMDCG55S=?SPU46_M\DS6^6)6_
M$K84EH(AV^,E$1R 20W<LU<$+/7*GZ*1E88)]&]K'KME[$X(B8W1>YL10O+.
M(3+4;"=7PPZLZ[OF@^=OEQ=D5HB+3"3&/$B&6U#1@"2%DPC+Z#F G"@^1,E[
M0/Z^N<29"M%'2%%@O<)C]0@;<J07):Z_"D8.AJ/ZF[ZL0TZ1;2O\QTQE15U<
M[SK.RS^J3G^1YMO' K4V;/TD\Y.&WM5%4R.!4W57X3K$)/22-#\I/ZU'=B%(
M'R4*@0;B!>[,9_ .N'@,K]F$E\!AMA-[(1TOR)5%-V?-%PGJ^9--.CP5MN5>
M[NK&%>DK_4X57KL1%:H15)6I5:LKEH-I+W:$=5=(I=TU.$/U..Z5IREDIBQ&
MN,LE.F.XN?J5P?2251OOB=T"86V\>WFM3[5CL:1:S.7?+[&B=IN16/,$WTS#
MK./,81BGL0UY=$DI"^6/R=J?'2ARI<:UM,U"%.".@V@^?FQMAF>O8_"#"QV4
M66S:6M>%!L6.TG5<K6E[GM$KHULUZO77WE[ZC&C>, )OR9'=@O'-F/BN2)HC
M#/ DV6U?(/_J[=$"0HDCYXC"WS%E@1X-&1(KLU:3B#B2&-WB9J?WL]B:OH*[
M13&5<WBO3Y76P\,AABZZ^:E=P!Q-$R$&.%-H?=!F=; XW75)"Z=CFORN(+.#
M$FM&;D^ZTY"(.3KO88-R(#/3V'?P=4,/+,I.W;K6,HEIOY5_N:6]J4U'H=;F
ME/G'66@P^M &2@IS?33U-#QV0'L-T^SZ)Y.'#5'D1'T^H[I^D:XS<TM/X_H2
M]KZ6Q]QV0\DSWTE4BW]S;CGG-C</81K5^L'2/*H,O&AH>V=-M<DJ04JH=#UB
MP(C^$?HVO=#Q[;?PG+D>]0:>L3[2CP(WM]'3Q8+":>^6A2*M/N99)U<G53PL
M<02]G"Q3WYR?+%\\D1$\M:3\,>S8V@QZ$'K<6.X5W802ED$_1!).@AZ'@_N1
MI\B9;6U-O]NPSN3O95$5,,F@UT<?Z0W4MFC^H:A_]<\(M>]9@$IK45'6MA)Q
M3?WFUM8U:'/[%D4[?G!F\;.@+I[O3G*!KW!+N+E_@>F- H=*RQL*W_RO6P(L
MT%)6ANY.*E2,S3RS\="P.PPE]CP?)@$,635-]<O9-TW2;1I@&VUW<7^V98>$
MQW"(6DJ_CW?W.5&;\BT*"Q[CSV"!I% $-'N<@Z7J\J? CK]B@6YJ\0-]6"(:
M.WH@V /U0+WGN"6Q#?VN6+B1O.L]!VE%0<JO=V5/5X6=Q=[T:96[[A1BH.?(
MZSQ1?<Z^3J*F,*8PP'%C1+&A75<Q9V8&[Q67[G<U5 K%Y^],-OQJ6I7K/Q7)
M=2TP-F9LT-?W\51"@*63S?E1OM3T&X539R4B?N4@>!'*E-$!<"*8; <^%((6
MN--"3AX$2R(ND&'Q+<-V!P.I!5G8QRP0]TAF8@U^XQZC< 97E?FY+/*NUC9A
M>O4![8PA\T.H<D8:=Y</382ND&S**-/%)V):6M "$'7D,,Z_C@1-00I.0<2"
MO87(R&YB'6^_ #S6"_T.>0;MWI/O-+5G_?;IX2F)S-RJ>>_WS1D0]Y,7WR"@
MQYC3[ G$I(K9A[OA#::D4_%-^?T[D@!VX,RE D-TOX=H"B+.CY2A.'^>]UYC
M6]VQW,"34R*_;]8=>='O^9[LL_F4'+"M1&!+!+:HF:;PK222++>A0:AD%DB
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M%/D9WMMK*FP2#IS]=/M)S63!.^*.Q),-EW2B0E24_%/##VU3-Z87JR',9-*
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M/1H4Q0=50'(?4\C&P&RJ1P,?.!;<C(<WNTZ43M77-_3?G1#N[,1<*[4\_]"
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M.<%+><L"V3<D.^^?\RX.9^>[!)Z 16UH'+!@WUONQS"3IYL%4MYEO(1N64U
M?^J36^-H[%'DO=IE%NAU7#XSQPQV -7KBEF6@;5R,AYZ6# K%T4:,'?0OP\'
MH:G_#W5O'@WE&_\/3XLD)'L(E:UB3&7+DOF4$$+(-H-)$F,:4I;!,&5?PH="
M$9,]ZR1C'R;&4B3+6&K$F!%9PHPL=PR>^7R?WW/.\\?O/,_S[_/'^YPY9\YU
M[FON^WJ_EO?]GNL2XIJW8>^R4>Y$U'GWNE\3]@KNMX]N0[Z:Q(C9N#EU_%^E
MR?^/(?35#U"%<%ZI]$"W_P)V^Z */&,V(JGT!V++\>\QSCPW?[@7_!R)?;(/
M(N!CH-M->W*.\\WAW)L1B/N78$7@)+R7W]3H)V](*DDZSI-UCQ/Z4;B_MXX4
M<CTF\_T^:"RSD3"<S1EKV >]_.@#W4Q1%=I%HA)#'GS/VDUD([9=3X1A9_X6
MKI<DGB.HN1N+W3[P/W$M,!#MB?8/"?'G*<XM$ODQZ>IJ(=M:5T<4)M;^<+%6
M5;S=+F ^;*&64M,C7=O"<SA5+K7;4 N(K(Z0_O9]7NYDFK,[D,S<X<^)&7GZ
M;WX3*R[*=L:Z=?1A]J4YV%+S[%YRB8M?RHQU[=COU%?3<D/&(6: #>J="YB>
MB$6Q13O_\%#@9LQ)(XJ>]DTN)C*-IV-98[EZ(I<+;R?^G?G,=_IP8N;2]#XH
MZD$2^F4>>-#KY/EPQJH<,&%"NOYV6=GB:KA"+JY5_(?CB4]'OM\+4+K)^V[(
MS=@PAFW:4>Q+NL1\A0TOA4]DO.C8,T@9L!Y3AVF09"'=V^(QQ$<N>E$B% (F
MS#XQ1%I#N?1>XII<:8>;WK !;'S,QBB\$)-JXDU%L$J:CCDO;:M^@7]*#PM(
M1X7UZ[$4#',K%X)U:(:%)SV08:H]FOZ@H)<VQB Q&Q=($BFL% -C]I@VU(P8
M6# GW677$4?G+0XWU_V^V:TS E%LS.8'BUYOR!&>0M%:^TMR#^&5E/+8!74O
M#S47D-(A@E@+MLYK?^: 5"KO=Y?K29(Q>W)&#WT?;ODBH40#=/4W5X2/Y!7/
MYV8%\U/2B8+//5"9]QLM@NB\)/'#U]3C$K5>/Z6X+4T9L-MJL3\W/ )Q3+[<
MXR$'(6#)&&-[^]L'%L4<7^!CC"S3PU*/ G^80K'J2D:S$_U,%/GD?-KGKQV:
MB%-X82._HVK![<66Q7]??_[WBJ-83H_<!99P"B0Q$Q8X$->3(<E1&^"'3U(*
MX#>79Q4 "L51U$<Z+IJ1T5&[)$'+;&',2[OOYH<7WJ@@'?KN_8Z1K1I?D,?G
MD<<W8Y:?+>E\-ON\F,'CKK,29@II)_7T+CG:2ID=EDY_^C]='?\%9XJURBEN
M8.)W"W<8O'M<X9DDOFV$R)F2Y2[N>@XW>X@X[.E]$#<YV?=:#5J D-+=I O[
MH$6K$Z_#\6S(")>+#W,A+)T[DD=E'U2[S$;LE5M'URU!ZR.JV-KTFX ]8S56
M[G+#X(:\&+ ==O5).\VK\RH_P[K3+R%;,"YV WU]AH(0P(8P754<A];Q)[ZY
M&B,)=)AY=N!70@&R85.B^>NK88/^GW26]>I?[J59MK@=0[HX=PY%@ 4B'/C%
MV'H:H3@?1_FOY5&&@3B%"5<_2Y:V3B*"-3JE[SMFYC_7&:+YU(_?-@KVE>)4
MO!M227#MN)G_2O(-%Z(Z<)M"3[FH)W!QYL,Z(NUO,$-HHK S5.69E@7BF#."
M<RUJNO0I5_O+81W&V@R!I!NLK,XJ(^MA0R5,7+L&($I!3U_5A[-PSTEPQDP^
M MG3'13<S^5H481Q/KRPK:SZQP!J7DYZ][W6*N\27C1@0+0RXG3-/BBZ=+.1
M_2 *QW1U$SQB+<3ES+SDZ5;4-9;Y1,[%"H'/3*FWC9DAV:NW+GWZFN7R>[5-
MCF.VF]YV>2GB$&LE@W6F@%4?@ZQRP9X XICX9[2@'%:.W0=6=XU@VUNRH,&=
M34<):4VC.\((I$-V;D,LW"7SP+OY1SZ7)Q+L%E)/8N2GE2O?+TP9LO =EL8J
M;'#7NH0A>,C@S.-:@-PIT;?9\FJY+LQ+%!/G4GMCY\XSF=NC8!N#&0/SQK4]
M1ZF_"PSK"7EF!J'33P[SPK:!U5;'&H!S^;(P'P88KG8]-II!'!E@_V(TQ*W\
M1!Q&#B&/3,!KJ!O]]EIAW^K.Y[>,G;9TL#A"E Y)GL>J[S9%*"-#5;C>"(%1
M<0!RH)RS^R#!NM2$//UFU^OZ+6EL.Z9C E:VQ,+]G?/"$("P0A^AWMP)&"#0
MG95;SPJ*FMT@&VF$?R^"_,ZO1$E.08?!$3P#!.Q5]EG,L9UN&R?,!;H=JS11
MT^+F.LI/H+Y5[<0/Y'9F[EU1<VKE3+-IY*!6QM,3<<_]%J=$=M\$[#ZA9$G_
MBFL3^(9)_;@I,@G8;UCJMP=EDV,"^LY;52A]350O2%FZ^?Y]8Z->::[WZ88/
MC6_H%<9J)0^@!  '!/#VRTMC+9E"DA'#A@J 104GB*WR>V<:<6COZ]@^2&(=
M[==!:XC#ZH=48S*WNF!SR>5 %GS4P-@]_$@5 Q%7+VV"5\]GD":0P1HHE&&+
M8OT<38NAO$L*[#_$U)0#U0Z3=+F(&^1VBAW[BBR^'A*(5A[OS-,&0EC&AFH^
M679BPU"&6!W:K^_B) 9!V8XM@\;]WN"7-:OC8[Y$LL/39E#RS^@B&\NJYD "
M5[UU&.J_'R0ITX4U$3(82D>;%%OE&;%*';Y>DT%<%?-9"/%"AEU,45TH>*I$
MW [PG^Q[-!]?F I407]_9U5<:]I]JX6/R9-@>ZXT!7,7_7$X)NHC7HBDR]P'
M20$??G6_@&-43:GK%14W)<*=M>(#SVDZG_0YR+=>9MAGD'H_\C1D"1YQ&EM3
MOO=-_E0@XBBFVC*807C& 7L6[_5EFRX+$1:G! %")3E!,URCA[]*)1H+950D
M<57D@Z_H4*UATJZ',RD2K&JM[E$39Z_/[S:"\QLXB8Q0 [)*G+&R+6TLKZ=G
M $K^PM2944+=5?5?=FQH.QE4^ER]&K*!7,\85 _8!XFX%'=GR.$+S$*JD2?J
M\EIPOF..L?RXTCUYK/4NWE!Q/D(G&\>/;#N(;Q_+AE!2$PQ/ '73K3H?]?9!
ML41=M.56-$>'Z0IQB]4W9646ET[5_8JQY6]9/>[6[G^%JHA,7SRWX+9$KWU)
ME^!X%!,Z)N5=@:0#+,<8@R?,'$A<J.Q?-#\S*RY0M57]EPM;\WV%&\8AG/=:
MY@"B)1T>?Z;.0D;U56G]I4JOWGW0^'K;70R.H^W7=?404[X=QX.] 7A-0P2^
M8TV'VV2Y;*1 -?!B0H4!W,W1O7,^VQF948QS@3E"1Z/R@11:+ZT7)<YN>\W8
ME>FFQ8QVYS"J/&%=<YEQW?04LD3$R8@1PTO9^LLJ]BRA&$-!K$H#R^_9 _;5
MK=@ ?;(\U@=H"69-]77)G^"JQ/>KTZX:-UL:DHN;X5FN^N8--J6P_O)%NPOA
MM56 QG32DIY.*LF8D1K+Z\;*3/8+?@M0G(9)ZEH0(4Q$^\?:9FK@Q*<;V[YI
MI9\#<U3CU>_5UJ0O)-=V; FX]<0O&PJB6 ,J2:<!5.6UF:IC?49YKN'82^'R
M21RN7Y)L#DI?\Y&[.QZ J.L+#''W:E[\XO+Y:C_QGD/:)]Y/4^*[57L7  (3
M$MUV8H$LB#WT9$:8C6#B*>1XVC:PZA#7'AJ4P:HU9L7%KW+,IGNL!:86:9.;
MQ:5 \X0E%Y?];L>VKR<'386%&SGL7-;JBH@:YV?@01QM5E&H0QI#B!?0H"PP
M#K>Y2E.N#:ZC=4E7\L[P*9<\O/NA/F&=4KV;K:O%=_9$_;N[SNJP)R?=)V_S
MMI.)JSUX*8X(D.]5X7UW:5L[><> *SYR,$=6[9),ACAFS&3]'KP !_IV %>>
MQ+^3"_U=QI3Y%#$N)LDGIG,YLRZC?J:W[6S$)%D\0NH[D'6++=1!.&3)1( X
M-]B0&&Q8I7<>F"W7,+TL0]E6H9#Y.28?V%+4A]C+]!-VYHVU;/NV9";D1#L#
M;6'"\NQZ3FNK(5NVUIKO*HUASS"@PKU>;-Y8 VBU5<#?]2CMFD(D[66I>7,S
ML:V)*I"5^4?W?6/K^YJ6O &H5^;<U[$0!22:>9^];'0#.,#68$*>1\A@XAB$
M**P=<Y7'E(&(E^,ZK.@7'T.5BWU\.>Y>N*)Y6J=>9KZ''GUQ;:%-\H5EZ\LY
M)MAPN/>K5YB[V,T#:[O[H.5B9I6=31J1+@"8T+E(DMAV&K,T'1=3%R[?M16:
MU8F2EP)0C)2*F6AV:T\<W3CJ%H[70ONU@<.G+(OR":0=TE"IY3D,D7,2SZ)N
M]H]"/VA"!3!99M0-V3 K-N)W&FMP"98:[U$_:N 1S-[ZZ";)/D)@QJ^S/>26
M^I5_V;=Y_WX8/;@H[]'X<L"[IK<F/ 3)P'W?Y5@P\?$.>O(=IFS?5*1_ 8;:
MK9UI*(SV,ZN%'_ *+@%RX#&"4WCYS3L'OR[2[1JC<[5YZEY;%JE*=ZG$0KV2
M!DX "ITB\_)'JDGV_IXEQJP9YQ>6K#O;&UVQT9&64ECQB,$ZSEBS)@:ML7/<
M(=4J'O_AE4V*\<(CJ"K7G5?OZ3M'?)70AOV*)^E#$C@>#(0L4-B.%\&"F>YE
MP,3-),:O94%&*L^B]I3>L+HF)B 'LIS+V_E^84Q2[WYZ\9O-X.RK(X_=SK4@
MWAL*17S;.P<4LIFKC$KZL55-W*$I3-(,;PQ12+)?N9"G,S2UO=^<>FM$/9!/
MBU_54L$QJ=.N+VC0"?,@;&) \&CE.-S+]9IB4AT05K77"UL/K2]ED&/V^+@J
MA-DO:CMB8,2L\F"L1G.4&*T^D.-8DQ$2Q#"UVB?X]H325%&;QG];<ECPST_I
M9YY8$NX=][VT##L>Q[K<UP-AI@HLX/G!;0K N&7CZ/&6 CC@ #T)E-Y\\-QM
MT8;^_=R85KBA8UW<<D.-V572 $J(YAG4D.J^BT-0#S&M^3"KCNS49$-%SBTV
M??E:)59N)$)FC[K]JR,<PG#9CHNYQQ*G1QE<V;R$-!0>(RF4?^\I]VE3 5X4
M]?DS]1$21F7U50^SQIX CQ6IQ+]@KSE-!'!.IS-5&-EVQI*?X1A5)QB!.\D!
M#47(:1<S$>( @L*%_3BN$Y07 5(IS4=:0M[Y3(EDP;(LJ2^N6<+H<"I1U(NI
MKU\B'9A;D^"&J-5<2OU.Z-X'R6Z<TQPXQKG"=NQ.%<!<[^G,VKM2RQJ/V6CU
MLAA6UT([=CQ"K@&]4_P5.Z[WAG_=:JO-,L]<5.W3Y[6_D+G%(].^=X+CNYNF
M11#UWA-GQ;7+D..T#7784Q4%@$:W'OWCA-!1+)2]U8F(@WVM=Z!0IB[4UF9V
MS'1F.Q07 9%<IE\J2]9;=/PP\F!0:D7BYG<.B5[*.:&+1FR6 AF[A/S%*4U6
M;.Y;#/R?W4(#)"O["U8/2"IS\<E3(P/(:;R\SYYJ,ULNJ0Q0GZ+Y";I. @]I
M\S !6(%/<+"J7]G4I%.1F1<4S$!,_)F13"*2!6@+Y(.:%A )S#ZH"W$X@'Y$
M2!R3U!DAPFK85.G.U>C:?F/''9HGU3:^ZDLZSQLCYQPH*W\]YP;[EF/%;K*F
MD-^%5*[_F"$_,Y0T%,H,@_"CDIG0YX*,\&/6_ O2*O&6<5VM8>;L(_DA(6'*
M^#GU5"9_GPSX'MC./I<YXKQ"FUJY#D$\YF@.&A[@_G@53R:>#ZO+@CPE[O3M
M*G1GZ072HSFJC'!'H_'9%*:@Z)VQWVB/\T6HH?9P?XFL1W^2XM^2T]24A2?U
MF@]]BN#?&W53!)+9JSW0(R3GZ=U#[0OYA.?XCJP32WK5Q>',"<AA%,WAV;NE
M;.7BX^E[)\;7FWZ-N&ZH7M5QB^MT$VA)H9NQ)9(V<[+RZ'-^H(AAO-PZ5!9K
M/Z@E@S^,:>ER P,#.T8]C 0#]$R_%X4NR.%G_=D,KAGJW#LUM'R6U>=B7.FS
M#YH8>_@@>446_7:$8UK]:7"!3>O?ULCW)A\D:3#]I#$42JA?1Q5OUYIKDG6\
MF^)0%>=\"? 4X?8U?3>GJ[DJFX(3G]SH-=;\=Y&J.-YP_M2P6NW9BU'V+/F/
MD'@])9)>3W2;**:/THQ/]-T(LV\=(BE5+TC'/=\ T6G2,4WI_#EPLO#B>;$$
MG,$#2Y-MQ73]DLR+2R;X\3 <?IHW+N(KURON@YYS4\-/SB>3YLCU8T)<S,Y+
M8 TP=)(#!3WLV/8;]&2\*U [S6;VZU\CLG;K([,M%IIOV P(CC49-ARB*\#Z
MO$H8LVMM(Y5H#4J>W)"OGU\ FM]TV$_K7$ ?VF3)DJI6Z0M97H=;O_=FN5FB
M!&Q=*,5.^Z#\A9I; [+)A.VK'[HD/\,U_W]5V\HO7\S44W[]#B5=Q!RW'*ZL
M#A2\/M^C5D#K_2K9V)1;&*G[(##VY)2)TTSPA5*?%UWZ5B,/Z\+XP7:6C18M
M@M=I_'WZK[8.Y]&86IE2H$!'UT^]YC?+SIZJ*&B\ #*8HL]84S+9",YI6FH"
ML56H6W1QG.:0P6B%;0]/.(P+)O^E1HP73?#E5K]M:G&\J7#8%7U];:([6I0&
MH#HO8K*[Y[:GQA:_P%#28\EJ.A'77O[PSL[]^MK@'7HN3SLR!)R->D(R^]D<
M4M.E/#\>/4Y28* O]-S&VWZP]("-D<S"@QDM[]9W=;D.IPIU.2D'A1:R\\Z$
M:]?D24&,UU^8@)<+,BVR, 47?F117%5[VJ2H@5>TP'[76]B^514^M*E"AJS;
MGL=AG0:=+4E)>5:*&ZU7J68H4.CB9)=FL\!LR<L^Q?-_(@^L&XMWF\V$7Q[O
MH''% P1-R+<^]GVQ0>[,\.D$B%:8U#K*D=1:DTCC.S;E\OE@93,F9G/QQ ]8
MWX&NC@-SH450X0CPPA0?V_HI]HD_JY:B[ KM_$3^MNW;4@7TF(P0LS#K58\[
M=J6I%/\;6X^L/"+#=HW5E]UDBNK;4YY>W4MD$JU/S6?W)!J83C?FS<F?P-BK
MX6]'KEUQEZS?RF199<>^_A#BMMC/T]_LTC_;6;^E45R;JJE'0/W#(V;S#T^(
M3C<TV9 /D&*TZG<9ZF?9)UF,8HU*,&Y?YK?MNVL":-65*MH^FYE?/OSE_;WF
M%_ACHMY4VB"E/%S%9I38JG3VA=V(6J5$B(!#Q\J<3%#S&P6SG[#*ZF3_1S92
MF4>->MO-[*\0<@PU.,@X:P!5 C0PMB(WN)EZ^X</3+LP+!_0.R_C5C-8F,[<
MW9!)OC!CU=223;-(UM)LA9ON:(96+(PW$/R0@8KR]]\<&M^3P>1TMZD,0U:P
M@=-2G /EWWW&)23&TE$PWSJ_JH4A(S]P6ZN',EZASQ,51#4[MK"=;O1NXK/?
MZ>RKR3(-!8Y0-!-]S%*I[L'([],?Z@^J]J"B[]0TWRZP.#_*:3K3G/SI.=Q,
M+%B@2]R][YTA'X/PO.WLN.$93#V]L]F53$'$&1XBCP1$LWD383O6M<!S7S"#
M-$RZ]A:!BI ?^EVIZ:HG'.CQ[A/MRX?Z%D^<IVQ=5Z338O _<JTS^Z!X&(+2
MQZ^Z;&$QOO$"]\3@DC,FJ(-_Z=OTAP^-(X'@ZY[-I/<-*7U6[^NRYV8D!8,-
M1>C6Q-:63-7@65((F]HN=Z3YPZ#EE^:ME,"JLW0XJ^<I\=T/3%SGF*/(UXK=
M3'6/Q+X!B4V]W/GZIN98I@5:??LFT_U0VB\\%Q83O!J!8/'4J !9.Z9<K7PR
M5AC\-6X:@&Q<=1@;FW"K;WMAYTSL5X'5-EB>I/54^&1N/VT(RSU.M8ELI]OG
M6#8TKEOJ^1V<7&@&_TJM\SNXM*<[_'L9K26+KB3NZCONC:2,VS7X_5[BC[;T
MNY7&&-&*)GY(4&@ZX890N^D0T@ *B( "A=/XV-M(6PS%I6[8U^!:L'(.8\+B
MV<47L-&/"7>IX*(4*??8L(J<'(N;]ULPX/[^2:(RXO(=!SRC)[G:\#3FWD2G
M8\1QMM\S]>)L"Q3^.#!NE60Y5J42>\7-=I#B_T2L?F+VDM'C] .J79 5JJ_J
MP#KQ_1ADYCV0D.]UG1H=ZO6LV@!> OLQ@?HWIP7>$@Z;"YN?PUN,9Z+X9>!P
MP9O?$2Y:D3[O.]=^=(-W+T]TU5,7_W@+?QS?;JU:S0B72.]>&;=X_\9@S'&[
MZG<%6C#'^B&9_>NUG]RL9R)-)O[VC]N\B/]5:N?]I<,1S]J[)3J#W\5RSN^#
M1@=8:V1CZ@IDIX(3$Q& :W?&_6PWU.7:Z8$._*X+EZ=4UUT-F?N@9O(GQU+'
MO1O?A':DYNC;2>E)%>N(-W&.<W5D3LDA&RZ-^#OAEBQ<'!<L(U#P?5#O72WY
M'5/QN#UB79=![<.^O2X,85<]_FJ;/V=HV\Y8S#'S8D'B.5!!(B-""06+C9JN
M>KQJ\L_V[(CVMG9T<>*S*M3X(V^:RQ?3_@]C:]NJ3=<YW>=.0;X8@_P??R=T
MK0J[]KQ32V51VIM;OBN_F4@?[]F##'O)/\RQE:GWD3O!JON-NQ]E':"=/9
M]ITC24K C(F.;K3_=8C62=!Q$.@12);''8.@T'#1'/T" &61?*]F2'/)U1!4
M0?S\TT0"GG#9B;AE%Y*E(Z*OT6?PP4)!H^72KX@+0*]?'/TX"3&C'^:]JFX
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M4+IW;UOF,QAATV2F&,M73*QOA-NG>6"M ]SK#_,@,UY?6_6I&\W(73?AG[!
M?9+1SV^.5(U/P>BFW _0E7U\[E#WF=VB"!ZWR6_(L?_^C*[[1+NJ6+WFGD=8
MF=H*L2S"OD6R8^3;T9PSSHJ-CJZ]LI*AO_YEI<;6(81=@-+.?=#1-A48QN)C
MWNDQ=<N2U%+ VF(</&'_(7E]UPO^/LL^[,$PXO;HO9POU/[DKHJK61/"3T(7
MR>;J^+OI$U\SM5%7W\@_(+Y&YSNCT?4Q.U=)SPZU'QF4[(VO#/M'QO_VM_EM
MA]?:^?ZER,U,#9\&U; R,]3A1UK+M';9#S]^A/@4F)'B[SW_1/&_(Z7X<Y#W
MA=,$,&,T@E4IP_[#-GG-=>STQ5"-^AS&9DTD//?Z^.]00T*9&WBYP_DSAFTF
MD*9$E+@XZ6/3/O=6.+::)ADO@&<E]#!DDN"98^.=EFQM?K+0YU)Y2.?Y,GV2
MK0\_,XTI4P$: WLW:R!MVA4*?)C?16BMY2O#8WNT,/T);_5E=0_O:G#U/;/I
M/)63WK.)QO?33@8ZV%ZM^%($V-S?4XQR1DAB-L''P4<LCU@?-&7F;+ R.JT?
MC]LLBG0U+AVR:?!*GSI_=DRA?H>?7Z<.DW;PJ3LF=O/O<H0*)N<66R*-L2JP
M0+,<"4TI*Y^OF?SNVI\_GX6C;2<NJCA2T]2(&ZH>_OYJMB:U3C\N]'I$)\Z1
M#E5A&GH,C[-XXR.DL7=8D/AU"QDTU)*MIA>1BL*5?K%Z7?QW4#G?LV*R_TAQ
MH:F&:Y)G]B0DNGY!)TNF,GD=LFGX8C>3)D5]:/5\,_7NMDW=TX55S[,GBXAA
MEV-Y&]*U[Z=+/"]*_")[TR,[XK\S'3D*][:]8M;!JI1M;):(:VMFFB=/3(5+
M[[M42)IO6O?)'C$;=;'#B>>8_]1T)X(,DLR JTRP3"==A./HQ>:QX\*@?XD+
MO8\W1FVY=(ANRMHMC?M=..1WO-1?39CHH+V5=791?TCK6\C!M^C"R2JF]]U(
MB4PSVCF/A)+7418:)HFQSDX78M.OZ[3PW'9*%SN4F/E_JGB6=8I\;3 %0I/
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M0=Y<N%*VZX4K-8NW_)O&\_F?RJ:#WLW\C]75QH.*0YW;YA<<:/QGV/RZP+!
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MW&->J/GY]'(D)Y80NW1]G/,6YG8DYZ2PAR9S>/R]L7],'VN:F@*HG@(XV41
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MH9-EX4L?G\R*7-V!ES+NY<''NXE?LCX>0LG!L?PTXV=2F_ZRN!PVJ)5+T*4
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M&=8&R=^89K)&'*8OIF8VL+-GBZ,A-?43)T!L1VZAM0U"B=LQHW31UGF-N"0
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M,7M0>&9@>;F9);>_^_8HW$-C>A>U>8IX.K6P^Z@%A7'=]EFO_R!NRVC/B+S
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M?[8Z(H!8IGN=,Z37^WMSPWZEM*Y #Z/2XT1U=("V4W=:DU1,]9]* FG E&3
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M7(*YT7O^.9=:9_-B ?NRN4)GR5U9V.D]VY:_1X3YN=3[.+(F01.=2V_]DVQ
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MPJY'Y![V#C5-M&F^JJ[H,6EJ4XJS>=_1/''KZ;38'YTP'S<$6JDW>SK^X!S
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MLM835G+12=0D31!1:Z>N3(\N)D@%SQLZ'F2?83M^UE-@_1,[ BTI"/#<F&Z
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MO;'1P"N=W)=PXDI6ZR#R)NUG@WK.E,=3NX_. 70^:C3P$+NH,^4+X,M;YF6
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M5%(MS,&I/?Q(>"8LG4295.QQ]7K:'6GLLO&\X2R[G7("BAH=2>4J#\0B*">
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M9.:T:0E"<TK-N2*TV)1T/K[5;E=D?7^N>*)J4R:/T4CUB8U9/>9():#%4^?
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MA.N5'P3[[$E$T\Z'R[ ME.-@UHS>,FSCC[.]'&^0+KU9F]:"J.YJ8V#;BO0
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M22,>_N$EY=8R[&YDI(^M:6+ELQ'" ?(U!#PM9I];=,S-ZRI#,0V33CO5G=]
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M7YWJ[X4W +Q4TVP"J'T;9<_"D>-_;_AA^/T?JUQ_S,?3G9]C]9;8\IV2K6-
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M>S_NZ<<OKD'[KPT'( O;S4U12[_+;]0LK6BY$%LL%E30PU';2O"X\:*CW%?
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M=<;R'-U  &Z@$(4 OVU"">?G$YGB-":T!P7KX.6P5II[%VV59)N_E><:DX(
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M47*NM K[8A#@O''6F#X8[9:[WY40YR$+EMG7YON:9I[)*>7PFES=N.DJ]1J
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M+6J<>P8H%4JT[I6$00I"Z?=%4E:JI\R#$=XW(F7AVZ/&F\T_>$:K<PZ!BC<
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M2,%RQ60^VFW3>VGFW;F&\=Y@M; 8B'6L0C.3]9V!#CL!V4$4IK6Q]0LJ0\*
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M/G,!VIX?GC\Q-GJ>R:BUPILT*Z7TR-</&&UF9)J1_(0P MEAP %I&_NV2K<
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M)EB90I7X(U#)KZ"1U>'*@L&W5>]'&F^X^N,G:E/CT(1+>IP :BT2?A_B?P-
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MU-J637WFH;2MG>UW!@WB,7KML4E@760\<V99:BS D=<W\SC@$(QA&E3CZ!9
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M&EW42W E]1L/C-$HG3KL.>R89'%1B8KSD# [E,O'%E]9#XH:#[/_'&'_.9K
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M>Q ,#%[.;P8G77EOS%]'=]GR)<7?*.*_*F5N3$1_T HJ0G4129C? GS*?D[
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M6)\'3X-6*U/&8:[H*(30XTQPPS!^.[[Q1G.,5RL=LSS*EJ?"H/>UURF_49]
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M]&U^Q[@#29>.M5CJ9^UH;!#M\230I.*SC2#P5F7BNV,@86RL!R !T$J)B,@
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M)/[8B<&L]X7W:(\KTS4XN/R6.:-1%%Y$?ZN+7EQ_NWD$"75HFK[R*&&&[7B
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MEXK?E IQ[I7$@CQG1LPQBH0SRJ1=GHC%>QMD[V\!V @H!$LS/V\)K6(VG^/
MWC2GRQC+V=3,95C&.;P/%R#B^!0K,*][='E&,'VZ?Q+B?49.JS.B5S-3M=$^
MC? 0/G#4PUDM6J'\""H"R%E^R ^L7\ I3?G)^"KFFYNR_$K&KJ_[3-)-O(:\
M_?SDH]'-H=S" G7MK[F</]:+K@,TBNLZZF>J!/^<7,(#]T MR8&6[1I%+4TM
M$0,&9HXQ6;*446IJ'!<_[@L&ZN8;37FZ5PG=+_E5TUK7!FKU^/.(KCDM(W<X
M.4* D-LG2?/X%G /JE,[+WP(9<7P#48%<SBOJY<YTU=SRL6#TI),?I2^*R_?
MF=<DB,4ZFIG5:5.]IMX]W0JA4J+%>V*,TVIFPB\<.TIJLU$WP*FOEGM9K'/O
MN!K:K,1[1^]D3=G-'9,=/EVP70[/H],T@]KE\(^MYO$D;Y5'EC=+E.\<E&E8
M+AGHB)L8EG!S\QD=B0-E4[G)WAOM&/?IAT58=5%+ZU(D%8V-E@^T&4!>6;%+
MS^(>TO)U!ACT&7JE G^<#(-^P<$QRI3!9#\M?^?3[Z_UY3$,Q0YBI-*(@78J
M3=QS'I_9ZZW.7S^@LH5]=N1LC B2_ 9)>H%3RZ>#%;A*+27D#%=RA:HZ/N^6
M&M)CQ<D0.%C=)3<1%^JSY61")'?2P;#>7P/DOG[HU'RO0VUJ-5.A1OOD)/75
MN^K'W8Z-0%OZQNZMK[YY(/[!'KU!])^SCNS4@NAO:SVQO>--;(7U">J!S'X;
MMP#V X30#=F5:E/-3Z%2[,K4"SV'FC?1(Q_O; Q3.26U9YV1P$,</,L6;5S^
M.G,U=3;E36'$[E"0]VG3Q(42;;)L<*P?6^$MUDS[;6O)?0))3MS>W0*DZ\H9
ME[='['^,UB!8,^RQFF^S!U[7FAGK>Q)&%QC$9ATG*<X7'/.BP%%Y+#AZE/*#
M/1O*]EM >(A1G&I#<^"*K/_"VD^S3S3_O(9#[T2F_<379$Y^^=YF4NNMW V*
M1Q"3747>@:92"<=%M_(B1H&W,W>2ZE<?5=3='THFK?7<_,7EP0,:"B;;-043
M7_E40VEP-!$2VRU!6CW2R:PU/W>:R;,A=KPD).I-I*$!TMT(1D2UI[O[*;.+
MP)^#U\C&KQ[)JUM<6;QLO]?C$RM09+ TCF.;+2<;(V\_%SO3>2^92)R99K*+
ML1E4Q8]_."%04Z-'26,Z0\)H?<-9OAXCXT2LRYQFBV.$KFKG;98[F \PY1BB
MD*@[#)-59([DDCK>%45,)]XTYT"=!#.CK;(JZ@P<10)2L0#BI(?C/EAIWSEK
M2N)/6*&%">2WA]GG0:=Z-% \4Y;<SR3/J^ 07@QY26?N/SSN96.=;.@"6.)+
MM_O:;@$H+6N! AQ;IGA%<_1V@HX)GV9#Z*3>(6C[W%$YJV-Y($L*CH":-N$=
MUN%!TL;8V!U_TU6A:;^MMCQYN@A&C\UI8;L0,4FW>)<#CW<')"]1KOL TP;V
M:/]@BN8D55Q^A)#O 1#D_3IED$JWE#O>BZA)(Y#D.O3E$H?>TS@D8GB1IT/@
M;KJA3G;/<X91-47#*DM2F^+'^IO3_R(NB&*\*KKLYU(5\WCRF4^)D\1$SCCW
M0_Z^V8"5#^<V]SASH6P4(MUZ58:D;(^+#!(TO^Y^G7#X\[IF5Z)<0&"J(":[
M;ZIO;6'A)!\ 65;!AZ$]Q/O:"&H;<W\1=ZYH_JEK,6+S**YH(9F4'BX&5+8X
MK*\K#[9EQ$CDD[IFY%%-_IJ7W P?M+6E'JB>>LGX8F2KC3. *VK!V@?_^LH<
MS4[OS$ZDQ$^$E*P(:D;[]SVX=*<;KNS")JZ-2:=C-8AO <8D.NB#?)+"";YW
M <K?7NX N;[4(=\!V^0^#__N%JO[TF-"\$B=@&4^)O.UB7E\D05-B2FA.8HZ
M*O*)>%PJ34H>_:.4^%E- YTT+9E6D([0U*M+'>;QS;Y,'7%"4UI=BNSUU*.K
M(&A;"?!S@KEA(]F$<$Z:A4%!;/%&#$KVN7?X>;F.PLPF]697.+C^,!]FML?&
MAR^Q=<'DL^%_,$HVS])ZIFC6I%W];G!3#UI6J#.N_A7Q,6 F_+&Z(M<MH)ZW
M-\8:F2!O/'V0F=G9 ]O]2S='VEY1U3G?Z]<MX)W7>$)KVM;>6!<#0[:&SM$P
M!KSE?EFDOVN]^/1JCW_;O.J5JN:/ 3M^'7BL$?:45R?5GJ9()U=.+T/ 5H?X
M.:7FCN!R>U J7B72>=UKX96:X<?^J9Y>DSY'A@\R\2^VI;9M.J#:9K+C51\2
MC=TT#?13?ZTD:PC?N05$&N$)N81I_Z"JV T#[I#[E67'91?JFE SID8.C3]=
M/P)MKL5UD4#U+X'P*T\\;<6>(43]13K_#<>51&=;RXSO#E2)T63K%J"ITO8R
MN=^'TU(M8H,!,A)ZJ52%RS]@QJ[U B?5RUD#]1V=#_8;/FU7'E>K?Q9*E7CR
M?(W/*EDGA)UL+F-C[>"^?:!C>A@Z!#4"U\IOT XA)3?4;Y;:'Z)?*+X%:'QN
MOY-)+.6@,?SHJ?*S-)/QG9E$3O&^(0=)BT2Q=&^+XC*[W_+ U'*]\@.03D/1
M%5,J?WDO3*!( C,1.W$+F"5)A65@Q^^F!7.A8 )-"%);OD'*=,R&DV:3,&O4
MF8R%C/.0<.54_[P77#V/JO2\<%P7(]U_"\"[NK$301_CM5A'VYP2]ANJW# \
M"$ED+0I]"WCXTKX%.74X OSZ-@>D$A;#%,)O(E;<&!SFG*5:^JG(18XM+U2>
ME5V[;NK@$4!JV6Q9W8V(PSM?B%MP]YT;.A_/NQG_7IG\RM+%F\:4:2PJ01*D
MJ&+E7&2YHJ_2&J[UI,R6O$6[IN]A'V$$@>F:\;8W<TEX'S*%6'NJ9[.QHJ55
M=\FHSTZ4$@;\&IO2X ]C,MIY/I*<0SNO4!Q$?Q=%_=4!A\F9:D-D;;>XRY4S
M>?F6O?;ZJFY"XR7!WZKSL['$IN-#HNZ2*5S(=!\-**RP4<2\"$:1&;Z"@.6T
MO_!>ZMQYB)IY/.;%! N_,L>(X%P[Q5HF]\&_DE&]9[AEYNA_2.E'VI!^0<>9
M<%;7MX(2$@EVOX3M^*@,@*FA][$W<UH(>CQ,<S+<M>I,PTE:KKB@A_\LZ,G0
M6S^MY&YHIVIQKMI+ M.)I:@!Y01VJIXZ/"5V0)M3L\6 'N/4;\L355A)AKY_
M\PG]_?YX594<69WE+N6.?NOW]WK%B5D;:"Q6J(BG8%TW],(_WN_K3RV*6*0N
MID-NV]R%:$AD#?^I^E3^:=42<>&KZWZ "5T5COZLH2D$GWHSGD<W8T]8W$7K
M2ZK.N?#]4AVC3'+_6B+EPPU\,KBL?_(68)]/@4^RJ,=E'%!ND/MO_(VKW+ZT
M3LB(H3CS1R$H?OXYID7*KLN;OZEI/#+[7&=C91,0MN6LWX*HV=^O/-DS<V^X
MU')CEG>> P5JR3QI; SE9C!#-W^BXBO2[RU\4L8" *%9[<\2KA%(":X,P^LH
MOX1WJQQ:&FCE>#:B&6XO9#YPICA%E//;(>1DXBLXI$>;,/07YP;A?M*E+E2R
M,9ZN968PE ?W/N,N[UK*01M-L%7T-^HTEO5U)YK[\Z<7_N?L93.FV_.H+CQ0
M>?\9CNU046YPP^0+VMI W2RD7NFQ^2K^R:D0\R>/)VZUEFKU83VZ$A]#8IL5
MC"_?7_%A,PY4L7%GP1TX^BA/B:X$&P+D_!7K!KF\:0-R&MR7WM8XEM89Y>U'
M,&7)/_LM5GG_&,DHQ.XBK_MPHIZT>J]TZ4_M7VTQ#<Y(Z73S?QM62];@<GBY
M\>)^YLI"Q MC@GI1 $"#@R0HP+2O*^JBN4_C2K)8 T,L@2!8!H\$;9#S]$T\
M@&$@W^*E<HNOVWC ]2Z.OSQG"@T0?A2'];'+%#II%C\B/HQ0J*_Z 5LTB^+M
MZ7D*=*1\RN7?&<9YQ^44PF14LKQ_#<[WH6L:7=>Q[P;M4F D# XF-)QR::[/
ML](L9H7*]4HF#FII.4D:'S^G905*5I09Y&NXX0A[Z)N3S2SP\!=96R):0#!J
MDX7E409W1 -,P2/128%-!IZ/_8H'CU+> MZ:/7!<(,X@,F.Q'^-0G>^\"IQ/
M@F2KXWW(STK0'J;/)GT3"%&K+&%Z#8G+NHU-R8'P4A'+(4>[!.Z\K=DO^ISW
M1U,T2_5&G\GD :8E$;$VU(U,_;D9$4A9%^ZM))Y<NGR/6P Q7:7$4-:X?*ZF
MRQ.'&O%^JN]#),6;7YO6B21W*]N)?B-?P6**HN)*2^3&DT,ZXG*EM9^+I06,
MBWI,A1N40"K2W,^3TO)"LE7H69IHZO8=[0T88J:+(A)Y,Z[32^0D;^J!L^6#
MA&JYFC$JE 8^>=S/X07A[T+#.Z/:<;Q1E90V?ZVF!(U3Q3)/F5_^A?N^(><3
M@-7J/3LM-8/DH[**XQ[F(ESHZT5[41YE%B/B;! S$T-.W_U29/,-;5085-I.
MZ$JZ<&>IP8)%V]._U+52,CV92%I+P4T1UYHN_WTVKD+>O7OID5=C6^=]O ?F
MFFG>*.SIM =':[C5LS(7T>J$(/>GCYML7&X!CEGT$9_(T[OY(PG(3"7*'':!
MKM521C];%2L*5&6T]VCEE);VLI1./"RF-#4%6]H_&-4NGNQ>\J./G$V-.MI0
M HYBKHU\+;W%OS=,*%4K_+CWMZ&@-&D^6;7IN(QR?9L0[(6+:F(1C-QQK\^$
MR?AR<6=I]N=K;042>+9)B[%1IY3V):*I&KJNMB4 8_MD)5G>)NFDW?G6M+B*
M;T4BZZV8IKZ')&2(E][W5+TYO$_ ABG]\;/IL]KV* 7@NR%I1E6CTDV=8J,4
M_7)B&1VI5%];51H3]9?_]=/\'[/QQOECWL9@W=#-<3>\^,1EO8Y)*&O)+< 5
M;+XCPEREN6.QM3K%' CR'JT?\_8A<^ZL2NE&L.'=+HTA(0.K4IY1P7Q8]00E
M.DAU".D*?EJC 5<5;S(GUQ5YLI-,KG.Q9AB14&FPH/7DNG#NO0:=X-2V:];=
M_[ MWE^IK!"9J:0 I4M!22N)Z<8&WU.BJ9]95FW#45QQ+>E-O9[]_'G)M[GT
MU_/F3,)'=,?,A*XY3/5E5^YXE6)SO*G^K!(WGJ<7-<AFC@W:G(\^^>Z!U.3Q
M2^29+ W\Q'J$3*R%/QTO6>#Q]WY:W5XTPX>0Q0?@E%'Y5,L#(/1D0!(!ONVR
M)ZO>^JFMAJ2UTM3PD;D@0S)O T1XW1D&3CORGNI@^O1_Q*]\@@6QZ1$;"0\N
M4<&<]?1MUA>P; 9[EDDMTLH:J^5714$=8\B*.A4YVPWOSQ_"IO2?,HK\MI 0
MC1[(?'T>KL*5O+BL4 \['+DN5*';R3*)E>46SA=[8>I>%PKJ1X/)G@7QP"BB
M)!C\^-.2/9X+LNLF7ACY'JV\:=?REH>K$;A7/2;+Y[\/J=KENY<?UQM,U]P0
MIQN&LF&/[&7.Z(@<%F3629P"#:D(9'A;<M>A6$=C#]G\GH&B7H^KL.R49L/4
M%4Q%%\RY1^D*!TC#&S\Y1?;KJ.885-J]/'CVR[*(Z-DO'M<#FOL9GGL7+]<E
M)R)6[^,>9/D&3CS<:;JP6NI/;PVQ+35?VDE?ZKC)EU[R )O\BR>7'[B_)ZX7
M]Z5G\>5^3:6=<[-R7JIA5:[__XNS"%W> L!38"]VT>#_H:4*YOV?^JI/B^I.
MP%\V\NG<3X-DD>(;!Y0(GHR>K&_YYE,'UA-G^9&(IU$F,:_!Z2Y5N/M3;QSL
M(PU@"NRFTXVD@A8#\P;3U7;(VHY0^6S+KRP*[U# 2#4#.186L1PQ$6"W"(>E
M@ZF)NMYP-QP$&!Y&W3=C"27B>O2,@(4)IVV/SH\Y:8=G_XFX$?U'G<:>/.(_
M\8$&]4P9D:.'6AJ*59WD WE3HB/]KB-W!,8YR7M.^(<3@0D"BJXUJ-F"\;+Y
M<L8VPQ)9?CE):YEQ;Z_LG)T9O50/635HN9I6;Y]A_V;+J(YM6._LJ A^5M-L
ME)8DU386%EV@K1\I3%(KZ?RCK.)' M LEJI*4VMA&JXQ_K:8^R -FW]@?*ER
M"W#J)^Q>"Q_MY,<W;YPQ 1=WM,_*KI1A-NP\1\?Z>3_;ED5C,ADSHQ93ZX<B
MF=5-,9[A70TAB8796G.=8CM*S#\.C?J]%'A+K"U<.RW?B"];)^=9AG\'BR;Z
ML_RMOER'[<]B-]8_6*_^IFN6FX@]51R#XR? G\%N?P_/Q3QR>RQE2H:.GS02
M<6V/.A'$_JUKP9[IW@)(S".!LN-R45T?A["^< &66I"%<;V"!\0 ;%(D;Y1.
M3ZY3\DHE%@9,_;;)B<%'PEB]+<P?:J0;H07R&2\K_\0<NZO1!30J=&H+Z%!'
M'>70NAN871E+RU&.^I"IDL@PC!OOH'&2]CH/\E&Z$5D4*-VP)?4PR4LWP?>*
M[&IY?_O\Z<^P/ZL+RH;N6>W.ZVYSWATU&J@C$WWYI8X<:GK)"U6<O!'?99/$
M+SOX5^*5U9IQP5T%4'$VRAEVG=@US5"7*L_M)VAAA>ZQ;*EX6C7C=R40Q%02
M]4Z*FPT3[F'26XSLJ0>%R33'Y]P"GJZ:EL:$D1 BTS1+Q=JL<\LS:NRO3J+K
M/ 7%=6;\%+E_C]QV[)4R8ODNP4BY!3[TJF.T_&_OFMJ0'T&\J(08J  (,;,:
MJ!MJ"6,]S5089/RZ>5(!:E>GB#6[4A.J*_VC,PN<+'BN/3!,RRHQE9N[9:7\
M*8,.*Z1[2N+]_0B:I-!O&S1;K2QPT]_M '$Q-:E892=-&+#G5]4Y;+P/QA3^
MZHB\[&9[G+BZ^:<3B&]C?4(:P-,F5;HTKZ]E]FA$7*BX8$E6H=C.X1&5V$O"
M$NCR+8#@!A^ 7B.#RN+#-G+9IM97K@S^W:NN1T-5KH:-9[55SN_E-E<ST=GP
M:S7];6OZ:0X-_;HG?=E?Z&40W[I<\IF:46L?NVB0QH_(O1W0ELOR+VYXD7.K
M@@]GU @%.?+UU52M<JK5-9U0S)[D5\3XQ]AE%!MHKJ'J@3 I!/1T"L$[(U30
M2 U>VJDAG;^K9IH5\#:^^E)%7IYE?@)I(DU+&QX/DS'*89_%GA10N!GP#SPT
M^FT8!Y<HX;[/#9*5!]4?S%FG.LPZ9!HER!GS_<AADV:.A9ONSG#S#7M'N#NX
M?D$99H=;ZSKNE+_KUUA49;X%L$K((%6Q28-+1O 4Z2B$8TRD=+]B85Q9:4);
MY9<&<Q,"RN_CQ'#E^XT^U5 @EJ=XZOR/=)3$KV2K[4 42:^&4E<[XU]$-M+O
MT@WZ,%_S7W[B&YA$A:^X".(UJO7]<25?9F5)F#7NW-(N2O25WZ,O_F/1>V\;
M%6S(66U&3P@IDA4=1+\.Z_=DM5YPT8R\!3R;DG9Y)Y%X-,ADH^!>B8LRVWR6
MKFY"D!BV6X9%4)H.78<-U]*4UA-A^ 2LRM932@S)^4RSTL5*B 84?J".?20#
M^^$EH&#;>!SH(];*@>P-).E^;(D06]]KT;KA'<RQ/XL.NWCO7/=4JEBEE)A/
M=B(G^] 0X]&2JXY@O];)!=)S ]Q_0($6#O=LE&__^FO^[;?TM:=3]D\LET?.
M'Q4_3-_+<"[\DC;^]-@<6O97_C5TSPT'.X/A(TWF>];NOL%*Y@Z+>%@.^)<[
M!-FV!FO<[Y@3+ 7E+C]_LW&OVJT-[W<I^?,91D;I\94]CAGZ%-?P*F71XGLU
M5+EP7*JMH[%R,_Y8E1?($I3.K^\0JA#!.6XNQ0R$'_@@;:AL^LLKF^_%H39J
M93)!DII^7HT@6^S)K_T*'3^KU(!4CE^!LRWU$AAWY5D98?XQ_NNW0CGX)(41
MT4PEZ_2I_'8%;3(A!RW2KXXR9<^&?A1HD9-H5H0A+!ZUO8,^P&OYN6&S^W0W
MLI6E^Y1IF?7FH?^+MK.,B@+J^CT*2DA(-ZAT=P\@*"W=0XE(#=(UP "*- Q(
M2TL.-71W(R72,N0,TC4# B-Y?=[UW/?#_7X_G*^GUEE[__[K[/7?2H[>F>Q-
M<0;130EY6M"QY_A'6JPW]0%A&P!'EDETPOZ^.\ZN7\:/&>O=NO%OJV,[WN.2
M26SFC?$:7/QUY8"<O"!4%TV "0%G9BT-77%JGC"-N&#@QML'^X\"$OLVV==(
M[WZZ#@O862[ZQIE(_X4+G1/:M]BSA44H[#&1GUC2=;I^Z$^7HP2.(^R<C./9
M0C2]<F7GYF6=]PL8A,,%.J#<-F;Y2FGOL?R1I5KI;]L0_;]_5;%5ZL. 7;(2
M:%_[Z$&M@/G*6+A)8XD+;VOL)'OI]+Z/ODH _MS_4(O([P21=C7UQ5*KM,?!
MHH-$WL+&_)IEN!Q?D6IM[/%DP]V!V#C4D<VK3-=.5V1'T F>C?:62K43;8:&
M]_NI+\F6-9EI/M<;Q'QI?[T_ PT+@#WB'ICP_;(6G9Q]WI 9#2ME4><UW7KM
M[IBO\X-Z ]Q3E#S]B:+&O,HY%=?<S1F 348@3V-;MKX54#[;%*/SZ=NH.PN\
M_-5[MX1GSB8V J<O6;N,G(:]>P7R0<MA8+=W"4$!=EGT1@"OP;[I^<A7?#S/
M/I]? !;']$$B8*_C924,"?(?O+G3O&:?EH@+<^.H%4M,2D>. PPL*&C XP\_
M^3]8: \E.# -)84H<84#E#QFP$%ZMHI13>9T3:T)!@P"]<E&*B]J*7AS5+?4
M O_R9MY^X/R'FT1/"\(JS6VY3->@EAT,,S[EF^X\AGFLE#6U0TH&86D%!CP=
M^59JSPN@XSNF0C4&W0IIM/$1C/T^WDP4+8V585OAO*_(([5EL>;M]9Z7>Y,W
M7#^ETB6!\60N9>:(=0MU@N2UTS7&,J:G2F3$NYC:9U^4# C834=":4(W\NYQ
MZA:'8QR[,#6]-8_N<5PGS&JB;Q3? J1JECL>$J=?7LDTB?2P1XITSXYM<BDZ
ML%56M(NV"Q-7%8O6LCT+$_W/C^<^S_PYS[FN:J/S<9?IJRW$<9/55:@V:WP6
M[(;\0!4-R:#M:=#]1P^O(41=_F=P^.)0B[7(S%$Q4S2R>1X6_>H!@,H80OHQ
M:X<+2W*/\R@%JT-VPY>/2$2:#H_SZ9^.8"R4DM<-NV)D.=^VF!F8Z,??%G%,
MX9>$K.OKG(P?FUX?>7I59[D$L\*0I2-(!?BU86@?,(1E[W(AG[+G'1G!C<5/
MQ-@Q">BZ=XV]95: I0_^6VOTC>CJBOH+)ZT&?!6K3'IFM4W60YM_:SO=%H0Z
MZK(<L. THT.C%01N6-LPUI4"/?VKEW?/,>X?D5US;D!7J0'9IARI# 'JB,'Z
MP73#(8'&*0HHIB+V;E*!!TP,T4&SQ@!P!7LJL:#Q(:#/E4)YQ:XHNVR[LVG9
M3Y#D@I0@86/6\?SO%EI]E!.-,N9IKVG&#?%M4H^C^]*(>N/,'<6- +HERK'9
M>+VF.]N]#)QWZIG",;\3[5Z4;Y0>4"PD7N)&3IPP\=0#5QOX@^?O7>#:U9_F
M["L93W^3E-F>\9/%H+_,-KWY\0C_D= HA$WBGW4"[&+?TWW>;L>HFZ#"Y@C4
M$YXW3L<I2^+)*0SIO,E;D%XI*F7-1/O"V.2QE@7)P+2J"]F(*MIF?Y%&4YI%
M$?:?6HQA536,D29XE,ML9<_.; 3!41NAT9WD95JHGD]7#7LID6+68-XKY ]H
MX*?,WXDZ?@(7!@.\S=7=EM4OQ;X!@N4K]M-E!7.#*D'^A"ZPO869U37+T=PO
MR_TEOY-J"?O+V#>,%<G <6H8G0SWJEW3.IN]RY=?8?&7S,:+%9($<A;X>"R1
M7<0L0O1A\?O3.F;.HP8U.E7,;S@<%D5A)D(K7I[:0S"&)%./Y/E\Q9PM&4%?
M@P0R1F[#B7+#/+X'-B319A_6">DTA=/Y\('99M'*$AP$<S-&G(@()VT%PQ$%
M9HC/+$ K<(T&XYNS]A335$0GZ).K'S+10LF# "[EA+O^=F.QT" EI;%$NJRW
M_ZD1Q&:B._H5G_Z90: $,\M_U63#P'G314US?\K9Y)*5?/QB7*<CMYO;'#^>
M^GV>A.1^"YEK5B0 J 2C#U UT>)3%,[-PN7HRP2 HE]6O'_5R'M9G0(BN5'J
M.[^BDR_1^<^2X\.Z"+9J)Y$&W;K*%8,SL7EL IK&#- 97P_?#UTEX@BO JFC
M;]6;1R^RK7%1Q*:$"P5AJ!4WEFZKZ.R2# SC!3A IGA%>&F81NA2(L>.@RF8
MX-:@,=G8+JJ<O>1DO9%KX""1$NQ&1N-$,(T=Z#U&#&>(/_M[::(7<G6/H_,W
MQ%FKOT:B^/V&5>%30HF>#=U8$VMNK"7 D;TL0S8D_P6H/"<[Z-J'/'?C[/-S
M@]_Q 6'&K'Z=92$SUOP8D2PA' @SQJWLV[NU>QRS^KQ%K8[5WB6/V(KHWC#Z
M44L6E\W$:%G8\$F$#8+A'020/*"+32H'3G'&V5:9CY>8CY19$[B]T-"=(@+*
M#^AZ$_#QB&ZP/ K$\F=3Q@WHCWN>D+PB?T7.T"H]/VP;W%*;DS)LNZ5AXAUO
M8(W(%]44\]9-D\OGR?7TP^69% %H)!E,U+7RASPL?2*32UPIFD"XZ6RX-=K
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M%BY_]P,=#X/1'2.*3P"TJ".ID6:_!6!U$^K:]=V:G$M-,WY38M\:S0Q'LD:
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MK!5RZ3>>L$792WF_ 8]=6**ME>E@:-2_\^4CY;7ZK=D^CCH&?CJJ+NQ?<\[
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M>"'J0)F:O80J.2XNM08O0Z@_N2EC-U/RA9D.:X$A/0?/VW*3 IE^KW+ZD2?
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M';$#]SAJWAC_NQNG>YP;4/=4X2?S@-N3FRD.K#;Z<LB&K/%(9VK(A@IBB%%
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M^PO !?>4#&-&RQ\[I5WV1HTKW-,<W6+)I.=2TU)ZR%ZOU:\\7[BO%T78>];
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M90#_HO^+_B_Z_QCZGPQP_./? %!+ P04    " #G@:%:Q_"-#;$( 0#]# $
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M19<!BOL'<G=%*"N>03EN&%J!&PP_4V :O2.-OV8\VM!TB=HG^IS#:)?T$NP
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M+(+UT".K.-/GRA-'L)*6-$-@<EZ;V6([=P#O646IZH=8'!#SW?ZV@(G!W /
MN6"A 9X-B3BW=-Z@"A.Y(:(U)=" BY$YL648UMZ8_QWU>Y'(X1TY=\B(UY]G
M>\,3:_0A7'>8?RO]8N%X:8;O=TW[M6CL%9WZ7=/]HU5G",T95+]OSHJA <M6
MM1O($0T;-=)K\RT+J#&5.<S>3:#_?+D56NR8?N\U-(4COU59>_3IKKS+8;>J
M_=DO2.\4NGT"K-.:/=ZMX>)[28;-/EH8\4N_#FX7E.YWIGKF9I?%[&S[(I67
MD-2\WYRC8:':'BMU_6QZH>:?XBXNYR/\)X3QCY@4A#B=E/]?4;G_@;P'N:?R
MTH9Q;XH8(-!K;<^:^59E[IP)J_JS26C<N7B1)=G995NYF>Q('/04W#3YI56<
M*2\X5%D>IV5@QV*L$&E)>^W=VMH4WL;0EV>PN2.]$ZJR8^G/HS,K2%R]IUP?
MF^*>GJTFLFQ9,LP6U&_DZT!I$^9_P(,>:MR5$%<S".VL34F)+_(_53!J+!JI
M;BL@![^=D%9!'4<] !:IFAIJ%JI'VMYY10D#&_%IA=F1+:R9S#)_7[^L9NF&
M4)ZMX2]:/0! B*:$4E,=P=!CW#VV8LUN59.$/_9,K^]?06CO*)RUZ(P:LGLI
MFUHC7V]**O]!2=O[?I-\M"M^P(TB6LQ87XO\;WA'F:W"<%G%+IO;7-,^&9#;
ML1=)L3S^8U#['L^F'L 0B'M1[[1F,>JXSJ5[X>W%$_Q"7+YQ-R@P=6],;6@^
MB:.#^V2EC,VY$1Q%I7C#%.G%<Y$ <8[YXZGIRBY4SF@?ETY$I-=!ZR*OUJM7
M0]TK'6MUT)&CQ3K?T\F!R8>A_@ AI%9.HE1F XF'6Y)IP_TA\RYE?RR47,J4
MYKA=1/]2-'Y5QTDMW_I2XW27%T+61Y"7#O7B:3!]%3K5>W*Q8@9I>#RMP:P\
M,DS_G6 -9)U3QN'.W&Y^ 0I[BTE*NO5 FI[E5%K:=8^6+8).]W4SIMV\063>
MB]"JDP)F-<T>6W/#9R@>O#.)F[F]#:R?DW>0;R2OF&[&.!J&J.]_':>;L]4^
MM1F,>/5Z\[<"HE(D@3;^#<7UA4]V;X>:?:O%:V48E32/!*B?+(%+[\+''2K>
MJO0A3?*]P?3[S9)H)^EOH9#!V]>])LLU+U5D44-I&!-IL$# K(D.&==?IY8J
M^Q<; C0("ZX@VB2IZVWF!D1GX.H\509\47+6@S#_LG<!+(:A7>H+89^ <<N8
MJ^18=*$#[,I4-@-D&=C[MY\F-*49^PU3, 6+?206GK%PRF!\ED+T;-]/W^G2
M+%IW_<VA"])%&S/(+,.U%Q]VD/2)Z(C/0;"/MSF#5JJ-HDHNRHI\JIVA; 7K
MMGZ?=)?A7+VOYRRY%EU3W)*C'?P)'3D#9& <<W#I-Z7)':764&3^Y9BYP7 9
MZJTE9MF,8<P+^K&_S0\3$?)?,LF3:P):*J\J/S_5>?_34E;*U !6WSW9_4<6
M.<AQRM6R._'K 0 +SC&T']; B2K-4ZV2-/B%<I U&2:BGHP/+N&$F;4[2(J6
M;N&_DRL&?706*#,",];I%GTM.>3>,87Z3Y?HF<876M.E3Q?1GI9ES94GY#E$
M(I ;/.RD!F\V?M:11("?:5D^Z<V^^-64$2+0V9C_3\.&H2NR,,HWK6PLRMM/
M+)A.K^.#WTO[1\RO4P2&O/0> /8F3MG-B=X04@M0_]@#P&#:)H9=*5+?]_,'
MRN,/ZU&Q1V11,<BM%YNV36<,5J=:<W;HM1A[G<,"%I?28O4!G!B1W7OSH-V>
M;DN%I:W(ZS6:9>3,H]SMKJ@J8!*U?_KUX0J?B(R=5E?MAR%FTH[X-ZN!G0;]
M%)[FCS*>1AZ ][&YMNE<'MX_YFC3+%B*GFF'V_&$$%1D@I0XR%>VRWP,!T.N
M;@RY@R1"K+^/VGM7WKEZ[R3UVS0HQ6?,"<*<IOXTB%=08PURPK<? 'X*[ZT/
M&O?&]'MZD)9L/"_..Q210\O\<=53$*+%/O=LG-BY*3;A@T%+83,:D\(9UY*7
M3\407WT1;A\V.4<P!#L)8(YU<; *,I@40N>_U-_Y>GJP(1;2L'=1L%C_ IE]
MO[VL.K&PY\M-.EY+89K6, ^<WY?4RD#\TU)8,_@8A9S+($>;!1=M1B%HJ[BZ
MG4G3E_*$-7.I&GA\EY>91PC_8BQVPLYV@3*/-6J>__.[IH056X@F5&J W.?;
M9&9G"_'PQQT@.Z^IFG[B18G&4<XG?Y$V:HG0( F#:@,WOHPX2'+32!IP#J6]
MT1*+](S73\--+-F*C> "ENLCVJ4#7LLZJN"7EG+PC:'%%Q?L4-I,\&F$#C=\
MHPZ;[1]O'^C*9%5"F^B]D0"O>*DW[#0_8"-H>+*[L<^CY,0X!E,%VR"#HKWG
M9FIXXS/,^I,(,A"6_-JMV:C%1<["!?9F>Q8NX660YLZS-"O4C.J($/>WWU/M
MP'4MN^[(U1-@;1>5+-,T4%2?QRQL>6]N0$?LA4XJ2TMRUL+"5X6!T 6*@^&@
M#1VB/H_GA85[G>Q>^/4B;=[;O?_>R^HSU,L';$.7M'I%2)Y2V_X !%P)(QBE
M)AJ#I33"!K+U]]I<YF/T]2;.9,PDJCY-UJP&, >_!@^ LM=\ARO-HU?>#QV2
M@F-_^&ZE>K2T%1CVRD'M&'$[<($@+:-$OK#BO5X*.Z) LD*)OJD$=5U/^&FE
MF ))B JQG9!% _ZI-%*#^T]1@3WVUI>T@R.\/'5CE1E8,=^C#=LS*DDH5(!*
M*VG*<KF7)7J;I]7!'(BH[CI]&!3UL)9R83S(V,%VPPV=%[<BII,:IA863M=Y
MU270 *%?R"4-6-ODEC%7#W\T/:.4&RU62FD&S('4(? WDK*4U'F&-3UJC#.G
M$]C#O^9AT:JM=2S4I(@U5[.SW-G^0).H!E2YJ$'W'2=T?1K56^M-;TNO1*T]
M_4?+T:?UU'SA3U/@3C18K'S)63*M;L;D\/2<EV\.U=__="1)I*YP[,A+ELG_
MGC]ZE?$!$)[QMBT.?D^";4!&5_.<1^>Y'=]R *<TW"IW28>=6.['YL[62!(4
M. ^/,D;BAB5>(9,FMORS_W)A8UO\M?V7F]*X,GEXN/03-+7>M-I@<,G_R7ZJ
MT(9I6IJT-):?WHSVD\A)H$8(J42&3PY$;?06^$GMG-=/<_MLG(U*,FRY-0CB
MNPW+S8D.=A7W_<&\^)UY]M%E8N*]'J$[E1)>$"*?.*9G_LW( @3T44FS&E_I
ME+0G:YOPJJ6\EQ]#Q%;'O\?O*)O\&I1XH960"KS<1*7@!P"F^<(=#1GHHKA]
MANGOJ'*:$^MZ+,ML?JN);I<$YS2NV*(7^YXL.%-"63V6S4:?.MJD1@4Y\+(Z
M:M#>#J(? /!QK,$]75R/9&?= ^ EQ5F@*]0!ZI^X-GXC<S>[M3YS1D0R2@$?
MY-+QG!AP]A[JD=XQPL71F7,+RQ=HGOOO&1T0V7F;Q"KVA0>SQZYLJM##Q&0Z
MI0#I4ZFGB6_TG@>P^N)6E,0,  =1[*:1 ULT?+;HE 1"$V2)<F.>VG219,&B
M."[0Z53"H#RLNHY\0]9O],5$MCIIK$Q!40WQ1@M_?,MX9'W\=L%<;4I-7.\G
M"1_^BLD^H[(P"]Z";6I--A-( ]+KH+,:MT-=* HH^3?>ARO%/WHVY_9^PO7<
M+:R@2>609IWHI9.QF74$V+G47V>#HC09/W/ZH%VEJ@?8'%?2# ,HO9AU&Z'R
M9'ZFA]EA^'?@(HPJBU4X; F2:N<W:C99FD[7'SR_9.^2[:3'ULLE,#'(2H9,
M&KU\A8;$^!"P(&O@4ED4DSXUN/Z$$E4^1&2+10D#.O,P3DK4D'Q$NGA>Y-OG
MG<W3T5<"GCA//55&ER__C&N> Z]RUHXZ;I8L;\=W^YK3FZ86K76PC$83ES>0
MF+;4KXI[3<7YQ>I8Z?,G]$28"R@1UD0RK'S!YG.>NV9B8/!;QIW$9P$,&5+R
M?PY>]KL+!0,D9/^.25[N\LX([.0^QIE!!S?\5^:EZF O%P<<SOTJ:5XJ?!-]
MT414E'LQ+A==I?:Q]??PLH[(R #KX.O/.V7N./H3C(+YJ7\S2H.>S/CN/-F5
M,IR),:?!F4\$R,0,_#K0.?F!^VF)P9WJB31 MBQ11W&,J(;B:O(F,&1.E@6K
MP10EY^#VE7U:]Z[T7MA\T.WG,'?1(E@0'11&"=TX]!9^Y")"3/,\#;]8>*P0
M31Y9T]@I=6N/SC@X_J]O"VANG;FJ8]:#23=T8T>C3WWR;.8')QLU5._/YFG3
M2]A@S>E9[BD-7R. 5\[H)Q<6UJ18O+XU6,VA(&%E\(W"K3]'WR?A(!Z==2:<
M_5=RX>UD95\4X/2T7N8:WM$5U6-&2I^>%KA%U1^(.N1\0/]=S(P5YYP+]P"Z
MS]A9M847%U'KE7 UVG$:Y,3S[?.IMFI/>>AF]&,N@K/0.[C;5_DJD=UV7A74
MDN="RZ(.\>5?NL=@XEX&E3&(J=X-+H5TVI2\$%7DSF&%0C[#4$K%/GP&\@GR
M-9L(3A1U<0] DS>L.B^>=2T] .A">)P:5/Q0$ 9L!:9]14$-AO,I#ZJ9P.IK
MI'IO0/RE0N+//ECCI]S!*>;Y0'\V+W0"Z[#!Z7)F36W*U9X,HLUZ[0+S[98U
M^[,3(,-HY*[Z!)CU*V24%A)UID6$\)5]C1D137HJ)GF7F%$U_G0NWVWE=R3P
M0WV DV?/S#=WX::,?L@C;R3Z'Z+S=3/V]T:PN6+2N]99QF&C=O,E4/[?@&\]
MS!12;"KB'%&**1W:D$+/-K#4UQH5G/ QI@M"24.A7".S$[#Y-1QJ1 S&QAK6
M\5'O4QCR:#^N0@YK39<B_=4;"]!$Y+;2RF.UXB,[P'48H\P?D$U+ Q_*!!.I
M^Q^O3/0@2ZP($ZUC>^Q7YYG[D?8QPUZW#+BK4^T>U)ES[Z$Z."^"/Z D6&+]
M64U=CNP24:O>KXNR:0RD/97AD4;Z,Q\=@"=KB*[()ED@-I92ZE\"'@+GG=@U
M>T=976R0\XUP9D3_2JD_]2\CQ=S'VH3NTBP7(9CQ?JBOU#BNOUV?F=;R*E.]
MJ4@7/K;P'<1EFB3T ?!SC;@^+>G5B^;TS30I^1J]^1 V[']LF"^ 'BO'X" 3
M#G.6>GSL>'<BMV]<\E!"*8<O7J\,O2%J9/3ZNCQO11<IG$\_AO$'4]IE& _H
M]J#LE//P[6G%%_I+^)VC/'OL#*FL\OQ[!2IIN<D4C,NU]3STI$>&^_AP,?RA
M0E6^P7 +M8Q-D^4U[GPQDH1!C\SEE 2P**^-US,-F4&VA.L(,/D_@\I(:-S]
MR CGD(CS5!GN]^(E)@2I?V3_S?I:_Y)C8Q?QJH)+HQMIVDDCU,FQG\<-V?*!
MDJZ^!S]<0(COS+.JFW'IP@(+A]Z*8W(? /BW+B)AAA,EM('#@A_:^D/'9,>Y
MTJ_L\U?9U7Y\7);^6=FR/J?=A7FR[M WROA?2TD63A7[V<."/><L6?2F^3.V
M37GYV %1"5]L"T-%A6.O'%#0FMA;*KDH&'?.+EBUC;YN -G%L)?QV"NXA-M>
MY-!RPTUX_*M@;=<Q];D=XRSC*AD''$-(1 =?2+<T9H=F*1CFF\<6&472)CK0
M^B;:)<]6I1KB:^H5)0W;B7&!IA!(-KT\0G7(DSR/=#ODME<R-@J^K!2Q 28B
M,"CZ"M9*LZMMC72(1SJU9(Z5$7J,,>%P&O@?5!>7Q/WQS_8&32-&42?+B^ET
M9$D7?Y/V<%=1=+]>MS;[I.!%IS@6ZZ?Y;[[_TYV(('9RPI9=2&(Q=AB.GKA"
M)^-D%:ACTS]6A8!D6M0P5T)#$#ZLH=98-^]'BC\.TZ>2K=PJ2JE*$#6:@B/F
M;\%;BD'@;6'^YM\QIE&/5FW)W'*4@$^)UBFW5^]EF9X,O0.=%#1OHPT$J6@G
MZ)>08W*OUNK+8F3/Y^ ?17O7$:=)< 9Q57,O(??-36:*]# IOBZ>@U9"6@L_
M8V]5'P"AOR ]\K<0-(XQNNO@ 8!F-IH(X<:VR<@9=F'Z#F$E?651WLZ_8UXU
M)>DT=L4Z!]U49L3JP,CHZ!S#[7'K;$.L@:,"K;*XI5+4.P?E+;T"98R!,"<#
M<..>?L*45\Y2MFZLVI">FF@(''D)P.#$@'6_(F7I2A1,(X4H*F<1=EPW^)1/
MGD1$-?9M8&"I3MK4GZ5Y_KO($"JA3KX[5:[G$7:'B[D\A-Y(@ 6P7?9HJ0$F
MXL\B3$Q.M-+7L["$WL9TV\7%.=2%OZM;X>FKAM\:YJ 2RF9E3HLW+XKK=QR4
M[HIO.3!VZV6QLMSW8YY*F- =K::90Q$9'-5L*>=1181OTH6CR%)+]2I5O;X4
MS]$EHTF0H4-\BA*$D%%HJK]YPYH>K( M0B5%6Q.?6Q-;,1@;8%@CG:6D1LTN
MAI"N?'W8-Q=47JN9J-BAEZ039C2X[\@%:I8AV%<[O?QQ;431LEQ@;0Q19+OB
M#S ?YGE2V5X(>>OOF>THE3D@70!%M>OZY#:;:[XXOCN#.MNS316>@^(W6/#W
M!&'Z>:FR+^G6&OMI^[86#EHS:6#@"R7U!/63V#PZ*]+XDJ->URKRCZUDE7=V
MJ.9)YS!I&70#0]\9=I@1&\7=O:F;A_]9P,"SZE@,,>M]JLFHH_P;_LEB*I(]
M @SDK("A9]RI8]/V#$TZ-7'V9R"UD*^RK"%C]RQ8%PP*B!%#6,>TE8PCF.AO
MWS4@K)@G.]F=:%H;9]LYRI&NC4MN+X<&[7\N*'$ML14+(0#FD1Y;7760@>,8
M:X)[UOVNVJA#_7*Z\3C&E],?9V0);S5_$SPKZ#^.-(JWK6V/!;FG^)<IP0R:
M9UT4 ^I?9/[R32J85<<RW>,^NA'8+V ,H=[+%\6"I!SE&OF[1S7![[! 5 XS
M[SE)U=Z30[\0JNRMMP$B7:3R>*9:;IPI%%E32O'"4DQ3&0[S;AQKTUVW3R'X
M,L!Y[9P52/?:\5$P1@E<?D-]/]7F=JB/INKM(K.#W?_!O(. T/,(.?SA$TNL
MPT#@TX(/&,(T#SPF(:#YG\6@3SZZK*3E;]\"SRW9H46,2"7R]T\89I^;2^<"
M)#AV.0W# /#"\W_8*4D<:@F&'@;Y<_**BB]<\8_>$OY/XK"F3P[+Y7:HLJ&E
M?MJ[5BMW,,S3UGR(@[E"38'5_$I4+3N9_)]CH\]E%'7S'YOK9%]/%J](1XK6
M-W!+@1M"NVQ"5AX 34E1#X"/<I$@T9Q/JP+8V8U!HJA.HEN1Z:A%6!(I-OWL
M+GWNR%P\3HLQV<:#6684_B913<&<D^? N.\!L)Z[5L<4?8^GB');5+R(ZF#D
MNZL*$1=VSA>=XW_1)OMR&DCJ^@'MFL!3F+_@8I/\JO,DEL)DJJ^^5J!"?>AX
M\W?7B37ZI5\@?\[B4@A_\VZPS@W3_9#5T[N4$ #6>KT@DM>E9FZNKUK:H4K'
MC4X#=4SFY/%\'J8E;R*6Q[!\S.,!?^TXM?2"W,T])'=:I$-*J;9IZBR'.UA*
MNT&':VYHBBUR<56FK[W%]BVIR+.8%S^X=@"/^JQ_EGDVX;[Y^>5_XX0I:15W
M+H3EEA*;LRY'%)QQX];7230GPBMV6"]B%/GO?9,CB>O']R/?:FWKA4(5OB<&
MU%C]S/8%0:=UC@C&AX.%+W";L#8;1(^QP^M=D6 V)*C=$-U@A)7 _-9).%KP
MOK&TAG\W6[Q50$MGB)'AR9'NM74=U:10?/61D3VQ%IS]#D++/7\ ]$B'\$!Z
M>:NQ^F:-8>ISTISK!'X]]\28R'*,L37F4QIJ*>=W:OH<.[IQ4::8EC"B4MZ-
M[)_@H,P(VG)9_1M/=,[X$1M%65/V(10V=RWFVD'67!KNJ3)^W;SC$MAPDH1:
M.]B[D0<[H]U"VXVKL'0](0",'SPIAE*6IQX;@-X8H(V*/ *;EYA@O=ZC#[[O
MRPHW3M&X *,W?VN,<C'5:3Q>@%^8;A.]LEN_L'XDRW<KCDU&\D?=O\2:KT.(
ML=_[Y)ZV.[NA-)CHL#G&&-$,)!-6LUT10IX=S\C3.96BI7Q/P;YA!+N1:4E?
M#W.T$JJ&^'"1N;DZ4"F_T/J3-$3UG/448<J[%=-T%2J#R/O:M/D]/IO"E,V9
MV[08UM0A]EMC[OJ(/O;R=U?P^)\EN06RC1KXBMG4*9Q6)53:APAN3>G_9.">
M@O:BG"\_7ZYU\I:L&FML-0'+G!NS*5OYJP.]ZU+L2'-E\:MO/A6MVYB^QPD9
M6B.Y%<1 >N2HI'U*L%QCS@DJJ)K8=GED!Z%*VS28Y!=V1Z>N;KK1FH NSO]V
MAO-3,RUT2@7WKM[T%OIG*>>L-%:[*ANT9/CI$-IVWIR_=.4H^RX[<.\.8AVM
MJT21]7]O!J/ #J+'+^*P=R@WIB4G2:;X$!;LXCY17/Z;B5M3]/^$RWDD_7H[
M6)!C42@&JP']&9$'0 RQN1++?J#5=SLW8''].*LQ5;T:?G2?4Q$.]^*B.42F
M37;E<_N@)ZS1=>=@A>)J W3C@84;39SQ&BO>Y<+NE&\LT'[_#06^9 X$/[[)
ML ,Z!^[W /C0CK'O6[Y0IIQUM;Y,9Z10NI_(>W&'E?%_ )"%K"Q>QOBX/7;J
MPFM_5L'?:QK"YJ\!EWV#32AW"C30LUIVDB1G9)X!L[DAU0HE8>U)#GX$%<Z=
M'DWF,^G M\3I-?:RPS6+B>EG+BL'Z8>[8?DR#P"<.\>0 EUK'*SSQ6*P"KSY
M_A5&KE?&KE<*C /"<"A/[V ^Q90O[^=3SH#50,A1R8#LQ47RZ1I7JW^']:8C
MK$'^10*M0D+9<UB'&SLM# >*X\NM,$ZO%D09S=]'B6G\CRF^^Z%D&%%KI@7=
ME!XZ-0-!R,P/EL:J3$[""Z9J7L*\@U_&?J@P?\F3J&QJ--]OX[Z<73+G_9RS
M"\^2[0H[=DN^F"77??]>U^#(AT'VC["5M>DB%_YOBQ5Y@.Y^O_';HN5UXX3_
M!%4Z]M%ZEAD3!=@:31DG)*@<^0\AJL6'F7WJKB;<X/&E H^L^^D$3HNAU"XC
MZKGJ$D'8&H,RH?CF1@DX0>YP%*VP#6G RA)%%Y#1URFY13X B,Z/R=^-2#X2
M$92G7O;7&R'?2>&6M%[,0)56:/A+7;S'Y@"+Z@>>/0 0+EZ*6,,GZCN?G;G\
M0_'*XAM(P@=]=P5S)YO6.[93];^[#BI)B%ZSIK@>_Y2M13\ HI"3V=N&^/8M
M<H(.GP ?14E4>T,]=<H'.D.L[NJ H-?_E82*X%ET;,-04G&9-@"AI(,@I18Q
MX>J 2"*1=-EBN^38ZK;CPUE4#+V)/].Z6^^2WQ93G^11P\92=-IO2)^@7ZG"
MR2\)?..A3_35T[%7QQLZ$9TR_N86:+EX60&P%GH^_K H R$ZX>_<:T59 +_6
M*M8JZYWW4N0][-LZN/1D*?90OJ2VH98B) AV>,YF'2LT_CD/!(&ID^2TY3F9
MX&ON*NN$6#N_X'"QFC=NNVWHETP3"*'UH*^MOZZ"(-GSG&J3.C1>QHQ[#IGL
MIZ)J1G5MG.:<]N=_-V9OIEE_S2>H;9J&-!QYWPG=[Y^SS?,>N1U&M[<F@H;6
MX&P'FFP?&UO^)K^F,R3T"+/*V7@ O-B5',FG1?_<?:_T2R>('48_UTPZ_"P'
MI,H.2U\7=E7]E-KH1O=L533L&_<@KXAY#;%C)V#.6RO$_^SXQ?(@I&IQKU[$
M:\5L9>6U/G"$![JU6"ZLYO@ 8*TD87-OK:D BSV#KL76G*M2ZX ^-@6RD@U&
MB96:3-T'A08\U6+H+7P2T0T /)=3&/7 +IHVB0FF_M/WYK+-I8*5:[4;T):\
M5,^UIWAQ?QUA2--_S@2SJ"!I[\)#AC -"M*_3G:_8!2G5QP1N++PX-]/=59.
M-[7DL51_CS JX;1U?@#4V=5.5RHX4:N[X7$:YC,W)/!V/=^;FY?4-*:UJD&-
MDIX\GI.$5C7+N34WSD"I58!MB_45T78NI3P"RO&YE(\['M.MD9L,,C1:L4P
MU4PUDTV=%NU 9(.T=Y?*#:;%J0#93R_< Z2_6X%0"2H(.2*?8"DC]'E>QW8:
MJD-[0&EV$3UXH<6(_,M67>ZMFQK^0JO0TXNU07F*\I5Q_2!R"8A1BHKGJV'@
M.VC,\HZ"L<I4_50P&7[<M&WJUT#^D260_&FN;9?$",:0P60F@=K6$47NI+BD
M7R;&Z#!LEE+)I=TLRPBJ5IW5O_ LXG#U+[M["3?5IMOW*K&F,^;M^V!G%J&*
M%*2.#9DJH77/QZ.09N.Q$/@&WQ9(274>Q]^K0/=-QEO7YEAY5#N:53=#+?_1
M7H0%R4S4-T7)MZ'G?C1T11V_HJ%-R%X#%J6G75Q-I#([-K]3D:CAF.CDXH^3
M=D.-/W6:6ZS.\_CP^2/&Z^^BFDQ_Z[-B#S@YK6DC*3/O3CJ=@>.::%"VR$KL
MQ3&3_[P1J! ]'W[ 4,WGYO+9YQ"D*UQHNE([HKHII/)KN:==A0;_@]Y'-O50
MX0]HOCRB.+<#$?=%@ELKABFW,Q>]OW4ML!FC^VWFRY12UHXH74<,.*6AZD?*
M<T'++'LP(1-1?%$<7#D/]/YZC$:OTG08APM6>W(]JZ0[KYM@2&%$_II&[8T*
M:1'.@9UU/^KS\^#,#<_/KI99.B2A90GW(P/C%%&]RC0=^(1X9&I;C92,XC1#
M_L:&$Y5)4/&I<LESSSW#7_E\I7@5!7V=9+^G$],"RIS+2ZX$ETIS7'Y:][DQ
MM"OYJIR\K=I_?)K[D?(<"/\G*X/N"@>K_-R7],VIDB_V3SAL)%#HY65W%N\O
MQ,N8/$JN)J7SW\Q;.F@FTV!^$\EZ2N]AU8'L(EYQ@CA/^X@&<R,6!0QGSP:)
M<IY&AVR7E#6 3_<NU:7_%!O)FMK1(;_@1,_"*OGIL&&];;9+<2N,8ACZ[,)L
MJI./&N8?(VF>$F3PTN]OTSP:$B?8)\J+N,[C\=XS[C5T,OFL65F2$)^+QA1R
MW:)3X$I:ZDYIZL+A:])W.5K+EUYO=JAS8],YGF3;3)5E;C6B/0/>[0T0)4'C
M2KY> /<> (Z#$[F.PV21?;KE*MGIC.+1;<[?M1//;^V@KQ,W%_WU>L'1AS;O
M9L%*[L6'[^'<SF5=3ZO0PQSIGE[3LD#4<829<0Q8W@XY?+"?$3GWSR+_G]7W
M&Z.CR4,6HRG+ZF+#5S+KR49 O0K/PAR7ST[WDO/W%-C*;BN"MDG76R5D$J4S
M*2@]1$R7=Z4OHFC@=>.4F^$+FP!Z**V*^\YPRE^IM-7,Z@? ._\:L/W&BD^G
MX?1F+7I9K_6Q'',OL"O_[<#6BQ0=9BGW1PI2M&LX235?H7'IA+J%].P,AD7Z
M1%K3"::V#NH)N+'ZGI6RI@;?<YT,RKE\'&=*^%2TW2T6QHELO,"$Z@U.>OW#
M$@-#D<R18F0Z%/I$.KR)S)UR!)+D >XM#G*5^A%B&GA1AFC_95DAPBI!$:XN
MBAEILDIL#;S-X<+HQZ),?P14T2,(>>40!.7T@5(:D"[RZ#$#TW)[5)9)RU=-
M'I//;ZD,K#"AQ@^&,7'FV!JTV;#.I#3=QDUEUJTS.J>/#L8?03L?S8]2!6H<
MTII0'$D#(0$-A\_WYY9YYO4D_D)S[^OVOE;=NE3MM\G%'IZ//[I5Z'0L:VF&
M2/*R("ZXAN9\C2O>L7/_2G^7&_&,_6]$7+.LY8VF?Y .)BF\77X]9H3R(AEK
M!B%>69:=I?U\K=G7Z'M*'7*P8BE< L\5?$O3D.(\U3N=+UF?1VNPAQ+T+K(F
MB@TOT891<PSJY:G/[ R;BN[;[-TX&N062;H,<17KGB[ '#_ZJT3V;0B*MS>P
M]DE32G%!U8%H\5PE?STH[ID =;8@-#PW0.#O@5ZO=@*7SR^4':X/FT)QP::!
M->P8H5%#D>7V ' X_+2/-TJZHY8]H(,!0E<S1!!D9$N6UEINWG.B!UZN4PHI
MB);%EQ2K_C@("*,L\%:6B4"6&9LRC%SKJ>2UW8+)1:WBM+5\1]P+P[+E/462
M*+"P.;HX2YHPKC50$S>/'])7[<U[ G^<Z,\U[6+5HR!_8DL0V=)":WA4K+4H
MI9LLY<9(J"ZL*!6?)(6(_HX-;;;W8Y(^8]AB=?CUY\T4 4*U P#N<TF/8XNK
M_N#L3Q(ZLQZ9:7H1$NNIG%S43BXS\!O'WN(=]50'KN02,X_4U R9>4EP<E,[
M2_>R,/S6X%2ZB#N=CD$R8 "&&*?*G-N$?^)_)/G7R<!#O"*U7#>? T>YF%,]
M-P]'VVKHO0^75W =DEKDCD5KVMN%>6Q>8^JL4I6G<46RGRURKG]H5>#;DCPI
MTDA$/O?\$]O?%*T@]@R^+?W?U#TT+/EQTW+E.XEIZXQ,'<MU38$;7P+&_*\W
M[PO2@ACC_%JXOI]Z;]Z$!G?)!MX8]Q74,S9\N.(RP'S!T28,^/, D)V=,6OI
MW?23& B1>W+U)';][%^HYX_<^"\J$Q_.COQQZK9_TTD(X8"_C@62K>5NG/T@
MS,8GQ?GQU&.>_O3J : ^%>,5S]CA,7,#^4_PX\\9-CQI3(ZO"2EJ?@!8P7ZV
M1,Y)'!U9VL'J8:V=+6F)%*_K0S6R:#*_/3Y,JM&D#YK V3P^='ES]POR^0'P
M5:YN%-:=@]SI-==P6Z3:Z*OR9.*Z=P9]P[+(_]8]&<;3QNAX@-@5 S[4KW\,
M;L:P06! )CRL]A1;+*^.;NP^ZL5;D\.S)8!TIJ'*2_+7[QQ_N!@:ZL9[7)'<
M<#I+WCT ^KJ8[E>NH<NGCM8,]W+^E<B.=M=XI;)0:0G?1;XHXF]H'LTJ#CWM
M/L'-1WTAW8X_98)0.-' -!M@9-3G-NV\-SW&H(#DB0T<+K_G# :Q=V+L0PYI
M]@NN >.TC1ZM(<)T+Y6 !QZ-'CY"6"27Z#E4V8THMBE_R['EIN+X:CS.OSJ)
M?.=6L1M3:(R7,(@-XQBL(]_7YMT0^NRK'X'"78 ]8ZC-K/ ^I:\XSJKXRY5<
MP)T2>L@6*13YA%9$_BD[^WM=%%YM__!$T9M-;]E9C,/A:^=RL R:*)IY\J]<
MQ*T]Q*9DV50*\D=T^V3W9?O70>*ALK3WRN+KA"%+:;C?OWD229R=/P#.@^8'
MNQI3[:PQ5#T00&:Z/UAI0ZEMY@,'X*^9,K2C;LW_0Q;U2G[:F321*3S:\US*
MH%>AN X[Y$.:RD!?G:#9-]O0S&NF@;^E'0CD&%KC*2[H\4>&A]]*C^\CKWY]
M2D.?>?*4=M"T&=K$H^)=R:)>1VVKM=K4R2VJ4\?RJJF3[,0FJ+NGANAB9W]:
M@:DP4;T%,?G$5Y^WT4=)+IYS+:*7QI+>&A0'^%210=B/WXB7=W9>D5CK8N<'
MK.AGI#G^T_DHQYD/L G66=YJMGR+/[S%K8:)SJ]?&*>;A^=]C)7RG]S.<1A*
M2+;(."1:7SIDZ0G,SZ%HG161D3QA"(+K" @QL-]/)#6:#+FKPK*)1"C&IMP]
MOEI+FC/0M -!ZSK$YIU%Z%,4^;5*_"V->+:C<@;*4G+C3G),*C./=L[#L^&%
M7<)W6YL_;!'!]_8:0BA9(OBG+*(+7ZFX^EQ9M_"ALAPCA,W)[1@9W @:UKL]
M6^OM(;Y(CNY<,41( W&QF3;NK:GHLXI!_?BNS/N66R &+Q[K0*-0;=Y+;QSU
MIR%K':2D+2V':*RT01=8=0_I1=!F^;IEVI\)I%1WY &C1T^>F1D\  (+]U<E
ML84_L4?7ECC(XVZ:>Y[]*%8GR;QV6LJXQ\T:6>=O]<Q=0SY%FDRA 5Z$3NEY
M-Z+-,6!.;FQGOUSD*L_,Q^^'DOSAYS?'9-C ,8!:L_W]3.R2S]3F2\/WS#NX
M!Q(U=8U:'!J3WAIX!)3]#)+=9F__X3_AY12LMF_+_<X[LT,#.F)4,XE/EQCU
M6.7'J#M.*1;ON4- V)3;\/KIC:MPNFL+R\,'@%'RW8'$L[JEDA 5Y-KMN^6L
M_H!+)MN&JL7V@$K[!67KB$%Q11Y0OU>BY=?J4_RQ$A[AN-@!!YI^/JC)J5$:
MCU2JX]3=6@)6&+Z\1&0NC+*B'ZQ+W7HQ?3'K>2MWD0:I,M4O4J$*+U(4J(E&
M2'"Y%ZHW'].W&IAM)U]!D<=/0 5X(;Q.5@PSP 0_1&5QO:7Y@&BAEYO=+Y6.
MC^T-V6,KJ<HI9E5?*AK>?"#Z/'_0$760AB8;N*>;!&LAL6!+)%D5Z"([K;-P
M/8G6V8QAI;WA'<-M3O16)L\W32N9)<F!H8N:/SK$H,#M/(P8PHJ_JX6JP3&?
MO6'R/"_S34QE]QY/>'+C &[K^\ @A^1KS V=_\;A*GD'&KA\LSW!SV>NL>HY
M6O9G6Y=VLR!=8']C84R\9J+=_D\YZB2W+/I7A6%=HWOFF^W,;(%X1G9#](QE
MX'?=<+JM/ N@?U-585R..K?B1F<4O4?T4$MEW*UTOP9%^!^,Q)B?+.6P8-J^
MH6DP/:5];-'7(J59J-GJ8CJ5<+>![G?7)EUE(:^,]M-.II"Q!T"C=>]QO*1H
M7?']= @;9J=[.%@2-:R']<-(,F%5V]4Z/2TY&C"F!KG#(&8$;W$R^17C1WS1
M5B V^0'P;#W*2B?1^NEY7 V^8[;1U^+=>)$' .W?86<_5(+ID>MFDDGM[ZF-
M@AN-@T"?AM>UJ6:P=J_&:K9E!-%^8-=KN?5*2.T (FGIB0+6&H).),)=Q)9U
MBZV^:I\]9_CTJ6[FN#'@[,Q9B[+_B."[:L-J_V;OU%/\=4S+SA59?*U)+OQ5
MW_M>O7*K=B>;BNE"-;[ SG$2K99BU-*6UHPK'^DE7UD;Y.!R,BGV1)L0$Q?E
MY<H\\.&DZF<IE>0PQK1:UI E<CA=BK-O*B*@Q;",;B8[D81K J$+,07/L/&9
MPJ\",9%0)#0(L4H[X0,U1[3IP,7/[UC@BT<1/RTJ@&>2WK5_K:PSCY7:_?C]
M"#:3G#_69ZZGXJ5[;-%#O.0:!B*DGZTGA781@H71_4>HF^XVATB1&?1AWW;)
M<ZCOG-Y2<0]?#70!E;[-R>I_1,& T.?N:SFH.;W!5!>ZDJ[!5_DF@'1$,9U$
MG?/M@IC'<K"<7SPUC7M6=!HO&O]>='26LB9R!+7T+JM',=KP"-_U0WHD><%>
M9?=_F'!$UABQM$R ?5$KZ@9+,;7$*S?[]DG7G^;_"&PQ*L<\1S#65N<87G9>
M'J<_(P@8V#C*\*J!9RJWG%/=Q$GX8C_WZM?)S&7M5 8_KWBK5J?*F]42SC><
MGIW6^TFEJ^]_H56BL-<2"68&Y0X2B31;^GTV1DS"%RVJ0^E^RK%5E7;.^B7J
M B:_=,O?K&/.[&/2&6;#N>ZZE,B-_Y5=U89(8>7ED(D/@/62_%=H5NKI3H*0
M94G@0(*TC&VKEIPJ=A[I_Q^[!Y/CBBXM$OCVE&:Y3(-25(P?15/<D%BG6Z.-
M:EY:]=W(^/MM[$3-F;2;W@B!-=!N?<&R1Y,>@=[F6K;3VABVE#\_NA:.O/_U
MBY'L.+-^S(_L4I,F0%7RTV.Y>V5%IK-HX7V=-!.W:I_L7'9YSSN$EG1C%#_N
MV%J$2T@\4Y4.T]K_?B67UJ4<8R;:"0J0F[J\AX:4QKXI?O\_?^",_Q3 U@[#
MUHD6Q'K2,ZX1QHP\V.^HO1Q5K#6Z4O[Y:5^(!(9\K:VQN7'Z$+[<5ZKD/GAQ
MIU1$HD2<;/<IV82#[48]9,%WC0#V-P0/3("&#@PP+3H@!%PF[AD=26-$"E[V
MB;_)9\-^AR+,EN!F%%DVTLD6DE:6/X40OP1&QT)&K.N4=D+;00$W*B%3^>S-
MV-$;/?]TXFEL^C;I/276P4;\%">\DW9//S).HW;Z,C@/QIK@>I0OFL;Z_B9K
M<<YM\_<#(.7VVD_M]V[S\22DY^2X=4NN[OC  ?/$!/O=[P9TOTA%><]Y5R2M
M3_R]1_8EV,+?8=TXDOU9E3<OY>3P4A*QDNL_AL,#)ZW*+)9$Y6_I2>>1L6]<
M'P!SJZJDS>>_<=_\_/9_-@']?P#WTB\]G5AF]GP6EE8OXG1)Y=7G]EBDGE60
M>U28U6EJ:(_\0RT_RT\^TR_25%_ %.O6^%B%';@5K@DK>G3K 1!=S4$Y/PQ.
M"JK>%\L(1 5#:3J]@OU\VH3Z?MC:;7QX,@ !!51KEZ&IM']_LGZVOT;C;>Y&
M3\G&DZ,3IC'+[VWB0_,(-ST%F[*F;M&*ZT!<+F%C73 _?*.]KXL=L)AJM\8H
M]LBAH>V<*"9J?^?>>WKT]G?03VQ77QCJ,N;SA[K90VL=AXY8'<*!C_USDT4I
MVPL;;<F979+*5!JKNK_-5^<[TE?T@\ZT.K/A:?DK<P\ ).2_@^6,JJ^K[KC'
MC=J1\27Z<"4I^BQ.YY%C,R/U9'6[!,I246GFJ)TM2+SE/ZT#M39G$C9 'Q5Q
M179,ESUB[[Z:JP="_@Y?^$&H0"&".<J=DZSUK5.;TV 9&Y04E+MGQVQ:Y.]9
M@IQA$GSHGX-H6YMEHZC"KFN^>9#W,S6]@=/(XXVH0_W@&VTK<RSIP 8/Y:4^
M^-V$CQLNMD:^L0,]VG6A$U;C0X2_+^E]D>Z^M)?>;-8N*!M!,)\3$,S.NY,%
M3S;7DXMI=T,?(ZV:?38> (OZB*954NP5^L88HW4<<\O8!KQ/0'$O45F3[EXD
MR]M_7FP.;\PS+192WV,5Y1?Y1L.>H"B:FT;%?RS6-/K;2RSH<OYW@\ZFCHCO
M5I?KA=%YH,\#(#0DW+_HXBWV$49YH-N/RK<--I:UGO=\#6[&FL^(T5J!ID.1
M2P1Z!$;SJO.,@XLRGKW31@V1)V_*/K.-F+)^,6IW1D(.K/W0\(NXW]A3E [3
M7\7UM9>*J(UUR$N3&)%Q(A Q=FB*CE=[_UBGY>-T(V@]E-4YKE)M^WZJ+8#/
M]2F[\I-A:2#*>M%-V3I\%:\NKB]R?.,P,0_O7[)_R-S8^/I1V7K>A]5_78N"
MYDL#SW/<-A*>K^Y1E,0GP4:)H[G%@7]N 1B=0T'46F(!B3<D,>3-#%,/?QG8
MN!%S"3_TZS&+*(TKWI7TLC:_E>VJP] GMEG66X#VG+UX?F7-:/;IDY:_4G<2
M4O_9S#WM.^T+XI82G4[\UQ13*M5WLC?KK6'8O#L_;,D3TH@]UL3X14NS_=I[
M !"U6X/6"\BL!AY-M1M[_%CTKUC2?FZRF6)39+EL;F9]-8?<2!K)T]6,>[/2
M^.14Z'ZX@-1G#[^ &.+,E"#9VRIK7_.UM [KX+@/)Z*)4_FNRT8D%?+!@&2>
MIOKF0J5C_IQI81AIN!;#N&VIKD/03QF$VKY ]4M59I[M'=V.YVJQI2BHNJI_
M=CT_\_DPFV.98^W%Z^RP.NZW>4>4>/  L''[0O2F!>.:@QJ/R: _*D#IQ)]W
MD:NQ!R Z/U_\V9#KU0<=$0111<@Y='V]?\ZU2H8U7 \F25.H--NEY!O"T00B
M] 58GN 3*HL##PST\/B&C[C,34P6")I\C=+CXEV:FB(?)68B5,.H-RAVK$EE
M*4%,9*[2M#[#2W_.'@ OL"E$)$UI>&)_8:W0T"O1P&R>Y.,F96M!E5'8F&_V
M.2X7EWZ$B;A!;"Z=5M_!U<?BZK;B*=^%Q;%_BI4OXQ'K@N08?\EI. K$%9OG
MY*L?U5@FJ>_A(FLJZ<-!P7:L?#OII"826VAH^!;W!]?7"8  X )@VVEZ5W.V
M5]U)JO;+M)_@(KEF]W1 XL^-#+1O8.$X*_-)DUA,JJHV^9<GC&GG,A^P1? V
MA[AVF2I_9Y.OKB(KSCJMTT<H5XR%LKYG?@6FCI2%T#"59*H#_)V)OD9LV.ME
MWU ^$4T45 ]W/NV-01(L5GOP5'_; EK"?=+TO15S"TK6B<'J1+>$Y"FI-[FE
MVM6:!-:[<)ED-[+7SEJD?(]J0'!Y[<3;OQ$_[9-@31HDX$>$D*/C)3_EPPT:
MYWR"<O*>]Q,PZQ)WF3N:TLJ\E3C9!%EIU4'H<[X .'FMY6\%9/FG13)%6-B_
M_UK;-6LTIIIKBQLNLY;IN!(R_3T2?>\8*VI./-[H]N5G"F!\I$CS-S88HZ.-
M=DO\K P%%>XWDX'FZ\P#%N/GS6P'GQ=P<QB9MY28HM($' 1"U9@[\#9$S*@2
M>6]YH<ZT!='M;"6.;7=ASFB%ML2X<FQI3\D#0*4I)4C"-F>HOF5%Q(-TE._D
MQQ?GBY%_>(F5DJF[RHD.BL $?%]SRWZ]<*C&PN3/_3X=XEFG%,2I)QN7>C4C
MVBG'&7L9ZJ5-7ZCQQ)K.F*XW<XP\7XH5527"QE3%]]G PZ3=G@=_W^;D#.VO
M:L^5RSV[V3<#_\1K'(>85EGPL^+4&-98(;-$YU?76?;.7:8L%9LEYCT>_,9!
M]/ED^2K]L,GQ,8+-E$)[<M2KDPR;0/GSTNI)T]S!$=BA:.CS#N9Y\0/ OFX:
M+%L7]KRTSNK*=)9R(676Q82&<9N3/969@FV5H1W#$2WR[T6C;1M5^$XL-;(M
MUIH%$0C+[XY=*A/">\V%8?U^W/KY6,T@=\XZ_/"> 0N5?>7(6_8CW]*DSWO-
M7HS*R C]+KUB:O] "SX.G!$22=BFY%IX&F^WSJ&#$UD86V85ZF/'Y9K 13%K
M,M77^H;?1;M99.E"MY*K1=W'GC8VZ>9=C9K\_9Y"M5?6QLG058@HQ*!<@[@N
M<^33<Q.GEOA\@00U:;;/3 UEU' *8QP=@AQ;]YD=]5+!]@YU\5:CI$E:?$FV
MI*BB)O0Y0C*A:CJS0$\MY41+43>MN^-W6YL"RKE9:CAEP0( P'UF^Z\-?&G%
MEZ-=_]N9&ZK?PSXTM!?@Z/K9C3V+[:GGBU7 AY> %!S-@ ,SMZ_23&X@RB3H
M*I;W,UQ@^BPGO2NHXRU*Q-Q2Z/B0$=S,91J51GLL,;@!C"C?A]!\PO!'P*2X
M9?@(N':=S+3R5AN8_K9K^=%/5!;)5"M!TT:B[F5L\T7YV>7IJZ4K:"PM%,LE
M4'OR* %L%TB?83S<"WJ0.Q6^=<@Y!YK2<THS'51:Z1=47]/*]! E J ;:Z]<
MV1L];^%<_F#1][^V.P=>U(GL2M@Z3AMPV^B;Q,C?.1-HYY81J@Y5U4#L9D1D
M% TGSX):W%P.I#T*S6HM[>ESWCGV#\<Q:&5R9@_= FK(0FV3T[WIBGI.C_&Q
M#X!>$NQO?5,C&=$'@/S$8>.=HM+TY'&^C.OV/4IC_BN4TG$K\D@T4?63@^%'
M'U(*]R%!-Q$\"*F3KYGA<>SY';^!I38=U&H)H2>:["%"1Y/-((3GQKYZSY')
M=?6=^[FR^!'W-'"%20WM,U>PP<NB4=\4IOT%%,)&>3%1M/J?Y1Y5 #'K;FN4
MCFG!)7BF7OIN_@)HO;'YU;KU-]N_;99-'O[$/$7<4<RTMZA0@T1WIMPL(L18
MG:DE_+79SU36U'\2+O&5F;8;BM&UXKEE+Z.NKQ$.)DS.QDQFN0*Y6'\[#W]\
MR5YDK<D(AU"?@0:3%=2" @?W;*;<AD6'J:^MJ:3*4;)XT2^J:+KJ=7.&KD8-
MB76?XZ35(K<.*+BXQW%>#Q[(KCK$$\>4N];F3I'=7M9M-I#@=BM8B377S8 W
M[!\2#&&3J]DZFCO2"5S96R+OA5V>)AY+^^%1Y7W=&J<K55Z>=P@(1FD%:<"F
MI16:?/^AK(G;8RX<2:R("$#Q;G9! 8^3!/D9J7^"EK@T2YZ+X28A+JXA4>=:
M<HBF*26[\BJ2JCE=59;6V;.8CVZB<XM\!*-S>2_57"8O";9.G@M(H8&_-/A,
MS/ZJBZSRE37!E=OM)7J]LTO4C/+4ZU.-F(LJM3V2^'DV%$I4/0=2,<)5SVT4
M8SBR/C18://?,(8+9$5\[O1&:I!HD#!5V^Y\+8OLG8XP3I]*)"-3;DRS"C04
M;/QEZ.I1X4YK%<</KXD4O)4)>T>;GU<H[P4!_9*O4+DK)RL96/K9F4XWUYQW
M85GE'J/P_8W+ER.7,D1[\$8"MSX:=A^SH>HC142-'9M":3FHPR)!/MQ2U(?K
ME%5Z;#:,>:R.S2FRQ[R,QO@]7RE:?_D'*=5AYU'',6U)L6[2YHQ==H5_09(6
M8F*D<!!;+OYPH>E>#,="V9>Q\J!?FG61&K^](W((E9C(;>9@H_R'E-GO)"D[
M(.37R@75:^1:KN9!$W*-E([/6:,T(_FS=5]SXMNK DZM+HG6*Q42J0CTGT0,
MK5C8>E<:0*VJ0,C71KEDY=I00PD>)5S=&K,TMO&H5/?I#.ERXY]@OVB:57/I
M:9$Q@:M[CWZ^2 VNK$@F@M">K=DZ>OFXGMD:(Q%!$7>?77E[TU*^@! ZNKBM
MHNQ^TQ(>$4?=OBWL+-KA\!'Z9,T(/;)&(BVQ.4H5/O7"9T]-EZ_,F<=61FPP
M!K+5E,9HVW944C_;=\O_^X8]V89,E.8G&:,*NVX7B_B8_%./Q)#,&PZX+/YO
M3'K#>E?H*J. 4S[#[];8T_[LWXMM2J)9-NX9M#\2C8>7\6)8*-UD#Z$[@-;M
MEN-%R#K%0'<7C2+4WW-*$;V#T"LX*"<79@\# X0<+XG&_F;>7GBV/II,YV\/
M)Y)#\% 2/8KN4<'3Y;3=,&J OSD9RB<-BV3"L6JT+%%OXAP@X5#6U0OGG/Z.
MG;VY?3)VFGOS+'=VU''(?9@CO%=Z2#]!W21W@[[RD\08#HX>X7N$C><OP^'R
M 1IMSP@G;.X[,M?4E&GT7#&N2LR+ISL,+?L2-)<,P=Q+9Y9O71+@>2. 5\0>
MTQQ+$GOQA,Z;;KC.YNVU#,J$'BFJ3^,3K_8&:IRNG[R=@3_%W?>4V,!A*0 '
MG6*-=W#.!,]<L[R+J[7]>R1NHS>6\>\I5DR67\N'S<0[2'"P_!C0_S=//Q_O
M>/U5ZBW7VWV)C>FUZ?CY(M#\EU^VPXEY06?=>V'S^7=2$SBE9IIE#&."\V=[
M8]J$ 36,=^7M3O]I7CG[XT6<_F_#F\N.<B]OS;T<D:'UJQKV%_ZB32KC6=K+
M/L ]46..5^FZ\8_N]W8#T4$AG><G<K?DGH=%=Q%RCB=9LFZA! U?4][IKYD7
MA^?# :[7IUJN'7HW?QD];F1O6>N;_S,CCK=OT F(_RB<%6OMO%$H[43J"%:I
MT&"OO7SQ%X7RQ:.&=&3L.^^N+4291B$@."(,YI"LBBS[AODP 5#A3%7/ESY!
M'%F;2/'EH\UTH'7/KY@;F9!Q1K*Z]Y F\*-U1UJV;H*RI;V)]JLG6+I"AIL=
MJ&<7+F\&4F7 +;K@A9J)"!.E.4<"F(%FF6+KK1SL<;J4O"]^+%6YA5U'R&!J
M'PK++3 L4]Q9%X'@8^[1G9KJ1N;1/P=1S)YR3O:+0R7<@5QF^\;WBJC8VB$P
M"'G$<4%L&N(2FA%E.B=XRJ$C-;+*'RUN5J(50,7SR\XS0L_JI#S?9K=Y^(WY
M?M;W5]^$]V7:(-?_-CL\6#%,AP[(2I;3OUBF[OGFJ7C7DW.Z2(<OZPP5"D)I
M'$_S,]>)H*ZN59\SZ?X-FZL. ZP"-MZ2YY(-^QY;$X%%,*5A8OU="?? WZTM
MG>9Q>5)O)U-Z5S5J)Q=LI9)XO[F\1WK^[6:IJT2J ^^B2#8<)\N-3#Z'443^
M0+[4N+RJ9L%++\%QMA('*W,5S:OV:RVP#V*L:;[X/P (A32-Q @4TNT'KEP=
M$A/,9C8^X[Q<]R)D3:U0&LY)"4A\PE-$-[!:;D02Z^EX/6X\=0#,X>X0-OSJ
M^IE_(P7OU\?W7N3=1?6;[D-5IJK]+Q@J3UD,T9MF8":23ARG868G1J+98DP2
MW,4D]/L[>\3:0O*?YUI0Q",6SRQ$[&'\=^L?GOX#B+:LI1]8/NS_8N2]HIIJ
MHW??*$HO(KT(*KWWCB @((3>.])KZ"4(@B*]%P'ITFOHO;<$!0$A% DUH4E/
M0#!"@.WWWWN<,\[5/A?/[1IS/&.M]?[F.\=\RHHS3DT#.]XG.8IHX>-]*+CD
MJI(XHSB^5P'^.%HDBE8<.Z6U=KT*H,L8C D,:$ZW,!-?O-GL<042]#CQLPDF
MK!B]VWSX3O?>PM@;WZRS*VP>=7@G(:I)?*!=,[ DWVD*Y9.9S&A0#1_32^'"
MLR@XJC,8"^51"]97Y,?L$>7L=0OBO9@\.PJ2#5%[7FE<B+H#M#0;-05B5>*I
M1;\C"JV<.8N>2.]@EW=R=Q_W\^@>F-5WV^]/YR?5"EX/*=(7PUCPT#<Q'YS_
MA,M$4I:Z=]0G/9L[Y<^9"+W.&++G,6*P)WLON8?H5QRUH8@=O74Z7JTRP#P\
M)PHD,[#-G91Y^*5SYJK+N 6@)XKO@8IX@%-&GXX6)\ZZRYK4N(0@&VGK)16X
M8M8R)0W6NFCS:N]-E#<V%Y[12O^)?!@>UU-& \YUC)\'4E>KL#>U_(U__DC!
M,>!96LI_0<"Q%3G&46==O.8ZOD1;-0M)-^55^@O>5#GSU1D[5>_K_[*I'!MD
M$5\P5TA,SB*#Y)C&I-W;L!T5FJNVP^W<CF8%9&\?CQJ61(-=(YQ]:4C%+^IL
MXX1] VNWR@<#XRN2A^VV= H9NG%L#LCA+6 Q(FB&%*9M;#*;<UJQGH]G[2SJ
M8[SRC9!PCQ__[9+_M3#X<DMM2=SZC7=\ S\D[X2 *^3=B]OQ4+S44PU2UVT6
M'__WO!M#G_M.*7$^W>G!EJO8B[)M4EEZ1PVE)\*C; W"/A[C."$F+"LJ.#Y,
MANLSVUR?5B A269[V['/24!2$2-W)SD!($7$UB$I24Q+D<I1PJ!XH8E!D#=9
MLK.*/T=PV!Z5$VPAC?_;S;P_T 7%H*JY*O 9[##^V6TB\GO7Q^2S,!"XER/.
MRF.,85?71&>Q<_Y@#QU]*PA6"E _G:J8E^KH^)-]PD+RV:&(RX#0=>?E@1(S
M"YE9(]V_BG2/BXDCG*<XKR'$=F[?)IEDZ+ZW>5L]^#JC$]E?.I@A\M-\L_ES
M$O_I6PD.Z@W$QS\E0AI*,."WXD-.8.[<M&@]OHM&@Y4-2Z&YJMR9<:> >WC;
M <PGW%=1L2_X#O!@Y"9YX#E.N1M;B%*,>=9G7@/.\*8Y#):4K9C*JARLM[)2
M]^='3!6\@88R 1^S\A_=4[+:3+<-_6F&<,N6? N*HD3\W+_,OI0T:6KX"8$(
M/ .&NC[7_^,00S\G;C/Q):C.R#0K=O@-.@,B+TA'$5L8PK.4Q:A7Q=MBVE8K
MK2K3'ES?6.==IS C@VK@0#$K6$;/M.*V9$8=?SO%3E0[AZ0(/5$7+)%XR"LM
M"TYH9XNMXM#\9.7&7<48L(4>X:'65PUDN8<<;-OX"%)X>CM]!V *8PI]K$W>
MCQZ$=22D1*I*\7VQM3)O5AE>#B8E?4'X==MT>@,-W&"T A]>4MT470"7IZ"W
MN4@9G$ $VV,S*ZREZ;RX<G*1DED]ZIXNK["LZ4JX0#PGNC&^) T_Q9;B4$2V
M*"G#K9-WZ)J&G=4=]_/?,?2RV_;GY<04^*,NM@1C,+=,L/K:$"8;;Y040$@D
MC9>4"55LP>7AO".^D=3^CLA3U/]5OV9H!@^P#.J9/T&U1[G@JYS+!;W^X53X
M$UU+P([JRS''V(YM4,4V8;V18'%@"*$:)B>E+&]][J&37'DS>EN(O*R:Y?(/
MRUM$-LEN)3PR)GA=$G/Z,9S9U=2& S,3+UY,ZIH=-\5Q4A?XI"LK*SB$-BW#
M2ZAAU9>F\)/8FN88OZ_(4],QQ'A*A&LJHB)?!<M!7H6FV(2NT ?:)A=QPQD5
MXVRXX;EY,IG(JJB32(UR57^65S9/EQBG#U8_<+0W<Q&LR\M=2X*-/)JP<%10
M1768#::/@[UC'N>R8_4K3ZPVDNV'/!\CYT?[)AE%Y[X,&$C#6#]Y':W]COG_
MI-/3 \@! !\ ,T!6_R;"%NW%9PO)V?IS!\A9!TL-12QW(DV/#K]8[;-2M*G?
M+BSL7'LGX-P@JY*-6[8,[@U W5ILSIB44J/WB5.0,U&W ,JZAIJ7CFN]NNSI
MW@-F9E:'7^\HGG^(IM9_^? _T>A[@_(P1P\^'NN/=)+1DK_2&E9QJ3+ YUV3
MHF.REOA'09" !;@UW%+407HF/UL_A[^ 8P*^\RF<NQ?$L>#5\^]!K[_\WZ*8
M_PF/U1I]&X]Z)ZO--L;H5 FIG)2 C&4'-Q/9B2U;04/<A)EI,M9W"2OCYV-,
M7RK!E!8HO] CNF"RY.HVX+VB\#[XKR_XA&7D<X0_Y!S\H_2.V]YX>3IN^HCJ
M$. EZ'(^K7B@'^7,;VA_S*\#I(&14'UC=RS2F-)0!7 NT , !$H?QN%P=#W$
M07E.XD9.?TXB60%Q!]!9@.3-&+07*@:'NF]Y*,D8-&!:DBN  5L5'OHO:8Z.
MC@.N+4.9F, @_N-G*>N+B'6)!!+PLY?IJM2N]\M=$VB,7P*(F_\G8/#_T3T,
MP;$QNOCX#R("*D<BUYM>8:9AAY)H,LDXF2 T=X&'J3S@)LV0S)7WH/D:)Y8O
MXP@JYVG,"^/ D .3R>\ 8T4"[<T8FJ78,KI.4]_5D'2EBE<KJNO%%=-UQ.(8
MD-@3F%K0TUKAH1O_  W*K73:U]LF&FR!Y"DIQ"VR3;P3$Z^=GD82/7CD<8YW
MF7Q3<()[)MB/VGAHH57T:"'#K3VN;3O##2<O:"59 N(LJC?9>MFO*/>-D2C@
M+T-^T%36U0;^'M9S\B$YX_=:PY*D*AH@Q[BI_Z6.(.A&K;YFNM#=W<NJQJ!Z
MX:U/E89!EH51F>5?7>@ _CAZ,=1P+)QE!-6\+,C;.N;;H)%32T);X#:7>KG[
MN(CWOS,_P$[-<!>JES!D7[L$G:'2)4J &HUX+>,L?\A35%;6IA]<LE!@.#Y=
MQ>2":BR^+@VPS@L>KT&*%NFC6A0R@T5,* &PY8EH[5BV%C1%(DZ*XU-.^*.>
MECG'!8&GF6,*['WMW3U%!UN^>4'M<]ET^KS?IV,L81^:OD1+TR#SN!+$R:1&
MQ-SR3E+)/JFKOIH+//?G;*RT?ME,Y>3K+0"?%/A(IQ>6H61BD)SBL2@@47QO
M8Y_1+M-T]G>AVW%]2=]\0-U/B+F]I6N19;==+&VKB#))R*S(.0E> >-O?](R
M\NIA>[\C:RW[,55CZ)S/&-+=J *8+?WYQW;M#C<,8J9C"#'QPH 3'M?)%'&J
M0KOVMS"LRU8:6<@SMYWS;"8.*._?( \5H@08O/YLHNO"EH!>K1S]65Z5-T!8
MVH)8/V/(8?_-KQ^=-?O^6,9%YZ7RA0:O]L0[0)L%L''=<D.W!C',^_G82R 7
M$E87F* L.?+^^ $ RU"[%,Z1,SJ 3]* 3=FP[D7#(/B=#C6CH&K(T>5BL+:L
MP+>,GWRKLJ_U/TF:/24JRIK\B0.V94S[EKAW*%**=_5-JEGSZ; 9FT;1N"X>
M< ")RI-CMLU0I-\!TV]5O#&\&U!9:$-.@UO>7G1] /V7@1RMA389[5U(R-S<
M@1%KSS5-T^CSUPV9VKLA"6H/P:S+$K4HMRUW/:A)1;2.@3<5BW<=3,^W@E2\
M*6U,50.1H%_&Z&NH/: J.7"!<68BR+;W(U40XQVV%S.')ST_0Z1'?N]V5P/7
M=A?*KW?<#TLOU+(V-:0SI#0QLF*CLY[3G94WQU0A$?L"$*:0/ENG=QZ@QVYH
M-]-D_AR#26K?,@V!/A#5LZS.)P=&#83,SAR]\^4=9"5FX+HC*6%!>;8Z2]5W
MY1K4F$C0>FBW?=X4_F9S7+:Q%;Z!!X%>!'[[3>%M;(/9_EO(PD9F"&UE"QGO
M-5BP+K0JFM*259R3H_61M*<(U[_>A^(.X!9!@-W=@++:+3C/><D_:W!G81AH
M6X2MO% WG/OQMZ[TN^8DNZ /*$/-?E:T<'6)<40MJD;E82Q4VR3V! W>US3<
M+=T^T*1^%A-9748.7"K_A*2NXHKU:SZJ'^EPB(:AQ#Q-K%6N)=M8Q!2^/=.A
M=YW]3D/_IL9>I/V<^&QDHN&Y=#0I.4^/64)KC5J!/R%\5_L'SG9+6N+O[[70
MD5C--O2V=ZF;1<7-:F=>8&7>.<>DY9I&5<7"J+62O'ZU2[P>-.VH+.$H<(-"
M"=7O/3K L21OS?'G4EPV?T4%V<@Y,B>1O;(;:2ZP;N[TX$DM1[(CER+W;G<J
M*?9J4A-^0EX18<?2BF):2;9!S:T6ZJ!T.[]]/M82%HT*!!#$6&W)G]NX8*R%
M K6%PA,5<<_RVDYYYMIU.RT1P,"W)19\1C_J$9QD/LNDYP2.QO+;V]=938_'
M4 7A5< '6T2&4?O#1E4VY<^F9'Z :W3J.>25 Y]H"5BDG.8O6_S"%O2^J,IR
M2FMHK;?QJ;*@::9NIG%1'K".&EM(YIX=KZ^E]KG8_S%962VOX! UJCHB6MI,
M?*"V_K'4#,NEUHEA20]TJ8B_*#3Q6'GB^]'B,TKT<;.U3 BDH6*S9Z6LM=OP
M[-S&-&0+.,BRYL$BO,C0IDCH5G7-.ZGI$G',=TW_.7_9?T% @N?U!\?4@!R]
MJ*1H7H]/F"<#5?Z;Q[I*F,;X;&]J)N>$"3 Y?T6QL9[%R0A]' E-;4UH_.<7
MHZ^%D[ZDA<=AJ=!XEIA71<08UF2!C-$1%HJ6CLZYMFZ'7$&<VXO2F,X%"6E.
M>X>YN;W [Y3?*RTSG\IU4.3L'RX,[XAC&!H\+&C<=6B,^:%5QQPDL#9A,*%Q
M0EW"F+T=;T -ZD EGX3"@X=;C899460$>:[#79?M,TYJ5VNW/]L8<S5.IC8=
MQ2L;800IW/N9)*#YV:I1<-+#< Q5YT3_=C6WT"4FF<>XT).?+W3O: 6]_@Y/
MK1>S/O@FVX8-$^737EF\$W<':)*7>,2Z_%;+=^N/@;BE2\\MEU]%O S>JGSP
M9@0Y3@W= 4%24)N-ORMW7SPEK1X*:=+XN+VVHI'\8W6E^[$*;YIQC%A;F@=.
M%?,G9H :2P&-H RS]I7(B>ZC*;'%?K0HFD, >^,"UD3QBR):+93EO^W\S+>/
M%NE.:#!RC,*", 2C$31]#Y%"\2R/NC-.1UG$?QS)JY1::;-FRN>%EQ'/>+G$
M^M.[$ X[1\>[EI,F3^3A6"6F=O*=/R=@$]+,:F>-RV*2&H]\FMR3Z96%UB_%
MR^CGDHI:?/TR_?V\KU-CI$6M^$;,B*5)67C-)2D>G1UT]_V2GH6Y&-=,LB9E
MO9U-*+O 619:@31%/#*H-!\E<P\+C;'&*Y+@M-%L,#C6P=JT:\Z+/:1/HI'?
M4Z =)!>N'[SYW-:2AW+UY6N9OY]HIF6]23U42+(?6N']O:\6LGE&3F (#1\-
M,\1:(B,2PVGZT(/QQS1SJF[B-VH2^N_*-[@5M'<*RKW438;2Q5J,)IJN*R*8
MP@+1I]#!A_+Z7#%]QGA -_X,R>B&L21^B3IAW2Q>C21UOUI 5X=#-SL9HFOF
M]9\;.J-5HSK?-)_7T[*L-3C?U+<7 EP&RK5^OC^#UH9>W)R]O=H=,$7?=J:S
M:,B<4*B<3@<E85)D=_L3U1>E#5@SAPE2P,._]Y@_++Y7B&GN)S42>PQ^NNV[
ME)YZ.,.,&@BYZ6Z+QQE?T]W.O16HW.N)B$8<_R;\\OC,K92I.45QF0O-V2\%
M7 BF?MB!]I']^'$I*3TS\Z_)>G?E"GAT1($?';V[S(_31R8'*W69,BCWI!2+
MOQ16!-,MIU^,TY>]4="]^:S <;#.CJ6YEL76FH,<,Q2C%1B;X2>-SYS:HM3=
M0>R%:,*TL6\=:@Q[F5.!Q6W!L7W6%998KBVK]:<))[9$AT$F4G/8<([DI9<+
ME68KH)'MMM='IT_EN67>R%( _C4M8 _=X&L>K.VH[+:(=L/M3 2-O"_:']H3
M%E=1,@=ICR?/W(.%.Z8 94B4K?!@2@#G@7/,'6!T[246.(;@C&0U0^?$!X16
M"P8PQ0A)?"AB8Z>S"&U>ZZ$=?5[S==I_/A71%2HS@L0P*Z9&RRNPB"8.H_;G
M*[3A8V^VU^F$1Y1[34;GZV+&C" Z@KR%YL8:$X)2.9B9./DGN;LRWBS;@2(,
M,0KMLLW3H@5J3)3QT6&#,A6,YJD4NPL^XCMAX:P4G]]P(^LTQ8K8R( D/(95
MTE/7+Y0V!_%5ODRA:FQ.+3\$\+3_\KH@6>:,,3,9/EG4%5*PF3,M\AUN?'*3
MT09\K<!P4,0)# W*A*X++U[$N;@:EU\SZ6!&&>7NOW+5B](_2W)D/K<)0;(F
M&*A<<X!O1PT_05&*L=DY V0];2&*<XN+NW9NE9&0ZQ$80IUL^#"I@/@J<;,Q
M-G.4E2CL7BF[O1A!;/T)HW#7<^#O:SMVYIW!B%2;%W]/IEP=6CQ37PQMB4C4
M&35"Z:TZ/E7)2"\,.YEI8O<L"@(2*N+,< .U.YH"FG+++%Q$#GXZXELI>#.B
M8;U$'T<W^_B_8W,8-+,8W2OI9%$%*P+?3*BH]-?+FZ6)MN65HC+JN P>1P.K
M!YRQC0C6K:!4- ERH&+KG07BG?*9BF ^<DIPS<_[(J<SPY56)3I%^LTKMQU1
MT;IZ)[%,V^G!\8AX5@:%Y]A6Y""L.&% MNAO&S"_W980:_KJ6B&]$JNNOW+Y
M6BB@5\:IH^C C=TQQSC(K6PE(^$+XW^9Q9&%V-:1(M:;@KT?[7]F*P<Q!/'B
M^=JR?(4Z<N\L-;,U]%2J?RY#N1!5;DXK+L)#JI'!0D7MV*.KKQ'1DA8ZB75
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M"1+=%[U)A.6]:WIJZR;UK"1OITRIK6%=D#ERHI9<Z8W'52=I$T-IS8<RZSN
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M*3OK4AS\JRB/@05FOIVRY86*---K$4:UW '<*>)[7&("3BEPPNC.C[\;X^X
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MN*@?DX<M0^F.+O>98V)1M:Z;HZAW>"IP>8<OWU,.SJU>F6@<9QGM+*#(#U.
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M>+**:=./@&N(:B7GM?D"QR,SM\6@RUE=?_] ?Q[B]%&2K;HL&X\?'E %J3
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M^^:C51?(#Z9!EP/LL71IO<MT",VZRU5X NU&PU*47=>:,Z:O.*VFRY%5,(R
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M5Z]M?^?V;FSV^R+N_.2/8^0UYY?P3Y^(>][KGJ73GS0/JQ]7-8X?+5]OP9V
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M,N6OR<8]Q"$PXJ)!/F%B7;!:R1Z(>H]DAR[CT#$_A!KOFSS+ @R $U1=3+;
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M_O6=6O5;#\\;*@^$73!0V1AUX8]X*I+"+[+QC":QK7MM%I70#CU?H%9&=5K
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M!A1MB?6#G"MNQ1-H<(6)A_$F67+P4+4ELDV%;X;_9>#O?*,;.FLSDU TA/I
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M&5QJ^G#N<DDK\L$*CWT2RQ[I9FVR 'PO\MEG[BK%KR)4\TVG7KV+_A#%O1=
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MV=(<719065'Q(4N:98:DG]D.+T$F*I7 2>?3U.9)[&B*P$',O,$' 8^QD)Z
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MA?)O2-VX;[% =]IQVW,CJ85TN"F"I/!8>/1=(D4'F5==82T+A"7U%"&SL.Z
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M JN&J^HLCU71%8Z>R(G,".P(7:B4!#'(E_"C^E^,01R776.F15:@%ZWDVG4
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M]%&"5K2D.CLM;66K[!?&<N6+OEF)[UW=@J>ON-C[7OF2OS=3(\ B/X2Y [;
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M/UX,0Y/BS?/[W#K5&'$V *'5J55QT[L:L-4Q=4A<!AG.$!D++?%#J!,9M,]
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M=A3F-=_#;P)*JHV8MW25I,"GI3 SB%XLD/61U ;CKY,2K9LX+;4?:.7+=9,
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M6"@\"#J8ABIHAY$K>[E%5:%$UE0651N_'C,; C?E[C\Z88&?&Y$\IPY7@+D
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MO-:H)&902\Z"B\Y@K%5T#OAUQ.$/-Q4P"TJDR[W[L1!IF]T#6P? EA&$VNJ
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MZ"?_3OT+.*038QF$AEK(]:<A\Z:S)87?;!LJ4?JCYDMAVP?9.GDWO5U;F2=
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ML$(_K#MS@AOJW7O%5#[]-!3?>X'Q+,!_J61T&#$4PE0?&\9WX7\%P%,(Q:]
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MYI'K++SM%\"-0!T+_TU:_SWEDG34'#"# V8P%ON$^U$GS+%: @&IA%Q@C9C
M38ZPZ@@QA?V.B-:HW0E=NN*DRM' F-PN _$R&4E_,;_N3M12]\?*YI+)],^\
M)M-QB,)TXN7,8>06)/%*/P8(#[V39'86<V[41+?CM;PUZ$A^*8J^^^3C[T*Z
M:.75MM)^E[7\%3UM269AU>8QR._U/^,O!J_^,L$75\%KPA]GKF<;KNY'+B^,
MY&&4HEM6UH@NY^TV Q<KU\X3![)\!OBWQB(D7^DDZ3B3&RQ^:B'?:>[T"]I
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M:S\9)B>JA('PSI]NA3=5$4TQ3BN%FVC*J]#[.KNX?Z?3%JZ;'T_E@_L@+E1
MH9SJ+D9]Y.J!JQ["S$9IB3U%'7FD"^U81#MN8QK/RZJ[+)8F,0.R'PU%5C2<
M&KDJ__BL*KFB\%2IU\"%ZS+DI(R0/5DD=>/9^V=CEML7WBR2/!V=)SXP#,8)
MN >=?KHZ*;H7=KAK:P:IW/NX;#"U@SLJ,TH>#9R=D$+Y%0#M>_.N/PB^H  7
M.Y-TG/5=H]Q[G\X=O]Z3OJ/\F8G[EB9ML=>+_A9RHE:K=:D ^?-$20QBU(UQ
M38)'GU;0KACA*@H%P'2CO"1%0,IG&-J8%?Z^_^1M9A1B0ZWN][PU:W1@9E3H
M9O\?V 3(H-&,;Z?\EZMH'<Y+HF'_V)U7"_EP,]TQ'#!"[0Y"! \C;Z;:-/"U
M,'(J?Q*?--6NTR-<K*<F4G.?4=ES>OCQK"<TN]#[C^KOE_5QPW?O.J](?>+2
M=+;WT649KG5@:P!?G=]0VQ3;S3T39JU]=ZT8G=.$>SX+5%=]?C2\*<*UN*U#
M^..!748A&;9%6T(2!<HE>)3;$MK:[M &BC81L0N[.[?+/N5"<[UJU_3NGT**
MRI[7L".YT4L'15=_EG\2A(EULJO?$?KD9+-*"MS%M/]<(Z9BUL_OLN>&1/N3
M-X8=D47.]R;E+NG:&+_Z3E0P]OREJ L-A5%F^GLOWB+^"C#+*#>3N+W6\^,6
MII+"C]HA/Q.0P$5F=JO6%1!(X&X7SFRC53L[X[%;%=IM;2A3,NCG(GQY'D<%
MS;4>M>'6G!!ZY)#"3\L1MM^!D?U(PQO@H9^VY56@:I<T<X/.B'<M6=W!?<XJ
MT+[:-X09RZ#?ZT>NSHQ$W @?\@L2?F(@,%U(T'[=QZ2<>]7Q$H.)Q'CJGS\F
MPZUI+GU.YF; SW6Z8SRK6;M7OB*DSAW@AL@;O<;+*_0[V+.2Q\OC\;/C_9Z[
M"J]_ 3GOTL>'<=-%##M;5MP7)-.'W9S@>)3E-<?FME#H"JL3[(LE5GGQN)=;
MY5G?H#[ZTAY_TT TOSN'*3,JE@([HG4_)^_J*#O192%"]RX#@2L'EJ$5I_A"
M4LVX6'>JE+'ZM%RM\*/YF6-U>@1BKQS/;R&OATM.#93?ZF!8^.2,= Z*48N[
M:'=!8D=H56O(F]*K9L#CT<9?*JYL43:RKVVH*-!O0\WO[)):W?/^>R1*DRT5
M+&B&&PT(Z?#)UQ1* G&=^2QX8(;8%>X&X6AW<3=31)"[]6X-&3=]@;WG?\?5
MTC J^UW=DN$&TF>N(M\>J3>\-"J8+(CN%HLM,R5PBZED8M#G/_*SM*P<FX9\
MZ> $VR 7+RB3;> T 489%)%_0;Q?>BUJH=AHIWQCJS12:[; Z8O C[O.W45&
M^5\UG(=L"PNCAK<!JYKN1VQ5[.L7".>D!Y34VG>7J'4/]5E5K#%O($IK>[J+
MJ^VW( +)4[C"$&+ZH_1'%QB\]D=E^Y''J.H#]\?<&#R._"N,9_LP_X=GW-LZ
MK5;=I,;YDQ6#E<<G*PI5WM1D(2HANE+GC>WVNI.3HKN5$]D% [4]WWZZ< RK
M+S ZN&%*X4B^'O.HRL9OP9)I]3WI+W,?;0-USI#JY+O"69UU5TFC80?"JQ)>
MBN*ZPI;ULI.V_&G$I$'>T*6\_-UKU+5>D?<CW9[)P1_F<JI;R)LJDY'2F$>B
M3+7=BKF1U6;CQ$,11AE@](W,N:4YEC#Z5?S 2\Y%V!LW'>E\"I1FGB?8.VUI
MUQDGS':6;?5"+?#'&+WS%"E@3,$H](C/F,WU 88IT\8!=E\AICX*X6?9F.M3
MZ)\6VG;[QEZX'(&SPC%5( <@C]+&&:MUST<UZCY*!U*,VWK'X>K#>_XOB\:3
M(;ZP"G[D&?,_%:-:U.8345Y'3^<#*G<U%0[ /Y*??D#C;<1MQ&K5XIUQ&WA8
MG1+9H#-A[^5R*MO 1.@&,IS)SNTZV4N4*1TGVH*2;7.?'XS4GH?]<DF7O8!\
MII YM,Y\<\66[R8/,*LWB8;\SOT2Y-#]6F574U^K*K+;AMFRF@O$[S[0 D8U
M20)V6!77;26:BT*%AT2H/0^<ND4#1Q1Q+URO/*I=N8I\X3KM<7$#\I9ZP9&!
M.IH!LZ32_<W3ER=9 ;-9+/)(9L"QDIO/Q<F])V/KW:I\?_X5&#7!+'<)7F6K
M&YB7T6W?UWU%V%7[<D^[KO? 2[_-E>&X'&J4^Q1VR>DNU^3X@0T#C"OSZ[<(
M#XUL(]_Y?$00GLE,TO;X?A#G@8QX633AT(:[?B](<$3-N8B-X.B>8)52;!O:
M?,9L@7HQ:07F@6(1YS$I[5H;$X, %PF?K>\@MQ0I!#'Z4K=S'[E%#0>LJ'TA
M.MCSW+:C63=Z@6%4Q*9'Q2^VQW1(%FQH\JHF!L[AU;[@36=+@W0WWB;O.6!?
M+D5?.JHXY&[KML/_X,:CMUUMS.YV2UZLDR)SZ5C&G:E57A95TL@U>^0U-TFZ
MB)@,>;))^>/#^#DK.CB&2SVDF_>^$ W-DZ[+01D?*0:3<@*VLG:O9=B\=.P_
M(4Y.: Q=J4L[<;Y:<69MKKV5+BE#]%T>N]5?LKHC*^+0&5;1IA1A=W<QNL8"
M@D^/.5LS;%^O[[@9\YTH:]<P:DZ&6<.<! \C<H89D+#=/I#$\S#QK5$P%(*^
M-LN;^#6'02#:F>9]L;"_7<MC4G@[@4]R*8A$R#6M&S:A*9V!9F?IJGJJT1[0
MZ!O>]?Z)>8U15GY7HW9C^],_J\-[ZOE[97E[?>0"4ZU.! 6>@4O62].$K(Q7
M&?OOT!*[L&1/5823>R%OSB?1T":Q8YCC*5%K)91_[@C!+D7CC_:7BRW%+C,.
MZ;[I[CCI>@LW*W4([ *>C?8V6PJ11%!JR?R74[^/I);3ZJPT!\821=@N/#[(
M&:L;!AYZ^EQP5-VNTU M+4YQO@TF6_7TUJZS>C#/$?&UP.<H^&W.FHG:0X5?
M"Z,H8[CJV?OG>HI[#KG?"WKQR^>B6T[W")D+/=E$\PRIX]G%H\3/4A0^QVLW
MM*WYG/(F#/3\B:W?;)M2>DY49[*D,QJ/,CCXC5MX;VCT7<>AH6'V6,A("7]B
M@&&1S(^^B_PB17 P63C9?3(LRG!D+(D.T(9_^7PLR"'4R<]Q,GP%]A)$FU;5
M'R-?B3G:FD&YMK=O$S_B3"O;J"?Z8,MK(GW[@F=O;'\<63<G>:"6IS0\,,">
MKS[UJ/?HM-^R4U^_<?FE]I&6^2BA_4]?C2Q#;DD=(1VU?N!Q-W1I\2.+'UZ*
MOAE7':E9AJ1UAUT^> WYL7;/,UHU]##9PG/;YJI5G1.U+6VA886"Q1O:++]_
M;IZN4E\_POSFXKGJ)<KS<7+$/G>^3=MRS@,)PM+)=C<2K*%*S;U1IH]SHX5Q
M&ZPRO>JY&:YRQ))DT>PBFT=FN]<9 S8"$^'6?6>M&"M5/A%#F @>/,=!A1G(
M.PHF/LQG+*H W<"]BTJAI[U]PN2O@+VKC9O#_3@]J#D#9UET[MK;P!D6^>CM
MI+,H(W(^R_0"2M==L<J!L6+E0([5!:]+C(56QUN,&R*AZR%@/=KMU Y<>53$
M*[B4SUBE\O:GED/$]#V+M,*3^-T<ZG@S>Y8@;X5A.#%0S]\-*42AK4O%'T%,
MM]N6<724OC>&;NL$9BYP%SK/2635K" &G6Q%__B9:L- K14HKP^3YFSJ(>G,
M215N7TG'U3XJ?$*0!.F\Z+.PLWPU=YY)[<I"81I<(*2_.B5&>=%*NGDPE-94
M.:+P'&PX@\[<)$;+7QY@]DEG.X_-,QGJ8FU[^BI@8\I/S[\_2@;Z'>U(01\S
M)V*,;B2NC3K7Z;A][8[G7<EEW2^M-[&-^/(UM.^CSF[9&/S\UB67Q\C[SE2A
M]EEY3$9?&S;X>)LR?]I[@Y#/)7.,@+[HG6/1?-9.$>%Q[A/Q2KWL!X?E(N3^
M;YO%+2S>]<:+\;X4VUFY\J&E%(1Y1!Z!55V=;1OY;)JOM2D<*3ZP^%&!4<&X
M.-@[+/>9;NLF.JGMJJLM]_PF<61 M"G*EO< UU%+^%S.R"(7722FR!L$#PSN
M#SI/R;<(B)<Y.HT'9%ON\'=PV09U'50PVACAF")\<(0I6B3*FK[G=CTG!LY)
MTIF)W<&,)O3NM5PB%_HT[2V<6T66+G$W<>TF2I>M]9>J.U^S@++^SJME 6[7
MI%N>O9$C/&Z]$)@^< :OO(@!"Z*GA;-M/4#;;Q/+.L0>,</X"D<$$7IP_\DL
MDNEV,"_\!7M6'[.BQ<)0ZJ (T5])<VCYE.8P+D"(%G&[;>18K6C.S)VQ!$(3
M#WLO_UO3D=HN0R45L]],-"3W5L=<8S(V#XU,Y#C3E8VC07CB\D]<!13QSL[E
MV><EBO)V!%J2B]4>%'O]YBOY>]J,WXZ3GXZ#FW8D'_G(!/(FQ[>9@S\W?&JV
M!V51ACK*PA26\IJ2(3=GJURSG2M+LRC@]??J5OG=&*69*5ZF)3",BAPTF,I-
M%<'$E  '^K(\(?Z2F@$Q4YZ]*QW[VWOX(VD>]9>BW6UM= %+J>=YQ<$'\E]8
M0#)9?+ '5$4\]*IS1* ?]5D,;0N:3.*/KMT6WD8(JC,#"JEC^);HCD)J@PB]
MJ;D;*/WE<Q-24*(R3>G$:JK/87&LC+;+9ENI!8W%YD?DMQQ7B&S7VYZWQ[^\
M3 :.9.M6B(8RA<D":N4EI5Y9RC<0B_##-0ZUQ76G_?*$=84?=F!KEROMDWW@
M*3M52#[2[0=I8&2K&?$+Y,J/=BVV)Z__=H-/8*(\??59U$('AC3G\.WSQ*^K
M],7^K.AQ1!K_B[;X@#NM15$U]2>/'JI,PM7>J#-&W+Z;<%M%J7YXZ:<V*W9A
MH'+?+>FO@!DP+"GL>SX6VGPF[L['K+%04Y^\JD_;C^XG \,)5X(/5D[NC$OL
MFLWE.;&>.39PT]PQNA<FOF"45B&_"YNXU3-D739*2!?;'3-!69B'C2FY&4-)
M]/X^N<Y),1CT@-KBB*@77Z$LIN0_6PS>W'?A>EJ GOC&=:*7.94BBI5T: =;
MYO-OQM:+UQ2P]:,Y^\NU662X1+)N$)_%"K<'UALF'FKZQ+&0C_!L,Y2P(XI$
MJ%DB/\Y3&RX?D7CO4F']>3.&\1Q<9Q+DFUNX.=/6J@&R.Y<G!58@G:WR!!+@
M5:A$)?\Y'F5P*5VBMD9 2.I;RC"_E)5?[.D>J>4J48=*HF?2(^E>;7:XZ/\X
M5=(\ZD/-^V01K]JX?3[276%G[RX/F34H]J5*3L\S06T0.%#DA9$(B;_O_G'V
M"??FD@@!N6SO,.JC(DJV!ZNZ9@Q]KUT/*7>-6JI>$E$?]15=B7SL>J@$\?WW
M3@/"VGAR ':B8G#%@(!Q;PSW\C"?*+A')Z3ZBW?MR]\R?S! H0<2_%&+.R@_
MG>7N#Z5\4CC2192"!B40?O[8\>WGF\36X?/%P=E(LL#Q&[H9<.)Y3/Z5T*"Z
MA<%) >:U;>&AJ\]AG/37Q5.#SICHW\<D+"!376V=:E\(4/%CP><3A-'4I*5V
MY=EWEOQ"9-WL/K<8"[&Y!HN:<=&];ET(9I9C=3V'U?+$7D7$)K?@C/DHDY^D
M+T35]W_I*#\QG_S1#>LU(B-NV D+F9#P)>%V;ON"G0VQ)*6O[;DME!OH3Q?>
M6K4QD5),+Q)&(N)2;))?< E(R^9(K0VL/$*G<B$.0C&S%K_GZOTGN(&16I?N
M@G$MI".LK+T0FJW($+=8;-L$WMB%FA,X^";4IX9PR@@(" 3=F.6!TT+BR:PF
MN]30O0+2//!BYA1!-&N<I[M]13<GD!X+,=B#)QAV:Y8J+'M>,2_60,]:>&N5
MWS_)W13<)PV!>*"A6UZ^6=)9DI-_W2#JHR_+H\OS>!!CXX0I%M2U^AJA3/V%
M1% HQJ_ ZLAQZ]#DW]#(=O-V\0QV.HS)]CP\9A(3EE1A/OJ(/??HI.RS6[W2
MJL-*GPOJK#6I?+)9&L_235-(]5=4;H?G#*C-;%WV>M?U.+-]2/(N&O4/'#_W
M#\1-@@-!,2<7$5:Q"_LK8.*GKV(;F-70-F]@W<\985U7>'W#GAOW(N:\''NK
MON"0[QCFTO=N*/-+1QY)DJ+);9)HH2VETJF*7+TX>758U((!'U9M4E(7ZQ8K
M1?5T^=$1,/ N$O/90'D&NGI=V8\XKU@),7Q=*_' Y>9D]JS1RIJB*)8\QF4L
M@#:[\6H7\AA-F1HHIL4V;%68ODSW0#8'=H;GL$KR2<O!_5\2_+^SI<4R,Q<O
M-[1S&L%)N:O;@B9-^_G:9H\>C_ \-H"L1W=&MA+]%Y.!BW<,63<5%SZ-J+J[
M/;^<U3\AWF7XH%W?N>*!;GA;_,#/R1<.=TI//;KS0&GI0T8':#>VC^KU#\A6
MW)S\ HP/VUYV)R Z\96OX'%JVWK7XW>Q@>WQN+9'^^MVRUYU%3I__:W_])M>
MZ5VPU^$QXU= O.- ]1ESX(>'KY07SC*OCO9-1SVQODH>=7XX&IJ1^L@J^IKS
M$&K9#@JKKO ,JUZ\[><]\6'(TJ$?""]%%;6_./"7;1]"+15'';H:WQ867*T:
M:EOS&BL^4U170:M9NPT$AC[+2:(+[\03]UV=(Z-4)7PL R@W5[N"K^-C0YXE
M74\2^:N!2;:1HK"7$R0RV]*F4M]X< "Z)EGR;$0X^Q.P=F&[3H7,QJESDDF)
M90&FY\EEJ@F.?1O@RCJ'6=(NJF?,I5"F4@2&[=I)*9&<O5]XH>:6RZ/\R$!V
MED""U8)[Y4^A@,7E8B#BPN]'1"*!Q<:?X2/9^G]/MWXOZ1@NB#8(3V2EY_-X
M%SMW+K>-Q^P7,#O1BO_#W)M');VW^]\@J:5ID[I3LU'=BMF@HFEJ6#GAC(**
M0SENAL#,G%"+:E<[3$W-(4Q#!640AP1GJEV9F5$J@VT<VFE98F;.F=5^P'W?
MYSZ_L\[O7F<]ZZQG/7]@\$U AN_K\[ZNSW6]+YUCSFZ!TGP*(!-OY-$LS2V2
M4M<&^5NO!#PWM5Y!Y$>0;PMOF?9X4YWU?_M2PV80)4/B._$[4(#QVC>3P0G'
MPHQ$]GK=K5?KM( %S01,<L#=?5+V'CQU7<='O1/<\[S@?D6/>%C=P3(T"#<5
MOK"MZ)@!;A-/@R_C/&%RMZ-!<-F7?:DU.,ZQ.DA1:DV"Y.[/8IN#RPQ]:^E<
MO'UO75M]9,?0,,YEY#QQ35BT =;T@*6;\!L/CJOM$+JM^U(UA6(UAS$%-@88
MTON3W->VV!IA@/I!)BC2]G+H%;^@>$'@R1(Z@/#("/UPV&RSQ/NVA->^W00$
M@PS[O,+L7.'AHYY2U6IN#A<D=R_29QT82EO'V.H:[MNVBS&[)J#:R!W86Q%L
M#XW#W<P6;0GX5B1S#<0^'@'<_ A>XRB./,1*))-,]T+ OR,[* 415+691_XU
M$/O3HDD-0,!&H03<_+9_^2Q0P56[8E>/IH++\9D&;FR7U]B,@]GJ7; P[LUW
M5!#> </U#?J:Z"K8-TTL 7PUY<(!V&MM0FDE55E5JYVYFJ'TT0]0]W^B 0A&
MH;!GJ_]5%RFG)Q:6[3,)U2TJG519^<(F_DU20,(2?]+8>X&3-G(W>CK@6K3&
MT5Z1^<'-?W=Q_Q>\J3FM.FJJ_-U5XJZS6GFB".GE3_T?6<G_3?OKOY.DO-5]
MY> ;JYO,>Q7#I?%8>C.VB4L^*O]BKS\CC^$/RK7NO^^SI^;1HR05Y]!*:@T&
M+FQ_5J^2YSG_(+VZ&>2[1^E5]1#C2>BVX?X?G_L'JR%&#[^)ZJ\' (G&4AYR
M=A*[4-WXQBOZM6" 4F\6%I[>1:D8D ?NGXR-<B" /.9&3-?^W36T@EOJ\^,U
MZTPO$-Q_H%ZTM3U)I;6T2.TD1E.?+ 4 5T9XXGAKSV!-OL#K?.H Y5%;ZU 7
M!1"\SY' ;7CY$O428R%ZFT>RWM.RQ#[HU=8P=LX9+;WXA&3UQNL+>T?4D!W\
MCZY^[A6Q'P7P_A-WACL3%'@C-8U=<[_%V5]PQHXWFJZ )\NG?CON-TEM)D&W
MMBBH3:,,EW/_^?4T$?#Y"3/W7;1&(<5%5;MN>UEL/OTLROMRNRK>2B4LZY)+
M);G=Z/?F<%[?7X#HU/CYVH307Y_H:T.C9'J3X-RVUG:.W_O\*U933@9O=_KO
M/=M<\'NG4TS6D>>IP/%VSN:DS&T2[Y** E^8Y.&CQ<1YJF;M0/B*W882;7QZ
M%(_T^NM :;C,!;)3[RD^XOEM""#M7O[HV)Z<.PMU3KWI3N/*A]GC?%! 1H^
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M@%F)Q*B?*>76]7( BJ:M\P4G0T^D]:H(QKE)WV7C"^81)4<@KI ^PD)^:J$
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M1<%RZ'KB-=FCLPQ4S5WC*HA#NPCOM#>+R1VO$BM^QU.I &-",[^F<X4QX2X
MJ53IE.>@HB# D^;N;25>XR0C9/4OY,NH.^WTM;H6O,.)Q]J*DB6DXUGN;IIR
MSOW7=NYY.,?<#"!-M$5C3UJ37<K_=M$R?1!92%;%7=;R\S_-NT@VH?E^/2/\
MB>[&9P"1=+F492@Y3[AJE3!-@$B:0ME>])6_F'_O7^-JY.[7#=6U*9V\([+3
M^[#_\, 1QEFKXFW#2\3N$C[N1'+-K?9>TM4O3-'KT6KD8TTYKT4>4CK*4_6\
MMOG/,_#^G_SF%0,(%6D, /'O;HLGU4(]DKYB())I]FJZ8K.;G->, 9[;_Z\+
M048PHF=A(H#LB@M3/< " C@J\$$R@K-LW:GJ^LPL%QF&P 4(N%F:6.<G6(3\
MO"UQJ/TDSLJ(FBTS8^=MQ#G*AK2M@._;"DMNSX1.24JZ1_G&LX^M4VI"./OC
M[7V-3V_&O$M#>&1:' Z,CZ>O(!$C)==GD.Z_OP[)I;R?CK0?2&-@WOY"'H_[
MZ&/OJZJ?K%O3790?9OXN]SWY20LOHLP$=!";(LTMW\/;J8P&P48\([G4$NW+
MVXK9?D/X:=B?V%"?5A_(<^Q? $>9,&_RS$)-3^-X;/$V0CDV.$?;Y3"\QHS9
MPI7'G2?JTWR50R!F@0;W4 '-9M(\Q"XT2.]+#(O/RK'@A)L:LP>92*KFE<Z+
M#/9/FS5XI=@OJ+)?GO6J6#/*8G&4%N&W)Q-AS@,""L>@)7;"-SCW%_K);#.W
MP>+*B1#KPCT&)AV-@[IC/,!IZ9,I6J!^!E;HAKLOQGMLZ8RJ+1IW%_(!"4EV
M'CJJVO<U\H_M@'TX^WW]R70>=@XV.R9_X7=P/VGHY5+&QCN22NJ(4_;.Z#-#
M@;LI:9 N[WF@*"4PX7G!)\?-^A%',\RZ._;0F]X>JHOLBS@PF#WDJWHLE;DV
M8E+:,?UX9*<T9)QS?B/696M(F7ALY&=),#VBC62GGA'UHF5E>%+8L>5@WO&Z
M._.'GQ1^2!CA3[^1%LU^ 'W8H?:^&S9E/CYH<&:[;@Z^+<.L/"W'W L0**E]
M>"D_/&[4'.&?#.G]DH_8Q$X7C]T#SP"0YRFD+0$28.PR6\_KN&5BK??*8WV:
M'-F:#2URFAXV:ADA]M^=KO%P@%K;<M"$2U$40'33A7:$N]6W]^2!S6;P-RC2
M 7V?+NQ%CZ-\-@V-:$>DXIT!"6>.(BL>J0U17DK9D#L.)DK7SU@LL6^,6$11
M?.YNDE:F!*-!<(.@*D=L7_. VMAXK5^F.82@BP;U[?UVW,41.]@X\[-/64>%
MV7CX0GD<VV*, E@\?&33_"KUH6/C=3H\R1_Q<TC!G=_D]Z:1%@<=3EL[8O]H
M%FLW"%(DI:/[B],71)@?.X=S*,7;;VGTIB?XQVF$9F77;-U :<83OCU/\%66
M9":Z1"RR?6O_!)\P)EFB]"Z\@=1$,*2#TIKU";IT!(0FX;YLU*:NC7C*_OPL
M4%OIH;,;RQF [CH;R ]K[CA\%9(C\%#?B ;5\#K^3 CL' !1QCD$M=%:SDL0
M!2 -N5[&B[3E3ZH=OA2XJV2$9 V'W3I!C^V"!+DSE&:;,-@VMT/,XS<!ES'6
M0H9<CWI<E\.[OAJO)4V2J9!NP[<<@_NNE^-BG=J)-[2*BP\I+J:B$O1.O,M#
M.O8:JV<7]EJ[B.-G0UR[1^%5^^MH%DG=KZT$MNHQN!I[ZSTL::+9]V^B '+B
M^DNXHIN(=;E^,-&PJ.8@QJG3Z#!^UZX'?6VWVK)$ZQ7VYS9^;:0=\AL"$6'5
M!=TR49\!7&$F9V =1 0K8 2*AB);=LHQ^&[2108S >RQ@D_1!Z%KN>UHD!97
M3B%CV<4NCCD$=:>)I-M4VCSA,S@%8T\%D)Q1Q/XI.H)Y4DNF+1?AQJ/]>#H=
M9 6X^8ZV1XL-[>7^YR&P_]TE&Y97F4>RB%OE.Z0W/+GVO.\'S ';]O\HCK9,
M+@=NF/%GWN_TYORVC<]",(IX,&ZQY@\PRF>43MM7.=%J)2-(5<"*PCY%*<QJ
MFL,3FW&0 >3*:7ZQ6*;@L)-AII2&RDH+R/Q7POE_838>0O&$ZM[RZ*-Z_TB5
ML&C:5YEQ;@&+RBXHVC#"\8!=4>&UO "+D7+@HTV5_T>F"#'&SM9D0(:3D3WE
MB@MU+:6,[?7R4#63JBHBB,8)X(X<Z&8S\6]O1QN_O:1496,!]T+(;$=;FB4B
MM8JZ-OHZ)"!/9)W"#IFP40-TMS2H\F*&,7^^)T]$^V)O]UYA[QR-XW+^&&T=
MG-*W7<;U[]O[**FFI]3*.H6ZP?1>G\\1\Y/AZ'<)LP.U(VCYO=[S-'ZJZX$_
MF,TL/52;4O,'YUE9P0?BE9RLU^8)S6W!:V8"5,%_H'">2.ZGO6KOR8+69K,R
M\*DUYF<S,!?Q"\A3G(T'A\"D>_7+!3^_<@HO,"\6H+NV[B8=W-YEP*)WWNGI
M;PML5F%[_=**!EWKX!W.T?8Z"1XVJVD7SDD;2WRDPR9*!1V)]KFEO"3](UA*
MR)$B.N#,DAF/V?1J"+RPT("T1[A5@A?V-A($3JB,M[;^?L'-VI%O[B>[:?KX
M-BN_U%:FW[#0-'-9=L)Z0/0[ :<PBV;<>#]94T0DP>RHX"&#D6BLH4O=8#%P
MZIAE?)#$[E#J58/)NR+J9MM*=^&%F_$C)(C]P0J\6M+ Z:813]7K\;YHY*Z
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M,^K=DPZD,"2+;XHW?XP]Q+[L(KUAJ=$RSY#J]4<SPDQ %F[8CAO(2E??CK/
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M/N]0-M@:"P@3R:YAG:>@ZGX\CR9*#W23_X?!*;F&5O?V]Y*OF05>#IA,N#E
MZZM71>$_9R#_#^:FNZ%(.G^///RG8?%_4T0(%C)O^J[AOJLRAU60]AZ3<D_*
MP+^JHZPG^ZD:^DD3@;[B0S_10[,O=B.OE&/0ZK]Q%R;<_F$K_M]=JIM*_ -.
MF0"K*5'F7L?,E6*0J.N<X!A&4Z][6&$QLL9"J(LVU9993_C?%7ERU]>(MVQ!
M!H-U=4AF;F*X.UC$1ABBZG=A,F3&-X6E8%74VDTT1]X6&)JP .(!;*L<>>I>
MTYY)#%T&<-8=$7T#[FX4D'<,NMGMP3C+:VM\?U&"7YDE5#<9N:L=&?:$8CO:
ME@S%TC[+H1LK7)X(H#6\IR?ZAV1UD>7:;)ZJF?SQW&NZ6],@[J0T!X8+R8$!
M!+/,ZRT<U:L<1)X=H.H[EGNE!L;'-JZGH%52(YAZ0YOZRSCP',JMV#!!64)G
MU'!06B#",()%:QJE:7IQ7V-]/GZZ'0@[]2BIVIPD?P*DQV956'D\UA4[%2O\
M8H^,D91.0;=%2]Z7F9YZXWARM'F?E?"E5A,1,Z>Z0Y'ZKQC,;VI;,;-X=HBE
MIU-X+MR,UR!,8HP6:]7,E[Y:QE7USQ>$QGMS&]7)@UQH"W4=YR,2HJJM_1?@
MTQCD_',U7B[;HU6O],'H-Z<41 AEMFYS^)9VRCPG59U09SFCS#Y(, 6^;^/2
M;[%+6D+SPUR86$0)^?V^0-PVT:OU$SH4/MA=/]]/V8I4@*0'+07$<X)@]5L^
MOF'J]1(1-R/@*MOZ3EM27DHK<>G(DLCRDR90WU?(K,>(JARKU^ K#[)B8IAC
M+3'3GK.,V:=,:(AB1[!5D^9*[(S9?<,-R="L, @QD T1GQPAMRRTQ-!7HC3G
M0S6E#E%)CEBQ\%/'^+:!.R'AE@?&VS=H-KKO[E6M2DGJ>ADSRH][*%V+OXH_
M7;:N8<Z^@[P4IX:)ZO$I)%ES#3;Y!;ZKK94(HKJT!O7]]#3!8P=0) .N265R
M?SG&%,'ZZ-7%.RY:9 QRE#?=1]69=OK\3&1:GL;L5A,>0=&M"JS>S@5$"P[H
M&A:H'W' /-=PD6N>8-,GW@6(8HZ5.U2GF4 ?I%R(9O9] *:S3E\IHP5T^"J?
MWZ\E><KVK"C/12NU/W,^MGA1P\,P,?B-%3#V<.4D<JQMJ88.YUDTH-1<VD)7
M1#T)T\'J^V$%L9T@:_C[;-[.UJ4:1.L>O@,A"W"*\Y(/:PZSK7%N6V+J3-(!
M>,[3+A1Q" D>#F#'"RD J4=V@86 \B1[M,8U?MJ9)-H,__05H=VR==)C\0)4
M!U6>6+7\8#271E6Y*SK%VS?-L<Y3:C2WQ ?M@>B;(Q[\=MW_3 ;8!17[# IL
M2_ >]AQT?\E?LT6EF@.MDJ.%0A$-BZZ+"$H'JS91$N"^H."4JJEJWNY>4 %F
M/E-:VD32$UW K* 'H6M5,$E"2>'%Y*UL;Y 6UQ=Q42X2U_W=^N*Q%V52C:]N
MT6#J9''QY0 "G38(!PM;UC7=9GL/SO;YG]Y65=I6[(#!;%2EX.U*FR[>Z*0K
M2L&)ZV&F27U--]8Y[Y/"%+GBX875LFLX@5JB\%6W\:^_7)&?:+Y3,:CZE0+'
MO\MQO/.?&7@YDA4K$ULW\%]I<1N&#0II^+ZN_3M.[\]97.3<M-Z3DFD]KG*L
M;;4K+(JY)[MXRR-)C3F432[ DLX-BRZ8#,/T:*HLM7,C8*,;_AW/ $@&I4S0
MEH_WU4 58)3\65"3P;;\1%L4:4L<3_\<]ZLO%R"X68[UN@^S_JZP/\2ZT*CK
M"IAB-1'[;_G]/Y'>J_,NE?[E@/3?5I:<(3N'+^SNA]HB:2<**?P))]TJ93:Q
MKWDJ./X?6YZ'B&+>!S#- 3N?P5Q_>JO\777_1Z'Y_\W(6HF_&GZQ/: ;><?%
M$5>UM^RW H9?.8$MPAM+ 37=?A:()["LRG$2F)NX/E<\GETN)^'SO"/8FMX%
MC@VY',UG/7B>@J4U(#MRQ;:5U$M@9]9=S0[DKPUB=QV2J1N86W!&?L0<X)_'
M[D9&HS@_:P'7;:4--^4R2YBAJMQB5G]W6Z$+:Q82M.GI&:^CCS@.E%MP4%):
M -[ RQG@G](F#B[GN(2#U^V9A&[-/Q90E:G=O!?B,KH#"WAZZI)W5IO_^-7Q
M*IJKPF#ZLBSRBOPL!&J!D)4YB0$YD/(XITA(;2#=G]*5C/U#O8"&=J)JQGKM
MCY^ _S%QI&.%=Z^I/ ?6BHFVT32!!O6='6Y/J:T:$8$UP=EWMEY7&T#JHX$D
M/!,Y1@!WY"&2;XB&-(P[7A+9\;MRL:Q6]J9:&31"IN-XILSLNH3K-7@/M6#-
M7<\WVX 0'C,=K=F@/#"?57(/-?<=_NJ)H#.M^1KW3D%+'7A&I:3)991TR';/
M8>;DNGG.NE-/\^D.^+8 (-0Y6V11P-%I9D0W.Q:<A,^MK7P)V5OXW@&L0Q(!
M,BIR+&Z]I=C?-:W?^S/$@A,8#H[)I^\T#.HT.^8U1ZI>+F<]N#PE4VUFKUSR
ME9D>L)!NTXOX[1.[WT2P=^.UK0&D276+YX?JCG\N+ X6DA_UG;U_L(B\$*>*
MMHU>QN;5;\_\,VQ_7%%G6LY5\_26(O+<7P#5"4=4=4]X)?W1N\>'JE0JW/:@
M+N)JB<+8?*Q8):&E5^6B>UN-&3)] ]+^HZ\3+EDBC\[L95%>$I)AKNRVP#L/
MR]P[C ;F);->M#+U8!%8P-68/<<Z@Q'55NF^*L?[QB!!3$YJN0">9\!G*%5]
M]"^4J];LN$*FE[44( YY5G;X]]"Q</RT3X[O$E6SE&#CWZQ2LS51\[;X5=R%
M::B>8U 4#._$B&S;SL,0M,1 E >>S]JB<0(#"CA50;M;]<R:%_2'6Q2S7CMS
MDWN'2*!]O(\"!3_#.I>,4&>SC()T)-A2XYKO8G W&= 7_#4!SNGBQRQS[Z4N
ML$"A8?&2.XMUQ*Z0'&)*RQC'35\]44C))5@&3<I)?(O@\ $4Y"'8]_6E_/]S
M?UFBJK<S.;Y[1=,6)".4M>A<C&VT%N Z5\"S?N.%7=O2B<J/XZE[4U6$8.2$
M'\]*R0\F1VCO@RBXN3UG9S@&N-M_L1\L9 "MR2@3*BB.I_5NP@E%]52HX22R
MI\JJ39LWJH2T4%T'<Z[FN/7>7*#1NUG.ZDW9IA:82<\UB.K+WTSH*.66=Y68
M<HP8<,4/%D(FC$$)YEH"40G#X)I)%:$R4:G^JZE"  =E0+*,92Y4I%PMRID-
MJE?DHEOD %)^W#U?'=V?,.6LU-)J%=TO%[ZA%)@)=9^6[Y,2:.>0_*E0Q-XU
M-R4T.G;-8\;X-#P@(9F:#Y[C)Q"+B!,*YBHLO9/F^#%'%CAFKSMPD'L+06U9
M@SZHZ]]H0E0&=WTCG/-+1JLKL5%#=CLA0+E!U^J>1X!D;H_XRQB2"3+KQA[3
MU:[YK%9GN!/>HE7@Y2E?-9KRBM5GOXJ\G=U]F]# FB>7L;@,&0Q0SX'O S.P
M!2C2WCY/9'7O:D&T"3 3SK':O_O._[Q;!^?/Y$#7_3-7(M?/\/H-%27Y+EX'
M#)QMC*]3Y%'#$,4"#12]8\RB_:%;S,T/IOE_ %2#*'AKTKZC\I!4+HZ##]K
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M%BA3;L"0_)VE ?]3H,"&;D#E$D4X?U?D#?6FW,(J!"UQE 1V/]HD#0:;OV*
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M4[.5[80[TP.<IFD],O'(JYLCF)3+(GTP=Z6R;U'F4:!#P]WN8;+J*--X$.$
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MUZ\MX0H_\\(VV6,^<#(P1BQJ%LQ7$N"S;W,:5%?TIPAT\UZ?"GE#\#7QFA#
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M0V( 0JYE=!2KC$,9/YJ,E233JUD9Y@E9Q!LO^+DR8_J10UK7*$</R#EQ4-I
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M9M?BS*J=#]>H?.-:[GGZ+<*M-JK=E]3E?%:LBC@"_<%ZP;6MS]?P4*-C)=P
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M]_R5$DG/K1K%VKIVJCA/B>X]E([(2OG<&\K@*[C;RR!)2OEU)'!X]SQ]J*(
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M1(\:YCJL:=O>6+]N*/;\T-JEK)Y3H7?6\C>=VR>H7"OUS=DHL!'-JUQ@;'/
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M33]<E_51?<5&'P>^VA"Y_&75P+."%=9I>SJ>->QAMNM:UM7F2!P(,IV 5?V
M'H)A[ZL(>%:20#%>J'ET['4YNW1=\L94D2U8P>P[B9,OO!09MH9R=_ 9V^BW
M(E;)[A<4*]\!;HCXICH?+'KP(=DO212Y]67(T3T/1+;[LGBM)?'G[=U3MTY%
M*9-J+ZG_N >H8VM&B-*'RL25I]!NG5C[SC2BM'<Z>7G2>Y%MP@C9M%&G'#JB
MR4E>]> ]=VQZ:#'ZQ$-E<&/\Q)E74W#5CM48"/6K)F]DW8EE;9>1CS9,=N?V
ME1DJ)_)>3:E+?_G88WI#[S?4F38:/;*?'M"$0M1Y-A\,GXJ:HISW]!LZTHNU
M?TKWEU71_>5EKZ9Z7T':X(INR%\[&K.1BGJZX:/F*EHW,E!D".J[=J0W2.?*
M0;=J<FC^T/W VJ,U5TFYJ9G:JD3738^X/'$"D[<Y@?<M]RFR>R>[LSK&IE]#
M.@K00ASA-,1E-W:_%[*?#\BPM&G! /OA[+Z&[\>"+N70F=<?^D\X;*-L]2YO
M9GJ@!L;O%%[N'^<W9&L>S?E#M^\B^U2NTGD8&]I<=$!CZ>RVHME\H-9\_BY)
MQV(;,/37$7)2Z\(Q\JP/*8I\>6#R&^.N/=VY#]D/V+]=&L/:7Z,[3L3C-P]<
ML_]%OJ0%#5#EOZ:,]UVZ*O[MSGWM$8?O^D6KW=XFH9?M;[!7G\)[Y+L'ZD,\
M\EUM$V[O[M+)&.-]X]*1.">!C61?S=$_4&_Q9\WC4+]#='I(N58JE/4HQ6\P
MF[*)UF6F[+7/9-^J;SUGW5C49+,SP3S\932W]-ML<@=]-KV^S4$T/W#)7-K+
MPQPYTM:'L=R_7,&<7\;PU!5$%B+$)6Z0#5D0>8;IIA9U!FL7+U^:SJL^MD4?
M&H T@]UN<B!H_4<5+_[99H3&5 4 WJP<Y-S;7XID7+WG.DZPA1>RC&Z["'JQ
MT8G(CR[F$'<.0.R$ )"S$CYYULF9M3ACV%6M5?/1Q>8D8Y*K)T9@H\]* SLC
M75NH=O.>TO$E_KI $&#R?!CAG6VP]X*,:,TJ+8(V&G7'6K7.\%JG;XY0;R!^
M.-1"-5K4JA'#'G/0WNP<44N.F"'KER$0CAJ5'[39%T\U0@N(!I[.!2&#5$F/
M,7Q[M?^^'/B76W;%L& H\)))($4$JZG:<CCR/CHA@T_2*[U+?D8R/JHA/72@
MUKN$IB$VM8%IWF5IBY?QY<[#> TP[(KH\@"\:W8:2 SD+1G"L9N^U9,'F2=&
M5IX%ER<ER'*J4?DF@I^<QN"^.RIN^L9 ,T3(S\6[[[OK6'SRR:X+"]^40JB<
M[$0?>M$H5H''=<?FX1@;=2(\/^U9\X>5[;PHZ)CI W^\NY_85I4CJ6=LR"+C
M(?K==C"/L4(GZ>!]!AKB&FBMVGB\CZ[DYK/M^'8Z"]IL<874@-2Y-/-9;<;:
MQZC/ 'W/9.9XG5QV8Y)6]?B(=NF/G3D_?"2UWLIQYS'6Z(JF5GX&TH\^>=5W
M__>V&-;#19(]4[Z5):BL7+G)DZZ3#W6UO$8Y=7F9/#J_6W?L[$GYI""(>E"E
M*&W7\?-OZXIV[-$__EUU97F5,:NWL7Y2<F:/@6B* Y_+PQ0#6KZB4NNFFZ)\
M&]V=/R!MVQ>U5"[J&Q#_NJOZ=O@[^O#MT!>:)RO)[\045NT'RI+; ;=^-E\4
M!KO?A]6/$6W=/Z R ^LROS]4T\E9&1G]YYI.22P\"+#1DI>]+Z<H4C@)#"<Q
MU6F1J]Z-T:IIF7'!.2 2I?<JCD;32*P3I;5J7(^M^]Y!'D7PX= O7MB?]1%*
MG/9K.4!J.AN9V-7ZIN_Z)2UM:7^D^S?$F%?RA&$P,W%#U [&F$[4'S.;U+;
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M=WH\-(1U3/X,F%V9VLA;]_VJ3VU909-[<_MKIC ;MZJ8&UY]LLZ=W(C;_N<
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M#!X>$1L7GY"8E)SR-"L[)S?OV?/\%Z5EY17HEY55]0V-3<TMK6WMO3A\7__
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MI[;R%S<.[<]S[-S(P%"%<[=?WSO>F?E'7:>#KF[^G9K^'3172K:+<>Z_K1(
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M;PS)I;4U$D?>0LDEZM8I6G^SCK?E]$H,R+&)>5D:*=O/VZ)L=M]Z7])SN_)
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MXN,FFF@TKK8A0N2+J,EI#)V39HV"O4P=%G:NT5XR]C_K<V-417VDGRMS7F
MORE*%00XR..]XIJ3W2)4F7H@DW+5CH)*VZ2>GPIUNR",%Q<BMSPJ':]13-],
M;1(QDUNW=MYPW&@T98[4K)7:\I0*A#M5H1L0J5]V"ZGDW>B1@CP4JB#WR]PB
M)CH@+%"S<:-B>A[]86!F@R_I=*=_B4M_WY/L"P_OE/(<%^4T016($I]#DU$G
MZ2 ?A@ CY($H<FS?.)RK'\E'A;V@@WHT=%DIZ@QYZ T@#CNM.W9V49J37[@9
MU !N:A-^2BBS_)]F 7AQS1CY37[D'<<YIUDCW1LOHQ^1T1OKQ)I(0G]YS2=
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M"O,8'A?<RLLQ$WM/,7^T-VO@:KY1<Z/AW;%KZQ7JHTNAW:FP01T62+ 6*LB
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M12^]9X&V2C6J)S?YNM@8L^.UC)8LZ<IBGJSC9"*_H)=L%AFV8&J<-^S7 %M
M_E'. I$K_['OR_TZ"RI]\3?:+LJ>UJXR"R-Q?4)_3QUD<IBS0/V6+- QNQ@6
M"!( HRH',I73=QZ>8Z)TF#P8%DB9[W\?]?_-H^9$*3)@\*=1TLGPULG7GW8.
MP%:X&88*MJ?X;CZTJZ(APCDAY:%6;=NY^=X1H."^W5U;:"1G>I2!=T,]A@R.
MX4>6[\_;:<^@3I/UY29P:J4^'=JM"RXM5B/&SW=+D8G/ZRE/,.UL/_3O6H</
M!9.F88+IQ3Z/1X+"9*!=$@XH#Y>6^A-U4B&J,-@4LS5F^,+'06[ESR%6]\L2
MRTS3Y*WR&JKLRL2L*_CJ/@#Q]8)J95F>;0HF?2\\)?D1PH]?%4#&4U$M>)79
M2/];#;^AMW,HMQ/Z]6R^(SC<6F2/KAFN"55:8:UPI@1>=,\$T,8"7=LDHQEG
MFQ',2\8,-5@R9CN J<@"]20;L4"4G#V-?Q;*/P?;7H=A.*+, I6LL6NJ!RJR
MQ0)5.P_1=@A>NTQ#=F1*[#[ZXTP:A+!:O<,(I2/^6X?<@J413C(/,3^R0%R=
MMVFME-8T340\AIMQO&RH!EG0CU>8=AJ$-[:F@)473HYX$B:Q97-^Y2N/SKOX
M2J1^R7":G1O63(IE@9Z&]2.V73U9(,"X9P&Q8Q86!6V%M6Z!]W6D%">8GIU!
MRRR0K3V60B#^SK,'IFB2O?MV9?5KBW_L1 H:CM4&X,S=':<Z74GS,+/QYCDQ
MIXAA0TM"^]LDXLC(])$PK[:WF;HE1JH?5:BA[*['5+! MU-#=U/2EX1D3M"*
MBA-#R(Z=XN6,4,+4MC,Z-CP]D:S=(/\Z_'5<0%US0?)<?'-,G_W9_-O'.;;C
M];D_!XA^P\YM[N8 !!:(X] !!J\1-043"D9+,S]BJ";@V';951AO%(_+%P00
M06EE",D.YH4:FP,A@93*3&^V]Z*6]A?+8<S3KU*E7Y?:TM2SY*>&/V6A'E:,
MPH18H*7X%LQ1]DVRV]&#ER%\<42=IS"?]'BWT[B#!J@2(.$GIP=[VGFQML2-
M<1-0F&[XHP$9"@?@&KO2V(R6W?.DST=.Y-7?A=:[OG.LDT!B-DZ<'Z'EJ-PL
MDM)S") LDY)V=,X3YS1.J(KP;28V>\^DWM"WRFLNL]QZ2W*^]%XETG5BR4VR
M)T+UJO)4*@]:U,8A_SSP!N>FF.BG:UT5O R!-6!%A=^[*;TWHQ]M!KIHQC>;
M<80)YB&_F5W1W4]NGQ=GD35_=C1V-;4G>N$ZFMJCPTZUX=KBQKW53X<F>1?=
M37WA(.C.%,'TC^[KH 79)6A4P@+1/C"#62"/12(?&<L0J"#-]*"3S\-I?+ML
MOHK68/A3,7&=84N;_-T*;'N9AGXS$$/1-_,W%7XN^V6U& 9(E^(HER-]-#/7
MBD]$B\MG3#HO<!/6+I)T$IE<J% @A 1+1G-"/%XQK@-^E+HS<Z[4O%2(8GU]
MW2N_<-?QGVD1SAUAQQQE;WUR)5J\67"8']0J^GK2U5#5Y)M9[\A9*U^IL$)3
M)7HC4ETXV<],![QSQRZ 6-.U%[Z(WF!$LU$O &E9SP(1_W]9ZOQK<P:-8U?;
MOU1/]K]4&.(!^S7AERS0J&0Z@ZN !4HJ_0?6PO_7)=QV0'C& HV])4$QO[0H
MZ1K[U5WLY)OI15";F>KHL0Z C:=<:FS;F&8C"M4%?F-[]@,3H"<O+\W-Y9Q'
M]QB16:"3L\,>92J,\BUN2;X+9O2GA\,RG,\;A=Z\$ [N^/>@7>XF1=.ZWA[R
M]KM^CI*Z4T8I/.$<3OYH9O;MQ%[J,,3HN%9P]:<JBV:-88O7"MD3Z?Q?)\LD
MLB%Z2S^F8ZS*E(&1\P.6J==G!VS//:\_6Q/?-Z#F.M8W7G.EQ$++QR8FVVMK
MIA<&<F)<HO:%GT&8U?KFY>7I#3[=6<N9>UBW-O/3HPN?82)_Y@NJQL%$027X
MJES&X,N91O2_&\5(D<,QU<O/5=413^)%XODXKXFA#,2FZ]1-;:9*"K\?MZG2
MJ:VVJ5*:K-%1SE%4^F"%5GI!?JA*.3?@V99[^DX0P#"Z8:?<F7UKU:Y&W4>+
MZWZ<WLW42:7QLF-6I1;GRTQ/5APS0LX+KV/^A1C_*6M<T:O?;C. 0(8XC&ES
M/]*N AFYR2#4P%2 _\+.QOMMS]%021;H*)P%RN&<\@U-6&"!AO:;M@BI8V[O
M_R.Q E>:P;\I02S0$VLTS09=\R+A%XE 92NMWS?_OW!@ACD%\0<P:D9[ ;RB
MUINK1X;_@B>8T@)C0SH2FL91SA[>#[T>Y/TEN2[1E<G\*1E_C4^@UN6!Q#.@
ME!8',B%X84Y":OI2_<BNTANS@POG.M/JQ[[_O CJNY6!>/AO4P%5!^=]J(<L
MM),]2U;ME8W7Y[<63>I>*LN]\^;B@)VO+<VFTG-6VUU5S>7&1%5BFDB9LG"-
M*3)Q;'?'SZ9F=Q+YRK;GUINV/9[[FP*30V^:[XNI]IZO*E[Z)8'DT5ONO55#
MOG"#HA*O'7\"\_-^UH E-K&71.%1/0^V*4UX94;" DYH4=B/>09[*.-$DEF@
MP;/L.Q6TA\S4Q3XV]UEZ$Q@/\,O_B1Y&T/AT:YC)M8OLL0><AYA5@1J#TWO_
M94A@US,WG/S]0)*0R )12\;0P'+DT'\RC7T0,G9?O0G-D"4%:NR7=1+ SIBY
MWWP'DFF"*RS013?=OY&I9H:VN!'EA;I[4+N3_AC,#0FC8<BCW</N/> 349)(
M/VN:5W*G426 N9(T9S&N6?.HV/-0N;76QW6!Z8%QR&A8A$%763ODU[74+<(Z
M.RH'"M"GPP'.'C98,<61IA'S%_M:/FD279AGQRG3#(WJ3N\9-VF:>?)KZY7P
MD>=;JO9C9EPEYQWY\T5-))<Q<XHPJGW@' MDP:80).-\,9.R*W>0!C%_!7S?
MI= ",$&0?%@_(?61E4+I4N L?M3*^)R;#U0X1W:&>6JNSY67/%CA>@U5H[2V
MO&&VJT2U7U]CMZD B*%?<C*"Q4+!S'G$X3- -]7BNT5.K7_P:!KA\,MT4QK;
MAP97ON0.*+6FWIB&GBD*$("U?.EY8_2M.<J!,@*!4BJ_3BT8#8I5?7]6PS4I
M^\*#H6_-Z9:JY;/TN_(NTOA*O>R+$;'\XFFA[Z9"WSFX<,J]PX.>LY%.SV]<
MXXQ^Z\[U9KQ*&>"K#_*_I^XA/L"?"C'R_6*FZB9CDY^] N=\^K)P+C7$B??L
MWW\%@AY )(9WO;;?MW_G_]"JL<C0,-2=3.";=_Z+;T\A.O2*<5#'*>J?6J'_
MRL:,GU3M9)K^$B&QE&I11^ZR?H>7I5]N^=1IW%9&M4]V.'_2<<W)E:2M%_6:
M\<?);M[)A-!\Z<3 =L8ENO$JDRM7384RVFM@=59TR) 2>/A]:,2=#_=Y1TI?
MF9)7O_"_*,\=MV]-O"";^':T>_D!63E[396>J(N1KXJN?/.[^(PXFN>;&$^K
MX(?R']\R>ZF9'R^@'TRY)PT_6%>W=4LI17#DN]^?2#M34C8 @4[L#\:C-"YW
M5TYE?@2^E>E9-SZJ&>JW*!,:;R]R"BHA_R;9O09?7"&0?!@N+%!I* W&%'+2
M8(&D2O^UT_M9[]Q. 3":/MP5_FY!88)A>+3?YT[3E)SH=$?"?.?$-^_-.O E
ML;>MZ7(";5(S+_\C=6,_G2OD[Q-C&*AZ<O;=B-(Y[J8<?-[!U$4VL7<Z!E=A
MVB4C7J2<\>A1MKP<O2OPA^'3M^&OW?6BI*DI)+E"#Y[%U&5Q-2TK%[L)Y]6"
MWP?8^']M=*TYXBK01BMT_B&C0=W(Z^5+./IS80WQ1J+:%Z],NRJ2)4=;.:'V
MKG5"U2-7TR_1SMCGYNWKRH<.0/\)HK0OB'T76WW0\XUA7^#Y(L1V*&FH&NU^
MR]O=QV<XOM_NPY:4B+:#4Y7NG;/6_59I9[)R)$:"*ZP$?_32_'E::L^_$.6@
MUIL5W$0!JL2< (6/08XAP7D*&AR&NJ._>/!B1($]ZN?\SWJ_>J93@L1"X/P6
M.0Y Y[E>?Q[M75HM>S,^PG^JQXCGNFR:UN''E4F@?9N<_Y26$&YO \%"F;G"
M9U]GVBIDFCC*Y:@)F,CE#KDO%<O4%F2_+E/27E8RM3!O??25Z-\RQ[Z$AN\
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M""&Y([GAV6O6%$W57]UU.T*S_59#ZO+U0:TYE$WZ!T\9Q0NE!!7K'103_,"
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M:(OYI1%?0#[VZHK07TT#$D,WE208-<K&FJ-#PRY]^8%]Z;,/70MN4K_H0.6
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MFBK'*G43IX)4^!V]2^VL&L,)0FRA,<K68+B\M)W-SRP0\_B1%;^7WA(I"X(
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M08^"*VCW9Y>LH'M9?&L5^61+:@R65H/:4%0:LTQ-/@&%]J.^6PB?@& /]VO
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MDVNV[ D6'F XJXW5NIY[KL!#5X;W3[.?ET0%(+2)VEF&A<OH2V$3\V.O'JJ
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M]F=DU2W-B"YMA2H-*S;I^B8S2M<)QWS-2W-[+]'G3T!=\CB/TO\<XGOF,G9
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MQP)Z#N&K.X-C"[P[<2F 667.@)NLM;W]ICK;F\&Y$2%RD:=_*QQO !Z&)YZ
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M@#HF8(Q*Z**8'C6X,P&>6 '$AM-'9&@O<5N0^TA26X\)<!(M'OU?2C-0"4E
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MX74G'VF",23!(IOC1.@,!'_,+_9^6N_R>'S&I?_)36<\O/I.<?K;9(?+SRH
MISMD^5Z-?!::=LOYGJ&:UY42$#M 2NIZ J.[@NRXX@<^@9,42=7:#VLUDL.T
MDPP>W"IASY#[FFG.7JGHX%!BA9PC5?_A!\H,[+2M=T"SI[X&"OXAW73R/\/V
M<:+;K59H%&,;(\L=/UC3/(J.Q9H$H5PSP\;05JTENNH+@I/EFTS TUHF #D
MI',T_NTD$E$SPD!<9P(HRD0F( 5TPB+XFW1^)N"3;0!=? -)_US$$$I=:CQF
M3T<L'3QD E:B003M948\0Y )Z*Y5^]LB#D@X7(Q$=2)V@60(W?@YD9'XMQO@
M40T17&H.F2W7O]3X3MGT4W=A[OZ VO3^2;9\^F05M!48A*XFT1EPR"?#!'1N
M-3,! ^Q T@<&!V*T7(O!'3+">&"S-ZS-!!0B8H#4ZX-TW'KJ'J,18K>$/92@
MRN#VS%=PQP)_6Q(?6#<X,0$C*T@&R]S?EE]_B/L9TW5SN-.=2U#%)I4VF^4(
MQ#_C=0;BP]Y; 5XS%<XCH6&C71[!M351FEED+_:$?TDUYS'6M"? *.*N@N5)
M"%D(8@*R^+[!M):(^(!3Z]P5-%!70Q:X[?T'1-U*UK8-+D6F]^?F:D<!:7/J
M4.?-@!<D\T.5T=+0C39WI"=M,%L@^]D6Z,W0C;T;VO,O)/0'@_0M.<5EQ <N
M4YH4\@RRQM'QF6R3T:P@(?-\A9IDIXIJU*^*T)4/53S_U7**!T4/:K]1ZUF!
M)3SX)<[>89:]\B&,-JB^[,Q>_>!;X#EWVRQAOF4V@OWG$%\'%)OMFQ*%A).]
M+<I$S<Z>NU+'/SVJ(QHUVBEZSVB+X^J50_MZV705^DXZ@Q9 *>K/9KPT8P+@
M6C300N\%>9.;F85IYD,_TTXXO*0]T@NO4ZXY7S@7^@(:6D7X3;<Q.63TW:M#
MWI_$^JEO<-P=; 01"!=GG6:[SY]SSOVXJ/THWDRD.'-*0/\]9 1"YU?I)1#K
M4;TJ,^X,-C7*@-V19^/FJ:HU)D 4YXLQ-6UV(H\!/8DQ+?6EQ2W2O_9K678Z
M9&$%(DI*DF:.H36-C>T-O$:2A#59.I_)]#J")@O93 ^X-""4NX^@)53..?US
M9TPF,U%3&V":MW]%F"$)7)K9?DNDV"8C]M,:CXO@!L\IC)&<D5BZWI*$&&UU
MV349#2. J*FO]:75=[P+.&FF+]&N7,Y6C>,>^>3&*25E E[8X?,-)<QDO.C-
ML#^1EW:ARWG+;&[^Y5V%@;9H.5DK<_/M'*YF$P7EG23_<;\"$[?$XSU.]K<H
M3H=\\XR%%6&;G/WW@>-C>7Y"9OU@U1>6,\!= XK V^#4TS33?RA5T>[G<DN\
MP0XIV:AO<R;OC7P\W?W$ZC%M=Q,JJO%G;7K_O9# #?XE[Y[RQ-C];)QYE'W1
MI68QMC[MM8)C'X8][O=7ZR,2KJL-)>0_V;J .F H;AMX+*69]?9+U;M"?G3L
MZ,JM32>D124\+VIX@=;4W;0-W/NBOBT#^;,B>TPADBQ-K#V(A4\M2UHMIK ;
M%<#SN*5F(HN^C\J7;0!C!LGR%)6^//)+DBIYY[BH[6(P11(WW7:31$B12&!P
M_HY5]"(C3R%\C&$7=JY5RP@6O$@";0!_'1\9P;6/"QG<]&LG)*7"LR9P*-L+
MC UC[0[@!)M&^.=$]Z9B?/:S@\S$<W82MV6MFILUM535 4:JE4&7WT<1!HD4
MN[^VN6D@#] #$1_)<YRJ[T;"G:9#IH(3/US7D!" @>>Z6QPQ)?T!ZN#&F.S-
M2K]@O2'_<=/:>D+5]1!GJ)!H!-8Z:];,!9BP3=-4(S$!FZ<H1 ;[$%61%-O7
M"A3W-E2A&1UITF]1OE&\DI1#S*Y1,"GHY>VS+A904KOF#Q_U.:[3ASML*DHB
MMU*4%%8'?38;7R9!IXNB'U2V8,SLDWP?Y:V<EUHPL\NQSD0->(=;NDFM>NDL
M*!;3PYJP%3_LU[KR2C@#:I-^S-HOVRJ5:/?K!%G,M)HKF:S?6/$?)OYL-C;[
M/L $Z!<S 1TB=+D=3R:@P!9!Y&+P?=\9^.-Y -RH.!IQSP$.2;0C7$"+IA #
M>@ 3\!Z])'N<Z0=D NZJ*/X,$DU0_6_=P/RSQ$>^W\B^/T7C6XP+L"S*'UW#
MUU2[.]D/VA_!<SF@_RECKK4T!;X7/4V^N^SU%#!^9?@!Z#_JP'=2I9_9T>>B
MA/YJ/H]=^Y_WAW?6]RJ&VB6M,H6#T+;^8]':YK:^\K4;VA)$\L/+5[>M&@2T
M/YG?/"BQ;9"4'O0>+3E;M6*+ ;]#62EL!>6Y7YY/BYPC8X+,*2,Q< NR2XBP
M)3>^A;\:"[U9@IW+WQT2[UJ^W_[@5P-N]KOF_L[Y?[\M>D2#SNA(",\Q9ETO
MUM!"*^DFU)'. #$:-ZGW/64'&-\A1N4BT\YT,X0(P6RE=0F+78K8<[18EPFZ
M++F<-+FI7$C9CA].+NL/T$>+!ES7NM&WKY(8/&3G2L'&[4:<<68"WH8Z3:L;
MF/>94-G!SKYFQ>L"66FF[N4:R>,6T#+GVVI]4ONUDCTA3SWBHD2%Z0-O]A5I
M^'(GVH+PQ!*DRR(90>*.IW.@O\$E.ZC=XCRT^F4#I]WR.IP0;*23\$)37(12
M'.8YG1N(X(6%6F2#CEQK0\\VJCD978@D<HOJ%ZGX26'DU/\4(Y7V5FKKB;_!
M?HCK=JL0CO@L&=6H3U:VQ_/I!X_()7XZ>=D:Z83LG/S-5A_C8SR*,291RVBL
M\HX43B5;OY:F.NSG^F%\P"Q#>XF^T_V&KSID=I;,>+((-F]NF4Z6UL78MZ;T
MLOGKXQ0T)=_G[N<=OV][Z:7U5F0YH.O8D=!C*1%KF8F*5WI4L$EW^/%@3L0B
MT9VOIWJJ..NNDH;SR\=.6_T/JG+<$OY(0(Y3F  ?H#!L#@]F A+@[DLLXVT&
M5$V(!-ZG%,JX6C_AMXM&GH(N7HC%:[IRUU(V8S(#T6O;F#\YL<D:[=;V4_5E
M?O'6M1$5T. MZ>-$NB]<A^PBS 7M?&^-9O03 8:G'GS]["KEV"%U0H]BSDZ$
M$!-%?S%U R.5)=U'21'H31Z!IN0;E1K[#^XVX0(4Z[EC+!;2\W-QM:UUX/S*
MG!7?K?51M+OG8 =61%;Z92=*O;RT;C_+LE_;90&NDM5?5$]S(1-G>)="VGL6
M"*F[ 5RT=+(^WNICAPS=S%J,%NLPWG:*[&?Q!:S.XTN8+:@-.)>(@O+_!M_F
M#.J^OF=1=*Z\%F0V9IA10YN@@&RH:S07-^J93@'$Q5];RK\FNAP/IFU]*1 G
M9\S*<72=>0%XG;^AJE'+T7$\HE3;+.MN5Y1I[R'DE_MRHC47W&QL6X/(.N\*
M&UE"=N-BP"&="7OC!'LJMB\"02Z)GAHP\_=PT27>G5+R4]%_-Y[O> XVVEVV
METFRGI%</D;U(J(--:F(Y#:A2I@S"=&#L>M[EL@%>5@-'>'V%3\_!5?Q*O9Q
M9:D>4V<"N-9FAY)[Z,_7&5>G-,2\' FG1=[ TO3CS/#<-L/6O++2PLDZ_1U>
M@M@G:8'^(TO0G/VZ]!KOG)";P5/:IJR"^)R<@\?MW[X.HU_DV?I:V5J:$"PU
M*M[O96^>1!JI L21B+X0$U#.%QW!'L;@H$?#-X[,A\16W[3ID 0%S3 P7%\!
MW^>Q38$?6>Y>%49E+O."G?-*F'\;95Y6UZC^%$R>VK4+,?PF\:X'S@^>I$TD
MK)XK$7X)9"-5:%3$7..#I?/JJD8HF'(G=4T_"ZN )=CZ3B0B(CZ@+EPD>0]I
M?RT-Z('E!(;ID%8M8BBC&+[I/#3IIKU]5DH)>[45)3,M00Y;96C_9]O"TWHV
MO:>B6]&2@KCE_7KI/TGJY4]?$3#YI?>CA-%7[YY?./^=9U("O .)0W)\I[XH
M*:+5XB.OM5*\4O4-+D_/>L55+J6LB^0;/@='2#I5OXO;#OXCL>J@ W/*+Q1!
M2F:*BQZC[%DD>"/Y/Y\YA>P$#^^?>>7L]TTDU?'+&9TOISNX62!JI'F3P+?E
M^.8.G]A>KP=T FOJ5\],AR)=G<P'9&F3]NO^7J^ZW:C:OA-H$YM]![DI%'M(
M^;1_\9KM49(G9V/<LS\F"LB+GD*NDFSIGG\<U5AR335*'/EJ9B$.R4\-'O([
MI>()^,?>MS*]!V8G,%9%:/.2RY_8,R.CY^?S\AIN/W]Y]ON;C?3^D3#;K5M1
MOV[M_%O=]7ZT;)B5E/!GE<%#G UG)'AUX>C7ZK&,>T7_^P3V]K%7+V),K*<=
MN#)\^V\_>];<HX^=#(P;\">6!*2+(4_@_=CI#Z1L.O(4G)<JD*K4(0<E<K0)
MH>E&=<T3VY^HGHSD@$!T!,[,)<?QDWH5^T/(6OG.-]>'IM(]%=$7_WL-$F]S
MZ9>JO60R;B&:N:N_N[\&T6<"NO2.K!%C]VB@DW#M6,\$]&<@_G]3F=8)@>,V
MMJ0+RK[R<N6V_X$3#H)!9*Y+'5\'K)M-HRDW_?H282;*5CN!Z(+2N?HY:.Q>
MQ%S'8O;AY5I-K9M/ >?,M,_\*_23]9$VM@#NVF4]>WMI,/#=CC/,@BQU<+ZM
M[L8\&&S,67/JP-:)I\A$FW/=/JA'A2Z)JUM;HEO2'IQ:RJ0XUC9QV^1VJ>IY
M\!04MD!BB1S^;6J8]0X-:FA\%1RZO. [;J"[#"Z8N5X9/*0@XR1@-J:^>[VA
M(<;ADIGD8Y\XD2]Z,_1!/$].H%3-8$?V!2\A%W:=:<N<Y< _=345ZG*DG:=]
M7#E'"NJ?7Y;J\<9UD]%N\FYNY\>2%0+1MNW@:OME]H*4,]Q9SWZIZ4>X7OVJ
MICM5<V]9L7-)]<./3/14MY?."TF%$*A]K^<'44,)KK=%29CXO'R?J7)=^Y_C
M)2H^\GC"!C66P5%^9$A+7);]I;0<($S7>VW:PP3,X)TI(YLJE +J_3_3B^HT
MQ0I3,NV=*K?&<OL81B-1JR'^?55QSOGX[U[[81TVQPV1BNM(%L23U 0<CWK
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MKUAR=P,IN;"^'F%LMX0(IBTK"]Q;]7[NF[?C1*"^\(7,\SO7[^ 5?N<?L%S
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MY48S/5!!H]M9^[BVS#_80637Z/)K%)M.5_%DGD<5TLD^Y#*F(6]ZA0:NGVY
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M'+AD3_A3&H?H0;V1\F^]T^04^TDYUIKS_5*,7TX+<B)[B]&.QF5<K]]J)7M
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M>C;F%CQ\82J->2KF(PLD:7Q\.483*.),9H+I%@!LG@&AH/H8>M?&C.5FZ%S
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M20) :I\S"\2[70#_54K-=O5^9IL[G>HXIEZ1+^O9V0<5@?IO2- O +7SD!/
M5E^,.*VA[$ +CG<$M!#4F?G$[C P85C,WU,$2%F7@5<Z4G.R$;QT9[*4U6"O
MYRGL:& I-9Z86Z;MNEL0H(I=;[0C=K"Q-66!*!@"F#OJ&"/C$7QFP/!Z4IH1
M]%8%_0[PB04ZJH,2AX^93FQCDE1#*GSS!WKUZ="0JN51>$&_[E[NX[QGZD87
M9 VC"2^$-%_.N"5Z4Z'"S!$6J)5>3TD-Y+3$8%*0J<:R\,@^::&WC&*LI?9P
M'.[4*$X?'OF>Q!UUAYW3)SU\1URB;-II4[T1BS3CDLK>*K_=7/O5O8[RVC*W
M9=,AO-_R:W _\D3,&*(-$A?EYE_B"@1Z "B1' H4R0+QUVO70\A2OYY28*)K
MQJ(:JR1NG *0ZX\$6Y)Y$(E[C_).PL/=8-QPU*4)WMW<#@+J6)=W1Y.=$@V_
M_I0=(>MYFX&^]/ ^!#5]18:\T4^2_ 8,VC)0=!L*0@"N16!R A#V,$4 ;W)X
M1I1ZV'P]=\^8.4VO3XE^G0.5HM+R*';&_$O9F(Z=X,SJ29UO>#PVK\$G'YH<
MZ@'K+3XSIA)6?Z1/PK.DU#]?MS) ^%=!K<]^??FD1/&K*I<A#,=L.B-[BS@[
M\R=2:'?S@U#*7S^Y."D6:2Q0 &S&PG:4/V?>#N1?K UD[\7HT^2+2F:BQ&D:
M5$(ME0'UNH&3 4[NJDNXK33!;WRHHMMUI!")RAY^"]=P[8EVW,,^>6(9-C;6
M"VWK*Q%H/\.DI"@7U:&"LB@I8)IF888?C3FTZHJKI7@$]L2H N R]CPW4BB3
M73+D&_5&9N$!E.'D<"5?L@WWZ-*-+W4M!X,F(9$EJUL08C?4KG'TODIHO>;H
M7*_-F,IZ"\.X9U0V=O0C84BHM:4%&WN^L3<P(/#4PUXAOVIV%K\^]]19\0@-
M3X"T+*W?\28C3_CM.P -PX3>A=:D>0R;U>R%PYF:5,A3ML<&[GC<FXTY X_L
MWX1#/5N!@HOK:$R2:T3]'9IJ:S'N]%NM%=TDNTP?A WNJ%^Q\223GVXX@5,D
M+1M6]DE=[MF/GDK9@?"N/"8DEWBN-M5JYQG&O,!,^Q)QJ%.-$7:J]3L)V2_<
MQ6.)[T7S)/8G_OE3;N?$F"_2!L#3>?5#)'\(W[:JG@?M)*^L877[P<4N#O>+
M??8S(4$A H=*8QW>_&4N>_]A]%!I,=>#.SX-9RU+'U[/-.,ME^8ZO3^EIL>G
M<@\L&)^A+!R;>S;=2EDTML@0_DFK6E38C<^A_MPXV;7H=_7'4#\S2WFR7(GP
MV:7C)K:AWTH7AFW0^K-N^6I6EI:A#U1A)?0MN/?"QL :"Y2>#TW9B38]Z,.I
MM_@?6$/X_!WF?/-Y!3PQ>4&!QPIN"ZN67A>SN/(]Z*^M\T&PUY8'ELR)OM.0
M8SBI8*'#Q*D43O>;6=]/118'P3S=Z2> "/7DGUVN^<*%$OV%B5<>G(T]?[E1
M,N,2Y]&'%J<SVC%.(DY/#NWZZ(,0-;:DA!B/GF+1A;>!QU_=\@/B"#>6TH<T
M# J#E 7S+@OH4Q1OKB@N^-T)_OFQ04%4-#&H^*QPU4@1]%Y)?,F@G+HRNX;I
M-:V3>[G@%S)5Y.EUSLK&2GNBQF"T9E'GKRG-[-MC3O&NX=^-3_GCY&@*<=L!
M;OW[-AG)%.L"KVAGF]&EXB6[UG;97]:6OUZHR3[CO86^-#WDOXB?:?,$DLF8
M)!C?#B;16"BOOUA^#*<--]^_ (_2JH=7;[^\'XH2]!QHX(.:Y2K=/CA6%GB3
M8W9UN%+FS]/M;=G?S+&[E)K7Q)J:LM=709 G[]"8B:JQ4)_1TM6)AA6'2INI
M!O*YB<+3I:N3.?J.%:OC_L5E"88/0P(( DXI.Y3V.V*S'S^H^;KE.SEUU65V
MSD[+16="N<XP2A$/0K_4TY5H"JZTC&0R _8>?SP,(T#W'L'?&URWZ'-5?X8[
MRQP2+=;J_GL;.H_9B [7@](NH%R!^GD7+Y7E 4A$6@?(>':/->QPJ?$AOJ[U
ML4#8G:1DIC2<7TJTCWF"^GT.TC(5%5(/1Y$].XT[%U;H4@=:4=P3VAZ<'C2+
M--G,F3_&=S"2\+B^?;E)]'U5S%GFA\X1 4G'D5^5=G./E>U1R5 ^J"]IQMF=
MNM$;$$()V!F.-=)94!> 7[ !*NM](8?I+A38*3K/1 401CL"FPI5ZE(IYFAI
MFHS2PT29C!D)S@=HN6#'Z&YAY.^=$[]VHA_V7TPLD59/"HQ1!/;Z2 )0+TBR
ML2$01^G$L)>-;=!G=!ME>-G[_;RXA+R?;=2-'L_#P(LJ?"+V@K+R$?ZG%(;5
M9.\?(P^TIQ5:FB:\QUL,^M$[_9_K8Y:=0GSV'5>_K U7?,6U!=[2S3M6-_FF
MM8R_(,1(SUE$P%-(3V!Z."3PZ)9;>:R27**2E$N9*0C*!]MM8'3-B1F=ZPC[
M7,1H2\>IP4,< 7;ARM5UB<2CCI52-Z7^J*:FS/1V:-+U4807<*ACWO4)%;I/
M&(Q?MS&@VB>/^"A]P?_)Z?8\X@.$#X;HJVIDH9Z\PP()PA4\&H&-B'F8A$^'
MZ,\-BKK0"NPXDY<(SW,;HVO1O'L>)]%E\ME"?A(UT"H1'B_MYJ,61@+,U^F1
MX55SRY/6Y \+;8S@TB=0L#:$"&5RBP=%0I\U:%]TMA\+A0C$#'5P)M&%%=Z+
M;\-CE($02G@?*;U8<J(KI-9?RS7=[7U;WMPA:ELO1&3ML5=U,Q8(#Z%8V)T@
MKKSQ0&/QF3/,+R0L.&D#)T=W+' &EBCJSXP5 &%J;>^^]U>\-^2$SQP8"*&E
M_&#;_[%J"O*P71D)N'RM::(%RK/:VDH4)F4$&%VH\UBU[RU'KNLV39#'1?>E
MV(,]L8,@KNW^107WD-*@6# R]/-=.,_\@\X#(](:_F@=\P3?!7=:WA,C&-7_
MW11">,-(O6'U^8Q_1V)G:90E;9'0=.9-^L(;+-6SC"S<)KJGI0*Y#K11O->%
MYTG@F _[>GT0X5G ]H P)XYO!T@TZW<P+O68L],S4>9MU!]%52N>Q]JHA%?E
M;"&DIOH8SD[\Z%:)4>P<^W2B+6%=>UH]H &;O15#HT$3C+06/*3MP #>9#3*
MNL2&;8""OA*SZ;BR2NOH$K]6UQ_(,%7TJ.71+-]\0M&MZNG.DO.>1+=O\K+)
M5Y8-0U^#^U[B?4@SM7T2I*10*0G$"5]BTC.<[ S@1G$/AS0WE E7OBM26UCH
M'HAOB3""UOBU7EW!78QS![R%#/MW:U5_--\J+R?-;)%NN%$^2$4>V#-GC<4,
M[RJ3 \(I]QK9# 03U@\/]SY6[U%F@<!^4X@3= [$@AN&@VY.(\UT&7;(86+I
MUTM]\W70]4EQ7?;>82)M#-2IQ]+8  I$MW=W- 5$!P/5!Y[,:?;_8WC]\0(Z
M* E,4M>%RJCSP#KM2.^<T1O@$ 4LN)H%7WHW)P:X5,%%R9"^=)&M]S%28W1U
MWP:__(&^@PF:5T-2A>_G$CC"JJU]BE#-M^6^)WV!T82_7R\_X/3%2'1>_010
M25%+J(H*QD]L S%\P"MMKBA1- #M(6[TU,-L:3='EJB$YO#S4VI8'C<;$1;H
M1OM417/'J-I]YHRW3C*CF*:0N T6 Q!N5%3*=H!>GZ<X33XON@2(NS1Y?WY<
MN\C?8GR]O'D\M-NV9U&VK>L-KB7?S;_390'N'6N1\L?=V_QH;)?((ZJK:Z]4
M=WV=AMN,6T_JJ?,FAU6NLBN,P^5!YC7/4@[75%T%'7X"/;F#1^+;^LO!-<O[
M!_X=>DDX<1A;K5 F +C63PN^&X'W@7' %:RHF&3TA)$R>;!;IM\)P8^%"JQ*
M-*#('IPVX  ._#/5FY&1RNUW9R81OAO$KW 9R\F !B/G"OB"*] 908:E&O/F
MS=^K#;QSH \$R  I^UH^QJ>SWLV=2:6$9=16+<\)CBK0= JEE9JL(\<[^2I9
M(!_T.+1Y^RHGBJ[03<M%4WO)OTIH_ M_=-(6]^*,],(7)#%\TZN/$4F_HBR#
MRHG6==]\)B7&18C=N04Z!\-R1165 8'1@3RR>N?[-0W57]N;@83^BX9@3?\O
M4$L#!!0    ( .>!H5I),CX/FLH! *[U 0 2    :6UG,30Y-#@Q,3DQ7S<N
M:G!GQ+EW5%-YU"Y\$!01D2HH"%%I(DVI2HN*B,@@BM)+5*2$B!F4$B0DBM+;
M"".,,!+I($V$@-1(5Q&1+B"DH"(E< Y".$+*S=SWN_?.O-\=U[ON_=;ZDO7[
MZYR<[/WLO9_]/ GO(X\&2)P[8W,&$-@B %SAOP'>)& )"/Q?OOYZR/_M,P1X
MKP#)[0*_"?TI*' 0V"(I("@IP.L$$  @L/4_;@#^GY? %D&AK=N$MXOL$.7?
M0)8 M@@("FX1$MRZ54B(?S62?QT0DMPJ=>#HR6W2%Z\*'PR2T;OW,'>[\JGJ
MMMT. Z"*_K5;42([9.7V[)5755,_I''8P-#(^-AQ$\O35F>LS]J<NW39T<G9
MQ=7-^[J/KY\_.N!V<$AH&"[\SOT'T3&Q<?$):>F_/\K(_.-Q5EY^06%1<4GI
MLQ<UM>2Z^I<-C>T=G5W=/:_?O!T<&AX9'?LX/D%GS'S^\G7VV]P\M/)]=8VU
M#O_8^"LO 4#P?Z;^O\U+DI_7%B$A02'AO_(2V!+VUPV20EL/'-TF=?*B\-4@
MZ8-Z][;+G'J86]TFHJSO .Z^=FM@AZR* 5T5^BNU_Y[9?RVQJ/^CS/YG8O\K
MKPE@IZ  OWB"D@ 2X'(/Y24 _^/$,'#,W#2&1QS#8;GV.NW.KMFL3A[P@&3+
M7>4!ZY]Y .08X<H#?O-<Y_R*_:KYMD1P@ ?0U0=Y0 N2\P/)=D2 Z7/$:1*7
M3>(>;F8D *M$V&:5LFS/ PC\L]N:K;*!6B_F 11U'I!0=2SOKCF"*Q6INSG$
M ZCI/*#K(@\0L<CDS/& Y3<\@%'V_M!3<>M_1G"9V&Y?R /N$#=7B/"S[PGL
M(!X0%8TBC)" 6F.8#,ZRZB&OS )<$Z,GJEF["&^>22_N2&Q1;F^T3C;SS,.%
MT*I';ZZ^68L\6?O2T.:F=@$E-"W<^_23NC1_P77GGT:S,L<^#BG3U=O#0ZJ2
M$/7(N(KLSM8#H$>6?0K[)#A#'\WD//CN3C7L>5"A%<PT^#A=')_CTCLU??IF
MQ?FLJ)$/MH?,=!,I-P(U:;/,:.%[7&VVQT#S<="1!_A^A1Y5?"7[8+'84EP;
MWCL?_5O 0ICW54,PHN)@Q&.+'@71$RHZU=NL]@NN\8"?!DFKVL,.A1TA!,V'
M!W1B8XFUA&0:4KBN(M]5O8LIVVL_%AB\\-C05$;^ZO.Q\NF/K56LN.!!/[+4
M*5W9LPFOGW58=I/(V,7OH+X5:$?IX@$I2O(#2\TV3]U0_A/3#8I=Y3E:=0F#
M T6C]/HA+?6ZZ)O<(;$AJSTIQ[B#I?+1>P#$+1[P]Q(A_]X@A'/<<039<S1Y
M\X@_59Z?. ^(<W/*]:[$I?_R8LC,N6#2+2##N$XO0*U[33GQ$OG7 EL9L!HG
M914<V")0U6K8<GYEZ-5&:S56I^_46'OFQI_Z-\Z(A&][J#U\:_'*!>831];N
M0T%11[N B,Q_]%K^/S!SIO4L%E')QDQ]FK8?([1Z\S:<^4I*G=_K<4J[R6#H
M8W"(KKU66/F83I2P*W;9VC02O#I\'<T<":N]6W?&\8\TS*H] \6T!(59$>D=
M7O+P&)3=H20+[2K-G^SWW?ANNW6I,6-2JS($58/.R#SBGEA6&ZYDN)*7_%E3
MZL=5.R"R])]%*_E/0[:B'L\#T%5W"3M!8G3K?EPQ@Q1M@-J&FS"--]-@:/:^
M<;8?<QC]./5)03A%.'RGTZMW;P?R [^)['=^-$EL.\D#KDVVB#M JO5,:9 ;
M*&?=6/UB>#EMUF'2[W;IWN@'ETX%TV^)O:G/[O6)3E\/;+C;?0)I^>^#W.H/
M4KI)T18&<"A)MEE[ID70';[)&G-.G!$U+3)!CI??5"$W/2I,._;YY-9./<O]
MN$?W<P7LPGO:ER>565?@$88Q&-M.2;;8"57%.ZC_^6W#:H0Z\>[B8\'F:_/O
M)XZ?^N'@UQN&/'"L"XAL^3DND%\<$4,:KVG/,4'L9%M"L>TFJ%3W"T/!N71,
M8F+=R)G\LG>C&SYEEKL+XEYX_9*\S[1@A^MYEUV8QZ/$FZ1QA8YIG?17=Z@]
MJ4+H'-V8>86]P:8-Y$-+,TTO'7%70[G]1O.#FJ4.OJ+?@;-F%X2IR+^!D/H/
M(D-E*IG",Y#P+YP&[BZ\\@#>4IYM!!'OW0R9<K:QU=R;P5UTQZ6XW'3@T#"O
MASDQ U$=)@=6?J >W]OLO3R\RI$[WSJRYO[RAL&4T2AF<G,R9GQK16%MH-;W
M=Q]-O1,,_6[?ORLN(S!/^?< HI OUIFE4'XW#Z@=^1,A'7),&49 9#S6&T39
MVXJ*A@Z124+P2]A\?]J/P"N-C7;!Z,:4&I&<^2^=#ONM3BO(K?8P*$QC4)P6
M^,D)(<O5P'F_RJQQZ2JUQ%3TWTKOO6JPXFX5LL]I=&P79 ;9[#DL\BGI+.![
MUZ+E9W3\@_@*H4B0P#N JF.=U%BJA)DY@R3@:E/2%<Y(-OIJOSCI:O!(O%2%
M&20C?7HTX.0?9I:"1;]BWN"--T,)KPE'H-VD!VQ#Z/NK+$K<FMAUW)T>F[K&
M5CGG.P-Z)4,5G75'>[3;COP"6!_&UW4$OQ:FHOX=H RB(-<,M\R?:7(]TPK\
MWI6C$H.-)8D9;-HNBXW;^'D'*CT4R7GUR5YU]8)UR*]1(D7>K,<^KXX+[G>N
MQ2%9_9R,9N(,&?:A49-S1,?8N)7I$SE[JQM:-O'I+A(Z,TE]/KMKDT7V'[&9
M#-JOMOA!^!/IWV,Q8*/A>"R82;=/X:I,:6&QM&5Q+XR>UCL'Y<\WK*8[?LO]
M? F^ J$47'%AK#_@PDU#/!*.Q6[:XC+IR.0;>)%*7&R7:"Y.\%46VT*EI2[;
MHZ5Z\QRF,4(UBA.MI?WZ><(1)P$UT:8,@(/Z67G8YSCWKG)*"48PP@KNA>18
M+R%?\E4LHP)SA@+N8!O 03X% 1D3EN,R>O,LMQORY*;S-8UO6*$.][>>Q[RC
M^)BC6*6<DEI*_+3^" ^XJ2N)-XCMH.[A*N.0-F#1(W"2;I$;&)@'8[NG#PP$
M?TR>)A>KLLNU@GM#T*J?%EVJ0]55!#>V_#3"6LY+BV/LTQP2=RL<UL$#Q,TL
ME6J@#H92OO#]9N&J>2,C#556P\WX9_,FOV==EUV7=>].QA(/=B@6/+]I]>-$
M[ZYEEA(\Q4 D4;?EVR,"0C<RNQ"Q=[BEX"Q#NS/H)-J<!\0WZ]1E3*14F2?7
M7G ?YP'^GK::6D9@UQ89S7T!VPX)KEK^7)-HSE*2*&3=5[IWUYWN&'=A$UKE
M0+6&\G&;H+RYC7=CR(#FG;XQ>Z\EC(XN;+]Y ->6>2WSE+CB"8O>GR9.YJ10
MT,NP"V*;A0'> RZ=X:C-MN>(PYL0IN..=:+. ?+0:B]" +Y:^SC8O]YUTG*V
M)Q!KWAL_K:$S*Q:+WG.HZJF%%%\%U=3W)"XP]>GB754[<,L7AJYN6JWE))N/
MD;#;!/3UO-S<,I*V>=1&O/HDL/_A"80/\5]7-5[P&6$:5<U*9%18MLE7]?
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M\>=!Y:^V(L%\RA[_($SK9TM/LI0YI&8L&.$,4;M2HXR<>8#$Y(Q?%_I,%4.
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M23B^E^A'^??9R:DP9AG#:X6$=\CM.N7-ZM)L-U@5XKM AF%Q1]DFT\B??:E
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MG?>W"?V1=A%(;+LKJ(BD): 0U7^D]:9G&)1LU%:A+M\0B*)P:.+\@]!@*>'
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M_T2.WR]:WPFDQT&BJ,[X#0;LHK^A>[$-NYS<JH7)J]R:W5M7'_.P\4?%K1Y
M;1L,-<=NB]\H\LT44HZ;@D@F'/#;UZSX32AT$^\3@&GO1WBK=WU\#(8/[9O>
MO#XUZ;I5GCGW(ECVDBRE0]R9$$O^$UE-WB_X*C4&8X62Q*X1^5Z,S'ZE]';+
MYQ:K@>DK/CD>CSTP-P=P'N8FHV76C.EVIG-P[2A,F"BS+]RY[\^S6QWZUI)]
M$P.WE1>J\OCSCQ9IZ=P&7_.[&)6(3?29]V.%>%LR;A@^<;?H,K*\U7>DT("(
M5\H3G:;/+2JVXN>M=N9](JPCT:E,)_2ID$LXS[8U=,K1V#S[X>>8\06#C0@[
M:TIW<N&7J7K*AR?62AC)ZU28%$R31%WU@L$:.>BMX=_[[8GEH\P_]&4OE5-X
MM+%T]C$XD&]LY86+[_L=GH.V3IJC$!^[/*>5='U8RZMDVV\;?EW3S$&H_@FR
M=8<+P(84J'ZF^$N:Q"U\8&;FXD0.7\HM JF(1BUU5$Q+/VE\4_0ZL<KL>[#D
M5M17\IQ \%NVWXC>\MA)C")3P<!;$$[%0AL4-?G";R;9"$1:/P>MO+6&(BZ2
M8^<L#\6L(VNZS+XH+"J21N+([YERR,G!:/&%6F^8P!\A.KD\16HN,@@*'PJL
M<_T>(Q!_K6[F%[!!4.DGJ7:AS?[C\" J'^P!CEH2 T[QQGWY5&'BN%9([ M@
MM\N1W(%P>28&0S#=H]UD/V9O&<[V1HZ$(RLX@JJ_Q5_YD,GOF:UGRS3X*)Q2
M%X1@15]DX$KZ($Y@'H4]!VT7>A,R'&]!(N'\XV$N[K@8_*L@5]O/DICRSY5/
M1^=MWTBFJB@4T)RU>&+G+U-F!9Z#7" ,!PA66&BG$]<H$8HUOF@:Y4;CGA4!
M:!:;]1I8X(1=^TLCA6UN80X.GXU2PJO[GGS?OY48+AES$\W/LL"KBHC&_+/4
M2IYSD"&)WWKW[%_4.HSIHC20G7U"N$K/LF"0,1VBQ+!,S+9= 8%BSKLK$(@.
M*MK(,,:)EUYKS#"6=+4RU$OY.;M0T9)XV.:%_R&!NBDCQD80V$83!'I/EKO-
M$M'U(]N)E:0A1./,CCT!W.O$"N&%T72"N=O45E"QFDSX@(["<L.2]2"XTFC]
M'MN<(Y2?K7%2@0>Q8UL?:I_/-L2585/)K6Z]PY! XB5J LDN4&28#EXT*BP8
M^6/X6-&*7P[?]P8;JF;\GE'OF+VQ93'Q@'V_[9'0(+-0+:@D+N*6]&6B'."+
MQ]*40V+S&8@L*VK0:?WV)KQKM+\T36<@(>/FS.WU#':9X:^.W^H_K1K74'BI
M@$@OT![H> C>',U+&A/ &^>*'I6=O84S$"F!4 XBZP.,Y&IL//'RJ:$NP<^F
ME< +OPHD9=C)=_"878*YS<\NS V$JK?DSR]HB]3[AN<2SP;.%*U_>O][&?C?
M U VXKX3J7>9 N&9#-R:(;+JF)X59&-C7\NCHL$,8.>;1,HB (*S[DV.#=&,
M5'?$XWJ;\J[#_%%D0'?W-(O))X>-P <.)K[>$A\-@B@O+P=-+.-Q9H!HTQDU
MA!=!$ >[FY%"6,E.CG7A=Q#=B>"5O.4#L;"+%M)3<58"_K-^_QST]P!!9"AB
MM(1PP=R8ZX[>G8/6"K4$D/RR@#MFF7NKXPJ!_V.:;CF,LL<<B-=OK4^O_)7J
M5NDM">\.$H:%)JIJP_8-7:_=5M]@K8A.,=B5VI;PGE9HKV]JM7G*W-/$)/Q!
MA36R5M#GSF=!QFX*1BJ%/P+_R:+Z1.4)TM6=<]"=S'X!HM'(W(-S4%XT"-XB
MTM#F-^C_]FXF2['OD&K?!UL+OB[A5"TEU3ZNQBO"4J8R6>4W4DI,7&[D2N6Z
MB+RJV!')GK\[/3S>G*KG9O3/C[:$X9]5MF]$A;.(Z>>@6&Y$IP9ZW0+ G8/>
MV)X:(?9'BTB\[A>%X^@<5&B,2R:)N.Z(G8-&[D2 K3FZ.GA-O*29JN(_)@;2
M:<C_HZ#M2CE?.%&483@^+)XO/92TZ))A2&&$(5?C:[[1N!HGADWE*C)\G,ZM
M\B1%ISCE\ZWUS2\Q5A;:%(S:O?"[_WNOH-)GP\ZEC?UH^HC=9W[NGI3GH[@E
MX;BE%?;K;O<M)5Y$;@>5TF6(JD\..3\[9@B<KE:8S%A^DKK2$^-:+_54<>@:
M3Q;=-F10^"/65 Z2\N_BXM]MQYQRHZG'.R:$L@=UQ6Q%PW'O>9A&D$+RO*=\
M?)D\)A@Y=Z_6K-B!YT6DB9QYA$;N679,Y.:T[;7W_$HN&GG)Q1LG5U)*W.Q,
MZ@-#G.(__MA0]2PV*F.KRO\XU^OJZLE=^M!FI3%&.>7AG6AS$(@,DOK?W];6
M(MN?J_^;D=,^!GF;_[^NP/93 *\/CIU3ZDQ.1N.M]EYVT$T2G?WPRQCIG>05
M 7JBYEB;"RZ?'2#M=8=(%9TJA]TFT/W*=:F$C=C,*"37#E5X-!T/L2S5!C?1
M:Y&#0/"=_Y8STO\IPWSR/V_^*I5)X)4D304<F(#HN$QV\<.B*?K;C9U:K9\O
M7LC]\5W7\#T3/W,$K^R._-&)341LH\/^'^&3_D^&3\333*H.I*C 3W/*,<2E
M>O/]0?C68&./L#^U#:_?LM!6?T/X'J;5QTI$ZZH(:P@.:8H[.-B#B(==K[87
MIS$XVI'FEJ/UEP690?Q()N'(E7@FR1Y32]FJI1\'*N<@\.0H92-@K?M*AW\[
MT[-"CX%/>?@%I4[2.2@QG*O@<F-CC#"/_2.)[MJ5IP%[45$Y:R7!BM'<NE?[
M+[^W])'IHR<C,CP__CH4&A1]L'%H7*EFVI0LM^1@;R^UD,IN:R';/WFK1J7?
MU(U\4SIBB3W&=D\]H/Q#>TP<]4;UUP+)WO4%Y_#*MZ0'W;&89B^#$;"VFQU_
M(4[#OT7H:^TW)WU0<2#A*5]/0D3I9_("\I<I-OF/&\;DAP2Z0OR?I]C-W_&:
MNPT.#[ZNYW5,NW^Z XA2D(]:NV"EV;3Q6YTIZ],4^4RPC!O:LI[,MO-RMZ5X
MKD6YL%!2EJTU@!P)WCT:XMTS3##1+B9[A_J[.I\VQU^ON;RE&W[[4Y.26ND-
MZ\^4)!DG9VSV'P4-2'>&#XO/6.5&&M=<86'""SUM4?<ON)0_^YH<X]>@&RC>
M05^Y F8UYIY61=O:?N'$13,-2H]MYDGI>/ERM[>7C<6;)%:>ICPW4/_IXIN/
M\HO*%U=RF+Q=CUX[@J;?6?Z>H1EM*$V\DI/]6W\9\!LR4QPAE)MM[Y+AB'9I
M@>8YG\WD.RTR48V]$PG>2/G4$%D-R-VFO#')76<]9G$AH9N>!1%7.RD% [;!
MU'^VM*>EVQBP)F;=UM:IG4B(]^=Q!SDJW-OT*])MG\ANZ%0+F,I-;/(Y8=7<
MG&2#ZFIH(3S-HKN,!B#7)*V?KA36_6 VOD,3UWMQT[)-C(MB],V+7Q!IFJ]X
M]_<VG,K^G%@9!AJ&]X\N7SF )K_ND,J3##1\.EZ/7C83^.?+R""H2/@Q?$/H
M;7=2^@G=1\"[4RF#Q=UJ3C>ZO:&-1XD&=K?RW2TY0:W9KK/M-?6SB_ZLA#-A
MZ<R4T2]C>Z/ 8U/I+:5R92[@29^UVLNYY>MY=.&B6('$OQ[<\9\\XE'N,Y67
MRP>\+Y<WI[J_%_Y]_=&W*$G!AP)*\$G:K0O4]@\SGRB)>@>OU'7BGFHB>Q4N
MX_C]N[&$=@=9F(7;!XJ?#$O?7NKITWQ![5Y'1S, 0E+-X#CT2LGRY3:38$Z.
MD*ES4)]Q1VL6CPV).LP\;DYR*9&VYN>E8*<VZV/(O]H_O]*I-O'V-$F.R %$
MXYNZ.Y0F23Q;3@JC28G.N'"N&VD/\/OMJQ6_%^>*.0+EU(R]*1I?W'+\8L?S
MGNQ%<1D)3+2_:%M%L=WY3<@(A/,58- W)$\50 3@F@C[,%/EU1K8<Z(.[#FX
M!M&8ZZ7>_>&YTA62+%VGM\3V'W2C$5$0*#L'B2T Y.>@9V=EB(WL_@.R4Q5\
MVA<HO@D3U#T2,UB:^SB,<F6$'J8;8-7$'GN?7V#<T[\SQ/-N'8W?"\DV'%6&
M-O]9]CR79NQ_%#FR50%V326B-' -N<Z=V;/'X:[)UD@P>RT9)HD9*W.<MS>N
M "*/:.*S/<5-D[!N)E/;HW8.W][>M;,R>/JH6*R_K/N6&>V#GB!]>7<)S[.?
M*3J%Q(<O4:O&)&ID$6F6NZG_*9"(W8M, >HPB B2,$S?""!7S"S;/ <YQXSO
MZ7!D+:$J;?I%*LNAOE!HJ8ZSXN!B!O/7O##[A(>GH@3O/C#^P3NSV&.!VKTN
MZ5D>&WSE7D1]*(JUG["'Y>B5IH&AC FA&EV.[G/AF5'J2I7N$VYC&QN/):R5
M.(P#9V07BNX*&<Q&J#\X"C@'O;NHYIV&Z.U9\./\,R9")/H)],\%^8[T\X#4
M5Y5?P.N_5P$E+Y*F2%R -D8ZWO4H_"P>USRN20G$]FJ*XF^M7Q7H+?RPH/,)
MUGUO7"%C2C1A.("3_[O]G2W&2$-RQ>5U^G_S 3[JKR='P%')WPM$I,Y!T-!$
M(:MI>?%C?')4!6[*G\[:?/0PWB! ("Z/?&*/+J:RQ,'.0Y'%Q#7 U\NUOCG&
M)<GZH0_G*.6F"QNP58+HI+^(\OP@5:=<7Z57).6V&79V/Z-E_!2B_I]%X4;"
MUYV7!!URB9Z51_1?Z&^=@_ZS+CO.2"48<0%Q0AAA@J=,D+?H_S[60'>C8N \
MP&-7U,821YP]5( 10#H1$G?:4KE8H4XB'>'Z5EFR/DRB+6]K^PHH0""3P/V-
MEO#OYR#WS[4->;CM/?>U05IOZ5DGW?0=8I_%DO'7N!W^0 [SGJ?4Q)3_/;#G
M4%17'P/1%'=SSNEJ)'GHQ8N^37!\O'1E3](AXVINX1OE(5F<64WK\E&Y<6BR
M+)?DS_U"0Z5.V7<9[ OTZS_O/!PE5B IF""I O]]2',CMF"=Q#V!&_?G4QPQ
MFGB2@77;KO#$-C8FV9?E83'CG/>%K#+<^?6O:;L^Z1=.LZKR7]3\#85FMXK;
M9\<KR=H-J3,-2+;6IDO3M&0DQM6)W=+N%"I4^,,/7HD5P)LI2I1C((G;@\?O
MX%/+]2GB>=D10%%*?@@ED1%'NOKKNSG,&A?L<OH-[+$W9U![9AEV_RM1%P1O
M-"MVMU;<MW-PG_:;6S#U0C9E+(G&V&<\&E)/J4T/-@89O[47Y)U CM?/ES08
M9],8C@\4A2ID4"W8M0D]-P&Y7+^1"+<4BRQZ^1*2*D2B^JM7[4O\:ZT KJ<"
M#4$[PC;DH^D"K"_(CEFC_N?\LYL=;,""(_QW\ESK4:I$\\;?>;G=F^0':&/
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M;I+M<#7%94HPV;PUM:Y9@ -/DRM_<!@[.S>C^-BM][Q,DC2<A*U K\63;4X
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MA1*55NSY-"R^+*$>\X1.0J($ )IJD=8\C$==2:[2N_!ND6G!*U?=#HFZ8:/
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MV_G)UPF(+@^F?BR0WADYS<=DVA 4;OYNJ;%W<D?DQ^?E>U]/ *WVQO$+=K$
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MZOF=M>2098@G\S/ 'DTP*8*8@14J(T(M2.L? B[,=EI@(C4ODY)T:T;J*!9
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MAU&N-!M336K!(K];WJ$TSO=RI?Q2B\PI<M7IB',^-[$PJLBX;JW)K+<$W8T
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MGM3TAYD!T6MPERZOXZ/-4404S]2/((F\7P:()TLMO%0QYR(%JD")J)N'IF?
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MP@S;7+_@2R.V\YA_G>8BPPP'\ *WIL0!)"8PS%!;GXK9)\2X';R#^@ZA97$
MG9=8Q>#?T^/?&OYS&%Q(**H36Y$#*#Z;R0&0?#,V.8 W/!CB?!26:97NR@&8
M%H&YMO #Q8;ML'-QEJC.BVB*+7"7GSV$HB>B:OVY4X0'_^W((";^S(_9G\$
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MI3Q'O#G *EO@<9/)N5Y]XX_,1G<!T1ZD,I;_0%I+X<U5CP\F>VON7$-K^BX
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M0\E[:*P(3^ALQ&8T0V O%C.[PF&D!Q'#X;RULB(D]H +KL$:^OKNQ*DJC"L
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M5O'8[XZ/R"7-3!\?(GZ,O_[YG/-".GJ \FMW859#_*=B^AMMBS.:(:G>;SB
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M0 SNMSA\K^V!!^;S9OS%G3^,SLP*L^\S7!J9^M4&S2&_^UUO*(A,4LZ8(Z.
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M07<4>74K-YR)DW(&EI%*J2C#IB"#/A;7A.!C3_9$APP8L76L\)J9#V.S>CD
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M>JSG_RA)6BF(ZPY2^'HLM$=M(^,RZ\%=\EBT 7#/\LF>JX?< [*C398*7G,
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M*D2GS5^;3GS4E,BCY7',<VK79^?W^NF.$4PF.>@*9$U?W%JKP]63<:OQW=E
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MZ.=EXRGS92 #D0K7=^A+<%NBB*$F>U)?.S\CKCFN)>+SW1)W]A%#94M-&X-
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M:SZE@_583H&VC)LH$#02#AY&W65F(YH,MB1FLSA;=[]3#\MTANQ(MPUWK33
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M[S[HBK.4@&5:G3\^Z^80]TV*CKMO>.G WD#,(N'T[KWB5.&T"723WI*JBHX
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M+#%=HL:7'OQXGCAW_MX)Y;']"0G/9F%Q7HD JYT%^K??.6E^O*]2XO/IUVU
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MFTJUQ50/TLIR"[8CC<<W.J6L4UT+#SK.Q'Y#G4 AND1YW5;C$Y8 ;R)-+1F
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MNEQ9H/&5IU]89)BB!^C9E#417^@^^UGC^^/.=V[.8I\#^R=$4/NW#6 S^D[
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MJ\5.*6&-YU;;=7W%5&VVYZO_LC<R^K?D1"^BVIZ[TV(R;?X'DP":K\"V8X)
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M$'YIM.W]G9>II[O>E%VO2RF/#Y3++ZK;5;B\5W_*]=-#V8*46V->6#_>W[(
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M?33*B*DQWD64D&0]DC$MJN&E8\E>PP!UZ\3M[KJ-%TY\T7#\]851,W2(14^
MBX(!^;B6:\QC]4JN 5T7*2>2?FDD+NH3;0?3E22,O!-5G8L>L]*/Y&HD["Z^
MT'\/H8316;?&R&S<0_@C1S67..ULH\R6>E@J7L9L#Q/_@+[#[$J1A]M,HW'O
M;WJ\B]S]R#<S81%1&?G!RH]F!\,<D-Z^>@L% 2;IEOIQJ!R$[Y[)'MHZAX\O
MT9Z=?L =I#!&BYVYH+3N;A*W(FJHK9O//O?B]KJ^VR;D&O=<-&THJB'?YNV"
MJ?L W?LYTN]VI?J=O42<E8D<5I:M;AK:7O)F.BO;C=86YJU:XN,99MIFH/NZ
M367LCNF"1-QP?H"7LO*W/OGX7#EQM;X\N8MF$:Z!E>9^NHD_K#-$!#^E6X]V
M/@[\<ECMYM7+S'N(-/JH!RIYS3$1YXN_MPF1YNJ4C_F3A?FPDX.H@<<RD,JG
M)0;S"\#1IKI,BFT 4O",D6AP>#"3/-^@AVQU^'7B@G[Y!;T@E( /K&@34CG$
ME<&QD ]Y\M@O6*V-7 0*Q6=)?/J(=FU"BG)#\S"20SQ9C!: C2GTEP*A9^T.
MVZ&D0%L;JMD50T6]V-]U;C=F%W[D&,JXBWQ0BE\TVLB(6Z3ZW\VRM0E6<C:L
M!9RK>L19G0&6Z0PQ6^7.7T8?=2NA3W.5'26"V:[-+L@V=^CDR\QD%$O/L\FE
MJ%7BL)VUNBT*/%VMY]%A7O_!.6-/@#0E,BIP^TEOJ^&F F^!W8+]C,3=<=IJ
M2IYQADF'TF\]+CZE<%1K^VNO=/N(]!?*C[\FZUY4K_CPQ4:I)%_RA>/%*W'F
M"EN3HOYSEP;9/WP9+G2Z?\4.Q3D"QA1,UPYE.905^V,5JJDK@?!^G?4NS466
M0Y).U$5:-_I'[<=L^Q?]BT>"U"+#57<_T;'\"IV^<OHX2?[0\_)K2<R]YH=Z
M%&T5]M\I*$CZ8FT6;6G^_;S(Y%(\;C(;)L?GQ*S)U58$S9'# HGK9]$XAN2+
M2>A#F"1V%YC/B.>#G. T3Y$]%?M;*3)-;%;G'2ASMI_8N?RZ(S+<3Z4F7Z^M
MH?^LQZ*H^FFU7^N<&79W?!AJ_3!7BWV.&!SP#G8_QX0M0L%O07<P1=I0#[ R
M ]PP'[9:!\&/&276BA#13$,.<6TD'AP>MF+@=SX#!@8??0Y5M_RQQW,C_<_M
M/]?U]<Q>YVZ-=.S<)KQE:_OX:\@6%D1<(.ES'3 53RBHS5H]V;?XH]K!UCDH
MI'/?]QK+&S>L59T4<AU\[NHHG'<>?IQQ%,+3P\IP[=_S1X.(#H,!E^B)2(5&
M!5"QDV, [C-IZG(\/63FS+"#M>*)N^K9X>Q'?2O(;;,N#K5,LM('>X%,8.CA
M-Y+.E.V;]KMMN.*L[HT/I-OLQAY.<G]V>\Y1T(^A'Q?ATP*]SQ\V6,0A@ WL
MJ<G:!'JK"(.7,:$]5%H-&UFU&R(=9Z[GE^O%=I<%L$SJ:Y,6G2;CC*,C[R-I
MWSKB2,?"9*OE7823@R6RA:OC6+8563H.;M?*6.G"3M:T#X=B$=J_=R)!%(66
M^V V0C*E.#M4- A5W:E3M45;P$'&3'K74Z'SLL;W=EZ]I2WX1P=,Q_E4L:!R
M2-XX8M=* XSIEB/=2\#NF*-+F'FRM2BJTFQ<*^NU;P?%-L\=O(&$3J S?MI*
M]R9#=PY+F#+;%1;+/4T>MT/E6?;2?BXUKX 1?NCRB;0T7TL;@\FH=6VTQ250
MRS,/G=;&$P$:B>NGC>C)I-% N2G&S\("=Q#?EAX.EW-])=+&*6-T$3P'W"<<
M.=!0!D'2XWG6\HF^()JPPX.QF;N'G[^ 7/;]^MZX)6G+6S=9#V$168U-2/QO
ME?--M)S$ G\]?PM7(TZVS]W 3]]W2;0:[$K8+545=/"XMN!4S_#$<KO\)J0*
MUAQ 5OY<:L=4:(2AG1=]V.('F\O'3M)4[D>S').$T4\NO("^0$O;['13.#A_
M,&#FG?]>RV1EWXKV)%FIG?OW%K>\>W?OW6L(_^_(EE?_S[:<^I^O2P,AZW:N
M]HW]*]ND?W9<J/Y8T5#[V,+J>-F8OE#K@8(=G]4OFA[<'2VZ5<KQ[PI@3R9T
M?E4S4Y^K?!0@3.):E"Q5#X/.ZP='0:TFK"J5>I)*<F?J7>)$#GE]VU,1Z;KO
M:N2XU94<&R.EXL"BNZ07$UY^RE/OP2HVE (C/B.WV(MC>SR4OV',F; '"*'?
M)82$56/:\;8"N&IU[RD:MFHRH,ORB-?I0;N?<Q]"]IUU='2@MF%JUK5.XO)<
MHY2LJQL&5HZYZYRK&0@E5*KXG*^MJ(E;=3#>H10@\W;<2KHGBG/L;D DDFBC
M/\+PW'ELQ[/2%,&F"5$@?]8 C6SFR0%C6:04XQ+-&,:&EG74.9_MA .OUZ(*
MZST^S28I+)XM;;XL?6*G !@+P%A6+62:&FL3PI5QT'^@NNU;/_+^A##(UF\5
M<[>BF)B>GFHNYKH#64,6?2%Z00IEK76:16_]Y>1-+].\:<-NEM,5I*"OT@3L
M")[H36C"@]I\F:Z_#8UO:S3H)QUB]HQXL@(7L_-\>V=-(HP+F?5*A/CST^SD
M@'"Y"?L='TGUBJ<$7'[=6D7Z7$K4X5 L $0T]W!4\2Q6"8B/,T.\#8#^G*7%
M);[V<[FR^%;S)^[PA;KWU=&10V-?1\N]'M<>5OZ>!2!D>9_)DF:!ZS;@,4X&
MVU".1D\TDYW$2X$Z-KU&43#[;X8/XEN#?8-MW^UKE E7C,WV/;^1X52V6H0_
M,'()<5!D><Z'A=^!GN,KDHJ?^'4[S'5P#NB9E)AJHB?!36O98??- IDP(1#?
M"E-]#8ZP-M1. /24%1T?F0DP"JX,(S87SDK\P/DYS^0>4K]U?Y%<F9: XAWC
M,ZF60:P.>S6EVO[>Q"Z0RGIE>PG,HA4N)7#M7G-/@,'A#-RVTR6-Y0NAFB6%
M<Z9GAWXJQ>@"UNPO#@:,DA4HIW0C&B.S?A;Q0/\FQCD2J+H"!.%#\_T(K\$P
MJR%#F7RDF\?X."UMVRP!%G^U/N,G+]S1(:ECW5+ZMO*LI,XHXD;/R!,&>;X-
MJ#4'D9/9^K6C,RYG73R*F,>O:]0/<<]4O.G(=&[\&%E2\OS[5GRE7:@1R?N[
M]NM/?R"\N_-8+=XWO"A/ 1/TI*V#K] >:FR\X@:7\CZ;>.P(/+E,<1A4%+XO
MS]6P+YNN@9@CTF(7.N+28F^J,E4<SS_WO]ZF,.A>3Q?!'N#J@S9L1XII!Q_/
MTF#5R#8==RN.UP>V8QL,RCW%SDS$!.;Z32 &,78%OK1[E?+]1N7QQ2[^I@6)
MT/BO@:$HK\J#N .:A.DJ%JP)'X]3:I0#.QE:R2'H,M)1EOWV  ]H?5UOK6_6
MQ)/"N<$W_7^XB-(9.^^WTV%Q!F6R$\_"?8)W)O[=?S*)PB2,9/)$<4 M)QQ\
M%<YVO,R^^Y9MY9'6+ '0*1FF2_'5KV0L^LQVA=I*>-]$A40=\#.DR\S.%?OU
MGIG0'"H[0!P1_AW0DCI[ B%+OIDFC!V!5=U]QB!$XZ!8#70ODD>%;>'MY&H#
MH=WQD>]&:^,:M=&7F))5S$U((N]PS8!>^7,7Y"Q?@R[-AWSX82$^S;DM$WQ0
M3!H,2\$:\,8G$* "6W&)G\79KNL(SFWVU/SXNOX8.@ZQ,R!'=<C,G=%E!L8W
MTZN+DD+U;K52_4PX^HP-8[99<#"GL#;CEYW-<O?2/.L2T!.W4O+*8-D)X"66
MN$]7?H:GA+[U<Y ?,CU+/?V]T_C%\0'ISFNZ[WFS-GHN6FB>I0;ZW2.T3O/@
MH.F;S$ &0L)UIFYLU=&E&R\<6]CF63*.//8Y,O@MS<K_/;(G3#W]^,#0A4[U
MQ<7^J@SU>SB-1E4V:N%)/N\SK%J,J\N.3S&BBWAT%9KKUNDO")JTX530WAG=
MPQ[P6+:@;6W25!,/\[CG.&!K.6[6W[FGT\@'+6U/LW+9>$GV77<_W'8'K&6T
MUB(@!S"R^0%(I=W@RCM?NOP3%BHF^WS=$^=8O>PSO9;9JMD_P:BR"WH:KO69
M'U'5!H25JCRN&2 2]WMT0XG2*,*GHP7^#VJ*"GTG%/NJ&TPN7#]HMY'R[*G<
MD%>TN8F4M;5Z6+$A+@XGP3WN&?K&E^^',KDSM;52[A,S:U:QAGK&7Q8713US
ME+)+7(]MNYK#5&#$^;[),$D_>CWUU-7I @A&91V"+NJH=:0K<-78[)5D'$W?
MDOUJ8?6A+L'(;T5/&"7J[Q+W>D)\ *-9F4?Q+/ P%\[5:'SANTRY=G-W[(U0
M"JP_J3O9JG_/P"*Q.*3!5.\Z9Y<>(=2W-#!_H'QAP2+9Z0 J8T^HF7&+S58I
M6YV"/6.6[W9-6?[GF07_]M7SOC]D7'\!-C)H7(,,>-X3S/&]J _W?-EYH,GD
MX^<_:699O7FOQK/JJ\9#[M)X]_A,>/?_=EO_YP6N<WZ"=I.P)'(5(2V/W1,3
M@E2P8>"@<Z93<64KKPSHEQ3O5M_4J+:=TR[?F]E9O^/+=/HI.?,<B:B8\VZC
MKA[F>F4_2/)WJ;FI 9'/\W-$\U&D=,I^TIT]B^6%]K=/P'JTFNT501\.!L!Q
MI:N8/>UZ8N>I7/E"7G>C-O#;PRC3+H-);5(<IU->F7Z)C/+P2;S>^YU];(PV
M<_?&3^8(48$1@'Y D#)GX05(5UYSC4 &$,;YR,;=6R%OY76%\0YM%&/TY CO
M0.R2574_R9W5\]"ACAR+B2SV&S)^;^6=-W?7Q;*L?!2=Y6-K4W: 14K]P?SH
MK+3F/L"%3I8%G*H%!BL84+'91N4JIXO4$P/5$IKKIXFV=\J":FA7OA74'-05
MNMQ2<2)O[[OS!X2.70 <8XA10F9Z)6A[B@L^3LTZWU[2WU0N,S)7_5;[]5@9
MZX_$3/LK27L]$T]_D,K5?KUO[SV$P2;DZLS/H85-2%#:0YIP_-N_'R;:8<FK
MJD;@):.?>/BCM?CX$/H#GA(PWO[6VT_W]J[73UI-58O9-E(A3^^;?ES6648P
MIA9B2T$J!2G(4T"[=GB8#3;NFX%5UR:';$+D1T2^J915VUX&G/I'6QWS'(UY
M2@/ECN>)_0>69&\2BER' Y/KSHC\IF]"MG&>0..G@.X7GM[YOK_\:B.\&U(S
M?5">WMZ!8>(5IB[.H^K&P-X_W<PCCV7"M2#I 5-+]Q"5\2T$/L.EU+H<B,GU
MC9C(CRQSFW.$:WTS,\K73]!,1U55&_^:W2M*T(CK=A(?;%Y\?EJWTLS_8>LC
MZ!34"GRLFE].8=$38;!-B-]Q?4YY-F=ZL!$V@3&H9#LFS3?"BEH6CC'MDZKQ
MHDUTZ-9-R(UXRJJJ<F5_*T_+<^-59-#%]4XIM]>PDQA7H*,=(06&<8+!%2#C
M$X6=QB(O/ YGV1EWNE2G']/3N@"D->-4N":Q2WM?MNMYDJB8HU/F9M$:Z^YC
M,@=6O24X&YE<:<')'T7M[B;,R_@=7+](AIT^2V6HHP077]NW41X.5W='QRVW
M+H2%LH59ES+;33R4DB\/$'@]DR.+WX&NAJ>]PQ9O"E\5DO:MU<K'FR'$3=U)
M+JJ/'OD&9Y<I[GDS,M]?GF2KY.[7^9WY9:8__-NBWH-+IET'??9:C0EP.]')
M3,.</7VX&_8"O'Z85.-Q[F[ +(*>&D).R:J-YD8R)0ZW4E@U:8SDR-%Q^3:/
M@U6IM OYS2$8TPFEP)-[Y'+?C=G[>>4QLH_!*H0V5A=. SZ,J?D_)JW01)XA
M4,\;A!%AJ2$]"1-F'P:#2(&>^9CM8)E*4?3ON86 B\^6GMN\F?UQ,TC5:7!C
MM]\":]@X;1A&&^)( R8+MGS?2"V"):*P"NBJYKH)8OEP $TUMG NPS1V->'F
M[OZ5@)2P%EKIXVG%'[]K#L82!XBNKIVC8OC]G'[K\C+&XZC#G"L;3^$*O,](
M<;Y/QC4*U$;^CG%C(Y)"H5+^%;I9[?E,>T5DBF.;2Y*-;J;^F]%9VN/()X4C
M]BJQE<^B)W;&&9X7X+X""9STC2I#_82_VWT9S3;J@GC//%ZKZB'V5 N>!FLV
M=HFK#\_G6O1BG)G0G7,>P@->U+W>T9L0A^I^(F&;;D0V)5)=KJ;?1>)=V'[,
MB2><,: H";X3M&7]-9)-Z"9$?)D!E1H!'S<>0W+%@++5MK)+;1Y:SHNB ]<;
M*]F2K[.\(G;7]WI^=*T(>FR6_B#K.'GDZ29$D@<;ZRBA!$^B1,9.,\42RE>F
MBX#N9-V(;V/;'E."2]0SSM:EM!YJ4SQM-)EEW6]X^:KLB; $ON(2:^OTRM$%
MK!Z8G<L*UIF98\(DIFG]PP:>GL[EA=YW]%X<-'Y^4K:I_2!?F![>*"8AUZ]-
MH*F,U%AV0-N$83\)]H8K#>S,@B9@#JV?[ (<*;2.Y!5[21=C\MMQL&V!$+(D
M/W>>WH8R2FDQ<'.UTZW<IQ?Z> 8GK[%1#TWCQY+$7:A)J[RIU3R2#9]B:7Z<
MW+AK2U"8RQ&*85G%>_8;0D70&90%^:*V,%.%/D(YR?Y&YJ4)O3?Y^RJV+-#T
M9S8A[F 8L EIDW-P025B)":7=LS0KN?YU2A.Q86XNW3:6[>4^GD&X+QO"^6U
M%]^7&U?;+GOR'J2]%:X,K%2Y-C3&Y)_@1$3.&*=)9GK*N,Q<-#@VDS'_:%^,
M?5B*RGR>SLVO">U[+^_X/\9X[(_,1_;6/Z$?=A_XI_@A]LNLZ6VFODSG'GON
MG56_U=?&(N.I\9V4GY=53_G+K*M+FRA=P*ZT5V]%YJRXF8LBHC.CS.8F+WDY
M+7#&FB]OC2[=.W3HDM*99];9WA&/MC=R[[;T6!RJ<^;&::'\"Z0<7<7^_R8
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M9A?EOCV;GLU0*JCZV%_]+'+!0NUMI&1GIV:6T-=8?T2PDY1W=NQQ6 /Q[,2
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M6GT^TT)B=7ETTZ S;PFW&;BZAP^QH';/<0VZ#/B0!;K5WY=0I;N9%' BVSN
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MD<]"-B.7[=^$8 &[-;GE63D</:ZH3W:CU.KB3F&B %=IJ.MXZ)8+KY%5!5(
M5;8WD4.B)\(G-2G1ZK[C&!WM^NE3CR.?>H:>69%8*BRZ\V-Y$'YO#OH?>NH_
M<!,YB/-;POD<8<E&>*>5V%76<76XYI>5CO,]\2&Y49\(#A,_:ZP=.J,J%*Q:
MG(DU&+!,E'G06T,ZBW)OX4B9GHB"*#(BU\\Z/R*R>^><#]&RX*)IE'*:M61P
MKV>;U:"F'/U-R_'Q7_M8U*_#V]<P<8!.>JWY*6X@:.^?H)IA+A,2I].])HB.
M[VU![(=?*@>EKW:.<SV>8&PF9ER;P,?D]US'[;#.PL:JJW-]Y8O%,;CU+)51
M@Q_1)"^OV)@4['PIXO"ZL;DV=7/R59Z@:H]]!KYACA&*.L!5!PQ?,*'[0"U$
MP%RZ7X_226 G-;]5.J;X8U_&.OJ881F,&F^SLG;8\V,_<>F.:=2=>U9;QQ=X
MP]1U$5"5#TGF0W9=ZP^COPN=E]*)=_5C*JETW^\80R67H GG(,?N$8*LS\I\
MI"19YMRI\1M4$<?HP %O4LHXLM$%1@Q,G^\ZVNO+S.O]S+7-Z:6+9=#AKMI=
MH>D48U_@194PU<"Z0.%IF;1)WPC!\@$A]4F-8X&PY *N'!:-"!+#S4EUQ#/Q
M8@. &ZL#+\0[CM;KF0[/6L_JM+C\& 489?L\;Z8V4 $C!EX,.;M4G$::W[DU
MZG#OBZDKT:<F.(Y<553K/G"R9>\T]CYJ4Q]\R8EGS,G L=L7T)/,4QDL/B2=
MVNB6M^LD;>5&YU63#780-J-<,\X15O^5<:X_:Q756]PYT<S6BK?K&M5TH[?#
M.>^7D(J/QH^*9-1%9V6PM@7_ =?/=P?(YJ+..=!\G]<XYIU)4WT@J.EO[$P4
M;E:WDH#9552:T+1H%<5)T<J'+H[55'X->&1XJ815IJK[*O*W$T<V;Y'NWAXX
M7CA!LBRPEHR4>$5K"K+L-'7QEW+,#W[1-E**"C:55+%G<K:AB:-=AEVF13W4
M#)2 MRUT$P$.;VN"'K: 8!K<WR=P<R[#-#SEQHVN8RM%<=_*XZ-/%NDP0V,F
MX&8^DJ[MOY^V4"J();Z^?=LT07P>/_62P9,&*;N:^J^7'&U<- &CN%-HD/='
MW"P^/*Q:ZULC2]%ZFUGP(8[WZ"2U#6>5@Q%-?.ZQ:YT(TEV-,%V%\14E[*H\
M'_(O:A(61'#F^!"]J%@^I"E\9R]/B ^9YT/ZL-R!B?$?F$EQ*5O6]QKG DW;
M R/E"EIR$80L K(T6H8F_"Z2X8)Y]]WQ0>FO@DEML300*^ RF89B&'".,*XU
M.#%\9_TRR(Y=* \AE)#)N]J9D!+ /:A:X]QH%?'[=R.)S^%3_9NZ'$IWF!_S
M5"49'*5MC:%V<X@_10$C,/9TI#8Z--8 >AA-8%46Y9$-5I1COO=43 =O#OJ8
M=?9MA7J?>2WS7<\%H[XM"?(AYP#HUT"F.$?/>G@#-45@MO8,[@_EP8#/A<^*
M2]^1.-),UW* #['BZ"0)3+DTO01FB;%'V[)(!6=$@MC9&:8)@?]DPEPNKYF0
M79N#V=\GG<1AC;O9<BK6'[:N!S>SC^SN?5<8F9NG]<*)*!TZ@M.\PKPI0V<"
M;<BKEC%RQL97".<-W\96*!AJ'.MU]%Q^^CB$*NI_YM87QV:Y>^TNR\3$4,Q)
M/B0IG'L%<&.(_=%E.&F@,]5O\Q+4#6;O*#,2CP'0).Y-JGB7P25V>"J2#_GC
M)&>.@5)"4Y#C&_%Y1PR)U<C0R2X%T?AGKV/CZU"B-X.IC5IA[91I5>:=3B!O
M4Q 4VH8O%;5_HVY;H7?G:3"-!P'S=JUK$L:6=58 _ &\"II[C]P9:]G4FT;;
MT,[00VNJ7M2"73]M1L,P.C&D/BW&S[.:"]M\R#^8JJ_X(P'O2^Z(R#[T?<YU
MCC#.-C]5*C-!'W)1327E,AQ2KV[#ZJ(4,?V2*R/W0\C"]^D$._&JI=@F$(H[
M;>(:7/@)/+B@4Q::W'LMU+?&)_+]"\?*//IG&;AMB&1IR&%"5IKTR?X)"7%!
M:5S/4.X9![(K.A6%G:?21>7GJ30LCBK<!)&W!513H_+$R.\./'#L;&RV7PT+
M^=3Z]N?TE]J?[3U<<EKAYA;+<<\MP:K)C%]_Z_V1#&K0A+%I3+=Q]_Q?!A1%
M.[]!>2[^JPC6*'SV.Q>,88<_5HK)*R*?;SG1['GA1L"1RI -523YDN^USZ8%
MUQ<<;[5\<WSP8/3.MMY:1%N'H9@HKIMYZT-OKKS(^5QY,4L9X>%4F*1Z;X&<
M0_OS;/5>W9R/]VT<OQ0,]E$5Q?^"'DB4))HE8VF!G(*6!^_GDW/;CJT;K&PL
M*.T!S,N91.X%EHY$*(D5+@_V?NEE,^2:FQ\LF9J1RQ[L;]E2Q<%-*CJ_/-FZ
MD_S4ZG;<)A\2TM4U1MD0M7(<VY"?"NAP#]M1JN]Y)U';63)^D98K5V3JF!T(
M,XYS)J@1J_OOO3ORZ5;V=78 ^^@O-V\/.S)<+YK8;@!C1;;A_=7/.Q$.VIWI
MC(L@PFZ5(H*(8[@FYP5C2X*^G^,SQY),M:<O[("GF6J0_W-2CG8XXINL<%Z]
M8_CYOFR_NX_O:A;.&@%G/YR,W5X5]GPULN=^EOYU@-99U6:O@!:TY]0$_<1.
M(RDXN WS\50T5 1LI7^?[B$'Q;B=EO=X?R]\56?]H\VE\;"++1/Z9MZT;>NQ
MIQ=/%K_WG@K^>:?4V/I/@JOULY+CKCDAVB':GKEDD_-ZD=X_4@)8"V\J50X%
M'K"[= $(T ^9*!>T%*Y$RI1HP_1+QLQJZ),$QTKC=S8%S@7& XX+D<FDUW(%
MZMUOGF$JF(BOK^?S<$I*8$%EZ* TH].#M<;(2\<>P22P$$>#BJUFHA_O2I5T
M*O3"88]7PS-!B5!@3,X^I2G>^,.O.+L'-[TZEE3\?BRD\2'7$E#,+SC@H[E4
MX@@?(@'?Q\[#S8EHF^\;8+_O,)C''IE%D^8'BC*:4>*@-*W]708K3,-AY.FD
MN6P5R;!@?E#FO:9<_E';6^V5+=5%]VGF!#XD19JM=E*G#U-GM\ON(ES88"L\
M_/K+'-F&G+<-O<\^I5PYG\P[C,J>6_>:Y$-$8U)WC95IYYO8.O-\SI'<V*3[
M/<X$-W&[NB.=<5+^U@5(2;:F&::F4LQ?V(5P8,BY0++BTK9YB*2"N6NKV/6-
MI?FE_I0?UN$ZNXDZB9SV-N+A96\E*8[,#9?@T5ZF<5JNWHJ4!C/8N4Q]$DW
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M-@-PFY<FS)4P8<GLA>PN8["5A<\992K^['ZA:2!V "W177;X.?"V2V.$>Y5
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MG"C_ QUB7$,Z"#@OP@TN#I%Q42O,B (UKCQS[CV)Y<:@2O$FD&X,2B;T"%P
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M64KQ/@E [V36!* #/.+\/\:RY*DYPWYTXGAQ E#'2-;73<*'_E^C6U;%$2;
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M4=P=SDSD\!C3!P\A[0$.7QD)2?ECC(F+6S(0;5;FN]N(Z;:-9.6I#ZC5/SN
M@M?]#*8V#ZW_#.B;T-1*!@+#B?,$<8A(*9#3AN/$ G@'CD_,,N4"4[PFIP\P
M#VEJ/M#)=N),,KJ]0[;C<&J=S]?3/OALZ69;:6<OSI[X]T8^_S.CF>#\Q0_Z
MN2 4^(I8&*<NB>+ A"49%;R#'H<:#F$=6>&'F<5MZ!VS$9"T[YL]5I^6[D:U
M11@ *=Q4=R0-] 6XY8ZZ%L1$G''GJG4^S9\S=LJ*7W]E-4Q01JG):-AD/;?0
M>FAUG* YSE@)LSB=D^P5XJ\9.-T_GY^.K4.-JA4TH6\O-G9W:I WU7Z19P$H
M+6H+AOO,Y(H(0-<G\>7?!*#/!4[<HHVDI0)*,_?;US^P.SCDF:X2[,T@5DZ]
M/IZ! ?H\X]H;_]!-=*W,8*D-QI9*UQ4 @4<'CO6?Y!W3';U1%;[;AO R0J^/
ME<Y-GS*G;"+B!EM%2<"*C;:7=IA#5GNZ?]?41FIT;194 7? K&C,KUSV>;I#
M4H=,J+WRI937%F\I3X,MD@H2@W\6Z,!#W!_I_@PR/3DVM"R9$Z!M<VF5W4YW
M.N68FSV=88 2@+XM&A=MC&N9%)=^[C>7LNR+D70XO^N_3+-:2TM#\[V9UN\7
MG$6.1I[;>?!/RZ,##N=E&19/"X$PF]I^?;'3;9?Z[Q4V9_=9#1!OOAE$W:&3
M*@U,+=S#M&ZG3LCJDK6:FK:Z4J0J=75\ZI_5O&U2O)1YN:WL\NQ;G5$IQ6>7
M:>/W]^RG]CY=NE)IV<F'<$AM*;O9'4IGZ '!N;]_HHT9:(6+ML,WW2RE*!M!
M'A-C -)J&(TZB5I"%>?-7&VH3>QDG$W(FS[]]Y$=U8<_['BB__)RDOP3E<>S
M4?M2S\2:*VB^>'P6M.^/+U^*L]ZR0E8R,K7?_DV]5C?ARFF[5<?=]<ZTI1+1
M2M7\A$4QMXTZH$<HA*N?0N(C!E\C//S@G8D;F1WQ-L\&UY9@-D,J=7^)GY[P
M6\Q/G9:V27J0N?>0Q:SO;RM6JI6W,R8LS^[Z>C?TZ'Z06X+ZCB?I[Z8<3^0_
MWO</,Y5I(7#G0@0@SR[^8_+HB.Q4'[#:* !5"GG%>?CB0BJ)J[8B  TXK'[6
MW8##F+C-ZY&))RH^OORO#Z;*0HU3";?K[!^&^_AF&J)*)II[Z1+:>7F1US9&
M;+5>UE5?V/FM\H[&[_%WU+HRMP)<IO&=]H_S-'#)8"4LDHG;(<1K+["0KPA
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M-<=JZ!##S=V>SGI+JZ*DM2Z:!6?6U6:)221.RX0;\Q!OM__Z=5Q763<!.=4
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M];_-*XB;\CQ"C'=3L\,*L.<>/528'#75BSS*+C'MLE[U_X%/IJU8\$_A1D\
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MZ>#+Q%VN&9*_U#1T9V3UK]4%3S\U5_G+]=2P*M2!DNK&BPQL&O%SQO"9/0]
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M=F^I.Z*-"1/QYY]\,D5?6Q:=SYX@Z!0%^NPFE.2@S'P^[Y#?^:;Y.&?;%&'
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M"E(5691R0$+N3@8IH>YZ5IG^*QM)IES5"V^[\FM\GT6?_*]!*1/S*^0ZO]G
M6_[6&(WW5P,#KB\K33;'4C>TWH[.A17?'GK.</C7EQ08RZ[)GR(\)0&H.AT
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M&.-A!T16_FPV=;)!F]L/6:\&65%7,$6"2W0.4),+1//HJX^  WSYEES$/4H
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MDX.++_"[%!*]---^O_+S9[NO78"F;(C#_]I57S$C-Q[QM"<EP/Q;PBTBT#0
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MK,^JBYT_4:/YLD_G)Q52Q3"X=;J]A9,1901N)-21(OL1)B"V@[T1Q->!6_W
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MWL_:0]&^^#=02P$"% ,4    " #G@:%:7)"U@S_@ 0!551X $0
M    @ $     87-N9"TR,#(U,#,S,2YH=&U02P$"% ,4    " #G@:%:1=KI
MN!X3 0!I]Q  $0              @ %NX $ 87-N9"TR,#(U,#,S,2YX<V10
M2P$"% ,4    " #G@:%:R-L)?$TP 0  2 $ $@              @ &[\P(
M:6UG,30Y-#@Q,3DQ7S N:G!G4$L! A0#%     @ YX&A6E8%<N3HK0( H6<#
M !(              ( !."0$ &EM9S$T.30X,3$Y,5\Q+FIP9U!+ 0(4 Q0
M   ( .>!H5HQ_K9,R% !  EY 0 2              "  5#2!@!I;6<Q-#DT
M.#$Q.3%?,BYJ<&=02P$"% ,4    " #G@:%:G\X4RW/=  !PY@  $@
M        @ %((P@ :6UG,30Y-#@Q,3DQ7S,N:G!G4$L! A0#%     @ YX&A
M6L?PC0VQ" $ _0P! !(              ( !ZP ) &EM9S$T.30X,3$Y,5\T
M+FIP9U!+ 0(4 Q0    ( .>!H5JSEW_I?+T! *;O @ 2              "
M <P)"@!I;6<Q-#DT.#$Q.3%?-2YJ<&=02P$"% ,4    " #G@:%:[E&DPRDM
M 0 G30$ $@              @ %XQPL :6UG,30Y-#@Q,3DQ7S8N:G!G4$L!
M A0#%     @ YX&A6DDR/@^:R@$ KO4! !(              ( !T?0, &EM
M9S$T.30X,3$Y,5\W+FIP9U!+ 0(4 Q0    ( .>!H5H,GB("']8   [O   2
M              "  9N_#@!I;6<Q-#DT.#$Q.3%?."YJ<&=02P4&      L
,"P"^ @  ZI4/

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>asnd-20250331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:asnd="http://ascendispharma.com/20250331"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2024-03-27/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="asnd-20250331.xsd" xlink:type="simple"/>
    <context id="C_819dfe51-28d5-4314-9ec5-4ee09ed7b84b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_8277197c-cb86-45e7-aa61-4d5b1f0fbafb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_83ada807-1cec-4221-a92a-f07c205009a0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_84ecf827-5c4e-400c-9fed-cfb85e09d515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_866661ff-8c14-41eb-b4d7-4a85755a6b03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_8782f887-b4d8-4794-87db-2dcfd88fdd71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8d1b9294-057e-40e2-8f1b-8022bb139c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_8d9f98d0-af51-4f11-9756-1b080f1adc54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_8dd8b82a-4cc6-45e8-bd7c-3ba7efecfb55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_8e42c784-999f-4c5e-ad5c-d7c4484f02e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_909af02d-d3e3-49eb-8ac9-f629568438a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_90ec9194-a47f-4c6f-ba12-88ada7bf522a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_9110cafd-2d7b-4304-9249-9a5b3d9c4dfe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_935a7fad-4793-4877-9ec1-f6ddf2e4a58c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_95321c00-437c-4833-bb27-d621eaa3e8b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_975c08fa-b467-40ed-8b0f-240242f397d5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_98da32b7-acae-4c20-a13b-26ca6c11a9ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_990b5b82-ee02-43ea-90c9-a7eeb3873527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:VisenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_99940134-84fa-4775-8956-5bbfab5ab4d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_99b14b08-2c6d-4423-a4ca-73022572e1c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_9c274d2a-5811-4366-95fa-54518a9e968b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9cac6737-58ef-4123-8b45-22b55e55c632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_9f6f334e-9595-42e6-a9bd-d1e679cfd8ad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_a4ee514e-86ba-4531-8150-a8cfaa788eb8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_a633f67b-4c57-46fb-bcde-1a16d86b23b4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a7a008d3-7a3d-4804-83b9-58bcf05b742c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_a904418f-a475-4203-9ad0-fc0801b5f9a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_a9ccce3c-1020-4eff-921e-177f04314020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_ac6e452f-b851-4366-98b0-9dbd4cb50f3e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_af8ce046-66d9-47ba-a2db-115fd2735a92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanOneYearAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_b125fc88-e513-4da8-966f-995e9855cd6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_b829287e-56df-49a2-b424-3fed6680c9cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_bf7f8faa-849d-4587-84f1-bdcde1f91d6f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_c21b8c71-d449-4b9c-a8e1-039a12e96fc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c4e71d44-6541-42a1-b85a-412e5d5807d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_c79f5454-5ba5-4cc3-9ef2-650e50056d2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesYorvipathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_cbd88d82-c8c4-4bcf-bb15-ad99f773c0e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ce5fb7a1-960a-40b8-96ca-a59d1361c834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesYorvipathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_cfea5658-1faf-4539-ad78-6f615eb69073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d09921c8-e6c9-41c6-87a5-4292b2ecb35e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-12</startDate>
            <endDate>2025-02-12</endDate>
        </period>
    </context>
    <context id="C_d0d9b779-1a60-4cc4-a381-04a9bc619b06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_d182cba3-f8ff-423d-8e1e-a44b81fe3740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d39182d1-57bd-4617-8a6a-98d8b663a8a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MajorCustomersAxis">asnd:CollaborationsAndLicenseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:PerformanceObligationsAxis">asnd:RoyaltiesAndMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d394cb1a-3b0a-4dbc-a6eb-8741f78af1f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_d6ec2449-d89f-452d-9858-a0c38174ef96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_d979433b-7c92-4bed-ad15-dbb8a17d94f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_d9cca70d-ddde-47cd-a1a3-3f846e0b2ad1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_da6b292e-7c16-4b6b-be4d-1a791f59c406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_dc16f5c8-e5a3-4b82-8f15-702a29cdd088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:HedgingInstrumentsAxis">asnd:ForeignCurrencyConversionOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:LaterThanThreeYearsAndNotLaterThanFiveYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_e21b606d-3548-4aad-9554-94ae80a18cab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_e430f24c-0233-4114-a208-350b297af714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_e98d5d36-1e29-442d-a2a2-e8e647fa92b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_ebf7f8d8-9a88-4b74-9ba0-b9f6929c0ab5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ed9a4cd9-a9ca-454a-9615-64678e2fdefe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ee51bcae-74d0-4e67-89b0-e987214d4543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_ef94f77b-e835-49b6-9fa5-da367d813217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:VisenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_f1cc25de-2681-466f-9005-4cacf85b0437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_f3608329-0a27-421b-9eed-d655fd107402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f365e58b-1e31-4938-9a9f-6ae4a53dfc7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_f73819d7-55e0-42b4-8ce8-858bcc257ffe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_f8d4e6cd-e972-4517-950c-c2e4ca607adc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_faaf4bfc-6ed7-4797-9957-11c2e997c3a3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_facec156-4e04-482e-8239-ca86a66ecd9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_ff030c5c-71d1-4446-bcd4-d002a0413fae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_ff410c6d-6879-4a59-a3ae-5c1857693086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_0180a343-84b5-4550-8e9e-0e9d94787b6a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialAssetsAxis">ifrs-full:FinancialAssetsAtAmortisedCostMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_043c9c52-1128-4558-9421-751a6d2b10ae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">asnd:RestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_04aedc44-3b7e-46d5-ade6-eeb4fd969b26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_06503dc6-abee-4161-b4cf-ae017326cf5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_080c73e3-b2aa-450a-ba77-af1301298b4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_084e81ae-053b-4124-8ea0-cf00fb92aefd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_08de1782-376b-48ac-8b33-acaf2bd1c052">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="C_0ce1e53d-f85e-4cd5-8a39-323d29baed2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0ed1d82f-1028-46f4-b7d1-1a4f01140861">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_0f12ae56-033f-4e22-8363-af8518013748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1226e5c0-e438-4068-ae93-f55dd69d5fc6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_13256690-d69b-40e3-a745-f42b7767f286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_1376235c-5b88-401d-85b1-b3795ce9a8cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_17a14604-dfe5-4082-bab4-5778ed12841c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_1c3c7589-8585-40b4-8f1e-8ae31626083c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_1c8e5090-f187-4c40-bee7-aaf30930188c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:AntidilutiveSecuritiesNotIncludedInDilutedEarningsPerShareAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_1d3ec492-aaf3-4c50-8780-bc2563b2b216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfInterestRatesAxis">ifrs-full:FixedInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="C_226651eb-e9b1-44d1-82dd-4b5f380929d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_27448f17-97d9-4695-8836-7cbae988447b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_290aeeba-a386-42b8-856c-a68d382312e1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentySixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_2a483356-316b-4a65-8bf7-a9551532b29b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_2c892acc-02da-4c15-9353-950413a810ff">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="C_2e1b63bd-d863-46b8-8fa6-18b4bf555975">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">asnd:AmericanDepositorySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">asnd:ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_351470c2-85b2-48d4-96cb-01998edc0281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_36356f4b-0e07-4b7c-876a-5c08a3b2de70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_36943fab-c0c6-4437-adcd-1f9a290d164c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesSkytrofaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="C_3b05cb12-2e51-444c-a128-f7f8902c20db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3c3f2d33-74af-4a32-80dc-2766d5dbca67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3cb7ddc6-ca0e-4f90-83dc-2681c7bb17c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_3d08e8ed-f880-4006-95c6-262b0ebc3c04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">ifrs-full:DerivativesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">asnd:SharePriceMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_41423738-faf9-4d2a-bcc1-37650e709689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_41b6f38d-a596-4e87-b38c-e28360d02d02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">asnd:FairValueHierarchyCarryingAmountMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_434feb09-9876-4024-9170-6094ccac6b87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="asnd:VestingOfSharesAxis">asnd:TwoThousandAndTwentyEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_4a04a12f-c2bb-4f60-9173-69088979902b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_4a87b703-b453-4069-82f0-40f1f09886fb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">country:DK</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4e24ca41-f7d8-4b85-bcc0-e6602bf707f4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="C_4f687d92-bd5b-418e-bafe-85fdef35c02e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_4ffe96aa-eccd-4c58-806f-aeb003cfacb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_53d7776f-82d5-4f1e-a852-ddb489a39552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_5b83b77f-547e-42d3-9a2c-5c6ae9438f49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:IncomeStatementAxis">asnd:ProfitLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_5eb53229-0864-44c9-9f9d-2c5f527f1088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:MaturityAxis">ifrs-full:NotLaterThanOneYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_62ad3de7-4eca-483d-b815-5062d2cbf5a5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="C_650908d3-c211-42ad-819c-acf17f2e9e86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:RoyaltyPharmaUnitedStatesYorvipathMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-09-03</startDate>
            <endDate>2024-09-03</endDate>
        </period>
    </context>
    <context id="C_65c9897b-d13e-4f01-a77c-114baa4945b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_685d7bbe-e597-4efe-81c5-62074784e614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:VisenPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-21</startDate>
            <endDate>2025-03-21</endDate>
        </period>
    </context>
    <context id="C_6d2a3784-98f4-4b88-81d4-8cfaf226f5fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfExchangeDifferencesOnTranslationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="C_6df1c7ad-9308-4d74-81ba-3a4e8314fa4f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfFinancialInstrumentsAxis">asnd:ConvertibleSeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_6f20e6a7-a161-4a7a-8def-bd1f1b851f84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">asnd:UnitedStatesSkytrofaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_76d949ec-eebb-4b57-b947-ed0df0081070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_76e6e803-d4db-4b29-9ab8-219028b47903">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:GeographicalAreasAxis">srt:NorthAmericaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_76ef0cc1-54a9-485d-af12-f694616423d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsAndPerformanceStockUnitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_79d64e56-848d-43de-a89c-390b0257c619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:RestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_7c0a269e-a617-410a-a9a6-957f53860b47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:TreasurySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="C_7dc36b02-c138-4fcc-b62f-16eb456e91be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="asnd:ShareBasedPaymentArrangementAwardTypeAxis">asnd:PerformanceStockUnitProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="C_7ebbd176-7e24-4431-8904-088669448bc7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001612042</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">asnd:Warrant1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <unit id="U_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_DkkPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:DKK</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_UnitedStatesOfAmericaDollarsShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_Multiple">
        <measure>asnd:Multiple</measure>
    </unit>
    <unit id="U_Days">
        <measure>asnd:Days</measure>
    </unit>
    <unit id="U_Segment">
        <measure>asnd:Segment</measure>
    </unit>
    <unit id="U_XBB">
        <measure>iso4217:XBB</measure>
    </unit>
    <unit id="U_EurPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:EUR</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_HkPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:HKD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_f2cf25c4-038c-4484-b84c-37f91bd227bb">0001612042</dei:EntityCentralIndexKey>
    <dei:DocumentPeriodEndDate
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_c0654d5c-1874-4d66-b463-3092a66edcbd">2025-03-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_72311a40-51cd-40a6-bc29-cfa61cfce1cf">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_37a85b0b-0f71-44f0-985d-5ff41358175d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_c451b9bd-d4fc-4fbd-bc67-4f897c1d8a45">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentType
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_57b57f06-d777-425f-ae5b-2898aed08b29">6-K</dei:DocumentType>
    <dei:DocumentFiscalYearFocus
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_e140cf13-9958-4211-b2d4-6d4cf1289dc5">2025</dei:DocumentFiscalYearFocus>
    <dei:EntityRegistrantName
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_a08824b7-7c36-4fdc-82ae-9c002e657968">Ascendis Pharma A/S</dei:EntityRegistrantName>
    <ifrs-full:Revenue
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_75db0625-7d60-47ca-9e63-264474ed104a"
      unitRef="U_EUR">100954000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_13b2878f-a76c-469f-b095-b15abf951f03"
      unitRef="U_EUR">95894000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_00757fb4-ccec-419e-b455-25adf7f0d093"
      unitRef="U_EUR">17517000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_329dbb35-d8ef-41ae-b64f-898aabb884ca"
      unitRef="U_EUR">7569000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_a80f5787-f38b-4a60-909f-39497046abc8"
      unitRef="U_EUR">83437000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_2346e90a-a178-4628-812e-a591762c8d75"
      unitRef="U_EUR">88325000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_7ba1e2d8-869a-43e9-9d80-095a609684e9"
      unitRef="U_EUR">86603000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_cbeedbe4-a48d-487b-977c-4666ed8d8e75"
      unitRef="U_EUR">70687000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_64d986a5-e866-488a-bd4b-5bf43fc610dc"
      unitRef="U_EUR">101046000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_470323ca-42a2-4d42-b527-5fbf7462b9d3"
      unitRef="U_EUR">66783000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_dbead0cd-f66a-4a39-bef3-0dc2f494205f"
      unitRef="U_EUR">-104212000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_77da58b6-846e-453e-911b-00ccef1d574f"
      unitRef="U_EUR">-49145000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_46eba6bc-5c2b-4eb7-ad5a-504689ab3a9a"
      unitRef="U_EUR">26579000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_6ad48c08-aaad-4c12-a947-12d827a28d0d"
      unitRef="U_EUR">-5796000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:FinanceIncome
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_a10ab0a1-1e4e-48c5-996f-2a19e00be422"
      unitRef="U_EUR">28854000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_1f0568b1-19a2-470d-ac44-cb881dedcc11"
      unitRef="U_EUR">3575000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_ef055c3a-c308-463c-8682-55f2c9ec577f"
      unitRef="U_EUR">44786000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_b0fa5691-78ef-41d7-8fb6-65bfdb2ea481"
      unitRef="U_EUR">77161000</ifrs-full:FinanceCosts>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_fde4415e-236f-48d0-b3d8-947b595f0789"
      unitRef="U_EUR">-93565000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:ProfitLossBeforeTax
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_f59f63e9-0d4a-4b19-8b62-ffa15c51322b"
      unitRef="U_EUR">-128527000</ifrs-full:ProfitLossBeforeTax>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_5bacf309-c117-495e-93b4-6a07f6e7116a"
      unitRef="U_EUR">1061000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_4b8277e3-70fb-44e9-a4b9-973e97d9f662"
      unitRef="U_EUR">2508000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:ProfitLoss
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_3bf475a7-5aec-44f5-ba4f-85751d04026b"
      unitRef="U_EUR">-94626000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_a3c29925-0784-440f-973f-3d686ad9657d"
      unitRef="U_EUR">-131035000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_f241af0d-99ce-4e25-b503-63fd9ed5f8f9"
      unitRef="U_EUR">-94626000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:ProfitLossAttributableToOwnersOfParent
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_42c06cb1-87db-4e59-898e-e90fc2f1a49a"
      unitRef="U_EUR">-131035000</ifrs-full:ProfitLossAttributableToOwnersOfParent>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="2"
      id="F_010e2736-aa71-406a-8cc7-fb86585be8b9"
      unitRef="U_EurPerShare">-1.58</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="2"
      id="F_7f58efb0-1dae-42d4-80e5-c88a60655465"
      unitRef="U_EurPerShare">-1.58</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="2"
      id="F_87653904-2912-4b4a-ad3c-c81105e00a1f"
      unitRef="U_EurPerShare">-2.3</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="2"
      id="F_0bbbb128-c349-435c-81b2-8f39f047af5f"
      unitRef="U_EurPerShare">-2.3</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="0"
      id="F_9e4d657f-478f-4433-bce1-27fd0273275a"
      unitRef="U_shares">60018550</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="0"
      id="F_54a2db4f-0a64-42f5-8719-d72d0fff50fc"
      unitRef="U_shares">56883257</ifrs-full:WeightedAverageShares>
    <ifrs-full:ProfitLoss
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_be73e098-e453-4629-90aa-48a4f3349b23"
      unitRef="U_EUR">-94626000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_7fa36d63-3c00-4050-8acc-365dc5de2372"
      unitRef="U_EUR">-131035000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_3f3b9d9b-bd3e-44d3-bac6-d1bebe3940b9"
      unitRef="U_EUR">-75000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_d64351c3-2098-42cc-b0f4-39f137a8c833"
      unitRef="U_EUR">63000</ifrs-full:OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_d5a7de9d-bcf9-4be7-a8b9-bd52c8df48f4"
      unitRef="U_EUR">-75000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_9001a691-c0dc-4c09-b1ee-f241a3a77ef3"
      unitRef="U_EUR">63000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_79f888bd-dd25-4a14-86d4-2045a8d5d69f"
      unitRef="U_EUR">-94701000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_0cfc78e8-4e7d-4601-b0c3-d891572f8b63"
      unitRef="U_EUR">-130972000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_037f0420-4498-4ecd-a7e5-913e4068a641"
      unitRef="U_EUR">-94701000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_6522d9b1-7660-4b76-b4b8-37efe57f8a01"
      unitRef="U_EUR">-130972000</ifrs-full:ComprehensiveIncomeAttributableToOwnersOfParent>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="0"
      id="F_ca4defbf-7d8e-42c3-ac39-3803aa7e3128"
      unitRef="U_shares">6017157</asnd:NumberOfWarrantsOutstanding>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="0"
      id="F_7ce0a0aa-a0c0-4512-a064-0b0293180562"
      unitRef="U_shares">6031498</asnd:NumberOfWarrantsOutstanding>
    <asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares
      contextRef="C_9c274d2a-5811-4366-95fa-54518a9e968b"
      decimals="0"
      id="F_aa94a497-32c1-498c-9312-edf9a920a758"
      unitRef="U_shares">575000</asnd:PotentialConversionOfConvertibleSeniorNotesIntoNumberOfOrdinaryShares>
    <asnd:NumberOfWarrantsOutstanding
      contextRef="C_1c8e5090-f187-4c40-bee7-aaf30930188c"
      decimals="0"
      id="F_cabc28a0-d2a6-4fc1-b4ec-66eef6b60ad2"
      unitRef="U_shares">3456785</asnd:NumberOfWarrantsOutstanding>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_6b7dceeb-2795-4594-ac46-2f88a5033d7e"
      unitRef="U_EUR">3909000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:IntangibleAssetsAndGoodwill
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_939eaeaa-6f21-4e06-b125-a4f7418bcf51"
      unitRef="U_EUR">4028000</ifrs-full:IntangibleAssetsAndGoodwill>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_757cac15-5ace-496d-b723-62e36f8d0c18"
      unitRef="U_EUR">92447000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_1226b186-3517-4217-8a3f-7430379b82fb"
      unitRef="U_EUR">98714000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:InvestmentsInAssociates
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_d9bd575f-d9c4-4828-ab45-c1c3a3cd9972"
      unitRef="U_EUR">40938000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:InvestmentsInAssociates
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_114675d2-77d7-49d5-a82f-a8137c556dd2"
      unitRef="U_EUR">13575000</ifrs-full:InvestmentsInAssociates>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_61bb4aee-1225-4469-8da4-d71027a9acb2"
      unitRef="U_EUR">2657000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:OtherNoncurrentReceivables
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_73b9b40d-7f69-44a0-90dc-1f9c10d4a0f9"
      unitRef="U_EUR">2317000</ifrs-full:OtherNoncurrentReceivables>
    <ifrs-full:NoncurrentAssets
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_a9124cea-5b21-4040-b982-05646f6e125f"
      unitRef="U_EUR">139951000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_d1ee9ba1-bc0b-4678-bf85-b83218aa94a6"
      unitRef="U_EUR">118634000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Inventories
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_29da52a2-88da-4b7d-a4fd-ab6c0c2d5d9f"
      unitRef="U_EUR">293071000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_dc3aec69-9f5d-44e5-99ce-b8acb0ea7238"
      unitRef="U_EUR">295609000</ifrs-full:Inventories>
    <ifrs-full:CurrentTradeReceivables
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_7b16d402-51ac-4294-a130-a34d9c1d1397"
      unitRef="U_EUR">66685000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTradeReceivables
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_bfea62af-a3f4-4f86-a92e-040a99c8e409"
      unitRef="U_EUR">166280000</ifrs-full:CurrentTradeReceivables>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_71cb1531-7a5b-413b-b0ff-8cf7cb6ee773"
      unitRef="U_EUR">1614000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:CurrentTaxAssetsCurrent
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_84029437-ef61-45ef-8ab9-f21d284825ec"
      unitRef="U_EUR">1775000</ifrs-full:CurrentTaxAssetsCurrent>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_2d4e5785-42fb-4561-8786-b84c25bb4ef5"
      unitRef="U_EUR">8522000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:OtherCurrentReceivables
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_fa99376a-4002-408f-998b-bf2c9eeeebff"
      unitRef="U_EUR">9385000</ifrs-full:OtherCurrentReceivables>
    <ifrs-full:CurrentPrepayments
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_80920282-aca6-4876-bc9b-bb2d4f18bb8e"
      unitRef="U_EUR">33672000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CurrentPrepayments
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_5533b535-f6da-4749-8e85-b1b12d41775c"
      unitRef="U_EUR">28269000</ifrs-full:CurrentPrepayments>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_cc30886e-96dd-448f-8884-a88961610f27"
      unitRef="U_EUR">517923000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_78eba5d8-980d-4125-a6f0-8038ddcebc9e"
      unitRef="U_EUR">559543000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentAssets
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_e9ae4e68-bb9e-4ccb-a960-2a3ba781680c"
      unitRef="U_EUR">921487000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_8acfffca-141c-4375-bd47-136c081ca9cf"
      unitRef="U_EUR">1060861000</ifrs-full:CurrentAssets>
    <ifrs-full:Assets
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_0261099a-0d73-4bb4-b90b-4c566cd80524"
      unitRef="U_EUR">1061438000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_e8d50a3b-1aee-4128-b7b0-e83adff5db13"
      unitRef="U_EUR">1179495000</ifrs-full:Assets>
    <ifrs-full:IssuedCapital
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_47551b81-81f7-4ca3-8664-b5324fa285a6"
      unitRef="U_EUR">8187000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_cd45d026-03ed-40a1-8e53-f5f7d2713abf"
      unitRef="U_EUR">8149000</ifrs-full:IssuedCapital>
    <asnd:DistributableEquity
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_63756cdb-d80e-46ce-8d0b-625f49fa5435"
      unitRef="U_EUR">-197994000</asnd:DistributableEquity>
    <asnd:DistributableEquity
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_c1781e5e-d827-471b-83c3-1ee4617483b0"
      unitRef="U_EUR">-113855000</asnd:DistributableEquity>
    <ifrs-full:Equity
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_f9dc2101-db1c-4a60-bb50-a626dc070448"
      unitRef="U_EUR">-189807000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_7c999d42-4e61-4b01-a786-a18aa247e2f0"
      unitRef="U_EUR">-105706000</ifrs-full:Equity>
    <ifrs-full:LongtermBorrowings
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_54ea4066-e937-4c60-bafb-28d62e845061"
      unitRef="U_EUR">357312000</ifrs-full:LongtermBorrowings>
    <ifrs-full:LongtermBorrowings
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_3f99752d-b49b-4c45-9182-7c7a3f309664"
      unitRef="U_EUR">365080000</ifrs-full:LongtermBorrowings>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_a9a8dc1d-f84a-4115-9203-31e5cda6e791"
      unitRef="U_EUR">692000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:NoncurrentContractLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_5158ed34-8415-4211-a2c3-81f1b78fa727"
      unitRef="U_EUR">5000000</ifrs-full:NoncurrentContractLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_a838692f-94b0-4d64-9034-344721ec9d35"
      unitRef="U_EUR">7733000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:DeferredTaxLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_0a46c21e-47a8-48ce-88a0-8f84fd75c75c"
      unitRef="U_EUR">7258000</ifrs-full:DeferredTaxLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_f878320d-7916-4476-8680-ed0bcd657d3b"
      unitRef="U_EUR">365737000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_e5b01b31-e4b5-4aab-abcc-b7c6489a30f1"
      unitRef="U_EUR">377338000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:ShorttermBorrowings
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_7080ecaf-bfc1-465c-8c0f-82799d1b59e8"
      unitRef="U_EUR">449562000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:ShorttermBorrowings
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_ec6c8c7c-15a5-4e3f-b779-7b56af22bb3e"
      unitRef="U_EUR">458207000</ifrs-full:ShorttermBorrowings>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_0779233d-a24b-456f-b815-f18d2353bc75"
      unitRef="U_EUR">174581000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_1201a739-e52a-48d8-ad6f-705dfe555097"
      unitRef="U_EUR">150670000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <asnd:ConvertibleNotesCurrent
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_fdd3ebb6-3f9c-44b0-a4d1-df7087f8897b"
      unitRef="U_EUR">624143000</asnd:ConvertibleNotesCurrent>
    <asnd:ConvertibleNotesCurrent
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_4934b513-87bd-45c0-b7a3-38afe53750be"
      unitRef="U_EUR">608877000</asnd:ConvertibleNotesCurrent>
    <asnd:ShortTermBorrowingOther
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_2dcad403-a876-4a62-b817-7095b7bbe6de"
      unitRef="U_EUR">40398000</asnd:ShortTermBorrowingOther>
    <asnd:ShortTermBorrowingOther
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_03079570-0d24-4c8b-b6c4-78a0540bdc75"
      unitRef="U_EUR">33329000</asnd:ShortTermBorrowingOther>
    <ifrs-full:CurrentContractLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_a95111a1-a025-4e81-a09a-fdfd9617d6fc"
      unitRef="U_EUR">1190000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:CurrentContractLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_c22a0164-0755-4863-8c2a-be533f4bb661"
      unitRef="U_EUR">936000</ifrs-full:CurrentContractLiabilities>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_1cf85990-c4e1-48e7-a7f1-99a90868d248"
      unitRef="U_EUR">84370000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_ddbbd8fc-3631-4fd3-a6ec-63ed035a898b"
      unitRef="U_EUR">96394000</ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_0da8e3fd-bdab-429e-b2ca-fd527185f160"
      unitRef="U_EUR">38062000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:OtherCurrentLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_a597b8d9-d692-4d75-806a-735ada7325de"
      unitRef="U_EUR">67956000</ifrs-full:OtherCurrentLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_436b4487-b105-4425-8344-0975eb3cf6a3"
      unitRef="U_EUR">1573000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentTaxLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_02aa0275-a410-42e2-84bd-30a22958ab34"
      unitRef="U_EUR">1222000</ifrs-full:CurrentTaxLiabilities>
    <ifrs-full:CurrentProvisions
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_e56774fb-a74a-47ff-aa45-cac0d42c9b09"
      unitRef="U_EUR">95772000</ifrs-full:CurrentProvisions>
    <ifrs-full:CurrentProvisions
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_fbc42b50-66f6-4da9-a250-a51e10e54e3a"
      unitRef="U_EUR">99149000</ifrs-full:CurrentProvisions>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_b881e958-e8cf-4fe8-ae70-263e93196401"
      unitRef="U_EUR">261365000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:OtherCurrentFinancialLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_08fa6aa8-bd86-4c9b-8252-8ebee5987701"
      unitRef="U_EUR">298986000</ifrs-full:OtherCurrentFinancialLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_05642524-f1e0-428b-86d4-9f5cc9173366"
      unitRef="U_EUR">885508000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_775f8892-781e-4e7c-b104-0a16f1512816"
      unitRef="U_EUR">907863000</ifrs-full:CurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_ad08ebed-f4d7-4ecb-8e08-95bab613b7aa"
      unitRef="U_EUR">1251245000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_cb3e32f2-ad26-4193-bd3e-2a98011c6687"
      unitRef="U_EUR">1285201000</ifrs-full:Liabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_088a18d9-ac12-4291-87ad-b33b03d041b1"
      unitRef="U_EUR">1061438000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_921b3e54-0974-4f61-9de5-64a50b1a01ec"
      unitRef="U_EUR">1179495000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="C_a904418f-a475-4203-9ad0-fc0801b5f9a8"
      decimals="-3"
      id="F_d3db7f86-8d28-460a-9440-4ab47e7050dd"
      unitRef="U_EUR">8149000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_d0d9b779-1a60-4cc4-a381-04a9bc619b06"
      decimals="-3"
      id="F_4b4bf6d0-806e-4c00-b27b-c1e329efe5ca"
      unitRef="U_EUR">2444175000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_7c0a269e-a617-410a-a9a6-957f53860b47"
      decimals="-3"
      id="F_97c8b315-09cf-4455-9c74-059630286fe1"
      unitRef="U_EUR">-113000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_226651eb-e9b1-44d1-82dd-4b5f380929d8"
      decimals="-3"
      id="F_26e54fa2-ae81-4130-8741-36f13ca54f93"
      unitRef="U_EUR">1783000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_8e42c784-999f-4c5e-ad5c-d7c4484f02e6"
      decimals="-3"
      id="F_1691dc2c-d3cd-4e1c-9b6e-dc3008647c92"
      unitRef="U_EUR">-2559700000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_371462b7-1097-4a3d-9970-25c113da8ce2"
      unitRef="U_EUR">-105706000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281"
      decimals="-3"
      id="F_250a7375-e2dc-42d9-b86c-bc7fa3e9a803"
      unitRef="U_EUR">-94626000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_23953e66-2211-4130-99d2-0cd65b0429f9"
      unitRef="U_EUR">-94626000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_53d7776f-82d5-4f1e-a852-ddb489a39552"
      decimals="-3"
      id="F_55b9f4d4-eba0-4e72-8395-9ca2f066155d"
      unitRef="U_EUR">-75000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_cf327139-9977-447d-ad58-25cf5a0fd271"
      unitRef="U_EUR">-75000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_53d7776f-82d5-4f1e-a852-ddb489a39552"
      decimals="-3"
      id="F_c5c9d277-663e-47cc-b1a4-bd870744a0a3"
      unitRef="U_EUR">-75000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281"
      decimals="-3"
      id="F_9ead8e43-0ee8-47ad-b74c-d5798315c387"
      unitRef="U_EUR">-94626000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_87437602-7f31-4a48-9e26-0d73c9cd223e"
      unitRef="U_EUR">-94701000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281"
      decimals="-3"
      id="F_2615997d-9e43-41b3-b1bc-98d90a6b8de6"
      unitRef="U_EUR">25558000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_cbcc3102-56aa-4d98-8946-8a497d70d32b"
      unitRef="U_EUR">25558000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="C_d6ec2449-d89f-452d-9858-a0c38174ef96"
      decimals="-3"
      id="F_b795aff1-373f-4ed1-a045-228fa4cbb647"
      unitRef="U_EUR">16000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281"
      decimals="-3"
      id="F_ec6e113f-636b-4211-be9e-b67b1eee769a"
      unitRef="U_EUR">17380000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:PurchaseOfTreasuryShares
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_7f0cf22e-d97e-4298-bd9c-1e30f8e2fc9d"
      unitRef="U_EUR">17396000</ifrs-full:PurchaseOfTreasuryShares>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_d6ec2449-d89f-452d-9858-a0c38174ef96"
      decimals="-3"
      id="F_3e956ae6-ca0c-402d-968e-565720a7eef9"
      unitRef="U_EUR">49000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281"
      decimals="-3"
      id="F_08d4ba98-06b1-43c6-a6b6-418f0794e2f5"
      unitRef="U_EUR">-49000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <asnd:NetSettlementUnderStockIncentivePrograms
      contextRef="C_351470c2-85b2-48d4-96cb-01998edc0281"
      decimals="-3"
      id="F_e67a78b7-e9b0-4cd2-a640-c8ab721671a8"
      unitRef="U_EUR">-11396000</asnd:NetSettlementUnderStockIncentivePrograms>
    <asnd:NetSettlementUnderStockIncentivePrograms
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_b55fd53b-fc08-4745-8456-45a249ba4317"
      unitRef="U_EUR">-11396000</asnd:NetSettlementUnderStockIncentivePrograms>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_ff410c6d-6879-4a59-a3ae-5c1857693086"
      decimals="-3"
      id="F_2a28a812-9ff1-4c79-8597-dd930c0d0956"
      unitRef="U_EUR">38000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_65c9897b-d13e-4f01-a77c-114baa4945b3"
      decimals="-3"
      id="F_e6437c33-a44e-4923-80e7-c25fb69c7db8"
      unitRef="U_EUR">13796000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_1b317c03-67c1-42fa-8cb6-314a59e6123e"
      unitRef="U_EUR">13834000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="C_a4ee514e-86ba-4531-8150-a8cfaa788eb8"
      decimals="-3"
      id="F_0905e98d-fa33-48ad-96fd-7d0397bea481"
      unitRef="U_EUR">8187000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_76d949ec-eebb-4b57-b947-ed0df0081070"
      decimals="-3"
      id="F_8a985ab4-87a0-4e8d-bb09-ec765f2a7a9b"
      unitRef="U_EUR">2457971000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_cbd88d82-c8c4-4bcf-bb15-ad99f773c0e4"
      decimals="-3"
      id="F_5317c889-c295-487b-9505-ed756c81be38"
      unitRef="U_EUR">-80000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_f8d4e6cd-e972-4517-950c-c2e4ca607adc"
      decimals="-3"
      id="F_d2550266-a050-4c1e-99ef-c357edc2a5ca"
      unitRef="U_EUR">1708000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_83ada807-1cec-4221-a92a-f07c205009a0"
      decimals="-3"
      id="F_34f86f73-3b96-4705-bc5c-1afa3b6c4849"
      unitRef="U_EUR">-2657593000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_7e2d8af0-eb7d-4f43-9f77-1f69b9814a30"
      unitRef="U_EUR">-189807000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_c4e71d44-6541-42a1-b85a-412e5d5807d3"
      decimals="-3"
      id="F_ef7b1dda-1421-40d1-b2b9-f84616de9280"
      unitRef="U_EUR">7749000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_1376235c-5b88-401d-85b1-b3795ce9a8cc"
      decimals="-3"
      id="F_3646271b-26cc-4c86-91fa-c621a5b492d5"
      unitRef="U_EUR">2123074000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_4e24ca41-f7d8-4b85-bcc0-e6602bf707f4"
      decimals="-3"
      id="F_83822012-a219-48be-b114-e14bd1aa70c6"
      unitRef="U_EUR">-146000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_866661ff-8c14-41eb-b4d7-4a85755a6b03"
      decimals="-3"
      id="F_cb5ebdca-7f79-4ce7-a629-8de6294bd1c8"
      unitRef="U_EUR">721000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_c21b8c71-d449-4b9c-a8e1-039a12e96fc6"
      decimals="-3"
      id="F_b0ebea4a-f61f-4763-bdf6-67e9f5258cb2"
      unitRef="U_EUR">-2277095000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_17a14604-dfe5-4082-bab4-5778ed12841c"
      decimals="-3"
      id="F_a42e8cc0-ba6b-483a-a96f-fa0d984c2a6d"
      unitRef="U_EUR">-145697000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c"
      decimals="-3"
      id="F_da758bc8-d9a0-45a3-96d0-480d2bded778"
      unitRef="U_EUR">-131035000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_b77db574-38a8-4dfa-bef4-a93bda9d4845"
      unitRef="U_EUR">-131035000</ifrs-full:ProfitLoss>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_6d2a3784-98f4-4b88-81d4-8cfaf226f5fc"
      decimals="-3"
      id="F_0606d50d-f5a4-4065-89a3-7d0cd2753757"
      unitRef="U_EUR">63000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_7aae737c-5875-4de5-976b-6a1e442c3778"
      unitRef="U_EUR">63000</ifrs-full:OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_6d2a3784-98f4-4b88-81d4-8cfaf226f5fc"
      decimals="-3"
      id="F_d532bad1-2a86-4bd0-8e0d-cd6f247699d2"
      unitRef="U_EUR">63000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c"
      decimals="-3"
      id="F_3082c5f6-efbb-4be9-a292-d109a05a99da"
      unitRef="U_EUR">-131035000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:ComprehensiveIncome
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_7b6219bf-1032-4593-b7e8-58cdbd2b23d9"
      unitRef="U_EUR">-130972000</ifrs-full:ComprehensiveIncome>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c"
      decimals="-3"
      id="F_9db77b79-0fc0-4ff6-b9e1-0e7a0b542b6d"
      unitRef="U_EUR">17281000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_e3e49c1a-d08c-4a7d-a9ed-afbf112b3159"
      unitRef="U_EUR">17281000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_a9ccce3c-1020-4eff-921e-177f04314020"
      decimals="-3"
      id="F_7032d2a9-d820-4441-be02-7e077376b235"
      unitRef="U_EUR">28000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:SaleOrIssueOfTreasuryShares
      contextRef="C_9800b9cb-666d-4730-bc1b-bd132e9f1a7c"
      decimals="-3"
      id="F_ee34a1c9-97dd-4bad-bb73-ca051d06b72b"
      unitRef="U_EUR">-28000</ifrs-full:SaleOrIssueOfTreasuryShares>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_98da32b7-acae-4c20-a13b-26ca6c11a9ae"
      decimals="-3"
      id="F_c24cabdb-3e34-421c-a60b-f01692346ebe"
      unitRef="U_EUR">69000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_4f687d92-bd5b-418e-bafe-85fdef35c02e"
      decimals="-3"
      id="F_8a459a0d-680e-44f6-996f-f263d5cc9d14"
      unitRef="U_EUR">21140000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_660f40bf-6814-4a9c-a356-83fe06cc90c0"
      unitRef="U_EUR">21209000</ifrs-full:IncreaseDecreaseThroughTransactionsWithOwners>
    <ifrs-full:Equity
      contextRef="C_41423738-faf9-4d2a-bcc1-37650e709689"
      decimals="-3"
      id="F_9ad6c852-45f1-4ef0-b8ed-0c3a9af2d6eb"
      unitRef="U_EUR">7818000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_8dd8b82a-4cc6-45e8-bd7c-3ba7efecfb55"
      decimals="-3"
      id="F_75a21b35-7ad1-43d2-a295-596936c82097"
      unitRef="U_EUR">2144214000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_95321c00-437c-4833-bb27-d621eaa3e8b8"
      decimals="-3"
      id="F_08e212cc-f7d9-4477-bddc-e5d15bc961a5"
      unitRef="U_EUR">-118000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_62ad3de7-4eca-483d-b815-5062d2cbf5a5"
      decimals="-3"
      id="F_55960f7c-5d32-4520-928c-f820af24e848"
      unitRef="U_EUR">784000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_9f6f334e-9595-42e6-a9bd-d1e679cfd8ad"
      decimals="-3"
      id="F_85329f3c-92a9-4833-9436-466d609da408"
      unitRef="U_EUR">-2390877000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4"
      decimals="-3"
      id="F_5e2206e9-67b4-4893-90c6-0c16d6cfd4b6"
      unitRef="U_EUR">-238179000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_53765ade-166e-400c-8a74-275c299c7d6c"
      unitRef="U_EUR">-94626000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_307dba81-ac9f-4d25-a288-ab210220d68a"
      unitRef="U_EUR">-131035000</ifrs-full:ProfitLoss>
    <ifrs-full:FinanceIncome
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_d2cc0650-87f3-4d22-839a-6ccd7e41ef4b"
      unitRef="U_EUR">28854000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_34054e9b-82da-42a5-8ea2-614325791208"
      unitRef="U_EUR">3575000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_ae8420b7-6db8-4747-be2b-46b4e81449f1"
      unitRef="U_EUR">44786000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_1a848538-4f5d-494e-92dd-f090165087df"
      unitRef="U_EUR">77161000</ifrs-full:FinanceCosts>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_e7c631ea-3e2c-4e2e-bde3-9b6c48c6e243"
      unitRef="U_EUR">0</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_114b354b-59f1-48b4-aaad-ec4cc7a980d6"
      unitRef="U_EUR">91000</ifrs-full:GainsLossesOnDisposalsOfPropertyPlantAndEquipment>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_97f33022-75f2-484f-aa12-905c9cc46ea8"
      unitRef="U_EUR">1061000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <ifrs-full:IncomeTaxExpenseContinuingOperations
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_41f6ea0b-9924-4642-b82b-35c30611ade9"
      unitRef="U_EUR">2508000</ifrs-full:IncomeTaxExpenseContinuingOperations>
    <asnd:AdjustmentsForNonCashConsiderationRegardingRevenue
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_fae34957-34a9-405c-8b87-233f79d115da"
      unitRef="U_EUR">1402000</asnd:AdjustmentsForNonCashConsiderationRegardingRevenue>
    <asnd:AdjustmentsForNonCashConsiderationRegardingRevenue
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_31cad99d-0faa-440c-a112-38c016f57331"
      unitRef="U_EUR">24770000</asnd:AdjustmentsForNonCashConsiderationRegardingRevenue>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_b2eeae59-53e9-427a-9587-532e9d6257e8"
      unitRef="U_EUR">26579000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_f2d157f2-971f-4ff3-87fd-5893c458b0ae"
      unitRef="U_EUR">-5796000</ifrs-full:ShareOfProfitLossOfAssociatesAccountedForUsingEquityMethod>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_de8a394d-d7ae-48a9-bb1d-946715dccf8e"
      unitRef="U_EUR">25558000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_6d36d971-f717-4cb6-a2c0-ac9b5f5ea8db"
      unitRef="U_EUR">17281000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_c83f99b7-30f7-479e-ae6a-a922a03579b5"
      unitRef="U_EUR">4426000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_44486be0-9b01-4683-8bee-dd2f3ef4cec0"
      unitRef="U_EUR">4359000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_d2c3b8f3-6c84-4ffc-822d-e0fe43628ba9"
      unitRef="U_EUR">7508000</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_9fb4dd5d-ccdf-43da-812d-36d7b4ff6068"
      unitRef="U_EUR">0</ifrs-full:AdjustmentsForImpairmentLossReversalOfImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_f04b6a8b-b2e4-4e88-98a9-546fca4fc6ef"
      unitRef="U_EUR">119000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_af351725-3250-4f0e-9c39-5b9498ef00b2"
      unitRef="U_EUR">118000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_ede7b8fe-0fa9-4b2b-8076-1caf6323813a"
      unitRef="U_EUR">2538000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_c900aa32-f9b7-4567-8f46-33d0dfbf520c"
      unitRef="U_EUR">-23750000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_076e5154-0239-4171-bd7a-50c62f7c2949"
      unitRef="U_EUR">98032000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_638a433e-be8a-48dd-ad1b-0faf0e08d885"
      unitRef="U_EUR">-11286000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_0cc67f51-d5d5-4788-95c3-7933e5fa5390"
      unitRef="U_EUR">-5521000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_8b9edacc-a146-44aa-a539-0fef8a0721f0"
      unitRef="U_EUR">-3904000</ifrs-full:AdjustmentsForDecreaseIncreaseInPrepaidExpenses>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_372981b2-9b9d-424c-a1d2-ab9f58c032c5"
      unitRef="U_EUR">-4054000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_5b056389-f721-4a1c-affa-bc08647e3f90"
      unitRef="U_EUR">-950000</ifrs-full:AdjustmentsForIncreaseDecreaseInDeferredIncomeIncludingContractLiabilities>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_89dcffc1-8a83-454b-a714-8dcb1974ef33"
      unitRef="U_EUR">-40767000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_b72c249b-3861-425f-b52b-7e83ba73e8c1"
      unitRef="U_EUR">-19025000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_d05c361a-2b6a-4de3-81f9-f9b040e7fa43"
      unitRef="U_EUR">260000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:AdjustmentsForProvisions
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_6ceacd0f-8f5e-4885-92c8-bf70505a3290"
      unitRef="U_EUR">7076000</ifrs-full:AdjustmentsForProvisions>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_ff4ec38e-72cd-4b5e-a85c-317039030df0"
      unitRef="U_EUR">-17515000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:CashFlowsFromUsedInOperations
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_9350fb55-04b4-4799-a872-3d3aa711c4a3"
      unitRef="U_EUR">-104087000</ifrs-full:CashFlowsFromUsedInOperations>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_e4ea1124-395d-485f-b6a0-7ff4ec45cbb5"
      unitRef="U_EUR">4208000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_959e86c0-6afb-4760-915c-dbb6554b83be"
      unitRef="U_EUR">3588000</ifrs-full:FinanceIncomeReceivedClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_5054e018-e6e3-4e1f-b539-2dceb292fb69"
      unitRef="U_EUR">954000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_84e4f7be-b75c-46ed-a57a-50a211f73e9f"
      unitRef="U_EUR">877000</ifrs-full:FinanceCostsPaidClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_faee241f-e336-4d76-8a77-a1a5f5a61428"
      unitRef="U_EUR">52000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_d769db85-e133-49b1-aa9f-7b6cb0bbc260"
      unitRef="U_EUR">206000</ifrs-full:IncomeTaxesPaidRefundClassifiedAsOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_b1ec8993-35a3-4616-9d44-f412fb9e6be0"
      unitRef="U_EUR">-14313000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_8296eae3-3921-4c6b-acf5-ebc3d7600102"
      unitRef="U_EUR">-101582000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_481b0b49-0f1c-4c62-874b-1d04d12a753f"
      unitRef="U_EUR">703000</asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment>
    <asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_465d0eb7-c531-4acd-885b-67770266c15c"
      unitRef="U_EUR">199000</asnd:PurchaseOfIntangibleAssetsAndPropertyPlantAndEquipment>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_91b2e269-ab2e-460d-bc1f-a76d6a37d83a"
      unitRef="U_EUR">0</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_18fa620b-9260-4d91-b668-8cff558ada8b"
      unitRef="U_EUR">7354000</ifrs-full:ProceedsFromSalesOrMaturityOfFinancialInstrumentsClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_df935dbf-8d23-4159-a58d-b1715d4a4094"
      unitRef="U_EUR">-703000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_381226d6-2378-4fb4-abe8-aefbfe973dad"
      unitRef="U_EUR">7155000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_3467c572-7470-4dda-bf77-f197c6d0d3ef"
      unitRef="U_EUR">3066000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_ffbe77b3-2146-4a28-b50c-275fb52b3ebe"
      unitRef="U_EUR">2786000</ifrs-full:RepaymentsOfBorrowingsClassifiedAsFinancingActivities>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_cf5415a4-06cf-4cad-a2b5-10d6c13524c3"
      unitRef="U_EUR">13834000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:ProceedsFromExerciseOfWarrants
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_a7677515-2b66-45e1-aaf2-34c20284984c"
      unitRef="U_EUR">21209000</ifrs-full:ProceedsFromExerciseOfWarrants>
    <ifrs-full:PaymentsToAcquireOrRedeemEntitysShares
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_0491fa69-4b94-4335-860e-79b939bd927d"
      unitRef="U_EUR">17396000</ifrs-full:PaymentsToAcquireOrRedeemEntitysShares>
    <asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_8a7712fe-afe6-4f0d-aacb-cf98980913a7"
      unitRef="U_EUR">11396000</asnd:PaymentOfWithholdingTaxesUnderStockIncentivePrograms>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_356e046b-8455-4161-a038-069d6d9245c3"
      unitRef="U_EUR">-18024000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_0c041424-9f31-495c-85c7-1484f2ca4500"
      unitRef="U_EUR">18423000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_f7357538-65b6-45b4-b90c-b3dda4973ad9"
      unitRef="U_EUR">-33040000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_881b0baa-d6e9-455a-93dc-69cb58f7647f"
      unitRef="U_EUR">-76004000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_a0ac9270-b735-46b3-b121-88792d2ac9f9"
      unitRef="U_EUR">559543000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_17a14604-dfe5-4082-bab4-5778ed12841c"
      decimals="-3"
      id="F_113b6618-6985-4dfd-b75b-037d86537909"
      unitRef="U_EUR">392164000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_cc6bfe71-8e2e-4533-a70c-12d0891b355f"
      unitRef="U_EUR">-8580000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_43824fec-bcd0-4fab-9731-148b63caa01e"
      unitRef="U_EUR">4079000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_da9e20dc-920f-41f9-a794-45bf9da48607"
      unitRef="U_EUR">517923000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4"
      decimals="-3"
      id="F_3b9f6b6b-6dcb-43f2-90a9-f8caf4781514"
      unitRef="U_EUR">320239000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:BalancesWithBanks
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_a9c36755-4a29-4201-b4df-9012b4f9c2e9"
      unitRef="U_EUR">517923000</ifrs-full:BalancesWithBanks>
    <ifrs-full:BalancesWithBanks
      contextRef="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4"
      decimals="-3"
      id="F_685c830e-5837-416b-95ae-22072a979463"
      unitRef="U_EUR">320239000</ifrs-full:BalancesWithBanks>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_7a41fdf8-eca1-4c8d-a905-a3e918e21647"
      unitRef="U_EUR">517923000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_5b0d0a15-8da6-4383-aa48-4eb33ecba1c4"
      decimals="-3"
      id="F_88045699-9041-40cd-8c40-cc675eef0110"
      unitRef="U_EUR">320239000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_b4a6956c-1b89-465f-b490-91eca49c4776">&lt;p id="notes" style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;te 1&#x2014;General Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Ascendis Pharma A/S, together with its subsidiaries, is a global biopharmaceutical company focused on applying its innovative TransCon technology platform to make a meaningful difference for patients. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to Ascendis Pharma A/S and its subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The address of the Company&#x2019;s registered office is Tuborg Boulevard 12, DK-2900, Hellerup, Denmark. The Company&#x2019;s registration number in Denmark is 29918791.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 2, 2015, the Company completed an initial public offering which resulted in the listing of American Depositary Shares (&#x201c;ADSs&#x201d;), representing the Company&#x2019;s ordinary shares, under the symbol &#x201c;ASND&#x201d; in the United States on the Nasdaq Global Select Market.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) approved these unaudited condensed consolidated interim financial statements on May 1, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_6042c995-1c53-433b-a94a-35a465af8226">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 2&#x2014;Summary of Material Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Preparation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#x201c;Interim Financial Reporting.&#x201d; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#x201c;IFRS&#x201d;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements for the year ended December 31, 2024 and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#x201c;IASB&#x201d;) and as adopted by the European Union (the &#x201c;EU&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New and Amended IFRS Accounting Standards and Interpretations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2023, the IASB amended IAS 21, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to help entities determine whether a currency is exchangeable into another currency and which spot exchange rate to use when it is not. These new requirements apply for annual reporting periods beginning on or after January 1, 2025. The Company does not expect these amendments to have a material impact on its operations or financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New IFRS Accounting Standards Not Yet Effective&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2024, the IASB issued IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d; (&#x201c;IFRS 18&#x201d;), which replaces IAS 1, &#x201c;Presentation in Financial Statements.&#x201d; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The unaudited condensed &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consolidated financial statements are not expected to be affected by other new or amended standards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</asnd:DisclosureOfSummaryOfSignificantAccountingPolicyExplanatory>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_756faa6e-da4e-47fa-9121-ffde483d87b7">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Basis of Preparation&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The unaudited condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, &#x201c;Interim Financial Reporting.&#x201d; Certain information and disclosures normally included in the annual consolidated financial statements prepared in accordance with IFRS Accounting Standards (&#x201c;IFRS&#x201d;) have been condensed or omitted. Accordingly, these unaudited condensed consolidated interim financial statements should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements for the year ended December 31, 2024 and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards Board (the &#x201c;IASB&#x201d;) and as adopted by the European Union (the &#x201c;EU&#x201d;).&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The accounting policies applied are consistent with those of the previous financial year. A description of the accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_e4153f92-69f1-48fa-b0b6-2b2fa51a7947">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New and Amended IFRS Accounting Standards and Interpretations&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In August 2023, the IASB amended IAS 21, &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201c;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Effects of Changes in Foreign Exchange Rates: Lack of Exchangeability,&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;&#x201d;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to help entities determine whether a currency is exchangeable into another currency and which spot exchange rate to use when it is not. These new requirements apply for annual reporting periods beginning on or after January 1, 2025. The Company does not expect these amendments to have a material impact on its operations or financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;New IFRS Accounting Standards Not Yet Effective&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The IASB has issued a number of new or amended standards, which have not yet become effective or have not yet been adopted by the EU. Therefore, these new standards have not been incorporated in these unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In April 2024, the IASB issued IFRS 18, &#x201c;Presentation and Disclosure in Financial Statements&#x201d; (&#x201c;IFRS 18&#x201d;), which replaces IAS 1, &#x201c;Presentation in Financial Statements.&#x201d; IFRS 18 introduces new categories and subtotals in the statement of profit or loss, into:&lt;/span&gt;&lt;/p&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Operating activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Investing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Financing activities;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Income taxes; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:4.7521786492374725%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;&#x2022;&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Discontinued operations.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition, IFRS 18 includes new requirements for the location, aggregation and disaggregation of financial information, and disclosure of management-defined performance measures, as defined, if any. IFRS 18 does not include any measurement changes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;If approved by the EU, the amendments will be effective for annual reporting periods beginning on or after January 1, 2027, and must be applied retrospectively, with early adoption permitted. While IFRS 18 will change the structure and subtotal in the statement of profit or loss, the full impact from implementing IFRS 18 is currently being analyzed by the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The unaudited condensed &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;consolidated financial statements are not expected to be affected by other new or amended standards.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;</ifrs-full:DescriptionOfInitialApplicationOfStandardsOrInterpretations>
    <ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_e6d7c98d-fd47-4637-a63c-2fd057423da0">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 3&#x2014;Significant Accounting Judgements and Estimates&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the application of the Company&#x2019;s accounting policies, management is required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. Judgements, estimates and assumptions applied are based on historical experience and other factors that are relevant, and which are available at the reporting date. Uncertainty concerning estimates and assumptions could result in outcomes that require a material adjustment to assets and liabilities in future periods.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The unaudited condensed consolidated interim financial statements do not include all disclosures for significant accounting judgements, estimates and assumptions, that are required in the annual consolidated financial statements, and therefore should be read in conjunction with the Company&#x2019;s audited consolidated financial statements as of and for the year ended December 31, 2024.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized prospectively. While the application of critical accounting estimates is subject to material estimation uncertainties, management&#x2019;s ongoing revisions of critical accounting estimates and underlying assumptions have not revealed any material impact in any of the periods presented in the unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;There have been no changes to the application of significant accounting judgements or estimation uncertainties regarding accounting estimates compared to December 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory>
    <asnd:SignificantEventsInTheReportingPeriodTextBlock
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_6586aab1-d732-4ced-ad59-04c0df71db4b">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 4&#x2014;Significant Events in the Reporting Period&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;VISEN Pharmaceuticals Initial Public Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 20, 2025, VISEN Pharmaceuticals (&#x201c;VISEN&#x201d;) announced the pricing of its initial public offering (&#x201c;IPO&#x201d;) on the Hong Kong Stock Exchange. The IPO closed on March 21, 2025, and VISEN&#x2019;s shares began trading under the stock code 2561.HK.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company&#x2019;s investment in VISEN is accounted for using the equity method in the consolidated financial statements as the Company has determined that it has significant influence over the investment. Following the IPO, the Company owned &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% in VISEN. As a result, a non-cash gain of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;33.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million was recognized in the consolidated statement of profit or loss as part of share of profit/(loss) of associates. The IPO did not change the accounting treatment of VISEN. As of March 31, 2025, VISEN&#x2019;s share price was HK$&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, reflecting a total market value of the Company&#x2019;s equity position of approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;260&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. As of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the carrying amount of VISEN using the equity method was &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The management and existing shareholders of VISEN, including Ascendis Pharma, have entered into customary lock-up agreements restricting the sale of VISEN shares for six months following the IPO; &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;additionally, certain significant shareholders of VISEN, including the Company, are subject to an additional lock-up obligation during the period commencing on the date that is six months after the IPO and ending on the date that is 12 months after the IPO during which such shareholders may not sell shares of VISEN to an extent that would cause such shareholder to cease being a controlling shareholder of VISEN pursuant to applicable listing rules.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Share Repurchase Program&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On February 12, 2025, the Company announced that the Board has authorized the Company to repurchase up to $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;18.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of the Company&#x2019;s ADSs, each of which represents one ordinary share of Ascendis Pharma A/S (the &#x201c;Share Repurchase Program&#x201d;). On March 4, 2025, the Share Repurchase Program was fully executed in compliance with Rules 10b-18 and 10b5-1 of the Securities Exchange Act of 1934, as amended.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, the Company was authorized to repurchase up to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,726,015&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; of the Company's ADSs.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The holding of treasury shares is disclosed in Note 9, &#x201c;Treasury Shares.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Impairment on Property, Plant and Equipment&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; includes an impairment charge of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;7.5&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, related to change in activities at one of our sites in the U.S. and is included as part of research and development expenses, and selling general and administrative expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Equity Development&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As of March 31, 2025, the unaudited condensed consolidated interim statements of financial position presented a negative balance of equity of &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;189.8&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million. Under Danish corporate law, as Ascendis Pharma A/S, the parent company of the Company, holds a positive balance of equity, the Company is currently not subject to legal or regulatory requirements to re-establish the balance of equity. There is no direct impact from the negative balance of equity to the liquidity and capital resources.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Based on its current operating plan, the Company believes that the existing capital resources as of March 31, 2025, will be sufficient to meet projected cash requirements for at least twelve months from the date of this report. However, the Company&#x2019;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;s operating plan may change as a result of many factors that are currently unknown, and the Company may need to seek additional funds sooner than planned. Further details regarding borrowings including maturity analysis are provided in Note 10, &#x201c;Financial Assets and Liabilities.&#x201d;&lt;/span&gt;&lt;/p&gt;</asnd:SignificantEventsInTheReportingPeriodTextBlock>
    <ifrs-full:ProportionOfOwnershipInterestInAssociate
      contextRef="C_685d7bbe-e597-4efe-81c5-62074784e614"
      decimals="3"
      id="F_a92a0131-d30f-4f94-96d9-4ab3ffa14b37"
      unitRef="U_pure">0.392</ifrs-full:ProportionOfOwnershipInterestInAssociate>
    <asnd:NonCashGainRecognizedOnOwnershipInterestInAssociate
      contextRef="C_685d7bbe-e597-4efe-81c5-62074784e614"
      decimals="-5"
      id="F_b31dfd38-913c-44ab-888a-936f59c85de4"
      unitRef="U_EUR">33600000</asnd:NonCashGainRecognizedOnOwnershipInterestInAssociate>
    <asnd:SharePriceOfEntity
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="2"
      id="F_5ce0f466-d439-43f4-aa6e-cbce7c34cf13"
      unitRef="U_HkPerShare">53.15</asnd:SharePriceOfEntity>
    <ifrs-full:Equity
      contextRef="C_990b5b82-ee02-43ea-90c9-a7eeb3873527"
      decimals="-6"
      id="F_eee8b18c-fb86-4f8a-92dc-c25bab3608c8"
      unitRef="U_EUR">260000000</ifrs-full:Equity>
    <ifrs-full:InvestmentAccountedForUsingEquityMethod
      contextRef="C_990b5b82-ee02-43ea-90c9-a7eeb3873527"
      decimals="-5"
      id="F_697e5323-f443-4dfe-8b87-ed417ce7c5e3"
      unitRef="U_EUR">28400000</ifrs-full:InvestmentAccountedForUsingEquityMethod>
    <asnd:SharesAgreementDescription
      contextRef="C_ef94f77b-e835-49b6-9fa5-da367d813217"
      id="F_ad7a215e-fd83-4b79-a692-a32ba8d41011">additionally, certain significant shareholders of VISEN, including the Company, are subject to an additional lock-up obligation during the period commencing on the date that is six months after the IPO and ending on the date that is 12 months after the IPO during which such shareholders may not sell shares of VISEN to an extent that would cause such shareholder to cease being a controlling shareholder of VISEN pursuant to applicable listing rules.</asnd:SharesAgreementDescription>
    <asnd:PaymentForRepurchaseOfShares
      contextRef="C_d09921c8-e6c9-41c6-87a5-4292b2ecb35e"
      decimals="-4"
      id="F_05f1b3c8-4dec-4345-85a8-bd690c40c142"
      unitRef="U_EUR">18250000</asnd:PaymentForRepurchaseOfShares>
    <asnd:SharesAuthorizedToRepurchase
      contextRef="C_2e1b63bd-d863-46b8-8fa6-18b4bf555975"
      decimals="0"
      id="F_648bef5d-818c-4760-8028-e109124055bb"
      unitRef="U_shares">1726015</asnd:SharesAuthorizedToRepurchase>
    <ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-5"
      id="F_92828342-a026-4a20-859b-5e7f08dd404b"
      unitRef="U_EUR">7500000</ifrs-full:ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment>
    <ifrs-full:Equity
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-5"
      id="F_d9e1a13b-9584-4e4d-91f7-b74b44a743d3"
      unitRef="U_EUR">-189800000</ifrs-full:Equity>
    <ifrs-full:DisclosureOfRevenueExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_31d86558-77a6-4be7-a7c2-5fd995553c34">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 5&#x2014;Revenue&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss with the following amounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rendering of services and clinical supply&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;95,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified per geographical area&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Europe &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rest of world&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;95,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div class="item-list-element-wrapper" style="margin-left:1.065%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:4.585839187345226%;word-break:keep-all;display:inline-flex;justify-content:flex-start;"&gt;(1)&lt;/span&gt;&lt;div style="width:100%;display:inline;"&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the three months ended March 31, 2025, Denmark, the country of domicile, contributed with &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue. For the three months ended March 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue was attributable to Denmark.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Revenue from Commercial Products&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue from sale of commercial products were as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue from commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;SKYTROFA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;YORVIPATH&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue from commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;96,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;66,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In the U.S., the Company has established an integrated organization to commercialize the Company&#x2019;s approved Endocrinology Rare Disease products, SKYTROFA&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and YORVIPATH&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:6.7pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. In Europe, the Company is expanding its presence by building integrated organizations in select countries (&#x201c;Europe Direct&#x201d;), where the Company has launched SKYTROFA and YORVIPATH. Beyond the U.S. and Europe Direct, SKYTROFA and YORVIPATH may also be sold through exclusive distribution agreements with geographic market leaders (&#x201c;International Markets&#x201d;) and under certain strategic collaboration agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;YORVIPATH and SKYTROFA is approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) and authorized by the European Commission (&#x201c;EC&#x201d;) and other regulatory agencies. The Company began selling YORVIPATH in Europe in the first quarter of 2024 and in the U.S. in December 2024. The Company began selling SKYTROFA in the U.S. in the fourth quarter of 2021 and in Europe in the third quarter of 2023.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Other Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Other revenue is attributable to collaborations and license agreements, and relates to Novo Nordisk A/S (&#x201c;Novo Nordisk&#x201d;), Eyconis, Inc. (&#x201c;Eyconis&#x201d;), Teijin Limited (&#x201c;Teijin&#x201d;) and VISEN. Under the collaborations and license agreements, the Company provides various research and development services and clinical supply. Costs associated with these activities are presented as cost of sales in the unaudited condensed consolidated statement of profit or loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the three months ended March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue from royalties or milestones has been recognized under the collaborations and license agreements.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRevenueExplanatory>
    <asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_9423c522-76af-4479-b2d3-be62831a76f8">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue has been recognized in the unaudited condensed consolidated interim statements of profit or loss with the following amounts:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rendering of services and clinical supply&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Licenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,402&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,770&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;95,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified per geographical area&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Europe &lt;/span&gt;&lt;span style="color:#000000;top:-4.6899999999999995pt;white-space:pre-wrap;font-size:6.7pt;position:relative;font-kerning:none;min-width:fit-content;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;21,328&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;North America&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;92,681&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Rest of world&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;5,940&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,646&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;100,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;95,894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For the three months ended March 31, 2025, Denmark, the country of domicile, contributed with &#x20ac;&lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.4&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of revenue. For the three months ended March 31, 2024&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;no&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; revenue was attributable to Denmark.&lt;/span&gt;</asnd:DisclosureOfSegmentRevenuesByDestinationOfMajorCustomersExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_df03be5f-61e6-4231-a5c4-a0bb23dc3bf5"
      unitRef="U_EUR">96028000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_8291bd2e-06b3-4902-b276-b214457599d1"
      unitRef="U_EUR">66499000</ifrs-full:RevenueFromSaleOfGoods>
    <asnd:RevenueFromRenderingOfServicesAndClinicalSupply
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_b9aba91d-b641-48c7-8b36-938f156c8f31"
      unitRef="U_EUR">3524000</asnd:RevenueFromRenderingOfServicesAndClinicalSupply>
    <asnd:RevenueFromRenderingOfServicesAndClinicalSupply
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_c92dc3cd-a29f-4e9a-b7ee-cfbe7b63fe50"
      unitRef="U_EUR">4625000</asnd:RevenueFromRenderingOfServicesAndClinicalSupply>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_e90120d2-5516-41fa-b4bb-e224547ef208"
      unitRef="U_EUR">1402000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:LicenceFeeIncome
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_4862a4f7-4bb7-4910-a692-702a10978c9f"
      unitRef="U_EUR">24770000</ifrs-full:LicenceFeeIncome>
    <ifrs-full:Revenue
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_64102551-5fa4-4dfd-b062-4e654dc9e321"
      unitRef="U_EUR">100954000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_10c7658e-3d33-4608-b6d1-de9bd6892b52"
      unitRef="U_EUR">95894000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_99940134-84fa-4775-8956-5bbfab5ab4d4"
      decimals="-3"
      id="F_cce6caaa-dd7a-4e9d-a0aa-edd0e8823674"
      unitRef="U_EUR">21328000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_e98d5d36-1e29-442d-a2a2-e8e647fa92b3"
      decimals="-3"
      id="F_350103fd-5724-4859-8c7a-e0f32aa99dba"
      unitRef="U_EUR">1567000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_76e6e803-d4db-4b29-9ab8-219028b47903"
      decimals="-3"
      id="F_53b521f1-f0bc-4a40-b891-701e079c8990"
      unitRef="U_EUR">73686000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_d394cb1a-3b0a-4dbc-a6eb-8741f78af1f4"
      decimals="-3"
      id="F_bb2b500b-4124-4326-84d8-f117c7cbac57"
      unitRef="U_EUR">92681000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_9cac6737-58ef-4123-8b45-22b55e55c632"
      decimals="-3"
      id="F_006564ed-48ad-4c02-a7ac-edf823904223"
      unitRef="U_EUR">5940000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_043c9c52-1128-4558-9421-751a6d2b10ae"
      decimals="-3"
      id="F_19d125a2-7c64-4726-925d-d1558c888b11"
      unitRef="U_EUR">1646000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_512b3bc3-ee95-4f99-9dd4-382f16d1b77a"
      unitRef="U_EUR">100954000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_ada2b7ef-ba1b-4f74-a63f-f6a61b72c439"
      unitRef="U_EUR">95894000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_da6b292e-7c16-4b6b-be4d-1a791f59c406"
      decimals="-5"
      id="F_6a3dcf1b-da28-46a8-a515-0ff70d878fdc"
      unitRef="U_EUR">2400000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="C_4a87b703-b453-4069-82f0-40f1f09886fb"
      decimals="INF"
      id="F_5e2da064-d99f-4dee-8908-3715075cdc97"
      unitRef="U_EUR">0</ifrs-full:Revenue>
    <asnd:DisclosureOfRevenueToCommercialProductsExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_309a20fa-0dec-4ac2-adf4-435d7c0325db">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Revenue from sale of commercial products were as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Three Months Ended&lt;br/&gt;March 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Revenue from commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;SKYTROFA&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;51,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;65,005&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;YORVIPATH&#xae;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;44,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,494&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total revenue from commercial products&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;96,028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;66,499&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</asnd:DisclosureOfRevenueToCommercialProductsExplanatory>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_6f20e6a7-a161-4a7a-8def-bd1f1b851f84"
      decimals="-3"
      id="F_df33290c-3945-4ea4-be15-0cbdb7fff40c"
      unitRef="U_EUR">51340000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_8782f887-b4d8-4794-87db-2dcfd88fdd71"
      decimals="-3"
      id="F_54b23a34-22c7-4490-b322-e7ea2003b839"
      unitRef="U_EUR">65005000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_ce5fb7a1-960a-40b8-96ca-a59d1361c834"
      decimals="-3"
      id="F_d56a1195-7c3e-45f9-b29d-6ad76f899895"
      unitRef="U_EUR">44688000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_c79f5454-5ba5-4cc3-9ef2-650e50056d2e"
      decimals="-3"
      id="F_cab843f3-68c7-4113-a571-fb4731bc2a6d"
      unitRef="U_EUR">1494000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_4516e69b-173d-46cd-9d36-04ae0111752e"
      unitRef="U_EUR">96028000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromSaleOfGoods
      contextRef="C_8d1b9294-057e-40e2-8f1b-8022bb139c20"
      decimals="-3"
      id="F_fcb5aa6a-76db-402d-9d60-091c666a7b1c"
      unitRef="U_EUR">66499000</ifrs-full:RevenueFromSaleOfGoods>
    <ifrs-full:RevenueFromContractsWithCustomers
      contextRef="C_d39182d1-57bd-4617-8a6a-98d8b663a8a6"
      decimals="INF"
      id="F_730fd49a-dece-476f-92ad-efa8d0359d6e"
      unitRef="U_EUR">0</ifrs-full:RevenueFromContractsWithCustomers>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_bcc74714-b748-4d15-84fe-69fc371dee23">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 6&#x2014;Segment Information&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company is managed and operated as &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;one&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; business unit. Accordingly, no additional information on business segments or geographical areas is disclosed apart from revenue on geographical areas as disclosed in Note 5 &#x201c;Revenue.&#x201d; Revenue is specified on geographical areas according to the location of the customer.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <asnd:NumberOfReportableOperatingSegments
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="INF"
      id="F_bebca6b8-0bac-4e9c-bbf6-446beaf1861b"
      unitRef="U_Segment">1</asnd:NumberOfReportableOperatingSegments>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_9036335c-5df1-4579-8dcb-83a6c6fdd535">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 7&#x2014;Share-based Payment&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;As an incentive to the senior management, other employees, members of the Board and select consultants, Ascendis Pharma A/S has established warrant programs, a Restricted Stock Unit (&#x201c;RSU&#x201d;) program adopted in December 2021, and a Performance Stock Unit (&#x201c;PSU&#x201d;) program adopted in February 2023, which are all classified as equity-settled share-based payment transactions.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based Compensation Costs&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Share-based compensation costs are determined using the grant date fair value and are recognized over the vesting period as research and development expenses, selling, general and administrative expenses, or cost of sales. For the three months ended March 31, 2025 and 2024, share-based compensation costs recognized in the unaudited condensed consolidated interim statement of profit or loss were &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;25.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;17.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Unit Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;RSUs are granted by the Board to members of senior management, other employees and members of the Board (the &#x201c;RSU-holders&#x201d;), as stipulated in the program. In addition, RSUs may be granted to select consultants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One RSU represents a right for the RSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting, if the vesting conditions are met. RSUs granted vest over three years with 1/3 of the RSUs vesting on each anniversary date from the date of grant, and require RSU-holders to be employed, appointed as member of the Board, or retained as a consultant (the &#x201c;service conditions&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Performance Stock Unit Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;PSUs are granted by the Board to certain members of senior management (the &#x201c;PSU-holders&#x201d;), as stipulated in the program. In addition, PSUs may be granted to other employees, select consultants and members of the Board.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;One PSU represents a right for the PSU-holder to receive one ADS representing ordinary shares of Ascendis Pharma A/S upon vesting. PSUs vest in a manner similar to the service conditions of the RSUs. &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;100&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%, nor will it result in additional grants. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;RSU and PSU Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the number of outstanding RSUs and PSUs:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.423%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.244%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;993,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,150,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;634,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;708,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Settled during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;321,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,221,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;165,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,386,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified by vesting year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;583,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;669,735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;427,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,221,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;165,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,386,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrant Program&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Warrants are granted by the Board in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S to all employees, members of the Board and select consultants. Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;. The exercise price is fixed at the fair market value of the Company&#x2019;s ordinary shares at the time of grant as determined by the Board.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Warrant Activity&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the number and weighted average exercise prices of, and movements in warrants:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,204,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,017,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;96.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,057,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;92.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The exercise prices of outstanding warrants under the Company&#x2019;s warrant programs range from &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;11.98&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; to &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;145.50&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;depending on the grant dates.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_ed9a4cd9-a9ca-454a-9615-64678e2fdefe"
      decimals="-5"
      id="F_3457be94-807a-44ad-ae21-1eac8a8178e1"
      unitRef="U_EUR">25600000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="C_5b83b77f-547e-42d3-9a2c-5c6ae9438f49"
      decimals="-5"
      id="F_2f4b9fc3-544a-40cb-bed9-ec3d5a63e3a4"
      unitRef="U_EUR">17300000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement
      contextRef="C_7dc36b02-c138-4fcc-b62f-16eb456e91be"
      id="F_30f79539-83a3-4d4b-a28b-8eb309721bd8">In addition to service conditions, vesting is also contingent upon achievement of long-term strategic goals as evaluated by the Board no later than two weeks prior to each vesting date. Exceeding performance targets will not result in vesting of more PSUs than 100%, nor will it result in additional grants. </ifrs-full:DescriptionOfVestingRequirementsForSharebasedPaymentArrangement>
    <asnd:PercentageOfVestingRightsForShareBasedPaymentArrangement
      contextRef="C_909af02d-d3e3-49eb-8ac9-f629568438a7"
      decimals="INF"
      id="F_1acd3baf-0a91-435f-9143-032c7d4b3377"
      unitRef="U_pure">1</asnd:PercentageOfVestingRightsForShareBasedPaymentArrangement>
    <asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_ef17e5e0-41e5-4266-b392-69f91a752f64">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the number of outstanding RSUs and PSUs:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.423%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.244%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Performance Stock Units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="10" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;993,807&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;156,667&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,150,474&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;634,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;73,583&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;708,172&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Settled during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,056&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,716&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;75,772&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;321,392&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46,588&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;25,760&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,688&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;28,448&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,221,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;165,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,386,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Specified by vesting year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;583,076&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;86,659&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;669,735&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2027&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;427,429&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,066&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;481,495&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2028&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;210,683&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;24,533&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;235,216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,221,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;165,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,386,446&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</asnd:SharebasedPaymentArrangementRestrictedStockUnitActivityTextBlock>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_084e81ae-053b-4124-8ea0-cf00fb92aefd"
      decimals="0"
      id="F_d5eca3eb-d370-4b6e-be77-8e2614e032b1"
      unitRef="U_pure">993807</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_06503dc6-abee-4161-b4cf-ae017326cf5f"
      decimals="0"
      id="F_a49653eb-c072-4754-8891-78bf7d6751f3"
      unitRef="U_pure">156667</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_f1cc25de-2681-466f-9005-4cacf85b0437"
      decimals="0"
      id="F_e8a81a8c-c8bb-448b-851e-1770f7dc6e7d"
      unitRef="U_pure">1150474</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_79d64e56-848d-43de-a89c-390b0257c619"
      decimals="0"
      id="F_1ce1a870-c7e7-40bf-be76-00061ed8d00a"
      unitRef="U_pure">634589</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_975c08fa-b467-40ed-8b0f-240242f397d5"
      decimals="0"
      id="F_52393215-83ed-45aa-af4c-07212acd71e4"
      unitRef="U_pure">73583</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_84ecf827-5c4e-400c-9fed-cfb85e09d515"
      decimals="0"
      id="F_5dc97203-13b1-4f78-a135-1a6ef3393f81"
      unitRef="U_pure">708172</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="C_79d64e56-848d-43de-a89c-390b0257c619"
      decimals="0"
      id="F_b179bd8b-f46c-440a-a51b-4d16f3db535f"
      unitRef="U_pure">60056</asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="C_975c08fa-b467-40ed-8b0f-240242f397d5"
      decimals="0"
      id="F_3136ce89-6bb1-44d6-9daf-01e7592481b9"
      unitRef="U_pure">15716</asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement
      contextRef="C_84ecf827-5c4e-400c-9fed-cfb85e09d515"
      decimals="0"
      id="F_eaf9212d-03a7-49c9-8b3d-f9a39123eb49"
      unitRef="U_pure">75772</asnd:NumberOfOtherEquityInstrumentsSettledInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_79d64e56-848d-43de-a89c-390b0257c619"
      decimals="0"
      id="F_9d60cca9-fdf0-4f0e-9567-6c807a01851f"
      unitRef="U_pure">-321392</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_975c08fa-b467-40ed-8b0f-240242f397d5"
      decimals="0"
      id="F_eb9d92f6-fbe5-4fc4-9a71-baa70f8527cc"
      unitRef="U_pure">-46588</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement
      contextRef="C_84ecf827-5c4e-400c-9fed-cfb85e09d515"
      decimals="0"
      id="F_b53532de-ca9a-4c1d-8748-5198696a70b7"
      unitRef="U_pure">-367980</asnd:NumberOfOtherEquityInstrumentsTransferredInShareBasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_79d64e56-848d-43de-a89c-390b0257c619"
      decimals="0"
      id="F_7a465a7c-f773-4e0a-8756-6fb132e166fa"
      unitRef="U_pure">25760</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_975c08fa-b467-40ed-8b0f-240242f397d5"
      decimals="0"
      id="F_74416a83-694e-475a-a366-fe6d7afe9a4d"
      unitRef="U_pure">2688</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_84ecf827-5c4e-400c-9fed-cfb85e09d515"
      decimals="0"
      id="F_b3298939-fa8f-41b8-b288-e39e01541f90"
      unitRef="U_pure">28448</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_9110cafd-2d7b-4304-9249-9a5b3d9c4dfe"
      decimals="0"
      id="F_1ae0d903-4966-47ef-8fb2-30500a092444"
      unitRef="U_pure">1221188</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_3cb7ddc6-ca0e-4f90-83dc-2681c7bb17c0"
      decimals="0"
      id="F_896b7bff-1dfd-4c99-a65b-44eaf72c93c5"
      unitRef="U_pure">165258</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_76ef0cc1-54a9-485d-af12-f694616423d3"
      decimals="0"
      id="F_d65535fe-c44a-495b-8573-74df70bec615"
      unitRef="U_pure">1386446</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_290aeeba-a386-42b8-856c-a68d382312e1"
      decimals="0"
      id="F_c5f63ec3-49f6-4954-abf6-da5e1d1072d8"
      unitRef="U_pure">583076</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_a633f67b-4c57-46fb-bcde-1a16d86b23b4"
      decimals="0"
      id="F_e10193d0-521a-4c2a-ac66-2aaa388182d7"
      unitRef="U_pure">86659</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_04aedc44-3b7e-46d5-ade6-eeb4fd969b26"
      decimals="0"
      id="F_c05b1662-9218-4796-8fcc-ef0877c8c919"
      unitRef="U_pure">669735</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_d182cba3-f8ff-423d-8e1e-a44b81fe3740"
      decimals="0"
      id="F_e74f2ec6-3fc5-455d-9424-cb5cbd8b61fc"
      unitRef="U_pure">427429</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_ee51bcae-74d0-4e67-89b0-e987214d4543"
      decimals="0"
      id="F_8a5ebb3e-a331-48b3-9d12-de8ca7beef12"
      unitRef="U_pure">54066</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_ebf7f8d8-9a88-4b74-9ba0-b9f6929c0ab5"
      decimals="0"
      id="F_f7ba6ccc-09b1-4720-93b6-4b48dc131084"
      unitRef="U_pure">481495</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_2c892acc-02da-4c15-9353-950413a810ff"
      decimals="0"
      id="F_7bc8d2c4-8442-4d8f-9255-d8aaa5fe7134"
      unitRef="U_pure">210683</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_434feb09-9876-4024-9170-6094ccac6b87"
      decimals="0"
      id="F_d6090db6-21b6-43ce-b21b-037e5574c8cf"
      unitRef="U_pure">24533</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_36356f4b-0e07-4b7c-876a-5c08a3b2de70"
      decimals="0"
      id="F_c1a9a6fc-cde5-47fa-bb51-9524812860d4"
      unitRef="U_pure">235216</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_9110cafd-2d7b-4304-9249-9a5b3d9c4dfe"
      decimals="0"
      id="F_d2bba917-0810-45ab-bf01-0c414b490996"
      unitRef="U_pure">1221188</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_3cb7ddc6-ca0e-4f90-83dc-2681c7bb17c0"
      decimals="0"
      id="F_972c8484-3697-46f1-b2df-7f848602b83e"
      unitRef="U_pure">165258</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_76ef0cc1-54a9-485d-af12-f694616423d3"
      decimals="0"
      id="F_1c59728f-9923-4d56-9dd7-06bcbae7d4d1"
      unitRef="U_pure">1386446</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:ParValuePerShare
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="0"
      id="F_6afe45ec-20fa-4af6-a87c-34bf8ad73378"
      unitRef="U_DkkPerShare">1</ifrs-full:ParValuePerShare>
    <ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_c78fd1d8-61d1-47bb-ba13-1951b6563709">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies the number and weighted average exercise prices of, and movements in warrants:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6,204,122&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Granted during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148,663&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;126.98&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Exercised during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;281,078&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;46.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Forfeited during the period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;54,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;95.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;6,017,157&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;96.26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Vested at March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;5,057,771&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;92.31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_4ffe96aa-eccd-4c58-806f-aeb003cfacb4"
      decimals="INF"
      id="F_3803b3b4-4506-449e-9eed-a272dae5046f"
      unitRef="U_pure">6204122</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_4ffe96aa-eccd-4c58-806f-aeb003cfacb4"
      decimals="2"
      id="F_cd26bd6a-ac61-4f29-8db3-30f70234baa6"
      unitRef="U_EurPerShare">93.25</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc"
      decimals="INF"
      id="F_457262cf-b84b-4b40-af3d-e91ca56be86c"
      unitRef="U_pure">148663</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019
      contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc"
      decimals="2"
      id="F_2205e64d-9c27-4f9e-9087-d2d01f2849a1"
      unitRef="U_EurPerShare">126.98</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsGrantedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement
      contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc"
      decimals="INF"
      id="F_4da12f65-ff98-408f-b89b-e39c4ed097db"
      unitRef="U_pure">281078</ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019
      contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc"
      decimals="2"
      id="F_3c452e75-eba4-4b26-ad17-3006e8f0aec7"
      unitRef="U_EurPerShare">46.66</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc"
      decimals="INF"
      id="F_38f03d8f-fac4-46ef-9553-fab918c8d12c"
      unitRef="U_pure">54550</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019
      contextRef="C_7fc33bda-c66c-4fd4-bcf0-35d18d6df6fc"
      decimals="2"
      id="F_8529f30d-e9fa-4b37-852e-e505df9dda71"
      unitRef="U_EurPerShare">95.24</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement2019>
    <ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement
      contextRef="C_13256690-d69b-40e3-a745-f42b7767f286"
      decimals="INF"
      id="F_03019cb8-1201-40b2-8065-d23b598be3fb"
      unitRef="U_pure">6017157</ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement>
    <ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019
      contextRef="C_13256690-d69b-40e3-a745-f42b7767f286"
      decimals="2"
      id="F_1ca80e77-7a33-44b0-9926-f38d3456961f"
      unitRef="U_EurPerShare">96.26</ifrs-full:WeightedAverageExercisePriceOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement2019>
    <asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_13256690-d69b-40e3-a745-f42b7767f286"
      decimals="INF"
      id="F_e4c38388-75f7-47b2-a57d-2699d999ba4f"
      unitRef="U_pure">5057771</asnd:NumberOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement
      contextRef="C_13256690-d69b-40e3-a745-f42b7767f286"
      decimals="2"
      id="F_407bac10-7321-4263-80bc-27ace6cd06be"
      unitRef="U_EurPerShare">92.31</asnd:WeightedAverageExercisePriceOfOtherEquityInstrumentsVestedInSharebasedPaymentArrangement>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_d979433b-7c92-4bed-ad15-dbb8a17d94f5"
      decimals="2"
      id="F_63dac866-a17e-48f8-95b0-cdef58bf90c2"
      unitRef="U_EurPerShare">11.98</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:ExercisePriceOfOutstandingShareOptions2019
      contextRef="C_935a7fad-4793-4877-9ec1-f6ddf2e4a58c"
      decimals="2"
      id="F_26b2594f-e870-404e-ae43-1f8b1460e40c"
      unitRef="U_EurPerShare">145.5</ifrs-full:ExercisePriceOfOutstandingShareOptions2019>
    <ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_81ee1130-2f1e-4f3f-8cc8-d8a1f400b814">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 8&#x2014;Share Capital&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The share capital of Ascendis Pharma A/S consists of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;60,970,565&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; fully paid shares at a nominal value of DKK &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all in the same share class, and which includes &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;597,055&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ordinary shares represented by ADSs held by Ascendis Pharma A/S. For the three months ended March 31, 2025, the share capital was increased with &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;white-space:pre-wrap;font-kerning:none;min-width:fit-content;color:#000000;"&gt;281,078&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; number of shares.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory>
    <ifrs-full:NumberOfSharesIssued
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="INF"
      id="F_7c98362e-e349-4872-8761-28c64df4ba71"
      unitRef="U_shares">60970565</ifrs-full:NumberOfSharesIssued>
    <ifrs-full:ParValuePerShare
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="0"
      id="F_479112f7-7425-4766-80b4-121666cadc25"
      unitRef="U_DkkPerShare">1</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesOutstanding
      contextRef="C_4a04a12f-c2bb-4f60-9173-69088979902b"
      decimals="INF"
      id="F_c14eb925-35f0-4a82-8ad8-fe8240889c0a"
      unitRef="U_shares">597055</ifrs-full:NumberOfSharesOutstanding>
    <ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="INF"
      id="F_f6edb24c-a60a-401e-b5f4-5971f19fe4c7"
      unitRef="U_shares">281078</ifrs-full:IncreaseDecreaseInNumberOfOrdinarySharesIssued>
    <asnd:DisclosureOfInformationAboutTreasurySharesExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_9c835721-5658-4e9a-9b91-843d53230ad7">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 9&#x2014;Treasury Shares&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development in the holding of treasury shares was as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.423%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.245%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nominal&lt;br/&gt;values&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Holding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Holding in&lt;br/&gt;% of total&lt;br/&gt;outstanding&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Treasury shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired from third parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred under stock incentive programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;597,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;</asnd:DisclosureOfInformationAboutTreasurySharesExplanatory>
    <ifrs-full:DisclosureOfTreasurySharesExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_f0c7503a-9634-4395-aa25-f2ea12d1f850">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The development in the holding of treasury shares was as follows:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:57.423%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.164%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:11.245%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Nominal&lt;br/&gt;values&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Holding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Holding in&lt;br/&gt;% of total&lt;br/&gt;outstanding&lt;br/&gt;shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(Number)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Treasury shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;113&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;845,887&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.4&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Acquired from third parties&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;119,148&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Transferred under stock incentive programs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;(&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;367,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-kerning:none;min-width:fit-content;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;80&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;597,055&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</ifrs-full:DisclosureOfTreasurySharesExplanatory>
    <asnd:TreasurySharesOfNominalValue
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_fc5004e9-3c8c-4b7f-84d7-b75ed9c9e325"
      unitRef="U_EUR">113000</asnd:TreasurySharesOfNominalValue>
    <asnd:NumberOfTreasurySharesOutstanding
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="0"
      id="F_aff91079-71bd-450b-a06e-56e5da1a2e6b"
      unitRef="U_shares">845887</asnd:NumberOfTreasurySharesOutstanding>
    <asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="3"
      id="F_d5a28fe3-921c-4d12-b78a-2482eac39cbc"
      unitRef="U_pure">0.014</asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares>
    <asnd:TreasurySharesAcquiredFromThirdParties
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_d1b4c352-f5b5-41b5-b5c3-c1ef6ddeb907"
      unitRef="U_EUR">16000</asnd:TreasurySharesAcquiredFromThirdParties>
    <asnd:IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="0"
      id="F_fc356da8-7762-4f21-b92a-4a505a87fcaf"
      unitRef="U_shares">119148</asnd:IncreaseDecreaseInTreasurySharesAcquiredFromThirdParties>
    <asnd:TreasurySharesHoldingInPercentageAcquiredFromThirdParties
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="2"
      id="F_e1443069-a8ff-486f-b659-c5eb52c08cac"
      unitRef="U_pure">0</asnd:TreasurySharesHoldingInPercentageAcquiredFromThirdParties>
    <asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      decimals="-3"
      id="F_66b1ca9b-c4e6-4b1c-b903-f45f1bace38b"
      unitRef="U_EUR">-49000</asnd:TreasurySharesTransferredUnderStockIncentiveProgramNominalValue>
    <asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="0"
      id="F_5f4e3ae4-bdf2-4dc9-88b3-b439bbe611b6"
      unitRef="U_shares">-367980</asnd:IncreaseDecreaseInTreasurySharesTransferredUnderStockIncentiveProgram>
    <asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="2"
      id="F_4f07d747-4754-41bc-822b-17dc992d0410"
      unitRef="U_pure">0</asnd:TreasurySharesHoldingInPercentageTransferredUnderStockIncentivePrograms>
    <asnd:TreasurySharesOfNominalValue
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_3e60536d-21ed-4a67-b9d6-28c04d2c8fa7"
      unitRef="U_EUR">80000</asnd:TreasurySharesOfNominalValue>
    <asnd:NumberOfTreasurySharesOutstanding
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="0"
      id="F_aebaa212-b5db-464a-9316-09320c8efd3a"
      unitRef="U_shares">597055</asnd:NumberOfTreasurySharesOutstanding>
    <asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="3"
      id="F_f7fef095-2adb-44e1-bbde-763b049db16b"
      unitRef="U_pure">0.01</asnd:TreasurySharesHoldingInPercentageOfTotalOutstandingShares>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_6e82cb6c-9160-4331-9959-971e7522eaac">&lt;p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 10&#x2014;Financial Assets and Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11pt;font-family:'Calibri',sans-serif;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial assets and liabilities comprise the following:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other receivables (excluding indirect tax receivables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;559,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;589,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;589,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;586,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;727,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;589,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;449,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other liabilities (excluding indirect tax, and employee related payables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;935,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;953,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,110,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,103,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;357,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;752,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;738,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,110,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,103,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Convertible Senior Notes&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In March 2022, the Company issued an aggregate principal amount of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;575.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million of fixed rate &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% convertible notes. The net proceeds from the offering of the convertible notes were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;557.9&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;503.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) after deducting the initial purchasers&#x2019; discounts and commissions and offering expenses. The convertible notes rank equally in right of payment with all future senior unsecured indebtedness. Unless earlier converted or redeemed, the convertible notes will mature on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 1, 2028&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The convertible notes accrue interest at a rate of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.25&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% per annum, payable semi-annually in arrears on April 1 and October 1 of each year. At any time before the close of business on the second scheduled trading day immediately before the maturity date, noteholders may convert their convertible notes at their option into the Company&#x2019;s ordinary shares represented by ADSs, together, if applicable, with cash in lieu of any fractional ADS, at the then-applicable conversion rate. The initial conversion rate is &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;6.0118&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; ADSs per $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,000&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; principal amount of convertible notes, which represents an initial conversion price of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166.34&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; per ADS. The conversion rate and conversion price will be subject to customary adjustments upon the occurrence of certain events.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The convertible notes will be optionally redeemable, in whole or in part (subject to certain limitations), at the Company&#x2019;s option at any time, and from time to time, on or after &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;April 7, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;but only if the last reported sale price per ADS exceeds &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;130&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% of the conversion price on (i) each of at least &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;20&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; trading days, whether or not consecutive, during the &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;30&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Royalty Funding Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Company has entered into capped synthetic royalty funding agreements with Royalty Pharma (the &#x201c;Purchaser&#x201d;), which is presented as part of borrowings, and represents the Company&#x2019;s contractual obligations to pay a predetermined percentage of future commercial revenue until reaching a predetermined multiple of proceeds received, according to the detailed provisions of the synthetic royalty funding agreements.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;YORVIPATH Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2024, the Company entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million capped synthetic royalty funding agreement (the &#x201c;Royalty Pharma Yorvipath Agreement&#x201d;) with the Purchaser. The net proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;148.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;134.2&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Royalty Pharma Yorvipath Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (the &#x201c;Yorvipath Purchase Price&#x201d;) in exchange for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty on net revenue from sales of YORVIPATH in the U.S. (the &#x201c;Yorvipath Revenue Payments&#x201d;). The Yorvipath Revenue Payments to the Purchaser will cease upon reaching a multiple of the Yorvipath Purchase Price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times if the Purchaser receives Yorvipath Revenue Payments in that amount by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2029&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Royalty Pharma Yorvipath Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to September 30, 2028, and the Company has paid the Purchaser, Yorvipath Revenue Payments equal to the Yorvipath Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the Yorvipath Purchase Price minus the Yorvipath Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;SKYTROFA Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;In September 2023, the Company entered into a $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million capped synthetic royalty funding agreement (the &#x201c;Royalty Pharma Skytrofa Agreement&#x201d;) with the Purchaser. The net proceeds were $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;146.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (&#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;136.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million) after deducting offering expenses.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Under the terms of the Royalty Pharma Skytrofa Agreement, the Company received an upfront payment of $&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million (the &#x201c;Skytrofa Purchase Price&#x201d;) in exchange for a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;9.15&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% royalty on net revenue from sales of SKYTROFA in the U.S., beginning on &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;January 1, 2025&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; (the &#x201c;Skytrofa Revenue Payments&#x201d;). The Skytrofa Revenue Payments to the Purchaser will cease upon reaching a multiple of the Skytrofa Purchase Price of &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.925&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times, or &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times if the Purchaser receives Skytrofa Revenue Payments in that amount by &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;December 31, 2031&lt;/span&gt;&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The Royalty Pharma Skytrofa Agreement includes a buy-out option, which provides the Company with the right to settle all outstanding liabilities at any time by paying a buy-out amount equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.925&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice. However, if the buy-out notice is provided on or prior to December 31, 2028, and the Company has paid the Purchaser, Skytrofa Revenue Payments equal to the Skytrofa Purchase Price as of the date of the buy-out notice, then the buy-out amount is equal to &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1.65&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; times the Skytrofa Purchase Price minus the Skytrofa Revenue Payments paid to the Purchaser as of the effective date of the buy-out notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Derivative Liabilities&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities relate to the foreign currency conversion option embedded in the convertible notes.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Fair value cannot be measured based on quoted prices in active markets or other observable inputs, and accordingly, derivative liabilities are measured by using the Black-Scholes option pricing model. Fair value of the option is calculated, applying the following assumptions: (1) conversion price; (2) the Company&#x2019;s share price; (3) maturity of the option; (4) a risk-free interest rate equaling the effective interest rate on a U.S. government bond with the same lifetime as the maturity of the option; (5) no payment of dividends; and (6) an expected volatility using the Company&#x2019;s share price (&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.7&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; and &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;49.6&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;%&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; as of March 31, 2025 and December 31, 2024, respectively).&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;For additional description of fair values, refer to the following section &#x201c;Fair Value Measurement.&#x201d;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Sensitivity Analysis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;On March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all other inputs and assumptions held constant, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% relative increase in volatility, will increase the fair value of derivative liabilities by approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15.0&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and indicates a decrease in profit or loss and equity before tax. Similarly, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% relative decrease in volatility indicates the opposite impact.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Similarly, on March 31, 2025&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;, all other inputs and assumptions held constant, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% increase in the share price, will increase the fair value of derivative liabilities by approximately &#x20ac;&lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35.3&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; million and indicates a decrease in profit or loss and equity before tax. Similarly, a &lt;/span&gt;&lt;span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;10&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;% decrease in the share price indicates the opposite impact.&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Fair Value Measurement&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Because of the short-term maturity for cash and cash equivalents, receivables and trade payables, their fair value approximate carrying amount. Fair value of lease liabilities are not disclosed. Fair value compared to carrying amount of convertible notes, royalty funding liabilities and derivative liabilities, and their level in the fair value hierarchy is summarized in the following table, where:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 1 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 2 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Level 3 &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;inputs are unobservable inputs for the asset or liability&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(1-3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;449,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;438,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;752,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;741,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;763,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;743,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies movements in level 3 fair value measurements:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remeasurement recognized in finance (income) or expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;197,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;/div&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt;Maturity Analysis&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10pt;font-family:Times New Roman;"&gt;&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&amp;lt; 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1-5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&amp;gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;contractual&lt;br/&gt;cash-flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;991,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,031,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;752,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables, accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;142,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,049,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;35,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,227,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;935,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Borrowings (excluding lease liabilities)&#x201d; comprise convertible notes and royalty funding liabilities. Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_cd3e28f8-7723-4378-b7bb-66a5e2468f1e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The financial assets and liabilities comprise the following:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31,&lt;br/&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31,&lt;br/&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade receivables&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;66,685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;166,280&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other receivables (excluding indirect tax receivables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;4,501&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;517,923&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;559,543&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial assets measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;589,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;589,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;2,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;586,452&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;727,470&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;589,109&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;729,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities by category&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;449,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;text-indent:10pt;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:1.853%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;93,030&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables and accrued expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;84,370&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;96,394&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Other liabilities (excluding indirect tax, and employee related payables)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;311&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;935,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;953,321&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,110,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,103,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Classified in the statement of financial position&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Non-current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;357,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;365,080&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;752,781&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;738,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,110,093&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,103,991&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</asnd:DisclosureOfFinancialAssetsAndLiabilitiesExplanatory>
    <ifrs-full:TradeReceivables
      contextRef="C_facec156-4e04-482e-8239-ca86a66ecd9e"
      decimals="-3"
      id="F_8397acdd-7623-4ea2-93cf-c8ed3d9a9428"
      unitRef="U_EUR">66685000</ifrs-full:TradeReceivables>
    <ifrs-full:TradeReceivables
      contextRef="C_0180a343-84b5-4550-8e9e-0e9d94787b6a"
      decimals="-3"
      id="F_8a37754d-2ea9-47eb-a898-66d4af69bdcc"
      unitRef="U_EUR">166280000</ifrs-full:TradeReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_facec156-4e04-482e-8239-ca86a66ecd9e"
      decimals="-3"
      id="F_bdde90ba-57b1-405f-bf6d-59c5b5375fd0"
      unitRef="U_EUR">4501000</ifrs-full:OtherReceivables>
    <ifrs-full:OtherReceivables
      contextRef="C_0180a343-84b5-4550-8e9e-0e9d94787b6a"
      decimals="-3"
      id="F_6132d99f-622c-4b82-9906-0161b3a6e7af"
      unitRef="U_EUR">3964000</ifrs-full:OtherReceivables>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_facec156-4e04-482e-8239-ca86a66ecd9e"
      decimals="-3"
      id="F_57fe67ae-82bd-4bdf-ae41-90a4115ed842"
      unitRef="U_EUR">517923000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="C_0180a343-84b5-4550-8e9e-0e9d94787b6a"
      decimals="-3"
      id="F_8be38b6b-64ec-479b-870e-21e1078f45f3"
      unitRef="U_EUR">559543000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_facec156-4e04-482e-8239-ca86a66ecd9e"
      decimals="-3"
      id="F_3e9fe951-d476-4522-901e-a162bdc80f8b"
      unitRef="U_EUR">589109000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssetsAtAmortisedCost
      contextRef="C_0180a343-84b5-4550-8e9e-0e9d94787b6a"
      decimals="-3"
      id="F_35c27f60-a9df-4bfe-94a0-a7280de8f59f"
      unitRef="U_EUR">729787000</ifrs-full:FinancialAssetsAtAmortisedCost>
    <ifrs-full:FinancialAssets
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_7b576df2-15ac-494a-ab92-32c8947042fc"
      unitRef="U_EUR">589109000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_84c29880-c30b-46cb-8ad7-943f657c0685"
      unitRef="U_EUR">729787000</ifrs-full:FinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_4f056295-9f59-4f4f-bf9b-efd8ec086149"
      unitRef="U_EUR">2657000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:NoncurrentFinancialAssets
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_0c088d14-dd56-4904-b32c-79508db42793"
      unitRef="U_EUR">2317000</ifrs-full:NoncurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_508b217f-8bdf-420d-b3de-1b6b6a026e61"
      unitRef="U_EUR">586452000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:CurrentFinancialAssets
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_1c240fac-4cdb-4192-9a88-34e30d00bb03"
      unitRef="U_EUR">727470000</ifrs-full:CurrentFinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_deab0556-bb08-4058-8a29-79ec0b746bfb"
      unitRef="U_EUR">589109000</ifrs-full:FinancialAssets>
    <ifrs-full:FinancialAssets
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_d34ede4f-0369-4f4f-be2d-f357ec160a62"
      unitRef="U_EUR">729787000</ifrs-full:FinancialAssets>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_9dadf656-1020-4039-a18d-40e6268ca053"
      unitRef="U_EUR">449562000</asnd:ConvertibleSeniorNotes>
    <asnd:ConvertibleSeniorNotes
      contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f"
      decimals="-3"
      id="F_fb1938fc-74d3-45c9-86ce-b00eceb30146"
      unitRef="U_EUR">458207000</asnd:ConvertibleSeniorNotes>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_10f7c8fc-72ce-4bd7-93dc-d8be2c4e3ee5"
      unitRef="U_EUR">303347000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f"
      decimals="-3"
      id="F_c3a52b06-0a17-48d7-b150-a8ace2a57e07"
      unitRef="U_EUR">305379000</asnd:RoyaltyFundingLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_c7abeb24-09fa-4bd7-bc21-cb124cbb5f88"
      unitRef="U_EUR">94363000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f"
      decimals="-3"
      id="F_655a4e00-e144-41be-b3a5-d7a75fb70557"
      unitRef="U_EUR">93030000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_dd9d2feb-a1a8-4501-85ee-246eadeb72ed"
      unitRef="U_EUR">84370000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:TradeAndOtherPayablesToTradeSuppliers
      contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f"
      decimals="-3"
      id="F_2063a04b-8cad-4dbb-8be0-482f34aeca9a"
      unitRef="U_EUR">96394000</ifrs-full:TradeAndOtherPayablesToTradeSuppliers>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_67410072-42eb-4c24-84f2-fca79c29af6f"
      unitRef="U_EUR">3870000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:OtherFinancialLiabilities
      contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f"
      decimals="-3"
      id="F_46c3bddf-3f89-4b0b-b9c9-0245a94d198d"
      unitRef="U_EUR">311000</ifrs-full:OtherFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_65f8affb-ba2e-47ca-b2ea-152e4419d744"
      unitRef="U_EUR">935512000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_b125fc88-e513-4da8-966f-995e9855cd6f"
      decimals="-3"
      id="F_489a21ad-9a46-4b75-a8c5-bcffbe4a2bd9"
      unitRef="U_EUR">953321000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_0ee96722-3ee1-461d-a04f-67c3ff6c907a"
      unitRef="U_EUR">174581000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_fbe9e628-3538-4bc1-9bae-c9cd227495b4"
      unitRef="U_EUR">150670000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_8277197c-cb86-45e7-aa61-4d5b1f0fbafb"
      decimals="-3"
      id="F_c40471c9-20c5-4ac5-bf18-a651a3523353"
      unitRef="U_EUR">174581000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_b829287e-56df-49a2-b424-3fed6680c9cc"
      decimals="-3"
      id="F_738b81d6-094f-409c-b1b5-155c4a865619"
      unitRef="U_EUR">150670000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_ce07d45a-44a2-4a42-b2d0-38b547bc27e0"
      unitRef="U_EUR">1110093000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_85b02a2b-622a-4266-8d9c-faddcda0e51e"
      unitRef="U_EUR">1103991000</ifrs-full:FinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_3d2f9d78-7722-4691-95b4-980eb4221484"
      unitRef="U_EUR">357312000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:NoncurrentFinancialLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_673d19ec-4a0b-4c84-9177-706eb728612f"
      unitRef="U_EUR">365080000</ifrs-full:NoncurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_c1dc12ab-0ac6-4b91-86cd-53af6c246385"
      unitRef="U_EUR">752781000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:CurrentFinancialLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_b464075e-e857-43dd-a03a-75eb0fedc770"
      unitRef="U_EUR">738911000</ifrs-full:CurrentFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_f35de755-ecf1-40c6-b309-7ce52964f91b"
      unitRef="U_EUR">1110093000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="-3"
      id="F_8ae80e7c-c827-411a-9ef8-bfc13badc431"
      unitRef="U_EUR">1103991000</ifrs-full:FinancialLiabilities>
    <ifrs-full:NotionalAmount
      contextRef="C_f73819d7-55e0-42b4-8ce8-858bcc257ffe"
      decimals="-5"
      id="F_278bcc7f-b567-4e50-9656-ca7a09853c27"
      unitRef="U_USD">575000000</ifrs-full:NotionalAmount>
    <ifrs-full:BorrowingsInterestRate
      contextRef="C_1d3ec492-aaf3-4c50-8780-bc2563b2b216"
      decimals="4"
      id="F_8278bf84-7446-4f65-8556-ade5e7aaa171"
      unitRef="U_pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="C_08de1782-376b-48ac-8b33-acaf2bd1c052"
      decimals="-5"
      id="F_f79f9c75-c653-4c2e-a970-5b41f89754c6"
      unitRef="U_USD">557900000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures
      contextRef="C_08de1782-376b-48ac-8b33-acaf2bd1c052"
      decimals="-5"
      id="F_e7802c11-6d0d-4c3c-9574-804c9fe334aa"
      unitRef="U_EUR">503300000</ifrs-full:ProceedsFromIssueOfBondsNotesAndDebentures>
    <ifrs-full:BorrowingsMaturity
      contextRef="C_08de1782-376b-48ac-8b33-acaf2bd1c052"
      id="F_bb9a1cfb-d468-44cf-900a-2341abbf0a01">April 1, 2028</ifrs-full:BorrowingsMaturity>
    <ifrs-full:BorrowingsInterestRate
      contextRef="C_1226e5c0-e438-4068-ae93-f55dd69d5fc6"
      decimals="4"
      id="F_435e74b2-6c3a-4e1c-9577-d8a2792a585c"
      unitRef="U_pure">0.0225</ifrs-full:BorrowingsInterestRate>
    <asnd:ConversionRatePerNote
      contextRef="C_6df1c7ad-9308-4d74-81ba-3a4e8314fa4f"
      decimals="4"
      id="F_87d32fbd-c74d-4d17-9bd0-6ccd6faecc43"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">6.0118</asnd:ConversionRatePerNote>
    <ifrs-full:NotionalAmount
      contextRef="C_819dfe51-28d5-4314-9ec5-4ee09ed7b84b"
      decimals="0"
      id="F_81243061-325f-490a-9415-1ed519871b2a"
      unitRef="U_USD">1000</ifrs-full:NotionalAmount>
    <asnd:ConversionPricePerShare
      contextRef="C_bf7f8faa-849d-4587-84f1-bdcde1f91d6f"
      decimals="2"
      id="F_64a82063-f43f-4001-96b7-334a546bbe15"
      unitRef="U_UnitedStatesOfAmericaDollarsShare">166.34</asnd:ConversionPricePerShare>
    <asnd:BorrowingsRedemptionPeriod
      contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b"
      id="F_045148c3-63d0-46a7-bd33-493faae562f5">April 7, 2025</asnd:BorrowingsRedemptionPeriod>
    <asnd:BorrowingsConditionForRedemption
      contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b"
      id="F_23f0a94b-948d-488f-9b0a-b9d99f2608ef">but only if the last reported sale price per ADS exceeds 130% of the conversion price on (i) each of at least 20 trading days, whether or not consecutive, during the 30 consecutive trading days ending on, and including, the trading day immediately before the date the Company sends the related optional redemption notice; and (ii) the trading day immediately before the date the Company sends such notice.</asnd:BorrowingsConditionForRedemption>
    <asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption
      contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b"
      decimals="2"
      id="F_8fdc7a97-5ed6-4f95-b8d4-a86f7e46aee4"
      unitRef="U_pure">1.30</asnd:BorrowingsThresholdPercentageOfSalePricePerShareForRedemption>
    <asnd:BorrowingsThresholdTradingDaysForRedemption
      contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b"
      decimals="0"
      id="F_bbaf6fb8-b78f-4f67-b1f5-9c6afb9b60df"
      unitRef="U_Days">20</asnd:BorrowingsThresholdTradingDaysForRedemption>
    <asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption
      contextRef="C_2a483356-316b-4a65-8bf7-a9551532b29b"
      decimals="0"
      id="F_a7ba30d9-4fa6-4f3d-a1a3-6e263238bb90"
      unitRef="U_Days">30</asnd:BorrowingsThresholdConsecutiveTradingDaysForRedemption>
    <asnd:FundingReceivedInExchangeOfRoyaltyPayments
      contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8"
      decimals="-5"
      id="F_dca93ad5-bdac-4f72-928e-b2cd693a812d"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchangeOfRoyaltyPayments>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8"
      decimals="-5"
      id="F_64e731c3-1d06-4033-97a4-c6820428fa3d"
      unitRef="U_USD">148200000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8"
      decimals="-5"
      id="F_a82b0719-e82a-4819-8e54-3a11bf6fd3e1"
      unitRef="U_EUR">134200000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:FundingReceivedInExchange
      contextRef="C_e21b606d-3548-4aad-9554-94ae80a18cab"
      decimals="-5"
      id="F_84361bda-2fd1-44e2-a95d-27b00ae888e3"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchange>
    <asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment
      contextRef="C_e21b606d-3548-4aad-9554-94ae80a18cab"
      decimals="2"
      id="F_26199328-1862-41de-a2df-252cec2c2bad"
      unitRef="U_pure">0.03</asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_650908d3-c211-42ad-819c-acf17f2e9e86"
      decimals="1"
      id="F_ffaa9146-e14b-461f-923d-a80aee64fcea"
      unitRef="U_Multiple">2</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_27448f17-97d9-4695-8836-7cbae988447b"
      decimals="2"
      id="F_b07ec019-7240-47ae-a920-d9cc92dfb10c"
      unitRef="U_Multiple">1.65</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:RoyaltyPaymentEndingPeriod
      contextRef="C_e21b606d-3548-4aad-9554-94ae80a18cab"
      id="F_35cfc049-06ae-4162-aca9-b3030af0d102">2029-12-31</asnd:RoyaltyPaymentEndingPeriod>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount
      contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8"
      decimals="1"
      id="F_2b34099d-17f3-4cbd-9c37-f8720df8fde6"
      unitRef="U_XBB">2</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount
      contextRef="C_2db2ad6b-3a3c-4dd2-81bb-a6ac5bea92b8"
      decimals="2"
      id="F_a082efb6-cb43-4ca7-b78f-953d58272682"
      unitRef="U_XBB">1.65</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount>
    <asnd:FundingReceivedInExchangeOfRoyaltyPayments
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      decimals="-5"
      id="F_14a27633-56e5-411e-803a-cd2b77ca655b"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchangeOfRoyaltyPayments>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      decimals="-5"
      id="F_38857d0e-a79b-4c6f-93b5-586b1cc903ce"
      unitRef="U_USD">146300000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      decimals="-5"
      id="F_828b5753-0153-4c26-ab1c-6561ebac7dd6"
      unitRef="U_EUR">136300000</asnd:ProceedsFromRoyaltyFundingLiabilitiesExcludingOfferingExpenses>
    <asnd:FundingReceivedInExchange
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      decimals="-5"
      id="F_7ac467e3-7f86-4312-a076-ce4ae1132f3a"
      unitRef="U_USD">150000000</asnd:FundingReceivedInExchange>
    <asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      decimals="4"
      id="F_1fb15e28-6c5c-499a-86e2-5b463a855246"
      unitRef="U_pure">0.0915</asnd:ExchangeRateForPercentageOfNetSalesToRoyaltyPayment>
    <asnd:RoyaltyPaymentBeginningPeriod
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      id="F_05a7e72e-1eff-495e-b35a-948d338cc2c6">2025-01-01</asnd:RoyaltyPaymentBeginningPeriod>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_36943fab-c0c6-4437-adcd-1f9a290d164c"
      decimals="3"
      id="F_c31b8262-e18f-4cf0-9e9b-7bfcd589a5be"
      unitRef="U_Multiple">1.925</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease
      contextRef="C_080c73e3-b2aa-450a-ba77-af1301298b4f"
      decimals="2"
      id="F_68f1546e-f998-4492-88ac-8f40cb901680"
      unitRef="U_Multiple">1.65</asnd:MultipleOfPurchasePriceWereRoyaltyPaymentWillCease>
    <asnd:RoyaltyPaymentEndingPeriod
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      id="F_49833bd5-113f-45a0-a65a-a24791202beb">2031-12-31</asnd:RoyaltyPaymentEndingPeriod>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      decimals="3"
      id="F_9ab6c38a-2191-4a7a-ac84-76f78541c6cc"
      unitRef="U_XBB">1.925</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeAsBuyoutAmount>
    <asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount
      contextRef="C_d0e60dd1-e424-4b0e-a70a-48f09c07ac1a"
      decimals="2"
      id="F_8b0d6ad3-fabe-4a67-85ad-1aa659c44a20"
      unitRef="U_XBB">1.65</asnd:AmountMultipliedToPurchasePriceMinusRevenueInterestPaymentsPaidToPurchaserOnEffectiveDateOfBuyOutNoticeProvidedOnOrPriorToPeriodAsBuyoutAmount>
    <asnd:SharePriceAppliedForValuation
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="INF"
      id="F_9d334c57-7057-42ff-83c2-a2a973161c18"
      unitRef="U_EurPerShare">49.7</asnd:SharePriceAppliedForValuation>
    <asnd:SharePriceAppliedForValuation
      contextRef="C_8d9f98d0-af51-4f11-9756-1b080f1adc54"
      decimals="INF"
      id="F_9745f22e-fa5b-4b9a-81a1-23344d8e69ab"
      unitRef="U_EurPerShare">49.6</asnd:SharePriceAppliedForValuation>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="C_99b14b08-2c6d-4423-a4ca-73022572e1c7"
      decimals="2"
      id="F_06d19c16-6e4c-428f-96ce-df272ea5f1ef"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_dc16f5c8-e5a3-4b82-8f15-702a29cdd088"
      decimals="-5"
      id="F_884597a5-7946-4808-8e89-7fe4f683d33e"
      unitRef="U_EUR">15000000</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="C_99b14b08-2c6d-4423-a4ca-73022572e1c7"
      decimals="2"
      id="F_abc426bc-de35-457e-84c7-062f224a8731"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities
      contextRef="C_0ce1e53d-f85e-4cd5-8a39-323d29baed2c"
      decimals="2"
      id="F_1b57ae6a-62e9-4aab-ab34-046cca841848"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleIncreaseInUnobservableInputLiabilities>
    <asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue
      contextRef="C_3d08e8ed-f880-4006-95c6-262b0ebc3c04"
      decimals="-5"
      id="F_2ae7c441-680f-4fb1-b7db-648bca9c6d39"
      unitRef="U_EUR">35300000</asnd:IncreaseDecreaseInDerivativeFinancialLiabilitiesFairValue>
    <ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities
      contextRef="C_0ce1e53d-f85e-4cd5-8a39-323d29baed2c"
      decimals="2"
      id="F_107c51f8-8154-414b-913c-22e2c37d736f"
      unitRef="U_pure">0.10</ifrs-full:PercentageOfReasonablyPossibleDecreaseInUnobservableInputLiabilities>
    <asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_8bcacf43-1a5c-43fb-8717-42af7f8b2415">
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;December 31, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Fair value level&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="14" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(1-3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Convertible senior notes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;449,562&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;433,666&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;458,207&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;438,288&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Royalty funding liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;303,347&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;308,018&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,379&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;305,673&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at amortized cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;752,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;741,684&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;763,586&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;743,961&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities measured at fair value through profit or loss&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;text-indent:25pt;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="margin-left:4.627%;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</asnd:DisclosureOfSummaryOfFairValueHierarchyTableTextBlock>
    <ifrs-full:NotesAndDebenturesIssued
      contextRef="C_0ed1d82f-1028-46f4-b7d1-1a4f01140861"
      decimals="-3"
      id="F_a327dfb5-4194-4911-b0d8-7d231f5717f8"
      unitRef="U_EUR">449562000</ifrs-full:NotesAndDebenturesIssued>
    <ifrs-full:NotesAndDebenturesIssued
      contextRef="C_3b05cb12-2e51-444c-a128-f7f8902c20db"
      decimals="-3"
      id="F_57d4a3e6-19e9-4773-a132-28545245e5cf"
      unitRef="U_EUR">433666000</ifrs-full:NotesAndDebenturesIssued>
    <ifrs-full:NotesAndDebenturesIssued
      contextRef="C_ff030c5c-71d1-4446-bcd4-d002a0413fae"
      decimals="-3"
      id="F_7443f6fb-66f1-4832-8252-4c320b5b656f"
      unitRef="U_EUR">458207000</ifrs-full:NotesAndDebenturesIssued>
    <ifrs-full:NotesAndDebenturesIssued
      contextRef="C_1c3c7589-8585-40b4-8f1e-8ae31626083c"
      decimals="-3"
      id="F_28034750-794a-4559-9f5d-339ee9a1c3a7"
      unitRef="U_EUR">438288000</ifrs-full:NotesAndDebenturesIssued>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_0ed1d82f-1028-46f4-b7d1-1a4f01140861"
      decimals="-3"
      id="F_31166c82-f9e6-4591-9b28-f65757b8b55c"
      unitRef="U_EUR">303347000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_3b05cb12-2e51-444c-a128-f7f8902c20db"
      decimals="-3"
      id="F_7a29f3d5-ddd1-4af3-a219-4d945da4c2d9"
      unitRef="U_EUR">308018000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_ff030c5c-71d1-4446-bcd4-d002a0413fae"
      decimals="-3"
      id="F_8f296cc5-2c43-4332-b0fa-ff6de42e52e9"
      unitRef="U_EUR">305379000</asnd:RoyaltyFundingLiabilities>
    <asnd:RoyaltyFundingLiabilities
      contextRef="C_1c3c7589-8585-40b4-8f1e-8ae31626083c"
      decimals="-3"
      id="F_375e8fd4-eab6-45ce-9387-c50d9c6ffd51"
      unitRef="U_EUR">305673000</asnd:RoyaltyFundingLiabilities>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_41b6f38d-a596-4e87-b38c-e28360d02d02"
      decimals="-3"
      id="F_504e3d70-7fd3-4a2f-96a5-6c400220cdb7"
      unitRef="U_EUR">752909000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_f365e58b-1e31-4938-9a9f-6ae4a53dfc7b"
      decimals="-3"
      id="F_64848f32-307b-4f88-a651-8f55bc76296a"
      unitRef="U_EUR">741684000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_0f12ae56-033f-4e22-8363-af8518013748"
      decimals="-3"
      id="F_60caf843-173f-4b66-93fe-aef016bd20a1"
      unitRef="U_EUR">763586000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:FinancialLiabilitiesAtAmortisedCost
      contextRef="C_d9cca70d-ddde-47cd-a1a3-3f846e0b2ad1"
      decimals="-3"
      id="F_60759da4-869e-42ac-a877-1550c831ebe9"
      unitRef="U_EUR">743961000</ifrs-full:FinancialLiabilitiesAtAmortisedCost>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_0ed1d82f-1028-46f4-b7d1-1a4f01140861"
      decimals="-3"
      id="F_656ca7bf-4766-411d-9714-8d18c804d83a"
      unitRef="U_EUR">174581000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_3b05cb12-2e51-444c-a128-f7f8902c20db"
      decimals="-3"
      id="F_f294cc78-7a1c-4859-9773-dba9aa5cc8fa"
      unitRef="U_EUR">174581000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_ff030c5c-71d1-4446-bcd4-d002a0413fae"
      decimals="-3"
      id="F_33ed9378-7462-46d7-9260-85fd05d9778a"
      unitRef="U_EUR">150670000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_1c3c7589-8585-40b4-8f1e-8ae31626083c"
      decimals="-3"
      id="F_21edf338-261e-419f-87b9-4359f93146a7"
      unitRef="U_EUR">150670000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_41b6f38d-a596-4e87-b38c-e28360d02d02"
      decimals="-3"
      id="F_524c4142-9430-40f8-8670-9321be641fc8"
      unitRef="U_EUR">174581000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_f365e58b-1e31-4938-9a9f-6ae4a53dfc7b"
      decimals="-3"
      id="F_7c75bf25-c39c-45fe-9787-919ea1a64959"
      unitRef="U_EUR">174581000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_0f12ae56-033f-4e22-8363-af8518013748"
      decimals="-3"
      id="F_20319a7b-4763-4489-940b-d704d14fd43e"
      unitRef="U_EUR">150670000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss
      contextRef="C_d9cca70d-ddde-47cd-a1a3-3f846e0b2ad1"
      decimals="-3"
      id="F_1f7489e0-d85a-4f80-91e0-05db46984240"
      unitRef="U_EUR">150670000</ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLoss>
    <asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_b2457973-6a0a-402b-8b41-4c9212bb3d0d">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table specifies movements in level 3 fair value measurements:&lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:66.967%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1.16%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:13.357%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="6" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Derivative liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;January 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;150,670&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;143,296&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Remeasurement recognized in finance (income) or expense&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;23,911&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;53,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;174,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #000000;padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;197,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="border-top:0.5pt solid #ffffff03;padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;</asnd:DisclosureOfMovementsInLevelThreeFairValueMeasurementsTableTextBlock>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_faaf4bfc-6ed7-4797-9957-11c2e997c3a3"
      decimals="-3"
      id="F_da29635f-1d03-46c3-b256-63276260b273"
      unitRef="U_EUR">150670000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_ac6e452f-b851-4366-98b0-9dbd4cb50f3e"
      decimals="-3"
      id="F_c3b6daab-854c-474c-aa41-06d05dde42f7"
      unitRef="U_EUR">143296000</ifrs-full:DerivativeFinancialLiabilities>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense
      contextRef="C_a7a008d3-7a3d-4804-83b9-58bcf05b742c"
      decimals="-3"
      id="F_33d5623d-224f-40f1-ad89-b86a90d966c9"
      unitRef="U_EUR">23911000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense>
    <asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense
      contextRef="C_e430f24c-0233-4114-a208-350b297af714"
      decimals="-3"
      id="F_42f255f6-c9b2-4e9d-971c-4bb45eb0a7f3"
      unitRef="U_EUR">53995000</asnd:DerivativeFinancialLiabilitiesAtFairValueRemeasurementRecognizedInFinancialIncomeOrExpense>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_3c3f2d33-74af-4a32-80dc-2766d5dbca67"
      decimals="-3"
      id="F_4294561e-e3d5-4d50-8e05-1061fbfaa501"
      unitRef="U_EUR">174581000</ifrs-full:DerivativeFinancialLiabilities>
    <ifrs-full:DerivativeFinancialLiabilities
      contextRef="C_90ec9194-a47f-4c6f-ba12-88ada7bf522a"
      decimals="-3"
      id="F_111430f3-ef55-4155-b731-a9a8f14a47fb"
      unitRef="U_EUR">197291000</ifrs-full:DerivativeFinancialLiabilities>
    <asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_d8225212-2468-40d0-a156-27b9c894807e">&lt;p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;The following table summarizes maturity analysis (on an undiscounted basis) for non-derivative financial liabilities recognized in the unaudited condensed consolidated statements of financial position as of &lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025:&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;
       &lt;table style="margin-left:auto;border-spacing:0;table-layout:auto;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
        &lt;tr style="visibility:collapse;"&gt;
         &lt;td style="width:44.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.04%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:8.42%;box-sizing:content-box;"&gt;&lt;/td&gt;
         &lt;td style="width:1%;box-sizing:content-box;"&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&amp;lt; 1 year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1-5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;&amp;gt;5 years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total&lt;br/&gt;contractual&lt;br/&gt;cash-flows&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Carrying&lt;br/&gt;amount&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="18" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;(EUR&#x2019;000)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:left;"&gt;&lt;p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;March 31, 2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td colspan="2" style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Borrowings (excluding lease liabilities)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;39,585&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;991,636&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;1,031,221&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;752,909&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;15,129&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;57,607&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;35,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;107,986&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;94,363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;Trade payables, accrued expenses and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;88,240&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:0.5pt solid #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
        &lt;tr style="height:10pt;background-color:#ffffff;word-break:break-word;"&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:top;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;Total financial liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;142,954&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,049,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;35,250&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;1,227,447&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:pre-wrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #000000;padding-right:0in;text-align:center;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-kerning:none;min-width:fit-content;"&gt;935,512&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
         &lt;td style="padding-top:0.01in;white-space:nowrap;padding-left:0in;vertical-align:bottom;padding-bottom:0in;border-bottom:2.25pt double #ffffff03;padding-right:0in;"&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="font-kerning:none;min-width:fit-content;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;/tr&gt;
       &lt;/table&gt;&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;&#x201c;Borrowings (excluding lease liabilities)&#x201d; comprise convertible notes and royalty funding liabilities. Expected maturity for royalty funding liabilities is based on anticipated amount and timing of future revenue from sale of commercial products. Further details regarding the payment structure of the royalty funding agreements are provided above.&lt;/span&gt;&lt;/p&gt;</asnd:MaturityAnalysisForFinancialLiabilitiesTextBlock>
    <ifrs-full:Borrowings
      contextRef="C_5eb53229-0864-44c9-9f9d-2c5f527f1088"
      decimals="-3"
      id="F_4f7ff782-ff0f-475f-8095-b8a147b782ab"
      unitRef="U_EUR">39585000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_af8ce046-66d9-47ba-a2db-115fd2735a92"
      decimals="-3"
      id="F_abb6b823-0ab2-43e2-a031-ba65b5b5cda5"
      unitRef="U_EUR">991636000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217"
      decimals="-3"
      id="F_0bfaeb4f-f7b8-4a42-b014-b55f540eb2c2"
      unitRef="U_EUR">0</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_10542aa7-99d3-45b8-9fae-f3247c694926"
      unitRef="U_EUR">1031221000</ifrs-full:Borrowings>
    <ifrs-full:Borrowings
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_f0be01d7-dbd5-482f-aa86-70daf96b4049"
      unitRef="U_EUR">752909000</ifrs-full:Borrowings>
    <ifrs-full:LeaseLiabilities
      contextRef="C_5eb53229-0864-44c9-9f9d-2c5f527f1088"
      decimals="-3"
      id="F_c46c2666-9d2d-4e54-9e80-422f8010a927"
      unitRef="U_EUR">15129000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_af8ce046-66d9-47ba-a2db-115fd2735a92"
      decimals="-3"
      id="F_142e481b-85c0-44d9-86ad-f28a93b64bca"
      unitRef="U_EUR">57607000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217"
      decimals="-3"
      id="F_18d035ea-305b-4796-81de-f8f44935f39d"
      unitRef="U_EUR">35250000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_e2e9fe2c-22da-4e50-9d52-8009e26daefe"
      unitRef="U_EUR">107986000</ifrs-full:LeaseLiabilities>
    <ifrs-full:LeaseLiabilities
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_6cb45085-beaf-4ae0-a017-a65800372e8e"
      unitRef="U_EUR">94363000</ifrs-full:LeaseLiabilities>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_5eb53229-0864-44c9-9f9d-2c5f527f1088"
      decimals="-3"
      id="F_27cf3dab-fde9-4523-93ef-04433381cfe4"
      unitRef="U_EUR">88240000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_af8ce046-66d9-47ba-a2db-115fd2735a92"
      decimals="-3"
      id="F_be9d4166-8ecc-42be-a992-97d196c0a570"
      unitRef="U_EUR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217"
      decimals="-3"
      id="F_c233b869-7874-462e-ac22-923969e223a8"
      unitRef="U_EUR">0</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_17c1c307-2e54-442b-93e8-fef9b167750e"
      unitRef="U_EUR">88240000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:TradeAndOtherPayables
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_dedbf337-a822-434c-ad82-f82ee787c26e"
      unitRef="U_EUR">88240000</ifrs-full:TradeAndOtherPayables>
    <ifrs-full:FinancialLiabilities
      contextRef="C_5eb53229-0864-44c9-9f9d-2c5f527f1088"
      decimals="-3"
      id="F_3da6c1fc-70ac-450b-b58c-5839e3bb4981"
      unitRef="U_EUR">142954000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_af8ce046-66d9-47ba-a2db-115fd2735a92"
      decimals="-3"
      id="F_842500e2-2f31-44c4-95dc-64feeac47053"
      unitRef="U_EUR">1049243000</ifrs-full:FinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_e0144bc5-88f7-47bf-b627-d99e3fe7e217"
      decimals="-3"
      id="F_5cc2760a-9b2e-4291-b2d1-0ebafe0f007a"
      unitRef="U_EUR">35250000</ifrs-full:FinancialLiabilities>
    <asnd:ContractualUndiscountedCashflowOfFinancialLiabilities
      contextRef="C_7ebbd176-7e24-4431-8904-088669448bc7"
      decimals="-3"
      id="F_be418eaa-d1c9-45db-bf0a-2af4129d83fc"
      unitRef="U_EUR">1227447000</asnd:ContractualUndiscountedCashflowOfFinancialLiabilities>
    <ifrs-full:FinancialLiabilities
      contextRef="C_f3608329-0a27-421b-9eed-d655fd107402"
      decimals="-3"
      id="F_2bdf08e2-6968-4106-a0e6-ffa13ae8e118"
      unitRef="U_EUR">935512000</ifrs-full:FinancialLiabilities>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="C_cfea5658-1faf-4539-ad78-6f615eb69073"
      id="F_a24ae31b-ac47-4dd9-8d7f-0fea10d40267">&lt;p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;Note 11&#x2014;Subsequent Events&lt;/span&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"&gt;&lt;span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"&gt;No events have occurred after the balance sheet date that would influence the evaluation of these unaudited condensed consolidated interim financial statements.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_9e4d657f-478f-4433-bce1-27fd0273275a"
          xlink:label="F_9e4d657f-478f-4433-bce1-27fd0273275a"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_54a2db4f-0a64-42f5-8719-d72d0fff50fc"
          xlink:label="F_54a2db4f-0a64-42f5-8719-d72d0fff50fc"
          xlink:type="locator"/>
        <link:footnote id="FNT_5dd3c7e2-62e7-4202-87b6-5365ff6957b5" xlink:label="FNT_5dd3c7e2-62e7-4202-87b6-5365ff6957b5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">As of </xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">March 31, 2025 and March 31, 2024</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;">, a total of </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,017,157</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> and </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">6,031,498</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> warrants outstanding, respectively, each carrying the right to subscribe for one ordinary share, and </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">575,000</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> convertible senior notes which can potentially be converted into </xhtml:span><xhtml:span style="font-size:8pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-kerning:none;min-width:fit-content;">3,456,785</xhtml:span><xhtml:span style="color:#000000;white-space:pre-wrap;font-size:8pt;font-family:Times New Roman;font-kerning:none;min-width:fit-content;"> ordinary shares, can potentially dilute earnings per share in the future but have not been included in the calculation of diluted earnings per share because they are antidilutive for the periods presented.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9e4d657f-478f-4433-bce1-27fd0273275a"
          xlink:to="FNT_5dd3c7e2-62e7-4202-87b6-5365ff6957b5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_54a2db4f-0a64-42f5-8719-d72d0fff50fc"
          xlink:to="FNT_5dd3c7e2-62e7-4202-87b6-5365ff6957b5"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
